<?xml version="1.0" encoding="UTF-8"?>
<search_results count="970">
  <query>Ribavirin</query>
<!-- Additional study fields may be added over time -->  <study rank="1">
    <nct_id>NCT01268579</nct_id>
    <title>Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell Carcinoma</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HEAD &amp; NECK Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Memorial Sloan Kettering Cancer Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>7</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>10-218</other_id>
    </other_ids>
    <first_received>December 29, 2010</first_received>
    <start_date>December 2010</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>April 29, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To explore if ribavirin therapy for 2 weeks decreases tumor expression</outcome_measure>
      <outcome_measure>to explore the pharmacodynamic effects of ribavirin</outcome_measure>
      <outcome_measure>To explore if ribavirin reduces the expression of HPV-16 oncoproteins E6 and E7</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01268579</url>
  </study>
  <study rank="2">
    <nct_id>NCT01726400</nct_id>
    <title>In Hepatitis C Patients Treated With Interferon and Ribavirin, Does Hepcidin Contribute to Treatment Induced Anaemia</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alpha</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Fremantle Hospital and Health Service</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>HEPCIDIN-11/225</other_id>
    </other_ids>
    <first_received>November 9, 2012</first_received>
    <start_date>December 2012</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>November 9, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Hepcidin levels</outcome_measure>
      <outcome_measure>iron metabolism markers</outcome_measure>
      <outcome_measure>heamolysis markers</outcome_measure>
      <outcome_measure>inosine triphosphatase genetic variants</outcome_measure>
      <outcome_measure>erythropoiesis markers</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01726400</url>
  </study>
  <study rank="3">
    <nct_id>NCT00993122</nct_id>
    <title>Ribavirin Pre-treatment Followed by Combined Standard Therapy in Hepatitis C Virus (HCV) Recipients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ribavirin pre-treatment</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Roma La Sapienza</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Ribavirin Pre-treatment</other_id>
    </other_ids>
    <first_received>October 8, 2009</first_received>
    <start_date>October 2009</start_date>
    <completion_date>February 2012</completion_date>
    <last_updated>June 19, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>RBV</acronym>
    <primary_completion_date>April 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HCV-RNA level, Transaminases level</outcome_measure>
      <outcome_measure>liver biopsy and Transient elastography at baseline and after six month since therapy conclusion</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00993122</url>
  </study>
  <study rank="4">
    <nct_id>NCT00500578</nct_id>
    <title>Intermittent Use of Aerosolized Ribavirin for Treatment of RSV</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hematological Malignancies</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>M.D. Anderson Cancer Center</lead_sponsor>
      <collaborator>ICN Pharmaceuticals</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>51</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ID03-0010</other_id>
    </other_ids>
    <first_received>July 10, 2007</first_received>
    <start_date>February 2003</start_date>
    <completion_date>January 2009</completion_date>
    <last_updated>July 27, 2012</last_updated>
    <last_verified>July 2012</last_verified>
    <firstreceived_results_date>June 1, 2010</firstreceived_results_date>
    <primary_completion_date>January 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Occurrences of Pneumonia</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00500578</url>
  </study>
  <study rank="5">
    <nct_id>NCT01056757</nct_id>
    <title>Treatment With Ribavirin for Patients With Metastatic Breast Cancer</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Metastatic Breast Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Jewish General Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>4</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Ribavirin-003</other_id>
    </other_ids>
    <first_received>January 25, 2010</first_received>
    <start_date>December 2009</start_date>
    <completion_date>November 2010</completion_date>
    <last_updated>November 3, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Overall response rate to therapy with daily oral ribavirin</outcome_measure>
      <outcome_measure>Time to and duration of response</outcome_measure>
      <outcome_measure>Time to relapse</outcome_measure>
      <outcome_measure>To determine the medical risk (safety and tolerability) that ribavirin may have on breast cancer patients as determined by laboratory tests, vital signs, and clinical adverse events.</outcome_measure>
      <outcome_measure>Correlation between activity of eIF4E and response</outcome_measure>
      <outcome_measure>Effect of ribavirin on the activity of eIF4E related pathways</outcome_measure>
      <outcome_measure>Evaluate pharmacokinetic parameters of ribavirin</outcome_measure>
      <outcome_measure>Correlate expression of eIF4E in fresh and archived tissue</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01056757</url>
  </study>
  <study rank="6">
    <nct_id>NCT01289496</nct_id>
    <title>Ribavirin Dose Optimization for the Treatment of Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-interferon alpha-2a, Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Centre hospitalier de l'Université de Montréal (CHUM)</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
      <collaborator>Centre de Recherche du Centre Hospitalier de l'Université de Montréal</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>13</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML25553</other_id>
      <other_id>Control Number: 143155</other_id>
    </other_ids>
    <first_received>January 25, 2011</first_received>
    <start_date>February 2011</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>February 24, 2014</last_updated>
    <last_verified>August 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Hepatitis C Virus-Ribonucleic Acid (HCV-RNA) analysis assay</outcome_measure>
      <outcome_measure>Viral Kinetics</outcome_measure>
      <outcome_measure>Neutrophils</outcome_measure>
      <outcome_measure>Hemoglobin</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01289496</url>
  </study>
  <study rank="7">
    <nct_id>NCT01937728</nct_id>
    <title>Tailored Regimens of PEGASYS® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">A: Peg-interferon alpha-2a &amp; Ribavirin</intervention>
      <intervention type="Drug">B: Peg-interferon alpha-2a &amp; Ribavirin</intervention>
      <intervention type="Drug">C: Peg-interferon alpha-2a &amp; Ribavirin</intervention>
      <intervention type="Drug">D: Peg-interferon alpha-2a &amp; Ribavirin</intervention>
      <intervention type="Drug">E: Peg-interferon alpha-2a &amp; Ribavirin</intervention>
      <intervention type="Drug">F: Peg-interferon alpha-2a &amp; Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kaohsiung Medical University Chung-Ho Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>750</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KMUH-IRB-970119</other_id>
    </other_ids>
    <first_received>June 21, 2013</first_received>
    <start_date>March 2010</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>September 4, 2013</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy</outcome_measure>
      <outcome_measure>Safety</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01937728</url>
  </study>
  <study rank="8">
    <nct_id>NCT00662220</nct_id>
    <title>High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Foundation for Liver Research</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>110</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HCV07-01</other_id>
      <other_id>2007-005344-25</other_id>
    </other_ids>
    <first_received>April 17, 2008</first_received>
    <start_date>April 2008</start_date>
    <completion_date>November 2013</completion_date>
    <last_updated>July 11, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>VIRID</acronym>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HCV-RNA negativity by qualitative assay 24 weeks after end of treatment (sustained virological response, SVR)</outcome_measure>
      <outcome_measure>HCV-RNA negativity at week 4 (rapid virological response, RVR)</outcome_measure>
      <outcome_measure>HCV-RNA negativity at week 12 (complete early virological response, cEVR)</outcome_measure>
      <outcome_measure>HCV-RNA ≥ 2log10 drop at week 12, but HCV-RNA still detectable (partial early virological response, pEVR)</outcome_measure>
      <outcome_measure>HCV- RNA negativity at week 48 (end of treatment response, ETR)</outcome_measure>
      <outcome_measure>Relapse rate after ETR</outcome_measure>
      <outcome_measure>Safety and tolerability of high-dose daily ribavirin (serious adverse events, grade 4 NCI toxicity, percentage of patients completing treatment on full or &gt;80% of total intended dose and reasons for dose adjustments)</outcome_measure>
      <outcome_measure>Biochemical response (normalization of serum ALT at the end of therapy and at the end of follow-up)</outcome_measure>
      <outcome_measure>Health related quality of life and psychopathology before, during and after treatment by SF-36 and SCL-90 questionnaires</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00662220</url>
  </study>
  <study rank="9">
    <nct_id>NCT00868946</nct_id>
    <title>Ribavirin for Hemorrhagic Fever With Renal Syndrome in Germany</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hemorrhagic Fever With Renal Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Virazole (Ribavirin)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>U.S. Army Medical Research and Materiel Command</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>A-15314</other_id>
      <other_id>BAMC HUC C.2008.197</other_id>
      <other_id>USAMRIID HUC FY05-18</other_id>
    </other_ids>
    <first_received>March 24, 2009</first_received>
    <start_date>October 2009</start_date>
    <completion_date>June 2016</completion_date>
    <last_updated>October 26, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HFRS</acronym>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of subject who develop oliguria</outcome_measure>
      <outcome_measure>Number of mortalities</outcome_measure>
      <outcome_measure>Number and type of adverse events for all subjects.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00868946</url>
  </study>
  <study rank="10">
    <nct_id>NCT00641654</nct_id>
    <title>Combination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon and Ribavirin</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa-2a and ribavirin</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a and ribavirin</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Göteborg University</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>EudractCT 2006-003409-18</other_id>
    </other_ids>
    <first_received>March 17, 2008</first_received>
    <start_date>January 2007</start_date>
    <completion_date>December 2009</completion_date>
    <last_updated>August 29, 2012</last_updated>
    <last_verified>March 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>RelapC</acronym>
    <primary_completion_date>December 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained viral response (SVR) rate defined as percentage of patients with non-detectable HCV-RNA 24 weeks after completion of the 24 or 48 week treatment period.</outcome_measure>
      <outcome_measure>Sustained viral response (SVR)rate and percentage of patients with normal serum ALT levels and its association with prespecified factors e.g. viral load</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Sweden</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00641654</url>
  </study>
  <study rank="11">
    <nct_id>NCT00992693</nct_id>
    <title>Treatment of Viral Hemorrhagic Fevers With Intravenous Ribavirin in Military Treatment Facilities</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crimean-Congo Hemorrhagic Fever</condition>
      <condition>Lassa Fever</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin (Virazole) Injection</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>U.S. Army Medical Research and Materiel Command</lead_sponsor>
      <collaborator>Valeant Pharmaceuticals International, Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>C2009.140</other_id>
    </other_ids>
    <first_received>October 8, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>January 2016</completion_date>
    <last_updated>October 28, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of adverse events</outcome_measure>
      <outcome_measure>Number of deaths of individuals with viral hemorrhagic fever (Crimean-Congo hemorrhagic fever or Lassa fever) who received at least four doses of IV Ribavirin</outcome_measure>
      <outcome_measure>Number of clinical events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00992693</url>
  </study>
  <study rank="12">
    <nct_id>NCT00421434</nct_id>
    <title>Study of Nitazoxanide, Peginterferon, and Ribavirin Combination Therapies in the Treatment of Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitazoxanide</intervention>
      <intervention type="Biological">Peginterferon alfa-2a</intervention>
      <intervention type="Biological">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Romark Laboratories L.C.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>121</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>RM01-3036</other_id>
    </other_ids>
    <first_received>January 10, 2007</first_received>
    <start_date>June 2006</start_date>
    <completion_date>September 2008</completion_date>
    <last_updated>September 23, 2008</last_updated>
    <last_verified>September 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>STEALTHC-1</acronym>
    <primary_completion_date>September 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response</outcome_measure>
      <outcome_measure>End of treatment virologic response</outcome_measure>
      <outcome_measure>Early virologic response</outcome_measure>
      <outcome_measure>Rapid virologic response</outcome_measure>
      <outcome_measure>ALT normalization</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00421434</url>
  </study>
  <study rank="13">
    <nct_id>NCT00491244</nct_id>
    <title>Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a and ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>National Science Council, Taiwan</collaborator>
      <collaborator>Department of Health, Executive Yuan, R.O.C. (Taiwan)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>377</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>200703010M</other_id>
    </other_ids>
    <first_received>June 23, 2007</first_received>
    <start_date>June 2007</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>January 13, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>September 29, 2013</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR)Rate</outcome_measure>
      <outcome_measure>Adverse Event (AE)-Related Withdrawal Rate</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00491244</url>
  </study>
  <study rank="14">
    <nct_id>NCT01590225</nct_id>
    <title>Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Peginterferon alpha-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P08034</other_id>
      <other_id>2010-024260-17</other_id>
    </other_ids>
    <first_received>May 1, 2012</first_received>
    <start_date>January 2013</start_date>
    <completion_date>August 2021</completion_date>
    <last_updated>February 20, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2021</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Participants Achieving Sustained Viral Response (SVR) at Follow-Up Week 24 in Study Part A</outcome_measure>
      <outcome_measure>Participants Achieving SVR at Follow-Up Week 24 in Study Part B</outcome_measure>
      <outcome_measure>Time to Viral Relapse in Study Part C</outcome_measure>
      <outcome_measure>Proportion of Participants With Alanine Aminotransferase (ALT) Normalization in Study Part A</outcome_measure>
      <outcome_measure>Participants With Early Virologic Response in Study Part A</outcome_measure>
      <outcome_measure>Proportion of Participants With Undetectable Hepatitis C Virus Ribonucleic Acid (HCV-RNA) in Study Part A</outcome_measure>
      <outcome_measure>Proportion of Participants With Undetectable HCV-RNA Who Also Achieved SVR in Study Part A</outcome_measure>
      <outcome_measure>Proportion of Participants With Alanine Aminotransferase (ALT) Normalization in Study Part B</outcome_measure>
      <outcome_measure>Proportion of Participants With Undetectable HCV-RNA in Study Part B</outcome_measure>
      <outcome_measure>Proportion of Participants With Undetectable HCV-RNA Who Also Achieved SVR in Study Part B</outcome_measure>
      <outcome_measure>Number of Participants Experiencing Treatment-Emergent Adverse Events (AEs) in Study Part A</outcome_measure>
      <outcome_measure>Number of Participants Experiencing Treatment-Emergent Treatment-Related AEs in Study Part A</outcome_measure>
      <outcome_measure>Number of Participants Experiencing Serious AEs (SAEs) in Study Part A</outcome_measure>
      <outcome_measure>Participants Discontinuing Treatment Due to AEs in Study Part A</outcome_measure>
      <outcome_measure>Change from Baseline in Participant Laboratory Values in Study Part A</outcome_measure>
      <outcome_measure>Change From Baseline in Participant Vital Signs in Study Part A</outcome_measure>
      <outcome_measure>Number of Participants Experiencing AEs in Study Part B</outcome_measure>
      <outcome_measure>Number of Participants Experiencing SAEs in Study Part B</outcome_measure>
      <outcome_measure>Change from Baseline in Participant Laboratory Values in Study Part B</outcome_measure>
      <outcome_measure>Change From Baseline in Participant Vital Signs in Study Part B</outcome_measure>
      <outcome_measure>Number of Participants Discontinuing From Study Treatment Due to AEs in Study Part B</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01590225</url>
  </study>
  <study rank="15">
    <nct_id>NCT00854802</nct_id>
    <title>A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Debio 025</intervention>
      <intervention type="Drug">Peg-IFNα2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Debio 025 placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Debiopharm International SA</lead_sponsor>
      <collaborator>Parexel</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>290</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>Debio 025-HCV-205</other_id>
      <other_id>2008-004605-34</other_id>
    </other_ids>
    <first_received>March 2, 2009</first_received>
    <start_date>January 2009</start_date>
    <completion_date>September 2010</completion_date>
    <last_updated>January 13, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants achieving sustained viral response (SVR) 72 weeks after treatment start</outcome_measure>
      <outcome_measure>Percentage of participants achieving a rapid viral response (RVR) after 4 weeks of treatment</outcome_measure>
      <outcome_measure>Percentage of participants achieving a complete early viral response (cEVR) after 12 weeks of treatment</outcome_measure>
      <outcome_measure>Percentage of participants achieving an early viral response (EVR) after 12 weeks of treatment</outcome_measure>
      <outcome_measure>Percentage of participants achieving an end-of-treatment response (ETR) at treatment end</outcome_measure>
      <outcome_measure>Percentage of participants achieving a sustained viral response 12 weeks after the end of treatment (SVR 12)</outcome_measure>
      <outcome_measure>Percentage of participants with sustained viral response 24 weeks after the end of treatment (SVR 24)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Poland</country>
      <country>Romania</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00854802</url>
  </study>
  <study rank="16">
    <nct_id>NCT01097395</nct_id>
    <title>Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Colorado, Denver</lead_sponsor>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>08-1198</other_id>
      <other_id>K23DK082621</other_id>
    </other_ids>
    <first_received>March 30, 2010</first_received>
    <start_date>February 2010</start_date>
    <completion_date>August 2015</completion_date>
    <last_updated>August 6, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>ribavirin AUC-12 variability</outcome_measure>
      <outcome_measure>safety - absolute hemoglobin declines</outcome_measure>
      <outcome_measure>efficacy - early and sustained virologic response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Colorado</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01097395</url>
  </study>
  <study rank="17">
    <nct_id>NCT01006031</nct_id>
    <title>Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Liver Cirrhosis</condition>
      <condition>Hepatitis C Virus</condition>
      <condition>HIV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa-2a and Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Sociedad Andaluza de Enfermedades Infecciosas</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HEPAVIR_IFN_2009</other_id>
    </other_ids>
    <first_received>October 29, 2009</first_received>
    <start_date>October 2009</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>December 28, 2011</last_updated>
    <last_verified>December 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained viral response (undetectable serum HCV-RNA)</outcome_measure>
      <outcome_measure>Relationships between the plasma interferon an ribavirin concentrations and efficacy</outcome_measure>
      <outcome_measure>safety and tolerability of the studied medications</outcome_measure>
      <outcome_measure>The evolution of liver fibrosis will be evaluated comparing the basal and end of treatment results of transient elastometry</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01006031</url>
  </study>
  <study rank="18">
    <nct_id>NCT00323804</nct_id>
    <title>Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Liver Fibrosis</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Ribavirin-Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
      <collaborator>Rennes University Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>372</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRS HC15 NRfi</other_id>
      <other_id>2005-002937-11</other_id>
    </other_ids>
    <first_received>May 9, 2006</first_received>
    <start_date>May 2006</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>September 3, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Rate of patients with at least a one point improvement in Metavir fibrosis score between the inclusion and the end-of-study liver biopsies.</outcome_measure>
      <outcome_measure>Distribution of the Metavir scoring on the end-of-study biopsy</outcome_measure>
      <outcome_measure>Distribution of the Chevallier fibrosis score</outcome_measure>
      <outcome_measure>Evolution of the area of fibrosis between the inclusion and the end-of -study biopsies</outcome_measure>
      <outcome_measure>Fibrosis serum markers</outcome_measure>
      <outcome_measure>Liver elasticity before and after treatment</outcome_measure>
      <outcome_measure>Safety of treatment and quality of life</outcome_measure>
      <outcome_measure>Frequency of occurrence of hepatic complications and/or liver transplantations</outcome_measure>
      <outcome_measure>Evolution of the hepatitis C viral load</outcome_measure>
      <outcome_measure>Rate of patients with loss of detectable hepatitis C virus RNA</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00323804</url>
  </study>
  <study rank="19">
    <nct_id>NCT01721525</nct_id>
    <title>Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Head and Neck Cancer</condition>
      <condition>Squamous Cell Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Afatinib, Ribavirin, and weekly carboplatin/paclitaxel</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Memorial Sloan Kettering Cancer Center</lead_sponsor>
      <collaborator>National Comprehensive Cancer Network</collaborator>
      <collaborator>Boehringer Ingelheim</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>22</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>12-150</other_id>
    </other_ids>
    <first_received>November 1, 2012</first_received>
    <start_date>November 2012</start_date>
    <completion_date>November 2016</completion_date>
    <last_updated>May 19, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>maximum tolerated dose (For Dose Escalation Portion of the study)</outcome_measure>
      <outcome_measure>expression of PTPN13 (For Expansion Cohort only)</outcome_measure>
      <outcome_measure>safety and tolerability (toxicity)</outcome_measure>
      <outcome_measure>objective response rate</outcome_measure>
      <outcome_measure>pharmacokinetics</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New Jersey</state>
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01721525</url>
  </study>
  <study rank="20">
    <nct_id>NCT00495131</nct_id>
    <title>Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for HCV Genotype 1-infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa-2a plus ribavirin</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a plus ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>National Science Council, Taiwan</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>308</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>200705080M</other_id>
    </other_ids>
    <first_received>June 29, 2007</first_received>
    <start_date>June 2006</start_date>
    <completion_date>July 2008</completion_date>
    <last_updated>September 7, 2009</last_updated>
    <last_verified>September 2009</last_verified>
    <firstreceived_results_date>December 21, 2008</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response</outcome_measure>
      <outcome_measure>Sustained Biochemical Response</outcome_measure>
      <outcome_measure>Treatment-related Withdrawal Rate</outcome_measure>
      <outcome_measure>Histologic Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00495131</url>
  </study>
  <study rank="21">
    <nct_id>NCT01428063</nct_id>
    <title>Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Asunaprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>228</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-026</other_id>
      <other_id>2011-000836-27</other_id>
    </other_ids>
    <first_received>September 1, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>February 6, 2015</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy based on the proportion of subjects with Sustained virologic response (SVR)12 [HCV Ribonucleic acid (RNA) &lt; LOQ at Follow-up week 12] for all subjects infected with genotype 1 who are prior non-responders to Peginterferon Alfa-2a/Ribavirin</outcome_measure>
      <outcome_measure>Efficacy as determined by the proportion of subjects with SVR12 in genotype 2, 3 &amp; 4 prior non-responders to pegIFNα-2a/RBV and treatment naive genotype 1b</outcome_measure>
      <outcome_measure>Safety measured by frequency of Serious Adverse Event(s) (SAE)s and discontinuations due to Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve HCV RNA &lt; Limit of quantitation (LOQ) (detectable or undetectable) for each HCV genotype and treatment regimen</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve HCV RNA undetectable for each HCV genotype and treatment regimen</outcome_measure>
      <outcome_measure>Drug-resistant variants associated with virologic failure for each HCV genotype and treatment regimen</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>Denmark</country>
      <country>France</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>Ireland</country>
      <country>Italy</country>
      <country>Korea, Republic of</country>
      <country>Mexico</country>
      <country>New Zealand</country>
      <country>Poland</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>Taiwan</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01428063</url>
  </study>
  <study rank="22">
    <nct_id>NCT01464827</nct_id>
    <title>ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Hepatitis C (HCV)</condition>
      <condition>Hepatitis C Genotype 1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450</intervention>
      <intervention type="Drug">ABT-333</intervention>
      <intervention type="Drug">ABT-267</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Ritonavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie (prior sponsor, Abbott)</lead_sponsor>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>580</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M11-652</other_id>
      <other_id>2010-022455-31</other_id>
    </other_ids>
    <first_received>September 28, 2011</first_received>
    <start_date>October 2011</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>April 2, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>December 23, 2014</firstreceived_results_date>
    <primary_completion_date>March 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose for 8 Weeks Versus 12 Weeks of Treatment With 3 DAAs and Ribavirin</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose Following Treatment of Different Durations With 3 Direct-acting Antiviral Agents (DAAs) and Ribavirin</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose Following Treatment for 12 Weeks With 2 DAAs and Ribavirin Versus 3 DAAs and Ribavirin</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose Following Treatment for 12 Weeks With 3 DAAs With Versus Without Ribavirin</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose in Treatment-naïve Versus Null-responders</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>France</country>
      <country>Germany</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01464827</url>
  </study>
  <study rank="23">
    <nct_id>NCT00545233</nct_id>
    <title>A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
      <intervention type="Drug">Pioglitazone</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>155</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML21301</other_id>
    </other_ids>
    <first_received>October 16, 2007</first_received>
    <start_date>January 2008</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>April 10, 2012</last_updated>
    <last_verified>April 2012</last_verified>
    <firstreceived_results_date>February 8, 2012</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Initiation of Pegasys Plus Copegus in log10 Hepatitis C Virus Ribonucleic Acid (HCV RNA) Viral Load to Week 12 of Anti-HCV Therapy</outcome_measure>
      <outcome_measure>Change From Initiation of Pegasys Plus Copegus in log10 HCV RNA Viral Load to Week 24 and Week 48 of Anti-HCV Therapy</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Virologic Response</outcome_measure>
      <outcome_measure>Percentage of Participants With a ≥ 2 log10 Decrease in HCV RNA From Initiation of Pegasys Plus Copegus to Weeks 4, 12, 24, 48, 60, 72</outcome_measure>
      <outcome_measure>Percentage of Participants With a Virological Relapse at Week 72 (24 Weeks After the End of Anti-HCV Treatment)</outcome_measure>
      <outcome_measure>Percentage of Participants With a Confirmed Virological Breakthrough up to 48 Weeks</outcome_measure>
      <outcome_measure>Percentage of Nonresponders During the 48 Week Anti-HCV Treatment Period</outcome_measure>
      <outcome_measure>Change in Log10 HCV RNA Viral Load at Assessments From Randomization to 16 Weeks of Pioglitazone Pretreatment Run-In Period for the Pioglitazone Arm Only</outcome_measure>
      <outcome_measure>Change From Baseline in Fasting Plasma Glucose Levels at Each Time Point Assessed</outcome_measure>
      <outcome_measure>Change From Baseline in Fasting Insulin Levels at Each Time Point Assessed.</outcome_measure>
      <outcome_measure>Change From Baseline in Fasting Hemoglobin A1C (HbA1c) Concentrations at Each Time Point Assessed</outcome_measure>
      <outcome_measure>Change From Baseline in Homeostasis Model Assessment (HOMA) Scores at Each Time Point Assessed</outcome_measure>
      <outcome_measure>Change From Baseline in Serum Triglyceride Concentrations at Each Time-point Assessed</outcome_measure>
      <outcome_measure>Change From Baseline in Total Cholesterol Levels at Each Time-point Assessed</outcome_measure>
      <outcome_measure>Change From Baseline in Low-density Lipoprotein (LDL-cholesterol) Levels at Each Time-point Assessed</outcome_measure>
      <outcome_measure>Change From Baseline in High-density Lipoprotein (HDL-cholesterol) Levels at Each Time-point Assessed</outcome_measure>
      <outcome_measure>Change From Baseline in Tumor Necrosis Factor Alpha (TNF-α) at Each Time Point Assessed</outcome_measure>
      <outcome_measure>Change From Baseline in Transforming Growth Factor Beta (TGF-β) Levels at Each Time Point Assessed</outcome_measure>
      <outcome_measure>Change From Baseline in Adiponectin Levels at Each Time Point Assessed</outcome_measure>
      <outcome_measure>Change From Baseline in Leptin Levels at Each Time Point Assessed</outcome_measure>
      <outcome_measure>Change From Baseline in Free Fatty Acid Levels at Each Time Point Assessed</outcome_measure>
      <outcome_measure>Percentage of Participants With Beck Depression Inventory Fast Screen (BDI-FS) Score ≥ 4 at Each Time Point Assessed</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Iowa</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maine</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New Hampshire</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00545233</url>
  </study>
  <study rank="24">
    <nct_id>NCT00725751</nct_id>
    <title>Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated interferon alfa-2b (PegIFN-2b)</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>353</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05255</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>September 2007</start_date>
    <completion_date>March 2011</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>March 23, 2012</firstreceived_results_date>
    <primary_completion_date>March 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Who Completed Treatment With PegIFN-2b/Ribavirin</outcome_measure>
      <outcome_measure>Number of Participants Who Achieved Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Number of Participants Who Received Antiviral Treatment Who Were Also on Substitution Therapy</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00725751</url>
  </study>
  <study rank="25">
    <nct_id>NCT02340962</nct_id>
    <title>A Study to Evaluate the Efficacy and Safety of TG-2349 in Combination With Peg-interferon and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1b Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TG-2349</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Interferon Alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>TaiGen Biotechnology Co., Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TG-2349-03</other_id>
    </other_ids>
    <first_received>January 8, 2015</first_received>
    <start_date>May 2015</start_date>
    <completion_date>June 2017</completion_date>
    <last_updated>November 2, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Antiviral efficacy of TG-2349 in combination with Peg-interferon (IFN) and Ribavirin (RBV) in treatment naïve East Asian subjects with HCV GT1b infection</outcome_measure>
      <outcome_measure>Proportion of subjects achieving sustained viral response at 4, 8, and 24 weeks after the end of treatment (SVR4, SVR8, and SVR24)</outcome_measure>
      <outcome_measure>Proportion of subjects achieving HCV RNA &lt; lower limit of quantification, target detected or target not detected (&lt; LLOQ, TD or TND)</outcome_measure>
      <outcome_measure>Proportion of subjects achieving HCV RNA &lt; LLOQ, TND</outcome_measure>
      <outcome_measure>Mean absolute values and change from baseline in HCV RNA (log10 IU/mL)</outcome_measure>
      <outcome_measure>Proportion of subjects experiencing virologic failure during treatment and viral relapse after the end of treatment.</outcome_measure>
      <outcome_measure>Number of subjects with virologic failure (VF)</outcome_measure>
      <outcome_measure>Proportion of subjects with abnormal alanine aminotransferase (ALT) levels at baseline who achieved normal limit of ALT at final treatment visit.</outcome_measure>
      <outcome_measure>Area under the plasma concentration time curve from 0 to the last measurable concentration (AUC0-t) of TG-2349 and Ribavirin</outcome_measure>
      <outcome_measure>Area under the plasma concentration time curve from 0 to infinity (AUC0-inf) of TG-2349 and Ribavirin</outcome_measure>
      <outcome_measure>Maximum plasma concentration (Cmax) of TG-2349 and Ribavirin</outcome_measure>
      <outcome_measure>Time at which maximum plasma concentration is observed (Tmax) of TG-2349 and Ribavirin</outcome_measure>
      <outcome_measure>Terminal elimination half-life (t1/2) of TG-2349 and Ribavirin</outcome_measure>
      <outcome_measure>Apparent terminal elimination rate constant (λz) of TG-2349 and Ribavirin</outcome_measure>
      <outcome_measure>Apparent total body clearance (CL/F) of TG-2349 and Ribavirin</outcome_measure>
      <outcome_measure>Apparent volume of distribution (V/F) of TG-2349 and Ribavirin</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02340962</url>
  </study>
  <study rank="26">
    <nct_id>NCT02593162</nct_id>
    <title>A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Viral Infection</condition>
      <condition>Chronic Hepatitis C</condition>
      <condition>Hepatitis C (HCV)</condition>
      <condition>Hepatitis C Genotype 4</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Faldaprevir</intervention>
      <intervention type="Drug">TD-6450</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Trek Therapeutics, PBC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>TRK-450-0201</other_id>
    </other_ids>
    <first_received>October 29, 2015</first_received>
    <start_date>October 2015</start_date>
    <completion_date>July 2016</completion_date>
    <last_updated>October 29, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of subjects achieving 12-week sustained virologic response following treatment with 2 direct acting anti-virals and ribavirin in Genotype 4 Hepatitis C infected adults</outcome_measure>
      <outcome_measure>Percentage of subjects with virologic response at Week 12 (HCV RNA less than lower limit of quantitation at end of therapy with Faldaprevir plus TD-6450 plus ribavirin)</outcome_measure>
      <outcome_measure>Percentage of subjects with virologic response 2, 4 and 8 weeks after treatment completion (HCV RNA less than lower limit of quantitation at 2, 4 and 8 weeks after end of therapy with Faldaprevir plus TD-6450 plus ribavirin)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02593162</url>
  </study>
  <study rank="27">
    <nct_id>NCT01056523</nct_id>
    <title>Use of Ribavirin and Low Dose Ara-C to Treat Acute Myeloid Leukemia</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Myeloid Leukemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Cytarabine arabinoside</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Jewish General Hospital</lead_sponsor>
      <collaborator>The Leukemia and Lymphoma Society</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Ribavirin-002</other_id>
    </other_ids>
    <first_received>January 25, 2010</first_received>
    <start_date>January 2010</start_date>
    <completion_date>January 2015</completion_date>
    <last_updated>April 1, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Recommended phase II dose of ribavirin when given in combination with low-dose ara-C</outcome_measure>
      <outcome_measure>Maximum tolerated dose</outcome_measure>
      <outcome_measure>Overall response rate (complete remission (CR), complete remission with incomplete blood count recovery (CRi), partial remission (PR) or blast response (BR))</outcome_measure>
      <outcome_measure>Time to response</outcome_measure>
      <outcome_measure>Duration of response</outcome_measure>
      <outcome_measure>Time to relapse</outcome_measure>
      <outcome_measure>One year and overall survival</outcome_measure>
      <outcome_measure>Hematological Improvement</outcome_measure>
      <outcome_measure>Safety and tolerability of ribavirin and low dose ara-C</outcome_measure>
      <outcome_measure>Correlation between expression and activity of eIF4E and response</outcome_measure>
      <outcome_measure>Effect of ribavirin and low dose ara-C on the activity of eIF4E related pathways.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01056523</url>
  </study>
  <study rank="28">
    <nct_id>NCT01731301</nct_id>
    <title>A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>End Stage Renal Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon</intervention>
      <intervention type="Drug">Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Liver Institute of Virginia</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
      <collaborator>Chronic Liver Disease Foundation</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>LIV01</other_id>
    </other_ids>
    <first_received>November 16, 2012</first_received>
    <start_date>January 2013</start_date>
    <completion_date>January 2015</completion_date>
    <last_updated>November 20, 2012</last_updated>
    <last_verified>November 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of patients who achieve eRVR at treatment week 28</outcome_measure>
      <outcome_measure>Tolerability of treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01731301</url>
  </study>
  <study rank="29">
    <nct_id>NCT01332955</nct_id>
    <title>Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>HIV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Biological">pegIFN alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
      <collaborator>Janssen-Cilag Ltd.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2010-023287-41</other_id>
      <other_id>ANRS HC26 TelapreVIH</other_id>
    </other_ids>
    <first_received>March 28, 2011</first_received>
    <start_date>April 2011</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>January 22, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>TelapreVIH</acronym>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Estimation of SVR following a 12 wks treatment by telaprevir combined with a 48 or 72 wks peginterferon-ribavirin treatment, based upon the rapid virological response, and comparison to 20% (which would correspond to a significant therapeutic benefit)</outcome_measure>
      <outcome_measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</outcome_measure>
      <outcome_measure>Estimation of the Sustained Virological Response defined as undetectable HCV-RNA at Week 12 after the end of HCV treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01332955</url>
  </study>
  <study rank="30">
    <nct_id>NCT00723892</nct_id>
    <title>Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepacivirus</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b (PegIntron)</intervention>
      <intervention type="Drug">Rebetol (Ribavirin)</intervention>
      <intervention type="Behavioral">Psychotherapy support program</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>614</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04252</other_id>
      <other_id>MK-4031-245</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>July 2005</start_date>
    <completion_date>May 2009</completion_date>
    <last_updated>October 29, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>August 25, 2010</firstreceived_results_date>
    <primary_completion_date>May 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Who Complete Treatment With PegIntron/Rebetol Therapy for Hepatitis C When Administered With a Patient Psychotherapy Support Program as Compared to a Group Without a Psychotherapy Support Program.</outcome_measure>
      <outcome_measure>the Average Length of Treatment for Participants on Treatment for Hepatitis C With PegIntron Pen/Rebetol</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00723892</url>
  </study>
  <study rank="31">
    <nct_id>NCT01309490</nct_id>
    <title>Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Malignant Solid Tumour</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Jewish General Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>37</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Ribavirin-004</other_id>
    </other_ids>
    <first_received>March 4, 2011</first_received>
    <start_date>March 2011</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>March 4, 2011</last_updated>
    <last_verified>March 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Phase I: Maximum Tolerated Dose (MTD) and/or recommended phase II dose (RP2D)</outcome_measure>
      <outcome_measure>Phase II: Determine the overall response rate to therapy with ribavirin</outcome_measure>
      <outcome_measure>Incidence and nature of DLTs</outcome_measure>
      <outcome_measure>Incidence, nature and severity of adverse events</outcome_measure>
      <outcome_measure>Time to and duration of response, defined as the first occurence of documented objective response until the time of recurrence or death from any cause</outcome_measure>
      <outcome_measure>Clinical benefit rate, defined as the overall response rate and stable disease for greater than or equal to 24 weeks</outcome_measure>
      <outcome_measure>Pharmacokinetic parameters of ribavirin determine by total exposure, maximum plasma concentration, etc.</outcome_measure>
      <outcome_measure>Correlation between eIF4E activity and response</outcome_measure>
      <outcome_measure>To determine the effect of ribavirin on the activity of eIF4E related pathways through correlative studies</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01309490</url>
  </study>
  <study rank="32">
    <nct_id>NCT02308241</nct_id>
    <title>Ribavirin for Patients With Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Human Papillomavirus (HPV)-Related Malignancies</condition>
      <condition>Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Memorial Sloan Kettering Cancer Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>14-211</other_id>
    </other_ids>
    <first_received>December 2, 2014</first_received>
    <start_date>December 2014</start_date>
    <last_updated>July 17, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Radiographic responses, determined by RECIST 1.1 criteria</outcome_measure>
      <outcome_measure>number and grade of toxicities</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New Jersey</state>
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02308241</url>
  </study>
  <study rank="33">
    <nct_id>NCT01479868</nct_id>
    <title>A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Virus Genotype-1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Pegylated interferon alpha-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>109</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR018334</other_id>
      <other_id>TMC435-TiDP16-C212</other_id>
    </other_ids>
    <first_received>October 18, 2011</first_received>
    <start_date>October 2011</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>October 28, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>August 26, 2014</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Week 12 (SVR 12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Week 24 (SVR 24)</outcome_measure>
      <outcome_measure>Percentage of Participants With Hepatitis C Virus Ribonucleic Acid (HCV-RNA) Less Than (&lt;) 25 International Units (IU/mL) Undetectable or Detectable/Undetectable</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Failure</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Percentage of Participants With Normalized Alanine Aminotransferase Levels</outcome_measure>
      <outcome_measure>Percentage of Human Immunodeficiency Virus (HIV) Participants With Virologic Failure</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Log10 Plasma Human Immunodeficiency Virus (HIV) Viral Load</outcome_measure>
      <outcome_measure>Mean Change From Baseline in CD4+ Cell Count</outcome_measure>
      <outcome_measure>Change From Baseline in CD4+ Cell Count in Percentage</outcome_measure>
      <outcome_measure>Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>France</country>
      <country>Germany</country>
      <country>Portugal</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01479868</url>
  </study>
  <study rank="34">
    <nct_id>NCT00882908</nct_id>
    <title>A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Ribavirin (R)</intervention>
      <intervention type="Drug">PegIFNα-2a (P)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>386</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR015799</other_id>
      <other_id>TMC435-TiDP16-C205</other_id>
      <other_id>2008-007147-13</other_id>
    </other_ids>
    <first_received>April 16, 2009</first_received>
    <start_date>June 2009</start_date>
    <completion_date>April 2011</completion_date>
    <last_updated>May 19, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>December 18, 2013</firstreceived_results_date>
    <acronym>PILLAR</acronym>
    <primary_completion_date>April 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels of Less Than 25 IU/mL Undetectable During Treatment and Follow-up</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels of Less Than 25 IU/mL Detectable or Undetectable During Treatment and Follow-up</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels of Greater Than or Equal to 2 log10 Drop During Treatment</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving an Early Virologic Response (EVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>Number of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>The Number of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normalized ALT Levels at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Plasma Concentrations of TMC435</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24h) for TMC435</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Denmark</country>
      <country>France</country>
      <country>Germany</country>
      <country>New Zealand</country>
      <country>Norway</country>
      <country>Poland</country>
      <country>Russian Federation</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Louisiana</state>
      <state>Minnesota</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Tennessee</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00882908</url>
  </study>
  <study rank="35">
    <nct_id>NCT00484328</nct_id>
    <title>Ribavirin, Its Dosing Regime</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Maastricht University Medical Center</lead_sponsor>
      <collaborator>Roche Pharma AG</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>MEC-07-3-007</other_id>
    </other_ids>
    <first_received>June 7, 2007</first_received>
    <start_date>July 2007</start_date>
    <completion_date>February 2012</completion_date>
    <last_updated>July 19, 2011</last_updated>
    <last_verified>July 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>Ribados</acronym>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The pharmacokinetics of ribavirin at different dosage regimes, measured by the area under the curve of the concentration-time graph</outcome_measure>
      <outcome_measure>The tolerability of the treatment at different dosage regimes of ribavirin</outcome_measure>
      <outcome_measure>The antioxidant capacity in plasma and erythrocytes at different dosing regimes</outcome_measure>
      <outcome_measure>The effect of ribavirin on the hemolysis</outcome_measure>
      <outcome_measure>The pharmacokinetics of ribavirin in erythrocytes in the different dosing regimes</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00484328</url>
  </study>
  <study rank="36">
    <nct_id>NCT02557646</nct_id>
    <title>An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>697</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML22453</other_id>
    </other_ids>
    <first_received>September 22, 2015</first_received>
    <start_date>May 2009</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>September 22, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Virological Response (SVR) According to Cumulative Dose of Ribavirin</outcome_measure>
      <outcome_measure>Percentage of Participants with Virologic Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Response According to Starting Dose of Ribavirin</outcome_measure>
      <outcome_measure>Percentage of Participants With SVR According to Starting Dose of Ribavirin</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Response According to Body Weight-normalized Dose of Ribavirin</outcome_measure>
      <outcome_measure>Percentage of Participants With SVR According to Body Weight-normalized Dose of Ribavirin</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Response According to Dose Reduction of Ribavirin</outcome_measure>
      <outcome_measure>Percentage of Participants With SVR According to Dose Reduction of Ribavirin</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Response According to interleukin-28B (IL-28B) Polymorphism</outcome_measure>
      <outcome_measure>Percentage of Participants With SVR According to IL-28B Polymorphism</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse or Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse or Breakthrough According to Cumulative Dose of Ribavirin</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse or Breakthrough According to Starting Dose of Ribavirin</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse or Breakthrough According to Body Weight-normalized Dose of Ribavirin</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse or Breakthrough According to Dose Reduction of Ribavirin</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Hungary</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02557646</url>
  </study>
  <study rank="37">
    <nct_id>NCT01433887</nct_id>
    <title>Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic Hepatitis C Genotypes 1 Versus 2/3 Versus 6</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">48-weeks course</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Third Affiliated Hospital, Sun Yat-Sen University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>535</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TAH5010G6HCV</other_id>
    </other_ids>
    <first_received>September 11, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>November 14, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (SVR)</outcome_measure>
      <outcome_measure>Change in health related quality as measured by short form 36 (SF-36) from baseline to 24 weeks after the end of treatment</outcome_measure>
      <outcome_measure>Sick leave in patients treated for 24 or 48 weeks treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01433887</url>
  </study>
  <study rank="38">
    <nct_id>NCT00723632</nct_id>
    <title>Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">peginterferon alfa-2b</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>901</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04588</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>September 2005</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>November 11, 2011</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Average Cost Per Participant With Sustained Virologic Response (SVR) Stratified by Weight Category</outcome_measure>
      <outcome_measure>Average Cost Per Participant With SVR Stratified by Ribavirin Dosage</outcome_measure>
      <outcome_measure>Average Cost Per Participant With SVR Stratified by Prior Treatment Status</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00723632</url>
  </study>
  <study rank="39">
    <nct_id>NCT00840489</nct_id>
    <title>Efficacy of Long-term Ribavirin in Non-responders With Chronic Hepatitis C and Advanced Fibrosis</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Colchicine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hospital Universitario Ramon y Cajal</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>RIBACIR-1</other_id>
    </other_ids>
    <first_received>February 9, 2009</first_received>
    <start_date>January 2009</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>January 30, 2013</last_updated>
    <last_verified>January 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>RIBACIR</acronym>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Hepatic disease progression defined by a difference of &gt;2 mmHg in the hepatic venous gradient between the basal values and the end of treatment values in both groups</outcome_measure>
      <outcome_measure>Decrease in the necroinflammatory activity and in the progression of fibrosis. Normalization of ALT levels.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00840489</url>
  </study>
  <study rank="40">
    <nct_id>NCT02261662</nct_id>
    <title>Off-Label Use of Ribavirin in Management of Mucocutaneous Extrahepatic Manifestations of HCV Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Lichen Planus</condition>
      <condition>Vasculitis</condition>
      <condition>Autoimmune Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Betamethasone</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tanta University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Ribavirin HCV mucocutaneous</other_id>
    </other_ids>
    <first_received>September 26, 2014</first_received>
    <start_date>June 2014</start_date>
    <completion_date>November 2014</completion_date>
    <last_updated>October 6, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants with improved skin manifestations of HCV infection after taking Ribavirin compared with topical steroids.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02261662</url>
  </study>
  <study rank="41">
    <nct_id>NCT00707772</nct_id>
    <title>Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Hemophilia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)</intervention>
      <intervention type="Drug">PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Baqiyatallah Medical Sciences University</lead_sponsor>
      <collaborator>Baqiyatallah Research Center for Gastroenterology and Liver Diseases</collaborator>
      <collaborator>Tehran Hepatitis Center</collaborator>
      <collaborator>Guilan Research Center for Gastroenterology and Liver Diseases</collaborator>
      <collaborator>Tabriz Research Center for Gastroenterology and Liver Diseases</collaborator>
      <collaborator>Shahid Beheshti Medical University</collaborator>
      <collaborator>Research Center for Gastroenterology and Liver Disease, Iran University of Medical Sciences, Firoozgar Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>BRCGL-07-03</other_id>
    </other_ids>
    <first_received>June 26, 2008</first_received>
    <start_date>March 2007</start_date>
    <completion_date>September 2009</completion_date>
    <last_updated>September 16, 2009</last_updated>
    <last_verified>September 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Early Virologic Response</outcome_measure>
      <outcome_measure>End of Treatment Response</outcome_measure>
      <outcome_measure>Sustained Virologic Response</outcome_measure>
      <outcome_measure>Rapid Virologic Response</outcome_measure>
      <outcome_measure>Tolerability of drugs for whole therapy period</outcome_measure>
      <outcome_measure>Biochemical response (ALT)</outcome_measure>
      <outcome_measure>Laboratory Parameters</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Iran, Islamic Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00707772</url>
  </study>
  <study rank="42">
    <nct_id>NCT01309932</nct_id>
    <title>Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated Interferon Lambda (pegIFNλ)</intervention>
      <intervention type="Drug">BMS-790052 (NS5A Inhibitor)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">BMS-650032 (NS3 Protease Inhibitor)</intervention>
      <intervention type="Biological">Pegylated Interferon Alfa-2a (pegIFNα-2a)</intervention>
      <intervention type="Biological">Pegylated Interferon Lambda (pegIFNλ)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Biological">Pegylated Interferon Lambda (pegIFNλ)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">BMS-790052 (NS5A Inhibitor)</intervention>
      <intervention type="Drug">BMS-650032 (NS3 Protease Inhibitor)</intervention>
      <intervention type="Drug">Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor)</intervention>
      <intervention type="Drug">Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor)</intervention>
      <intervention type="Drug">Placebo for Ribavirin (RBV)</intervention>
      <intervention type="Drug">Placebo for Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>165</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI452-008</other_id>
      <other_id>2010-022568-11</other_id>
    </other_ids>
    <first_received>March 4, 2011</first_received>
    <start_date>March 2011</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>D-LITE</acronym>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and tolerability (as measured by the frequency of serious adverse events (SAEs), dose reductions and discontinuations due to adverse events (AEs)</outcome_measure>
      <outcome_measure>Antiviral activity as determined by the proportion of Hepatitis C virus (HCV) genotype 1 subjects with 24-week sustained virologic response (SVR24)</outcome_measure>
      <outcome_measure>Proportion of HCV genotype 1 subjects with Protocol definition of virologic response (PDR) for Part A and Part B</outcome_measure>
      <outcome_measure>Proportion of subjects with either a 2-log or greater decrease in Hepatitis C virus (HCV) Ribonucleic acid (RNA) levels from baseline or undetectable levels of HCV RNA</outcome_measure>
      <outcome_measure>Proportion of subjects with viral breakthrough, defined as confirmed &gt; 1 log10 increase in HCV RNA over nadir or confirmed HCV RNA ≥ Lower limit of quantitation (LLOQ) after confirmed undetectable HCV RNA while on treatment</outcome_measure>
      <outcome_measure>Proportion of subjects with undetectable HCV RNA at the end of treatment that develop detectable levels of HCV RNA in the post-treatment follow-up period</outcome_measure>
      <outcome_measure>Serum HCV Ribonucleic acid (RNA) levels over time</outcome_measure>
      <outcome_measure>Proportion of subjects with undetectable HCV RNA over time</outcome_measure>
      <outcome_measure>Time to viral clearance, defined as an absence of detectable HCV RNA</outcome_measure>
      <outcome_measure>Serum levels of pegIFNλ and pegIFNα-2a and plasma levels of BMS-790052 and BMS-650032: In PK sub-study group Maximum observed serum/plasma concentration (Cmax)</outcome_measure>
      <outcome_measure>Serum levels of pegIFNλ and pegIFNα-2a and plasma levels of BMS-790052 and BMS-650032: In PK sub-study group Time to maximum concentration (Tmax)</outcome_measure>
      <outcome_measure>Serum levels of pegIFNλ and pegIFNα-2a and plasma levels of BMS-790052 and BMS-650032: In PK sub-study group Minimal observed serum/plasma concentration (Cmin)</outcome_measure>
      <outcome_measure>Serum levels of pegIFNλ and pegIFNα-2a and plasma levels of BMS-790052 and BMS-650032: In PK sub-study group Area under the serum/plasma concentration-time curve during one dose interval AUC(TAU)</outcome_measure>
      <outcome_measure>Serum levels of pegIFNλ and pegIFNα-2a and plasma levels of BMS-790052 and BMS-650032: In all subjects, trough concentrations will be assessed (Ctrough)</outcome_measure>
      <outcome_measure>Proportion of subjects with 12-week sustained virologic response (SVR12), defined as undetectable HCV RNA</outcome_measure>
      <outcome_measure>Proportion of subjects with 4-week sustained virologic response (SVR4), defined as undetectable HCV RNA</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Japan</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01309932</url>
  </study>
  <study rank="43">
    <nct_id>NCT00982553</nct_id>
    <title>The Raltegravir and Ribavirin Pharmacokinetics (PK) Study</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Raltegravir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Imperial College London</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>14</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2009-010005-36</other_id>
    </other_ids>
    <first_received>September 22, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>December 2009</completion_date>
    <last_updated>November 4, 2011</last_updated>
    <last_verified>November 2011</last_verified>
    <firstreceived_results_date>February 28, 2011</firstreceived_results_date>
    <primary_completion_date>November 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Ribavirin Alone Maximum Plasma Concentration</outcome_measure>
      <outcome_measure>Raltegravir Alone Maximum Plasma Concentration</outcome_measure>
      <outcome_measure>Ribavirin Maximum Plasma Concentration When Co-administered</outcome_measure>
      <outcome_measure>Raltegravir Maximum Plasma Concentrations When Co-administered</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00982553</url>
  </study>
  <study rank="44">
    <nct_id>NCT00028093</nct_id>
    <title>Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a with Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>020065</other_id>
      <other_id>02-DK-0065</other_id>
    </other_ids>
    <first_received>December 11, 2001</first_received>
    <start_date>December 2001</start_date>
    <completion_date>June 2010</completion_date>
    <last_updated>September 4, 2013</last_updated>
    <last_verified>May 2013</last_verified>
    <firstreceived_results_date>May 26, 2011</firstreceived_results_date>
    <primary_completion_date>June 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Hepatitis C Virus RNA Levels During Phase I</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00028093</url>
  </study>
  <study rank="45">
    <nct_id>NCT00718172</nct_id>
    <title>Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Liver Biopsy</intervention>
      <intervention type="Drug">Peginterferon &amp; amp; Ribavirin for Hepatitis C</intervention>
      <intervention type="Drug">Pre-treatment Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>81</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>080182</other_id>
      <other_id>08-DK-0182</other_id>
    </other_ids>
    <first_received>July 16, 2008</first_received>
    <start_date>July 2008</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>August 20, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Improved viral kinetics with ribavirin pretreatment.</outcome_measure>
      <outcome_measure>Changes in gene expression during peginterferon and/or ribavirin thereapy, effect of treatment on NK cell function.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00718172</url>
  </study>
  <study rank="46">
    <nct_id>NCT01195181</nct_id>
    <title>Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
      <condition>Chronic Liver Disease</condition>
      <condition>Viral Hepatitis</condition>
      <condition>Therapeutic Uses</condition>
      <condition>Antiviral Agents</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon plus ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Azienda Ospedaliera di Padova</lead_sponsor>
      <collaborator>Regione Veneto</collaborator>
      <collaborator>University of Padua</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>506</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HEPCOVE protocol</other_id>
      <other_id>DRG N.2920/2002</other_id>
    </other_ids>
    <first_received>August 31, 2010</first_received>
    <start_date>September 2005</start_date>
    <completion_date>August 2010</completion_date>
    <last_updated>September 3, 2010</last_updated>
    <last_verified>September 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evaluation of real dose drugs intake in relation to sustained virological response (SVR).</outcome_measure>
      <outcome_measure>Description of the profile of the virus decay during antiviral therapy in relation to virological response.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01195181</url>
  </study>
  <study rank="47">
    <nct_id>NCT00248339</nct_id>
    <title>Trial of Peg-Interferon Plus Epoetin-Alfa for Treatment of Chronic Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon-alpha-2b (PEG-Intron)</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Epoetin-alpha (Procrit)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Virginia Commonwealth University</lead_sponsor>
      <collaborator>Ortho Biotech, Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1988 WIRB</other_id>
    </other_ids>
    <first_received>November 2, 2005</first_received>
    <start_date>May 2002</start_date>
    <completion_date>July 2005</completion_date>
    <last_updated>December 14, 2007</last_updated>
    <last_verified>November 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>The mean dose of ribavirin utilized in each of the 3 treatment arms will be compared.</outcome_measure>
      <outcome_measure>Number of patients in each group who required a dose reduction of ribavirin</outcome_measure>
      <outcome_measure>Rate of virologic response and sustained virologic response observed in each group</outcome_measure>
      <outcome_measure>Rate of decline in HCV RNA titer in each group</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00248339</url>
  </study>
  <study rank="48">
    <nct_id>NCT00532701</nct_id>
    <title>Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-IFN + WB RBV for 16 weeks</intervention>
      <intervention type="Drug">Peg-IFN + LD RBV for 16 weeks</intervention>
      <intervention type="Drug">Peg-IFN + WB RBV for 24 weeks</intervention>
      <intervention type="Drug">Peg-IFN + WB RBV for 48 weeks</intervention>
      <intervention type="Drug">Peg-IFN + LD RBV for 24 weeks</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>National Science Council, Taiwan</collaborator>
      <collaborator>Department of Health, Executive Yuan, R.O.C. (Taiwan)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>880</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>200709014M</other_id>
    </other_ids>
    <first_received>September 18, 2007</first_received>
    <start_date>November 2007</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>June 3, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (SVR)</outcome_measure>
      <outcome_measure>Histologic response (HR)</outcome_measure>
      <outcome_measure>Biochemical response (BR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00532701</url>
  </study>
  <study rank="49">
    <nct_id>NCT01010646</nct_id>
    <title>Study Comparing the Tolerability and Viral Reduction of the Combination of IFN a-2b XL + Ribavirin Versus Peg IFN a-2b + Ribavirin in Patients With Chronic Hepatitis C, Genotype 1 or 4</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">IFN alfa-2b XL 27 MUI + Ribavirin</intervention>
      <intervention type="Drug">IFN alfa-2b XL 36 MUI + Ribavirin</intervention>
      <intervention type="Drug">IFN peg alfa-2b 1.5 µg/kg + Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
      <collaborator>Flamel Technologies</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>84</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2009-015121-37</other_id>
      <other_id>ANRS HC 23 COAT-IFN</other_id>
    </other_ids>
    <first_received>November 9, 2009</first_received>
    <start_date>March 2010</start_date>
    <completion_date>November 2013</completion_date>
    <last_updated>September 19, 2013</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>COAT IFN</acronym>
    <primary_completion_date>September 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Viral load decrease at Week 4 and Week 12 of treatment with IFN alfa-2b XL 27 MIU, IFN alfa-2b XL 36 MIU and the marketed reference product (PEG IFN alfa-2b 1.5μg/kg) in combination with ribavirin</outcome_measure>
      <outcome_measure>Percentage of patients with early virologic response (EVR) (reduction of at least 2 log viral load) at the end of week 12</outcome_measure>
      <outcome_measure>Percentage of patients with complete early virologic response (EVR) (viral load &lt;15 IU) at the end of the week 12</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01010646</url>
  </study>
  <study rank="50">
    <nct_id>NCT01641666</nct_id>
    <title>Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Peginterferon Alfa-2b 1.5 mcg/kg/week</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P08599</other_id>
    </other_ids>
    <first_received>July 11, 2012</first_received>
    <start_date>May 2014</start_date>
    <completion_date>September 2016</completion_date>
    <last_updated>September 7, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing a Serious Adverse Event (SAE) During the Study Therapy Period</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01641666</url>
  </study>
  <study rank="51">
    <nct_id>NCT01226771</nct_id>
    <title>Ribavirin Loading Dose or Priming and Concentration Targeting for HCV Genotype 1</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin &quot;loading&quot; dose given</intervention>
      <intervention type="Drug">&quot;Priming&quot; dose of ribavirin given</intervention>
      <intervention type="Drug">Group C (&quot;Standard-of-Care&quot;)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Göteborg University</lead_sponsor>
      <collaborator>The Swedish Research Council</collaborator>
      <collaborator>Roche Pharma AG</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>105</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Eu-nr 2010-018332-41</other_id>
      <other_id>2010-018332-41</other_id>
    </other_ids>
    <first_received>October 21, 2010</first_received>
    <start_date>September 2010</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>March 23, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>RibaC</acronym>
    <primary_completion_date>September 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The early virological response as measured by decline in HCV-RNA during the first 12 weeks of peginterferon alpha-2a and ribavirin therapy in the three study arms.</outcome_measure>
      <outcome_measure>VRVR, RVR, cEVR, pEVR, SVR, and Relapse rates</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Sweden</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01226771</url>
  </study>
  <study rank="52">
    <nct_id>NCT01098097</nct_id>
    <title>Post Marketing Observational Study of Retreatment of Chronic Hepatitis C With Peginterferon Alpha and Ribavirin (Study P06011)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alpha</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>963</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P06011</other_id>
    </other_ids>
    <first_received>April 1, 2010</first_received>
    <start_date>June 2009</start_date>
    <completion_date>October 2011</completion_date>
    <last_updated>November 14, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>October 17, 2012</firstreceived_results_date>
    <acronym>POMOSCH</acronym>
    <primary_completion_date>October 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Incidence of Serious Adverse Events (SAEs) and/or Clinically Significant Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Incidence of Thrombocytopenia</outcome_measure>
      <outcome_measure>Incidence of Treatment Discontinuations Due to Adverse Events</outcome_measure>
      <outcome_measure>Incidence of Particular Adverse Events Resulting in Treatment Discontinuation</outcome_measure>
      <outcome_measure>Incidence of Dose Modifications Due to Adverse Events</outcome_measure>
      <outcome_measure>Proportion of Participants Who Achieve Undetectable Hepatitis C Virus Ribonucleic Acid (HCV-RNA)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01098097</url>
  </study>
  <study rank="53">
    <nct_id>NCT00277862</nct_id>
    <title>Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated IFN- alpha 2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ain Shams University</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
      <collaborator>Fulbright</collaborator>
      <collaborator>TEMPUS</collaborator>
      <collaborator>International Society for Infectious Diseases</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>280</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>G43230832638</other_id>
    </other_ids>
    <first_received>January 15, 2006</first_received>
    <start_date>April 2002</start_date>
    <completion_date>April 2007</completion_date>
    <last_updated>February 25, 2008</last_updated>
    <last_verified>February 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>sustained virologic response defined as undetectable serum HCV RNA levels (Amplicor HCV, Roche Molecular Systems; lower limit of detection (LLD) of 50 IU/mL)</outcome_measure>
      <outcome_measure>Virologic response at the end of treatment (EOT) defined as undetectable HCV RNA serum levels (50 IU/ml) at the end of the scheduled treatment period</outcome_measure>
      <outcome_measure>sustained virologic response (primary) histological response (secondary) biochemical response (secondary)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00277862</url>
  </study>
  <study rank="54">
    <nct_id>NCT00255008</nct_id>
    <title>Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">peginterferon alfa-2b</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Biological">peginterferon alfa-2b</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>121</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04212</other_id>
    </other_ids>
    <first_received>November 15, 2005</first_received>
    <start_date>March 2005</start_date>
    <completion_date>December 2007</completion_date>
    <last_updated>February 4, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>December 5, 2008</firstreceived_results_date>
    <primary_completion_date>December 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Subjects Who Achieved a Sustained Virologic Response (SVR)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00255008</url>
  </study>
  <study rank="55">
    <nct_id>NCT01446250</nct_id>
    <title>Study of DEB025/Alisporivir Plus Pegylated Interferon alfa2a and Ribavirin and Boceprevir Plus Pegylated Interferon alfa2a and Ribavirin in African American Chronic Hepatitis C Genotype 1 Patients That Have Never Received Treatment for Their Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Liver Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DEB025 plus peg-IFN alpha 2a and ribavirin fixed duration treatment</intervention>
      <intervention type="Drug">DEB025 plus peg-IFN alpha 2a and ribavirin response guided treatment duration</intervention>
      <intervention type="Drug">Boceprevir plus peg-IFN alpha 2a and ribavirin per label response guided treatment</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>210</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CDEB025A2307</other_id>
    </other_ids>
    <first_received>September 26, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>October 12, 2013</last_updated>
    <last_verified>October 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients that discontinue study drug or require dose reduction or dose interruption due to treatment-emergent Adverse Events.</outcome_measure>
      <outcome_measure>Proportion of patients with emergence of resistant mutations in each treatment arm.</outcome_measure>
      <outcome_measure>Proportion of patients that achieve Sustained Viral Response Week 24 (SVR24) defined as serum HCV RNA undetectable by limit of detection (LOD) 24 weeks after end of treatment.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01446250</url>
  </study>
  <study rank="56">
    <nct_id>NCT01051921</nct_id>
    <title>Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CTS-1027</intervention>
      <intervention type="Drug">Pegylated interferon</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Conatus Pharmaceuticals Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>67</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CTS-1027-04</other_id>
    </other_ids>
    <first_received>January 18, 2010</first_received>
    <start_date>January 2010</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>April 10, 2012</last_updated>
    <last_verified>April 2012</last_verified>
    <firstreceived_results_date>March 13, 2012</firstreceived_results_date>
    <acronym>CTS-1027-04</acronym>
    <primary_completion_date>November 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Early Virologic Response (EVR)</outcome_measure>
      <outcome_measure>&gt; 2 Log Decline in Hepatitis C Virus Ribonucleic Acid (HCV-RNA) at 24 Weeks</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Georgia</state>
      <state>Louisiana</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>Ohio</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01051921</url>
  </study>
  <study rank="57">
    <nct_id>NCT01335529</nct_id>
    <title>Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV Coinfection</condition>
      <condition>HIV-1 Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir, Peg-interferon alfa 2b and Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
      <collaborator>Rennes University Hospital</collaborator>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>69</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRS HC27 BOCEPREVIH</other_id>
    </other_ids>
    <first_received>March 25, 2011</first_received>
    <start_date>May 2011</start_date>
    <completion_date>May 2014</completion_date>
    <last_updated>October 10, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>BocepreVIH</acronym>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response</outcome_measure>
      <outcome_measure>HCV viral load</outcome_measure>
      <outcome_measure>Predictive factors of Sustained virologic Response (SVR)</outcome_measure>
      <outcome_measure>HIV virologic endpoints</outcome_measure>
      <outcome_measure>Residual plasmatic concentration (Cres) of Ribavirin</outcome_measure>
      <outcome_measure>Hepatic factors: liver fibrosis score</outcome_measure>
      <outcome_measure>Alcohol consumption</outcome_measure>
      <outcome_measure>Evaluation of Pharmacokinetic parameters of anti-retroviral treatments</outcome_measure>
      <outcome_measure>Clinical and biological adverse events</outcome_measure>
      <outcome_measure>Number of participants classified by virologic failure type: non responder, relapser, null responder</outcome_measure>
      <outcome_measure>ITPA gene polymorphism</outcome_measure>
      <outcome_measure>CYP3A4 Polymorphism</outcome_measure>
      <outcome_measure>Maximal Concentration (Cmax) of antiretroviral treatments</outcome_measure>
      <outcome_measure>Area Under the Curve (AUC) of antiretrovirals</outcome_measure>
      <outcome_measure>Insulin resistance</outcome_measure>
      <outcome_measure>Metabolic syndrome</outcome_measure>
      <outcome_measure>Reasons and dates of treatment discontinuation</outcome_measure>
      <outcome_measure>Perceived symptoms</outcome_measure>
      <outcome_measure>French AIDS questionnaire of compliance</outcome_measure>
      <outcome_measure>Tobacco consumption</outcome_measure>
      <outcome_measure>Cannabis consumption</outcome_measure>
      <outcome_measure>Intravenous/nasal drugs consumption</outcome_measure>
      <outcome_measure>Residual Concentration (Cres) of atazanavir boosted or not by ritonavir</outcome_measure>
      <outcome_measure>Residual concentration (Cres) of ritonavir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01335529</url>
  </study>
  <study rank="58">
    <nct_id>NCT00800735</nct_id>
    <title>A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated-interferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV21928</other_id>
      <other_id>2008-002022-10</other_id>
    </other_ids>
    <first_received>October 23, 2008</first_received>
    <start_date>April 2009</start_date>
    <completion_date>March 2012</completion_date>
    <last_updated>September 30, 2013</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>July 5, 2013</firstreceived_results_date>
    <primary_completion_date>March 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Who Experienced at Least 1 Adverse Event.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Austria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Maryland</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oregon</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00800735</url>
  </study>
  <study rank="59">
    <nct_id>NCT01609933</nct_id>
    <title>A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Hepatitis C (HCV)</condition>
      <condition>Hepatitis C Genotype 1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450/r</intervention>
      <intervention type="Drug">ABT-267</intervention>
      <intervention type="Drug">pegylated interferon alpha-2a (pegIFN)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie (prior sponsor, Abbott)</lead_sponsor>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>93</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M13-101</other_id>
      <other_id>2011-005393-32</other_id>
    </other_ids>
    <first_received>May 30, 2012</first_received>
    <start_date>December 2012</start_date>
    <completion_date>May 2017</completion_date>
    <last_updated>October 10, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of subjects achieving 12-week sustained virologic response following treatment with 2 direct acting anti-virals and peginterferon alpha-2a and ribavirin in Hepatitis C infected adults.</outcome_measure>
      <outcome_measure>Percentage of subjects achieving 24-week sustained virologic response following treatment with 2 direct acting anti-viral and peginterferon alpha-2a and ribavirin in Hepatitis C infected adults.</outcome_measure>
      <outcome_measure>Percentage of subjects with extended rapid virologic response (Hepatitis C ribonucleic acid less than lower limit of quantitation at Weeks 4 through 12 of therapy with ABT 450/r plus ABT-267 plus peginterferon alpha-2a plus ribavirin)</outcome_measure>
      <outcome_measure>Number and percentage of subjects having treatment-emergent adverse events.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Germany</country>
      <country>Hungary</country>
      <country>Italy</country>
      <country>Netherlands</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
      <country>Slovakia</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oregon</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01609933</url>
  </study>
  <study rank="60">
    <nct_id>NCT00491179</nct_id>
    <title>Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Hemodialysis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa-2a and ribavirin</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>National Science Council, Taiwan</collaborator>
      <collaborator>Department of Health, Executive Yuan, R.O.C. (Taiwan)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>35</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>200703032M</other_id>
    </other_ids>
    <first_received>June 23, 2007</first_received>
    <start_date>June 2006</start_date>
    <completion_date>July 2008</completion_date>
    <last_updated>October 7, 2009</last_updated>
    <last_verified>October 2009</last_verified>
    <firstreceived_results_date>December 21, 2008</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>1.Number of Participants With Sustained Virologic Response (SVR) 2.Number of Participants Who Droppoed Out of the Study Prematurely Due to Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Number of Participants With Histologic Response(HR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00491179</url>
  </study>
  <study rank="61">
    <nct_id>NCT01151397</nct_id>
    <title>Does 3 Months Therapy With Vitamin D + Peg + Ribavirin Improve Sustained Virologic Response (SVR) in Genotype 2, 3 Chronic Hepatitis C Patients?</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg + Vitamin D + Ribavirin</intervention>
      <intervention type="Drug">Peg + Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ziv Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Genotype 2,3 HCV +Vitamin D</other_id>
    </other_ids>
    <first_received>June 16, 2010</first_received>
    <start_date>August 2011</start_date>
    <completion_date>July 2012</completion_date>
    <last_updated>April 27, 2011</last_updated>
    <last_verified>June 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>sustained virologic response (SVR)rate</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Israel</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01151397</url>
  </study>
  <study rank="62">
    <nct_id>NCT00887081</nct_id>
    <title>Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hemoglobinopathies</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Azienda Ospedaliera V. Cervello</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AOVCervello1</other_id>
    </other_ids>
    <first_received>April 21, 2009</first_received>
    <start_date>January 2009</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>April 22, 2009</last_updated>
    <last_verified>April 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>IFNRIBAHE</acronym>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>A sustained virological response (SVR), defined as absence of HCV RNA in serum by a highly sensitive test at the end of treatment and 6 months late.</outcome_measure>
      <outcome_measure>Early virological response (EVR) , defined as the loss of HCV RNA during the first 12 weeks of therapy; main side effects enclosing changes in blood transfusion requirement; increase in ferritin levels and variations in chelation treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00887081</url>
  </study>
  <study rank="63">
    <nct_id>NCT02165189</nct_id>
    <title>An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitits C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Scientific Affairs, LLC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>46</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR104281</other_id>
      <other_id>TMC435HPC2009</other_id>
    </other_ids>
    <first_received>June 10, 2014</first_received>
    <start_date>August 2014</start_date>
    <completion_date>November 2015</completion_date>
    <last_updated>October 21, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>GALAXY</acronym>
    <primary_completion_date>October 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response After 12 Weeks of end of Treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response After 4 Weeks of end of Treatment (SVR4)</outcome_measure>
      <outcome_measure>Percentage of Participants With Undetectable Hepatitis C Virus Ribonucleic Acid (HCV-RNA)</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Change From Baseline in Hepatitis C Symptom and Impact Questionnaire Version 4 (HCV-SIQv4) Score at Week 24 (for Arms 1 and 2) and Week 36 (for Arm 3)</outcome_measure>
      <outcome_measure>Change From Baseline in EuroQol 5 - Dimension (EQ-5D) Questionnaire Score at Weeks 4, 8, 12, 16, 20, 24 (for all treatment arms) and Week 36 (for Arm 3)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Colorado</state>
      <state>Florida</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02165189</url>
  </study>
  <study rank="64">
    <nct_id>NCT01596517</nct_id>
    <title>Efficacy and Effectiveness of PegInterferon and Ribavirin in Korean Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a plus ribavirin for HCV genotype 1</intervention>
      <intervention type="Drug">Peginterferon alfa-2a plus ribavirin for HCV genotype 2/3</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Asan Medical Center</lead_sponsor>
      <collaborator>Samsung Medical Center</collaborator>
      <collaborator>Severance Hospital</collaborator>
      <collaborator>Gangnam Severance Hospital</collaborator>
      <collaborator>Seoul St. Mary's Hospital</collaborator>
      <collaborator>Korea University Guro Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>272</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AMC2003-0059</other_id>
    </other_ids>
    <first_received>May 7, 2012</first_received>
    <start_date>June 2003</start_date>
    <completion_date>May 2012</completion_date>
    <last_updated>May 12, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The proportion of patients achieving sustained virological response (SVR)</outcome_measure>
      <outcome_measure>The proportion of patients achieving early virological response (EVR)</outcome_measure>
      <outcome_measure>the proportion of patients achieving complete EVR (cEVR)</outcome_measure>
      <outcome_measure>The proportion of patients achieving end-of-treatment response (ETR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Korea, Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01596517</url>
  </study>
  <study rank="65">
    <nct_id>NCT00018031</nct_id>
    <title>Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>010194</other_id>
      <other_id>01-I-0194</other_id>
    </other_ids>
    <first_received>June 27, 2001</first_received>
    <start_date>June 2001</start_date>
    <completion_date>April 2009</completion_date>
    <last_updated>September 25, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>January 18, 2013</firstreceived_results_date>
    <acronym>HEPCPR</acronym>
    <primary_completion_date>April 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Participants With Viral Decline at Day 3 &amp; 28 With Predictors of Post Treatment Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00018031</url>
  </study>
  <study rank="66">
    <nct_id>NCT00160251</nct_id>
    <title>Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir (BOC)</intervention>
      <intervention type="Biological">PegIntron (PEG)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>357</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>P03659</other_id>
    </other_ids>
    <first_received>September 8, 2005</first_received>
    <start_date>September 2005</start_date>
    <completion_date>July 2007</completion_date>
    <last_updated>October 13, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>May 13, 2011</firstreceived_results_date>
    <primary_completion_date>July 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percent of Participants Who Were Hepatitis C Virus Ribonucleic Acid (HCV-RNA) Negative at the End of Treatment (EoT)</outcome_measure>
      <outcome_measure>Percent of Participants Who Achieved Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Percent of Participants Who Achieved Sustained Viral Response (SVR) by Time to First Negative HCV-RNA</outcome_measure>
      <outcome_measure>Percentage of Participants Who Were HCV-RNA Negative at EoT After Receiving 1 Week of Treatment With PegIntron (PEG) by Log Drop</outcome_measure>
      <outcome_measure>Percent of Participants With Virologic Response Prior to Amendment 2</outcome_measure>
      <outcome_measure>Peak Plasma Concentration of Boceprevir (BOC)</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve of Boceprevir Plasma Concentration for an 8-hour Dosing Period</outcome_measure>
      <outcome_measure>Trough Plasma Concentration Level</outcome_measure>
      <outcome_measure>Change in Alanine Aminotransferase (ALT) Levels</outcome_measure>
      <outcome_measure>Number of Participants Who Were HCV-RNA Negative During Amendment 2 (AM2) for Those Who Started on Arms 2 (PEG+BOC 100), 3 (PEG+BOC 200), 4 (PEG+BOC 400 [48 Weeks]), 6 (PEG+BOC 400 [24 Weeks])</outcome_measure>
      <outcome_measure>Number of Participants Who Were HCV-RNA Negative During Amendment 2 (AM2) for Those Who Started on PegIntron (PEG) + Rebetol (RVB) + Boceprevir (BOC) 400 (Arm 5)</outcome_measure>
      <outcome_measure>Number of Participants Who Were HCV-RNA Negative During Amendment 2 (AM2) for Those Who Started on PegIntron (PEG) + Boceprevir (BOC) 800 (Arm 7)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00160251</url>
  </study>
  <study rank="67">
    <nct_id>NCT02073838</nct_id>
    <title>Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Myeloid Leukemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Vismodegib</intervention>
      <intervention type="Drug">Decitabine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Sarit Assouline</lead_sponsor>
      <collaborator>Jewish General Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Ribavirin=005</other_id>
    </other_ids>
    <first_received>February 21, 2014</first_received>
    <start_date>May 2015</start_date>
    <completion_date>January 2018</completion_date>
    <last_updated>June 23, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy will be measured by overall response rate (ORR).</outcome_measure>
      <outcome_measure>Time to response</outcome_measure>
      <outcome_measure>Duration of response</outcome_measure>
      <outcome_measure>One year survival</outcome_measure>
      <outcome_measure>Overall survival</outcome_measure>
      <outcome_measure>Hematologic improvement defined by the number of individual, positively affected cell lines (erythroid, neutrophil and platelet cells) per patient.</outcome_measure>
      <outcome_measure>Number of participants with Adverse Events as a Measure of Safety and Tolerability</outcome_measure>
      <outcome_measure>Changes in eIF4E expression, localization, and signalling pathways (measured by immuno-histochemical analysis, PCR or western blot) and correlating with each patient's overall response.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02073838</url>
  </study>
  <study rank="68">
    <nct_id>NCT01023035</nct_id>
    <title>Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2b (PEG2b)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">Erythropoietin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>687</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P06086</other_id>
      <other_id>2009-012782-63</other_id>
    </other_ids>
    <first_received>November 24, 2009</first_received>
    <start_date>December 2009</start_date>
    <completion_date>October 2011</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>October 16, 2012</firstreceived_results_date>
    <primary_completion_date>October 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Discontinued Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01023035</url>
  </study>
  <study rank="69">
    <nct_id>NCT00056862</nct_id>
    <title>Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>58</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>030136</other_id>
      <other_id>03-DK-0136</other_id>
    </other_ids>
    <first_received>March 25, 2003</first_received>
    <start_date>March 2003</start_date>
    <completion_date>June 2010</completion_date>
    <last_updated>November 13, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>November 12, 2010</firstreceived_results_date>
    <primary_completion_date>January 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Virological Response (Intention to Treat)</outcome_measure>
      <outcome_measure>Virological Response Category (Per Protocol)</outcome_measure>
      <outcome_measure>First Phase Decline in Logarithm of HCV RNA Level</outcome_measure>
      <outcome_measure>Slope of Second Phase Decline in HCV Levels</outcome_measure>
      <outcome_measure>Time to Negativity</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00056862</url>
  </study>
  <study rank="70">
    <nct_id>NCT01859962</nct_id>
    <title>Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PPI-668</intervention>
      <intervention type="Drug">BI 207127 Dose 1</intervention>
      <intervention type="Drug">BI 207127 Dose 2</intervention>
      <intervention type="Drug">Faldaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">BI 207127 Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Presidio Pharmaceuticals, Inc.</lead_sponsor>
      <collaborator>Boehringer Ingelheim</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>38</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>PPI-668-201</other_id>
    </other_ids>
    <first_received>May 17, 2013</first_received>
    <start_date>May 2013</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>November 24, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>the proportion of patients achieving sustained viral response (SVR)</outcome_measure>
      <outcome_measure>Proportion of patients with &quot;virologic relapse&quot; post-treatment, defined as confirmed and quantifiable (&gt;LLOQ) serum HCV RNA in a patient who achieved non-detectable serum HCV RNA by the end of treatment</outcome_measure>
      <outcome_measure>Proportion of patients with confirmed viral breakthrough during study treatment</outcome_measure>
      <outcome_measure>Proportions of study participants who receive at least one dose of study drug and who prematurely discontinue study treatment, and proportions prematurely discontinuing treatment for clinical adverse events or laboratory abnormalities</outcome_measure>
      <outcome_measure>Proportions of study participants experiencing treatment-emergent adverse events (serious and non-serious) considered to be possibly or probably attributable to study treatment, overall and by body system</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01859962</url>
  </study>
  <study rank="71">
    <nct_id>NCT01447394</nct_id>
    <title>Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus (HCV)</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated Interferon Lambda</intervention>
      <intervention type="Biological">Pegylated Interferon Alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI452-013</other_id>
      <other_id>2011-003748-31</other_id>
    </other_ids>
    <first_received>October 4, 2011</first_received>
    <start_date>March 2012</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>February 2, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy of Lambda + Ribavirin (RBV) compared to Alfa + RBV in achieving a sustained virological response</outcome_measure>
      <outcome_measure>The safety of Lambda + RBV compared to Alfa + RBV in reducing cytopenic abnormalities</outcome_measure>
      <outcome_measure>Proportion of interferon-associated symptoms: a) Flu-like symptoms b) Musculoskeletal symptoms c) Neurologic symptoms d) Psychiatric symptoms e) Constitutional symptoms</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>China</country>
      <country>Colombia</country>
      <country>Czech Republic</country>
      <country>Egypt</country>
      <country>Hong Kong</country>
      <country>Hungary</country>
      <country>India</country>
      <country>Ireland</country>
      <country>Korea, Republic of</country>
      <country>Netherlands</country>
      <country>Poland</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Singapore</country>
      <country>Spain</country>
      <country>Taiwan</country>
      <country>Turkey</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>New York</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01447394</url>
  </study>
  <study rank="72">
    <nct_id>NCT00085917</nct_id>
    <title>Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Double dose pegylated interferon with weight based Ribavirin</intervention>
      <intervention type="Drug">standard dose pegylated interferon alfa -2a and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>29</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>040187</other_id>
      <other_id>04-I-0187</other_id>
    </other_ids>
    <first_received>June 16, 2004</first_received>
    <start_date>June 2004</start_date>
    <completion_date>November 2008</completion_date>
    <last_updated>June 21, 2011</last_updated>
    <last_verified>June 2011</last_verified>
    <firstreceived_results_date>April 12, 2010</firstreceived_results_date>
    <acronym>PIFNPK</acronym>
    <primary_completion_date>November 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Number of Participants With Normalization of Liver Enzymes</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00085917</url>
  </study>
  <study rank="73">
    <nct_id>NCT01445795</nct_id>
    <title>Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">200 mg INX-08189 Fasted</intervention>
      <intervention type="Drug">Placebo QD Fasted</intervention>
      <intervention type="Drug">100 mg INX-08189 QD with ribavirin</intervention>
      <intervention type="Drug">Placebo QD with ribavirin</intervention>
      <intervention type="Drug">100 mg INX-08189 with low-fat meal</intervention>
      <intervention type="Drug">Placebo with low-fat meal</intervention>
      <intervention type="Drug">100 mg INX-08189 BID Fasted</intervention>
      <intervention type="Drug">Placebo BID Fasted</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI472-006</other_id>
      <other_id>INH-189-006</other_id>
    </other_ids>
    <first_received>September 27, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>May 2012</completion_date>
    <last_updated>October 12, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>INH-189-006</acronym>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from baseline in HCV RNA 24 hours following the final dose of Study Drug (INX-08189/placebo)</outcome_measure>
      <outcome_measure>Change in HCV RNA over time during the 7 days of dosing and during the follow-up period and the maximum change from baseline in HCV RNA.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01445795</url>
  </study>
  <study rank="74">
    <nct_id>NCT01463956</nct_id>
    <title>Clinical Trial to Evaluate the Efficacy of Pegylated Interferon-Ribavirin-Boceprevir Triple Therapy in Patients Infected With Genotype 1 HCV With Cirrhosis and Awaiting Liver Transplantation (ANRS HC 29 BOCEPRETRANSPLANT)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV Infection</condition>
      <condition>Liver Cirrhosis, Experimental</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Biological">Peg-Interferon α-2b or Peg-Interferon α-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Agency for Research on AIDS and Viral Hepatitis</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
      <collaborator>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>58</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2011- 001089 -17</other_id>
    </other_ids>
    <first_received>October 14, 2011</first_received>
    <start_date>January 2012</start_date>
    <completion_date>January 2015</completion_date>
    <last_updated>January 14, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR) Rate</outcome_measure>
      <outcome_measure>Number of participants with adverse events as a measure of safety and tolerability</outcome_measure>
      <outcome_measure>Perceived symptoms</outcome_measure>
      <outcome_measure>Compliance rate.</outcome_measure>
      <outcome_measure>SVR prognosis factors</outcome_measure>
      <outcome_measure>The predictive value of on-treatment HCV RNA on SVR</outcome_measure>
      <outcome_measure>The percentage of virologic failure</outcome_measure>
      <outcome_measure>The percentage of relapse after transplantation</outcome_measure>
      <outcome_measure>Boceprevir resistant mutations</outcome_measure>
      <outcome_measure>Resistant mutations in plasma and liver samples (both explanted liver and graft)</outcome_measure>
      <outcome_measure>Sepsis according to Systemic Inflammatory Response System (SIRS) Criteria</outcome_measure>
      <outcome_measure>Cirrhosis impairment</outcome_measure>
      <outcome_measure>Survival after transplantation</outcome_measure>
      <outcome_measure>Survival rate within one year after liver transplantation</outcome_measure>
      <outcome_measure>The mean time elapsed between registration on the transplantation list and the date of transplantation</outcome_measure>
      <outcome_measure>Measurement of the residual plasma concentration (Cres) of ribavirin</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration Time Curve (AUC) From 0-8h of Boceprevir</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of Boceprevir</outcome_measure>
      <outcome_measure>Time of Maximum Plasma Concentration (Tmax) of Boceprevir</outcome_measure>
      <outcome_measure>Minimum Plasma Concentration (Cmin) of Boceprevir</outcome_measure>
      <outcome_measure>Correlation study between the presence of an elevated level of IP-10 during triple therapy and the absence of sustained virologic response</outcome_measure>
      <outcome_measure>Histological severity of HCV recurrence after liver transplantation</outcome_measure>
      <outcome_measure>Insulin Resistance (HOMA-IR)</outcome_measure>
      <outcome_measure>Virological Response in participants with and without Insulin Resistance</outcome_measure>
      <outcome_measure>Relationship between the presence of a polymorphism in the IL28B gene (donor and recipient) and SVR</outcome_measure>
      <outcome_measure>Relationship between the presence of a polymorphism to the ITPA gene and the onset of hemolytic anemia</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01463956</url>
  </study>
  <study rank="75">
    <nct_id>NCT00880763</nct_id>
    <title>A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Vaniprevir</intervention>
      <intervention type="Drug">Pegylated Interferon (peg-IFN)</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Comparator: Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>7009-016</other_id>
      <other_id>2009_576</other_id>
    </other_ids>
    <first_received>April 10, 2009</first_received>
    <start_date>April 2009</start_date>
    <completion_date>February 2012</completion_date>
    <last_updated>September 1, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>September 26, 2014</firstreceived_results_date>
    <primary_completion_date>June 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Rapid Viral Response</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving a &gt; or = 2-log10 Decrease in HCV RNA From Baseline to Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving a &gt; or = 3-log10 Decrease in HCV RNA From Baseline to Week 4</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA in log10 at Week 4</outcome_measure>
      <outcome_measure>Number of Participants Who Experienced at Least One Adverse Event</outcome_measure>
      <outcome_measure>Number of Participants Who Discontinued Study Drug Due to an Adverse Event</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00880763</url>
  </study>
  <study rank="76">
    <nct_id>NCT00948220</nct_id>
    <title>Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Liver Diseases</condition>
      <condition>Virus Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Ulm</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>26</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>OSTEO</other_id>
    </other_ids>
    <first_received>July 24, 2009</first_received>
    <start_date>July 2003</start_date>
    <completion_date>March 2008</completion_date>
    <last_updated>June 6, 2011</last_updated>
    <last_verified>May 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change of the bone mineral density of the lumbar spine and right hip measured by DEXA in patients with chronic hepatitis C with or without antiviral combination treatment with peginterferon and ribavirin</outcome_measure>
      <outcome_measure>Change in markers of bone formation and resorption over time during antiviral therapy and after cessation of therapy.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00948220</url>
  </study>
  <study rank="77">
    <nct_id>NCT02247440</nct_id>
    <title>HCV-HIV Co-infected Patient Cohort in Thailand</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
      <condition>HIV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-interferon + ribavirin under HIV physician supervision</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institut de Recherche pour le Developpement</lead_sponsor>
      <collaborator>Ministry of Health, Thailand</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>PHPT-HCV</other_id>
    </other_ids>
    <first_received>September 9, 2014</first_received>
    <start_date>August 2014</start_date>
    <completion_date>April 2018</completion_date>
    <last_updated>May 24, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response 6 months after treatment discontinuation</outcome_measure>
      <outcome_measure>Safety of treatment</outcome_measure>
      <outcome_measure>Impact of HCV treatment on HIV</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Thailand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02247440</url>
  </study>
  <study rank="78">
    <nct_id>NCT01846832</nct_id>
    <title>A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a (PegIFNα-2a)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen-Cilag International NV</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>232</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100981</other_id>
      <other_id>TMC435HPC3014</other_id>
      <other_id>2012-004905-29</other_id>
    </other_ids>
    <first_received>May 1, 2013</first_received>
    <start_date>September 2013</start_date>
    <completion_date>August 2015</completion_date>
    <last_updated>October 16, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The proportion (percentage) of participants infected wtih genotype 1 HCV with a sustained virologic response 12 weeks after planned end of treatment (SVR12)</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants infected wtih genotype 4 HCV with a sustained virologic response 12 weeks after planned end of treatment (SVR12)</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants who achieve rapid virologic response (RVR)</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants who achieve virologic response at Week 2 (W2VR)</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants with sustained virologic response 24 weeks after planned end of treatment (SVR24)</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants with sustained virologic response 12 weeks after planned end of treatment (SVR12)</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants with &gt; or = 2 log decrease in hepatitis C virus (HCV) RNA at each time point</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants with hepatitis C virus (HCV) RNA &lt; 25 IU/mL undetectable at each time point</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants with viral breakthrough</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants with viral relapse</outcome_measure>
      <outcome_measure>Change from Baseline in the Hepatitis C Treatment Symptom &amp; Impact Questionnaire (HCV SIQ) symptom and impact scores</outcome_measure>
      <outcome_measure>Change from Baseline in The Fatigue Severity Scale (FSS) total score</outcome_measure>
      <outcome_measure>Change from Baseline in The Center for Epidemiologic Studies Depression Scale (CES-D) score</outcome_measure>
      <outcome_measure>Change from Baseline in The Work Productivity and Activity Index (WPAI) for Hepatitis C missed work time, daily activity impairment, and productivity scores</outcome_measure>
      <outcome_measure>Change from Baseline in The EuroQol 5 Dimension (EQ5D) Visual Analog Scale (VAS) valuation index, and Descriptive System scores</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants with normalized alanine aminotransferase (ALT) levels</outcome_measure>
      <outcome_measure>Change from Screening in liver disease stage assessment</outcome_measure>
      <outcome_measure>The number of participants reporting adverse events as a measure of safety and tolerability</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Saudi Arabia</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01846832</url>
  </study>
  <study rank="79">
    <nct_id>NCT02464631</nct_id>
    <title>To Evaluate the Safety and Efficacy of Sofosbuvir and Ribavirin in Patients With HCV (Genotype 3) Related Decompensated Cirrhosis</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV Related Cirrhosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir + Ribavirin 1</intervention>
      <intervention type="Drug">Sofosbuvir + Ribavirin 2</intervention>
      <intervention type="Drug">Sofosbuvir + Ribavirin 3</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute of Liver and Biliary Sciences, India</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>450</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ILBS-HCV-001</other_id>
    </other_ids>
    <first_received>May 22, 2015</first_received>
    <start_date>June 2015</start_date>
    <completion_date>June 2018</completion_date>
    <last_updated>June 26, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Primary efficacy end point is SVR 24 defined as HCV RNA &lt;LLOQ (lower limit of quantification)</outcome_measure>
      <outcome_measure>The secondary endpoint is any AE (Adverse Event) leading to permanent discontinuation of study drugs.</outcome_measure>
      <outcome_measure>Mortality at 6 months post therapy in all the 3 groups.</outcome_measure>
      <outcome_measure>Improvement in the liver function as determined by CTP (Child-Turcotte-Pugh score), MELD (Model for End Stage liver Disease)more than 2 points at 6 months and 1 year.</outcome_measure>
      <outcome_measure>Number of new cases of Hepatocellular Carcinoma at end of therapy and at 6 months post therapy in all the 3 groups.</outcome_measure>
      <outcome_measure>Reduction in HVPG &gt;20% to baseline after 1 year in all the 3 groups.</outcome_measure>
      <outcome_measure>SVR 4 defined as HCV RNA &lt;LLOQ (lower limit of quantification)</outcome_measure>
      <outcome_measure>SVR 12 defined as HCV RNA &lt;LLOQ (lower limit of quantification)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>India</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02464631</url>
  </study>
  <study rank="80">
    <nct_id>NCT00255034</nct_id>
    <title>Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b</intervention>
      <intervention type="Biological">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>146</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04143</other_id>
    </other_ids>
    <first_received>November 15, 2005</first_received>
    <start_date>February 2005</start_date>
    <completion_date>June 2008</completion_date>
    <last_updated>March 30, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>June 4, 2009</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virological Response (SVR), Defined by Undetectable HCV RNA in Serum at 24 Weeks After Completion of Therapy</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00255034</url>
  </study>
  <study rank="81">
    <nct_id>NCT01616524</nct_id>
    <title>Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus (HCV)</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated interferon lambda (pegIFNλ)</intervention>
      <intervention type="Biological">Pegylated interferon lambda (pegIFNλ)</intervention>
      <intervention type="Biological">Pegylated interferon alfa-2a (pegIFNα-2a)</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Placebo matching Daclatasvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>880</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI452-017</other_id>
      <other_id>2011-004885-14</other_id>
    </other_ids>
    <first_received>June 7, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PRINCIPAL</acronym>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects who achieve Sustained Virologic Response at post-treatment follow-up week 12 (SVR12)</outcome_measure>
      <outcome_measure>Proportion of subjects with Rapid virologic response (RVR) [undetectable Hepatitis C virus (HCV) Ribonucleic acid (RNA)]</outcome_measure>
      <outcome_measure>Proportion of subjects with treatment emergent cytopenic abnormalities (anemia as defined by Hb &lt; 10 g/dL, neutropenia as defined by ANC &lt; 750 mm3 or thrombocytopenia as defined by platelets &lt; 50,000 mm3)</outcome_measure>
      <outcome_measure>Proportion of subjects with on-treatment interferon-associated flu-like symptoms (as defined by pyrexia or chills or pain)</outcome_measure>
      <outcome_measure>Proportion of subjects with on-treatment musculoskeletal symptoms (as defined by arthralgia or myalgia or back pain)</outcome_measure>
      <outcome_measure>Proportion of subjects with Sustained Virologic Response at post-treatment follow-up week 24 (SVR24) by treatment group</outcome_measure>
      <outcome_measure>Proportion of subjects with on-treatment Serious adverse events (SAEs)</outcome_measure>
      <outcome_measure>Proportion of subjects with dose reductions</outcome_measure>
      <outcome_measure>Proportion of subjects who discontinue due to Adverse events (AEs)</outcome_measure>
      <outcome_measure>Proportion of subjects with SVR12 in subjects with genotype-3 (GT-3) chronic HCV infection</outcome_measure>
      <outcome_measure>Proportion of subjects with on-treatment constitutional symptoms (fatigue or asthenia)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Belgium</country>
      <country>Chile</country>
      <country>Finland</country>
      <country>France</country>
      <country>Greece</country>
      <country>Hong Kong</country>
      <country>Italy</country>
      <country>Japan</country>
      <country>Korea, Republic of</country>
      <country>Mexico</country>
      <country>Netherlands</country>
      <country>New Zealand</country>
      <country>Russian Federation</country>
      <country>Singapore</country>
      <country>Taiwan</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Michigan</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Utah</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01616524</url>
  </study>
  <study rank="82">
    <nct_id>NCT01457937</nct_id>
    <title>Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Menopause</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon, Ribavirin, Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Modena and Reggio Emilia</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Female</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>240</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>EudraCT 2011-002459-33</other_id>
    </other_ids>
    <first_received>October 8, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>September 29, 2012</last_updated>
    <last_verified>September 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>MEN_BOC</acronym>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Improvement of sustained virological response in previous treatment failure or naive HCV-positive menopausal women.</outcome_measure>
      <outcome_measure>Early virological response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01457937</url>
  </study>
  <study rank="83">
    <nct_id>NCT00356486</nct_id>
    <title>Viral Kinetics of Treatment With Peginterferon Alpha-2a, Ribavirin and Epoetin β in Patients Coinfected HCV/HIV</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a, Ribavirin, epoetin-β</intervention>
      <intervention type="Drug">Peginterferon alfa-2a + Ribavirin for 12 weeks</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Germans Trias i Pujol Hospital</lead_sponsor>
      <collaborator>Fundacio Lluita Contra la SIDA</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>74</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CORAL-2</other_id>
      <other_id>2004 - 000907 -16</other_id>
    </other_ids>
    <first_received>July 25, 2006</first_received>
    <start_date>October 2005</start_date>
    <completion_date>March 2009</completion_date>
    <last_updated>September 2, 2009</last_updated>
    <last_verified>September 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of patients with undetectable RNA-HCV</outcome_measure>
      <outcome_measure>Variations of the levels of RNA-HCV</outcome_measure>
      <outcome_measure>Percentage of patients with undetectable HCV RNA</outcome_measure>
      <outcome_measure>Levels of ALT</outcome_measure>
      <outcome_measure>Percentage of patients that must reduce the dose of peginterferon alpha-2a (40 KD) and ribavirin.</outcome_measure>
      <outcome_measure>Percentage of patients that drop out of the study for adverse effects or intolerance</outcome_measure>
      <outcome_measure>Variations in levels of haemoglobin, neutrophil, and platelet count</outcome_measure>
      <outcome_measure>AIDS-defining events or death</outcome_measure>
      <outcome_measure>Changes in the CD4/CD8 cell count</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00356486</url>
  </study>
  <study rank="84">
    <nct_id>NCT00629824</nct_id>
    <title>Pegylated Interferon Plus Ribavirin in Treating Older Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon alpha and plus ribavirin</intervention>
      <intervention type="Drug">pegylated interferon alpha and plus ribavirin</intervention>
      <intervention type="Drug">pegylated interferon alpha and plus ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kaohsiung Medical University Chung-Ho Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>250</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KMUH-IRB- 960047</other_id>
    </other_ids>
    <first_received>February 26, 2008</first_received>
    <start_date>February 2007</start_date>
    <completion_date>April 2009</completion_date>
    <last_updated>September 6, 2010</last_updated>
    <last_verified>February 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy: Sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.</outcome_measure>
      <outcome_measure>RVR, rapid virological response, defined as HCV RNA &lt; 50 IU/mL at treatment week 4</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00629824</url>
  </study>
  <study rank="85">
    <nct_id>NCT00704184</nct_id>
    <title>Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Comparator: Vaniprevir</intervention>
      <intervention type="Drug">Comparator: Pegylated-Interferon (Peg-IFN)</intervention>
      <intervention type="Drug">Comparator: Ribavirin</intervention>
      <intervention type="Drug">Comparator: placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>95</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>7009-007</other_id>
      <other_id>MK7009-007</other_id>
      <other_id>2007_658</other_id>
    </other_ids>
    <first_received>June 23, 2008</first_received>
    <start_date>July 2008</start_date>
    <completion_date>April 2010</completion_date>
    <last_updated>September 1, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>September 26, 2014</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving RVR</outcome_measure>
      <outcome_measure>Number of Participants Experiencing an Adverse Event (AE)</outcome_measure>
      <outcome_measure>Number of Participants Discontinuing From Study Therapy Due to AEs</outcome_measure>
      <outcome_measure>Number of Participants With ≥2-log10 Decrease in HCV RNA</outcome_measure>
      <outcome_measure>Number of Participants With ≥3-log10 Decrease in HCV RNA</outcome_measure>
      <outcome_measure>Mean Log Change From Baseline in HCV RNA</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00704184</url>
  </study>
  <study rank="86">
    <nct_id>NCT00302081</nct_id>
    <title>Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">peginterferon alfa-2b (SCH 54031)</intervention>
      <intervention type="Biological">peginterferon alfa-2b (SCH 54031)</intervention>
      <intervention type="Biological">peginterferon alfa-2b (SCH 54031)</intervention>
      <intervention type="Drug">ribavirin (SCH 18908)</intervention>
      <intervention type="Drug">ribavirin (SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
      <collaborator>Integrated Therapeutics Group</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>696</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P03548</other_id>
    </other_ids>
    <first_received>March 10, 2006</first_received>
    <start_date>August 2003</start_date>
    <completion_date>April 2008</completion_date>
    <last_updated>April 7, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>April 29, 2009</firstreceived_results_date>
    <primary_completion_date>April 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Number of Participants Who Achieve a Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Virologic Response Rates at the End of Therapy. Biochemical Responses as Determined by ALT and AST Levels at the End of Treatment and at the End of Follow up.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00302081</url>
  </study>
  <study rank="87">
    <nct_id>NCT00540345</nct_id>
    <title>Four Arms, Multicenter Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon alpha 2a and plus ribavirin</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a and ribavirin</intervention>
      <intervention type="Drug">pegylated interferon alpha 2a and ribavirin</intervention>
      <intervention type="Drug">pegylated interferon alpha 2a and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kaohsiung Medical University Chung-Ho Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KMUH-IRB-960057</other_id>
    </other_ids>
    <first_received>October 5, 2007</first_received>
    <start_date>October 2006</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>December 24, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy - Rapid virologic response (RVR), HCV RNA seronegative by PCR at week 4 Sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period</outcome_measure>
      <outcome_measure>Safety - adverse event rate and profile</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00540345</url>
  </study>
  <study rank="88">
    <nct_id>NCT01448044</nct_id>
    <title>Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-790052 (NS5A Replication Complex Inhibitor)</intervention>
      <intervention type="Drug">Placebo matching BMS-790052</intervention>
      <intervention type="Drug">Pegylated-interferon alfa 2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>152</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-042</other_id>
      <other_id>2011-002793-23</other_id>
    </other_ids>
    <first_received>October 5, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>September 11, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>August 7, 2015</firstreceived_results_date>
    <primary_completion_date>October 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With 12 Week Sustained Virologic Response (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieve HCV Ribonucleic Acid (RNA) &lt; Limit of Quantification (LLOQ)</outcome_measure>
      <outcome_measure>Percentage of Participants With Undetectable Hepatitis C Virus (HCV) RNA Levels</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) or Sustained Virologic Response at Follow-up Week 24 (SVR24) by rs12979860 Single Nucleotide Polymorphism (SNP) in the IL28B Gene</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs) and Who Died</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>France</country>
      <country>Greece</country>
      <country>Italy</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Massachusetts</state>
      <state>Rhode Island</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01448044</url>
  </study>
  <study rank="89">
    <nct_id>NCT01292239</nct_id>
    <title>A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Peginterferon alfa-2a (pegIFN alfa-2a)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Pharmaceutical K.K.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>183</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017686</other_id>
      <other_id>TMC435HPC3003</other_id>
    </other_ids>
    <first_received>February 1, 2011</first_received>
    <start_date>February 2011</start_date>
    <completion_date>October 2012</completion_date>
    <last_updated>December 16, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>October 15, 2013</firstreceived_results_date>
    <primary_completion_date>October 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants With a Sustained Virologic Response at the End of Treatment (EOT) and 12 Weeks After the Last Dose of Treatment (SVR12)</outcome_measure>
      <outcome_measure>The Percentage of Participants With a Sustained Virologic Response at the End of Treatment (EOT) and 24 Weeks After the Last Dose of Treatment (SVR24)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up</outcome_measure>
      <outcome_measure>The Percentage of Participants With Undetectable Plasma Levels of Hepatitis C Virus Ribonucleic Acid (HCV RNA) During Treatment and at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>The Number of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>The Number of Participants Demonstrating Viral Relapse</outcome_measure>
      <outcome_measure>The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal ALT Levels at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>The Percentage of Participants in the TMC435 Treatment Group Who Met Response Guided Treatment (RGT) Criteria and Completed Treatment With Peginterferon Alpha-2a (PegIFN Alpha-2a) and Ribavirin (RBV) at Week 24</outcome_measure>
      <outcome_measure>Plasma Concentrations of TMC435</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24h) for TMC435</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01292239</url>
  </study>
  <study rank="90">
    <nct_id>NCT01754974</nct_id>
    <title>Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus (HCV)</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon Lambda-1a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Biological">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI452-033</other_id>
      <other_id>2012-003508-11</other_id>
    </other_ids>
    <first_received>December 19, 2012</first_received>
    <start_date>March 2013</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>January 27, 2015</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>BASIS</acronym>
    <primary_completion_date>September 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects who develop treatment emergent cytopenic abnormalities (anemia as defined by Hb &lt; 10 g/dL, and/or neutropenia as defined by ANC &lt; 750 mm3 and/or thrombocytopenia as defined by platelets &lt; 50,000 mm3) in treatment-naive subjects</outcome_measure>
      <outcome_measure>Proportion of subjects with Sustained Virologic Response at Post-Treatment Follow-up Week 24 (SVR24), defined as Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt; Lower Limit of Quantitation of Assay (LLOQ)</outcome_measure>
      <outcome_measure>Proportion of subjects with Rapid Virologic Response (RVR) (HCV RNA not detected)</outcome_measure>
      <outcome_measure>Proportion of subjects with on-treatment Serious Adverse Events (SAEs) through end of treatment</outcome_measure>
      <outcome_measure>Proportion of subjects with dose reductions through end of treatment</outcome_measure>
      <outcome_measure>Proportion of subjects who discontinue due to Adverse Events (AEs) through end of treatment</outcome_measure>
      <outcome_measure>Proportion of subjects with on-treatment Interferon (IFN)-associated symptoms as determined by adverse event reporting</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Czech Republic</country>
      <country>Korea, Republic of</country>
      <country>Mexico</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01754974</url>
  </study>
  <study rank="91">
    <nct_id>NCT01288209</nct_id>
    <title>A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Peginterferon alfa-2a (PegIFNα-2a )</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Pharmaceutical K.K.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>106</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017689</other_id>
      <other_id>TMC435HPC3004</other_id>
    </other_ids>
    <first_received>February 1, 2011</first_received>
    <start_date>February 2011</start_date>
    <completion_date>September 2012</completion_date>
    <last_updated>December 18, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>October 15, 2013</firstreceived_results_date>
    <primary_completion_date>September 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants With a Sustained Virologic Response at the End of Treatment (EOT) and 12 Weeks After the Last Dose of Treatment (SVR12)</outcome_measure>
      <outcome_measure>The Percentage of Participants With a Sustained Virologic Response 24 Weeks After the End of Treatment (EOT) and 24 Weeks After the Last Dose of Treatment (SVR24)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up</outcome_measure>
      <outcome_measure>The Percentage of Participants With Undetectable Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) During Treatment and at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels During Treatment for Participants Who Did Not Achieve Undetectable Plasma HCV RNA Levels at Week 12</outcome_measure>
      <outcome_measure>The Number of Participants With Viral Breakthrough During the Study</outcome_measure>
      <outcome_measure>The Number of Participants Demonstrating Viral Relapse During the Study</outcome_measure>
      <outcome_measure>The Number Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal ALT Levels at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Met Response Guided Treatment (RGT) Criteria and Completed Treatment With Peginterferon Alpha-2a (PegIFNα-2a) and Ribavirin (RBV) at Week 24</outcome_measure>
      <outcome_measure>Plasma Concentrations of TMC435</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24h) for TMC435</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01288209</url>
  </study>
  <study rank="92">
    <nct_id>NCT00537407</nct_id>
    <title>A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Debio 025</intervention>
      <intervention type="Drug">Peg-IFNα2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Debiopharm International SA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Debio 025-HCV-207</other_id>
    </other_ids>
    <first_received>September 28, 2007</first_received>
    <start_date>September 2007</start_date>
    <completion_date>April 2010</completion_date>
    <last_updated>May 1, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>April 1, 2015</firstreceived_results_date>
    <primary_completion_date>April 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in log10 Hepatitis C Virus RNA at Day 29 in the Debio 025 Triple Therapy Treatment Arms (A, D, and E)</outcome_measure>
      <outcome_measure>Change From Baseline in log10 Hepatitis C Virus RNA at Day 29 in the Debio 025 Monotherapy and Dual Therapy Treatment Arms (B and C)</outcome_measure>
      <outcome_measure>log10 Hepatitis C Virus RNA at Day 29</outcome_measure>
      <outcome_measure>Percentage of Participants With a Rapid Viral Response at Day 29</outcome_measure>
      <outcome_measure>Percentage of Participants With an Early Viral Response at Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With an End-of-treatment Response at the End of Treatment (Week 48 or 72)</outcome_measure>
      <outcome_measure>Percentage of Participants With a Sustained Viral Response 24 Weeks After the End of Treatment (Week 72 or 96)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00537407</url>
  </study>
  <study rank="93">
    <nct_id>NCT00637923</nct_id>
    <title>Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitazoxanide</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Biological">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Romark Laboratories L.C.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>112</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>RM01-2026</other_id>
    </other_ids>
    <first_received>March 11, 2008</first_received>
    <start_date>March 2008</start_date>
    <completion_date>April 2010</completion_date>
    <last_updated>January 9, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>November 18, 2013</firstreceived_results_date>
    <acronym>STEALTHC-3</acronym>
    <primary_completion_date>April 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (HCV RNA Below Lower Limit of Detection)</outcome_measure>
      <outcome_measure>End of Treatment Response (HCV RNA Below Lower Limit of Detection)</outcome_measure>
      <outcome_measure>Early Virologic Response (HCV RNA Below Lower Limit of Detection)</outcome_measure>
      <outcome_measure>Rapid Virologic Response (HCV RNA Below Lower Limit of Detection)</outcome_measure>
      <outcome_measure>Changes in ALT</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Massachusetts</state>
      <state>New York</state>
      <state>Tennessee</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00637923</url>
  </study>
  <study rank="94">
    <nct_id>NCT01939197</nct_id>
    <title>A Two Part, Open-label Study to Evaluate the Safety and Effectiveness of ABT-450/r/ABT-267 or ABT-450/r/ABT-267 and ABT-333 Given With or Without a Drug Called Ribavirin in People With Both Hepatitis C Virus Genotype 1 or 4 Infection and Human Immunodeficiency Virus, Type 1 Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
      <condition>Human Immunodeficiency Virus Infection</condition>
      <condition>Chronic Hepatitis C</condition>
      <condition>Compensated Cirrhosis and Non-cirrhotics</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450/r/ABT-267</intervention>
      <intervention type="Drug">ABT-333</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>320</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M14-004</other_id>
      <other_id>2012-005143-24</other_id>
    </other_ids>
    <first_received>September 6, 2013</first_received>
    <start_date>August 2013</start_date>
    <completion_date>September 2016</completion_date>
    <last_updated>October 3, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>TURQUOISE-I</acronym>
    <primary_completion_date>July 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of subjects in genotype 1 Analysis Group 1 in Part 2 achieving sustained virologic response 12 weeks post-treatment (SVR12) compared to the historical SVR12 rate for sofosbuvir plus ribavirin as reported in the PHOTON-1 study</outcome_measure>
      <outcome_measure>The percentage of subjects in genotype 1 Analysis Group 2 of Part 2 achieving sustained virologic response 12 weeks post-treatment (SVR12) compared to the historical rate for sofosbuvir plus ribavirin</outcome_measure>
      <outcome_measure>The percentage of Part 1a subjects achieving sustained virologic response 12 weeks post-treatment (SVR12) in the 24-week treatment group compared to the 12-week treatment group using Fisher's exact test</outcome_measure>
      <outcome_measure>The percentage of subjects of Part 1b subjects achieving sustained virologic response 12 weeks post-treatment (SVR12) in the darunavir once-daily arm compared to the darunavir twice-daily arm using Fisher's exact test</outcome_measure>
      <outcome_measure>The percentage of Part 1b subjects achieving sustained virologic response 12 weeks post-treatment (SVR12)</outcome_measure>
      <outcome_measure>The percentage of Part 2 GT 1b cirrhotic subjects achieving sustained virologic response 12 weeks post-treatment (SVR12) in Arm F (without ribavirin) compared to Arm G (with ribavirin) using Fisher's exact test</outcome_measure>
      <outcome_measure>The percentage of genotype 4 subjects in Part 2 achieving sustained virologic response 12 weeks post-treatment (SVR12) by arm and overall</outcome_measure>
      <outcome_measure>Percentage of subjects with on treatment Hepatitis C Virus virologic failure during the Treatment Period for each arm in Part 1, set of all subjects in Part 1b, the genotype 1 Analysis Group 1 and 2 in Part 2, the GT4 Analysis Group by arm and overall</outcome_measure>
      <outcome_measure>The percentage of subjects with Hepatitis C Virus post-treatment relapse (analyses performed as described for secondary endpoint 7).</outcome_measure>
      <outcome_measure>Percentage of subjects with plasma HIV-1 RNA suppression at end of treatment and 12 weeks post-treatment (analyses performed as described for secondary endpoint 7) and comparison of the darunavir once-daily and twice-daily arms in Part 1b</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01939197</url>
  </study>
  <study rank="95">
    <nct_id>NCT00571714</nct_id>
    <title>Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alpha-2a and ribavirin</intervention>
      <intervention type="Drug">Peginterferon alpha-2a , ribavirin and betaine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Nebraska</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>44</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>159-07-FB</other_id>
    </other_ids>
    <first_received>December 11, 2007</first_received>
    <start_date>April 2008</start_date>
    <completion_date>March 2010</completion_date>
    <last_updated>June 23, 2010</last_updated>
    <last_verified>June 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Viral Response 24 weeks following the end of anti-viral therapy</outcome_measure>
      <outcome_measure>Comparison of rapid and early virologic response in the first 4 and 12 weeks of therapy</outcome_measure>
      <outcome_measure>Comparison of the safety of the two treatment regimens</outcome_measure>
      <outcome_measure>Comparison of ALT normalization between the two regimens</outcome_measure>
      <outcome_measure>Comparison of the effect on interferon gene signaling in peripheral blood mononuclear cells between the two regimens in the first 12 weeks of therapy.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Nebraska</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00571714</url>
  </study>
  <study rank="96">
    <nct_id>NCT00707850</nct_id>
    <title>Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Thalassemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Baqiyatallah Medical Sciences University</lead_sponsor>
      <collaborator>Baqiyatallah Research Center for Gastroenterology and Liver Diseases</collaborator>
      <collaborator>Tehran Hepatitis Center</collaborator>
      <collaborator>Guilan Research Center for Gastroenterology and Liver Diseases</collaborator>
      <collaborator>Tabriz Research Center for Gastroenterology and Liver Diseases</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>BRCGL-08-06</other_id>
    </other_ids>
    <first_received>June 26, 2008</first_received>
    <start_date>May 2007</start_date>
    <completion_date>September 2009</completion_date>
    <last_updated>August 30, 2010</last_updated>
    <last_verified>September 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Early Virologic Response</outcome_measure>
      <outcome_measure>End of Treatment Response</outcome_measure>
      <outcome_measure>Sustained Virologic Response</outcome_measure>
      <outcome_measure>Rapid Virologic Response</outcome_measure>
      <outcome_measure>Tolerability of drugs for whole therapy period</outcome_measure>
      <outcome_measure>Biochemical response (ALT)</outcome_measure>
      <outcome_measure>Laboratory Parameters</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Iran, Islamic Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00707850</url>
  </study>
  <study rank="97">
    <nct_id>NCT00623428</nct_id>
    <title>A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>235</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>MV21371</other_id>
      <other_id>2007-004993-15</other_id>
    </other_ids>
    <first_received>February 18, 2008</first_received>
    <start_date>June 2008</start_date>
    <completion_date>May 2012</completion_date>
    <last_updated>July 15, 2013</last_updated>
    <last_verified>July 2013</last_verified>
    <firstreceived_results_date>May 2, 2013</firstreceived_results_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With a Sustained Virologic Response 24 Weeks After Scheduled Completion of Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With a Sustained Virologic Response 24 Weeks After Actual End of Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Virological Response 72 Weeks After Treatment Initiation</outcome_measure>
      <outcome_measure>Percentage of Participants With Virological Response at End of Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Virological Relapse</outcome_measure>
      <outcome_measure>Percentage of Participants With a Sustained Virologic Response 12 Weeks After Actual End of Treatment</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events (AEs)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>Germany</country>
      <country>Mexico</country>
      <country>Puerto Rico</country>
      <country>Switzerland</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Louisiana</state>
      <state>Massachusetts</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00623428</url>
  </study>
  <study rank="98">
    <nct_id>NCT00991289</nct_id>
    <title>Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>HIV Infection</condition>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitazoxanide (NTZ)</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a (PEG)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>68</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>A5269</other_id>
      <other_id>10764</other_id>
      <other_id>ACTG A5269</other_id>
    </other_ids>
    <first_received>October 7, 2009</first_received>
    <start_date>January 2010</start_date>
    <completion_date>January 2012</completion_date>
    <last_updated>November 19, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>August 29, 2011</firstreceived_results_date>
    <primary_completion_date>November 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Early Virologic Response (EVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events of Grade 2 or Higher</outcome_measure>
      <outcome_measure>Change in Hemoglobin Level From Study Entry</outcome_measure>
      <outcome_measure>Percent Change in Fasting Insulin Level From Study Entry</outcome_measure>
      <outcome_measure>Percent Change in Fasting Glucose Level From Study Entry</outcome_measure>
      <outcome_measure>Percent Change in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) From Study Entry</outcome_measure>
      <outcome_measure>Change in log10 HCV Viral Load After 4 Weeks of Nitazoxanide (NTZ) Monotherapy.</outcome_measure>
      <outcome_measure>Number of Participants With HCV Genotype 1</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Massachusetts</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00991289</url>
  </study>
  <study rank="99">
    <nct_id>NCT01797848</nct_id>
    <title>Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa 2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Placebo matching Daclatasvir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-047</other_id>
    </other_ids>
    <first_received>February 21, 2013</first_received>
    <start_date>June 2014</start_date>
    <completion_date>November 2016</completion_date>
    <last_updated>November 21, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>COMMAND-Asia</acronym>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of Genotype 1 subjects with SVR24, defined as HCV RNA &lt; Limit of quantification (LOQ) at follow-up Week 24 for each cohort</outcome_measure>
      <outcome_measure>Proportion of Genotype (GT) 4 subjects with SVR24</outcome_measure>
      <outcome_measure>Proportion of GT 1 &amp; 4 subjects who achieve HCV RNA &lt; LOQ or undetectable</outcome_measure>
      <outcome_measure>Frequency of Serious Adverse Events (SAEs)/discontinuations due to Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Discontinuations due to Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Proportion of subjects with Sustained Virologic Response at follow up week 12 (SVR12) or SVR24 by rs12979860 Single nucleotide polymorphism (SNP) in the IL28B gene</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01797848</url>
  </study>
  <study rank="100">
    <nct_id>NCT01664845</nct_id>
    <title>Effects of Metformin, Pegylated Interferon Alpha and Ribavirin for Chronic Hepatitis C With Insulin Resistance</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis c</condition>
      <condition>Insulin Resistance</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">metformin</intervention>
      <intervention type="Drug">pegylated-IFN</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kaohsiung Veterans General Hospital.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VGHKS12-CT3-16</other_id>
    </other_ids>
    <first_received>August 10, 2012</first_received>
    <start_date>August 2012</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>August 13, 2012</last_updated>
    <last_verified>August 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>sustained virological response</outcome_measure>
      <outcome_measure>change of HOMA-IR</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01664845</url>
  </study>
  <study rank="101">
    <nct_id>NCT00724620</nct_id>
    <title>PEG-IFN Alfa-2b Plus Ribavirin for Treatment of Mexican naïve Patients With Chronic Hepatitis C Infected With Genotype 1 (Study P04511)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b (SCH 054031)</intervention>
      <intervention type="Drug">Ribavirin (SCH 018908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Schering-Plough</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>103</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04511</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>June 2005</start_date>
    <completion_date>February 2008</completion_date>
    <last_updated>July 25, 2008</last_updated>
    <last_verified>July 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate the overall SVR of chronic hepatitis C Genotype 1 Naïve Mexican patients with different durations of treatment.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00724620</url>
  </study>
  <study rank="102">
    <nct_id>NCT02156570</nct_id>
    <title>DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kirby Institute</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VHCRP1206</other_id>
    </other_ids>
    <first_received>June 3, 2014</first_received>
    <start_date>October 2014</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>April 6, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>DARE-CII</acronym>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR 12</outcome_measure>
      <outcome_measure>SVR 24</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
      <country>New Zealand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02156570</url>
  </study>
  <study rank="103">
    <nct_id>NCT02107365</nct_id>
    <title>Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Genotype 4 Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Asunaprevir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated Interferon alpha-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
      <collaborator>Bristol-Myers Squibb</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRS HC32 QUATTRO</other_id>
    </other_ids>
    <first_received>March 31, 2014</first_received>
    <start_date>November 2013</start_date>
    <completion_date>September 2015</completion_date>
    <last_updated>August 25, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR12 Rate</outcome_measure>
      <outcome_measure>Number of patients with adverse events</outcome_measure>
      <outcome_measure>Treatment discontinuations</outcome_measure>
      <outcome_measure>Self-reported symptoms</outcome_measure>
      <outcome_measure>Patients' adherence</outcome_measure>
      <outcome_measure>SVR 24 rate</outcome_measure>
      <outcome_measure>HCV viral load</outcome_measure>
      <outcome_measure>Number of patients with virological failure under treatment</outcome_measure>
      <outcome_measure>HCV subtypic distribution</outcome_measure>
      <outcome_measure>Proportion of patients with resistance mutations to Asunaprevir and/or Daclatasvir in case of virological failure</outcome_measure>
      <outcome_measure>Cirrhosis evaluation</outcome_measure>
      <outcome_measure>Insulin resistance : HOMA-IR score</outcome_measure>
      <outcome_measure>Metabolic syndrome parameters</outcome_measure>
      <outcome_measure>Liver fibrosis</outcome_measure>
      <outcome_measure>Polymorphism of the gene of IL28B</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02107365</url>
  </study>
  <study rank="104">
    <nct_id>NCT00100659</nct_id>
    <title>PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon/ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>Roche Pharma AG</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>114</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>67767 (completed)</other_id>
    </other_ids>
    <first_received>January 4, 2005</first_received>
    <start_date>December 2004</start_date>
    <completion_date>February 2010</completion_date>
    <last_updated>July 10, 2013</last_updated>
    <last_verified>July 2013</last_verified>
    <firstreceived_results_date>May 10, 2013</firstreceived_results_date>
    <primary_completion_date>August 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Viral Response (SVR)</outcome_measure>
      <outcome_measure>Vital Signs Events.</outcome_measure>
      <outcome_measure>Laboratory Assessments</outcome_measure>
      <outcome_measure>Adverse Events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>New York</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00100659</url>
  </study>
  <study rank="105">
    <nct_id>NCT00800748</nct_id>
    <title>A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>373</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML19387</other_id>
      <other_id>2005-003932-23</other_id>
    </other_ids>
    <first_received>December 1, 2008</first_received>
    <start_date>January 2006</start_date>
    <completion_date>August 2010</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Incidence of adverse events</outcome_measure>
      <outcome_measure>Percentage of participants with sustained viral response</outcome_measure>
      <outcome_measure>Percentage of participants with viral response rate</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Czech Republic</country>
      <country>Slovakia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00800748</url>
  </study>
  <study rank="106">
    <nct_id>NCT01366638</nct_id>
    <title>A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Peginterferon alfa-2b (pegIFN alfa-2b)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Pharmaceutical K.K.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>79</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017935</other_id>
      <other_id>TMC435HPC3010</other_id>
    </other_ids>
    <first_received>June 2, 2011</first_received>
    <start_date>May 2011</start_date>
    <completion_date>November 2012</completion_date>
    <last_updated>April 10, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>October 17, 2013</firstreceived_results_date>
    <primary_completion_date>November 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants With a Sustained Virologic Response 12 Weeks After the Actual End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>The Percentage of Participants With a Sustained Virologic Response 24 Weeks After the Actual End of Treatment (SVR24)</outcome_measure>
      <outcome_measure>The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment</outcome_measure>
      <outcome_measure>The Number of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>The Number of Participants Demonstrating Viral Relapse</outcome_measure>
      <outcome_measure>The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal Limit of ALT at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Met Response Guided Treatment (RGT) Criteria and Completed Treatment With Peginterferon Alpha-2b (PegIFNα-2b) and Ribavirin (RBV) at Week 24</outcome_measure>
      <outcome_measure>The Area Under the Plasma Concentration-Time Curve (From 0 to 24 Hours) (AUC24h)</outcome_measure>
      <outcome_measure>Plasma Concentrations of TMC435</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01366638</url>
  </study>
  <study rank="107">
    <nct_id>NCT00237484</nct_id>
    <title>Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin</intervention>
      <intervention type="Drug">Combination of (a) pegylated interferon alfa-2b and (b) ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>89</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04257</other_id>
    </other_ids>
    <first_received>October 10, 2005</first_received>
    <start_date>July 2005</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>Pegade</acronym>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects who have achieved sustained virological response (SVR) in the infliximab (induction dose) plus PEGETRON and the PEGETRON groups at 24 weeks post treatment end</outcome_measure>
      <outcome_measure>Early virological response (EVR)</outcome_measure>
      <outcome_measure>Safety parameters</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00237484</url>
  </study>
  <study rank="108">
    <nct_id>NCT01718158</nct_id>
    <title>Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon Lambda-1a</intervention>
      <intervention type="Biological">Peginterferon Alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>444</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI452-021</other_id>
      <other_id>2011‐005409‐65</other_id>
    </other_ids>
    <first_received>October 29, 2012</first_received>
    <start_date>January 2013</start_date>
    <completion_date>October 2014</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>STRUCTURE</acronym>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects with Sustained Virologic Response at post-treatment follow-up Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve SVR12 in treatment-naive subjects</outcome_measure>
      <outcome_measure>Proportion of subjects with rash related dermatologic events</outcome_measure>
      <outcome_measure>Proportion of subjects who develop treatment emergent cytopenic abnormalities</outcome_measure>
      <outcome_measure>Proportion of subjects with on-treatment interferon (IFN) associated flu like/musculoskeletal symptoms</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve SVR24 [Hepatitis C virus (HCV) Ribonucleic acid (RNA) &lt; Lower limit of quantitation (LLOQ)] at post-treatment follow-up Week 24</outcome_measure>
      <outcome_measure>Proportion of subjects with adverse events (AEs), Serious adverse events (SAEs), dose reductions, and discontinuations due to AEs through end of follow-up</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve SVR12 with a 24-week treatment regimen</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve Extended rapid virologic response (eRVR) (HCV RNA &lt; LLOQ target not detected at Weeks 4 and 12 of treatment)</outcome_measure>
      <outcome_measure>Patient Health Questionnaire-9 (PHQ-9) score through end of follow-up</outcome_measure>
      <outcome_measure>Proportion of subjects with treatment emergent laboratory abnormalities by toxicity grade through End of treatment (EOT)</outcome_measure>
      <outcome_measure>Proportion of subjects with the following on-treatment interferon-associated neuropsychiatric symptoms through EOT</outcome_measure>
      <outcome_measure>Association of Single nucleotide polymorphism (SNPs) in Interleukin 28B (IL28B) (including rs12979860) or equilibrative nucleoside transporter 1 (ENT1) with clinical responses</outcome_measure>
      <outcome_measure>Resistant variants associated with virologic failure through end of follow-up</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Argentina</country>
      <country>France</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Italy</country>
      <country>Japan</country>
      <country>Korea, Republic of</country>
      <country>Poland</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Taiwan</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Georgia</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01718158</url>
  </study>
  <study rank="109">
    <nct_id>NCT00728494</nct_id>
    <title>Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b; SCH 54031)</intervention>
      <intervention type="Drug">Rebetol (ribavirin; SCH 18908)</intervention>
      <intervention type="Behavioral">Patient Assistance Program</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>99</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04671</other_id>
    </other_ids>
    <first_received>July 31, 2008</first_received>
    <start_date>October 2005</start_date>
    <completion_date>December 2007</completion_date>
    <last_updated>July 20, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>December 5, 2008</firstreceived_results_date>
    <primary_completion_date>December 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Number of Participants Who Complete Treatment With PegIntron/Rebetol Therapy for Hepatitis C</outcome_measure>
      <outcome_measure>The Number of Participants With a Sustained Virologic Response at 6 Months Post-treatment</outcome_measure>
      <outcome_measure>The Number of Participants Who Relapsed at 6 Months Post-treatment</outcome_measure>
      <outcome_measure>Average Length of Treatment</outcome_measure>
      <outcome_measure>Average Dosage of PegIntron</outcome_measure>
      <outcome_measure>Average Dosage of Rebetol</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00728494</url>
  </study>
  <study rank="110">
    <nct_id>NCT00705224</nct_id>
    <title>Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated Interferon</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>250</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05562</other_id>
    </other_ids>
    <first_received>June 23, 2008</first_received>
    <start_date>May 2008</start_date>
    <completion_date>August 2010</completion_date>
    <last_updated>June 4, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>August 9, 2011</firstreceived_results_date>
    <primary_completion_date>August 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Who Achieved Sustained Virological Response as Assessed at End of Study</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieved Sustained Virological Response as Assessed at End of Study by HCV Genotype and Presence of Insulin-Resistance at Baseline</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieved Response Following Treatment as Assessed at End of Treatment by HCV Genotype and Presence of Insulin-Resistance at Baseline</outcome_measure>
      <outcome_measure>Percentage of Participants Who Demonstrated Virological Relapse as Assessed at End of Study by HCV Genotype and Presence of Insulin-Resistance at Baseline</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieved Early Virological Response as Assessed at Visit 2 by HCV Genotype and Presence of Insulin-Resistance at Baseline</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00705224</url>
  </study>
  <study rank="111">
    <nct_id>NCT01726946</nct_id>
    <title>A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">VX-135</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX12-135-101</other_id>
    </other_ids>
    <first_received>November 7, 2012</first_received>
    <start_date>November 2012</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>March 27, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The safety and tolerability as assessed by adverse events, vital signs, 12-lead electrocardiograms, echocardiograms (Cohorts 1 and 2 only), and laboratory assessments</outcome_measure>
      <outcome_measure>The proportion of subjects who have an SVR at 4 weeks after the last planned dose of treatment (SVR4)</outcome_measure>
      <outcome_measure>The proportion of subjects who have an SVR at 12 weeks after the last planned dose of treatment (SVR12)</outcome_measure>
      <outcome_measure>The proportion of subjects who have an SVR at 24 weeks after the last planned dose of treatment (SVR24)</outcome_measure>
      <outcome_measure>The proportion of subjects who have virologic relapse</outcome_measure>
      <outcome_measure>Viral kinetics, as determined at different time points by the proportion of subjects who achieve: -Undetectable HCV RNA -&lt;LLOQ HCV RNA</outcome_measure>
      <outcome_measure>The proportion of subjects who have virologic breakthrough</outcome_measure>
      <outcome_measure>The proportion of subjects who achieve SVR12 by IL-28B genotype (CC versus non-CC)</outcome_measure>
      <outcome_measure>The amino acid sequence of the nonstructural (NS)5B protein in subjects who fail treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01726946</url>
  </study>
  <study rank="112">
    <nct_id>NCT00830609</nct_id>
    <title>High Dose Versus Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa 2 A</intervention>
      <intervention type="Drug">Peginterferon alfa 2 A, ribavirin + Epo Beta</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa 2</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Dr. Conrado Fernandez</lead_sponsor>
      <collaborator>Hospital Universitario Fundación Alcorcón</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>101</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ROCHE FARMA S.A.</other_id>
    </other_ids>
    <first_received>January 27, 2009</first_received>
    <start_date>November 2008</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>March 12, 2012</last_updated>
    <last_verified>March 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>DARGEN-3</acronym>
    <primary_completion_date>September 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Rate of patients with RNA-HCV negative in each arm at week 24 after the end of treatment.</outcome_measure>
      <outcome_measure>Rate of patients with undetectable RNA-HCV in each arm at week 4 and 24 of treatment. Rate of adverse effects in each arm.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00830609</url>
  </study>
  <study rank="113">
    <nct_id>NCT00470210</nct_id>
    <title>Peginterferon Alfa-2a, Ribavirin and Epoetin β in Coinfected Patients HCV/HIV Not Responding to Previous Treatment Regimens</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week</intervention>
      <intervention type="Drug">Ribavirin (Copegus®) 1600 mg/day</intervention>
      <intervention type="Drug">Epoetin β (450 UI/kg/week)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Germans Trias i Pujol Hospital</lead_sponsor>
      <collaborator>Fundacio Lluita Contra la SIDA</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>MORE</other_id>
      <other_id>2006-005554-74</other_id>
    </other_ids>
    <first_received>May 4, 2007</first_received>
    <start_date>May 2007</start_date>
    <completion_date>June 2009</completion_date>
    <last_updated>April 15, 2010</last_updated>
    <last_verified>April 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Rate of sustained virologic response measured as serum HCV-RNA loads of &lt; 50 IU/mL</outcome_measure>
      <outcome_measure>Changes in serum HCV-RNA titers</outcome_measure>
      <outcome_measure>Percentage of patients with serum HCV-RNA loads of &lt; 50 IU/mL</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00470210</url>
  </study>
  <study rank="114">
    <nct_id>NCT01687257</nct_id>
    <title>Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Cirrhosis</condition>
      <condition>Portal Hypertension</condition>
      <condition>With or Without Liver Decompensation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0125</other_id>
      <other_id>2012-002457-29</other_id>
    </other_ids>
    <first_received>September 12, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>October 2015</completion_date>
    <last_updated>October 8, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Change in Hepatic Venous Pressure Gradient (HVPG) measurements</outcome_measure>
      <outcome_measure>Change in Child-Pugh-Turcotte (CPT) score</outcome_measure>
      <outcome_measure>Change in Model for End-Stage Liver Disease (MELD) score</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response at 4, 24, and 48 weeks after discontinuation of therapy (SVR4, SVR24, SVR48)</outcome_measure>
      <outcome_measure>Proportion of participants experiencing viral breakthrough</outcome_measure>
      <outcome_measure>Proportion of participants experiencing viral relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>France</country>
      <country>New Zealand</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Colorado</state>
      <state>Massachusetts</state>
      <state>Minnesota</state>
      <state>Pennsylvania</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01687257</url>
  </study>
  <study rank="115">
    <nct_id>NCT00630084</nct_id>
    <title>Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Neoplasms</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon alpha 2a and plus ribavirin</intervention>
      <intervention type="Drug">pegylated interferon alpha 2a and plus ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kaohsiung Medical University Chung-Ho Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KMUH-IRB-960044</other_id>
    </other_ids>
    <first_received>February 26, 2008</first_received>
    <start_date>August 2006</start_date>
    <completion_date>October 2008</completion_date>
    <last_updated>September 3, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy - Sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.</outcome_measure>
      <outcome_measure>Rapid virologic response (RVR), HCV RNA seronegative by PCR at week 4.</outcome_measure>
      <outcome_measure>Early virological response (EVR), by PCR-negative or at least 2 logs decline from baseline of serum HCV RNA at 12 weeks of treatment.</outcome_measure>
      <outcome_measure>Safety - adverse event rate and profile</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00630084</url>
  </study>
  <study rank="116">
    <nct_id>NCT01265511</nct_id>
    <title>Study of SCY-635, Pegasys and Copegus in Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">SCY-635</intervention>
      <intervention type="Drug">peginterferon alfa 2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Scynexis, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>SCY-635-201</other_id>
    </other_ids>
    <first_received>November 23, 2010</first_received>
    <start_date>November 2010</start_date>
    <completion_date>October 2011</completion_date>
    <last_updated>May 29, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Undetectable HCV RNA</outcome_measure>
      <outcome_measure>Partial early virologic response</outcome_measure>
      <outcome_measure>Incidence and severity of treatment emergent adverse events and changes in laboratory values as measures of Safety and tolerability</outcome_measure>
      <outcome_measure>Pharmacokinetic assessment of SCY-635</outcome_measure>
      <outcome_measure>Pharmacokinetics of peginterferon alfa 2a and Ribavirin (trough concentrations)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>North Carolina</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01265511</url>
  </study>
  <study rank="117">
    <nct_id>NCT01318694</nct_id>
    <title>Efficacy and Safety Study of DEB025/Alisporivir Combined to Peg-IFN and Ribavirin in Chronic Hepatitis C Genotype 1 Treatment-naïve Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-IFN once weekly + Ribavirin BID + DEB025 600 mg QD</intervention>
      <intervention type="Drug">Peg-IFN once weekly + Ribavirin BID + DEB025 400 mg BID</intervention>
      <intervention type="Drug">Peg-IFN once weekly + Ribavirin BID + DEB025 600 mg QD</intervention>
      <intervention type="Drug">PegIFN once weekly + Ribavirin + Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1073</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CDEB025A2301</other_id>
      <other_id>2010-022867-37</other_id>
    </other_ids>
    <first_received>March 17, 2011</first_received>
    <start_date>March 2011</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>October 13, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Viral Response Week 12 (SVR 12) defined as serum HCV RNA undetectable by limit of detection (LOD) 24 weeks after treatment completion</outcome_measure>
      <outcome_measure>Rapid Virological response by limit of detection (RVR4LOD), Rapid Virological response by limit of quantification (RVR4LOQ) - defined as serum HCV RNA below LOD or LOQ respectively after 4 weeks of treatment</outcome_measure>
      <outcome_measure>Early Virological Response (EVR): serum HCV RNA reduction by at least 2Log10 or serum HCV RNA below LOQ 12 weeks after treatment start</outcome_measure>
      <outcome_measure>End of treatment response (ETR) - defined as HCV RNA undetectable by limit of detection</outcome_measure>
      <outcome_measure>Change in liver enzyme (ALT and bilirubin) and hematological patient profiles (platelets, neutrophils, hemoglobin) during treatment phase.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Hong Kong</country>
      <country>Hungary</country>
      <country>Italy</country>
      <country>Korea, Republic of</country>
      <country>Mexico</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Taiwan</country>
      <country>Thailand</country>
      <country>United Kingdom</country>
      <country>Vietnam</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>Nebraska</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01318694</url>
  </study>
  <study rank="118">
    <nct_id>NCT01648140</nct_id>
    <title>Dose Ranging of GSK2336805 in Combination Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GSK2336805 40 mg</intervention>
      <intervention type="Drug">GSK2336805 60 mg</intervention>
      <intervention type="Drug">Pegylated interferon alpha-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
      <collaborator>PPD</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>286</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>115879</other_id>
    </other_ids>
    <first_received>July 12, 2012</first_received>
    <start_date>August 2012</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>September 10, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HAI115879</acronym>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Frequency of adverse events and absolute values.</outcome_measure>
      <outcome_measure>Antiviral activity of 40 and 60 mg of GSK2336805 when given in combination with pegylated interferon alpha-2a and ribavirin.</outcome_measure>
      <outcome_measure>Changes over time from predose values for hematology, clinical chemistry, urinalysis, vital sign measurements and electrocardiograms.</outcome_measure>
      <outcome_measure>GSK2336805 plasma pharmacokinetics</outcome_measure>
      <outcome_measure>Very rapid virologic response (vRVR)</outcome_measure>
      <outcome_measure>Rapid virologic response (RVR)</outcome_measure>
      <outcome_measure>Complete early virologic response (cEVR)</outcome_measure>
      <outcome_measure>Sustained virologic response (SVR12)</outcome_measure>
      <outcome_measure>Sustained virologic response (SVR24)</outcome_measure>
      <outcome_measure>Sustained virologic response rates between GSK2336805 and standard of care</outcome_measure>
      <outcome_measure>Resistance against GSK2336805</outcome_measure>
      <outcome_measure>Antiviral activity and safety of 60 mg of GSK2336805 in subjects with genotype 4 hepatitis C virus (HCV) infection</outcome_measure>
      <outcome_measure>GSK2336805 exposure-response relationships</outcome_measure>
      <outcome_measure>Frequency of adverse events and absolute values</outcome_measure>
      <outcome_measure>Changes over time from predose values for hematology, clinical chemistry, urinalysis, vital sign measurements and electrocardiograms</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Belgium</country>
      <country>Bulgaria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Nevada</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01648140</url>
  </study>
  <study rank="119">
    <nct_id>NCT00526448</nct_id>
    <title>Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">epoetin beta</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hospital Carlos III, Madrid</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>384</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2006-005940-99</other_id>
    </other_ids>
    <first_received>September 5, 2007</first_received>
    <start_date>June 2007</start_date>
    <completion_date>February 2010</completion_date>
    <last_updated>January 28, 2009</last_updated>
    <last_verified>January 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PERICO</acronym>
    <outcome_measures>
      <outcome_measure>% patients with RNA-HCV &lt; 50 UI/ml</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00526448</url>
  </study>
  <study rank="120">
    <nct_id>NCT00423800</nct_id>
    <title>Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>56</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05016</other_id>
    </other_ids>
    <first_received>January 17, 2007</first_received>
    <start_date>December 2006</start_date>
    <completion_date>October 2009</completion_date>
    <last_updated>October 8, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>January 27, 2011</firstreceived_results_date>
    <primary_completion_date>October 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With a Sustained Virologic Response</outcome_measure>
      <outcome_measure>Number of Participants With a Virological Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00423800</url>
  </study>
  <study rank="121">
    <nct_id>NCT01724086</nct_id>
    <title>A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC647055</intervention>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Ritonavir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated interferon alpha-2a (PegIFN)</intervention>
      <intervention type="Drug">GSK2336805</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100882</other_id>
      <other_id>TMC647055HPC2001</other_id>
      <other_id>2012-002555-42</other_id>
    </other_ids>
    <first_received>September 26, 2012</first_received>
    <start_date>October 2012</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>January 23, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of patients with a sustained virologic response (SVR) 12 Weeks after the actual end of treatment</outcome_measure>
      <outcome_measure>Number of patients with adverse events</outcome_measure>
      <outcome_measure>Number of patients with a sustained virological response (SVR at 4 and/or 24 Weeks after the actual end of treatment)</outcome_measure>
      <outcome_measure>HCV RNA levels over time</outcome_measure>
      <outcome_measure>Number of patients with undetectable hepatitis C virus (HCV) RNA (less than 25 IU/mL undetectable) and/or HCV RNA levels less than 25 IU/mL at all time points</outcome_measure>
      <outcome_measure>Number of patients with on-treatment virologic failure</outcome_measure>
      <outcome_measure>Number of patients with viral relapse</outcome_measure>
      <outcome_measure>Number of patients with presence of HCV variants associated with reduced susceptibility to investigational treatment</outcome_measure>
      <outcome_measure>Maximum plasma analyte concentration of TMC435</outcome_measure>
      <outcome_measure>Minimum plasma analyte concentration of TMC435</outcome_measure>
      <outcome_measure>Area under the plasma concentration-time curve of TMC435</outcome_measure>
      <outcome_measure>Maximum plasma analyte concentration of TMC647055</outcome_measure>
      <outcome_measure>Minimum plasma analyte concentration of TMC647055</outcome_measure>
      <outcome_measure>Area under the plasma concentration-time curve of TMC647055</outcome_measure>
      <outcome_measure>Maximum plasma analyte concentration of ritonavir (RTV)</outcome_measure>
      <outcome_measure>Minimum plasma analyte concentration of RTV</outcome_measure>
      <outcome_measure>Area under the plasma concentration-time curve of RTV</outcome_measure>
      <outcome_measure>Minimum and maximum plasma concentrations of GSK233680k</outcome_measure>
      <outcome_measure>Area under the plasma concentration-time curve of GSK233680k</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01724086</url>
  </study>
  <study rank="122">
    <nct_id>NCT01466790</nct_id>
    <title>A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">PSI-7977 (GS7977)</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
      <collaborator>Gilead Sciences</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>168</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR018724</other_id>
      <other_id>TMC435HPC2002</other_id>
    </other_ids>
    <first_received>November 3, 2011</first_received>
    <start_date>January 2012</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>January 26, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>October 17, 2014</firstreceived_results_date>
    <acronym>COSMOS</acronym>
    <primary_completion_date>November 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With a Sustained Virologic Response (SVR) 12 Weeks After the Planned End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Number of Participants With a Sustained Virologic Response (SVR) 4 Weeks After the Planned End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Number of Participants With a Sustained Virologic Response (SVR) 24 Weeks After the Planned End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Number of Participants With a Sustained Virologic Response (SVR) at Week 48</outcome_measure>
      <outcome_measure>Number of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Number of Participants With Inadequate Virologic Response</outcome_measure>
      <outcome_measure>Number of Participants With Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>New Hampshire</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01466790</url>
  </study>
  <study rank="123">
    <nct_id>NCT01272310</nct_id>
    <title>Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN alpha-2a) and Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Sheba Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>SHEBA-10-8033-YM-CTIL</other_id>
      <other_id>HCQ-001-IL</other_id>
    </other_ids>
    <first_received>January 3, 2011</first_received>
    <start_date>January 2011</start_date>
    <completion_date>July 2013</completion_date>
    <last_updated>January 6, 2011</last_updated>
    <last_verified>January 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from baseline in physical examination</outcome_measure>
      <outcome_measure>Change from baseline in vital Signs</outcome_measure>
      <outcome_measure>Change from baseline in clinical laboratory parameters</outcome_measure>
      <outcome_measure>Change from baseline in adverse events</outcome_measure>
      <outcome_measure>HCV RNA level</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01272310</url>
  </study>
  <study rank="124">
    <nct_id>NCT01592006</nct_id>
    <title>Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant Recipients</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>3</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>12-0156</other_id>
    </other_ids>
    <first_received>April 27, 2012</first_received>
    <start_date>April 2012</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>January 5, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>January 5, 2015</firstreceived_results_date>
    <primary_completion_date>September 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Efficacy of Triple Antiviral Therapy</outcome_measure>
      <outcome_measure>Safety of Triple Antiviral Therapy in HCV Infected OLT Recipients</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Illinois</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01592006</url>
  </study>
  <study rank="125">
    <nct_id>NCT00485342</nct_id>
    <title>RIBAJUSTE Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of Ribavirin</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-interferon alpha 2a and ribavin</intervention>
      <intervention type="Drug">ribavirin with adaptation dose</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hospices Civils de Lyon</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>236</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2005-400</other_id>
    </other_ids>
    <first_received>June 8, 2007</first_received>
    <start_date>April 2006</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>January 6, 2012</last_updated>
    <last_verified>January 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>RIBAJUSTE</acronym>
    <primary_completion_date>March 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Inter-group comparison of sustained virological response rates as defined by the proportion of subjects with a negative PCR HCV-RNA test at Week 72</outcome_measure>
      <outcome_measure>Efficacy endpoints</outcome_measure>
      <outcome_measure>safety endpoints</outcome_measure>
      <outcome_measure>Economic endpoints</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00485342</url>
  </study>
  <study rank="126">
    <nct_id>NCT01938625</nct_id>
    <title>A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>35</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR102639</other_id>
      <other_id>TMC435HPC3016</other_id>
      <other_id>2013-002726-23</other_id>
    </other_ids>
    <first_received>September 5, 2013</first_received>
    <start_date>December 2013</start_date>
    <completion_date>July 2015</completion_date>
    <last_updated>September 24, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants with a sustained virologic response (SVR)12 Weeks after the end of treatment</outcome_measure>
      <outcome_measure>Maximum Observed Plasma Concentration (Cmax) of cyclosporine and tacrolimus</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Time at Last Observed Quantifiable Concentration (AUC[last]) of cyclosporine and tacrolimus</outcome_measure>
      <outcome_measure>Maximum Observed Plasma Concentration (Cmax) of simprevir and daclatasvir</outcome_measure>
      <outcome_measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of simprevir and daclatasvir</outcome_measure>
      <outcome_measure>Predose (trough) concentration (C0h) of simprenavir and daclatasvir</outcome_measure>
      <outcome_measure>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of simprevir and daclatasvir</outcome_measure>
      <outcome_measure>Number of participants with dose adjustment of cyclosporine and tacrolimus during treatment with regimen simeprevir, daclatasvir and RBV</outcome_measure>
      <outcome_measure>Number of patients with a sustained virological response SVR4 after the end of treatment</outcome_measure>
      <outcome_measure>Number of participants with a sustained virologic response SVR24 after the end of treatment</outcome_measure>
      <outcome_measure>Number of participants with adverse events</outcome_measure>
      <outcome_measure>Number of participants with Undetectable HCV RNA (less than 25 IU/mL undetectable) and HCV RNA less than 25 IU/mL detectable</outcome_measure>
      <outcome_measure>Number of participants with HCV RNA level less than 100 IU/mL</outcome_measure>
      <outcome_measure>Number of participants with on-treatment failure after treatment with regimen simeprevir, daclatasvir and RBV</outcome_measure>
      <outcome_measure>Number of participants with viral relapse after treatment with regimen simeprevir, daclatasvir and RBV</outcome_measure>
      <outcome_measure>Number of participants with HCV NS3/4A and NS5A sequences</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
      <country>Poland</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01938625</url>
  </study>
  <study rank="127">
    <nct_id>NCT00559091</nct_id>
    <title>A Study of Ribavirin to Treat M4 and M5 Acute Myelocytic Leukemia</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Myelocytic Leukemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Jewish General Hospital</lead_sponsor>
      <collaborator>The Leukemia and Lymphoma Society</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR0620KB</other_id>
      <other_id>REC:06-112</other_id>
    </other_ids>
    <first_received>November 15, 2007</first_received>
    <start_date>April 2007</start_date>
    <completion_date>February 2010</completion_date>
    <last_updated>May 6, 2011</last_updated>
    <last_verified>September 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>Borden-001</acronym>
    <primary_completion_date>February 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Measure: Overall response rate</outcome_measure>
      <outcome_measure>Measure: Safety and tolerability, correlative studies</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00559091</url>
  </study>
  <study rank="128">
    <nct_id>NCT00495391</nct_id>
    <title>Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitazoxanide</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Biological">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Romark Laboratories L.C.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>64</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>RM01-2025</other_id>
    </other_ids>
    <first_received>July 2, 2007</first_received>
    <start_date>July 2007</start_date>
    <completion_date>February 2010</completion_date>
    <last_updated>April 8, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>November 18, 2013</firstreceived_results_date>
    <acronym>STEALTHC-2</acronym>
    <primary_completion_date>February 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (HCV RNA Below Lower Limit of Detection)</outcome_measure>
      <outcome_measure>End of Treatment Response (HCV RNA Below Lower Limit of Detection)</outcome_measure>
      <outcome_measure>Early Virologic Response (HCV RNA Below Lower Limit of Detection)</outcome_measure>
      <outcome_measure>Rapid Virologic Response (HCV RNA Below Lower Limit of Detection)</outcome_measure>
      <outcome_measure>Changes in ALT</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>New York</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00495391</url>
  </study>
  <study rank="129">
    <nct_id>NCT01178996</nct_id>
    <title>Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Thymosin alpha 1</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Biological">PEGinterferon alfa2a</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>sigma-tau i.f.r. S.p.A.</lead_sponsor>
      <collaborator>SciClone Pharmaceuticals</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>552</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>ST1472-DM-03-004</other_id>
      <other_id>2004-001277-25</other_id>
    </other_ids>
    <first_received>August 9, 2010</first_received>
    <start_date>December 2004</start_date>
    <completion_date>July 2009</completion_date>
    <last_updated>August 9, 2010</last_updated>
    <last_verified>August 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virological Response (SVR)</outcome_measure>
      <outcome_measure>Sustained Biochemical Response (SBR)</outcome_measure>
      <outcome_measure>End of Treatment Biochemical Response (EBR)</outcome_measure>
      <outcome_measure>End of Treatment Virological Response [EVR]</outcome_measure>
      <outcome_measure>Safety</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>Italy</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01178996</url>
  </study>
  <study rank="130">
    <nct_id>NCT01790100</nct_id>
    <title>A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">VX-135</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Alios Biopharma Inc.</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>ALS-135-101</other_id>
      <other_id>2012-005633-37</other_id>
    </other_ids>
    <first_received>February 11, 2013</first_received>
    <start_date>February 2013</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>June 23, 2014</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety</outcome_measure>
      <outcome_measure>evidence of HCV RNA viral load reduction</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Moldova, Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01790100</url>
  </study>
  <study rank="131">
    <nct_id>NCT01120795</nct_id>
    <title>Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon and ribavirin</intervention>
      <intervention type="Drug">Pegylated interferon and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Melbourne Health</lead_sponsor>
      <collaborator>The University of New South Wales</collaborator>
      <collaborator>St Vincent's Hospital, Sydney</collaborator>
      <collaborator>Western Hospital, Australia</collaborator>
      <collaborator>Monash University</collaborator>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>55</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HREC 2000.175</other_id>
    </other_ids>
    <first_received>May 6, 2010</first_received>
    <start_date>February 2004</start_date>
    <completion_date>July 2006</completion_date>
    <last_updated>May 27, 2010</last_updated>
    <last_verified>May 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01120795</url>
  </study>
  <study rank="132">
    <nct_id>NCT01415141</nct_id>
    <title>Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Vermont</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>240</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M11-219</other_id>
    </other_ids>
    <first_received>August 1, 2011</first_received>
    <start_date>July 2011</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response among subjects receiving a three drug versus two drug regimen of treatment</outcome_measure>
      <outcome_measure>Extended rapid virological response in patients receiving three drug versus two drug regimen</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Georgia</state>
      <state>Vermont</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01415141</url>
  </study>
  <study rank="133">
    <nct_id>NCT00629967</nct_id>
    <title>A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Genotype</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon alpha 2a and ribavirin</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kaohsiung Medical University Chung-Ho Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KMUH-IRB-94045</other_id>
    </other_ids>
    <first_received>February 26, 2008</first_received>
    <start_date>April 2005</start_date>
    <completion_date>May 2007</completion_date>
    <last_updated>February 26, 2008</last_updated>
    <last_verified>January 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy - Sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.</outcome_measure>
      <outcome_measure>Safety - adverse event rate and profile</outcome_measure>
      <outcome_measure>Early virological response (EVR), by PCR-negative or 2 logs decline from baseline at week 12</outcome_measure>
      <outcome_measure>Rapid virologic response (RVR), HCV RNA seronegative by PCR at week 4.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00629967</url>
  </study>
  <study rank="134">
    <nct_id>NCT01698723</nct_id>
    <title>A Trial of Ribavirin in Patients With ACLF Due to Hepatitis E Virus</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute on Chronic Hepatic Failure</condition>
      <condition>Liver Failure</condition>
      <condition>Hepatitis E Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>All India Institute of Medical Sciences, New Delhi</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>HEV-RIBA</other_id>
    </other_ids>
    <first_received>September 27, 2012</first_received>
    <start_date>September 2012</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>September 29, 2012</last_updated>
    <last_verified>September 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HEVRibavirin</acronym>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Improvement in survival</outcome_measure>
      <outcome_measure>Child Score</outcome_measure>
      <outcome_measure>Viremia</outcome_measure>
      <outcome_measure>Variceal bleeding</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>India</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01698723</url>
  </study>
  <study rank="135">
    <nct_id>NCT00209755</nct_id>
    <title>Plasma Ribavirin Assay During Combination Therapy for Chronic Hepatitis C</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">therapeutic drug monitoring of ribavirin and dose adaptation</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hopital A Michallon</lead_sponsor>
      <collaborator>University Hospital, Grenoble</collaborator>
      <collaborator>Central Hospital, Nancy, France</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ribatop - afssaps #031161</other_id>
      <other_id>N.A.</other_id>
    </other_ids>
    <first_received>September 13, 2005</first_received>
    <start_date>October 2003</start_date>
    <completion_date>July 2004</completion_date>
    <last_updated>September 13, 2005</last_updated>
    <last_verified>September 2004</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>relationship between plasma ribavirin concentration and early virological response</outcome_measure>
      <outcome_measure>safety</outcome_measure>
      <outcome_measure>relationship between plasma ribavirin concentration and hemoglobin drop</outcome_measure>
      <outcome_measure>dose effect of ribavirin on ribavirin plasma concentration</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00209755</url>
  </study>
  <study rank="136">
    <nct_id>NCT01684787</nct_id>
    <title>Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a + ribavirin in normal ALT</intervention>
      <intervention type="Drug">Peginterferon alfa-2a + ribavirin in elevated ALT</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Miguel Santin</lead_sponsor>
      <collaborator>Hospital Universitari de Bellvitge</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Miguel Santín</other_id>
    </other_ids>
    <first_received>June 11, 2010</first_received>
    <start_date>September 2006</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>September 12, 2012</last_updated>
    <last_verified>September 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>CONTRA</acronym>
    <primary_completion_date>May 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>% patients with RNA-HCV negative</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01684787</url>
  </study>
  <study rank="137">
    <nct_id>NCT00353418</nct_id>
    <title>A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>415</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV18209</other_id>
    </other_ids>
    <first_received>July 17, 2006</first_received>
    <start_date>June 2006</start_date>
    <completion_date>April 2009</completion_date>
    <last_updated>July 30, 2010</last_updated>
    <last_verified>July 2010</last_verified>
    <firstreceived_results_date>May 14, 2010</firstreceived_results_date>
    <primary_completion_date>April 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virological Response (SVR)</outcome_measure>
      <outcome_measure>Incidence of Adverse Events, Dose Reductions and Withdrawals Due to Anemia</outcome_measure>
      <outcome_measure>Virological Response at End of Treatment Period</outcome_measure>
      <outcome_measure>Virological Response at Weeks 4, 12 and 24</outcome_measure>
      <outcome_measure>Relapse of Virological Response</outcome_measure>
      <outcome_measure>Rapid Virological Response (RVR) by Week 4</outcome_measure>
      <outcome_measure>Early Virological Response (EVR), Partial EVR and Complete EVR by Week 12</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00353418</url>
  </study>
  <study rank="138">
    <nct_id>NCT00433069</nct_id>
    <title>Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pioglitazone</intervention>
      <intervention type="Drug">Interferon Alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Geneva</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>5</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GE-DMI-05-116</other_id>
    </other_ids>
    <first_received>February 8, 2007</first_received>
    <start_date>January 2007</start_date>
    <completion_date>January 2008</completion_date>
    <last_updated>May 27, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Early virological response</outcome_measure>
      <outcome_measure>Undetectable serum HCV RNA after 4, 24 weeks and 48 weeks of therapy</outcome_measure>
      <outcome_measure>Changes (vs. baseline) of body weight, HOMA score, after 4, 12 and 48 weeks of therapy and after 24 weeks of follow-up</outcome_measure>
      <outcome_measure>Improvement (vs. baseline) of glucose tolerance parameters after 12 and 48 weeks of therapy and after 24 weeks of follow-up</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Switzerland</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00433069</url>
  </study>
  <study rank="139">
    <nct_id>NCT01849562</nct_id>
    <title>Safety, Tolerability and Efficacy of 12-weeks of Sovaprevir, ACH-3102 and Ribavirin in Treatment-naive GT-1 HCV Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sovaprevir</intervention>
      <intervention type="Drug">ACH-3102</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Achillion Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>ACH102-007</other_id>
    </other_ids>
    <first_received>April 18, 2013</first_received>
    <start_date>April 2013</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>September 1, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>January 26, 2015</firstreceived_results_date>
    <primary_completion_date>November 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Incidence of Sustained Virologic Response 4 Weeks (SVR4) After the Completion of Treatment.</outcome_measure>
      <outcome_measure>Safety and Tolerability of 12 Weeks of Sovaprevir and 3102 in Combination With Ribavirin in Subjects With Chronic Hepatitis C Genotype 1 Viral Infection.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Georgia</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01849562</url>
  </study>
  <study rank="140">
    <nct_id>NCT00561353</nct_id>
    <title>A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Peginterferon (PegIFNα-2a)</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>121</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR012607</other_id>
      <other_id>TMC435350-TiDP16-C201</other_id>
    </other_ids>
    <first_received>November 19, 2007</first_received>
    <start_date>January 2008</start_date>
    <completion_date>May 2010</completion_date>
    <last_updated>May 14, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>December 18, 2013</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) at Week 4 in Treatment-Naïve HCV-Infected Participants (Cohort 1 and 2, Panel A)</outcome_measure>
      <outcome_measure>Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) at Week 4 in Treatment-Naïve HCV-Infected Participants (Cohort 1 and 2, Panel B)</outcome_measure>
      <outcome_measure>Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) at Week 4 in Treatment-Experienced HCV-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) on Day 7 in Treatment-Naïve HCV-Infected Participants (Cohort 1 and 2, Panel A)</outcome_measure>
      <outcome_measure>Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) on Day 7 in Treatment-Naïve HCV-Infected Participants (Cohort 1 and 2, Panel B)</outcome_measure>
      <outcome_measure>Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) on Day 7 in Treatment-Experienced HCV-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Virologic Responses Following Treatment With TMC435 in Treatment-Naive Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A)</outcome_measure>
      <outcome_measure>Virologic Responses Following Treatment With TMC435 in Treatment-Naive Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel B)</outcome_measure>
      <outcome_measure>Virologic Responses Following Treatment With TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Virologic Response Parameters in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B Combined)</outcome_measure>
      <outcome_measure>Virologic Response Parameters Following Treatment With TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Initial Suboptimal Responses Following Treatment With TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A)</outcome_measure>
      <outcome_measure>Initial Suboptimal Responses Following Treatment With TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel B)</outcome_measure>
      <outcome_measure>Initial Suboptimal Responses Following Treatment With TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Viral Breakthrough in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1, Panel A and B)</outcome_measure>
      <outcome_measure>Viral Breakthrough in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Viral Relapse in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B Combined)</outcome_measure>
      <outcome_measure>Viral Relapse in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Sustained Virologic Response (SVR) in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B Combined)</outcome_measure>
      <outcome_measure>Sustained Virologic Response (SVR) in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B)</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Predose Plasma Concentration (C0h) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B)</outcome_measure>
      <outcome_measure>Predose Plasma Concentration (C0h) of TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Average Steady-state Plasma Concentration (Css,av) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B)</outcome_measure>
      <outcome_measure>Average Steady-state Plasma Concentration (Css,av) of TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B)</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Netherlands</country>
      <country>Poland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00561353</url>
  </study>
  <study rank="141">
    <nct_id>NCT00686517</nct_id>
    <title>Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated interferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
      <collaborator>Biokos Farma srl</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>130</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P03552</other_id>
    </other_ids>
    <first_received>May 27, 2008</first_received>
    <start_date>December 2003</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>July 6, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>December 22, 2011</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Sustained Response (SR) at the End of the 6-month Follow-up Period</outcome_measure>
      <outcome_measure>Virologic Response at the End of Treatment Follow-up (ETR)</outcome_measure>
      <outcome_measure>Virologic Response at 12 Months Post-treatment Follow-up (Long-term Response, [LTR]).</outcome_measure>
      <outcome_measure>Number of Participants Presenting With Alanine Transferase (ALT) Level Normalization</outcome_measure>
      <outcome_measure>Number of Participants With Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Number of Peripheral Blood Mononuclear Cells (PBMCs)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00686517</url>
  </study>
  <study rank="142">
    <nct_id>NCT01770483</nct_id>
    <title>The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>DIABETES MELLITUS Type 2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">nitazoxanide</intervention>
      <intervention type="Drug">conventional interferon alfa</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Services Institute of Medical Sciences, Pakistan</lead_sponsor>
      <collaborator>Getz Pharma</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>66</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>SIMS</other_id>
    </other_ids>
    <first_received>January 8, 2013</first_received>
    <start_date>July 2011</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>September 15, 2013</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>March 7, 2013</firstreceived_results_date>
    <acronym>HEP-C-FM</acronym>
    <primary_completion_date>March 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Viral Response,</outcome_measure>
      <outcome_measure>Normalization of Alanine Transferase Test</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Pakistan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01770483</url>
  </study>
  <study rank="143">
    <nct_id>NCT00207402</nct_id>
    <title>Infergen, Ribavirin &amp; Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">rosiglitazone</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Brooke Army Medical Center</lead_sponsor>
      <collaborator>InterMune</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>34</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>C2005.143</other_id>
    </other_ids>
    <first_received>September 13, 2005</first_received>
    <start_date>October 2005</start_date>
    <completion_date>July 2010</completion_date>
    <last_updated>February 13, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>There is change in viral kinetics with improvement of insulin sensitivity</outcome_measure>
      <outcome_measure>There is significant improvement in the SVR obtained when treating insulin resistant patients with the insulin sensitizing medication, Avandia, prior to and during treatment with Infergen and ribavirin when compared to Infergen</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00207402</url>
  </study>
  <study rank="144">
    <nct_id>NCT00708500</nct_id>
    <title>Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir (SCH 503034)</intervention>
      <intervention type="Biological">Pegylated interferon alfa-2b (SCH 54031)</intervention>
      <intervention type="Drug">Ribavirin (SCH 18908)</intervention>
      <intervention type="Drug">Boceprevir placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>404</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05101</other_id>
      <other_id>2007-005151-42</other_id>
    </other_ids>
    <first_received>June 27, 2008</first_received>
    <start_date>August 2008</start_date>
    <completion_date>April 2010</completion_date>
    <last_updated>September 24, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>May 13, 2011</firstreceived_results_date>
    <primary_completion_date>April 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR) Rate in the Full Analysis Set (FAS) Population.</outcome_measure>
      <outcome_measure>Sustained Virologic Response (SVR) Rate in the Modified Intent to Treat (mITT) Population.</outcome_measure>
      <outcome_measure>Number of Participants With Early Virologic Response.</outcome_measure>
      <outcome_measure>Number of Participants With Undetectable HCV-RNA at Follow-up Week 12 and at 72 Weeks After Randomization.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00708500</url>
  </study>
  <study rank="145">
    <nct_id>NCT00874770</nct_id>
    <title>Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Peginterferon alpha-2a</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>74</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-014</other_id>
      <other_id>EUDRACT# 2009-010149-29</other_id>
    </other_ids>
    <first_received>April 2, 2009</first_received>
    <start_date>June 2009</start_date>
    <completion_date>January 2011</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>August 6, 2015</firstreceived_results_date>
    <primary_completion_date>November 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Extended Rapid Virologic Response (eRVR) at Weeks 4 and 12</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Virologic Response (RVR) at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Early Virologic Response (EVR) at Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With a Complete Early Virologic Response (cEVR) at Week 12</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00874770</url>
  </study>
  <study rank="146">
    <nct_id>NCT00910624</nct_id>
    <title>Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Biological">Peginterferon alfa-2b (SCH 54031)</intervention>
      <intervention type="Drug">Ribavirin (SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>168</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05514</other_id>
    </other_ids>
    <first_received>May 28, 2009</first_received>
    <start_date>June 2009</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>July 6, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>September 18, 2013</firstreceived_results_date>
    <acronym>PROVIDE</acronym>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Follow-Up Week 24 (SVR24);</outcome_measure>
      <outcome_measure>Percentage of Participants With Adverse Events (AEs) Leading to Dose Modification (DM) or Discontinuation (DC), Treatment-Related Serious AEs (SAEs), Neutrophil Count &lt;0.75 × 10^9/L, or Hemoglobin (Hgb) &lt;10 g/dL</outcome_measure>
      <outcome_measure>Percentage of Participants With Early Virologic Response (EVR)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00910624</url>
  </study>
  <study rank="147">
    <nct_id>NCT00686777</nct_id>
    <title>Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated Interferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05172</other_id>
      <other_id>JPC-06-320-40</other_id>
    </other_ids>
    <first_received>May 27, 2008</first_received>
    <start_date>January 2008</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>September 24, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>December 12, 2011</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) at 24 Weeks After the End of Treatment (EOT) or Discontinuation</outcome_measure>
      <outcome_measure>Number of Participants Discontinuing Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV-RNA Negativity at 24 Weeks of Treatment and at EOT</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00686777</url>
  </study>
  <study rank="148">
    <nct_id>NCT01017575</nct_id>
    <title>Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>55</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-022</other_id>
    </other_ids>
    <first_received>November 19, 2009</first_received>
    <start_date>December 2009</start_date>
    <completion_date>October 2011</completion_date>
    <last_updated>August 13, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>August 13, 2015</firstreceived_results_date>
    <primary_completion_date>October 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With a Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With a Sustained Virologic Response (SVR) at Follow-up Week 12 and Follow-up Week 24</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01017575</url>
  </study>
  <study rank="149">
    <nct_id>NCT01170962</nct_id>
    <title>Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-790052</intervention>
      <intervention type="Drug">BMS-790052</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">peginterferon alfa-2a</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>512</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-011</other_id>
      <other_id>2010-019378-34</other_id>
    </other_ids>
    <first_received>July 16, 2010</first_received>
    <start_date>August 2010</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>September 11, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>August 10, 2015</firstreceived_results_date>
    <acronym>HEPCAT</acronym>
    <primary_completion_date>June 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With 24-week Sustained Virologic Response (SVR24)</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs) and Who Died On-treatment</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs) and Who Died During Follow-up Period</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Number of Participants With Genotypic-1A Substitution at Baseline, On-treatment and During Follow-up Associated With Virologic Failures</outcome_measure>
      <outcome_measure>Number of Participants With Genotypic-1B Substitution at Baseline, On-treatment and During Follow-up Associated With Virologic Failures</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Denmark</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Mexico</country>
      <country>Puerto Rico</country>
      <country>Sweden</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01170962</url>
  </study>
  <study rank="150">
    <nct_id>NCT01016912</nct_id>
    <title>Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-790052</intervention>
      <intervention type="Drug">BMS-790052</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>51</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-021</other_id>
    </other_ids>
    <first_received>November 19, 2009</first_received>
    <start_date>December 2009</start_date>
    <completion_date>September 2010</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>August 17, 2015</firstreceived_results_date>
    <primary_completion_date>September 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With a Sustained Virologic Response (SVR) at Weeks 4, 12, and 24</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01016912</url>
  </study>
  <study rank="151">
    <nct_id>NCT01434498</nct_id>
    <title>GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Genotype 1a or 1b HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GS-5885 tablet</intervention>
      <intervention type="Drug">GS-9451 tablet</intervention>
      <intervention type="Drug">tegobuvir capsule</intervention>
      <intervention type="Drug">ribavirin tablet</intervention>
      <intervention type="Drug">placebo matching ribavirin tablet</intervention>
      <intervention type="Device">placebo matching tegobuvir capsule</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>163</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-248-0132</other_id>
    </other_ids>
    <first_received>September 9, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>January 2013</completion_date>
    <last_updated>November 26, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and Tolerability</outcome_measure>
      <outcome_measure>Antiviral Activity</outcome_measure>
      <outcome_measure>Viral Dynamics</outcome_measure>
      <outcome_measure>Composite (or Profile) of Pharmacokinetics</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Kansas</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01434498</url>
  </study>
  <study rank="152">
    <nct_id>NCT00723879</nct_id>
    <title>Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepacivirus</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b (SCH 54031)</intervention>
      <intervention type="Drug">Ribavirin (SCH 18908)</intervention>
      <intervention type="Behavioral">Patient assistance program</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>115</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04206</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>October 2004</start_date>
    <completion_date>July 2008</completion_date>
    <last_updated>November 2, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients who complete treatment with PegIntron plus Rebetol therapy for hepatitis C when administered with a patient assistance program.</outcome_measure>
      <outcome_measure>Average length of treatment for patients receiving a patient assistance program as part of their treatment for hepatitis C with PegIntron plus Rebetol.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00723879</url>
  </study>
  <study rank="153">
    <nct_id>NCT01380938</nct_id>
    <title>Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alpha-2a + Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Casa Sollievo della Sofferenza IRCCS</lead_sponsor>
      <collaborator>Casa di Cura Mater Dei</collaborator>
      <collaborator>IRCCS L. Spallanzani</collaborator>
      <collaborator>Ospedale Francesco Ferrari</collaborator>
      <collaborator>Azienda Ospedaliero Universitaria di Sassari</collaborator>
      <collaborator>IRCCS Policlinico S. Matteo</collaborator>
      <collaborator>Arcispedale S. Anna, Ferrara</collaborator>
      <collaborator>Azienda Ospedaliero-Universitaria, Catania</collaborator>
      <collaborator>Ospedale di Venosa</collaborator>
      <collaborator>Ospedale R. Dimiccoli, Barletta</collaborator>
      <collaborator>IRCCS De Bellis, Castellana</collaborator>
      <collaborator>USL Napoli 1</collaborator>
      <collaborator>Ospedale San Giuseppe Moscati, Avellino</collaborator>
      <collaborator>Cardarelli Hospital</collaborator>
      <collaborator>Ospedale Civile Vittorio Emanuele II, Bisceglie</collaborator>
      <collaborator>Azienda Ospedaliero-Universitaria Careggi</collaborator>
      <collaborator>Azienda Ospedaliera V. Cervello</collaborator>
      <collaborator>Ospedale Civile Spirito Santo</collaborator>
      <collaborator>Ospedale di Canosa di Puglia</collaborator>
      <collaborator>University of Palermo</collaborator>
      <collaborator>San Camillo Hospital, Rome</collaborator>
      <collaborator>Campus Bio-Medico University</collaborator>
      <collaborator>Ospedale Sandro Pertini, Roma</collaborator>
      <collaborator>Ospedali Riuniti di Foggia</collaborator>
      <collaborator>Ospedale SS. Annunziata, Taranto</collaborator>
      <collaborator>Ospedale di Mottola</collaborator>
      <collaborator>Ospedale Santa Caterina Novella, Galatina</collaborator>
      <collaborator>University of Florence</collaborator>
      <collaborator>Ospedale Valduce, Como</collaborator>
      <collaborator>University of Bari</collaborator>
      <collaborator>Azienda Ospedaliera, Siracusa</collaborator>
      <collaborator>Azienda Ospedaliera, Lucca</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Single Blind (Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>EPAT-01-2010</other_id>
    </other_ids>
    <first_received>June 23, 2011</first_received>
    <start_date>October 2010</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>April 14, 2012</last_updated>
    <last_verified>April 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>WRITE</acronym>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological Response (SVR)</outcome_measure>
      <outcome_measure>Rapid virological response (RVR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01380938</url>
  </study>
  <study rank="154">
    <nct_id>NCT00394277</nct_id>
    <title>A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>1175</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV18210</other_id>
    </other_ids>
    <first_received>October 30, 2006</first_received>
    <start_date>February 2007</start_date>
    <completion_date>April 2009</completion_date>
    <last_updated>July 30, 2010</last_updated>
    <last_verified>July 2010</last_verified>
    <firstreceived_results_date>May 27, 2010</firstreceived_results_date>
    <primary_completion_date>April 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virological Response (SVR)-24 (Scheduled Treatment Period)</outcome_measure>
      <outcome_measure>SVR-24 (Actual Treatment Period)</outcome_measure>
      <outcome_measure>SVR-12 (Scheduled Treatment Period)</outcome_measure>
      <outcome_measure>SVR-12 (Actual Treatment Period)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>Denmark</country>
      <country>France</country>
      <country>Germany</country>
      <country>Hungary</country>
      <country>Netherlands</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Sweden</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Alaska</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Iowa</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Hampshire</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
      <state>Wyoming</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00394277</url>
  </study>
  <study rank="155">
    <nct_id>NCT00196586</nct_id>
    <title>Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV/HCV Coinfected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Interleukin 2</intervention>
      <intervention type="Drug">pegylated interferon alpha 2a</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Agency for Research on AIDS and Viral Hepatitis</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRS HC09 SECOIIA</other_id>
    </other_ids>
    <first_received>September 12, 2005</first_received>
    <start_date>April 2003</start_date>
    <completion_date>November 2006</completion_date>
    <last_updated>November 15, 2007</last_updated>
    <last_verified>November 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response, defined by undetectable serum HCV-RNA at week 72, six months after the end of treatment; Safety of IL-2 in combination with pegylated interferon and ribavirin</outcome_measure>
      <outcome_measure>Virologic response at the end of treatment at week 48, Biochemical response, CD4 cell counts and HIV-RNA plasma levels from baseline to week 72</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00196586</url>
  </study>
  <study rank="156">
    <nct_id>NCT00623168</nct_id>
    <title>Ribavirin for Hemorrhagic Fever With Renal Syndrome</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hemorrhagic Fever With Renal Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>U.S. Army Medical Research and Materiel Command</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>A-14474</other_id>
      <other_id>TAMC HUC 23H07</other_id>
    </other_ids>
    <first_received>February 13, 2008</first_received>
    <start_date>February 2008</start_date>
    <completion_date>February 2018</completion_date>
    <last_updated>October 28, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number clinical events that occur with HFRS including oliguria, dialysis requirement, cardiac arrhythmias, and severe hemorrhage</outcome_measure>
      <outcome_measure>Number of mortalities</outcome_measure>
      <outcome_measure>Number and nature of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Korea, Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00623168</url>
  </study>
  <study rank="157">
    <nct_id>NCT00705666</nct_id>
    <title>Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepacivirus</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b (SCH 54031)</intervention>
      <intervention type="Drug">Ribavirin (SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>789</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04437</other_id>
    </other_ids>
    <first_received>June 23, 2008</first_received>
    <start_date>February 2006</start_date>
    <completion_date>July 2008</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>March 30, 2010</firstreceived_results_date>
    <acronym>ADEQUATION</acronym>
    <primary_completion_date>July 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Number of Participants Receiving the Recommended Treatment Duration (24 Weeks for Genotypes 2 and 3 and 48 Weeks for Genotype 1 According to the French 2002 Consensus Meeting).</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00705666</url>
  </study>
  <study rank="158">
    <nct_id>NCT01890772</nct_id>
    <title>Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Dietary Supplement">Vitamin D</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Timothy Morgan, MD</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
      <collaborator>Southern California Institute for Research and Education</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1217</other_id>
    </other_ids>
    <first_received>May 31, 2013</first_received>
    <start_date>August 2013</start_date>
    <last_updated>May 13, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HCV RNA</outcome_measure>
      <outcome_measure>adverse event profile</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>Pennsylvania</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01890772</url>
  </study>
  <study rank="159">
    <nct_id>NCT01629732</nct_id>
    <title>Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">BMS-986094</intervention>
      <intervention type="Drug">BMS-986094</intervention>
      <intervention type="Drug">BMS-986094</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Placebo for BMS-986094</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI472-007</other_id>
      <other_id>2012-002519-24</other_id>
    </other_ids>
    <first_received>June 26, 2012</first_received>
    <start_date>March 2013</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>May 8, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects with SVR4 defined as HCV RNA &lt; LOQ (25 IU/mL; detectable or undetectable) at 4 weeks post treatment to be evaluated in GT1 (naive and NR) subjects randomized to the 12-week treatment arm (arms 1a, 2a, 3a, 4a)</outcome_measure>
      <outcome_measure>Proportion of treated subjects with SVR4 in genotype (GT) 1 naive and non-responder (NR) subjects randomized to the 24-week treatment arms (arms 1b, 2b, 3b, 4b)</outcome_measure>
      <outcome_measure>Proportion of treated subjects with SVR4 in genotype 1 protease inhibitor (PI)failures, genotype 4 naive, and genotype 2/3 NR/relapse subjects (arms 5, 6, 7)</outcome_measure>
      <outcome_measure>Proportion of treated subjects in each study population (GT1 naive, GT1 NR, or GT1 PI-failure, GT4 naive, GT2/3 NR/relapse), for each regimen and duration, who achieve HCV RNA &lt; LOQ at post-treatment</outcome_measure>
      <outcome_measure>Proportion of treated subjects in each study population, by regimen, who achieve HCV RNA &lt; LOQ (detectable/undetectable)</outcome_measure>
      <outcome_measure>Proportion of subjects in each study population, be regimen, who achieve HCV RNA undetectable</outcome_measure>
      <outcome_measure>Safety and tolerability of BMS-986094 and DCV ± RBV as measured by the frequency of deaths, serious adverse events (SAEs), discontinuations due to Adverse Events (AEs), and severity Grade 3/4 laboratory abnormalities</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Florida</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01629732</url>
  </study>
  <study rank="160">
    <nct_id>NCT01054742</nct_id>
    <title>Observational Study of Patients With Chronic Hepatitis C Virus (HCV) Infected With HCV Genotype 1 Low Virus Load (LVL 1) and Effect of PegIntron Plus Rebetol Treatment (Study P04793 Part 2)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Standard of Care PegIntron</intervention>
      <intervention type="Drug">Standard of Care Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>2</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04793 Part 2</other_id>
    </other_ids>
    <first_received>January 21, 2010</first_received>
    <start_date>December 2009</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>January 7, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>May 15, 2012</firstreceived_results_date>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Undetectable Hepatitis C Virus Ribonucleic Acid (HCV-RNA) Levels During Part 2 of the Study</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01054742</url>
  </study>
  <study rank="161">
    <nct_id>NCT01492426</nct_id>
    <title>Study Comparing BMS-790052 (Daclatasvir) to Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Untreated Hepatitis C Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-790052 (Daclatasvir)</intervention>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>605</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-052</other_id>
      <other_id>2011-004237-14</other_id>
    </other_ids>
    <first_received>December 13, 2011</first_received>
    <start_date>January 2012</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>May 5, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>COMMAND-3</acronym>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of genotype 1b patients with SVR12, defined as HCV RNA less than limit of quantitation at follow-up Week 12 in each group</outcome_measure>
      <outcome_measure>Proportion of genotype 1b patients with hemoglobin value less than 10 g/dL</outcome_measure>
      <outcome_measure>Proportion of genotype 1b patients with rash events</outcome_measure>
      <outcome_measure>Proportion of genotype1b patients with HCV RNA undetectable Week 12</outcome_measure>
      <outcome_measure>Proportion of genotype 1b patients with HCV RNA undetectable Week 4</outcome_measure>
      <outcome_measure>Proportion of genotype 1b patients with HCV RNA undetectable Weeks 4 and 12</outcome_measure>
      <outcome_measure>Proportion of genotype 1b patients with SVR24, defined as HCV RNA &lt; Limit of Quantification (LOQ) at follow-up Week 24 for each cohort</outcome_measure>
      <outcome_measure>Proportion of genotype 1b patients with SVR12 based on IL28B rs12979860 Single nucleotide polymorphism (SNP) genotype (CC or non-CC)</outcome_measure>
      <outcome_measure>Proportion of genotype 1a patients with SVR12 defined as HCV RNA &lt; LOQ at follow-up Week 12 for each cohort</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>Brazil</country>
      <country>Denmark</country>
      <country>France</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Italy</country>
      <country>Poland</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Switzerland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01492426</url>
  </study>
  <study rank="162">
    <nct_id>NCT00553930</nct_id>
    <title>Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa-2a and Ribavirin</intervention>
      <intervention type="Drug">Pegylated interferon alfa 2a and Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Sociedad Andaluza de Enfermedades Infecciosas</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>71</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>SAEI_IFN_1</other_id>
    </other_ids>
    <first_received>November 3, 2007</first_received>
    <start_date>November 2007</start_date>
    <completion_date>May 2010</completion_date>
    <last_updated>May 16, 2010</last_updated>
    <last_verified>May 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>SAEI_IFN_1</acronym>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained viral response(undetectable serum HCV-RNA)</outcome_measure>
      <outcome_measure>Relationships between the plasma interferon an ribavirin concentrations and efficacy. The safety and tolerability of the studied medications will be evaluated by means of clinical adverse events, physical examination and laboratory results.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00553930</url>
  </study>
  <study rank="163">
    <nct_id>NCT00086541</nct_id>
    <title>Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Valeant Pharmaceuticals International, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>515</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRHC-001</other_id>
      <other_id>DIRECT 1</other_id>
    </other_ids>
    <first_received>July 2, 2004</first_received>
    <start_date>June 2004</start_date>
    <completion_date>January 2007</completion_date>
    <last_updated>May 3, 2007</last_updated>
    <last_verified>May 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Evaluate sustained virologic response (SVR) rate of daily Infergen at two dose levels plus ribavirin and no treatment in chronically HCV-infected patients who are nonresponders to previous pegylated interferon alfa plus ribavirin therapy.</outcome_measure>
      <outcome_measure>Evaluate safety &amp; tolerability of therapy detailed in primary objective, and proportion of patients with (a) undetectable plasma HCV RNA levels at weeks 24 &amp; 48 (b) abnormal baseline serum ALT levels that are normal at week 24, week 48 and weeks 48 &amp; 72.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00086541</url>
  </study>
  <study rank="164">
    <nct_id>NCT02292719</nct_id>
    <title>A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With and Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ombitasvir/ABT-450/r</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M14-567</other_id>
      <other_id>2014-003147-35</other_id>
    </other_ids>
    <first_received>November 13, 2014</first_received>
    <start_date>December 2014</start_date>
    <completion_date>May 2017</completion_date>
    <last_updated>October 16, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants with sustained virologic response 12 weeks (SVR12) post-treatment</outcome_measure>
      <outcome_measure>Percentage of participants with on-treatment virologic failure</outcome_measure>
      <outcome_measure>Percentage of participants with virologic relapse after treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>New Zealand</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Georgia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02292719</url>
  </study>
  <study rank="165">
    <nct_id>NCT00215891</nct_id>
    <title>PEG-Interferon a-2b + Ribavirin for Treatment of Chronic HRN 005 Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection in HIV-Infected Persons</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG-Interferon a-2b + Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hepatitis Resource Network</lead_sponsor>
      <collaborator>Integrated Therapeutics Group</collaborator>
      <collaborator>Subsidiary of Schering-Plough</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HRN 005</other_id>
    </other_ids>
    <first_received>September 20, 2005</first_received>
    <last_updated>October 24, 2005</last_updated>
    <last_verified>September 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Objectives:</outcome_measure>
      <outcome_measure>Primary</outcome_measure>
      <outcome_measure>To compare the sustained virologic response (SVR) of PEGIntron plus ribavirin among patients receiving 48 weeks versus 72 weeks of therapy (defined as undetectable HCV RNA level 24 weeks after discontinuing therapy).</outcome_measure>
      <outcome_measure>Secondary</outcome_measure>
      <outcome_measure>· To evaluate the safety and tolerability PEG Intron in combination with ribavirin for treatment of Chronic Hepatitis C (CHC) infection in patients co-infected with Human Immunodeficiency Virus (HIV).</outcome_measure>
      <outcome_measure>· To determine the early virologic response of patients receiving PEGIntron plus ribavirin at Treatment Week 24</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00215891</url>
  </study>
  <study rank="166">
    <nct_id>NCT00162734</nct_id>
    <title>Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Valeant Pharmaceuticals International, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>144</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRHC-002</other_id>
      <other_id>DIRECT 2</other_id>
    </other_ids>
    <first_received>September 8, 2005</first_received>
    <start_date>February 2005</start_date>
    <completion_date>June 2007</completion_date>
    <last_updated>June 21, 2012</last_updated>
    <last_verified>June 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evaluate sustained virologic response (SVR) rate of daily Infergen at two dose levels plus ribavirin and no treatment in chronically HCV-infected patients who are nonresponders to previous pegylated interferon alfa plus ribavirin therapy.</outcome_measure>
      <outcome_measure>Evaluate safety &amp; tolerability of therapy detailed in primary objective, and proportion of patients with (a) undetectable plasma HCV RNA levels at weeks 24 &amp; 48 (b) abnormal baseline serum ALT levels that are normal at week 24, week 48 and weeks 48 &amp; 72.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00162734</url>
  </study>
  <study rank="167">
    <nct_id>NCT02216045</nct_id>
    <title>Effect of Camel Milk on Chronic Hepatitis C</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon, Ribavirin, camel milk</intervention>
      <intervention type="Drug">Peginterferon, Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mashhad University of Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Mashhad UMS</other_id>
    </other_ids>
    <first_received>July 26, 2014</first_received>
    <start_date>June 2014</start_date>
    <completion_date>February 2015</completion_date>
    <last_updated>August 12, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HCV</acronym>
    <primary_completion_date>February 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Early Virologic Responses(EVR)</outcome_measure>
      <outcome_measure>Complete early virological response (cEVR)</outcome_measure>
      <outcome_measure>o Complete early virological response (cEVR)</outcome_measure>
      <outcome_measure>o Sustained virological response (SVR)</outcome_measure>
      <outcome_measure>o Normalization of ALT( Alanine Aminotransferase)</outcome_measure>
      <outcome_measure>o Normalization of ALT</outcome_measure>
      <outcome_measure>o Adverse events(AE)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Iran, Islamic Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02216045</url>
  </study>
  <study rank="168">
    <nct_id>NCT02601976</nct_id>
    <title>Evaluation of Unipeg® for Response and Ongoing Safety in Pakistani Population</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Getz Pharma</lead_sponsor>
      <collaborator>Dimension Research</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>64</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GETZ-UNIP- 4010810</other_id>
    </other_ids>
    <first_received>November 2, 2015</first_received>
    <start_date>August 2010</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>November 9, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>EUROP</acronym>
    <primary_completion_date>September 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virological Response (SVR)</outcome_measure>
      <outcome_measure>End Treatment Response</outcome_measure>
      <outcome_measure>Reporting And Assessment of Adverse Events through CRF</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02601976</url>
  </study>
  <study rank="169">
    <nct_id>NCT02405013</nct_id>
    <title>Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir and Ribavirin for the Treatment of Genotype 1, 2 and 4 Hepatitis C Virus-infected Patients in West and Central Africa</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRS 12311 TAC</other_id>
    </other_ids>
    <first_received>February 20, 2015</first_received>
    <start_date>November 2015</start_date>
    <completion_date>November 2016</completion_date>
    <last_updated>December 2, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>TAC</acronym>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Viral Load Response (SVR)</outcome_measure>
      <outcome_measure>Tolerance</outcome_measure>
      <outcome_measure>Viral kinetics as measured by SVR 24 and HCV-RNA</outcome_measure>
      <outcome_measure>HIV treatment clinical parameters</outcome_measure>
      <outcome_measure>Liver fibrosis</outcome_measure>
      <outcome_measure>Adherence measured by number of remaining tablets at each visit based on the number of tablets should have been taken as a percentage of the total dose</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
      <outcome_measure>Performance of an unit of nanotechnology</outcome_measure>
      <outcome_measure>Setting up the network:</outcome_measure>
      <outcome_measure>Integration Access initiatives evaluated by the number of patients off protocol that will have access to new anti-HCV treatment due to &quot;ACCESS&quot; programs of pharmaceutical companies conducting such programs in Sub-Saharan Africa</outcome_measure>
      <outcome_measure>Biological events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Cameroon</country>
      <country>Côte D'Ivoire</country>
      <country>Senegal</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02405013</url>
  </study>
  <study rank="170">
    <nct_id>NCT00834860</nct_id>
    <title>Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Hepatocellular Carcinoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alpha-2a and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kaohsiung Medical University Chung-Ho Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>179</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KMUH-IRB-960043</other_id>
    </other_ids>
    <first_received>February 1, 2009</first_received>
    <start_date>January 2007</start_date>
    <completion_date>February 2010</completion_date>
    <last_updated>February 11, 2010</last_updated>
    <last_verified>February 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy: sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.</outcome_measure>
      <outcome_measure>Rapid virologic response (RVR), HCV RNA seronegative by PCR at week 4.</outcome_measure>
      <outcome_measure>Early virological response (EVR), by PCR-negative or at least 2 logs decline from baseline of serum HCV RNA at 12 weeks of treatment.</outcome_measure>
      <outcome_measure>Safety: adverse event rate and profile.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00834860</url>
  </study>
  <study rank="171">
    <nct_id>NCT00489385</nct_id>
    <title>An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>HCV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Albinterferon</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Albuferon</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>41</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>070001</other_id>
      <other_id>07-I-0001</other_id>
    </other_ids>
    <first_received>June 20, 2007</first_received>
    <start_date>June 2007</start_date>
    <completion_date>March 2011</completion_date>
    <last_updated>September 26, 2015</last_updated>
    <last_verified>January 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and tolerability of two doses of Albinterferon alpha 2b with ribavirin.</outcome_measure>
      <outcome_measure>Histologic, virologic responses to Albinterferon alpha 2b and ribavirin</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00489385</url>
  </study>
  <study rank="172">
    <nct_id>NCT02006745</nct_id>
    <title>An Open Label Trial of Pegylated Interferon, Ribavirin and Telaprevir Versus Pegylated Interferon and Ribavirin Alone in the Treatment of Hepatitis C Genotype 1 Virus Infection in Patients With HIV-1 Co-infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>St Stephens Aids Trust</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>SSAT 052</other_id>
    </other_ids>
    <first_received>December 5, 2013</first_received>
    <start_date>January 2014</start_date>
    <completion_date>February 2016</completion_date>
    <last_updated>October 9, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>CHAT</acronym>
    <primary_completion_date>February 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>• Comparison of rates of sustained virologic response(SVR24) between treatment arms; defined as HCV RNA not detectable at 24 weeks after planned completion of therapy</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02006745</url>
  </study>
  <study rank="173">
    <nct_id>NCT01795911</nct_id>
    <title>Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated Interferon Lambda</intervention>
      <intervention type="Drug">Ribasphere</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>165</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI452-008 (Substudy Part C)</other_id>
      <other_id>2010-022568-11</other_id>
    </other_ids>
    <first_received>February 20, 2013</first_received>
    <start_date>March 2013</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>D-LITE</acronym>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Antiviral activity, as determined by the proportion of non-cirrhotic HCV GT-1b subjects with 12-week sustained virologic response (SVR12), defined as HCV RNA &lt; LLOQ target detected or not detected</outcome_measure>
      <outcome_measure>Proportion of non-cirrhotic HCV GT-1b subjects with eRVR, defined as HCV RNA &lt; LLOQ target not detected</outcome_measure>
      <outcome_measure>Proportion of non-cirrhotic HCV GT-1b subjects with treatment-emergent cytopenic abnormalities (anemia as defined by Hb &lt; 10 g/dL, and/or neutropenia as defined by ANC &lt; 750 mm3, and/or thrombocytopenia as defined by platelets &lt; 50,000 mm3) on treatment</outcome_measure>
      <outcome_measure>Proportion of non-cirrhotic HCV GT-1b subjects with on-treatment (maximum of 12 weeks) interferon-associated flu-like symptoms (pyrexia or chills or pain)</outcome_measure>
      <outcome_measure>Proportion of non-cirrhotic HCV GT-1b subjects with on-treatment (maximum of 12 weeks) interferon-associated musculoskeletal symptoms (arthralgia or myalgia or back pain)</outcome_measure>
      <outcome_measure>Proportion of non-cirrhotic HCV GT-1b subjects with SVR24, defined as HCV RNA &lt; LLOQ target detected or not detected</outcome_measure>
      <outcome_measure>Frequency of deaths among non-cirrhotic HCV GT-1b subjects through the end of follow-up (maximum of 60 weeks)</outcome_measure>
      <outcome_measure>Frequency of Serious adverse events (SAEs) among non-cirrhotic HCV GT-1b subjects through the end of follow-up (maximum of 60 weeks)</outcome_measure>
      <outcome_measure>Frequency of drug related Adverse events (AEs) among non-cirrhotic HCV GT-1b subjects through the end of treatment (maximum of 12 weeks)</outcome_measure>
      <outcome_measure>Frequency of dose reductions and discontinuations due to AEs among non-cirrhotic HCV GT-1b subjects through the end of treatment (maximum of 12 weeks)</outcome_measure>
      <outcome_measure>Frequency of treatment emergent laboratory abnormalities among non-cirrhotic HCV GT-1b subjects through the end of treatment (maximum of 12 weeks)</outcome_measure>
      <outcome_measure>Proportion of non-cirrhotic HCV GT-1b subjects with interferon-associated constitutional symptoms (fatigue or asthenia) through the end of treatment (maximum of 12 weeks)</outcome_measure>
      <outcome_measure>Proportion of non-cirrhotic HCV GT-1b subjects with interferon-associated neurologic symptoms (headache or dizziness) through the end of treatment (maximum of 12 weeks)</outcome_measure>
      <outcome_measure>Proportion of non-cirrhotic HCV GT-1b subjects with psychiatric symptoms (depression or irritability or insomnia) through the end of treatment (maximum of 12 weeks)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01795911</url>
  </study>
  <study rank="174">
    <nct_id>NCT00456248</nct_id>
    <title>Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Infergen and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kadmon Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>5</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VRX-CIFN-402</other_id>
    </other_ids>
    <first_received>April 2, 2007</first_received>
    <start_date>February 2007</start_date>
    <completion_date>October 2007</completion_date>
    <last_updated>October 11, 2012</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ENHANCE</acronym>
    <primary_completion_date>October 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate the proportion of patients with a sustained viral response (SVR) defined as undetectable serum HCV RNA at the end of the 24 week post-treatment follow-up period.</outcome_measure>
      <outcome_measure>Compare proportion of patients with SVR after switching treatment with Infergen/Ribavirin for 48 weeks versus those treated for 36 weeks</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Georgia</state>
      <state>Louisiana</state>
      <state>North Carolina</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00456248</url>
  </study>
  <study rank="175">
    <nct_id>NCT01142700</nct_id>
    <title>A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus Genotype 1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-824393</intervention>
      <intervention type="Drug">BMS-824393</intervention>
      <intervention type="Drug">BMS-824393</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Peginterferon Alpha-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI451-004</other_id>
      <other_id>2010-018702-36</other_id>
    </other_ids>
    <first_received>June 3, 2010</first_received>
    <start_date>July 2010</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>March 14, 2011</last_updated>
    <last_verified>March 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety as measured by the frequency of serious adverse events (SAEs) and discontinuations due to adverse events (AEs)</outcome_measure>
      <outcome_measure>Antiviral activity as determined by the proportion of subjects with extended rapid virologic response (eRVR) defined as undetectable HCV RNA</outcome_measure>
      <outcome_measure>Proportion of subjects with rapid virologic response (RVR), defined as undetectable RNA</outcome_measure>
      <outcome_measure>Proportion of subjects with complete early virologic response (cEVR), defined as undetectable HCV RNA</outcome_measure>
      <outcome_measure>Proportion of subjects with a sustained virologic response (SVR), defined as HCV RNA undetectable</outcome_measure>
      <outcome_measure>Resistant variants associated with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01142700</url>
  </study>
  <study rank="176">
    <nct_id>NCT01353911</nct_id>
    <title>Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Grazoprevir</intervention>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Placebo for Grazoprevir</intervention>
      <intervention type="Drug">Placebo for Boceprevir</intervention>
      <intervention type="Drug">Peg-interferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>368</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>5172-003</other_id>
    </other_ids>
    <first_received>May 12, 2011</first_received>
    <start_date>June 2011</start_date>
    <completion_date>March 2015</completion_date>
    <last_updated>April 9, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Achieving complete Early Viral Response (cEVR) in the Grazoprevir Treatment Arms</outcome_measure>
      <outcome_measure>Number of participants experiencing adverse events</outcome_measure>
      <outcome_measure>Number of participants discontinued from study due to adverse events</outcome_measure>
      <outcome_measure>Number of Participants Achieving Sustained Viral Response 24 weeks After the End of All Study Therapy (SVR24)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01353911</url>
  </study>
  <study rank="177">
    <nct_id>NCT01439373</nct_id>
    <title>Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GSK2336805</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">GSK2336805 Matching Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
      <collaborator>PPD</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>17</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>115519</other_id>
    </other_ids>
    <first_received>July 7, 2011</first_received>
    <start_date>July 2011</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>November 15, 2012</last_updated>
    <last_verified>June 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety/tolerability of GSK2336805 in comparison with placebo.</outcome_measure>
      <outcome_measure>HCV viral load reduction from baseline</outcome_measure>
      <outcome_measure>Composite of pharmacokinetics, Day 1</outcome_measure>
      <outcome_measure>Composite of pharmacokinetics, Days 7, 14, 21</outcome_measure>
      <outcome_measure>Composite of pharmacokinetics, Day 28</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Nevada</state>
      <state>Oklahoma</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01439373</url>
  </study>
  <study rank="178">
    <nct_id>NCT02596880</nct_id>
    <title>Sofosbuvir, Daclatasvir, Ribavirin for HCV Cirrhotics</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Cirrhosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tehran University of Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>94-02-159-30278</other_id>
    </other_ids>
    <first_received>November 3, 2015</first_received>
    <start_date>September 2015</start_date>
    <completion_date>May 2016</completion_date>
    <last_updated>November 9, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>SD100</acronym>
    <primary_completion_date>March 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The sustained viral response rate</outcome_measure>
      <outcome_measure>Adverse drug events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Iran, Islamic Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02596880</url>
  </study>
  <study rank="179">
    <nct_id>NCT01911845</nct_id>
    <title>An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450/r/ABT-267</intervention>
      <intervention type="Drug">ABT-333</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>38</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M14-103</other_id>
    </other_ids>
    <first_received>May 13, 2013</first_received>
    <start_date>April 2013</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>September 16, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>December 23, 2014</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Failure During Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Relapse Post-treatment</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve (AUC) for ABT-450, Ritonavir, ABT-267, ABT-333, ABT-333 M1 Metabolite, and Ribavirin</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) for ABT-450, Ritonavir, ABT-267, ABT-333, ABT-333 M1 Metabolite, and Ribavirin</outcome_measure>
      <outcome_measure>Time to Maximum Plasma Concentration (Tmax) for ABT-450, Ritonavir, ABT-267, ABT-333, ABT-333 M1 Metabolite, and Ribavirin</outcome_measure>
      <outcome_measure>Plasma Trough Concentration (Ctrough) for ABT-450, Ritonavir, ABT-267, ABT-333, ABT-333 M1 Metabolite, and Ribavirin</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01911845</url>
  </study>
  <study rank="180">
    <nct_id>NCT00296972</nct_id>
    <title>Tolerability of Peginterferon Plus Ribavirin for Chronic Hepatitis C and HIV for Patients Receiving Antiretroviral Medication vs Not Receiving Antiretroviral Medication</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peg interferon plus ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Health Network, Toronto</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML 18562A</other_id>
    </other_ids>
    <first_received>February 23, 2006</first_received>
    <start_date>July 2005</start_date>
    <completion_date>April 2007</completion_date>
    <last_updated>April 19, 2007</last_updated>
    <last_verified>April 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>To compare the safety and tolerability of PEG-IFN with ribavirin in HIV/HCV co-infected patients who continue HAART therapy compared to those who discontinue HAART therapy in the first 12 weeks</outcome_measure>
      <outcome_measure>To compare the sustained virological response.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00296972</url>
  </study>
  <study rank="181">
    <nct_id>NCT00704522</nct_id>
    <title>Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepacivirus</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b (SCH 54031)</intervention>
      <intervention type="Drug">Ribavirin (SCH 18908)</intervention>
      <intervention type="Behavioral">Patient assistance program</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>601</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04281</other_id>
    </other_ids>
    <first_received>June 23, 2008</first_received>
    <start_date>March 2005</start_date>
    <completion_date>April 2009</completion_date>
    <last_updated>October 5, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>April 21, 2010</firstreceived_results_date>
    <primary_completion_date>April 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Who Complete Treatment With PegIntron Pen/Rebetol Therapy for Hepatitis C When Administered With a Patient Assistance Program</outcome_measure>
      <outcome_measure>Average Length of Treatment With PegIntron/Rebetol</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00704522</url>
  </study>
  <study rank="182">
    <nct_id>NCT01052701</nct_id>
    <title>Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Ribavrin</intervention>
      <intervention type="Drug">Abacavir plus Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Johns Hopkins University</lead_sponsor>
      <collaborator>GlaxoSmithKline</collaborator>
      <collaborator>University of Nebraska</collaborator>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>28</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NA_00023807</other_id>
    </other_ids>
    <first_received>January 19, 2010</first_received>
    <start_date>December 2009</start_date>
    <completion_date>June 2012</completion_date>
    <last_updated>June 22, 2011</last_updated>
    <last_verified>January 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate the effect of abacavir (ABC) on Ribavirin Triphosphate (RBV-TP) intracellular concentrations.</outcome_measure>
      <outcome_measure>To evaluate the effect of ABC on plasma RBV trough concentrations.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01052701</url>
  </study>
  <study rank="183">
    <nct_id>NCT01467479</nct_id>
    <title>A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Biological">Pegylated Interferon Alfa-2a</intervention>
      <intervention type="Drug">Highly Active Antiretroviral Therapy (HAART)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>185</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX11-950-115</other_id>
    </other_ids>
    <first_received>November 3, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>March 3, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>March 3, 2015</firstreceived_results_date>
    <primary_completion_date>February 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR 24)</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Viral Response (RVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Extended Rapid Viral Response (eRVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Undetectable HCV RNA at End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
      <outcome_measure>Maximum (Cmax), Minimum (Cmin), and Average Plasma Concentration (Cavg)</outcome_measure>
      <outcome_measure>Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Germany</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maine</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>South Carolina</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01467479</url>
  </study>
  <study rank="184">
    <nct_id>NCT01314261</nct_id>
    <title>Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Hepatitis C Virus (HCV) Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-267</intervention>
      <intervention type="Drug">Pegylated interferon (pegIFN)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Other">Placebo for ABT-267</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie (prior sponsor, Abbott)</lead_sponsor>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>37</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>M12-114</other_id>
    </other_ids>
    <first_received>March 11, 2011</first_received>
    <start_date>March 2011</start_date>
    <completion_date>February 2013</completion_date>
    <last_updated>January 21, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>December 29, 2014</firstreceived_results_date>
    <primary_completion_date>January 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With 4-week Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of ABT-267</outcome_measure>
      <outcome_measure>Time to Maximum Plasma Concentration (Tmax) of ABT-267</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of ABT-267</outcome_measure>
      <outcome_measure>Plasma Concentrations of Ribavirin (RBV)</outcome_measure>
      <outcome_measure>Serum Concentrations of Pegylated Interferon (pegIFN)</outcome_measure>
      <outcome_measure>Percentage of Participants With Partial Early Virologic Response (pEVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-pegylated Interferon/Ribavirin (pegIFN/RBV) Dosing</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 24 Weeks (SVR24) Post-pegylated Interferon/Ribavirin (pegIFN/RBV) Dosing</outcome_measure>
      <outcome_measure>Median Time to Suppression of Hepatitis C Virus Ribonucleic Acid (HCV RNA)</outcome_measure>
      <outcome_measure>Percentage of Participants With Extended Rapid Virologic Response (eRVR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Florida</state>
      <state>Hawaii</state>
      <state>Indiana</state>
      <state>Missouri</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01314261</url>
  </study>
  <study rank="185">
    <nct_id>NCT01471574</nct_id>
    <title>Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Genotype 1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-790052 (Daclatasvir)</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peg-Interferon alfa 2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>301</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-043</other_id>
      <other_id>2011-003067-30</other_id>
    </other_ids>
    <first_received>November 4, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>February 6, 2015</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects with SVR12, defined as HCV RNA &lt; LLOQ, target detected or not detected at post-treatment Week 12</outcome_measure>
      <outcome_measure>Proportion of subjects with Genotype 1 infection who achieve HCV RNA &lt; LLOQ , target detected or not detected</outcome_measure>
      <outcome_measure>Proportion of subjects with Genotype 1 infection who achieve HCV RNA &lt; LLOQ, target not detected</outcome_measure>
      <outcome_measure>Safety, as measured by the frequency of SAEs and discontinuations due to AEs</outcome_measure>
      <outcome_measure>Proportion of subjects who are receiving HAART and who maintain their HIV RNA &lt; 40 copies/mL and the proportion of subjects who experience confirmed HIV RNA ≥ 400 copies/mL at end of treatment for subjects who are receiving HAART</outcome_measure>
      <outcome_measure>Proportion of subjects with SVR12 by rs12979860 Single nucleotide polymorphism (SNP) in the IL28B gene</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Puerto Rico</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01471574</url>
  </study>
  <study rank="186">
    <nct_id>NCT00081770</nct_id>
    <title>Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b; SCH 54031)</intervention>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b; SCH 54031)</intervention>
      <intervention type="Drug">REBETOL (ribavirin; SCH 18908)</intervention>
      <intervention type="Biological">PEGASYS (peginterferon alfa-2a)</intervention>
      <intervention type="Drug">COPEGUS (ribavirin)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>4469</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P03471</other_id>
      <other_id>2552898</other_id>
    </other_ids>
    <first_received>April 20, 2004</first_received>
    <start_date>March 2004</start_date>
    <completion_date>November 2007</completion_date>
    <last_updated>March 31, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>November 3, 2008</firstreceived_results_date>
    <primary_completion_date>November 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR) Rate</outcome_measure>
      <outcome_measure>Mean Change From Baseline in the Log Viral Load at Treatment Week 4</outcome_measure>
      <outcome_measure>Virologic Response Rate at Treatment Week 12</outcome_measure>
      <outcome_measure>Mean Change From Baseline in the Log Viral Load at Treatment Week 2</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00081770</url>
  </study>
  <study rank="187">
    <nct_id>NCT01306617</nct_id>
    <title>A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
      <condition>Hepatitis C</condition>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450</intervention>
      <intervention type="Drug">ABT-333</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">ritonavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie (prior sponsor, Abbott)</lead_sponsor>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M12-746</other_id>
    </other_ids>
    <first_received>February 28, 2011</first_received>
    <start_date>February 2011</start_date>
    <completion_date>October 2012</completion_date>
    <last_updated>December 29, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>December 29, 2014</firstreceived_results_date>
    <primary_completion_date>November 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Suppressed Below the Lower Limit of Detection (LLOD) From Week 4 Through Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; 1000 International Units Per Milliliter (IU/mL)</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA Below the Lower Limit of Quantitation (LLOQ; &lt;25 IU/mL) at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 24 Weeks (SVR24) Post-Treatment</outcome_measure>
      <outcome_measure>Time to Failure to Suppress or Rebound During Treatment</outcome_measure>
      <outcome_measure>Time to Virologic Relapse Post-treatment</outcome_measure>
      <outcome_measure>Resistance-Associated Variants and Phenotypic Resistance</outcome_measure>
      <outcome_measure>Pharmacokinetics (C Trough) of ABT 450 in HCV Infected Participants</outcome_measure>
      <outcome_measure>Pharmacokinetics (C Trough) of ABT-333 in HCV Infected Participants</outcome_measure>
      <outcome_measure>Pharmacokinetics (C Trough) of Ritonavir in HCV Infected Participants</outcome_measure>
      <outcome_measure>Pharmacokinetics (C Trough) of Ribavirin in HCV Infected Participants</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01306617</url>
  </study>
  <study rank="188">
    <nct_id>NCT00215865</nct_id>
    <title>PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEGIntron plus ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hepatitis Resource Network</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HRN 003</other_id>
    </other_ids>
    <first_received>September 20, 2005</first_received>
    <last_updated>September 20, 2005</last_updated>
    <last_verified>September 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>1. To compare the Sustained Virologic Response (SVR) of PEGIntron plus ribavirin among patients receiving a fixed dose of PEGIntron versus weighted-adjusted dosing</outcome_measure>
      <outcome_measure>2. To evaluate the safety and tolerability PEG Intron in combination with ribavirin given as a fixed dose versus weight adjusted.</outcome_measure>
      <outcome_measure>3. To determine the Early Virologic Response (EVR) at week 24.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00215865</url>
  </study>
  <study rank="189">
    <nct_id>NCT02118012</nct_id>
    <title>Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl Alone or in Combination With Ribavirin in Patients With Chronic Hepatitis C</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Chlorcyclizine HCL plus Ribavirin</intervention>
      <intervention type="Drug">Chlorcyclizine HCL Only</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>140084</other_id>
      <other_id>14-DK-0084</other_id>
    </other_ids>
    <first_received>April 16, 2014</first_received>
    <start_date>March 2014</start_date>
    <completion_date>March 2017</completion_date>
    <last_updated>December 2, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Decline in serum HCV RNA viral titer during therapy as compared to baseline measured by PCR. The ability to tolerate the drug at the prescribed dose for the duration of therapy.</outcome_measure>
      <outcome_measure>1. A significant change in alanine aminotransferase (ALT) levels compared to baseline.2. Quantification of chlorcyclizine HCL and its metabolites in serum during therapy.3. Changes in symptom scale measurements during and after therapy.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02118012</url>
  </study>
  <study rank="190">
    <nct_id>NCT02319031</nct_id>
    <title>Safety and Efficacy Study of Daclatasvir 60mg, Sofosbuvir 400mg, and Ribavirin (Dosed Based Upon Weight) in Subjects With Chronic Genotype 3 Hepatitis C Infection With or Without Prior Treatment Experience and Compensated Advanced Cirrhosis for 12 or 16 Weeks</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-326</other_id>
    </other_ids>
    <first_received>December 12, 2014</first_received>
    <start_date>February 2015</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects with sustained virologic response a follow up Weeks 12 (SVR12), defined as HCV RNA &lt; lower limit of quantification (LLOQ) target detected (TD) or target not detected (TND)</outcome_measure>
      <outcome_measure>On treatment safety, as measured by frequency of Serious Adverse Event (SAE)s, discontinuation due to Adverse Event (AE)s, Grade 3/4 AEs, and Grade 3/4 laboratory abnormalities</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve HCV RNA &lt; LLOQ-TD/TND</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02319031</url>
  </study>
  <study rank="191">
    <nct_id>NCT01872936</nct_id>
    <title>Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Miravirsen</intervention>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Santaris Pharma A/S</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>SPC3649-205</other_id>
    </other_ids>
    <first_received>June 3, 2013</first_received>
    <start_date>June 2013</start_date>
    <completion_date>January 2015</completion_date>
    <last_updated>November 17, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The proportion of subjects with a Sustained Virological Response at 24 weeks after the end of therapy.</outcome_measure>
      <outcome_measure>The proportion of subjects with undetectable HCV RNA levels at end of treatment.</outcome_measure>
      <outcome_measure>The proportion of subjects with a Sustained Virological Response at 12 and 48 weeks after the end of therapy.</outcome_measure>
      <outcome_measure>Change in HCV RNA levels from baseline throughout the study.</outcome_measure>
      <outcome_measure>The proportion of subjects who experience virological failure throughout the study.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01872936</url>
  </study>
  <study rank="192">
    <nct_id>NCT01853254</nct_id>
    <title>A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>272</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV17590</other_id>
    </other_ids>
    <first_received>May 10, 2013</first_received>
    <start_date>September 2003</start_date>
    <completion_date>September 2011</completion_date>
    <last_updated>June 25, 2013</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>June 25, 2013</firstreceived_results_date>
    <primary_completion_date>September 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With at Least 1 Adverse Event</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>Brazil</country>
      <country>France</country>
      <country>Greece</country>
      <country>Italy</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>Taiwan</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Idaho</state>
      <state>Indiana</state>
      <state>Iowa</state>
      <state>Kansas</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Minnesota</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01853254</url>
  </study>
  <study rank="193">
    <nct_id>NCT00780416</nct_id>
    <title>Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MP-424</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon Alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon Alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>189</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>G060-A6</other_id>
    </other_ids>
    <first_received>October 24, 2008</first_received>
    <start_date>November 2008</start_date>
    <completion_date>August 2010</completion_date>
    <last_updated>April 16, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>June 5, 2012</firstreceived_results_date>
    <primary_completion_date>August 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Subjects Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00780416</url>
  </study>
  <study rank="194">
    <nct_id>NCT01725542</nct_id>
    <title>Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV-HIV Co-Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
      <collaborator>Bristol-Myers Squibb</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRS HC30 QUADRIH</other_id>
      <other_id>2012-002589-11</other_id>
    </other_ids>
    <first_received>October 22, 2012</first_received>
    <start_date>December 2012</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>September 5, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>QUADRIH</acronym>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HCV Sustained virological response rate</outcome_measure>
      <outcome_measure>Number of participants with adverse events as a measure of safety and tolerability</outcome_measure>
      <outcome_measure>Kinetics of HCV Virological response</outcome_measure>
      <outcome_measure>Immunological and virological evolution of HIV infection</outcome_measure>
      <outcome_measure>Evolution of cirrhosis (for cirrhotic patients)</outcome_measure>
      <outcome_measure>Number of Participants with HIV and non HIV related clinical events</outcome_measure>
      <outcome_measure>Minimum Plasma Concentration (Cmin) of ribavirin</outcome_measure>
      <outcome_measure>Pharmacokinetics of Antiretroviral drugs</outcome_measure>
      <outcome_measure>Pharmacokinetics of Asunaprevir and Daclatasvir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01725542</url>
  </study>
  <study rank="195">
    <nct_id>NCT02371408</nct_id>
    <title>A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ravidasvir hydrochloride</intervention>
      <intervention type="Drug">sofosbuvir</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pharco Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>PPI-668-202</other_id>
    </other_ids>
    <first_received>February 1, 2015</first_received>
    <start_date>January 2015</start_date>
    <completion_date>May 2016</completion_date>
    <last_updated>October 22, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportions of patients who achieve Sustained Virologic Response at 12 weeks post-treatment (SVR12)</outcome_measure>
      <outcome_measure>Proportions of patients who achieve Sustained Virologic Response at 4 weeks post-treatment (SVR4)</outcome_measure>
      <outcome_measure>Proportions of patients who achieve Sustained Virologic Response at 24 weeks post-treatment (SVR 24)</outcome_measure>
      <outcome_measure>Proportion of treated study participants prematurely discontinuing study treatment for any reason, proportion prematurely discontinuing treatment for lack of efficacy or for clinical adverse events or laboratory abnormalities</outcome_measure>
      <outcome_measure>Proportion of patients experiencing treatment-emergent adverse events, and proportion of patients experiencing adverse events considered to be probably or possibly related to one or more of the study drugs</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02371408</url>
  </study>
  <study rank="196">
    <nct_id>NCT02498015</nct_id>
    <title>A Phase IV Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir for Chronic Hepatitis C Genotype 1 Virus Infection</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">&quot;3D&quot; regimen</intervention>
      <intervention type="Drug">&quot;3D&quot; regimen with ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kirby Institute</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VHCRP1405</other_id>
    </other_ids>
    <first_received>June 26, 2015</first_received>
    <start_date>November 2015</start_date>
    <completion_date>October 2018</completion_date>
    <last_updated>July 12, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>D3FEAT</acronym>
    <primary_completion_date>July 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The proportion of participants with undetectable HCV RNA at 12 weeks post end of treatment (SVR12)</outcome_measure>
      <outcome_measure>The proportion of participants with undetectable HCV RNA at 2 weeks following the initiation of treatment - week 2</outcome_measure>
      <outcome_measure>The proportion of participants with undetectable HCV RNA at 4 weeks following the initiation of treatment - week 4</outcome_measure>
      <outcome_measure>The proportion of participants with undetectable HCV RNA at the end of treatment - week 12</outcome_measure>
      <outcome_measure>The proportion of participants with undetectable HCV RNA at 24 weeks post end of treatment (SVR24)</outcome_measure>
      <outcome_measure>Treatment adherence</outcome_measure>
      <outcome_measure>Association between adherence and response to treatment</outcome_measure>
      <outcome_measure>Safety and tolerability (number and type of adverse events and serious adverse events)</outcome_measure>
      <outcome_measure>Change in injecting drug use and injecting risk behaviour</outcome_measure>
      <outcome_measure>Change in mental health</outcome_measure>
      <outcome_measure>Change in health-related quality of life Questionnaire</outcome_measure>
      <outcome_measure>Impact of mixed HCV infection on treatment response</outcome_measure>
      <outcome_measure>Change in opioid substitution therapy</outcome_measure>
      <outcome_measure>HCV reinfection rate</outcome_measure>
      <outcome_measure>Emergence of viral resistance-associated variants (RAVs)</outcome_measure>
      <outcome_measure>Utility of HCV core antigen testing as a simple method for HCV monitoring</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02498015</url>
  </study>
  <study rank="197">
    <nct_id>NCT01502072</nct_id>
    <title>Respiratory Syncytial Virus - RSV Protocol</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Bone Marrow Transplant Infection</condition>
      <condition>Infection in Marrow Transplant Recipients</condition>
      <condition>Respiratory Syncytial Virus Infections</condition>
      <condition>Respiratory Syncytial Virus Pneumonia</condition>
      <condition>Cancer</condition>
      <condition>Acute Leukemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>M.D. Anderson Cancer Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>96</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2011-0813</other_id>
      <other_id>NCI-2012-00021</other_id>
    </other_ids>
    <first_received>December 22, 2011</first_received>
    <start_date>December 2011</start_date>
    <last_updated>October 28, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants with Progression to Lower Respiratory Tract Infection (LRI)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01502072</url>
  </study>
  <study rank="198">
    <nct_id>NCT01716156</nct_id>
    <title>A Study of Different Durations of Treatment With Grazoprevir (MK-5172) in Combination With Ribavirin in Participants With Chronic Hepatitis C (MK-5172-039 AM1)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Grazoprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>26</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>5172-039</other_id>
    </other_ids>
    <first_received>October 25, 2012</first_received>
    <start_date>January 2013</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>November 9, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants achieving Sustained Virologic Response 12 weeks after the end of all study therapy (SVR12)</outcome_measure>
      <outcome_measure>Number of participants experiencing at least one adverse event (AE) on study</outcome_measure>
      <outcome_measure>Number of participants discontinuing study therapy due to an AE</outcome_measure>
      <outcome_measure>Time to first achievement of undetectable hepatitis C virus ribonucleic acid (HCV RNA)</outcome_measure>
      <outcome_measure>Number of participants achieving undetectable HCV RNA at Week 2</outcome_measure>
      <outcome_measure>Number of participants achieving undetectable HCV RNA at Week 4</outcome_measure>
      <outcome_measure>Number of participants achieving undetectable HCV RNA at Week 12</outcome_measure>
      <outcome_measure>Number of participants achieving HCV RNA &lt;25 IU/mL at Week 2</outcome_measure>
      <outcome_measure>Number of participants achieving HCV RNA &lt;25 IU/mL at Week 4</outcome_measure>
      <outcome_measure>Number of participants achieving HCV RNA &lt;25 IU/mL at Week 12</outcome_measure>
      <outcome_measure>Number of participants achieving end-of-treatment response (EOTR)</outcome_measure>
      <outcome_measure>Number of participants achieving sustained virologic response 4 weeks after the end of all study therapy (SVR 4)</outcome_measure>
      <outcome_measure>Number of participants achieving sustained virologic response 24 weeks after the end of all study therapy (SVR 24)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01716156</url>
  </study>
  <study rank="199">
    <nct_id>NCT00845065</nct_id>
    <title>Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Other">Placebo</intervention>
      <intervention type="Biological">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>202</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05685</other_id>
    </other_ids>
    <first_received>February 13, 2009</first_received>
    <start_date>February 2009</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>September 24, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>October 10, 2011</firstreceived_results_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR) Rate in Full Analysis Set (FAS) Population.</outcome_measure>
      <outcome_measure>SVR Rate in the Modified Intent-to-Treat (mITT) Population</outcome_measure>
      <outcome_measure>Percentage of Participants With Early Virologic Response (EVR) Who Achieved SVR</outcome_measure>
      <outcome_measure>Number of Participants With Undetectable HCV-RNA at Follow-up Week 12</outcome_measure>
      <outcome_measure>Mean Log Change From Baseline to TW 4 in Viral Load by Visit</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00845065</url>
  </study>
  <study rank="200">
    <nct_id>NCT00863239</nct_id>
    <title>Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">Locteron™ (controlled-release interferon alpha 2b)</intervention>
      <intervention type="Drug">PEG-Intron™</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Biolex Therapeutics, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>116</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>BLX883-203</other_id>
    </other_ids>
    <first_received>March 16, 2009</first_received>
    <start_date>March 2009</start_date>
    <completion_date>November 2011</completion_date>
    <last_updated>February 1, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>SELECT-2</acronym>
    <primary_completion_date>November 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>EVR: the proportion of subjects in each arm that have at least a 2 log drop in HCV RNA from Baseline</outcome_measure>
      <outcome_measure>SVR: the proportion of subjects in each arm demonstrating HCV RNA undetectable (&lt; 10 IU/mL) at the end of the follow-up period</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Bulgaria</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Kentucky</state>
      <state>Maryland</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>Ohio</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00863239</url>
  </study>
  <study rank="201">
    <nct_id>NCT01425970</nct_id>
    <title>Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">INX-08189</intervention>
      <intervention type="Drug">INX-08189</intervention>
      <intervention type="Drug">INX-08189</intervention>
      <intervention type="Drug">Placebo matching with INX-08189</intervention>
      <intervention type="Biological">Pegylated interferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">INX-08189</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>210</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI472-003</other_id>
      <other_id>INH-189-003</other_id>
    </other_ids>
    <first_received>August 25, 2011</first_received>
    <start_date>May 2012</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>October 12, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Part A: Change in Hepatitis C Viral Load Measurements at protocol specific timepoints</outcome_measure>
      <outcome_measure>Part B: proportion of subjects with SVR defined as HCV RNA ≤ LOQ (Limit of Quantitation)</outcome_measure>
      <outcome_measure>Part B: proportion of subjects with SVR defined as HCV RNA ≤ LOQ</outcome_measure>
      <outcome_measure>Safety assessments is measured by Physical Exams, vital signs, laboratory assessments, ECGs, pregnancy test, viral resistance testing, adverse event assessment</outcome_measure>
      <outcome_measure>Proportion of subjects with RVR (Rapid Virologic Response), undetectable HCV RNA</outcome_measure>
      <outcome_measure>Proportion of subjects with Complete EVR (Early Virologic Response), undetectable HCV RNA</outcome_measure>
      <outcome_measure>Proportion of subjects with Extended RVR</outcome_measure>
      <outcome_measure>Proportion of subjects with SVR24</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Missouri</state>
      <state>Oklahoma</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01425970</url>
  </study>
  <study rank="202">
    <nct_id>NCT01544920</nct_id>
    <title>Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">peginterferon alfa-2a</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>737</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P07755</other_id>
      <other_id>2011-001345-32</other_id>
      <other_id>MK-3034-040</other_id>
      <other_id>CTRI/2012/12/003200</other_id>
      <other_id>PHRR131022-000133</other_id>
    </other_ids>
    <first_received>February 28, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>May 2015</completion_date>
    <last_updated>June 18, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Overall Number of Participants Achieving Sustained Viral Response (SVR) at Follow-up Week 24</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR at Follow-up Week 24 Among Those Participants Who Had Achieved Rapid Virologic Response (RVR)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01544920</url>
  </study>
  <study rank="203">
    <nct_id>NCT02505243</nct_id>
    <title>Evaluation of RIBAvirin Plasma COncentrations in Patients With Chronic Hepatitis C Infection Routinely Treated With Modern DAA Regimens</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV Coinfection</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Radboud University</lead_sponsor>
      <collaborator>Erasmus Medical Center</collaborator>
      <collaborator>University Medical Center Groningen</collaborator>
      <collaborator>UMC Utrecht</collaborator>
      <collaborator>Maastricht University Medical Center</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
    </study_designs>
    <other_ids>
      <other_id>UMCN-AKF-15.03</other_id>
    </other_ids>
    <first_received>July 15, 2015</first_received>
    <start_date>June 2015</start_date>
    <completion_date>February 2016</completion_date>
    <last_updated>July 21, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>RIBACOP</acronym>
    <primary_completion_date>January 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Ribavirin concentration</outcome_measure>
      <outcome_measure>Sustained virological response (SVR12)</outcome_measure>
      <outcome_measure>Hemoglobin concentrations</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02505243</url>
  </study>
  <study rank="204">
    <nct_id>NCT01056172</nct_id>
    <title>PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a and Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa-2a and Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pusan National University Yangsan Hospital</lead_sponsor>
      <collaborator>Severance Hospital</collaborator>
      <collaborator>Pusan National University Hospital</collaborator>
      <collaborator>Incheon St.Mary's Hospital</collaborator>
      <collaborator>Soon Chun Hyang University</collaborator>
      <collaborator>Inje University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>164</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>PNUYH-CHC001</other_id>
    </other_ids>
    <first_received>January 25, 2010</first_received>
    <start_date>January 2010</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>April 18, 2012</last_updated>
    <last_verified>April 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (SVR)</outcome_measure>
      <outcome_measure>AEs</outcome_measure>
      <outcome_measure>laboratory parameters</outcome_measure>
      <outcome_measure>vital signs</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Korea, Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01056172</url>
  </study>
  <study rank="205">
    <nct_id>NCT02455167</nct_id>
    <title>Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprivir (SMV)</intervention>
      <intervention type="Drug">Sofosbuvir (SOF)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Colorado, Denver</lead_sponsor>
      <collaborator>Janssen Scientific Affairs, LLC</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>14-0919</other_id>
      <other_id>UL1TR001082</other_id>
    </other_ids>
    <first_received>April 21, 2015</first_received>
    <start_date>May 2015</start_date>
    <completion_date>August 2016</completion_date>
    <last_updated>October 2, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The sustained virologic response (SVR) in patients infected with HCV genotype 1, cirrhosis, and early clinical decompensation</outcome_measure>
      <outcome_measure>Hepatic improvement during and after Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) treatment using a new test of liver function, HepQuant-SHUNT.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Colorado</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02455167</url>
  </study>
  <study rank="206">
    <nct_id>NCT00221650</nct_id>
    <title>Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in HIV-Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Treatment Failure</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Bordeaux</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
      <collaborator>Ministry of Health, France</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>17</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>9232-01</other_id>
      <other_id>2000-023</other_id>
    </other_ids>
    <first_received>September 13, 2005</first_received>
    <start_date>April 2002</start_date>
    <completion_date>June 2004</completion_date>
    <last_updated>June 12, 2007</last_updated>
    <last_verified>June 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ROCO2</acronym>
    <outcome_measures>
      <outcome_measure>Proportion of patients with a sustained virological response, defined as an undetectable HCV RNA level</outcome_measure>
      <outcome_measure>Proportion of patients with a virological response</outcome_measure>
      <outcome_measure>Safety of treatment</outcome_measure>
      <outcome_measure>Influence of anti-HCV treatment on CD4 count and HIV RNA</outcome_measure>
      <outcome_measure>Proportion of patients with histological response 24 weeks after the end of anti-HCV treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00221650</url>
  </study>
  <study rank="207">
    <nct_id>NCT01710501</nct_id>
    <title>A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038 AM2)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C (CHC)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Grazoprevir</intervention>
      <intervention type="Biological">PegIFN-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>87</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>5172-038</other_id>
      <other_id>2012-003333-42</other_id>
    </other_ids>
    <first_received>October 17, 2012</first_received>
    <start_date>December 2012</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of subjects achieving Sustained Virologic Response (SVR) at 12 weeks (SVR12) after the end of treatment</outcome_measure>
      <outcome_measure>Number of participants experiencing at least one adverse event (AE)</outcome_measure>
      <outcome_measure>Number of participants discontinued from study treatment due to AEs</outcome_measure>
      <outcome_measure>Number of subjects achieving undetectable hepatitis C virus ribonucleic acid (HCV RNA) at Week 2</outcome_measure>
      <outcome_measure>Number of subjects achieving undetectable HCV RNA at Week 4</outcome_measure>
      <outcome_measure>Number of subjects achieving undetectable HCV RNA at Week 12</outcome_measure>
      <outcome_measure>Number of subjects achieving undetectable HCV RNA at Week 24</outcome_measure>
      <outcome_measure>Number of participants achieving HCV RNA &lt;25 IU/mL at Week 2</outcome_measure>
      <outcome_measure>Number of participants achieving HCV RNA &lt;25 IU/mL at Week 4</outcome_measure>
      <outcome_measure>Number of participants achieving HCV RNA &lt;25 IU/mL at Week 12</outcome_measure>
      <outcome_measure>Number of participants achieving HCV RNA &lt;25 IU/mL at Week 24</outcome_measure>
      <outcome_measure>Number of subjects achieving SVR4</outcome_measure>
      <outcome_measure>Number of subjects achieving SVR24</outcome_measure>
      <outcome_measure>Number of participants who develop antiviral resistance to grazoprevir</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01710501</url>
  </study>
  <study rank="208">
    <nct_id>NCT00980330</nct_id>
    <title>A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Peg-IFN-alfa-2a (P)</intervention>
      <intervention type="Drug">Ribavirin (R)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>463</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR016063</other_id>
      <other_id>TMC435-TiDP16-C206</other_id>
      <other_id>2009-010590-20</other_id>
    </other_ids>
    <first_received>September 10, 2009</first_received>
    <start_date>October 2009</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>May 30, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>December 18, 2013</firstreceived_results_date>
    <acronym>ASPIRE</acronym>
    <primary_completion_date>August 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response at the End of Treatment (EOT) and 24 Weeks After the EOT (SVR24)</outcome_measure>
      <outcome_measure>The Percentage of Participants With a Greater Than 2 log10 Drop in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Time Points During Treatment</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving Plasma Levels of Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Undetectable During Treatment and Follow-up</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving Plasma Levels of Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Detectable or Undetectable During Treatment and Follow-up</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving an Early Virologic Response (EVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>The Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>The Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>The Number of Participants Who Achieved Normalized Alanine Aminotransferase (ALT) Levels at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Plasma Concentrations of TMC435</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24h) for TMC435</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>New Zealand</country>
      <country>Norway</country>
      <country>Poland</country>
      <country>Portugal</country>
      <country>Russian Federation</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Mississippi</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00980330</url>
  </study>
  <study rank="209">
    <nct_id>NCT01440595</nct_id>
    <title>Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012 AM1)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Grazoprevir</intervention>
      <intervention type="Drug">Placebo to Grazoprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2b (Peg-IFN)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>5</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>5172-012</other_id>
    </other_ids>
    <first_received>September 22, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>May 2012</completion_date>
    <last_updated>November 9, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants achieving complete early virologic response (cEVR) in the grazoprevir treatment arms</outcome_measure>
      <outcome_measure>Time to first achievement of undetectable HCV ribonucleic acid (RNA)</outcome_measure>
      <outcome_measure>Number of participants achieving rapid viral response (RVR)</outcome_measure>
      <outcome_measure>Number of participants achieving sustained viral response 12 weeks after completion of therapy (SVR12)</outcome_measure>
      <outcome_measure>Number of participants achieving sustained viral response 24 weeks after completion of therapy (SVR24)</outcome_measure>
      <outcome_measure>Number of participants achieving undetectable HCV RNA at Week 12 in the Placebo arm</outcome_measure>
      <outcome_measure>Number of participants achieving complete early virologic response (cEVR) at Week 24 in the Placebo arm</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01440595</url>
  </study>
  <study rank="210">
    <nct_id>NCT02112630</nct_id>
    <title>Boceprevir in End Stage Renal Disease (ESRD)</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
      <condition>End Stage Renal Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">P-IFN alfa 2a</intervention>
      <intervention type="Drug">P-IFN alfa 2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Columbia University</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AAAL5200</other_id>
    </other_ids>
    <first_received>April 2, 2014</first_received>
    <start_date>May 2013</start_date>
    <completion_date>February 2015</completion_date>
    <last_updated>September 21, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients who achieve sustained virologic response</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02112630</url>
  </study>
  <study rank="211">
    <nct_id>NCT01281423</nct_id>
    <title>Safety and Efficacy of ANA598 Administered With Pegylated Interferon and Ribavirin in Genotype-1 Patients With Chronic HCV Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">ANA598</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated Interferon</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>274</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANA598-505</other_id>
      <other_id>Control No. 143490</other_id>
    </other_ids>
    <first_received>January 20, 2011</first_received>
    <start_date>December 2010</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>November 20, 2012</last_updated>
    <last_verified>November 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR 24 (Sustained Virologic Response)</outcome_measure>
      <outcome_measure>Undetectable HCV RNA</outcome_measure>
      <outcome_measure>SVR 12</outcome_measure>
      <outcome_measure>Proportion of treatment-naive patients eligible to stop all treatment at Week 28</outcome_measure>
      <outcome_measure>Safety and tolerability of ANA598</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>New Zealand</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01281423</url>
  </study>
  <study rank="212">
    <nct_id>NCT00084279</nct_id>
    <title>CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>InterMune</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>81</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AGHC-002</other_id>
    </other_ids>
    <first_received>June 9, 2004</first_received>
    <start_date>April 2004</start_date>
    <completion_date>April 2006</completion_date>
    <last_updated>July 1, 2009</last_updated>
    <last_verified>July 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Virologic response defined as &gt;2 log (base 10) reduction in HCV RNA</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00084279</url>
  </study>
  <study rank="213">
    <nct_id>NCT01273064</nct_id>
    <title>Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CTS-1027</intervention>
      <intervention type="Drug">pegylated interferon</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Conatus Pharmaceuticals Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>114</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CTS-1027-05</other_id>
    </other_ids>
    <first_received>December 21, 2010</first_received>
    <start_date>January 2011</start_date>
    <completion_date>October 2011</completion_date>
    <last_updated>June 4, 2012</last_updated>
    <last_verified>June 2012</last_verified>
    <firstreceived_results_date>March 29, 2012</firstreceived_results_date>
    <primary_completion_date>September 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response</outcome_measure>
      <outcome_measure>Greater Than 2 Log Decline in HCV-RNA at Study Weeks 12, 24 and 48</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Kansas</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01273064</url>
  </study>
  <study rank="214">
    <nct_id>NCT01405937</nct_id>
    <title>Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">vaniprevir</intervention>
      <intervention type="Biological">peg-IFN</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>51</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>7009-044</other_id>
    </other_ids>
    <first_received>July 28, 2011</first_received>
    <start_date>August 2011</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>September 4, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>October 3, 2014</firstreceived_results_date>
    <primary_completion_date>February 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Completion of All Study Therapy (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With One or More Specific Adverse Events (AEs) of Special Interest During the Study</outcome_measure>
      <outcome_measure>Percentage of Participants Who Discontinued Study Drug Due to an AE</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR12</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Undetectable HCV RNA at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Mean Change From Baseline in HCV RNA (Log 10)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01405937</url>
  </study>
  <study rank="215">
    <nct_id>NCT00856024</nct_id>
    <title>ATHENAS - Retrospective Study of Compliance in Chronic Hepatitis C With Pegylated Interferon Alfa-2b/Ribavirin in Brazil (P05632)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>902</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05632</other_id>
      <other_id>BR 002-07</other_id>
    </other_ids>
    <first_received>March 4, 2009</first_received>
    <start_date>July 2008</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>June 4, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>October 14, 2011</firstreceived_results_date>
    <acronym>ATHENAS</acronym>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percent of Participants Who Were Compliant to Treatment in the First 12 Weeks</outcome_measure>
      <outcome_measure>Percent of Participants Who Achieved Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Percent of Participants Who Achieved Early Virologic Response (EVR)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00856024</url>
  </study>
  <study rank="216">
    <nct_id>NCT00953589</nct_id>
    <title>480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Biolex Therapeutics, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>74</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>BLX883-204</other_id>
    </other_ids>
    <first_received>August 5, 2009</first_received>
    <start_date>July 2009</start_date>
    <completion_date>January 2011</completion_date>
    <last_updated>February 1, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>480S</acronym>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Primary efficacy endpoint: EVR: the proportion of subjects in each arm that have at least a 2 log drop in HCV RNA from Baseline</outcome_measure>
      <outcome_measure>the proportion of subjects in each arm demonstrating HCV RNA undetectable (&lt; 10 IU/mL) after 12 weeks of randomized treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Bulgaria</country>
      <country>Israel</country>
      <country>Romania</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00953589</url>
  </study>
  <study rank="217">
    <nct_id>NCT01639547</nct_id>
    <title>Sustained Virological Response (SVR)Rate of Pegasys Plus Ribavirin in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a plus Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Chang Gung Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>410</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CTC-133</other_id>
    </other_ids>
    <first_received>June 28, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>July 27, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response</outcome_measure>
      <outcome_measure>Virological Response Rate at week 2</outcome_measure>
      <outcome_measure>Virological response at end of treatment</outcome_measure>
      <outcome_measure>Correlation of virological response and SVR rate</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01639547</url>
  </study>
  <study rank="218">
    <nct_id>NCT01030432</nct_id>
    <title>Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-650032</intervention>
      <intervention type="Drug">BMS-650032</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Peginterferon Alfa-2a</intervention>
      <intervention type="Drug">Peginterferon Alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>285</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI447-016</other_id>
      <other_id>2009-013652-69</other_id>
    </other_ids>
    <first_received>December 10, 2009</first_received>
    <start_date>February 2010</start_date>
    <completion_date>October 2012</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Phase 2a and Phase 2b: Safety, as measured by the frequency of SAEs and discontinuations due to AEs</outcome_measure>
      <outcome_measure>Antiviral activity as determined by proportion of HCV genotype 1 subjects with extended rapid virologic response (eRVR), defined as undetectable HCV RNA</outcome_measure>
      <outcome_measure>Phase 2b only: Antiviral activity, as determined by the proportion of HCV genotype 1 subjects with 24-week sustained virologic response (SVR24), defined as undetectable HCV RNA</outcome_measure>
      <outcome_measure>Proportion of HCV genotype 1 subjects with rapid virologic response (RVR), defined as undetectable HCV RNA at Week 4</outcome_measure>
      <outcome_measure>Proportion of HCV genotype 1 subjects with complete early rapid virologic response (eEVR), defined as undetectable HCV RNA at Week 12 (Stage 2 only)</outcome_measure>
      <outcome_measure>Proportion of HCV genotype 1 subjects with early virologic response (EVR) defined as ≥2 log10 decrease in HCV RNA from baseline at Week 12 (Stage 1 only)</outcome_measure>
      <outcome_measure>Proportion of HCV genotype 1 subjects with 12-week sustained virologic response (SVR12), defined as undetectable HCV RNA at follow-up Week 12</outcome_measure>
      <outcome_measure>Proportion of HCV genotype 1 subjects with 24-week sustained virologic response (SVR24) defined as undetectable HCV RNA at follow-up Week 24 (Stage 1 only)</outcome_measure>
      <outcome_measure>Resistant variants associated with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Argentina</country>
      <country>France</country>
      <country>Germany</country>
      <country>Ireland</country>
      <country>Italy</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01030432</url>
  </study>
  <study rank="219">
    <nct_id>NCT01290679</nct_id>
    <title>An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>393</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017380</other_id>
      <other_id>TMC435-TiDP16-C216</other_id>
      <other_id>2010-021174-11</other_id>
    </other_ids>
    <first_received>January 7, 2011</first_received>
    <start_date>March 2011</start_date>
    <completion_date>February 2013</completion_date>
    <last_updated>June 10, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>February 3, 2014</firstreceived_results_date>
    <acronym>QUEST-2</acronym>
    <primary_completion_date>February 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Sustained Virologic Response 4 Weeks After the Planned End of Treatment (SVR4)</outcome_measure>
      <outcome_measure>Change From Baseline in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>Actual Values of log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Virologic Response at All Time Points</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Early Virologic Response (EVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants With &lt;1 log10 Decrease in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) From Baseline at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels &gt;1000 IU/mL at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Null Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Partial Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Percentage of Participants Who Completed All Study Treatment at Week 24 Because of the Treatment Duration Rule</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Failure</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Undetectable or Detectable</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Undetectable</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;100 IU/mL</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;1000 IU/mL</outcome_measure>
      <outcome_measure>The Percentage of Participants With Viral Breakthrough at Different Time Points</outcome_measure>
      <outcome_measure>Time From End-of-treatment to Viral Relapse</outcome_measure>
      <outcome_measure>The Percentage of Participants With Normalization of Alanine Aminotransferase (ALT)</outcome_measure>
      <outcome_measure>Median Time to Normalization of Alanine Aminotransferase (ALT) Levels</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h)</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Predose Plasma Concentration (C0h)</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Systemic Clearance (CL)</outcome_measure>
      <outcome_measure>Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for the Fatigue Severity Scale (FSS) Total Scores</outcome_measure>
      <outcome_measure>Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for Impairment in Overall Work Productivity Due to Hepatitis C Virus (HCV) Infection and Its Treatment</outcome_measure>
      <outcome_measure>Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for Impairment in Daily Activities Due to Hepatitis C Virus (HCV) Infection and Its Treatment</outcome_measure>
      <outcome_measure>Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for Time Missed From Work Due to Hepatitis C Virus (HCV) Infection and Its Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>Bulgaria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Netherlands</country>
      <country>Poland</country>
      <country>Portugal</country>
      <country>Puerto Rico</country>
      <country>Slovakia</country>
      <country>Spain</country>
      <country>Turkey</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Minnesota</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01290679</url>
  </study>
  <study rank="220">
    <nct_id>NCT00687544</nct_id>
    <title>Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepacivirus</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b (SCH 054031)</intervention>
      <intervention type="Drug">Ribavirin (SCH 018908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04469</other_id>
    </other_ids>
    <first_received>May 27, 2008</first_received>
    <start_date>December 2005</start_date>
    <completion_date>September 2008</completion_date>
    <last_updated>September 11, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>September 22, 2011</firstreceived_results_date>
    <primary_completion_date>September 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Who Achieved Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Number of Participants Who Achieved Virologic Response (VR)</outcome_measure>
      <outcome_measure>Number of Participants Who Achieved Sustained Biochemical Response (SBR)</outcome_measure>
      <outcome_measure>Number of Participants Experiencing Opportunistic Infection</outcome_measure>
      <outcome_measure>Number of Participants Who Died</outcome_measure>
      <outcome_measure>Number of Participants Experiencing Adverse Events</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00687544</url>
  </study>
  <study rank="221">
    <nct_id>NCT01467505</nct_id>
    <title>An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated Interferon Alfa-2a</intervention>
      <intervention type="Drug">Immunosuppressant Regimen</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>61</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX11-950-117</other_id>
    </other_ids>
    <first_received>November 3, 2011</first_received>
    <start_date>February 2012</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>June 1, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>May 2, 2015</firstreceived_results_date>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Viral Response (RVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Extended Rapid Viral Response (eRVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With On-Treatment Virologic Failure</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Pharmacokinetics of Telaprevir, Peg-IFN, RBV , and Selected Immunosuppressant Medications (Tacrolimus and Cyclosporine)</outcome_measure>
      <outcome_measure>Percentage of Participants Requiring Dose Titration of Immunosuppressant Medications</outcome_measure>
      <outcome_measure>Percentage of Participants With Biopsy Confirmed and Treated Rejection</outcome_measure>
      <outcome_measure>Percentage of Participants With Histological Evidence of Stabilization or Improvement in Inflammation Grade or Fibrosis Stage</outcome_measure>
      <outcome_measure>Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>Nebraska</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01467505</url>
  </study>
  <study rank="222">
    <nct_id>NCT00743795</nct_id>
    <title>Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">placebo</intervention>
      <intervention type="Drug">GS-9190</intervention>
      <intervention type="Drug">Peginterferon Alfa 2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>252</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-196-0103</other_id>
    </other_ids>
    <first_received>August 27, 2008</first_received>
    <start_date>October 2008</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>October 11, 2013</last_updated>
    <last_verified>October 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Undetectable HCV RNA level</outcome_measure>
      <outcome_measure>Safety and tolerability</outcome_measure>
      <outcome_measure>GS-9190 plasma concentrations</outcome_measure>
      <outcome_measure>Undetectable HCV RNA</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Belgium</country>
      <country>Germany</country>
      <country>Ireland</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00743795</url>
  </study>
  <study rank="223">
    <nct_id>NCT01459913</nct_id>
    <title>Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Pegylated Interferon Alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>239</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX11-950-114</other_id>
    </other_ids>
    <first_received>October 24, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>May 14, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>January 26, 2015</firstreceived_results_date>
    <acronym>CONCISE</acronym>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Subjects With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Subjects With Sustained Viral Response 4 Weeks After Last Planned Dose of Study Drug (SVR4)</outcome_measure>
      <outcome_measure>Percentage of Subjects With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Subjects With Sustained Viral Response at Week 72 (SVR72)</outcome_measure>
      <outcome_measure>Percentage of Subjects With Viral Relapse</outcome_measure>
      <outcome_measure>Percentage of Subjects With On-Treatment Virologic Failure</outcome_measure>
      <outcome_measure>Number of Subjects With Rapid Viral Response (RVR)</outcome_measure>
      <outcome_measure>Number of Subjects With Extended Rapid Viral Response (eRVR)</outcome_measure>
      <outcome_measure>Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Austria</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Poland</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New Hampshire</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01459913</url>
  </study>
  <study rank="224">
    <nct_id>NCT00059358</nct_id>
    <title>Zidovudine Levels in HIV Infected Patients Being Treated for HCV</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin plus interferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1R01AI09141-01A1</other_id>
      <other_id>5R01AI049141-02</other_id>
    </other_ids>
    <first_received>April 23, 2003</first_received>
    <start_date>September 2001</start_date>
    <completion_date>June 2005</completion_date>
    <last_updated>August 6, 2009</last_updated>
    <last_verified>August 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2005</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Steady state area under the concentration time curve (AUC) between 0 and 12 hours of zidovudine (ZDV)-MP, ZDV-TP, and dTTP in PBMCs from HIV and hepatitis C virus (HCV) coinfected patients before and after peginterferon alfa-2b with or without ribavirin</outcome_measure>
      <outcome_measure>Systemic exposure (AUC over 0 to 12 hours) of nelfinavir before and after peginterferon alfa-2b with or without ribavirin in HIV and HCV coinfected patients</outcome_measure>
      <outcome_measure>Effect of peginterferon alfa-2b with or without ribavirin in HCV RNA viral titers, alanine aminotransferase (ALT) levels, CD4+, and HIV-RNA viral titers in HIV and HCV coinfected patients</outcome_measure>
      <outcome_measure>Effect of peginterferon alfa-2b with or without ribavirin on liver histology</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00059358</url>
  </study>
  <study rank="225">
    <nct_id>NCT00944684</nct_id>
    <title>High Dose Ribavirin in the Treatment of Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">High ribavirin dose</intervention>
      <intervention type="Drug">Standard ribavirin dose</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Bern</lead_sponsor>
      <collaborator>Roche Pharma AG</collaborator>
      <collaborator>University of Lausanne</collaborator>
      <collaborator>Cantonal Hospital of St. Gallen</collaborator>
      <collaborator>Stadtspital Waid, Zürich, Switzerland</collaborator>
      <collaborator>University of Basel</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>091/07</other_id>
      <other_id>ML21071</other_id>
      <other_id>SASL-24</other_id>
    </other_ids>
    <first_received>July 17, 2009</first_received>
    <start_date>November 2007</start_date>
    <completion_date>April 2011</completion_date>
    <last_updated>November 10, 2011</last_updated>
    <last_verified>November 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response</outcome_measure>
      <outcome_measure>Adverse Events</outcome_measure>
      <outcome_measure>Rapid virological response at 4 weeks of treatment</outcome_measure>
      <outcome_measure>Early virological response at 12 weeks of treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Switzerland</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00944684</url>
  </study>
  <study rank="226">
    <nct_id>NCT00575224</nct_id>
    <title>Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Asian Americans</condition>
      <condition>Novel Genotypes</condition>
      <condition>Treatment</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pacific Health Foundation</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>PEG-183</other_id>
      <other_id>IRB Protocol #20041038</other_id>
      <other_id>IRB Study #1059635</other_id>
    </other_ids>
    <first_received>December 15, 2007</first_received>
    <start_date>October 2004</start_date>
    <completion_date>September 2009</completion_date>
    <last_updated>November 23, 2009</last_updated>
    <last_verified>November 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00575224</url>
  </study>
  <study rank="227">
    <nct_id>NCT02483156</nct_id>
    <title>Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Tablet Plus Ribavirin Tablet (Part A) Versus Single Tablet of EHCV Containing Sofosbuvir, Ribavirin, and Natural Anti-hemolytic (B) in Egyptian Adults With Chronic Genotype 4 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis c</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">single tablet of EHCV containing Sofosbuvir, Ribavirin, and Natural anti-hemolytic</intervention>
      <intervention type="Drug">Sofosbuvir tablet (SOF)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Egyptian Liver Hospital</lead_sponsor>
      <collaborator>Wadi El Nil Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ELH - 2015</other_id>
    </other_ids>
    <first_received>June 19, 2015</first_received>
    <start_date>July 2015</start_date>
    <last_updated>September 15, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Who Experienced Adverse Events During Treatment Period</outcome_measure>
      <outcome_measure>Change in Circulating HCV RNA</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02483156</url>
  </study>
  <study rank="228">
    <nct_id>NCT00000833</nct_id>
    <title>A Phase I Study of Combination Therapy With Didanosine (ddI) and Ribavirin in HIV-Infected Children.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Didanosine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>ACTG 274</other_id>
      <other_id>11250</other_id>
    </other_ids>
    <first_received>November 2, 1999</first_received>
    <completion_date>July 1998</completion_date>
    <last_updated>May 1, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Louisiana</state>
      <state>Massachusetts</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00000833</url>
  </study>
  <study rank="229">
    <nct_id>NCT01180790</nct_id>
    <title>Safety, Tolerability and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in HCV Positive Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ACH-0141625 (Sovaprevir)</intervention>
      <intervention type="Drug">ACH-0141625 (Sovaprevir)</intervention>
      <intervention type="Drug">ACH-0141625 (Sovaprevir)</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Pegylated Interferon alpha-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Achillion Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>122</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>ACH625-003</other_id>
      <other_id>2010-022092-65</other_id>
    </other_ids>
    <first_received>August 11, 2010</first_received>
    <start_date>September 2010</start_date>
    <completion_date>April 2013</completion_date>
    <last_updated>September 8, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>July 29, 2014</firstreceived_results_date>
    <primary_completion_date>March 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Segment 1: Safety</outcome_measure>
      <outcome_measure>Segment 1 : Rapid Viral Response at Week 4 (RVR4)</outcome_measure>
      <outcome_measure>Segment 2: Safety</outcome_measure>
      <outcome_measure>Segment 2: Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>Segment 1: Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>Segment 2: RVR4 (Rapid Viral Response at 4 Weeks)</outcome_measure>
      <outcome_measure>Segment 1 and Segment 2: End of Treatment Response</outcome_measure>
      <outcome_measure>Segment 1 and Segment 2: Sustained Virologic Response 12 Weeks ( Three Months Post Dosing) (SVR12)</outcome_measure>
      <outcome_measure>Segment 1 and Segment 2: Sustained Virologic Response ( Six Months Post Dosing) (SVR24)</outcome_measure>
      <outcome_measure>Segment 1 and Segment 2: HCV RNA Change From Baseline</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Belgium</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Kansas</state>
      <state>Missouri</state>
      <state>Nevada</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01180790</url>
  </study>
  <study rank="230">
    <nct_id>NCT00705263</nct_id>
    <title>Satisfaction in Patients Receiving the PegIntron Pen Plus Rebetol for Hepatitis C (Study P04244)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepacivirus</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b (SCH 54031)</intervention>
      <intervention type="Drug">Ribavirin (SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Schering-Plough</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>113</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04244</other_id>
    </other_ids>
    <first_received>June 23, 2008</first_received>
    <start_date>October 2005</start_date>
    <completion_date>May 2008</completion_date>
    <last_updated>August 20, 2009</last_updated>
    <last_verified>August 2009</last_verified>
    <firstreceived_results_date>May 28, 2009</firstreceived_results_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Satisfied With the PegIntron Pen, Including the Assessment of the Device Accuracy and Ease of Use.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00705263</url>
  </study>
  <study rank="231">
    <nct_id>NCT00154869</nct_id>
    <title>Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon Alfa-2a plus Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>320</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>921003</other_id>
      <other_id>ML17862</other_id>
    </other_ids>
    <first_received>September 8, 2005</first_received>
    <start_date>June 2004</start_date>
    <completion_date>August 2007</completion_date>
    <last_updated>August 10, 2007</last_updated>
    <last_verified>August 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>To demonstrate the efficacy of peginterferon alfa-2a (PEG-IFN alfa-2a) (Pegasys®) plus ribavirin (RBV) for sustained virological response (SVR) in HBV-coinfected versus monoinfected chronic hepatitis C (CHC) patients</outcome_measure>
      <outcome_measure>To demonstrate the efficacy of peginterferon alfa-2a (PEG-IFN alfa-2a) (Pegasys®) plus ribavirin (RBV) on the reduction of HCV viremia after 24 and 48 weeks of treatment (depending on genotype) in coinfected versus monoinfected CHC patients</outcome_measure>
      <outcome_measure>To demonstrate the efficacy of PEG-IFN alfa-2a plus RBV in dual chronic hepatitis C and B on:</outcome_measure>
      <outcome_measure>1) the biochemical response rate</outcome_measure>
      <outcome_measure>2) the score of histologic change</outcome_measure>
      <outcome_measure>3) serum HBV DNA disappearance</outcome_measure>
      <outcome_measure>4) HBsAg disappearance</outcome_measure>
      <outcome_measure>5) combined response of HBV DNA disappearance and normalization of ALT</outcome_measure>
      <outcome_measure>6) end of treatment virological response</outcome_measure>
      <outcome_measure>To assess the influence of serum HBV load on the clearance of serum HCV RNA, the loss of serum HBV DNA, and normalization of serum ALT</outcome_measure>
      <outcome_measure>To assess the influence of HBV genotype on the clearance of serum HCV RNA, the loss of serum HBV DNA, and normalization of serum ALT</outcome_measure>
      <outcome_measure>To assess the safety profile of the PEG-IFN alfa-2a plus RBV combination therapy in dual chronic hepatitis C and B</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00154869</url>
  </study>
  <study rank="232">
    <nct_id>NCT01718301</nct_id>
    <title>HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV Infections</condition>
      <condition>COINFECTION</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">boceprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Anna Cruceta</lead_sponsor>
      <collaborator>Fundacion Clinic per a la Recerca Biomédica</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>128</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>BOC-HIV</other_id>
      <other_id>2012-003984-23</other_id>
    </other_ids>
    <first_received>October 25, 2012</first_received>
    <start_date>March 2013</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>July 8, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>BOC-HIV</acronym>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Achievement of sustained virological response (SVR) at week 24</outcome_measure>
      <outcome_measure>Achievement of sustained virological response at weeks 2,4,8,12.</outcome_measure>
      <outcome_measure>The proportion of subjects with undetectable HCV-RNA at FW 12.</outcome_measure>
      <outcome_measure>The proportion of subjects with undetectable HCV-RNA at 72 weeks after randomization.</outcome_measure>
      <outcome_measure>Number of adverse events</outcome_measure>
      <outcome_measure>Resistance of HCV after boceprevir (BOC) containing regimen</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01718301</url>
  </study>
  <study rank="233">
    <nct_id>NCT00001854</nct_id>
    <title>Long-Term Therapy With Ribavirin for Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>990042</other_id>
      <other_id>99-DK-0042</other_id>
    </other_ids>
    <first_received>November 3, 1999</first_received>
    <start_date>February 1999</start_date>
    <completion_date>January 2008</completion_date>
    <last_updated>September 26, 2015</last_updated>
    <last_verified>January 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2007</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00001854</url>
  </study>
  <study rank="234">
    <nct_id>NCT01225380</nct_id>
    <title>A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GS-9190</intervention>
      <intervention type="Drug">GS-9256</intervention>
      <intervention type="Biological">Pegasys®</intervention>
      <intervention type="Drug">Copegus®</intervention>
      <intervention type="Drug">GS-9190 placebo</intervention>
      <intervention type="Drug">GS-9256</intervention>
      <intervention type="Biological">Pegasys®</intervention>
      <intervention type="Drug">Copegus®</intervention>
      <intervention type="Drug">GS-9190 placebo</intervention>
      <intervention type="Drug">GS-9256 placebo</intervention>
      <intervention type="Biological">Pegasys®</intervention>
      <intervention type="Drug">Copegus®</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>324</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-196-0123</other_id>
    </other_ids>
    <first_received>October 18, 2010</first_received>
    <start_date>October 2010</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>December 20, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (SVR) defined as undetectable HCV RNA 24 weeks after treatment cessation</outcome_measure>
      <outcome_measure>Safety and tolerability of therapy as measured by frequency of laboratory abnormalities, reported adverse events, and discontinuations due to adverse events</outcome_measure>
      <outcome_measure>Emergence of viral resistance following initiation of therapy with GS-9190 and GS-9256</outcome_measure>
      <outcome_measure>Viral dynamics and steady state pharmacokinetics of GS-9190 and GS-9256 when administered in combination with PEG and RBV; measured by HCV RNA levels and plasma concentrations of GS-9190 and GS-9256 over time</outcome_measure>
      <outcome_measure>Long-term assessment of plasma HCV RNA in subjects who achieve SVR</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Czech Republic</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Poland</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01225380</url>
  </study>
  <study rank="235">
    <nct_id>NCT00441584</nct_id>
    <title>The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b)</intervention>
      <intervention type="Drug">Rebetol (ribavirin)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
      <collaborator>Integrated Therapeutics Group</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>117</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P03833</other_id>
      <other_id>ESPECIAL</other_id>
    </other_ids>
    <first_received>February 28, 2007</first_received>
    <start_date>July 2005</start_date>
    <completion_date>June 2008</completion_date>
    <last_updated>October 7, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>June 18, 2009</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Subjects Who Have Achieved Sustained Virological Response (SVR) at 24 Weeks Post End of Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00441584</url>
  </study>
  <study rank="236">
    <nct_id>NCT00000733</nct_id>
    <title>Phase I Pharmacokinetic and Tolerance Study of Ribavirin in Human Immunodeficiency Virus (HIV) - Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>42</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ACTG 035</other_id>
      <other_id>11011</other_id>
    </other_ids>
    <first_received>November 2, 1999</first_received>
    <completion_date>October 1991</completion_date>
    <last_updated>March 28, 2012</last_updated>
    <last_verified>March 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Louisiana</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00000733</url>
  </study>
  <study rank="237">
    <nct_id>NCT00114712</nct_id>
    <title>Ribavirin Pregnancy Registry</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Birth Defects</condition>
      <condition>Pregnancy Complications</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>INC Research</lead_sponsor>
      <collaborator>Aurobindo Pharma</collaborator>
      <collaborator>Genentech, Inc.</collaborator>
      <collaborator>Sandoz Inc.</collaborator>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
      <collaborator>Teva Pharmaceuticals USA</collaborator>
      <collaborator>Kadmon Pharmaceuticals, LLC</collaborator>
      <collaborator>Zydus Pharmaceuticals USA, Inc.</collaborator>
    </sponsors>
    <gender>Female</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>RPR-1</other_id>
    </other_ids>
    <first_received>June 16, 2005</first_received>
    <start_date>January 2004</start_date>
    <completion_date>December 2027</completion_date>
    <last_updated>March 30, 2015</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2027</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate association between ribavirin and birth defects</outcome_measure>
      <outcome_measure>Estimate risk of birth defects in exposed pregnancies</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>North Carolina</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00114712</url>
  </study>
  <study rank="238">
    <nct_id>NCT01331850</nct_id>
    <title>A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">RO5024048</intervention>
      <intervention type="Drug">danoprevir</intervention>
      <intervention type="Drug">ritonavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>381</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>WV21913</other_id>
      <other_id>2010-019585-90</other_id>
    </other_ids>
    <first_received>March 28, 2011</first_received>
    <start_date>May 2011</start_date>
    <completion_date>January 2013</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (SVR) of danoprevir/ritonavir with RO5024048 and Copegus in patients with previous partial or null response to peginterferon/ribavirin treatment</outcome_measure>
      <outcome_measure>Sustained virological response (SVR) of danoprevir/ritonavir with Pegasys and Copegus in patients with previous partial response to peginterferon/ribavirin treatment</outcome_measure>
      <outcome_measure>Sustained virological response (SVR) of danoprevir/ritonavir and RO5024048 with Pegasys and Copegus in patients with previous partial or null response to peginterferon/ribavirin treatment</outcome_measure>
      <outcome_measure>Sustained virological response (SVR) of danoprevir/ritonavir and RO5024048 with Pegasys and Copegus followed by 24 weeks of Pegasys and Copegus treatment in patients with previous null response to peginterferon/ribavirin treatment</outcome_measure>
      <outcome_measure>Safety (Incidence of adverse events) of danoprevir, RO5024048 and Copegus</outcome_measure>
      <outcome_measure>Safety (Incidence of adverse events) of danoprevir, Pegasys and Copegus</outcome_measure>
      <outcome_measure>Safety (Incidence of adverse events) of danoprevir, RO5024048, Pegasys and Copegus</outcome_measure>
      <outcome_measure>Virological response over time</outcome_measure>
      <outcome_measure>Change in danoprevir plasma concentration</outcome_measure>
      <outcome_measure>Change in RO5024048 plasma concentration</outcome_measure>
      <outcome_measure>Hepatitis C virus drug resistance profile</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>Brazil</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Mexico</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Louisiana</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oregon</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01331850</url>
  </study>
  <study rank="239">
    <nct_id>NCT01508286</nct_id>
    <title>Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects</title>
    <recruitment open="N">No longer available</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir + peginterferon alfa + ribavirin</intervention>
      <intervention type="Drug">peginterferon alfa + ribavirin</intervention>
      <intervention type="Drug">peginterferon alfa + ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen-Cilag International NV</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Expanded Access</study_types>
    <study_designs/>
    <other_ids>
      <other_id>CR017857</other_id>
      <other_id>VX-950HEP3002</other_id>
      <other_id>2010-023669-23</other_id>
    </other_ids>
    <first_received>January 9, 2012</first_received>
    <last_updated>July 22, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>Australia</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>Czech Republic</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>Hungary</country>
      <country>Luxembourg</country>
      <country>New Zealand</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Serbia</country>
      <country>Spain</country>
      <country>Switzerland</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01508286</url>
  </study>
  <study rank="240">
    <nct_id>NCT00606086</nct_id>
    <title>Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Genotype 1 Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GI-5005</intervention>
      <intervention type="Drug">Pegylated Interferon and Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlobeImmune</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>140</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GI-5005-02</other_id>
    </other_ids>
    <first_received>January 18, 2008</first_received>
    <start_date>December 2007</start_date>
    <completion_date>November 2012</completion_date>
    <last_updated>June 17, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>May 5, 2014</firstreceived_results_date>
    <primary_completion_date>November 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>EVR (Early Virologic Response)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00606086</url>
  </study>
  <study rank="241">
    <nct_id>NCT00956982</nct_id>
    <title>PEG-IFN Plus Ribavirin Combination Therapy for Older Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alpha-2b plus ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kyushu University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1251</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KULDS2009</other_id>
    </other_ids>
    <first_received>August 6, 2009</first_received>
    <start_date>December 2004</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>August 10, 2009</last_updated>
    <last_verified>August 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>antiviral effect by PEG-IFN alpha-2b plus RBV treatment</outcome_measure>
      <outcome_measure>the tolerance of older patients by PEG-IFN alpha-2b plus RBV treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00956982</url>
  </study>
  <study rank="242">
    <nct_id>NCT02551861</nct_id>
    <title>A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-377</other_id>
      <other_id>2015-003468-36</other_id>
    </other_ids>
    <first_received>September 15, 2015</first_received>
    <start_date>December 2015</start_date>
    <completion_date>June 2017</completion_date>
    <last_updated>November 18, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects with sustained virologic response (SVR12) treated with Daclatasvir + Sofosbuvir (DCV+SOF)</outcome_measure>
      <outcome_measure>Safety measured by number of incidence of deaths, serious adverse events (SAE)s, discontinuation due to adverse events (AE)s, Grade 3/4 AEs and Grade 3/4 laboratory abnormalities observed from clinical laboratory testing</outcome_measure>
      <outcome_measure>Antiviral activity measured by the proportion of subjects who achieve HCV RNA &lt; lower limit of quantification (LLOQ) - at during and after treatment in each treatment arm</outcome_measure>
      <outcome_measure>Proportion of subjects with CC, CT or TT IL28B genotype who achieve SVR12 in each treatment arm</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02551861</url>
  </study>
  <study rank="243">
    <nct_id>NCT00735969</nct_id>
    <title>High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>080149</other_id>
      <other_id>08-DK-0149</other_id>
    </other_ids>
    <first_received>August 14, 2008</first_received>
    <start_date>August 2008</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>October 10, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>June 16, 2014</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virological Response, (HCV RNA Neg.) in Serum 24 Weeks Off Therapy.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00735969</url>
  </study>
  <study rank="244">
    <nct_id>NCT02609659</nct_id>
    <title>Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ombitasvir/paritaprevir/ritonavir</intervention>
      <intervention type="Drug">Dasabuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M15-582</other_id>
    </other_ids>
    <first_received>November 18, 2015</first_received>
    <start_date>October 2015</start_date>
    <completion_date>October 2016</completion_date>
    <last_updated>November 18, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>GEODE II</acronym>
    <primary_completion_date>October 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving a 12-week Sustained Virologic Response (SVR12) Post-treatment</outcome_measure>
      <outcome_measure>Number of Participants with Hemoglobin less than 10 g/dL</outcome_measure>
      <outcome_measure>Percentage of Participants with On-treatment Virologic Failure.</outcome_measure>
      <outcome_measure>Percentage of Participants with Post-treatment Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02609659</url>
  </study>
  <study rank="245">
    <nct_id>NCT00761735</nct_id>
    <title>5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>94</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P02538: Part 2</other_id>
      <other_id>2004-000558-22</other_id>
    </other_ids>
    <first_received>September 5, 2008</first_received>
    <start_date>July 2007</start_date>
    <completion_date>January 2013</completion_date>
    <last_updated>September 11, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>October 28, 2013</firstreceived_results_date>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Who Relapsed At End of LTFU Year 5</outcome_measure>
      <outcome_measure>Mean Height Percentiles of Participants Over LTFU</outcome_measure>
      <outcome_measure>Mean Weight Percentiles of Participants Over LTFU</outcome_measure>
      <outcome_measure>Mean Body Mass Index (BMI) Percentiles of Participants Over LTFU</outcome_measure>
      <outcome_measure>Mean Age at Attained Tanner Stages (Sexual Maturity) at End of LTFU (Last Observation) By Gender</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00761735</url>
  </study>
  <study rank="246">
    <nct_id>NCT00000772</nct_id>
    <title>A Phase I Open-Label Study of the Safety, Tolerance, and Pharmacokinetic Interactions of Combination Didanosine and Ribavirin in HIV-Positive Individuals</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Didanosine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>Bristol-Myers Squibb</collaborator>
      <collaborator>ICN Pharmaceuticals</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ACTG 231</other_id>
      <other_id>11208</other_id>
    </other_ids>
    <first_received>November 2, 1999</first_received>
    <completion_date>February 1995</completion_date>
    <last_updated>March 30, 2012</last_updated>
    <last_verified>March 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Massachusetts</state>
      <state>Minnesota</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00000772</url>
  </study>
  <study rank="247">
    <nct_id>NCT00725205</nct_id>
    <title>Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (Peginterferon alfa-2b)</intervention>
      <intervention type="Drug">Rebetol (Ribavirin)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>294</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04690</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>March 2006</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>October 7, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>October 10, 2011</firstreceived_results_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Who Are Triple-80 Compliant</outcome_measure>
      <outcome_measure>Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up</outcome_measure>
      <outcome_measure>Number Of Participants Self-Administering Pegylated Interferon Alfa-2b</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00725205</url>
  </study>
  <study rank="248">
    <nct_id>NCT00538811</nct_id>
    <title>Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Non-responders</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Genotype 3</condition>
      <condition>Non-responders</condition>
      <condition>Relapsers</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">interferon alpha-2b, ribavirin, interferon-gamma,</intervention>
      <intervention type="Drug">interferon alpha-2b, ribavirin, amantadine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Aga Khan University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>648-Med</other_id>
    </other_ids>
    <first_received>October 2, 2007</first_received>
    <last_updated>October 26, 2010</last_updated>
    <last_verified>October 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>Pakistan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00538811</url>
  </study>
  <study rank="249">
    <nct_id>NCT00122629</nct_id>
    <title>Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peg-interferon alfa-2b</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">amantadine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Agency for Research on AIDS and Viral Hepatitis</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
    </sponsors>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>405</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRSHC03 BITRI</other_id>
    </other_ids>
    <first_received>July 20, 2005</first_received>
    <start_date>October 2000</start_date>
    <completion_date>May 2003</completion_date>
    <last_updated>July 28, 2005</last_updated>
    <last_verified>July 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response, defined as an undetectable HCV-RNA 24 weeks after treatment discontinuation at week 72</outcome_measure>
      <outcome_measure>Biochemical response at week 72 defined as ALT normalization</outcome_measure>
      <outcome_measure>Histological benefit</outcome_measure>
      <outcome_measure>Tolerance</outcome_measure>
      <outcome_measure>Virological and biochemical responses during therapy at weeks 12, 24 and 48</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00122629</url>
  </study>
  <study rank="250">
    <nct_id>NCT00727259</nct_id>
    <title>Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b (SCH 54031)</intervention>
      <intervention type="Drug">Ribavirin (SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1995</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04067</other_id>
    </other_ids>
    <first_received>July 30, 2008</first_received>
    <start_date>October 2004</start_date>
    <completion_date>April 2008</completion_date>
    <last_updated>April 7, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>June 18, 2009</firstreceived_results_date>
    <acronym>SATISFACTION</acronym>
    <primary_completion_date>April 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evaluation of the Satisfaction of the PegPen (PegIntron Preparation and Injection Easiness) Using a Patient Questionnaire Answered at 1 Month and 3 Months</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00727259</url>
  </study>
  <study rank="251">
    <nct_id>NCT02504099</nct_id>
    <title>A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ombitasvir/Paritaprevir/Ritonavir</intervention>
      <intervention type="Drug">Dasabuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M14-726</other_id>
      <other_id>2015-001049-10</other_id>
    </other_ids>
    <first_received>July 20, 2015</first_received>
    <start_date>July 2015</start_date>
    <completion_date>March 2020</completion_date>
    <last_updated>October 16, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Failure During Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Relapse After Treatment</outcome_measure>
      <outcome_measure>The percentage of participants with long term clinical outcomes from treatment through 3 years of follow-up.</outcome_measure>
      <outcome_measure>The percentage of participants with recurrent HCV infection post liver transplant out of all participants with liver transplant during the study.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Florida</state>
      <state>Illinois</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02504099</url>
  </study>
  <study rank="252">
    <nct_id>NCT00580801</nct_id>
    <title>An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Pegylated-interferon-alfa-2a</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec BVBA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR013714</other_id>
      <other_id>VX-950-TiDP24-C210</other_id>
    </other_ids>
    <first_received>December 20, 2007</first_received>
    <start_date>January 2008</start_date>
    <completion_date>January 2010</completion_date>
    <last_updated>August 27, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>March 7, 2013</firstreceived_results_date>
    <primary_completion_date>January 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Day 15</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Response (Undetectable HCV RNA)</outcome_measure>
      <outcome_measure>Median Time to First Viral Response (Undetectable HCV RNA)</outcome_measure>
      <outcome_measure>Number of Participants With Viral Breakthrough (Detectable HCV RNA)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Viral Response (SVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Relapse</outcome_measure>
      <outcome_measure>Area Under the Serum Concentration-Time Curve (AUC)</outcome_measure>
      <outcome_measure>Maximum Serum Concentration (Cmax) of Telaprevir</outcome_measure>
      <outcome_measure>Pre-Dose Serum Concentration (C[0h]) of Telaprevir</outcome_measure>
      <outcome_measure>Minimum Serum Concentration (Cmin) of Telaprevir on Day 15</outcome_measure>
      <outcome_measure>Time to Reach the Maximum Serum Concentration (Tmax) of Telaprevir</outcome_measure>
      <outcome_measure>Average Steady-State Serum Concentration (Css,av) of Telaprevir</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00580801</url>
  </study>
  <study rank="253">
    <nct_id>NCT00726557</nct_id>
    <title>Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Substance Abuse, Intravenous</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (pegylated interferon alfa-2b; SCH 54031)</intervention>
      <intervention type="Drug">Rebetol (ribavirin; SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>246</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04408</other_id>
    </other_ids>
    <first_received>July 30, 2008</first_received>
    <start_date>October 2005</start_date>
    <completion_date>January 2009</completion_date>
    <last_updated>October 8, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>April 15, 2010</firstreceived_results_date>
    <acronym>SUPPORT</acronym>
    <primary_completion_date>January 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Drug-substituted Participants Who Achieved Sustained Virological Response (SVR) With PegIntron 1.5 μg/kg/Week and Rebetol (10.6 mg/kg/Day) in Substitution Centers Under Routine Conditions</outcome_measure>
      <outcome_measure>Number of Participants Who Tolerated Treatment With PegIntron 1.5 mcg/kg/Week + Rebetol 10.6 mg/kg/Week</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00726557</url>
  </study>
  <study rank="254">
    <nct_id>NCT01296971</nct_id>
    <title>A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML25246</other_id>
    </other_ids>
    <first_received>December 21, 2010</first_received>
    <start_date>December 2009</start_date>
    <completion_date>December 2009</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety of individualized Copegus treatment in combination with Pegasys: Adverse events</outcome_measure>
      <outcome_measure>Influence of dose reductions in case of adverse events on sustained virological response (HCV-RNA)</outcome_measure>
      <outcome_measure>Virological response/sustained virological response (serum HCV RNA levels)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01296971</url>
  </study>
  <study rank="255">
    <nct_id>NCT00378599</nct_id>
    <title>Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Liver Transplantation</condition>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Liver Cirrhosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Combination of (a) pegylated interferon alfa-2b and (b) rebetol</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>125</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04590</other_id>
    </other_ids>
    <first_received>September 18, 2006</first_received>
    <start_date>May 2006</start_date>
    <completion_date>July 2009</completion_date>
    <last_updated>April 7, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>June 17, 2010</firstreceived_results_date>
    <primary_completion_date>July 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>A Sustained Virologic Response (SVR), Defined as a Plasma HCV RNA Level Below the Lower Level of Quantitation (LLQ) at 24 Weeks Post-treatment</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00378599</url>
  </study>
  <study rank="256">
    <nct_id>NCT00148863</nct_id>
    <title>Interferon Gamma With Peg-Interferon Alpha 2a and Ribavirin in Non Responders Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-interferon alpha 2a (drug)</intervention>
      <intervention type="Drug">Ribavirin (drug)</intervention>
      <intervention type="Drug">Interferon gamma (drug)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Agency for Research on AIDS and Viral Hepatitis</lead_sponsor>
      <collaborator>InterMune</collaborator>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>65</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2004-005033-19</other_id>
      <other_id>ANRS HC16 Gammatri</other_id>
    </other_ids>
    <first_received>September 7, 2005</first_received>
    <start_date>June 2004</start_date>
    <completion_date>August 2007</completion_date>
    <last_updated>August 29, 2007</last_updated>
    <last_verified>August 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Virological response as defined by an HCV RNA measure non detectable at W28 with qualitative PCR (centralized measure)</outcome_measure>
      <outcome_measure>Virological response at W72</outcome_measure>
      <outcome_measure>Biochemical response at W72 (ALT below normal value)</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
      <outcome_measure>Immunologic response (CD4 and CD8 HCV specific)</outcome_measure>
      <outcome_measure>Safety</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00148863</url>
  </study>
  <study rank="257">
    <nct_id>NCT00803309</nct_id>
    <title>Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon alpha-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">pegylated Interferon alpha-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>HepNet Study House, German Liverfoundation</lead_sponsor>
      <collaborator>Hannover Clinical Trial Center GmbH</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>99</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05498</other_id>
    </other_ids>
    <first_received>December 4, 2008</first_received>
    <start_date>November 2008</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>March 18, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>OPTEX2/3</acronym>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Reduction of Relapse rate (HCV-RNA positive in serum by a standard HCV-PCR with a detection limit of at least 15 IU/ml) 24 weeks after the end of treatment and thus improvement of sustained virological response rates (SVR)</outcome_measure>
      <outcome_measure>Virological response rates (HCV-RNA negative in serum by a standard HCV-PCR with a detection limit of at least 15 IU/ml) at the end of therapy</outcome_measure>
      <outcome_measure>Biochemical responses as determined by ALT and AST levels at the end of treatment and at the end of follow up.</outcome_measure>
      <outcome_measure>Severity and frequency of adverse event</outcome_measure>
      <outcome_measure>Analysis of quality of life</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00803309</url>
  </study>
  <study rank="258">
    <nct_id>NCT01559844</nct_id>
    <title>Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Hepatocellular Carcinoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>61</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P7977-2025</other_id>
    </other_ids>
    <first_received>March 5, 2012</first_received>
    <start_date>March 2012</start_date>
    <completion_date>October 2014</completion_date>
    <last_updated>June 2, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>May 12, 2015</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Posttransplant Virologic Response (pTVR) at Posttransplant Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Any Adverse Event Leading to Permanent Discontinuation of Sobosbuvir Prior to Receiving Transplant</outcome_measure>
      <outcome_measure>Percentage of Participants With Graft Loss Following Transplant</outcome_measure>
      <outcome_measure>Number of Participants Who Died</outcome_measure>
      <outcome_measure>Percentage of Participants With Posttransplant Virologic Response (pTVR) Through Posttransplant Week 48</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ (ie, 25 mL/IU) During Treatment Through Week 48</outcome_measure>
      <outcome_measure>HCV RNA and Change From Baseline in HCV RNA Through Week 8</outcome_measure>
      <outcome_measure>Proportion of Participants With Virologic Failure Prior to Transplant</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>New Zealand</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01559844</url>
  </study>
  <study rank="259">
    <nct_id>NCT01641640</nct_id>
    <title>Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">PEG</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>328</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0110</other_id>
    </other_ids>
    <first_received>July 9, 2012</first_received>
    <start_date>June 2012</start_date>
    <completion_date>April 2013</completion_date>
    <last_updated>April 8, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>February 25, 2014</firstreceived_results_date>
    <acronym>NEUTRINO</acronym>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response (SVR)12</outcome_measure>
      <outcome_measure>Number of Participants Experiencing Adverse Events Leading to Permanent Discontinuation of Study Drug</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR4</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR24</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01641640</url>
  </study>
  <study rank="260">
    <nct_id>NCT00455832</nct_id>
    <title>Influence of Ribavirin and Interferon on Semen Quality, IRIS Study</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sperm Motility (Focus of Study)</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">peginterferon alpha and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Foundation for Liver Research</lead_sponsor>
      <collaborator>Erasmus Medical Center</collaborator>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>23</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRIS Study</other_id>
    </other_ids>
    <first_received>April 2, 2007</first_received>
    <start_date>November 2006</start_date>
    <completion_date>July 2011</completion_date>
    <last_updated>February 28, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>IRIS</acronym>
    <primary_completion_date>July 2011</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00455832</url>
  </study>
  <study rank="261">
    <nct_id>NCT01984294</nct_id>
    <title>Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">GS-9669</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>101</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-0133</other_id>
    </other_ids>
    <first_received>November 8, 2013</first_received>
    <start_date>October 2013</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>April 30, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>April 30, 2015</firstreceived_results_date>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants Permanently Discontinuing Any Study Drug Due to an Adverse Event</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 2, 4, 8, and 24 Weeks After Discontinuation of Therapy (SVR2, SVR4, SVR8, and SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing On-treatment Virologic Failure</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01984294</url>
  </study>
  <study rank="262">
    <nct_id>NCT01371604</nct_id>
    <title>Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">IDX184</intervention>
      <intervention type="Biological">Peginterferon alfa-2a (Peg-IFN)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>68</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>2355-005</other_id>
      <other_id>IDX-08C-005</other_id>
      <other_id>2011-001878-25</other_id>
    </other_ids>
    <first_received>June 9, 2011</first_received>
    <start_date>July 2011</start_date>
    <completion_date>October 2014</completion_date>
    <last_updated>February 5, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants who experience a serious adverse event</outcome_measure>
      <outcome_measure>Percentage of participants who experience an adverse event</outcome_measure>
      <outcome_measure>Percentage of participants who experience a grade 1-4 laboratory abnormality</outcome_measure>
      <outcome_measure>Percentage of participants who achieve undetectable HCV ribonucleic acid (RNA) viral levels at Week 12</outcome_measure>
      <outcome_measure>Percentage of participants who achieve undetectable HCV RNA viral levels at Week 4</outcome_measure>
      <outcome_measure>Percentage of participants who achieve undetectable HCV RNA viral levels at the end of treatment</outcome_measure>
      <outcome_measure>Percentage of participants who achieve sustained virologic response (SVR)</outcome_measure>
      <outcome_measure>Percentage of participants who achieve HCV RNA viral levels below the lower level of quantification (LLOQ) at Week 4</outcome_measure>
      <outcome_measure>Percentage of participants who achieve HCV RNA viral levels below LLOQ at the end of treatment</outcome_measure>
      <outcome_measure>Percentage of participants who achieve HCV RNA viral levels below LLOQ at follow-up (24 weeks after the last dose)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01371604</url>
  </study>
  <study rank="263">
    <nct_id>NCT02558114</nct_id>
    <title>Ribavirin for Severe Acute and Chronic Hepatitis E Virus Infection.</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis E</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hospital Universitari Vall d'Hebron Research Institute</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>56</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>RACHE</other_id>
    </other_ids>
    <first_received>September 18, 2015</first_received>
    <start_date>December 2015</start_date>
    <completion_date>October 2018</completion_date>
    <last_updated>September 22, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response measured by HEV RNA</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02558114</url>
  </study>
  <study rank="264">
    <nct_id>NCT01290731</nct_id>
    <title>A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Pegylated interferon (pegIFN alpha-2a)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Pharmaceutical K.K.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>49</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017698</other_id>
      <other_id>TMC435HPC3008</other_id>
    </other_ids>
    <first_received>February 3, 2011</first_received>
    <start_date>January 2011</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>December 16, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>October 17, 2013</firstreceived_results_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants With a Sustained Virologic Response 12 Weeks After the Actual End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>The Percentage of Participants With a Sustained Virologic Response 24 Weeks After the Actual End of Treatment (SVR24)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up</outcome_measure>
      <outcome_measure>The Percentage of Participants With Undetectable Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) During Treatment and at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>The Number of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>The Number of Participants Demonstrating Viral Relapse</outcome_measure>
      <outcome_measure>Plasma Concentrations of TMC435</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hrs (AUC24h) for TMC435</outcome_measure>
      <outcome_measure>The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal ALT Levels at the End of Treatment (EOT)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01290731</url>
  </study>
  <study rank="265">
    <nct_id>NCT01271790</nct_id>
    <title>A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tegobuvir (GS-9190)</intervention>
      <intervention type="Drug">GS-9451</intervention>
      <intervention type="Biological">Pegasys®</intervention>
      <intervention type="Drug">Copegus®</intervention>
      <intervention type="Drug">GS-9451</intervention>
      <intervention type="Drug">Tegobuvir placebo</intervention>
      <intervention type="Biological">Pegasys®</intervention>
      <intervention type="Drug">Copegus®</intervention>
      <intervention type="Drug">Tegobuvir placebo</intervention>
      <intervention type="Drug">GS-9451 placebo</intervention>
      <intervention type="Biological">Pegasys®</intervention>
      <intervention type="Drug">Copegus®</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>245</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-196-0140</other_id>
    </other_ids>
    <first_received>January 5, 2011</first_received>
    <start_date>October 2010</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>January 8, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response</outcome_measure>
      <outcome_measure>Safety and tolerability of therapy</outcome_measure>
      <outcome_measure>Emergence of viral resistance following initiation of therapy with GS 9190 and GS 9451</outcome_measure>
      <outcome_measure>Viral dynamics and steady state pharmacokinetics</outcome_measure>
      <outcome_measure>Durability of response in subjects who achieve SVR</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Netherlands</country>
      <country>Poland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01271790</url>
  </study>
  <study rank="266">
    <nct_id>NCT00983853</nct_id>
    <title>Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">telaprevir or matching placebo</intervention>
      <intervention type="Drug">telaprevir or matching placebo</intervention>
      <intervention type="Biological">peginterferon alfa-2a</intervention>
      <intervention type="Drug">ribavirin (fixed dose)</intervention>
      <intervention type="Drug">ribavirin (weight-based dose)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
      <collaborator>Tibotec Pharmaceutical Limited</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>62</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX08-950-110</other_id>
    </other_ids>
    <first_received>September 22, 2009</first_received>
    <start_date>October 2009</start_date>
    <last_updated>August 2, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>August 2, 2013</firstreceived_results_date>
    <primary_completion_date>March 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of Subjects Achieving Undetectable HCV RNA at Week 12</outcome_measure>
      <outcome_measure>Proportion of Subjects Achieving Undetectable HCV RNA at Week 4 and Week 12</outcome_measure>
      <outcome_measure>Proportion of Subjects Who Have Undetectable HCV RNA 12 Weeks (SVR12) and 24 Weeks (SVR24) After Last Planned Dose of Study Treatment</outcome_measure>
      <outcome_measure>Effect of Efavirenz-based (EFV) and Atazanavir-based (ATV/r) Highly Active Antiretroviral Therapy(HAART) on Telaprevir Exposure</outcome_measure>
      <outcome_measure>Median Trough Plasma Concentration (Ctrough) Ratios of Efavirenz and Tenofovir (Part B Only, Subjects on EFV-based HAART)</outcome_measure>
      <outcome_measure>Median Trough Plasma Concentration (Ctrough) Ratios of Atazanavir (ATZ), Ritonavir, and Tenofovir (Part B Only, Subjects on ATV-based HAART)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>France</country>
      <country>Germany</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>New York</state>
      <state>Ohio</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00983853</url>
  </study>
  <study rank="267">
    <nct_id>NCT00947349</nct_id>
    <title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Pharmacokinetics</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ribavirin (RBV)</intervention>
      <intervention type="Drug">pegylated interferon (PegIFN) alfa-2a</intervention>
      <intervention type="Drug">pegylated interferon (PegIFN) alfa-2a</intervention>
      <intervention type="Drug">ribavirin (RBV)</intervention>
      <intervention type="Drug">BI 201335 NA low placebo</intervention>
      <intervention type="Drug">pegylated interferon (PegIFN) alfa-2a</intervention>
      <intervention type="Drug">ribavirin (RBV)</intervention>
      <intervention type="Drug">BI 201335 NA high</intervention>
      <intervention type="Drug">BI 201335 NA low</intervention>
      <intervention type="Drug">BI 201335 NA high placebo</intervention>
      <intervention type="Drug">BI 201335 NA high</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>22</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>1220.14</other_id>
    </other_ids>
    <first_received>July 21, 2009</first_received>
    <start_date>July 2009</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>July 3, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>January 22, 2015</firstreceived_results_date>
    <primary_completion_date>August 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Investigator Defined Drug-related Adverse Events in Triple Combination Therapy</outcome_measure>
      <outcome_measure>Number of Patients With Possible Clinically Significant Laboratory Abnormalities in Triple Combination Therapy</outcome_measure>
      <outcome_measure>Assessment of Tolerability in Triple Combination Therapy</outcome_measure>
      <outcome_measure>Week 2 Virological Response (W2VR)</outcome_measure>
      <outcome_measure>Week 4 Virological Response (W4VR)</outcome_measure>
      <outcome_measure>Rapid Virological Response (RVR)</outcome_measure>
      <outcome_measure>Change From Baseline in HCV Viral Load</outcome_measure>
      <outcome_measure>Day 28 Virologic Response</outcome_measure>
      <outcome_measure>Early Virological Response (EVR)</outcome_measure>
      <outcome_measure>Complete Early Virological Response (cEVR)</outcome_measure>
      <outcome_measure>End of Treatment Response (ETR)</outcome_measure>
      <outcome_measure>Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Number of Participants With Investigator Defined Drug-related Adverse Events in Standard of Care (SOC) With PegIFN α-2a and RBV</outcome_measure>
      <outcome_measure>Number of Patients With Possible Clinically Significant Laboratory Abnormalities in Standard of Care (SOC) With PegIFN α-2a and RBV</outcome_measure>
      <outcome_measure>Assessment of Tolerability in Standard of Care (SOC) With PegIFN α -2a and RBV</outcome_measure>
      <outcome_measure>AUCτ,1 for BI 201335 ZW</outcome_measure>
      <outcome_measure>Cmax of BI 201335 ZW</outcome_measure>
      <outcome_measure>AUCτ,ss of BI 201335 ZW</outcome_measure>
      <outcome_measure>Cmax,ss of BI 201335 ZW</outcome_measure>
      <outcome_measure>AUCτ,1 for Ribavirin (RBV)</outcome_measure>
      <outcome_measure>Cmax of RBV</outcome_measure>
      <outcome_measure>AUCτ,ss of RBV</outcome_measure>
      <outcome_measure>Cmax,ss of RBV</outcome_measure>
      <outcome_measure>Tmax for BI 201335 ZW</outcome_measure>
      <outcome_measure>Tmax for RBV</outcome_measure>
      <outcome_measure>Tmax, ss for BI 201335 ZW</outcome_measure>
      <outcome_measure>Tmax, ss for RBV</outcome_measure>
      <outcome_measure>t1/2,ss for BI 201335 ZW</outcome_measure>
      <outcome_measure>Cmin,ss for BI 201335 ZW</outcome_measure>
      <outcome_measure>Cmin,ss for RBV</outcome_measure>
      <outcome_measure>Cavg for BI 201335 ZW</outcome_measure>
      <outcome_measure>Cavg for RBV</outcome_measure>
      <outcome_measure>CL/F,ss for BI 201335 ZW</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00947349</url>
  </study>
  <study rank="268">
    <nct_id>NCT02483260</nct_id>
    <title>Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Viral Hemorrhagic Fever</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>U.S. Army Medical Research and Materiel Command</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>S-13-08</other_id>
    </other_ids>
    <first_received>June 24, 2015</first_received>
    <start_date>September 2015</start_date>
    <completion_date>June 2019</completion_date>
    <last_updated>June 24, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Adverse reactions</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02483260</url>
  </study>
  <study rank="269">
    <nct_id>NCT00093093</nct_id>
    <title>Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Viramidine</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">pegylated interferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Valeant Pharmaceuticals International, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>900</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>RNA003142-302</other_id>
    </other_ids>
    <first_received>September 30, 2004</first_received>
    <start_date>June 2004</start_date>
    <completion_date>May 2006</completion_date>
    <last_updated>June 21, 2012</last_updated>
    <last_verified>June 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>VISER2</acronym>
    <primary_completion_date>May 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>- Efficacy: Undetectable plasma HCV RNA (less than 100 copies/mL) at the end of the 24-week post-treatment follow-up period.</outcome_measure>
      <outcome_measure>- Safety: The proportion of patients with hemoglobin less than 10 g/dL at any time during treatment or at least 2.5 g/dL drop from baseline.</outcome_measure>
      <outcome_measure>- Efficacy: Undetectable plasma HCV RNA at treatment week 24</outcome_measure>
      <outcome_measure>- Efficacy: Undetectable or at least a 2-log drop from baseline at treatment weeks 12 and 24</outcome_measure>
      <outcome_measure>- Safety: Monitoring of adverse events</outcome_measure>
      <outcome_measure>- Safety: Monitoring of abnormal changes in laboratory parameters that are not disease-related</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>France</country>
      <country>Israel</country>
      <country>Italy</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00093093</url>
  </study>
  <study rank="270">
    <nct_id>NCT00230958</nct_id>
    <title>Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment-Naive</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Viramidine</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">pegylated interferon alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Valeant Pharmaceuticals International, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>900</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>RNA003142-301</other_id>
    </other_ids>
    <first_received>September 29, 2005</first_received>
    <start_date>December 2003</start_date>
    <completion_date>January 2006</completion_date>
    <last_updated>June 21, 2012</last_updated>
    <last_verified>June 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>- Efficacy: Undetectable plasma HCV RNA (less than 100 copies/mL) at the end of the 24-week post-treatment follow-up period.</outcome_measure>
      <outcome_measure>- Safety: The proportion of patients with hemoglobin less than 10 g/dL at any time during treatment or at least 2.5 g/dL drop from baseline.</outcome_measure>
      <outcome_measure>- Efficacy: Undetectable plasma HCV RNA at treatment week 24</outcome_measure>
      <outcome_measure>- Efficacy: Undetectable or at least a 2-log drop from baseline at treatment weeks 12 and 24</outcome_measure>
      <outcome_measure>- Safety: Monitoring of adverse events</outcome_measure>
      <outcome_measure>- Safety: Monitoring of abnormal changes in laboratory parameters that are not disease-related</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00230958</url>
  </study>
  <study rank="271">
    <nct_id>NCT02168361</nct_id>
    <title>The SIM-SOF Trial for Hepatitis C</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon alfa-2b</intervention>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Center For Hepatitis C, Atlanta, GA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>82</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CHC-21</other_id>
    </other_ids>
    <first_received>June 17, 2014</first_received>
    <start_date>December 2013</start_date>
    <completion_date>November 2014</completion_date>
    <last_updated>June 19, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response 12 (SVR-12)</outcome_measure>
      <outcome_measure>Virologic Relapse</outcome_measure>
      <outcome_measure>Virologic Breakthrough</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Georgia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02168361</url>
  </study>
  <study rank="272">
    <nct_id>NCT02377856</nct_id>
    <title>Peginterferon Plus Ribavirin Combination Therapy for Hepatitis C Six Months After Onset of Acute Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon alpha 2a, ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kaohsiung Medical University Chung-Ho Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KMUH-IRB-960056</other_id>
      <other_id>KMUH</other_id>
    </other_ids>
    <first_received>September 9, 2014</first_received>
    <start_date>June 2007</start_date>
    <completion_date>December 2020</completion_date>
    <last_updated>March 5, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <outcome_measures>
      <outcome_measure>treatment efficacy in terms of SVR rate</outcome_measure>
      <outcome_measure>safety issues regarding adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02377856</url>
  </study>
  <study rank="273">
    <nct_id>NCT00001015</nct_id>
    <title>A Study of Ribavirin in the Treatment of Patients With AIDS and AIDS-Related Problems</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>96</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ACTG 034</other_id>
      <other_id>11010</other_id>
    </other_ids>
    <first_received>November 2, 1999</first_received>
    <completion_date>June 1990</completion_date>
    <last_updated>March 28, 2012</last_updated>
    <last_verified>March 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Massachusetts</state>
      <state>New York</state>
      <state>North Carolina</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00001015</url>
  </study>
  <study rank="274">
    <nct_id>NCT00275938</nct_id>
    <title>Interferon Alpha 2b Plus Ribavirin for Chronic Hepatitis B</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">interferon alpha 2b plus ribavirin</intervention>
      <intervention type="Drug">interferon alpha 2b plus placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>145R3</other_id>
    </other_ids>
    <first_received>January 11, 2006</first_received>
    <start_date>October 1998</start_date>
    <completion_date>June 2001</completion_date>
    <last_updated>January 11, 2006</last_updated>
    <last_verified>January 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Undetected serum HBV DNA level (i.e. less than 2.5 pg/ml) at the end of the 24-week follow-up period</outcome_measure>
      <outcome_measure>HBV DNA level at the end of treatment</outcome_measure>
      <outcome_measure>clearance of HBeAg and rate of ALT normalization both at the end of the 32-week treatment period and at the end of the 24-week follow-up</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00275938</url>
  </study>
  <study rank="275">
    <nct_id>NCT00851890</nct_id>
    <title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-333</intervention>
      <intervention type="Other">Placebo for ABT-333</intervention>
      <intervention type="Drug">Pegylated interferon</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie (prior sponsor, Abbott)</lead_sponsor>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>M10-380</other_id>
    </other_ids>
    <first_received>February 24, 2009</first_received>
    <start_date>March 2009</start_date>
    <completion_date>July 2009</completion_date>
    <last_updated>December 29, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>December 29, 2014</firstreceived_results_date>
    <primary_completion_date>July 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Mean Maximal Change From Baseline in Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels During ABT-333 Monotherapy Treatment</outcome_measure>
      <outcome_measure>Mean Maximal Change From Baseline in Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels Through Day 28</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of ABT-333</outcome_measure>
      <outcome_measure>Time to Maximum Plasma Concentration (Tmax) of ABT-333</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From 0 to 12 Hours Post-dose (AUC12) of ABT-333</outcome_measure>
      <outcome_measure>Serum Concentrations of Pegylated Interferon (pegIFN)</outcome_measure>
      <outcome_measure>Plasma Concentrations of Ribavirin (RBV)</outcome_measure>
      <outcome_measure>Number of Participants Having Treatment-emergent Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Change From Baseline in Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels Through Day 28 or Final Visit</outcome_measure>
      <outcome_measure>Percentage of Participants With at Least a 2 log10 Maximal Decrease in Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels During ABT-333 Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels ≤ 25 IU/mL (the Lower Limit of Quantitation [LLOQ]) at Day 28 or Final Visit</outcome_measure>
      <outcome_measure>Percentage of Participants With Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels ≤ 10 IU/mL (Lower Limit of Detection [LLOD]) at Day 28 or Final Visit</outcome_measure>
      <outcome_measure>Number of Participants With Resistance-Associated Variants in Non-structural Viral Protein 5B (NS5B) Through Day 28</outcome_measure>
      <outcome_measure>Number of Participants With Maximal Phenotypic Resistance to ABT-333 &gt;10 Fold Relative to Baseline Through Day 28</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Louisiana</state>
      <state>North Carolina</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00851890</url>
  </study>
  <study rank="276">
    <nct_id>NCT00002298</nct_id>
    <title>The Safety and Effectiveness of Ribavirin in the Early Stages of HIV-Infection</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>ICN Pharmaceuticals</lead_sponsor>
      <collaborator>NIH AIDS Clinical Trials Information Service</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>013A</other_id>
    </other_ids>
    <first_received>November 2, 1999</first_received>
    <last_updated>June 23, 2005</last_updated>
    <last_verified>March 1998</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00002298</url>
  </study>
  <study rank="277">
    <nct_id>NCT01725529</nct_id>
    <title>An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Peginterferon-alpha (PegIFNα-2a)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>457</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017962</other_id>
      <other_id>TMC435HPC3005</other_id>
    </other_ids>
    <first_received>November 9, 2012</first_received>
    <start_date>November 2012</start_date>
    <completion_date>November 2014</completion_date>
    <last_updated>July 15, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>July 15, 2015</firstreceived_results_date>
    <primary_completion_date>August 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After End of Study Drug Treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 24 Weeks After End of Study Drug Treatment (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Week 72 (SVRW72)</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Failure</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Normalization of Alanine Aminotransferase Level</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
      <country>Korea, Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01725529</url>
  </study>
  <study rank="278">
    <nct_id>NCT01655966</nct_id>
    <title>Vitamin D as an add-on Therapy With Pegylated Interferon and Ribavirin for Chronic Hepatitis c</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis c</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">vitamin D +pegylated interferon + ribavirin</intervention>
      <intervention type="Drug">pegylated interferon + ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Cairo University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>RAIL002</other_id>
    </other_ids>
    <first_received>July 31, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>January 28, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response</outcome_measure>
      <outcome_measure>rapid virologic response</outcome_measure>
      <outcome_measure>End-of-treatment response</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>early virologic response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01655966</url>
  </study>
  <study rank="279">
    <nct_id>NCT00000699</nct_id>
    <title>A Phase I/II Trial of Ribavirin (With Escalation) + Isoprinosine in Asymptomatic HIV-Viremic Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Inosine pranobex</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NS 403</other_id>
    </other_ids>
    <first_received>November 2, 1999</first_received>
    <last_updated>August 25, 2008</last_updated>
    <last_verified>April 2003</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>District of Columbia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00000699</url>
  </study>
  <study rank="280">
    <nct_id>NCT00151580</nct_id>
    <title>Treatment of Recurrent Hepatitis C After Liver Transplantation</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Liver Transplantation</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Rennes University Hospital</lead_sponsor>
      <collaborator>Ministry of Health, France</collaborator>
      <collaborator>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AFSSAPS 010588</other_id>
      <other_id>PHRC/00-02</other_id>
      <other_id>CIC0203/049</other_id>
    </other_ids>
    <first_received>September 8, 2005</first_received>
    <start_date>February 2002</start_date>
    <completion_date>July 2006</completion_date>
    <last_updated>May 18, 2012</last_updated>
    <last_verified>November 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>TRANSPEG</acronym>
    <outcome_measures>
      <outcome_measure>Negative viral PCR</outcome_measure>
      <outcome_measure>Histological improvement</outcome_measure>
      <outcome_measure>Biological hepatic markers</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
      <outcome_measure>Intensity, severity and delay to acute transplant rejection, histologically proven</outcome_measure>
      <outcome_measure>Incidence of death or graft loss</outcome_measure>
      <outcome_measure>Number of patients stopping the treatment and causes</outcome_measure>
      <outcome_measure>Incidence of adverse events classically related to treatment</outcome_measure>
      <outcome_measure>Incidence of adverse events possibly related to treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00151580</url>
  </study>
  <study rank="281">
    <nct_id>NCT00031473</nct_id>
    <title>Ribavirin to Prevent RSV Pneumonia in Bone Marrow Transplant Patients</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Respiratory Syncytial Virus Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Virazole (Ribavirin) Inhalation Solution</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
      <study_design>Masking: Single Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>97-038</other_id>
    </other_ids>
    <first_received>March 6, 2002</first_received>
    <start_date>November 1997</start_date>
    <completion_date>March 2003</completion_date>
    <last_updated>August 26, 2010</last_updated>
    <last_verified>December 2003</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>Nebraska</state>
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00031473</url>
  </study>
  <study rank="282">
    <nct_id>NCT00925990</nct_id>
    <title>CTS-1027 in Interferon-Naive Hepatitis C Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">CTS-1027</intervention>
      <intervention type="Drug">Placebo for ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Conatus Pharmaceuticals Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CTS-1027-03</other_id>
    </other_ids>
    <first_received>June 19, 2009</first_received>
    <start_date>June 2009</start_date>
    <completion_date>July 2010</completion_date>
    <last_updated>February 27, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>February 9, 2012</firstreceived_results_date>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Mean Change in HCV-RNA (Hepatitis C Virus Ribonucleic Acid) Levels From Baseline Through 24 Weeks of Treatment</outcome_measure>
      <outcome_measure>Mean Change in Aminotransferases From Baseline to 24 Weeks of Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Louisiana</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00925990</url>
  </study>
  <study rank="283">
    <nct_id>NCT00627926</nct_id>
    <title>A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated Interferon Alfa 2a</intervention>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
      <collaborator>Tibotec Pharmaceutical Limited</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1095</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX07-950-108</other_id>
    </other_ids>
    <first_received>February 22, 2008</first_received>
    <start_date>March 2008</start_date>
    <completion_date>May 2010</completion_date>
    <last_updated>July 16, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>June 22, 2011</firstreceived_results_date>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Subjects Achieving Sustained Viral Response (SVR), Demonstrated by Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels 24 Weeks After Last Planned Dose of Study Treatment</outcome_measure>
      <outcome_measure>Number of Subjects With Undetectable HCV RNA at Week 72</outcome_measure>
      <outcome_measure>Number of Subjects Achieving Rapid Viral Response (RVR), Demonstrated by Achieving Undetectable HCV RNA 4 Weeks After Starting Study Treatment</outcome_measure>
      <outcome_measure>Number of Subjects Achieving Extended Rapid Viral Response (eRVR), Demonstrated by Achieving Undetectable HCV RNA at Week 4 and at Week 12</outcome_measure>
      <outcome_measure>Number of Subjects With Undetectable HCV RNA at Week 12</outcome_measure>
      <outcome_measure>Number of Subjects With Undetectable HCV RNA at End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Number of Subjects With Undetectable HCV RNA 12 Weeks After Last Planned Dose of Study Treatment</outcome_measure>
      <outcome_measure>Number of Subjects With Undetectable HCV RNA 24 Weeks After Last Actual Dose of Study Treatment</outcome_measure>
      <outcome_measure>Number of Subjects With Viral Relapse Planned and Viral Relapse Actual</outcome_measure>
      <outcome_measure>Biochemical Response: Number of Subjects With Grade 3 and 4 Shifts From Baseline in Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Levels</outcome_measure>
      <outcome_measure>Noninvasive Markers of Fibrosis: Number of Subjects With Improvement in FibroTest Analysis</outcome_measure>
      <outcome_measure>Fatigue Severity Scale (FSS) Total Score</outcome_measure>
      <outcome_measure>Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Italy</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Maine</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>Nebraska</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00627926</url>
  </study>
  <study rank="284">
    <nct_id>NCT00199719</nct_id>
    <title>Study of the Pharmacokinetic Action of Amantadine and Ribavirin in Chronic Hepatitis C. CINAM</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Limoges</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>I02022</other_id>
    </other_ids>
    <first_received>September 14, 2005</first_received>
    <start_date>June 2003</start_date>
    <completion_date>September 2006</completion_date>
    <last_updated>October 30, 2007</last_updated>
    <last_verified>June 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>CINAM</acronym>
    <outcome_measures>
      <outcome_measure>-Study of the complete pharmacokinetics of ribavirin at day 1, and day 84 (week 12).</outcome_measure>
      <outcome_measure>-Study of the complete pharmacokinetics of amantadin and ribavirin at week 12 + one day and at week 24</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00199719</url>
  </study>
  <study rank="285">
    <nct_id>NCT01281839</nct_id>
    <title>An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Peginterferon alpha-2a (PegIFN alpha-2a)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>394</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017371</other_id>
      <other_id>TMC435HPC3007</other_id>
      <other_id>2010-021113-23</other_id>
    </other_ids>
    <first_received>January 7, 2011</first_received>
    <start_date>February 2011</start_date>
    <completion_date>February 2013</completion_date>
    <last_updated>March 26, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>February 3, 2014</firstreceived_results_date>
    <acronym>PROMISE</acronym>
    <primary_completion_date>February 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Sustained Virologic Response 4 Weeks After the Planned End of Treatment (SVR4)</outcome_measure>
      <outcome_measure>Change From Baseline in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>Actual Values of log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>The Percentage of Participants With On-treatment Virologic Response at All Time Points</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Early Virologic Response (EVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants With &lt;1 log10 Decrease in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) From Baseline at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels &gt;1000 IU/mL at Week 4</outcome_measure>
      <outcome_measure>The Percentage of Participants With Null Response</outcome_measure>
      <outcome_measure>The Percentage of Participants With Partial Response</outcome_measure>
      <outcome_measure>The Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>The Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Completed All Study Treatment at Week 24 Because of the Treatment Duration Rule</outcome_measure>
      <outcome_measure>The Percentage of Participants With On-treatment Failure</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Undetectable</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Undetectable or Detectable</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;100 IU/mL</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;1000 IU/mL</outcome_measure>
      <outcome_measure>The Percentage of Participants With Viral Breakthrough at Different Time Points</outcome_measure>
      <outcome_measure>Time From End-of-treatment to Viral Relapse</outcome_measure>
      <outcome_measure>The Percentage of Participants With Normalization of Alanine Aminotransferase (ALT)</outcome_measure>
      <outcome_measure>Median Time to Normalization of Alanine Aminotransferase (ALT) Levels</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h)</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Predose Plasma Concentration (C0h)</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Systemic Clearance (CL)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>New Zealand</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Kentucky</state>
      <state>Minnesota</state>
      <state>Mississippi</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01281839</url>
  </study>
  <study rank="286">
    <nct_id>NCT01571583</nct_id>
    <title>An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus (HCV) Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen-Cilag International NV</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>74</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR018721</other_id>
      <other_id>VX-950HPC3006</other_id>
      <other_id>2011-004724-35</other_id>
    </other_ids>
    <first_received>December 16, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>July 14, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>REPLACE</acronym>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of patients achieving sustained virologic response (SVR) 12 planned</outcome_measure>
      <outcome_measure>Number of patients achieving SVR12 planned(c)</outcome_measure>
      <outcome_measure>Number of patients achieving SVR24 planned</outcome_measure>
      <outcome_measure>Number of patients achieving SVR24 planned(c)</outcome_measure>
      <outcome_measure>Number of patients having an undetectable HCV RNA level at Week 4 of treatment</outcome_measure>
      <outcome_measure>Number of patients having an undetectable HCV RNA level at Week 12 of treatment</outcome_measure>
      <outcome_measure>Number of patients having undetectable HCV RNA levels at Week 4 and Week 12 of treatment</outcome_measure>
      <outcome_measure>Number of patients having an undetectable HCV RNA level at the actual end of treatment</outcome_measure>
      <outcome_measure>Number of patients having an undetectable HCV RNA level at the planned end of treatment</outcome_measure>
      <outcome_measure>Number of patients having less than 25 IU/mL at the planned end of treatment</outcome_measure>
      <outcome_measure>Number of patients with on-treatment virologic failure</outcome_measure>
      <outcome_measure>Number of patients with relapse after undetectable HCV RNA at actual end of treatment</outcome_measure>
      <outcome_measure>Number of patients with relapse after undetectable HCV RNA at planned end of treatment</outcome_measure>
      <outcome_measure>Number of patients with relapse after previous HCV RNA less than 25 IU/mL at planned end of treatment</outcome_measure>
      <outcome_measure>Number of patients with viral breakthrough</outcome_measure>
      <outcome_measure>Change from baseline in log HCV RNA values</outcome_measure>
      <outcome_measure>Number of patients who have changes in liver graft biopsy histology</outcome_measure>
      <outcome_measure>Number of patients with adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01571583</url>
  </study>
  <study rank="287">
    <nct_id>NCT00959933</nct_id>
    <title>Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Non-Fasting Conditions</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)</intervention>
      <intervention type="Drug">Rebetol 200 Capsules (Schering Corporation, U.S.A.)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Sandoz Inc.</lead_sponsor>
      <collaborator>Sandoz</collaborator>
    </sponsors>
    <gender>Female</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Bio-equivalence Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P1BH01001</other_id>
    </other_ids>
    <first_received>August 13, 2009</first_received>
    <start_date>April 2001</start_date>
    <completion_date>May 2001</completion_date>
    <last_updated>August 14, 2009</last_updated>
    <last_verified>August 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2001</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Bioequivalence based on AUC and Cmax</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00959933</url>
  </study>
  <study rank="288">
    <nct_id>NCT00158496</nct_id>
    <title>Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon alpha2a</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Agency for Research on AIDS and Viral Hepatitis</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRS 1211</other_id>
    </other_ids>
    <first_received>September 8, 2005</first_received>
    <start_date>August 2002</start_date>
    <completion_date>January 2005</completion_date>
    <last_updated>April 23, 2007</last_updated>
    <last_verified>April 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>- Disappearance of HCV RNA by qualitative PCR 24 weeks after the end of treatment</outcome_measure>
      <outcome_measure>Evaluation of HCV RNA at 12 and 24 weeks</outcome_measure>
      <outcome_measure>changes in HCV RNA load during treatment</outcome_measure>
      <outcome_measure>Normalization of ALT during treatment and 24 weeks after the end of treatment</outcome_measure>
      <outcome_measure>Study of side effects</outcome_measure>
      <outcome_measure>Histological changes 24 weeks after the end of treatment (decrease by at least 1 point of the Metavir score)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00158496</url>
  </study>
  <study rank="289">
    <nct_id>NCT00960479</nct_id>
    <title>Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Fasting Conditions</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)</intervention>
      <intervention type="Drug">Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Sandoz Inc.</lead_sponsor>
      <collaborator>Sandoz</collaborator>
    </sponsors>
    <gender>Female</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>38</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Bio-equivalence Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P1BH00001</other_id>
    </other_ids>
    <first_received>August 13, 2009</first_received>
    <start_date>January 2001</start_date>
    <completion_date>February 2001</completion_date>
    <last_updated>August 14, 2009</last_updated>
    <last_verified>August 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2001</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Bioequivalence based on AUC and Cmax</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00960479</url>
  </study>
  <study rank="290">
    <nct_id>NCT01513941</nct_id>
    <title>An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated-Interferon-alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen-Cilag International NV</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>163</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100778</other_id>
      <other_id>VX-950HPC3008</other_id>
      <other_id>2011-004928-35</other_id>
    </other_ids>
    <first_received>January 16, 2012</first_received>
    <start_date>April 2012</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>May 22, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>INSIGHT</acronym>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients achieving undetectable plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels</outcome_measure>
      <outcome_measure>Change from baseline in log HCV RNA values</outcome_measure>
      <outcome_measure>Proportiond of patients achieving undetectable HCV RNA levels</outcome_measure>
      <outcome_measure>Proportion of patients achieving undetectable HCV RNA levels at Week 4</outcome_measure>
      <outcome_measure>Proportion of patients achieving undetectable HCV RNA levels at Week 12</outcome_measure>
      <outcome_measure>Proportion of patients achieving undetectable HCV RNA levels at Week 4 and Week 12 (eRVR)</outcome_measure>
      <outcome_measure>Proportion of patients achieving undetectable HCV RNA at the actual end of treatment</outcome_measure>
      <outcome_measure>Proportion of patients achieving less than 25 IU/mL</outcome_measure>
      <outcome_measure>Proportion of patients with on-treatment virologic failure</outcome_measure>
      <outcome_measure>Proportion of patients with relapse achieving detectable HCV RNA levels after previously undetectable HCV RNA levels</outcome_measure>
      <outcome_measure>Proportion of patients with relapse achieving detectable HCV RNA levels after previous HCV RNA levels</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
      <country>Brazil</country>
      <country>France</country>
      <country>Poland</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01513941</url>
  </study>
  <study rank="291">
    <nct_id>NCT00015652</nct_id>
    <title>Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Aldesleukin</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>A5088</other_id>
      <other_id>AACTG A5088</other_id>
      <other_id>10676</other_id>
      <other_id>ACTG A5088</other_id>
    </other_ids>
    <first_received>April 26, 2001</first_received>
    <completion_date>March 2005</completion_date>
    <last_updated>May 21, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Illinois</state>
      <state>Iowa</state>
      <state>Maryland</state>
      <state>New York</state>
      <state>Ohio</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00015652</url>
  </study>
  <study rank="292">
    <nct_id>NCT00203606</nct_id>
    <title>Pegylated Interferon Plus Ribavirin in the Treatment of Active and Past Intravenous Drug Users Infected With Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis c</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon alfa-2a ( Roche) and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Calgary</lead_sponsor>
      <collaborator>Canadian Institutes of Health Research (CIHR)</collaborator>
      <collaborator>Roche Pharma AG</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>66</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>21995</other_id>
    </other_ids>
    <first_received>September 13, 2005</first_received>
    <start_date>January 2004</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>August 3, 2011</last_updated>
    <last_verified>August 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained viral response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00203606</url>
  </study>
  <study rank="293">
    <nct_id>NCT02265237</nct_id>
    <title>A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ombitasvir/ABT-450/ritonavir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>190</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M11-665</other_id>
      <other_id>2014-001496-31</other_id>
    </other_ids>
    <first_received>October 10, 2014</first_received>
    <start_date>October 2014</start_date>
    <completion_date>April 2017</completion_date>
    <last_updated>November 23, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of subjects with sustained virologic response 12 (SVR12) weeks post treatment</outcome_measure>
      <outcome_measure>Percentage of subjects with treatment-emergent adverse events</outcome_measure>
      <outcome_measure>Percentage of subjects with SVR12 in subjects receiving 12 weeks of treatment compared to subjects receiving 16 weeks of treatment.</outcome_measure>
      <outcome_measure>Percentage of subjects with on-treatment virologic failure</outcome_measure>
      <outcome_measure>Percentage of subjects with post-treatment relapse</outcome_measure>
      <outcome_measure>Percentage of subjects with SVR12 in subjects receiving 16 weeks of treatment compared to subjects receiving 24 weeks of treatment.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>Italy</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02265237</url>
  </study>
  <study rank="294">
    <nct_id>NCT01227967</nct_id>
    <title>Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Influenza</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Amantadine, Ribavirin, Oseltamivir</intervention>
      <intervention type="Drug">Oseltamivir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>1200</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>10-I-0210</other_id>
      <other_id>IRC003</other_id>
    </other_ids>
    <first_received>October 22, 2010</first_received>
    <start_date>September 2010</start_date>
    <completion_date>September 2016</completion_date>
    <last_updated>December 2, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>IRC003</acronym>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evaluate the reproducibility of virologic samples, comparison between culture and PCR, and the impact of missing data between randomized groups.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Mexico</country>
      <country>Thailand</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Iowa</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>Nebraska</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>South Dakota</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01227967</url>
  </study>
  <study rank="295">
    <nct_id>NCT01529073</nct_id>
    <title>Efficacy of Pegylated Interferon Plus Ribavirin Plus Nitazoxanide in HCV Genotype 4 and HIV Coinfection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV Coinfection</condition>
      <condition>HIV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitazoxanide</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Juan Macías</lead_sponsor>
      <collaborator>Spanish National Health System</collaborator>
      <collaborator>Andaluz Health Service</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NTZSPA001</other_id>
      <other_id>2010-024336-42</other_id>
    </other_ids>
    <first_received>February 5, 2012</first_received>
    <start_date>February 2012</start_date>
    <completion_date>February 2015</completion_date>
    <last_updated>January 13, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response</outcome_measure>
      <outcome_measure>Safety of Peg-interferon plus ribavirin plus nitazoxanide</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01529073</url>
  </study>
  <study rank="296">
    <nct_id>NCT01896609</nct_id>
    <title>Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis c</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Reiferon Retard in Arm 1</intervention>
      <intervention type="Drug">Bon one in Arm 3</intervention>
      <intervention type="Drug">Xerovirinc in Arm 2</intervention>
      <intervention type="Drug">Ribavirin in Arm 1</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>MinaPharm Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HCV05012012</other_id>
    </other_ids>
    <first_received>June 19, 2013</first_received>
    <start_date>June 2013</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>July 10, 2013</last_updated>
    <last_verified>July 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>Quadritherapy</acronym>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Early virological response</outcome_measure>
      <outcome_measure>Sustained Virological Response ( SVR )</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01896609</url>
  </study>
  <study rank="297">
    <nct_id>NCT01278134</nct_id>
    <title>A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus placebo</intervention>
      <intervention type="Drug">RO5024048</intervention>
      <intervention type="Drug">danoprevir</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
      <intervention type="Drug">ritonavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>170</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>PP25213</other_id>
      <other_id>2010-022067-35</other_id>
    </other_ids>
    <first_received>January 14, 2011</first_received>
    <start_date>February 2011</start_date>
    <completion_date>October 2012</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response, defined as undetectable HVC RNA measured by Roche COBAS TaqMan HCV test</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
      <outcome_measure>Virological response (HCV RNA measured by Roche COBAS Taqman HCV test)</outcome_measure>
      <outcome_measure>Impact of Copegus (ribavirin) on efficacy of the direct-acting antiviral combination regimen: viral response (HCV RNA measured by Roche COBAS TaqMan HCV test)</outcome_measure>
      <outcome_measure>Comparison of 12 and 24 weeks of treatment duration: viral response (HCV RNA measured by Roche COBAS TaqMan HCV test)</outcome_measure>
      <outcome_measure>Pharmacokinetics: Plasma concentrations of danoprevir, ritonavir, RO4995855 (parent drug of RO5024048) and ribavirin</outcome_measure>
      <outcome_measure>Viral resistance: HCV RNA sequencing and phenotypic analyses</outcome_measure>
      <outcome_measure>Effect of interleukin 28B genotype on efficacy: viral response (HCV RNA measured by Roche COBAS TaqMan HCV test)</outcome_measure>
      <outcome_measure>Quality of life: SF-36 questionnaire, Fatigue Severity Scale</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>France</country>
      <country>Germany</country>
      <country>New Zealand</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01278134</url>
  </study>
  <study rank="298">
    <nct_id>NCT01717326</nct_id>
    <title>A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Grazoprevir</intervention>
      <intervention type="Drug">Elbasvir</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>573</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>5172-035</other_id>
      <other_id>2012-003354-89</other_id>
    </other_ids>
    <first_received>October 26, 2012</first_received>
    <start_date>February 2013</start_date>
    <completion_date>May 2015</completion_date>
    <last_updated>May 15, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>C-WORTHy</acronym>
    <primary_completion_date>May 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants achieving Sustained Virologic Response 12 weeks after the end of all study therapy (SVR12)</outcome_measure>
      <outcome_measure>Number of participants experiencing at least one Adverse Event (AE) on study</outcome_measure>
      <outcome_measure>Number of participants discontinuing study therapy due to an AE</outcome_measure>
      <outcome_measure>Time to first achievement of undetectable hepatitis C virus ribonucleic acid (HCV RNA)</outcome_measure>
      <outcome_measure>Number of participants achieving undetectable HCV RNA at Week 2</outcome_measure>
      <outcome_measure>Number of participants achieving undetectable HCV RNA at Week 4</outcome_measure>
      <outcome_measure>Number of participants achieving undetectable HCV RNA at Week 12</outcome_measure>
      <outcome_measure>Number of participants achieving HCV RNA &lt;25 IU/mL at Week 2</outcome_measure>
      <outcome_measure>Number of participants achieving HCV RNA &lt;25 IU/mL at Week 4</outcome_measure>
      <outcome_measure>Number of participants achieving HCV RNA &lt;25 IU/mL at Week 12</outcome_measure>
      <outcome_measure>Number of participants achieving End-Of-Treatment Response (EOTR)</outcome_measure>
      <outcome_measure>Number of participants achieving Sustained Virologic Response 4 weeks after the end of all therapy (SVR4)</outcome_measure>
      <outcome_measure>Number of participants achieving Sustained Virologic Response 24 weeks after the end of all study therapy (SVR24)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01717326</url>
  </study>
  <study rank="299">
    <nct_id>NCT00117533</nct_id>
    <title>Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
      <condition>Chronic Hepatitis D</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated IFN alfa-2b plus ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>National Health Research Institutes, Taiwan</collaborator>
      <collaborator>National Science Council, Taiwan</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>930904</other_id>
    </other_ids>
    <first_received>June 30, 2005</first_received>
    <start_date>September 2005</start_date>
    <completion_date>June 2007</completion_date>
    <last_updated>May 24, 2006</last_updated>
    <last_verified>September 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>the efficacy of 24-week pegylated IFN alfa-2b plus RBV for SVR of HDV in patients with dual chronic hepatitis D and B</outcome_measure>
      <outcome_measure>the efficacy of pegylated IFN alfa-2b plus RBV in patients with dual chronic hepatitis D and B on: The biochemical response rate</outcome_measure>
      <outcome_measure>The degree of histologic change</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00117533</url>
  </study>
  <study rank="300">
    <nct_id>NCT01516918</nct_id>
    <title>A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">VX-222</intervention>
      <intervention type="Drug">telaprevir</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Biological">peginterferon-alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>103</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX11-222-106</other_id>
    </other_ids>
    <first_received>January 13, 2012</first_received>
    <start_date>February 2012</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>October 9, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The proportion of subjects who have a sustained virologic response at 12 weeks after the last planned dose of treatment (SVR12)</outcome_measure>
      <outcome_measure>The safety and tolerability as assessed by adverse events, vital signs, 12-lead electrocardiograms and laboratory assessments.</outcome_measure>
      <outcome_measure>The proportion of subjects who have an SVR 24 weeks after the last planned dose of the study drug (SVR24)</outcome_measure>
      <outcome_measure>The proportion of subjects who achieve undetectable HCV RNA at Weeks 2, 4, 8, and 12 after the first dose of study drug, and at the end of planned study drug treatment</outcome_measure>
      <outcome_measure>The proportion of subjects who have on-treatment virologic failure defined as subjects who either meet a futility rule or who complete the assigned treatment duration and have HCV RNA at the end of study drug treatment</outcome_measure>
      <outcome_measure>The association of the IL-28B genotype with SVR12</outcome_measure>
      <outcome_measure>The amino acid sequence of the nonstructural (NS)3 and NS5B proteins in subjects who have treatment failure</outcome_measure>
      <outcome_measure>VX-222, telaprevir, and RBV plasma concentrations and Peg-IFN serum concentrations</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Germany</country>
      <country>Poland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>New Hampshire</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01516918</url>
  </study>
  <study rank="301">
    <nct_id>NCT00087568</nct_id>
    <title>A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>58</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML16965</other_id>
    </other_ids>
    <first_received>July 12, 2004</first_received>
    <start_date>December 2002</start_date>
    <completion_date>August 2006</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients able to complete prescribed length of Pegasys plus ribavirin therapy\n</outcome_measure>
      <outcome_measure>Sum score of Beck Depression Inventory and Fatigue Severity Score, proportion of patients with each flu-like symptom, &gt;=2 log drop or undetectable HCV-RNA, or normal ALT levels, adverse events, laboratory values\n</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00087568</url>
  </study>
  <study rank="302">
    <nct_id>NCT01932762</nct_id>
    <title>Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Grazoprevir</intervention>
      <intervention type="Drug">Elbasvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>98</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>5172-047</other_id>
      <other_id>2013-002169-21</other_id>
    </other_ids>
    <first_received>August 27, 2013</first_received>
    <start_date>October 2013</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>April 9, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After The End of Study Therapy (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants with Adverse Events (AEs), Serious AEs (SAEs), Drug-Related AE, Drug-Related SAE, or Discontinuation Due to AE</outcome_measure>
      <outcome_measure>Time to First Achievement of Undetectable HCV RNA</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Undetectable HCV RNA</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving HCV RNA &lt;25 IU/mL</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR4</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR24</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01932762</url>
  </study>
  <study rank="303">
    <nct_id>NCT01585324</nct_id>
    <title>A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML25186</other_id>
      <other_id>2011-001256-10</other_id>
    </other_ids>
    <first_received>April 24, 2012</first_received>
    <start_date>January 2012</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>June 25, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>June 25, 2015</firstreceived_results_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virological Response (SVR) 24 Weeks After End of Treatment</outcome_measure>
      <outcome_measure>Change From Baseline in Hemoglobin Level at Week 12 of Treatment Among Participants With or Without SVR</outcome_measure>
      <outcome_measure>Number of Participants With Decrease in Hemoglobin</outcome_measure>
      <outcome_measure>Lowest Hemoglobin Level During Treatment Among Participants With or Without SVR</outcome_measure>
      <outcome_measure>Number of Participants With Reduction in Ribavirin Dose Due to Drop in Hemoglobin Among Participants With or Without SVR</outcome_measure>
      <outcome_measure>Number of Participants With Neutropenia Among Participants With or Without SVR</outcome_measure>
      <outcome_measure>Number of Participants With Thrombocytopenia Among Participants With or Without SVR</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Czech Republic</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01585324</url>
  </study>
  <study rank="304">
    <nct_id>NCT02601573</nct_id>
    <title>Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic HCV GT3 Infection</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Grazoprevir</intervention>
      <intervention type="Drug">Elbasvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>125</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>5172-083</other_id>
      <other_id>2015-003187-37</other_id>
    </other_ids>
    <first_received>November 9, 2015</first_received>
    <start_date>December 2015</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>December 10, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants achieving SVR12 (Sustained Virologic Response 12 weeks after the end of all study therapy)</outcome_measure>
      <outcome_measure>Number of participants experiencing an adverse event (AE)</outcome_measure>
      <outcome_measure>Number of participants discontinuing from study therapy due to an AE</outcome_measure>
      <outcome_measure>Percentage of participants achieving SVR24 (Sustained Virologic Response 24 weeks after the end of all study therapy)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02601573</url>
  </study>
  <study rank="305">
    <nct_id>NCT01389323</nct_id>
    <title>BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Peg-Interferon Alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>448</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-038</other_id>
    </other_ids>
    <first_received>July 6, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>September 19, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>August 17, 2015</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response at Post-treatment Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response at Post-treatment Week 12 (SVR12) With rs12979860 Single Nucleotide Polymorphisms at Baseline in the Interleukin-28B Gene</outcome_measure>
      <outcome_measure>Percentage of Participants With Hepatitis C Virus (HCV) RNA Levels &lt;Lower Limit of Quantitation (LLOQ), Target Detected or Target Not Detected, at Specified Time Points</outcome_measure>
      <outcome_measure>Percentage of Participants With Hepatitis C Virus (HCV) RNA Levels &lt;Lower Limit of Quantitation (LLOQ), Target Not Detected, at Specified Time Points</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), Treatment-related AEs, and Who Died</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Mississippi</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oregon</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01389323</url>
  </study>
  <study rank="306">
    <nct_id>NCT01405560</nct_id>
    <title>Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Vaniprevir</intervention>
      <intervention type="Biological">peg-IFN</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>42</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>7009-045</other_id>
    </other_ids>
    <first_received>July 28, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>September 7, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>October 6, 2014</firstreceived_results_date>
    <primary_completion_date>March 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response (SVR)24</outcome_measure>
      <outcome_measure>Percentage of Participants With One or More Specific Adverse Events (AEs) of Special Interest During the Study</outcome_measure>
      <outcome_measure>Percentage of Participants Who Discontinued Study Drug Due to an AE</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR12</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Undetectable HCV Ribonucleic Acid (RNA) at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Mean Change From Baseline in HCV RNA (Log 10)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01405560</url>
  </study>
  <study rank="307">
    <nct_id>NCT00977054</nct_id>
    <title>Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DFPP + Peg-IFN + RBV</intervention>
      <intervention type="Drug">Peg-IFN + RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>National Science Council, Taiwan</collaborator>
      <collaborator>Department of Health, Executive Yuan, R.O.C. (Taiwan)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>59</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>200904053D</other_id>
    </other_ids>
    <first_received>September 13, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>December 19, 2012</last_updated>
    <last_verified>December 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (SVR)</outcome_measure>
      <outcome_measure>Rapid virologic response (RVR)</outcome_measure>
      <outcome_measure>Treatment-related withdrawal rate</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00977054</url>
  </study>
  <study rank="308">
    <nct_id>NCT01615393</nct_id>
    <title>A Study to Compare the Bioavailability of Copegus and Vilona® in Healthy Volunteers</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy Volunteer</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
      <intervention type="Drug">ribavirin [Vilona]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Bio-availability Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single Blind (Subject)</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML28199</other_id>
    </other_ids>
    <first_received>June 6, 2012</first_received>
    <start_date>June 2011</start_date>
    <completion_date>October 2011</completion_date>
    <last_updated>November 2, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Bioavailability</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Mexico</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01615393</url>
  </study>
  <study rank="309">
    <nct_id>NCT00788918</nct_id>
    <title>Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Cognition Disorders</condition>
      <condition>Fatigue Syndrome, Chronic</condition>
      <condition>Major Depressive Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Interferon and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Aarhus University Hospital</lead_sponsor>
      <collaborator>University of Aarhus</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>SKS-0078-HCVCNS</other_id>
      <other_id>EudraCT 2007-005707-18</other_id>
    </other_ids>
    <first_received>November 10, 2008</first_received>
    <start_date>November 2008</start_date>
    <completion_date>November 2012</completion_date>
    <last_updated>January 10, 2013</last_updated>
    <last_verified>January 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Neuropsychological test results, cytokine profile and MRI findings</outcome_measure>
      <outcome_measure>Interferon-induced depression</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Denmark</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00788918</url>
  </study>
  <study rank="310">
    <nct_id>NCT01370642</nct_id>
    <title>Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">vaniprevir</intervention>
      <intervention type="Drug">Placebo to vaniprevir</intervention>
      <intervention type="Biological">Peg-IFN</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>294</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>7009-043</other_id>
    </other_ids>
    <first_received>June 8, 2011</first_received>
    <start_date>June 2011</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>September 26, 2014</firstreceived_results_date>
    <primary_completion_date>July 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Completion of All Study Therapy (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With One or More Tier 1 Adverse Events (AEs) During the Study</outcome_measure>
      <outcome_measure>Percentage of Participants Who Discontinued Study Drug Due to an AE</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR12</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Undetectable HCV RNA at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Least Squares (LS) Mean Change From Baseline in HCV RNA (Log 10)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01370642</url>
  </study>
  <study rank="311">
    <nct_id>NCT00680173</nct_id>
    <title>Peripheral Blood Mononuclear Cell (PBMC) Gene Expression in HCV Genotype 1 Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon alpha 2a and plus ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kaohsiung Medical University Chung-Ho Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KMUH-IRB- 950419</other_id>
    </other_ids>
    <first_received>May 15, 2008</first_received>
    <start_date>August 2006</start_date>
    <completion_date>October 2017</completion_date>
    <last_updated>April 1, 2015</last_updated>
    <last_verified>August 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PBMC</acronym>
    <primary_completion_date>April 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy - Sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.</outcome_measure>
      <outcome_measure>Rapid virologic response (RVR), HCV RNA seronegative by PCR at week 4.</outcome_measure>
      <outcome_measure>Early virological response (EVR), by PCR-negative or at least 2 logs decline from baseline of serum HCV RNA at 12 weeks of treatment.</outcome_measure>
      <outcome_measure>Safety - adverse event rate and profile</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00680173</url>
  </study>
  <study rank="312">
    <nct_id>NCT01945294</nct_id>
    <title>Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Biological">Peg-interferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>236</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>3034-107</other_id>
    </other_ids>
    <first_received>September 13, 2013</first_received>
    <start_date>October 2013</start_date>
    <completion_date>November 2015</completion_date>
    <last_updated>November 24, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Undetectable HCV RNA at TW 8 Who Achieve Sustained Viral Response at Follow-up Week 12 (SVR12) [16-Week Arm vs. 28-Week Arm]</outcome_measure>
      <outcome_measure>Percentage of Participants with SVR12 By Virologic Response At End of Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Relapse</outcome_measure>
      <outcome_measure>Percentage of Participants With Neutrophil Count &lt;0.75 x10^9/L</outcome_measure>
      <outcome_measure>Percentage of Participants With Hemoglobin (Hgb) &lt;10 g/dL</outcome_measure>
      <outcome_measure>Percentage of Participants With Dose Discontinuation/Modification Due to Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Percentage of Participants With Treatment-Related Serious AEs (SAEs)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01945294</url>
  </study>
  <study rank="313">
    <nct_id>NCT01072695</nct_id>
    <title>Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GS-9256</intervention>
      <intervention type="Drug">GS-9190</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>46</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-196-0112</other_id>
    </other_ids>
    <first_received>February 19, 2010</first_received>
    <start_date>February 2010</start_date>
    <completion_date>January 2012</completion_date>
    <last_updated>May 30, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of subjects achieving rapid virologic response (RVR)</outcome_measure>
      <outcome_measure>AEs, physical examination and clinical laboratory test findings, vital signs, ECGs</outcome_measure>
      <outcome_measure>Plasma pharmacokinetics</outcome_measure>
      <outcome_measure>Viral resistance</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01072695</url>
  </study>
  <study rank="314">
    <nct_id>NCT00704405</nct_id>
    <title>Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Vaniprevir</intervention>
      <intervention type="Drug">Pegylated Interferon (Peg-IFN)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">Placebo (PBO)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>285</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>7009-009</other_id>
      <other_id>2007_659</other_id>
    </other_ids>
    <first_received>June 23, 2008</first_received>
    <start_date>March 2009</start_date>
    <completion_date>September 2012</completion_date>
    <last_updated>September 1, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>September 26, 2014</firstreceived_results_date>
    <primary_completion_date>March 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving SVR24 Following Treatment With Vaniprevir 600 mg b.i.d.</outcome_measure>
      <outcome_measure>Number of Participants Experiencing an Adverse Event (AE)</outcome_measure>
      <outcome_measure>Number of Participants Discontinuing From Study Treatment Due to AEs</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR24 Following Treatment With Vaniprevir 300 mg b.i.d.</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving cEVR</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR24 After 24 Weeks of Vaniprevir 600 mg b.i.d.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00704405</url>
  </study>
  <study rank="315">
    <nct_id>NCT00411385</nct_id>
    <title>Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">albumin interferon alfa-2b</intervention>
      <intervention type="Drug">peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Human Genome Sciences Inc.</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>933</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HGS1008-C1067</other_id>
      <other_id>ACHIEVE-2/3</other_id>
    </other_ids>
    <first_received>December 13, 2006</first_received>
    <start_date>February 2007</start_date>
    <completion_date>October 2008</completion_date>
    <last_updated>August 1, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (SVR)</outcome_measure>
      <outcome_measure>Rapid virologic response</outcome_measure>
      <outcome_measure>Early virologic response</outcome_measure>
      <outcome_measure>Undetectable HCV RNA</outcome_measure>
      <outcome_measure>Normalization of ALT (a liver enzyme)</outcome_measure>
      <outcome_measure>Quality of life evaluation</outcome_measure>
      <outcome_measure>Safety assessments (physical exams, Ae reporting, lab testing/analysis, HADS and Immunogenicity results)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>France</country>
      <country>Germany</country>
      <country>India</country>
      <country>Israel</country>
      <country>Korea, Republic of</country>
      <country>Malaysia</country>
      <country>Mexico</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Singapore</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>Taiwan</country>
      <country>Thailand</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Minnesota</state>
      <state>New Hampshire</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00411385</url>
  </study>
  <study rank="316">
    <nct_id>NCT00402428</nct_id>
    <title>Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">albumin interferon alfa-2b</intervention>
      <intervention type="Drug">peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Human Genome Sciences Inc.</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1331</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HGS1008-C1060</other_id>
      <other_id>ACHIEVE-1</other_id>
    </other_ids>
    <first_received>November 20, 2006</first_received>
    <start_date>December 2006</start_date>
    <completion_date>February 2009</completion_date>
    <last_updated>August 1, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (SVR)</outcome_measure>
      <outcome_measure>Rapid virologic response</outcome_measure>
      <outcome_measure>Early virologic response</outcome_measure>
      <outcome_measure>Undetectable HCV RNA</outcome_measure>
      <outcome_measure>Normalization of ALT (a liver enzyme)</outcome_measure>
      <outcome_measure>Quality of life evaluation</outcome_measure>
      <outcome_measure>Safety assessments (physical exams, AE reporting, lab testing/analysis, HADS and Immunogenicity testing)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>Czech Republic</country>
      <country>France</country>
      <country>Germany</country>
      <country>India</country>
      <country>Israel</country>
      <country>Italy</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Iowa</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00402428</url>
  </study>
  <study rank="317">
    <nct_id>NCT02027493</nct_id>
    <title>Hansenula-Derived Pegylated-Interferon Alpha-2a in Egyptian Children With Chronic HCV</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Reiferon R</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Liver Institute, Egypt</lead_sponsor>
      <collaborator>Yassin Abdel Ghaffar Charity Center for Liver Disease and Research, Cairo, Egypt</collaborator>
      <collaborator>National Hepatology &amp; Tropical Medicine Research Institute</collaborator>
      <collaborator>Ain Shams University</collaborator>
      <collaborator>Cairo University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>46</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NLI-YAGCC-CUPH-HCV-PEG-PED</other_id>
    </other_ids>
    <first_received>January 1, 2014</first_received>
    <start_date>February 2009</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>January 3, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To study the safety of Hansenula-Derived Pegylated-Interferon Alpha-2a (Reiferon retard) in attaining sustained virological response in children with chronic hepatitis C virus infection</outcome_measure>
      <outcome_measure>Efficacy of treatment customization on the outcome</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02027493</url>
  </study>
  <study rank="318">
    <nct_id>NCT00687219</nct_id>
    <title>Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Liver Cirrhosis</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>102</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05116</other_id>
      <other_id>JPC-06-320-35</other_id>
    </other_ids>
    <first_received>May 27, 2008</first_received>
    <start_date>June 2007</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>September 18, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>October 27, 2011</firstreceived_results_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Undetectable HCV-RNA at Week 72 (Sustained Virologic Response)</outcome_measure>
      <outcome_measure>Number of Participants With Undetectable HCV-RNA at Week 24</outcome_measure>
      <outcome_measure>Number of Participants With Undetectable HCV-RNA at End of Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00687219</url>
  </study>
  <study rank="319">
    <nct_id>NCT00192647</nct_id>
    <title>A Study of Induction Dosing With Peginterferon Alfa-2a (40KD) and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>896</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML17908</other_id>
    </other_ids>
    <first_received>September 13, 2005</first_received>
    <start_date>September 2004</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants with sustained virologic response</outcome_measure>
      <outcome_measure>Percentage of participants with undetectable hepatitis C virus (HCV) ribonucleic acid (RNA)</outcome_measure>
      <outcome_measure>Percentage of participants with at least a 2-log drop in HCV RNA or unquantifiable/undetectable HCV RNA</outcome_measure>
      <outcome_measure>Incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Mexico</country>
      <country>New Zealand</country>
      <country>Thailand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00192647</url>
  </study>
  <study rank="320">
    <nct_id>NCT01001754</nct_id>
    <title>Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG-rIL-29</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>ZymoGenetics</lead_sponsor>
      <collaborator>Bristol-Myers Squibb</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>526H04</other_id>
      <other_id>2009-011786-80</other_id>
    </other_ids>
    <first_received>October 23, 2009</first_received>
    <start_date>May 2010</start_date>
    <completion_date>May 2012</completion_date>
    <last_updated>December 2, 2011</last_updated>
    <last_verified>December 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>EMERGE</acronym>
    <primary_completion_date>November 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HCV RNA</outcome_measure>
      <outcome_measure>Incidence and severity of adverse events</outcome_measure>
      <outcome_measure>Incidence and severity of adverse events and laboratory abnormalities</outcome_measure>
      <outcome_measure>PD biomarkers</outcome_measure>
      <outcome_measure>Quality of life assessments</outcome_measure>
      <outcome_measure>Serum drug concentration profile</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01001754</url>
  </study>
  <study rank="321">
    <nct_id>NCT00968357</nct_id>
    <title>Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SCV-07</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>SciClone Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>SCI-SCV-HCV-P2-001</other_id>
    </other_ids>
    <first_received>August 27, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>January 2011</completion_date>
    <last_updated>June 6, 2012</last_updated>
    <last_verified>June 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To assess the safety of SCV-07 at 2 dose levels given as a monotherapy and to assess the immunomodulatory effects of SCV-07 given at 2 dose levels for 4 weeks and in combination with ribavirin for 4 weeks after monotherapy, respectively.</outcome_measure>
      <outcome_measure>To assess the pharmacodynamic effects of SCV 07 and the pharmacokinetics as a monotherapy and in combination with ribavirin</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Kentucky</state>
      <state>Maryland</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00968357</url>
  </study>
  <study rank="322">
    <nct_id>NCT01653236</nct_id>
    <title>Boceprevir With Peginterferon Alfa-2b and Ribavirin in the Treatment-naive Patients Infected With Genotype 4 Chronic Hepatitis C Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Genotype 4 Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Theodor Bilharz Research Institute</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>3034-108</other_id>
    </other_ids>
    <first_received>July 26, 2012</first_received>
    <start_date>December 2013</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>December 25, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy</outcome_measure>
      <outcome_measure>Week 8 Response</outcome_measure>
      <outcome_measure>12 Weeks response</outcome_measure>
      <outcome_measure>IL-28B polymorphism</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01653236</url>
  </study>
  <study rank="323">
    <nct_id>NCT00215839</nct_id>
    <title>HRN 004- Peginterferon a-2a Plus Ribavirin for Chronic Hepatitis C Infection in HIV Infected Persons Who Have Failed to Achieve a Sustained Virologic Response Following Previous Interferon Therapy</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection in HIV Infected Persons</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon a-2a plus Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hepatitis Resource Network</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HRN 004</other_id>
    </other_ids>
    <first_received>September 20, 2005</first_received>
    <last_updated>October 24, 2005</last_updated>
    <last_verified>September 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>evaluate the safety, tolerability, and efficacy of Peginterferon a-2a plus Ribavirin for the treatment of chronic hepatitis C (CHC) infection in persons co-infected with human immunodeficiency virus (HIV) who have failed to achieve a sustained virologi</outcome_measure>
      <outcome_measure>To evaluate the virological response at weeks 12 and 24 as compared to baseline values.</outcome_measure>
      <outcome_measure>To evaluate the sustained virological response at post-treatment weeks 4, 12, and 24 as compared to baseline.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00215839</url>
  </study>
  <study rank="324">
    <nct_id>NCT00724373</nct_id>
    <title>Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b (SCH 54031)</intervention>
      <intervention type="Drug">Ribavirin (SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>442</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05269</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>November 2007</start_date>
    <completion_date>February 2009</completion_date>
    <last_updated>September 24, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>May 6, 2010</firstreceived_results_date>
    <primary_completion_date>February 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Participants With Treatment Success</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00724373</url>
  </study>
  <study rank="325">
    <nct_id>NCT02219477</nct_id>
    <title>A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Decompensated Cirrhosis</condition>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450/ritonavir/ABT-267</intervention>
      <intervention type="Drug">ABT-333</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M14-227</other_id>
      <other_id>2014-001477-13</other_id>
    </other_ids>
    <first_received>August 15, 2014</first_received>
    <start_date>November 2014</start_date>
    <completion_date>February 2017</completion_date>
    <last_updated>October 16, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>TURQUOISE-CPB</acronym>
    <primary_completion_date>June 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants with Sustained Virologic Response 12 weeks post-treatment</outcome_measure>
      <outcome_measure>Percentage of participants with virologic failure during treatment</outcome_measure>
      <outcome_measure>Percentage of participants with virologic relapse post-treatment</outcome_measure>
      <outcome_measure>Percentage of participants with improvement in laboratory parameters associated with hepatic function</outcome_measure>
      <outcome_measure>Percentage of Genotype 4 participants with Sustained Virologic Response 12 weeks post-treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Colorado</state>
      <state>Louisiana</state>
      <state>Michigan</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02219477</url>
  </study>
  <study rank="326">
    <nct_id>NCT01697436</nct_id>
    <title>A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy Volunteer</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>BP28307</other_id>
    </other_ids>
    <first_received>September 28, 2012</first_received>
    <start_date>September 2012</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Pharmacokinetics: area under the plasma concentration time curve</outcome_measure>
      <outcome_measure>Pharmacokinetics: maximum plasma concentration</outcome_measure>
      <outcome_measure>Safety: incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Kansas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01697436</url>
  </study>
  <study rank="327">
    <nct_id>NCT00725842</nct_id>
    <title>Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peg-IFN alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>97</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05484</other_id>
    </other_ids>
    <first_received>July 28, 2008</first_received>
    <start_date>January 2009</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>September 18, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>June 13, 2012</firstreceived_results_date>
    <acronym>RE-CHUT</acronym>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Positive Hepatitis C Virus (HCV)-Ribonucleic Acid (RNA) at 24 Weeks Off-treatment</outcome_measure>
      <outcome_measure>Number of Participants With Rapid Virologic Response (RVR), Early Virologic Response (EVR), or Slow Response Who Relapsed After Treatment</outcome_measure>
      <outcome_measure>Assessment of Pre-treatment Risk Factors of Relapse in Participants With Sustained Virologic Response</outcome_measure>
      <outcome_measure>Number of Participants With Positive HCV-RNA at 72 Weeks Off-treatment</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00725842</url>
  </study>
  <study rank="328">
    <nct_id>NCT01701063</nct_id>
    <title>An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
      <collaborator>Janssen Pharmaceuticals</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>42</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX11-950-118</other_id>
    </other_ids>
    <first_received>September 27, 2012</first_received>
    <start_date>January 2013</start_date>
    <completion_date>April 2015</completion_date>
    <last_updated>May 12, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety parameters, including AEs, study drug modifications or discontinuations, clinical laboratory values, vital signs, and electrocardiogram (ECG) assessments</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve undetectable HCV RNA 12 weeks after the last planned dose of study drug (SVR12)</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve undetectable HCV RNA 24 weeks after the last planned dose of study drug (SVR24)</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve undetectable HCV RNA at Week 4, at Week 12, at both Weeks 4 and 12 (eRVR), and at the planned end of treatment (EOT)</outcome_measure>
      <outcome_measure>Proportion of subjects with on-treatment virologic failure, defined as either meeting a futility rule or completing the assigned treatment duration with detectable HCV RNA at the EOT</outcome_measure>
      <outcome_measure>Proportion of subjects with virological relapse, defined as having undetectable HCV RNA at planned EOT followed by detectable HCV RNA after planned EOT</outcome_measure>
      <outcome_measure>Part A only, then Part B: Composite of Pharmacokinetics of telaprevir</outcome_measure>
      <outcome_measure>Changes from baseline in the amino acid sequence of the HCV NS3•4A protease</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Belgium</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01701063</url>
  </study>
  <study rank="329">
    <nct_id>NCT01353248</nct_id>
    <title>GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GS-5885</intervention>
      <intervention type="Drug">Tegobuvir</intervention>
      <intervention type="Drug">GS-9451</intervention>
      <intervention type="Drug">ribavirin tablet</intervention>
      <intervention type="Drug">GS-5885</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>141</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-248-0120</other_id>
    </other_ids>
    <first_received>April 22, 2011</first_received>
    <start_date>May 2011</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>November 26, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (SVR)</outcome_measure>
      <outcome_measure>Safety and tolerability</outcome_measure>
      <outcome_measure>HCV RNA &lt; Lower Limit Of Quantification</outcome_measure>
      <outcome_measure>Rescue Therapy Substudy SVR</outcome_measure>
      <outcome_measure>Emergence of viral resistance</outcome_measure>
      <outcome_measure>Viral dynamics of GS-5885, GS-9451 and Tegobuvir when administered in combination with RBV</outcome_measure>
      <outcome_measure>Pharmacokinetics of GS-5885, GS-9451 and Tegobuvir when administered in combination with RBV</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Mississippi</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01353248</url>
  </study>
  <study rank="330">
    <nct_id>NCT00446134</nct_id>
    <title>Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Taribavirin</intervention>
      <intervention type="Drug">Taribavirin</intervention>
      <intervention type="Drug">Taribavirin</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Valeant Pharmaceuticals International, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>278</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>RNA003142-204</other_id>
    </other_ids>
    <first_received>March 8, 2007</first_received>
    <start_date>March 2007</start_date>
    <completion_date>April 2009</completion_date>
    <last_updated>June 20, 2012</last_updated>
    <last_verified>June 2012</last_verified>
    <firstreceived_results_date>September 20, 2011</firstreceived_results_date>
    <primary_completion_date>April 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Patients With Either Undetectable Serum HCV RNA (&lt;100 Copies/ml) or at Least a 2-log Decrease From Baseline in Serum Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Treatment Week 12.</outcome_measure>
      <outcome_measure>Patients With Anemia (Hemoglobin &lt;10 g/dL) Up to Follow-up Week 24</outcome_measure>
      <outcome_measure>Patients With Undetected Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) (&lt;100 Copies/mL) at Treatment Week Follow-Up 24</outcome_measure>
      <outcome_measure>Relapsers at Follow-Up Visit 24</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00446134</url>
  </study>
  <study rank="331">
    <nct_id>NCT01715415</nct_id>
    <title>A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450/r/ABT-267, ABT-333</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Placebo for ABT-450/r/ABT-267</intervention>
      <intervention type="Drug">Placebo for ABT-333</intervention>
      <intervention type="Drug">Placebo for ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie (prior sponsor, Abbott)</lead_sponsor>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>395</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>M13-098</other_id>
      <other_id>2012-002035-29</other_id>
    </other_ids>
    <first_received>October 25, 2012</first_received>
    <start_date>November 2012</start_date>
    <completion_date>October 2014</completion_date>
    <last_updated>October 23, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>December 23, 2014</firstreceived_results_date>
    <primary_completion_date>November 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Normalization of Alanine Aminotransferase (ALT) at Final Treatment Visit During the Double-Blind Treatment Period</outcome_measure>
      <outcome_measure>Percentage of HCV Genotype 1a-infected Participants With Sustained Virologic Response 12 Weeks After Treatment</outcome_measure>
      <outcome_measure>Percentage of HCV Genotype 1b-infected Participants With Sustained Virologic Response 12 Weeks After Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Virologic Failure During the Double-blind Treatment Period: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Relapse After Treatment: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01715415</url>
  </study>
  <study rank="332">
    <nct_id>NCT00299923</nct_id>
    <title>Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous (Peg)Interferon/ Ribavirin Combination Therapy</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Relapse</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a, Ribavirin, Amantadine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Hamburg</lead_sponsor>
      <collaborator>Universitätsklinikum Hamburg-Eppendorf</collaborator>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML 18545 (TRELA)</other_id>
      <other_id>EudraCT-Nr.: 2005-001207-19</other_id>
    </other_ids>
    <first_received>March 6, 2006</first_received>
    <start_date>November 2005</start_date>
    <last_updated>March 8, 2007</last_updated>
    <last_verified>March 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>- Comparison of the rate of relapse under the combination of standard dose PegIFN alfa-2a, Ribavirin and Amantadine given for 72 vs. 48 weeks.</outcome_measure>
      <outcome_measure>relationship between EVR during the first twelve weeks and SVR</outcome_measure>
      <outcome_measure>virological response to the combination of standard dose defined as reduction of HCV RNA at week 4, 12, 24, 48 and 72 of treatment, separated between HCV-Genotypes.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00299923</url>
  </study>
  <study rank="333">
    <nct_id>NCT00221624</nct_id>
    <title>Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV Infection</condition>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">amantadine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Bordeaux</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>131</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>7929-01</other_id>
      <other_id>2000-030</other_id>
    </other_ids>
    <first_received>September 13, 2005</first_received>
    <start_date>November 2001</start_date>
    <completion_date>April 2004</completion_date>
    <last_updated>June 12, 2007</last_updated>
    <last_verified>June 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PEGARI</acronym>
    <outcome_measures>
      <outcome_measure>sustained virological response, defined as an undetectable HCV RNA level 24 weeks after the end of anti HCV treatment (i.e. overall 72 weeks after randomization)</outcome_measure>
      <outcome_measure>ALT &lt; upper limit of normal values,</outcome_measure>
      <outcome_measure>histological response according to METAVIR score</outcome_measure>
      <outcome_measure>adverse effects</outcome_measure>
      <outcome_measure>quality of life assessed</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00221624</url>
  </study>
  <study rank="334">
    <nct_id>NCT01221298</nct_id>
    <title>A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HCV</condition>
      <condition>Chronic Hepatitis C Infection</condition>
      <condition>Hepatitis C Genotype 1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450</intervention>
      <intervention type="Drug">ABT-072</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Ritonavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie (prior sponsor, Abbott)</lead_sponsor>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M12-267</other_id>
    </other_ids>
    <first_received>October 13, 2010</first_received>
    <start_date>October 2010</start_date>
    <completion_date>April 2012</completion_date>
    <last_updated>December 29, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>December 29, 2014</firstreceived_results_date>
    <primary_completion_date>May 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Suppressed Below the Lower Limit of Quantitation (LLOQ) From Week 4 Through Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt; 1000 International Units Per Milliliter (IU/mL)</outcome_measure>
      <outcome_measure>Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Below the Lower Limit of Quantitation (LLOQ) at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 24 Weeks (SVR24) Post-Treatment</outcome_measure>
      <outcome_measure>Time to Failure to Suppress or Rebound During Treatment</outcome_measure>
      <outcome_measure>Time to Virologic Relapse Through 24 Weeks Post-treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Illinois</state>
      <state>Texas</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01221298</url>
  </study>
  <study rank="335">
    <nct_id>NCT02304159</nct_id>
    <title>Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Cirrhosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">daclatasvir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tarek I. Hassanein, M.D., FACP, FAG, AGAF</lead_sponsor>
      <collaborator>Southern California Research Center</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444284</other_id>
    </other_ids>
    <first_received>November 17, 2014</first_received>
    <start_date>January 2015</start_date>
    <completion_date>November 2017</completion_date>
    <last_updated>November 21, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants with adverse events</outcome_measure>
      <outcome_measure>Number of participants with abnormal safety laboratory tests (ALT and/or Total Bilirubin) that required discontinuing study drugs</outcome_measure>
      <outcome_measure>Number of participants with undetectable HCV virus 12 weeks after stopping study drugs</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02304159</url>
  </study>
  <study rank="336">
    <nct_id>NCT02517528</nct_id>
    <title>ABT-450/Ritonavir/ ABT 267 (ABT-450/r/ABT-267) and ABT -333 Co-administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450/r/ABT-267</intervention>
      <intervention type="Drug">ABT-333</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M14-491</other_id>
    </other_ids>
    <first_received>August 5, 2015</first_received>
    <start_date>July 2015</start_date>
    <completion_date>March 2017</completion_date>
    <last_updated>October 16, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants Achieving Sustained Virologic Response (SVR) 12 Weeks Post-treatment</outcome_measure>
      <outcome_measure>Percentage of participants Achieving Sustained Virologic Response (SVR) 24 Weeks Post-treatment</outcome_measure>
      <outcome_measure>Percentage of participants with on treatment virologic failure</outcome_measure>
      <outcome_measure>Percentage of participants with virologic relapse by post-treatment Week 12</outcome_measure>
      <outcome_measure>Percentage of participants with virologic relapse by post-treatment Week 24</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
      <country>Korea, Republic of</country>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02517528</url>
  </study>
  <study rank="337">
    <nct_id>NCT00039871</nct_id>
    <title>PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis</condition>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Fibrosis</condition>
      <condition>Liver Cirrhosis</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b; SCH 54031)</intervention>
      <intervention type="Drug">REBETOL (ribavirin; SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>2333</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P02370</other_id>
    </other_ids>
    <first_received>June 13, 2002</first_received>
    <start_date>May 2002</start_date>
    <completion_date>September 2007</completion_date>
    <last_updated>March 26, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>September 29, 2008</firstreceived_results_date>
    <primary_completion_date>September 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR) Rate</outcome_measure>
      <outcome_measure>Sustained Virologic Response (SVR) for Participants With Undetectable HCV-RNA at Treatment Week 12</outcome_measure>
      <outcome_measure>Sustained Virologic Response (SVR) for Participants With Detectable But ≥2 Log Drop in HCV-RNA at Treatment Week 12</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00039871</url>
  </study>
  <study rank="338">
    <nct_id>NCT02493855</nct_id>
    <title>Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Hepatitis C (HCV)</condition>
      <condition>Hepatitis C Genotype 1a</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ombitasvir/ABT-450/ritonavir</intervention>
      <intervention type="Drug">dasabuvir</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M14-242</other_id>
      <other_id>2014-001478-32</other_id>
    </other_ids>
    <first_received>July 2, 2015</first_received>
    <start_date>June 2015</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>October 16, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Slope of the second phase decline in plasma HCV RNA levels during treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02493855</url>
  </study>
  <study rank="339">
    <nct_id>NCT00984620</nct_id>
    <title>Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BI 201335</intervention>
      <intervention type="Drug">BI 201335</intervention>
      <intervention type="Drug">Pegylated Interferon-alpha (IFN)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>160</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1220.40</other_id>
      <other_id>2009-012579-90</other_id>
    </other_ids>
    <first_received>September 24, 2009</first_received>
    <start_date>September 2009</start_date>
    <last_updated>August 7, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>July 3, 2015</firstreceived_results_date>
    <primary_completion_date>April 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Virological Response at Week 28 (W28VR)</outcome_measure>
      <outcome_measure>Rapid Virological Response at Week 4 (RVR)</outcome_measure>
      <outcome_measure>Virological Response at Week 24 (W24VR)</outcome_measure>
      <outcome_measure>Virological Response at Week 36 (W36VR)</outcome_measure>
      <outcome_measure>End of Treatment Response (ETR)</outcome_measure>
      <outcome_measure>Sustained Virological Response (SVR24) at 24 Weeks After Completion of All Therapy</outcome_measure>
      <outcome_measure>Viral Load (HCV RNA) at All Visits During Treatment and Follow-up</outcome_measure>
      <outcome_measure>Time to Reach a Plasma HCV RNA Level BLD While on Treatment</outcome_measure>
      <outcome_measure>Laboratory Test Abnormalities and Study Medication Tolerabilities</outcome_measure>
      <outcome_measure>Number of Participants With Clinically Relevant Abnormalities Vital Signs, and Physical Examination</outcome_measure>
      <outcome_measure>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (1)</outcome_measure>
      <outcome_measure>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (2)</outcome_measure>
      <outcome_measure>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (3)</outcome_measure>
      <outcome_measure>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (4)</outcome_measure>
      <outcome_measure>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (5)</outcome_measure>
      <outcome_measure>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (6)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Austria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Romania</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Mississippi</state>
      <state>New York</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00984620</url>
  </study>
  <study rank="340">
    <nct_id>NCT01125189</nct_id>
    <title>Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">peg-interferon alfa-2a</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>558</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-010</other_id>
      <other_id>2010-018295-24</other_id>
    </other_ids>
    <first_received>May 17, 2010</first_received>
    <start_date>July 2010</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>August 13, 2015</firstreceived_results_date>
    <acronym>HEPCAT</acronym>
    <primary_completion_date>April 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Hepatitis C Virus (HCV) Genotype 1 Participants With Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>Percentage of Hepatitis C Virus (HCV) Genotype 1 Participants With Sustained Virologic Response (SVR24)</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), and Who Died</outcome_measure>
      <outcome_measure>Percentage of Hepatitis C Virus (HCV) Genotype 1 Participants With Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Percentage of Hepatitis C Virus (HCV) Genotype 1 Participants With Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>Percentage of Hepatitis C Virus (HCV) Genotype 1 Participants With 12-week Sustained Virologic Response (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Resistant Variants Associated With Virologic Failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Denmark</country>
      <country>Egypt</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Mexico</country>
      <country>Puerto Rico</country>
      <country>Sweden</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01125189</url>
  </study>
  <study rank="341">
    <nct_id>NCT01359644</nct_id>
    <title>Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PSI-7977</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
      <collaborator>Pharmasset</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>350</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-040</other_id>
    </other_ids>
    <first_received>May 23, 2011</first_received>
    <start_date>June 2011</start_date>
    <completion_date>October 2013</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>August 21, 2015</firstreceived_results_date>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Post Treatment Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Post Treatment Week 24 (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough During the Treatment Period</outcome_measure>
      <outcome_measure>Percentage of Participants Who Experienced Viral Relapse During Follow-up Period</outcome_measure>
      <outcome_measure>Change From Baseline in log10 Hepatitis C Virus (HCV) RNA at Follow-up Week 24</outcome_measure>
      <outcome_measure>Number of Participants Who Died and With Serious Adverse Events (SAEs) and Grade 3-4 Adverse Events (AEs), During the Treatment Period Prior to Addition of Rescue Therapy</outcome_measure>
      <outcome_measure>Number of Participants Who Died and With Serious Adverse Events (SAEs), Grade 3-4 Adverse Events (AEs), and Grade 3-4 Abnormalities on Laboratory Test Results During Follow-up Period</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>Oklahoma</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01359644</url>
  </study>
  <study rank="342">
    <nct_id>NCT01704755</nct_id>
    <title>A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
      <condition>Compensated Cirrhosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450/r/ABT-267, ABT-333</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie (prior sponsor, Abbott)</lead_sponsor>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>381</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M13-099</other_id>
      <other_id>2012-003088-23</other_id>
    </other_ids>
    <first_received>September 28, 2012</first_received>
    <start_date>October 2012</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>September 24, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>December 23, 2014</firstreceived_results_date>
    <acronym>TURQUOISE-II</acronym>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment in the 24-week Arm Compared to the 12-week Arm</outcome_measure>
      <outcome_measure>Percentage of Participants in Each Arm With On-treatment Virologic Failure During the Treatment Period</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Relapse After Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01704755</url>
  </study>
  <study rank="343">
    <nct_id>NCT01193361</nct_id>
    <title>Ph IIA Study (SOC +/- NS5B)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-791325</intervention>
      <intervention type="Drug">BMS-791325</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Peg-interferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>39</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI443-012</other_id>
    </other_ids>
    <first_received>August 25, 2010</first_received>
    <start_date>October 2010</start_date>
    <completion_date>November 2012</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HEPCAT</acronym>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety, as measured by the frequency of serious adverse events (SAEs) and discontinuations due to adverse events (AEs)</outcome_measure>
      <outcome_measure>Antiviral activity, as determined by the proportion subjects with eRVR</outcome_measure>
      <outcome_measure>Proportion of subjects with rapid virologic response (RVR), defined as undetectable HCV RNA</outcome_measure>
      <outcome_measure>Proportion of subjects with complete early virologic response (cEVR), defined as undetectable HCV RNA</outcome_measure>
      <outcome_measure>Proportions of subjects with a 12-week SVR (SVR12) and 24-week SVR (SVR24), defined as undetectable HCV RNA at off treatment follow-up</outcome_measure>
      <outcome_measure>Resistant HCV variants associated with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01193361</url>
  </study>
  <study rank="344">
    <nct_id>NCT01258101</nct_id>
    <title>A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>393</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML17087</other_id>
    </other_ids>
    <first_received>November 29, 2010</first_received>
    <start_date>May 2003</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response rate (Hepatitis C Virus-RNA determined by AMPLICOR HCV test)</outcome_measure>
      <outcome_measure>Hepatitis C Virus-RNA determined by AMPLICOR HCV test)</outcome_measure>
      <outcome_measure>Virologic response rates (Hepatitis C Virus-RNA determined by AMPLICOR HCV test)</outcome_measure>
      <outcome_measure>Safety: incidence of adverse events</outcome_measure>
      <outcome_measure>Hemoglobin levels at end of treatment</outcome_measure>
      <outcome_measure>Health Survey (Short Form 36)</outcome_measure>
      <outcome_measure>Fatigue Severity Scale</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01258101</url>
  </study>
  <study rank="345">
    <nct_id>NCT00265395</nct_id>
    <title>Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®)</intervention>
      <intervention type="Drug">Combination of pegylated interferon alfa-2b and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1428</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P03685</other_id>
      <other_id>SUCCESS</other_id>
    </other_ids>
    <first_received>December 13, 2005</first_received>
    <start_date>December 2004</start_date>
    <completion_date>May 2008</completion_date>
    <last_updated>October 7, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>May 15, 2009</firstreceived_results_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response, Defined as a Plasma HCV-RNA (Hepatitis C Ribonucleic Acid) Level Below the LLQ (Lower Level of Quantitation) at 24 Weeks Post-treatment.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00265395</url>
  </study>
  <study rank="346">
    <nct_id>NCT01402583</nct_id>
    <title>Menopause is a Critical Factor in Determining Failure of Antiviral Therapy in Women With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG IFN/Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Prof. Facchinetti Fabio</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
      <collaborator>University of Modena and Reggio Emilia</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>RSO-321</other_id>
    </other_ids>
    <first_received>July 25, 2011</first_received>
    <start_date>July 2011</start_date>
    <completion_date>September 2011</completion_date>
    <last_updated>October 20, 2011</last_updated>
    <last_verified>October 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>MEN_EPID</acronym>
    <primary_completion_date>August 2011</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01402583</url>
  </study>
  <study rank="347">
    <nct_id>NCT01833845</nct_id>
    <title>Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Hydroxychloroquine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>BioLineRx, Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>4</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>BL-8020.01</other_id>
    </other_ids>
    <first_received>April 15, 2013</first_received>
    <start_date>April 2013</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>August 27, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>July 30, 2014</firstreceived_results_date>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy</outcome_measure>
      <outcome_measure>Safety: Number of Participants With Adverse Events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01833845</url>
  </study>
  <study rank="348">
    <nct_id>NCT02583685</nct_id>
    <title>Switching Regimen in Treating Cirrhotic HCV GT1b Subjects</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PR4 + LDV/SOF + ASV 4 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + SMV 4 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + ASV 6 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + SMV 6 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + ASV 8 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + SMV 8 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + ASV 12 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + SMV 12 wk</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Humanity &amp; Healthy GI and Liver Centre</lead_sponsor>
      <collaborator>Beijing 302 Hospital</collaborator>
      <collaborator>Nanfang Hospital of Southern Medical University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>160</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>H&amp;H_SWITCH-1</other_id>
    </other_ids>
    <first_received>October 12, 2015</first_received>
    <start_date>May 2015</start_date>
    <completion_date>September 2016</completion_date>
    <last_updated>October 20, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>SWITCH-1</acronym>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks (SVR12) after discontinuation of therapy</outcome_measure>
      <outcome_measure>Proportion of participants with adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with unquantifiable HCV viral load at specified time points during and after treatment</outcome_measure>
      <outcome_measure>Treatment adherence</outcome_measure>
      <outcome_measure>Change in health related quality of life evaluated with questionnaires</outcome_measure>
      <outcome_measure>Change in mental health evaluated with questionnaires</outcome_measure>
      <outcome_measure>Liver disease progression</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02583685</url>
  </study>
  <study rank="349">
    <nct_id>NCT01356160</nct_id>
    <title>GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GS-5885</intervention>
      <intervention type="Drug">GS-9451</intervention>
      <intervention type="Biological">peginterferon alfa-2a</intervention>
      <intervention type="Drug">ribavirin tablet</intervention>
      <intervention type="Drug">GS-9451 Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>351</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-256-0148</other_id>
    </other_ids>
    <first_received>May 2, 2011</first_received>
    <start_date>July 2011</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>January 2, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate the antiviral efficacy of response guided therapy.</outcome_measure>
      <outcome_measure>To evaluate the safety and tolerability of each regimen.</outcome_measure>
      <outcome_measure>To characterize viral dynamics of GS-5885 and GS-9451 when administered with PEG and RBV.</outcome_measure>
      <outcome_measure>To characterize the viral resistance to GS-5885 and GS-9451 when administered in combination with PEG and RBV.</outcome_measure>
      <outcome_measure>To characterize steady state pharmacokinetics of GS-5885 and GS-9451 when administered with PEG and RBV.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01356160</url>
  </study>
  <study rank="350">
    <nct_id>NCT01606800</nct_id>
    <title>Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG-IFN alfa-2b</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>8908B-059</other_id>
    </other_ids>
    <first_received>May 24, 2012</first_received>
    <start_date>January 2013</start_date>
    <completion_date>January 2015</completion_date>
    <last_updated>November 4, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>START 4</acronym>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Achieving Sustained Virologic Response (SVR)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01606800</url>
  </study>
  <study rank="351">
    <nct_id>NCT00087646</nct_id>
    <title>REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>948</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>MV17150</other_id>
    </other_ids>
    <first_received>July 12, 2004</first_received>
    <start_date>September 2003</start_date>
    <completion_date>May 2008</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response rate</outcome_measure>
      <outcome_measure>Percentage of patients with &gt;=2log drop in HCV-RNA</outcome_measure>
      <outcome_measure>Percentage of patients with undetectable HCV-RNA</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>France</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>Italy</country>
      <country>Portugal</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>Switzerland</country>
      <country>Turkey</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Iowa</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Vermont</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00087646</url>
  </study>
  <study rank="352">
    <nct_id>NCT01371578</nct_id>
    <title>Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GS-5885 tablet</intervention>
      <intervention type="Drug">GS-9451 tablet</intervention>
      <intervention type="Biological">peginterferon alfa-2a</intervention>
      <intervention type="Drug">ribavirin tablet</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>163</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-256-0124</other_id>
    </other_ids>
    <first_received>June 9, 2011</first_received>
    <start_date>July 2011</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>January 14, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Sustained Virologic Response(SVR) of each regimen administered for 24 to 48 weeks</outcome_measure>
      <outcome_measure>Safety and Tolerability</outcome_measure>
      <outcome_measure>Characterize the viral dynamics of GS-5885, GS-9451 when administered in combination with PEG and RBV</outcome_measure>
      <outcome_measure>Characterize the pharmacokinetics of GS-5885 and GS-9451 when administered in combination with PEG and RBV</outcome_measure>
      <outcome_measure>Emergence of Viral Resistance</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Mississippi</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01371578</url>
  </study>
  <study rank="353">
    <nct_id>NCT02220868</nct_id>
    <title>Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
      <condition>HIV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir, Ribavirin, and Stribild</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Saint Michael's Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>IN-US-334-1527</other_id>
    </other_ids>
    <first_received>August 18, 2014</first_received>
    <start_date>July 2014</start_date>
    <completion_date>August 2015</completion_date>
    <last_updated>August 19, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>• SVR,12 defined as undetectable HCV RNA levels for 12 weeks after the completion of therapy</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New Jersey</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02220868</url>
  </study>
  <study rank="354">
    <nct_id>NCT00127777</nct_id>
    <title>Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Amantadine sulphate (in addition to standard treatment)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Saarland</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>700</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML17002</other_id>
    </other_ids>
    <first_received>August 4, 2005</first_received>
    <start_date>July 2002</start_date>
    <completion_date>December 2006</completion_date>
    <last_updated>August 24, 2005</last_updated>
    <last_verified>August 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Proof that peginterferon alfa-2a, ribavirin and amantadine sulphate over a period of 50 weeks improves the permanent virological efficacy by more than 10% compared to peginterferon alfa-2a and ribavirin</outcome_measure>
      <outcome_measure>Verification of the initial virological efficacy up to week 12, defined as negative HCV-RNA test results by means of quantitative proof methods, e.g. Roche AmplicorTM HCV Monitor v.2.0 (sensitivity &lt;600 IE/ml)</outcome_measure>
      <outcome_measure>Biochemical efficacy, defined by the serum GPT values 24 weeks after the end of the therapy</outcome_measure>
      <outcome_measure>Virological efficacy, measured on the basis of the HCV-RNA values at the end of the therapy</outcome_measure>
      <outcome_measure>Biochemical efficacy defined by the serum GPT values at the end of the therapy</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00127777</url>
  </study>
  <study rank="355">
    <nct_id>NCT00704964</nct_id>
    <title>Impact of Patient Support by the Medical Staff on Adherence to Therapy With PegIntron Plus Rebetol (Study P04413)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron</intervention>
      <intervention type="Drug">Rebetol</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>746</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04413</other_id>
    </other_ids>
    <first_received>June 23, 2008</first_received>
    <start_date>May 2005</start_date>
    <completion_date>October 2009</completion_date>
    <last_updated>October 5, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>March 24, 2011</firstreceived_results_date>
    <acronym>@dhere</acronym>
    <primary_completion_date>October 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Biometrical Adherence to Therapy</outcome_measure>
      <outcome_measure>Number of Participants With Adherence to Therapy According to Physician Approximation</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00704964</url>
  </study>
  <study rank="356">
    <nct_id>NCT02442284</nct_id>
    <title>A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Cirrhosis</condition>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ombitasvir</intervention>
      <intervention type="Drug">Paritaprevir</intervention>
      <intervention type="Drug">Ritonavir</intervention>
      <intervention type="Drug">Dasabuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M14-251</other_id>
    </other_ids>
    <first_received>May 11, 2015</first_received>
    <start_date>May 2015</start_date>
    <completion_date>November 2016</completion_date>
    <last_updated>November 23, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants with Sustained Virologic Response 12 weeks post-treatment</outcome_measure>
      <outcome_measure>Percentage of participants with virologic failure during treatment</outcome_measure>
      <outcome_measure>Percentage of participants with virologic relapse post-treatment</outcome_measure>
      <outcome_measure>Percentage of participants with Sustained Virologic Response 12 weeks post-treatment among participants with ongoing psychiatric disorders</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Iowa</state>
      <state>Massachusetts</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02442284</url>
  </study>
  <study rank="357">
    <nct_id>NCT02068222</nct_id>
    <title>A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450/r</intervention>
      <intervention type="Drug">ABT-530</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M14-213</other_id>
    </other_ids>
    <first_received>February 19, 2014</first_received>
    <start_date>April 2014</start_date>
    <completion_date>March 2015</completion_date>
    <last_updated>March 13, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The percentage of subjects who achieve 12-week sustained virologic response (SVR12) in each treatment arm</outcome_measure>
      <outcome_measure>The percentage of subjects who achieve 24-week sustained virologic response (SVR24) in each treatment arm</outcome_measure>
      <outcome_measure>The percentage of subjects with virologic failure during treatment</outcome_measure>
      <outcome_measure>The percentage of subjects with Post-Treatment relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Texas</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02068222</url>
  </study>
  <study rank="358">
    <nct_id>NCT00375661</nct_id>
    <title>Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">interferon-alfa-2b and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kyoto University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>O2006-415</other_id>
    </other_ids>
    <first_received>September 12, 2006</first_received>
    <start_date>September 2006</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>September 1, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Incidence of adverse effect of interferon</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00375661</url>
  </study>
  <study rank="359">
    <nct_id>NCT01852604</nct_id>
    <title>Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Samatasvir</intervention>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">TMC647055</intervention>
      <intervention type="Drug">Ritonavir (RTV)</intervention>
      <intervention type="Biological">Pegylated interferon (Peg-IFN)</intervention>
      <intervention type="Other">Samatasvir matching placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
      <collaborator>Janssen Research &amp; Development, LLC</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>143</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>1894-005</other_id>
      <other_id>IDX-06A-005</other_id>
    </other_ids>
    <first_received>May 6, 2013</first_received>
    <start_date>March 2013</start_date>
    <completion_date>April 2015</completion_date>
    <last_updated>April 22, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants who experienced an adverse event (AE)</outcome_measure>
      <outcome_measure>Percentage of participants who experienced a serious adverse event (SAE)</outcome_measure>
      <outcome_measure>Percentage of participants who experienced a Grade 1-4 laboratory abnormality</outcome_measure>
      <outcome_measure>Percentage of participants who experienced sustained virologic response 4 weeks after the end of treatment (SVR4)</outcome_measure>
      <outcome_measure>Percentage of participants who experienced rapid virologic response (RVR)</outcome_measure>
      <outcome_measure>Percentage of participants who experienced early virologic response (EVR)</outcome_measure>
      <outcome_measure>Percentage of participants who experienced sustained virologic response 8 weeks after the end of treatment (SVR8)</outcome_measure>
      <outcome_measure>Percentage of participants who experienced sustained virologic response 12 weeks after the end of treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of participants who experienced sustained virologic response 24 weeks after the end of treatment (SVR24)</outcome_measure>
      <outcome_measure>Pharmacokinetic Parameter:Area under the concentration-time curve from time zero to t</outcome_measure>
      <outcome_measure>Pharmacokinetic Parameter: Maximum observed drug concentration (Cmax)</outcome_measure>
      <outcome_measure>Pharmacokinetic Parameter: Trough drug concentration (Ctrough)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01852604</url>
  </study>
  <study rank="360">
    <nct_id>NCT00835146</nct_id>
    <title>Ribavirin 200 mg Tablets Under Fasting Conditions</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Healthy</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin 200 mg tablets</intervention>
      <intervention type="Drug">COPEGUS™</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Teva Pharmaceuticals USA</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>28</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Bio-equivalence Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>B036552</other_id>
    </other_ids>
    <first_received>January 30, 2009</first_received>
    <start_date>September 2003</start_date>
    <completion_date>October 2003</completion_date>
    <last_updated>September 1, 2009</last_updated>
    <last_verified>September 2009</last_verified>
    <firstreceived_results_date>July 2, 2009</firstreceived_results_date>
    <primary_completion_date>October 2003</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Cmax (Maximum Observed Concentration of Drug Substance in Plasma)</outcome_measure>
      <outcome_measure>AUC0-72 (Area Under the Concentration-time Curve From Time Zero to Time of 72 Hours)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00835146</url>
  </study>
  <study rank="361">
    <nct_id>NCT00724464</nct_id>
    <title>Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-naïve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b, pegylated interferon alfa-2b)</intervention>
      <intervention type="Drug">Rebetol (ribavirin)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>332</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05209</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>December 2007</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>October 16, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>October 4, 2011</firstreceived_results_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up</outcome_measure>
      <outcome_measure>Number of Participants Who Demonstrated Virological Relapse as Assessed at 24-week Post-treatment Follow-up</outcome_measure>
      <outcome_measure>Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up by Subgroups Based on HCV Genotype at Baseline</outcome_measure>
      <outcome_measure>Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up by Subgroups Based on Liver Fibrosis Stage at Baseline</outcome_measure>
      <outcome_measure>Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up by Subgroups Based on HCV-RNA Viral Load at Baseline</outcome_measure>
      <outcome_measure>Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up by Subgroups Based on Alanine Aminotransferase (ALT) Levels at Baseline</outcome_measure>
      <outcome_measure>Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up by Subgroups Based on Study Treatment Dosage Modification</outcome_measure>
      <outcome_measure>Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up by Subgroups Based on Achievement of Rapid Virological Response</outcome_measure>
      <outcome_measure>Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up by Subgroups Based on Compliance With the 80/80/80 Rule</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00724464</url>
  </study>
  <study rank="362">
    <nct_id>NCT00835536</nct_id>
    <title>Ribavirin 200 mg Tablets Under Non-Fasting Conditions</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Healthy</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin 200 mg tablets</intervention>
      <intervention type="Drug">COPEGUS™ 200 mg Tablets</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Teva Pharmaceuticals USA</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>27</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Bio-equivalence Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>B036553</other_id>
    </other_ids>
    <first_received>January 30, 2009</first_received>
    <start_date>September 2003</start_date>
    <completion_date>October 2003</completion_date>
    <last_updated>September 1, 2009</last_updated>
    <last_verified>September 2009</last_verified>
    <firstreceived_results_date>July 2, 2009</firstreceived_results_date>
    <primary_completion_date>October 2003</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Cmax (Maximum Observed Concentration of Drug Substance in Plasma)</outcome_measure>
      <outcome_measure>AUC0-72 (Area Under the Concentration-time Curve From Time Zero to Time of 72 Hours)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00835536</url>
  </study>
  <study rank="363">
    <nct_id>NCT00996476</nct_id>
    <title>A Study to Assess the Effectiveness, Safety, and Pharmacokinetics of TMC435 in Combination With Peginterferon Alfa-2a and Ribavirin in Hepatitis-C Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">PegIFNα-2a</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Pharmaceutical K.K.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>92</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR016402</other_id>
      <other_id>TMC435-TiDP16-C215</other_id>
    </other_ids>
    <first_received>October 15, 2009</first_received>
    <start_date>July 2009</start_date>
    <completion_date>January 2011</completion_date>
    <last_updated>March 21, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>October 17, 2013</firstreceived_results_date>
    <acronym>DRAGON</acronym>
    <primary_completion_date>January 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels From Baseline to Week 4</outcome_measure>
      <outcome_measure>The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels During the Study</outcome_measure>
      <outcome_measure>The Percentage of Participants With a Decrease of Greater Than or Equal to 2 log10 IU/mL From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Through the Post-treatment Follow-up Period</outcome_measure>
      <outcome_measure>The Percentage of Participants With Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Undetectable or Below the Limit of Quantification (&lt;1.2 log10 IU/mL Detectable) During Treatment and During Post Treatment Follow-up</outcome_measure>
      <outcome_measure>The Number of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>The Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Actual Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values up to Week 24 in the Post-treatment Follow-up Period</outcome_measure>
      <outcome_measure>The Number of Participants With Alanine Aminotransaminase (ALT) Values Within the Normal Range at the End-of-treatment (EOT)</outcome_measure>
      <outcome_measure>The Percentage of Participants With Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Predose Plasma Concentrations (C0h) of TMC435 (Sparse Blood Sampling)</outcome_measure>
      <outcome_measure>Predose Plasma Concentrations (C0h) of TMC435 (Intensive Blood Sampling)</outcome_measure>
      <outcome_measure>The Area Under the Plasma Concentration-time Curve From the Time of Administration up to 24 Hours After Dosing (AUC24) for TMC435</outcome_measure>
      <outcome_measure>Time to Reach the Maximum Plasma Concentration (Tmax) of TMC435</outcome_measure>
      <outcome_measure>The Number of Participants Who Met Virologic Stopping/Continuation Rules and Completed All Study Medications</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00996476</url>
  </study>
  <study rank="364">
    <nct_id>NCT01025765</nct_id>
    <title>The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pioglitazone</intervention>
      <intervention type="Drug">Acarbose</intervention>
      <intervention type="Drug">Metformin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>200905056M</other_id>
    </other_ids>
    <first_received>December 2, 2009</first_received>
    <start_date>November 2009</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>November 23, 2012</last_updated>
    <last_verified>November 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response</outcome_measure>
      <outcome_measure>serum ALT normalization, and histologic improvement</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01025765</url>
  </study>
  <study rank="365">
    <nct_id>NCT00665353</nct_id>
    <title>Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>HIV-1 and Hepatitis C Co-Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pioglitazone</intervention>
      <intervention type="Drug">peginterferon</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AIDS Clinical Trials Group</lead_sponsor>
      <collaborator>National Institute of Allergy and Infectious Diseases (NIAID)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>19</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ACTG A5239</other_id>
      <other_id>1U01AI068636</other_id>
    </other_ids>
    <first_received>April 22, 2008</first_received>
    <start_date>March 2009</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>May 14, 2013</last_updated>
    <last_verified>May 2013</last_verified>
    <firstreceived_results_date>June 7, 2012</firstreceived_results_date>
    <primary_completion_date>May 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Proportion of All Subjects With HCV Viral Load &lt; 60 IU/mL at Week 24 of Step 2.</outcome_measure>
      <outcome_measure>Safety and Tolerability</outcome_measure>
      <outcome_measure>The Proportion of All Subjects With HCV Viral Load &lt; 60 IU/mL at Week 72of Step 2.</outcome_measure>
      <outcome_measure>Absolute Change From Entry to Week 24 of Step 1 in AST and ALT.</outcome_measure>
      <outcome_measure>Absolute Change From Entry to Week 24 of Step 1 in Homeostasis Model of Assessment - Insulin Resistance (HOMA-IR)</outcome_measure>
      <outcome_measure>Absolute Change From Entry to Week 24 of Step 1 in Fasting Total Cholesterol and Triglycerides.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Illinois</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>Ohio</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00665353</url>
  </study>
  <study rank="366">
    <nct_id>NCT00437476</nct_id>
    <title>Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LPV/r</intervention>
      <intervention type="Drug">Nucleoside Reverse Transcriptase Inhibitors</intervention>
      <intervention type="Drug">PEG-IFNa 2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>IRCCS San Raffaele</lead_sponsor>
      <collaborator>Abbott</collaborator>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Kamon 1</other_id>
    </other_ids>
    <first_received>February 20, 2007</first_received>
    <start_date>February 2007</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>February 5, 2009</last_updated>
    <last_verified>February 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To assess if the combination of LPV/r monotherapy in association with</outcome_measure>
      <outcome_measure>anti-HCV therapy (PEG IFN alfa 2a + Ribavirin) does not match with additional</outcome_measure>
      <outcome_measure>toxicity induced by the combination of optimized HAART (Lopinavir/ritonavir + selected Nucs) and PEG-IFN alfa 2a+Ribavirin</outcome_measure>
      <outcome_measure>in patients naïve for HIV and HCV</outcome_measure>
      <outcome_measure>To assess if LPV/r monotherapy during the HCV treatment</outcome_measure>
      <outcome_measure>is associated with anti HIV efficacy and a better patient satisfaction</outcome_measure>
      <outcome_measure>vs optimized HAART.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00437476</url>
  </study>
  <study rank="367">
    <nct_id>NCT02219490</nct_id>
    <title>A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus (HCV) Infection Genotype 1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450/r/ABT-267</intervention>
      <intervention type="Drug">ABT-333</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1650</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M14-423</other_id>
      <other_id>2014-001022-14</other_id>
    </other_ids>
    <first_received>August 15, 2014</first_received>
    <start_date>November 2014</start_date>
    <completion_date>June 2021</completion_date>
    <last_updated>October 7, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>TOPAZ-I</acronym>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Incidence of pre-defined clinical outcomes observed during the study</outcome_measure>
      <outcome_measure>Change in fibrosis</outcome_measure>
      <outcome_measure>Percentage of subjects with sustained virologic response 12 weeks post-treatment (SVR12)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
      <country>Australia</country>
      <country>Algeria</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Bulgaria</country>
      <country>Denmark</country>
      <country>Finland</country>
      <country>France</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>Ireland</country>
      <country>Israel</country>
      <country>Italy</country>
      <country>Netherlands</country>
      <country>Norway</country>
      <country>Poland</country>
      <country>Portugal</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Saudi Arabia</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>Switzerland</country>
      <country>Turkey</country>
      <country>United Arab Emirates</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02219490</url>
  </study>
  <study rank="368">
    <nct_id>NCT02167945</nct_id>
    <title>A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus (HCV) Infection Genotype 1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450/r/ABT-267</intervention>
      <intervention type="Drug">ABT-333</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M14-222</other_id>
    </other_ids>
    <first_received>June 18, 2014</first_received>
    <start_date>June 2014</start_date>
    <completion_date>March 2020</completion_date>
    <last_updated>October 22, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>(TOPAZ II)</acronym>
    <primary_completion_date>July 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Incidence of pre-defined clinical outcomes observed during the study</outcome_measure>
      <outcome_measure>Percentage of subjects with sustained virologic response 12 weeks post-treatment (SVR12)</outcome_measure>
      <outcome_measure>Change in fatigue</outcome_measure>
      <outcome_measure>Change in Quality of Life</outcome_measure>
      <outcome_measure>Evaluation of adherence to study drug regimens</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Washington</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02167945</url>
  </study>
  <study rank="369">
    <nct_id>NCT01628692</nct_id>
    <title>Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
      <collaborator>Janssen Research &amp; Development, LLC</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>230</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-062</other_id>
      <other_id>2012-000070-28</other_id>
    </other_ids>
    <first_received>June 25, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>November 2013</completion_date>
    <last_updated>October 29, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>August 13, 2015</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response Rate at Post-treatment Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Virologic Response (RVR) at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With End of Treatment Response (EOTR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Week 12 (SVR12) by rs12979860 Single Nucleotide Polymorphisms in the IL-28B Gene Categories</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs) and Discontinuations Due to Adverse Events (AEs) and Who Died</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Argentina</country>
      <country>France</country>
      <country>Germany</country>
      <country>Hungary</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01628692</url>
  </study>
  <study rank="370">
    <nct_id>NCT00703118</nct_id>
    <title>A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Peg-IFN-alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec BVBA</lead_sponsor>
      <collaborator>Tibotec Pharmaceutical Limited</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>663</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR014842</other_id>
      <other_id>VX-950-TIDP24-C216</other_id>
    </other_ids>
    <first_received>June 19, 2008</first_received>
    <start_date>October 2008</start_date>
    <completion_date>July 2010</completion_date>
    <last_updated>December 5, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>July 18, 2011</firstreceived_results_date>
    <primary_completion_date>July 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Sustained Virologic Response (SVR) 24 Weeks After the Last Planned Dose of Study Medication - SVR24 Planned</outcome_measure>
      <outcome_measure>Number of Participants Acheiving Rapid Virologic Response (RVR) at Week 4</outcome_measure>
      <outcome_measure>Number of Participants Acheiving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Week 48 (End of Treatment)</outcome_measure>
      <outcome_measure>Number of Participants With Sustained Virologic Response (SVR) 12 Weeks After the Last Planned Dose of Study Medication - SVR12 Planned</outcome_measure>
      <outcome_measure>Number of Participants Who Meet the Telaprevir Stopping Rule at Week 4, Week 6, or Week 8</outcome_measure>
      <outcome_measure>Number of Participants Who Have Viral Relapse During Entire Follow-up Period (up to Week 72)</outcome_measure>
      <outcome_measure>Change From Baseline in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 4</outcome_measure>
      <outcome_measure>Number of Participants Acheiving Extended Rapid Virologic Response at Week 4 and Week 12</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>France</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Netherlands</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>Switzerland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00703118</url>
  </study>
  <study rank="371">
    <nct_id>NCT01057667</nct_id>
    <title>A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">RO5024048</intervention>
      <intervention type="Drug">Ribavirin [Copegus]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>168</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV22621</other_id>
    </other_ids>
    <first_received>January 26, 2010</first_received>
    <start_date>February 2010</start_date>
    <completion_date>April 2012</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (undetectable HCV DNA as measured by Roche COBAS TaqMan HCV test)</outcome_measure>
      <outcome_measure>Virologic response over time</outcome_measure>
      <outcome_measure>Pharmacokinetics of RO4995855 when RO5024048 is administered with peginterferon alfa-2a and ribavirin</outcome_measure>
      <outcome_measure>Resistance profile of RO5024048</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Kansas</state>
      <state>Missouri</state>
      <state>New Hampshire</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01057667</url>
  </study>
  <study rank="372">
    <nct_id>NCT01628094</nct_id>
    <title>ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">RO5024048</intervention>
      <intervention type="Drug">RO5190591</intervention>
      <intervention type="Drug">RO5466731</intervention>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
      <intervention type="Drug">ritonavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>110</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NP28266</other_id>
      <other_id>2012-000638-21</other_id>
    </other_ids>
    <first_received>June 22, 2012</first_received>
    <start_date>June 2012</start_date>
    <completion_date>November 2013</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (defined as undetectable serum HCV RNA) 12 weeks after end of treatment</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
      <outcome_measure>Antiviral activity: Change in serum HCV RNA levels</outcome_measure>
      <outcome_measure>Pharmacokinetics in coadministration: Area under the concentration-time curve (AUC)</outcome_measure>
      <outcome_measure>HCV drug resistance</outcome_measure>
      <outcome_measure>Quality of life: Short-Form 36v2/Brief Fatigue Inventory questionnaires</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>Germany</country>
      <country>New Zealand</country>
      <country>Poland</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Kansas</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01628094</url>
  </study>
  <study rank="373">
    <nct_id>NCT00881582</nct_id>
    <title>Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Renal Transplant</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa-2a plus ribavarin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>King Abdulaziz Medical City</lead_sponsor>
      <collaborator>Riyadh Military Hospital</collaborator>
      <collaborator>King Faisal Specialist Hospital &amp; Research Center</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>RMH-01-09</other_id>
    </other_ids>
    <first_received>April 14, 2009</first_received>
    <start_date>January 2009</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>September 13, 2012</last_updated>
    <last_verified>September 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response</outcome_measure>
      <outcome_measure>Adverse event rate and number of cases of graft rejection</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Saudi Arabia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00881582</url>
  </study>
  <study rank="374">
    <nct_id>NCT01257204</nct_id>
    <title>Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>196</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-031</other_id>
      <other_id>2010-022408-28</other_id>
    </other_ids>
    <first_received>December 1, 2010</first_received>
    <start_date>December 2010</start_date>
    <completion_date>September 2012</completion_date>
    <last_updated>November 10, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>August 5, 2015</firstreceived_results_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response at Follow-up Week 24 (SVR24) for Hepatitis C Virus (HCV) Genotype 2</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response at Follow-up Week 24 (SVR24) for Hepatitis C Virus (HCV) Genotype 3</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Rapid Virologic Response (RVR) at Week 4 for Hepatitis C Virus (HCV) Genotype 2</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Rapid Virologic Response (RVR) at Week 4 for Hepatitis C Virus (HCV) Genotype 3</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Complete Early Virologic Response (cEVR) at Week 12 for Hepatitis C Virus (HCV) Genotype 2</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Complete Early Virologic Response (cEVR) at Week 12 for Hepatitis C Virus (HCV) Genotype 3</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response at Follow-up Week 12 (SVR12) for Hepatitis C Virus (HCV) Genotype 2</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response at Follow-up Week 12 (SVR12) for Hepatitis C Virus (HCV) Genotype 3</outcome_measure>
      <outcome_measure>Number of Participants With Virologic Failure for Hepatitis C Virus (HCV) Genotype 2</outcome_measure>
      <outcome_measure>Number of Participants With Virologic Failure for Hepatitis C Virus (HCV) Genotype 3</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations Due to AEs, and Treatment-related AEs and Who Died During Treatment Period</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Who Died During Follow-up Period</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Denmark</country>
      <country>France</country>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Maryland</state>
      <state>Oklahoma</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01257204</url>
  </study>
  <study rank="375">
    <nct_id>NCT01749150</nct_id>
    <title>A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">danoprevir + ritonavir</intervention>
      <intervention type="Drug">danoprevir + ritonavir</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>61</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>YV28218</other_id>
    </other_ids>
    <first_received>December 11, 2012</first_received>
    <start_date>April 2013</start_date>
    <completion_date>February 2015</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
      <outcome_measure>Pharmacokinetics: Area under the concentration-time curve (AUC) for danoprevir/ritonavir</outcome_measure>
      <outcome_measure>Antiviral activity: Change in HCV RNA levels, measured using Roche COBAS TaqMan HCV Test v2.0 for High Pure System</outcome_measure>
      <outcome_measure>Antiviral activity: Proportion of patients with unquantifiable/undetectable HCV RNA during the study</outcome_measure>
      <outcome_measure>Incidence of viral resistance to danoprevir</outcome_measure>
      <outcome_measure>Rapid virological response (RVR): Proportion of patients with undetectable HCV RNA at Week 4</outcome_measure>
      <outcome_measure>Complete early virological response (cEVR): Proportion of patients with undetectable HCV RNA at Week 12</outcome_measure>
      <outcome_measure>Sustained virological response 12 weeks after end of treatment (SVR-12), defined as unquantifiable HCV RNA 8-20 weeks after the last day of study drug administration</outcome_measure>
      <outcome_measure>Sustained virological response 24 weeks after end of treatment (SVR-24), defined as unquantifiable HCV RNA &gt; 20 weeks after the last day of study drug administration</outcome_measure>
      <outcome_measure>SVR measured as HCV RNA log10 IU/mL change from baseline to Week 12</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Korea, Republic of</country>
      <country>Taiwan</country>
      <country>Thailand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01749150</url>
  </study>
  <study rank="376">
    <nct_id>NCT00202839</nct_id>
    <title>Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b; SCH 54031)</intervention>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b; SCH 54031)</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>160</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04144</other_id>
    </other_ids>
    <first_received>September 12, 2005</first_received>
    <start_date>March 2005</start_date>
    <completion_date>July 2008</completion_date>
    <last_updated>April 7, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>August 28, 2009</firstreceived_results_date>
    <primary_completion_date>July 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants Who Achieved a Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Virologic Response 48 Weeks After Randomization.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00202839</url>
  </study>
  <study rank="377">
    <nct_id>NCT00104052</nct_id>
    <title>Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">peginterferon alfa-2b (PEG2b) (SCH 54031)</intervention>
      <intervention type="Drug">ribavirin (SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>107</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P02538: Part 1</other_id>
    </other_ids>
    <first_received>February 22, 2005</first_received>
    <start_date>February 2005</start_date>
    <completion_date>November 2007</completion_date>
    <last_updated>March 26, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>November 14, 2008</firstreceived_results_date>
    <primary_completion_date>November 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With a Sustained Virologic Response (SVR) at 24 Weeks Post-treatment</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00104052</url>
  </study>
  <study rank="378">
    <nct_id>NCT01391117</nct_id>
    <title>TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">placebo.</intervention>
      <intervention type="Drug">placebo.</intervention>
      <intervention type="Drug">TMC649128.</intervention>
      <intervention type="Drug">placebo.</intervention>
      <intervention type="Drug">placebo</intervention>
      <intervention type="Drug">TMC649128</intervention>
      <intervention type="Drug">TMC649128.</intervention>
      <intervention type="Drug">TMC649128</intervention>
      <intervention type="Drug">TMC649128.</intervention>
      <intervention type="Drug">placebo.</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec BVBA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>14</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017992</other_id>
      <other_id>TMC649128HPC1002</other_id>
    </other_ids>
    <first_received>June 13, 2011</first_received>
    <start_date>June 2011</start_date>
    <completion_date>November 2011</completion_date>
    <last_updated>October 25, 2012</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in the steady-state plasma concentrations of TMC649128.</outcome_measure>
      <outcome_measure>Change in the steady-state plasma concentrations of TMC649128 following co-administration with pegylated interferon + ribavirin.</outcome_measure>
      <outcome_measure>Viral load decreases and/or changes of viral load from baseline (HCV RNA copies/ml) (PK/PD).</outcome_measure>
      <outcome_measure>Number of participants with adverse events as a measure of safety and tolerability - TMC649128 as monotherapy and when co-administered with pegylated interferon + ribavirin.</outcome_measure>
      <outcome_measure>Antiviral activity (HCV RNA levels) of TMC649128 as monotherapy and when co-administered with pegylated interferon + ribavirin.</outcome_measure>
      <outcome_measure>Antiviral activity (viral breakthrough) of TMC649128 as monotherapy and when co-administered with pegylated interferon + ribavirin.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
      <country>Poland</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01391117</url>
  </study>
  <study rank="379">
    <nct_id>NCT00543244</nct_id>
    <title>Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>National Science Council, Taiwan</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>200709053R</other_id>
    </other_ids>
    <first_received>October 10, 2007</first_received>
    <start_date>January 2006</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>November 20, 2008</last_updated>
    <last_verified>February 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (SVR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Israel</country>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00543244</url>
  </study>
  <study rank="380">
    <nct_id>NCT00882193</nct_id>
    <title>Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Genotype 1</condition>
      <condition>Relapse</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Betaine</intervention>
      <intervention type="Drug">Peginterferon alpha 2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Nebraska</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>133-09</other_id>
    </other_ids>
    <first_received>April 15, 2009</first_received>
    <start_date>May 2009</start_date>
    <completion_date>May 2011</completion_date>
    <last_updated>August 8, 2011</last_updated>
    <last_verified>August 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To examine the safety and efficacy of betaine when combined with standard antiviral therapy in previously teated subjects with chronic hepatitis c genotype 1</outcome_measure>
      <outcome_measure>The effect on interferon gene signaling in peripheral blood mononuclear cells in the first 12 weeks of treatment and 6 months following the end of therapy.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Nebraska</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00882193</url>
  </study>
  <study rank="381">
    <nct_id>NCT00207363</nct_id>
    <title>Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin, Peg interferon alfa 2b</intervention>
      <intervention type="Drug">induction therapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Brooke Army Medical Center</lead_sponsor>
      <collaborator>T.R.U.E. Research Foundation</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>610</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>C2002.076</other_id>
    </other_ids>
    <first_received>September 14, 2005</first_received>
    <start_date>February 2002</start_date>
    <completion_date>January 2010</completion_date>
    <last_updated>February 13, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary objective of this study is to compare the efficacy of Induction PEG-Interferon alfa-2b (PEG-Intron) and Ribavirin (Rebetol) to standard PEG-Interferon alfa-2b (PEG-Intron) and Ribavirin (Rebetol) in patients with chronic hepatitis C.</outcome_measure>
      <outcome_measure>The loss of HCV-RNA at 6 months of follow up. If the HCV-RNA has not decreased by one log at treatment week 24, the patient will be classified as a treatment nonresponder and medications are discontinued.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00207363</url>
  </study>
  <study rank="382">
    <nct_id>NCT00724295</nct_id>
    <title>Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2b</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1077</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04505</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>April 2005</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>February 3, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Overall incidence of adverse events and adverse drug reactions.</outcome_measure>
      <outcome_measure>Assessment of trends of adverse drug reactions by patient factors and concomitant medications. Incidence of adverse events (AEs) in the elderly vs younger patients; rates of hematologic AEs; dose reduction and discontinuation rates.</outcome_measure>
      <outcome_measure>Sustained virologic response rate and improvement of ALT (alanine transaminase).</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00724295</url>
  </study>
  <study rank="383">
    <nct_id>NCT02615145</nct_id>
    <title>Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P15-398</other_id>
    </other_ids>
    <first_received>November 24, 2015</first_received>
    <start_date>November 2015</start_date>
    <completion_date>February 2018</completion_date>
    <last_updated>November 24, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>LIFE-C</acronym>
    <primary_completion_date>February 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants with Sustained Virologic Response (SVR12)</outcome_measure>
      <outcome_measure>Patient Support Program (PSP) Utilization and Satisfaction Assessment</outcome_measure>
      <outcome_measure>Evaluate the Usage Pattern of the Treatment Regimen</outcome_measure>
      <outcome_measure>Adherence of Participants Per Questionnaire</outcome_measure>
      <outcome_measure>Change of Participant Activation with the Patient Activation Measure (PAM-13) Questionnaire.</outcome_measure>
      <outcome_measure>Percentage of Participants with Relapse or Reinfection</outcome_measure>
      <outcome_measure>Change in Functional Assessment of Chronic Illness Therapy- Fatigue (FACIT-F) Scale</outcome_measure>
      <outcome_measure>Change in Participants Workability Measured with the Work Productivity and Activity Impairment (WPAI):Hepatitis C Questionnaire</outcome_measure>
      <outcome_measure>Change in Participants Burden of Suffering Measured with The Pictorial Representation of Illness and Self-Measure (PRISM) tool</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02615145</url>
  </study>
  <study rank="384">
    <nct_id>NCT01273948</nct_id>
    <title>Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Bavituximab</intervention>
      <intervention type="Drug">Pegylated interferon (PEG-IFN)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Peregrine Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>66</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>PPHM 1003</other_id>
    </other_ids>
    <first_received>January 7, 2011</first_received>
    <start_date>January 2011</start_date>
    <completion_date>February 2012</completion_date>
    <last_updated>February 2, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Reduction in Hepatitis C Virus RNA</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Georgia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01273948</url>
  </study>
  <study rank="385">
    <nct_id>NCT01871662</nct_id>
    <title>Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Legalon® SIL (Silibinin)</intervention>
      <intervention type="Drug">Pegylated interferon alfa2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Rottapharm</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>LEG-SIL-2-02</other_id>
    </other_ids>
    <first_received>May 30, 2013</first_received>
    <start_date>August 2013</start_date>
    <completion_date>February 2016</completion_date>
    <last_updated>March 4, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HEPASIL</acronym>
    <primary_completion_date>February 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Undetectable HCV-RNA at 24 Weeks After the end of the Study Treatment</outcome_measure>
      <outcome_measure>Undetectable HCV-RNA</outcome_measure>
      <outcome_measure>HCV-RNA decrease ≥ 2 log10 IU/mL</outcome_measure>
      <outcome_measure>Normalization of Serum Alanine Aminotransferase</outcome_measure>
      <outcome_measure>Number of Participants with adverse events (AEs)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01871662</url>
  </study>
  <study rank="386">
    <nct_id>NCT00940420</nct_id>
    <title>A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus (ribavirin)</intervention>
      <intervention type="Drug">Copegus (ribavirin)</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>2695</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML16837</other_id>
    </other_ids>
    <first_received>July 6, 2009</first_received>
    <start_date>October 2002</start_date>
    <completion_date>November 2009</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>safety and tolerability with regard to clinical AEs and laboratory parameters</outcome_measure>
      <outcome_measure>safety with regard to hematological parameters</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Israel</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00940420</url>
  </study>
  <study rank="387">
    <nct_id>NCT00575627</nct_id>
    <title>Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-Interferon alpha2a plus Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Turin, Italy</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>pNNALTHCV</other_id>
      <other_id>NNALT</other_id>
    </other_ids>
    <first_received>December 14, 2007</first_received>
    <start_date>September 2007</start_date>
    <completion_date>September 2010</completion_date>
    <last_updated>June 3, 2008</last_updated>
    <last_verified>June 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate the efficacy of treatment and the outcome of treated patients compared with a control group of untreated patients.</outcome_measure>
      <outcome_measure>evaluation of liver fibrosis by Fibroscan after 48-72 weeks of inclusion</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00575627</url>
  </study>
  <study rank="388">
    <nct_id>NCT01838590</nct_id>
    <title>Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>103</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0138</other_id>
    </other_ids>
    <first_received>April 15, 2013</first_received>
    <start_date>March 2013</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>May 7, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>May 5, 2015</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing On-treatment Virologic Failure</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Virologic Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01838590</url>
  </study>
  <study rank="389">
    <nct_id>NCT01604850</nct_id>
    <title>Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">Placebo to match SOF</intervention>
      <intervention type="Drug">Placebo to match RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>202</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0108</other_id>
    </other_ids>
    <first_received>May 21, 2012</first_received>
    <start_date>June 2012</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>May 9, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>March 31, 2014</firstreceived_results_date>
    <acronym>FUSION</acronym>
    <primary_completion_date>February 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving SVR12</outcome_measure>
      <outcome_measure>Adverse Events Leading to Permanent Discontinuation of Study Drug</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR4</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR24</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01604850</url>
  </study>
  <study rank="390">
    <nct_id>NCT00943761</nct_id>
    <title>A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Vaniprevir 600 mg b.i.d.</intervention>
      <intervention type="Drug">Vaniprevir 300 mg b.i.d.</intervention>
      <intervention type="Drug">Pegylated interferon</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>7009-028</other_id>
      <other_id>2009_615</other_id>
      <other_id>2009-013053-15</other_id>
    </other_ids>
    <first_received>July 21, 2009</first_received>
    <start_date>October 2009</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>September 1, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>September 26, 2014</firstreceived_results_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Who Experienced an Adverse Event</outcome_measure>
      <outcome_measure>Number of Participants Who Experienced a Serious Adverse Event</outcome_measure>
      <outcome_measure>Number of Participants Who Discontinued Study Treatment Due to an Adverse Event</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieved Sustained Viral Response 24 Weeks After the End of Treatment (SVR24)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00943761</url>
  </study>
  <study rank="391">
    <nct_id>NCT01185028</nct_id>
    <title>A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
      <condition>HIV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitazoxanide With Pegylated Interferon And Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institutes of Health Clinical Center (CC)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>8</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>100183</other_id>
      <other_id>10-CC-0183</other_id>
    </other_ids>
    <first_received>August 18, 2010</first_received>
    <start_date>August 2010</start_date>
    <completion_date>October 2011</completion_date>
    <last_updated>May 16, 2013</last_updated>
    <last_verified>May 2013</last_verified>
    <firstreceived_results_date>March 21, 2013</firstreceived_results_date>
    <primary_completion_date>October 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Adverse Events</outcome_measure>
      <outcome_measure>Sustained Viral Response Rate</outcome_measure>
      <outcome_measure>Tolerability</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>District of Columbia</state>
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01185028</url>
  </study>
  <study rank="392">
    <nct_id>NCT01686789</nct_id>
    <title>Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alpha-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>King Abdulaziz Medical City</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>190</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>RC08-064</other_id>
    </other_ids>
    <first_received>September 13, 2012</first_received>
    <start_date>January 2011</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>September 18, 2012</last_updated>
    <last_verified>September 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response</outcome_measure>
      <outcome_measure>Requirement of blood-related products</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Saudi Arabia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01686789</url>
  </study>
  <study rank="393">
    <nct_id>NCT01779518</nct_id>
    <title>Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C</title>
    <recruitment open="N">Approved for marketing</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Post-transplant Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated Interferon</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Expanded Access</study_types>
    <study_designs/>
    <other_ids>
      <other_id>GS-US-334-0139</other_id>
    </other_ids>
    <first_received>January 23, 2013</first_received>
    <last_updated>January 15, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01779518</url>
  </study>
  <study rank="394">
    <nct_id>NCT01808248</nct_id>
    <title>Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">PEG</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>47</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0151</other_id>
    </other_ids>
    <first_received>March 1, 2013</first_received>
    <start_date>February 2013</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>September 5, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>September 5, 2014</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing On-treatment Virologic Failure</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01808248</url>
  </study>
  <study rank="395">
    <nct_id>NCT01851330</nct_id>
    <title>Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>647</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-0108</other_id>
    </other_ids>
    <first_received>May 3, 2013</first_received>
    <start_date>May 2013</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>December 18, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>December 18, 2014</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of Adverse Events Leading to Permanent Discontinuation From Any Study Drug</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 2</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 8</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 2</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 4</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 8</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Virologic Failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01851330</url>
  </study>
  <study rank="396">
    <nct_id>NCT01768286</nct_id>
    <title>Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>441</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-0109</other_id>
    </other_ids>
    <first_received>January 10, 2013</first_received>
    <start_date>January 2013</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>November 21, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>November 21, 2014</firstreceived_results_date>
    <acronym>ION-2</acronym>
    <primary_completion_date>November 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of Adverse Events Leading to Permanent Discontinuation From Any Study Drug</outcome_measure>
      <outcome_measure>Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 1</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 2</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 8</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 24</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 1</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 2</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 4</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 8</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01768286</url>
  </study>
  <study rank="397">
    <nct_id>NCT02413593</nct_id>
    <title>Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>111</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-1701</other_id>
    </other_ids>
    <first_received>April 7, 2015</first_received>
    <start_date>April 2015</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>September 28, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of any adverse events leading to permanent discontinuation of study drug</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response 4 weeks after discontinuation of therapy (SVR4)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV RNA &lt; LLOQ on treatment</outcome_measure>
      <outcome_measure>HCV RNA change from Day 1</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02413593</url>
  </study>
  <study rank="398">
    <nct_id>NCT00299936</nct_id>
    <title>Comparison of PEG-Intron and Two Different Doses of Ribavirin for the Treatment of Chronic Hepatitis C In Treatment Naïve Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin, PEG-Intron</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Weill Medical College of Cornell University</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>5000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P02314</other_id>
      <other_id>WIN-R</other_id>
    </other_ids>
    <first_received>March 3, 2006</first_received>
    <last_updated>March 3, 2006</last_updated>
    <last_verified>March 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00299936</url>
  </study>
  <study rank="399">
    <nct_id>NCT00016081</nct_id>
    <title>Ribavirin Compared With Standard Care in Treating Patients With Respiratory Syncytial Virus Following Stem Cell Transplantation</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Fred Hutchinson Cancer Research Center</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>1290.00</other_id>
      <other_id>FHCRC-1290.00</other_id>
      <other_id>NCI-G01-1939</other_id>
      <other_id>CDR0000068593</other_id>
    </other_ids>
    <first_received>May 6, 2001</first_received>
    <start_date>March 1998</start_date>
    <completion_date>March 2003</completion_date>
    <last_updated>March 26, 2010</last_updated>
    <last_verified>March 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2003</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Illinois</state>
      <state>Missouri</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00016081</url>
  </study>
  <study rank="400">
    <nct_id>NCT00148837</nct_id>
    <title>Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Fibrosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-interferon alpha 2b (drug)</intervention>
      <intervention type="Drug">Ribavirin (drug)</intervention>
      <intervention type="Drug">Prazosin (drug)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Agency for Research on AIDS and Viral Hepatitis</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>112</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>2004-001326-24</other_id>
      <other_id>ANRSHC17 Prazor</other_id>
    </other_ids>
    <first_received>September 7, 2005</first_received>
    <start_date>September 2004</start_date>
    <last_updated>February 6, 2008</last_updated>
    <last_verified>February 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients presenting a decrease of fibrosis as measured on the liver biopsy and considered as clinically interesting (decrease of fibrosis pre- and post-therapeutic (W96) measures of at least 10 percent)</outcome_measure>
      <outcome_measure>Metavir scoring system; immunostaining of alpha-smooth muscle actin; indirect markers of fibrosis (Fibrotest) at W96</outcome_measure>
      <outcome_measure>Sustained virological response: undetectable HCV RNA at W96</outcome_measure>
      <outcome_measure>Sustained biochemical response: ALT level at W96</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00148837</url>
  </study>
  <study rank="401">
    <nct_id>NCT00014391</nct_id>
    <title>Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">palivizumab</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Fred Hutchinson Cancer Research Center</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>1379.00</other_id>
      <other_id>FHCRC-1379.00</other_id>
      <other_id>NCI-G01-1929</other_id>
      <other_id>CDR0000068540</other_id>
    </other_ids>
    <first_received>April 10, 2001</first_received>
    <start_date>February 1999</start_date>
    <completion_date>October 2001</completion_date>
    <last_updated>March 31, 2010</last_updated>
    <last_verified>March 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2001</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00014391</url>
  </study>
  <study rank="402">
    <nct_id>NCT01542788</nct_id>
    <title>Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">Placebo to match SOF</intervention>
      <intervention type="Drug">Placebo to match RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>278</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0107</other_id>
    </other_ids>
    <first_received>February 17, 2012</first_received>
    <start_date>March 2012</start_date>
    <completion_date>February 2013</completion_date>
    <last_updated>May 8, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>January 6, 2014</firstreceived_results_date>
    <acronym>POSITRON</acronym>
    <primary_completion_date>November 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving SVR12</outcome_measure>
      <outcome_measure>Number of Participants Experiencing Adverse Events Leading to Permanent Discontinuation of Study Drug</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR4</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR24</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01542788</url>
  </study>
  <study rank="403">
    <nct_id>NCT01384383</nct_id>
    <title>GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GS-5885</intervention>
      <intervention type="Drug">GS-9451</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">PEG</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>248</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-248-0121</other_id>
    </other_ids>
    <first_received>June 22, 2011</first_received>
    <start_date>August 2011</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>January 2, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (SVR)</outcome_measure>
      <outcome_measure>Safety and tolerability of therapy</outcome_measure>
      <outcome_measure>Virologic response</outcome_measure>
      <outcome_measure>Compare SVR</outcome_measure>
      <outcome_measure>Viral resistance</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>New Zealand</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Indiana</state>
      <state>Massachusetts</state>
      <state>Nevada</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oregon</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01384383</url>
  </study>
  <study rank="404">
    <nct_id>NCT00262483</nct_id>
    <title>Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">VX-950</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX05-950-102</other_id>
    </other_ids>
    <first_received>December 2, 2005</first_received>
    <start_date>December 2005</start_date>
    <completion_date>April 2006</completion_date>
    <last_updated>December 17, 2007</last_updated>
    <last_verified>December 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Safety of triple combination therapy.</outcome_measure>
      <outcome_measure>Pharmacokinetics of VX-950, peginterferon alfa-2a and ribavirin.</outcome_measure>
      <outcome_measure>Plasma HCV RNA levels</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00262483</url>
  </study>
  <study rank="405">
    <nct_id>NCT00399672</nct_id>
    <title>Evaluation of a Multi-disciplinary Approach for the Treatment of Hepatitis C in IDUs (HI-LO Study)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Interferon injections and ribavirin</intervention>
      <intervention type="Drug">Interferon injections and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of British Columbia</lead_sponsor>
      <collaborator>Canadian Institutes of Health Research (CIHR)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>370</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>C06-0192</other_id>
    </other_ids>
    <first_received>November 14, 2006</first_received>
    <start_date>June 2007</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>July 9, 2012</last_updated>
    <last_verified>July 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Rate of sustained virologic response (SVR) six months after completion of treatment.</outcome_measure>
      <outcome_measure>Adherence to therapy</outcome_measure>
      <outcome_measure>Cost</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00399672</url>
  </study>
  <study rank="406">
    <nct_id>NCT00437684</nct_id>
    <title>Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LPV/r</intervention>
      <intervention type="Drug">PEG-IFNa 2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">NUCS</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>IRCCS San Raffaele</lead_sponsor>
      <collaborator>Abbott</collaborator>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Kamon 2</other_id>
      <other_id>NTC00437684</other_id>
    </other_ids>
    <first_received>February 20, 2007</first_received>
    <start_date>February 2007</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>February 5, 2009</last_updated>
    <last_verified>February 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To assess if the combination of LPV/r monotherapy in association with anti-HCV</outcome_measure>
      <outcome_measure>Nucs) and PEG-IFN alfa 2a +Ribavirin in patients naïve for HCV treatment</outcome_measure>
      <outcome_measure>without previous failure or detection of any mutations related to PI resistance.</outcome_measure>
      <outcome_measure>To assess if LPV/r monotherapy during the HCV treatment is associated with</outcome_measure>
      <outcome_measure>anti HIV/HCV efficacy and a better patient satisfaction vs optimized HAART.</outcome_measure>
      <outcome_measure>To assess the number and type of HIV-1 resistance mutations in patients with</outcome_measure>
      <outcome_measure>virological failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00437684</url>
  </study>
  <study rank="407">
    <nct_id>NCT00483938</nct_id>
    <title>IMPROVE Study(The Individualized Management With PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>226</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML21035</other_id>
    </other_ids>
    <first_received>June 7, 2007</first_received>
    <start_date>June 2007</start_date>
    <completion_date>May 2010</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response</outcome_measure>
      <outcome_measure>SVR</outcome_measure>
      <outcome_measure>Viral kinetics</outcome_measure>
      <outcome_measure>AEs, laboratory parameters</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00483938</url>
  </study>
  <study rank="408">
    <nct_id>NCT00978497</nct_id>
    <title>Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">placebo</intervention>
      <intervention type="Drug">ANA598</intervention>
      <intervention type="Drug">ANA598</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>97</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANA598-504</other_id>
    </other_ids>
    <first_received>September 16, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>November 12, 2012</last_updated>
    <last_verified>November 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Undetectable HCV RNA</outcome_measure>
      <outcome_measure>Safety and Tolerability</outcome_measure>
      <outcome_measure>ANA598, Peg-IFN-a-2-a, ribavirin concentrations</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00978497</url>
  </study>
  <study rank="409">
    <nct_id>NCT00910975</nct_id>
    <title>Individualized Duration of Peg-interferon/Ribavirin Treatment of Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C, Genotype 1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-interferon-alfa2a (Pegasys)</intervention>
      <intervention type="Drug">Ribavirin (Copegus)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Göteborg University</lead_sponsor>
      <collaborator>Sahlgrenska University Hospital, Sweden</collaborator>
      <collaborator>Sodra Alvsborgs Hospital</collaborator>
      <collaborator>Skaraborg Hospital</collaborator>
      <collaborator>Uddevalla Hospital</collaborator>
      <collaborator>Skane University Hospital</collaborator>
      <collaborator>Lund University Hospital</collaborator>
      <collaborator>Karolinska University Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TTG1_081119</other_id>
    </other_ids>
    <first_received>May 28, 2009</first_received>
    <start_date>November 2007</start_date>
    <completion_date>September 2011</completion_date>
    <last_updated>September 3, 2012</last_updated>
    <last_verified>September 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>TTG1</acronym>
    <primary_completion_date>June 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Medication dose per cured patient</outcome_measure>
      <outcome_measure>Sustained virological response and relapse rate</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Sweden</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00910975</url>
  </study>
  <study rank="410">
    <nct_id>NCT00372385</nct_id>
    <title>Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated Interferon Alfa 2a</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>334</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX05-950-104EU</other_id>
    </other_ids>
    <first_received>September 1, 2006</first_received>
    <start_date>August 2006</start_date>
    <completion_date>June 2008</completion_date>
    <last_updated>June 25, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>June 22, 2011</firstreceived_results_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Study Drug Dosing</outcome_measure>
      <outcome_measure>Percentage of Subjects With Undetectable Plasma HCV RNA at Week 12 After the Completion of Study Drug Dosing</outcome_measure>
      <outcome_measure>Percentage of Subjects With Undetectable Plasma HCV RNA at Completion of Study Drug Dosing</outcome_measure>
      <outcome_measure>Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
      <outcome_measure>Number of Subjects With Viral Relapse</outcome_measure>
      <outcome_measure>Maximum (Cmax), Minimum (Cmin) and Average (Cavg) Plasma Concentration of Telaprevir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
      <country>France</country>
      <country>Germany</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00372385</url>
  </study>
  <study rank="411">
    <nct_id>NCT00304551</nct_id>
    <title>A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Liver Cirrhosis</condition>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a 180μg</intervention>
      <intervention type="Drug">peginterferon alfa-2a 90μg</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Chugai Pharmaceutical</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>180</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>JV19595</other_id>
    </other_ids>
    <first_received>March 5, 2006</first_received>
    <start_date>June 2006</start_date>
    <completion_date>June 2010</completion_date>
    <last_updated>June 1, 2010</last_updated>
    <last_verified>June 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response, defined as undetectable hepatitis C virus (HCV)-RNA (&lt; 50 IU per milliliter [IU/mL])</outcome_measure>
      <outcome_measure>Biochemical response (normalization of serum alanine aminotransferase activity)</outcome_measure>
      <outcome_measure>Virological response (HCV-RNA &lt; 50 IU per milliliter)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00304551</url>
  </study>
  <study rank="412">
    <nct_id>NCT00704717</nct_id>
    <title>Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b; SCH 54031) pen</intervention>
      <intervention type="Drug">Rebetol (ribavirin; SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>185</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04301</other_id>
    </other_ids>
    <first_received>June 23, 2008</first_received>
    <start_date>September 2005</start_date>
    <completion_date>December 2007</completion_date>
    <last_updated>April 8, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>February 11, 2009</firstreceived_results_date>
    <primary_completion_date>December 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Satisfaction of Patients Receiving PegIntron Pen Plus Rebetol Therapy, Assessed by a Survey.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00704717</url>
  </study>
  <study rank="413">
    <nct_id>NCT00351403</nct_id>
    <title>Individually Adapted Therapy Duration for the Treatment of Chronic Hepatitis C Genotype 1 Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa 2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>FGK Clinical Research GmbH</lead_sponsor>
      <collaborator>University Hospital, Saarland</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>390</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>INDIV-2</other_id>
      <other_id>2006-000358-38</other_id>
    </other_ids>
    <first_received>July 11, 2006</first_received>
    <start_date>July 2006</start_date>
    <completion_date>January 2010</completion_date>
    <last_updated>February 5, 2010</last_updated>
    <last_verified>February 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained viral response (HCV RNA negativity 24 weeks after end of treatment)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00351403</url>
  </study>
  <study rank="414">
    <nct_id>NCT00336479</nct_id>
    <title>Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated Interferon Alfa 2a</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>263</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX05-950-104</other_id>
    </other_ids>
    <first_received>June 9, 2006</first_received>
    <start_date>June 2006</start_date>
    <completion_date>February 2008</completion_date>
    <last_updated>June 25, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>June 22, 2011</firstreceived_results_date>
    <primary_completion_date>February 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Study Drug Dosing</outcome_measure>
      <outcome_measure>Percentage of Subjects With Undetectable Plasma HCV RNA at Week 12 After the Completion of Study Drug Dosing</outcome_measure>
      <outcome_measure>Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
      <outcome_measure>Number of Subjects With Viral Relapse</outcome_measure>
      <outcome_measure>Maximum (Cmax), Minimum (Cmin) and Average (Cavg) Plasma Concentration of Telaprevir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00336479</url>
  </study>
  <study rank="415">
    <nct_id>NCT01910636</nct_id>
    <title>Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>153</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0118</other_id>
    </other_ids>
    <first_received>July 23, 2013</first_received>
    <start_date>February 2013</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>March 13, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>March 13, 2015</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01910636</url>
  </study>
  <study rank="416">
    <nct_id>NCT01581138</nct_id>
    <title>VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">VX-222</intervention>
      <intervention type="Drug">telaprevir</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>64</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX11-222-108</other_id>
    </other_ids>
    <first_received>April 17, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>July 2, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The proportion of subjects who have a sustained viral response (SVR) at 12 weeks after the last planned dose of treatment</outcome_measure>
      <outcome_measure>The safety and tolerability as assessed by adverse events (AEs), vital signs, 12-lead electrocardiograms (ECGs), and laboratory assessments (serum chemistry, hematology, and urinalysis)</outcome_measure>
      <outcome_measure>The proportion of subjects who have an SVR 24 weeks after the last planned dose of the study drug</outcome_measure>
      <outcome_measure>The proportion of subjects who have an SVR 4 weeks after the last planned dose of the study drug</outcome_measure>
      <outcome_measure>The proportion of subjects who relapse (i.e., who had &lt;lower limit of quantitation LLOQ hepatitis C virus (HCV) RNA at the end of planned study drug treatment (planned EOT) followed by ≥LLOQ HCV RNA after planned EOT)</outcome_measure>
      <outcome_measure>The proportion of subjects who achieve undetectable HCV RNA (below the lower limit of detection (&lt; (LLOQ) undetectable) at Weeks 2, 4, 8, 12, and 16 after the first dose of study drug, and &lt;LLOQ at the end of planned study drug treatment (planned EOT)</outcome_measure>
      <outcome_measure>Time to achieve &lt;LLOQ undetectable HCV RNA</outcome_measure>
      <outcome_measure>The proportion of subjects who have on-treatment virologic failure defined as subjects who either have viral breakthrough or who complete the assigned treatment and have ≥LLOQ HCV RNA at the end of study drug treatment (EOT)</outcome_measure>
      <outcome_measure>The association of the interleukin-28B (IL-28B) genotype (CC versus CT versus TT) with SVR12</outcome_measure>
      <outcome_measure>The amino acid sequence of the nonstructural (NS)3/4A and NS5B proteins in subjects who have treatment failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01581138</url>
  </study>
  <study rank="417">
    <nct_id>NCT00328549</nct_id>
    <title>A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN (NATURAL HISTORY-HCV)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Anemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon and Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ortho Biotech Products, L.P.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>105</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR005116</other_id>
    </other_ids>
    <first_received>May 19, 2006</first_received>
    <start_date>October 2001</start_date>
    <completion_date>December 2002</completion_date>
    <last_updated>May 17, 2011</last_updated>
    <last_verified>April 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Primary endpoints were change in Hb and sEPO from baseline to week 8 (or early withdrawal)</outcome_measure>
      <outcome_measure>Other endpoints measured were changes in reticulocytes, platelets, total bilirubin, and RBV dose from baseline to week 8.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00328549</url>
  </study>
  <study rank="418">
    <nct_id>NCT02021643</nct_id>
    <title>Efficacy and Safety of Sofosbuvir Plus Ribavirin in Subjects With Chronic HCV Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">PegIFNα</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>657</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0115</other_id>
    </other_ids>
    <first_received>November 26, 2013</first_received>
    <start_date>December 2013</start_date>
    <completion_date>October 2016</completion_date>
    <last_updated>November 30, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Proportion of participants permanently discontinuing study drug(s) due to an adverse event (AE)</outcome_measure>
      <outcome_measure>Proportion of participants with: HCV RNA &lt; LLOQ at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants experiencing viral breakthrough</outcome_measure>
      <outcome_measure>Proportion of participants experiencing viral relapse</outcome_measure>
      <outcome_measure>Change from baseline in HCV RNA (log10 IU/mL)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
      <country>Hong Kong</country>
      <country>Korea, Republic of</country>
      <country>Taiwan</country>
      <country>Vietnam</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02021643</url>
  </study>
  <study rank="419">
    <nct_id>NCT01329978</nct_id>
    <title>Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">PEG</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>332</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P7977-0724</other_id>
    </other_ids>
    <first_received>March 30, 2011</first_received>
    <start_date>March 2011</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>April 24, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>January 6, 2014</firstreceived_results_date>
    <acronym>ATOMIC</acronym>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 24 Weeks Following Completion of Treatment (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Experienced Adverse Events</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks Following Completion of Treatment (SVR12)</outcome_measure>
      <outcome_measure>Change in HCV RNA at Week 2</outcome_measure>
      <outcome_measure>Change in HCV RNA at Week 4</outcome_measure>
      <outcome_measure>Change in HCV RNA at Week 8</outcome_measure>
      <outcome_measure>Change in HCV RNA at Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LOD at Week 2</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA Below &lt; LOD at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA Below &lt; LOD at Week 8</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA Below &lt; LOD at Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA Below &lt; LOD at Week 24</outcome_measure>
      <outcome_measure>Percentage of Participants With ALT Normalization at Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With ALT Normalization at Week 24</outcome_measure>
      <outcome_measure>Percentage of Participants With ALT Normalization at Post-treatment Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Failure During Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Failure Following Treatment (Viral Relapse).</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arkansas</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>South Carolina</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01329978</url>
  </study>
  <study rank="420">
    <nct_id>NCT00115908</nct_id>
    <title>A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Albuferon</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">PEG-IFNalfa2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Human Genome Sciences Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>458</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ALFR-HC-04</other_id>
    </other_ids>
    <first_received>June 26, 2005</first_received>
    <start_date>May 2005</start_date>
    <completion_date>May 2007</completion_date>
    <last_updated>November 5, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (SVR), defined as undetectable HCV RNA at 24 weeks after the end of therapy.</outcome_measure>
      <outcome_measure>Virologic response at Week 4 (VR4), defined as undetectable HCV RNA or a &gt; 2-log reduction in HCV RNA.</outcome_measure>
      <outcome_measure>Early virologic response at Week 12 (EVR12), defined as undetectable HCV RNA or a &gt; 2-log reduction in HCV RNA.</outcome_measure>
      <outcome_measure>Undetectable HCV RNA at Week 24.</outcome_measure>
      <outcome_measure>End of treatment response (ETR), defined as undetectable HCV RNA at Week 48</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
      <country>Australia</country>
      <country>Czech Republic</country>
      <country>France</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Poland</country>
      <country>Romania</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00115908</url>
  </study>
  <study rank="421">
    <nct_id>NCT01767116</nct_id>
    <title>A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450/r/ABT-267, ABT-333</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Placebo for ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie (prior sponsor, Abbott)</lead_sponsor>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>419</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>M13-961</other_id>
      <other_id>2012-003687-52</other_id>
    </other_ids>
    <first_received>November 30, 2012</first_received>
    <start_date>December 2012</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>August 19, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>December 23, 2014</firstreceived_results_date>
    <acronym>PEARL-III</acronym>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Noninferiority Analyses of Each Treatment Arm Compared to Historical Rate</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Noninferiority Analysis of ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV Compared With ABT-450/r/ABT-267 and ABT-333, Plus RBV</outcome_measure>
      <outcome_measure>Percentage of Participants With Hemoglobin Decrease to Below the Lower Limit of Normal (LLN) At End of Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Superiority Analyses of Each Treatment Arm Compared to Historical Rate</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Failure During Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Relapse After Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01767116</url>
  </study>
  <study rank="422">
    <nct_id>NCT01833533</nct_id>
    <title>A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450/r/ABT-267, ABT-333</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Placebo for Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>305</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>M14-002</other_id>
      <other_id>2012-005522-29</other_id>
    </other_ids>
    <first_received>February 27, 2013</first_received>
    <start_date>March 2013</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>September 4, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>December 23, 2014</firstreceived_results_date>
    <acronym>PEARL-IV</acronym>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Primary Analyses</outcome_measure>
      <outcome_measure>Percentage of Participants With Hemoglobin Decrease to Below the Lower Limit of Normal (LLN) At End of Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Secondary Analyses</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Failure During Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Relapse After Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01833533</url>
  </study>
  <study rank="423">
    <nct_id>NCT00528528</nct_id>
    <title>An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Peg-IFN-alfa-2a</intervention>
      <intervention type="Drug">Peg-IFN-alfa-2b</intervention>
      <intervention type="Drug">Ribavirin (RBV) tablet</intervention>
      <intervention type="Drug">Ribavirin (RBV) capsule</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec BVBA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>166</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR013516</other_id>
      <other_id>VX-950-TIDP24-C208</other_id>
      <other_id>2007-001044-44</other_id>
    </other_ids>
    <first_received>September 10, 2007</first_received>
    <start_date>October 2007</start_date>
    <completion_date>August 2009</completion_date>
    <last_updated>June 13, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>March 18, 2013</firstreceived_results_date>
    <primary_completion_date>July 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Virologic Response at Week 12</outcome_measure>
      <outcome_measure>Time to First Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Level</outcome_measure>
      <outcome_measure>Number of Participants With Viral Breakthrough at End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Percentage of Participants With Partial Response</outcome_measure>
      <outcome_measure>Change From Baseline in Log 10-Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values at Week 12</outcome_measure>
      <outcome_measure>Change From Baseline in Log 10-Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values at End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Viral Response 24 Weeks After End of Treatment (SVR24)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Netherlands</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00528528</url>
  </study>
  <study rank="424">
    <nct_id>NCT01687270</nct_id>
    <title>Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Recurrent Chronic Hepatitis C Virus</condition>
      <condition>Post Liver Transplant</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0126</other_id>
      <other_id>2012-002417-19</other_id>
    </other_ids>
    <first_received>September 12, 2012</first_received>
    <start_date>November 2012</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>December 11, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>December 11, 2014</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Discontinue Study Drug Due to an Adverse Event</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) at 4, 24, and 48 Weeks After Discontinuation of Therapy (SVR4, SVR24, and SVR48)</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ at Weeks 12 and 24</outcome_measure>
      <outcome_measure>HCV RNA and Change From Baseline at Weeks 2, 4, and 8</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>France</country>
      <country>Germany</country>
      <country>New Zealand</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Indiana</state>
      <state>Kansas</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01687270</url>
  </study>
  <study rank="425">
    <nct_id>NCT02541409</nct_id>
    <title>Directly Observed Therapy for HCV in Chennai, India</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Pegylated Interferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Johns Hopkins Bloomberg School of Public Health</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>YR Gaitonde Centre for AIDS Research and Education</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>R01DA02672</other_id>
      <other_id>R01DA026727</other_id>
    </other_ids>
    <first_received>August 31, 2015</first_received>
    <start_date>September 2015</start_date>
    <completion_date>September 2016</completion_date>
    <last_updated>September 1, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>C-DOT</acronym>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects that complete their course of treatment</outcome_measure>
      <outcome_measure>Sustained virologic response 12 weeks after treatment is completed (SVR12) as assessed by undetectable HCV RNA measured 12 weeks after treatment completion</outcome_measure>
      <outcome_measure>Number of participants with treatment-related serious adverse events by laboratory tests and physician examination</outcome_measure>
      <outcome_measure>Change in insulin resistance as assessed by homeostasis model assessment - insulin resistance (HOMA-IR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>India</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02541409</url>
  </study>
  <study rank="426">
    <nct_id>NCT00797745</nct_id>
    <title>A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">peginterferon alfa 2b</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">SCH 900518</intervention>
      <intervention type="Drug">ritonavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>111</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05104</other_id>
    </other_ids>
    <first_received>November 24, 2008</first_received>
    <start_date>November 2008</start_date>
    <completion_date>September 2010</completion_date>
    <last_updated>January 21, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>NEXT-1</acronym>
    <primary_completion_date>July 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary efficacy endpoint is the proportion of subjects with undetectable HCV-RNA after 4 weeks of treatment with SCH 900518.</outcome_measure>
      <outcome_measure>Rate of viral decline during the first 4 weeks of dosing with SCH 900518</outcome_measure>
      <outcome_measure>Proportion of subjects with undetectable HCV-RNA at both 4 and 12 weeks of dosing with SCH 900518</outcome_measure>
      <outcome_measure>Proportion of subjects with undetectable HCV-RNA at end of treatment (EOT) and follow-up week 24 (FW24)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00797745</url>
  </study>
  <study rank="427">
    <nct_id>NCT00420784</nct_id>
    <title>A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated Interferon Alfa 2a</intervention>
      <intervention type="Drug">Matching Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>465</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX06-950-106</other_id>
    </other_ids>
    <first_received>January 8, 2007</first_received>
    <start_date>February 2007</start_date>
    <completion_date>April 2009</completion_date>
    <last_updated>July 9, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>June 22, 2011</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Study Drug Dosing</outcome_measure>
      <outcome_measure>Percentage of Subjects With Undetectable Plasma HCV RNA at Completion of Study Drug Dosing</outcome_measure>
      <outcome_measure>Percentage of Subjects With Undetectable Plasma HCV RNA</outcome_measure>
      <outcome_measure>Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
      <outcome_measure>Number of Subjects With Viral Relapse</outcome_measure>
      <outcome_measure>Maximum (Cmax), Minimum (Cmin) and Average (Cavg) Plasma Concentration of Telaprevir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Germany</country>
      <country>Netherlands</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maine</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>Nebraska</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00420784</url>
  </study>
  <study rank="428">
    <nct_id>NCT01903954</nct_id>
    <title>A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">placebo</intervention>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
      <intervention type="Drug">setrobuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>283</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NP28302</other_id>
    </other_ids>
    <first_received>July 17, 2013</first_received>
    <start_date>January 2011</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients achieving sustained virologic response (SVR24), defined as undetectable HCV RNA at 24 weeks after discontinuation of all study drugs</outcome_measure>
      <outcome_measure>Proportion of patients achieving undetectable HCV RNA (defined as HCV RNA &lt; 15 IU/mL) at each visit through Week 24</outcome_measure>
      <outcome_measure>Proportion of treatment-naïve patients eligible to stop all treatment at Week 28</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01903954</url>
  </study>
  <study rank="429">
    <nct_id>NCT00727311</nct_id>
    <title>Real-life Surveillance Study of Patients With Chronic Hepatitis C Treated With PegIntron Injector and Rebetol (Study P04538)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b; SCH 54031) injector</intervention>
      <intervention type="Drug">Rebetol (ribavirin; SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>2302</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04538</other_id>
    </other_ids>
    <first_received>July 30, 2008</first_received>
    <start_date>August 2005</start_date>
    <completion_date>June 2009</completion_date>
    <last_updated>October 8, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>December 22, 2010</firstreceived_results_date>
    <primary_completion_date>June 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Hepatitis C Virus Ribonucleic Acid (HCV-RNA) Negative Participants at End of Therapy (EoT)</outcome_measure>
      <outcome_measure>Number of Participants With Early Virologic Response (EVR)</outcome_measure>
      <outcome_measure>Number of Participants With Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Number of HCV-RNA Negative Participants at Follow-up</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00727311</url>
  </study>
  <study rank="430">
    <nct_id>NCT01153919</nct_id>
    <title>Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia</title>
    <recruitment open="N">Suspended</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
      <condition>Thrombocytopenia</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">romiplostim</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Other">placebo</intervention>
      <intervention type="Biological">PEG-interferon alfa-2a</intervention>
      <intervention type="Other">laboratory biomarker analysis</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Southern California</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NC-HEM-07-5</other_id>
      <other_id>NCI-2010-00358</other_id>
    </other_ids>
    <first_received>June 24, 2010</first_received>
    <start_date>March 2010</start_date>
    <completion_date>April 2017</completion_date>
    <last_updated>October 24, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Mean platelet count for actively treated and placebo treated subjects</outcome_measure>
      <outcome_measure>Incidence of adverse events, including clinically significant changes in laboratory values and the incidence of antibody formation</outcome_measure>
      <outcome_measure>Number of subjects in each treatment group who achieve a platelet count of greater or equal to 100,000/L</outcome_measure>
      <outcome_measure>Number of patients originally receiving active treatment who maintain a platelet count &amp;gt; 50,000/L while receiving anti-viral therapy with pegylated interferon and ribavirin</outcome_measure>
      <outcome_measure>Changes in plasma HCV viral load during treatment with romiplostim alone</outcome_measure>
      <outcome_measure>Incidence of sustained viral response achieved during treatment with anti-viral therapy in combination with romiplostim</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01153919</url>
  </study>
  <study rank="431">
    <nct_id>NCT01185860</nct_id>
    <title>A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">danoprevir</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">placebo</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">ritonavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>59</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Single Blind (Subject)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NP22660</other_id>
      <other_id>2009-012426-36</other_id>
    </other_ids>
    <first_received>August 19, 2010</first_received>
    <start_date>August 2009</start_date>
    <completion_date>January 2012</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and tolerability: Adverse events, ECG, laboratory parameters</outcome_measure>
      <outcome_measure>Pharmacokinetics: Cmax, AUC, Cmin, Tmax, Cl, T1/2</outcome_measure>
      <outcome_measure>Antiviral activity: HCV RNA (COBAS Taqman HCV Test)</outcome_measure>
      <outcome_measure>Viral resistance development</outcome_measure>
      <outcome_measure>Effects on cytochrome P450(CYP)2C9 and 3A isozymes</outcome_measure>
      <outcome_measure>Virological response in prior null-responders</outcome_measure>
      <outcome_measure>Comparison of pharmacokinetics and antiviral activity between treatment-naïve patients and prior null-responders to standard of care treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
      <country>New Zealand</country>
      <country>Poland</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01185860</url>
  </study>
  <study rank="432">
    <nct_id>NCT01289782</nct_id>
    <title>An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Peginterferon alpha-2a (PegIFN alpha-2a)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>395</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017386</other_id>
      <other_id>TMC435-TiDP16-C208</other_id>
    </other_ids>
    <first_received>January 7, 2011</first_received>
    <start_date>February 2011</start_date>
    <completion_date>January 2013</completion_date>
    <last_updated>May 20, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>January 27, 2014</firstreceived_results_date>
    <acronym>QUEST-1</acronym>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Sustained Virologic Response 4 Weeks After the Planned End of Treatment (SVR4)</outcome_measure>
      <outcome_measure>Change From Baseline in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>Actual Values of log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Virologic Response at All Time Points</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Early Virologic Response (EVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants With &lt;1 log10 Decrease in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) From Baseline at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels &gt;1000 IU/mL at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Null Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Partial Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Percentage of Participants Who Completed All Study Treatment at Week 24 Because of the Treatment Duration Rule</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Failure</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Undetectable or Detectable</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Undetectable</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;100 IU/mL</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;1000 IU/mL</outcome_measure>
      <outcome_measure>The Percentage of Participants With Viral Breakthrough at Different Time Points</outcome_measure>
      <outcome_measure>Time From End-of-treatment to Viral Relapse</outcome_measure>
      <outcome_measure>The Percentage of Participants With Normalization of Alanine Aminotransferase (ALT)</outcome_measure>
      <outcome_measure>Median Time to Normalization of Alanine Aminotransferase (ALT) Levels</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h)</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Predose Plasma Concentration (C0h)</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Systemic Clearance (CL)</outcome_measure>
      <outcome_measure>Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for the Fatigue Severity Scale (FSS) Total Scores</outcome_measure>
      <outcome_measure>Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for Impairment in Overall Work Productivity Scores Due to Hepatitis C Virus (HCV) Infection and Its Treatment</outcome_measure>
      <outcome_measure>Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for Impairment in Daily Activity Scores Due to Hepatitis C Virus (HCV) Infection and Its Treatment</outcome_measure>
      <outcome_measure>Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) in Work Productivity and Activity (WPAI) Absenteeism Scores Due to Hepatitis C Virus (HCV) Infection and Its Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Germany</country>
      <country>Mexico</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Ukraine</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01289782</url>
  </study>
  <study rank="433">
    <nct_id>NCT00926614</nct_id>
    <title>Efficacy of Actos Lipitor Pegasys &amp; Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis c</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pioglitazone (Actos)</intervention>
      <intervention type="Drug">atorvastatin (Lipitor)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Brooke Army Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>C.2008.153</other_id>
    </other_ids>
    <first_received>June 22, 2009</first_received>
    <start_date>September 2008</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>February 13, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Improvement is seen in insulin resistance patients to be in a position to respond more favorably to current antiviral therapy consisting of pegylated interferon and ribavirin.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00926614</url>
  </study>
  <study rank="434">
    <nct_id>NCT02087111</nct_id>
    <title>Telaprevir in Genotype 3 HCV</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">40 Kd Pegylated interferon alfa 2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Queen Mary University of London</lead_sponsor>
      <collaborator>Janssen-Cilag Ltd.</collaborator>
      <collaborator>Barts &amp; The London NHS Trust</collaborator>
      <collaborator>St George's Healthcare NHS Trust</collaborator>
      <collaborator>Bradford Teaching Hospitals NHS Foundation Trust</collaborator>
      <collaborator>Nottingham University Hospitals NHS Trust</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>9132</other_id>
      <other_id>2013-003729-27</other_id>
      <other_id>13/LO/1473</other_id>
    </other_ids>
    <first_received>March 12, 2014</first_received>
    <start_date>April 2014</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>July 11, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>TIG3</acronym>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (SVR) 12 weeks after end of treatment (SVR12)</outcome_measure>
      <outcome_measure>Response rate prediction</outcome_measure>
      <outcome_measure>Sustained virological response 24 weeks after end of treatment.</outcome_measure>
      <outcome_measure>Treatment Success</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02087111</url>
  </study>
  <study rank="435">
    <nct_id>NCT01435044</nct_id>
    <title>Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">GS-0938</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">Placebo to match sofosbuvir</intervention>
      <intervention type="Drug">Placebo to match GS-0938</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
      <collaborator>Quintiles</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>239</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P2938-0721</other_id>
    </other_ids>
    <first_received>September 9, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>January 7, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>QUANTUM</acronym>
    <primary_completion_date>April 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants with sustained virologic response (SVR) 12 weeks after discontinuation of study drug (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Experienced Adverse Events</outcome_measure>
      <outcome_measure>Change from baseline in HCV RNA</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ during treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With ALT Normalization</outcome_measure>
      <outcome_measure>Percentage of participants with SVR at 4 and 24 weeks after discontinuation of study drug (SVR4; SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Developed Resistance to Sofosbuvir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01435044</url>
  </study>
  <study rank="436">
    <nct_id>NCT01591460</nct_id>
    <title>A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">boceprevir</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin (Copegus]</intervention>
      <intervention type="Drug">ribavirin (Copegus]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>165</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>MV28073</other_id>
      <other_id>2011-004810-41</other_id>
    </other_ids>
    <first_received>May 2, 2012</first_received>
    <start_date>August 2012</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>July 10, 2015</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virological Response (SVR) at 12 Weeks After End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Percentage of Participants With SVR at 24 Weeks After EOT</outcome_measure>
      <outcome_measure>HCV RNA Levels</outcome_measure>
      <outcome_measure>Percentage of Participants With Virological Response</outcome_measure>
      <outcome_measure>Percentage of Participants With at Least a 1-Log, 2-Log, or 3-Log Reduction in HCV RNA</outcome_measure>
      <outcome_measure>Percentage of Participants With Virological Relapse Following EOT Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Virological Breakthrough Following On-Treatment Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Virological Rebound Following On-Treatment Decline in HCV RNA</outcome_measure>
      <outcome_measure>Percentage of Participants With Treatment Discontinued Based Upon Elevated (Week 12) or Detectable (Week 24) HCV RNA</outcome_measure>
      <outcome_measure>Duration of Treatment With PEG-IFN, RBV, and Boceprevir</outcome_measure>
      <outcome_measure>Percentage of Participants With a Dose Modification of PEG-IFN, RBV, or Boceprevir By Reason</outcome_measure>
      <outcome_measure>Percentage of Participants Receiving Target Administrations of PEG-IFN, RBV, and Boceprevir</outcome_measure>
      <outcome_measure>Number of Participants With a Safety-Related Dose Modification</outcome_measure>
      <outcome_measure>Time to Safety-Related Dose Modification</outcome_measure>
      <outcome_measure>Percentage of Participants Using Concomitant Hematopoietic Stimulants During Treatment and Follow-Up</outcome_measure>
      <outcome_measure>Percentage of Participants With a Concomitant Disease Prior to or During the Study</outcome_measure>
      <outcome_measure>Percentage of Participants Using Concomitant Medications During Treatment and Follow-Up</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
      <country>Germany</country>
      <country>Hungary</country>
      <country>Poland</country>
      <country>Romania</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01591460</url>
  </study>
  <study rank="437">
    <nct_id>NCT02249182</nct_id>
    <title>Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/-Ribavirin in Adolescents and Children With Chronic HCV-Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">Placebo to match LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-1116</other_id>
    </other_ids>
    <first_received>September 23, 2014</first_received>
    <start_date>November 2014</start_date>
    <completion_date>October 2017</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>For the PK Lead-in Phase, PK parameters of GS-331007, SOF, and LDV as measured by AUCtau to determine the appropriate LDV/SOF FDC dose.</outcome_measure>
      <outcome_measure>For the Treatment Phase, any adverse event leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>For the PK Lead-in Phase, serum HCV RNA values and change from baseline</outcome_measure>
      <outcome_measure>For the PK Lead-in Phase, adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>For the Treatment Phase, growth and development as measured by height</outcome_measure>
      <outcome_measure>For the Treatment Phase, growth and development as measured by weight</outcome_measure>
      <outcome_measure>For the Treatment Phase, growth and development as measured by Tanner Stage Assessment</outcome_measure>
      <outcome_measure>For the Treatment Phase, proportion of participants with sustained virologic response (SVR) at 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>For the Treatment Phase, proportion of participants with sustained virologic response (SVR) at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>For the Treatment Phase, proportion of participants experiencing viral breakthrough</outcome_measure>
      <outcome_measure>For the Treatment Phase, proportion of participants experiencing viral relapse</outcome_measure>
      <outcome_measure>For the Treatment Phase, HCV RNA change from baseline</outcome_measure>
      <outcome_measure>For the Treatment Phase, alanine aminotransferase (ALT) normalization</outcome_measure>
      <outcome_measure>For the Treatment Phase, viral kinetic parameters</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>New Zealand</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>Nebraska</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Washington</state>
      <state>West Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02249182</url>
  </study>
  <study rank="438">
    <nct_id>NCT01683786</nct_id>
    <title>36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegintron + Riba</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Chang Gung Memorial Hospital</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>MISP39068</other_id>
    </other_ids>
    <first_received>January 31, 2012</first_received>
    <start_date>August 2011</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>September 11, 2012</last_updated>
    <last_verified>September 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The rate of sustained virologic response</outcome_measure>
      <outcome_measure>the factors associated with sustained virologic response(SVR) between groups</outcome_measure>
      <outcome_measure>the rate of end-of-treatment response(EOT)</outcome_measure>
      <outcome_measure>The relapse rate</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01683786</url>
  </study>
  <study rank="439">
    <nct_id>NCT00097045</nct_id>
    <title>Omega Interferon Alone or in Combination With Ribavirin in Subjects With Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">omega interferon</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Intarcia Therapeutics</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Biomed 510-CLP-07</other_id>
    </other_ids>
    <first_received>November 17, 2004</first_received>
    <start_date>November 2004</start_date>
    <completion_date>December 2006</completion_date>
    <last_updated>August 21, 2007</last_updated>
    <last_verified>August 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>HCV RNA levels at clinically relevant timepoints</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Russian Federation</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00097045</url>
  </study>
  <study rank="440">
    <nct_id>NCT01188772</nct_id>
    <title>Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Placebo to match sofosbuvir</intervention>
      <intervention type="Drug">PEG</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>147</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P7977-0422</other_id>
    </other_ids>
    <first_received>August 23, 2010</first_received>
    <start_date>August 2010</start_date>
    <completion_date>May 2012</completion_date>
    <last_updated>April 2, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>January 6, 2014</firstreceived_results_date>
    <primary_completion_date>April 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Who Experienced Adverse Events During the Sofosbuvir Treatment Period</outcome_measure>
      <outcome_measure>Change in HCV RNA From Baseline to Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Virologic Response at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Complete Early Virologic Response at Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With Extended Rapid Virologic Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Response at the End of Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Post-treatment Week 12 (SVR12) and 24 (SVR24)</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007 (Cmax at Day 8)</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007 (Cmax at Day 15)</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007 (Cmax at Day 29)</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007 (AUCtau at Day 8)</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007 (AUCtau at Day 15)</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007 (AUCtau at Day 29)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Developed Resistance to Sofosbuvir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Texas</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01188772</url>
  </study>
  <study rank="441">
    <nct_id>NCT00724451</nct_id>
    <title>Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Biological">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1128</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05488</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>July 2008</start_date>
    <completion_date>October 2011</completion_date>
    <last_updated>September 24, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>October 5, 2012</firstreceived_results_date>
    <primary_completion_date>October 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Not Eligible for Antiviral Treatment by Reason for Non-eligibility</outcome_measure>
      <outcome_measure>Number of Participants Discontinued From Treatment by Reason for Discontinuation</outcome_measure>
      <outcome_measure>Number of Participants With Treatment Failure by Reason for Failure</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00724451</url>
  </study>
  <study rank="442">
    <nct_id>NCT02556307</nct_id>
    <title>A Study of the Effictiveness of Peginterferon Alfa-2a (Pegasys) and Ribavirin Treatment in Slovenian Hepatitis C (HCV) Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribaverin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>270</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML22263</other_id>
    </other_ids>
    <first_received>September 21, 2015</first_received>
    <start_date>March 2009</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>September 21, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Virological Response (SVR) According to Genotype and Previous Treatment</outcome_measure>
      <outcome_measure>Percentage of participants with undetectable hepatitis C virus (HCV) ribonucleic acid (RNA)</outcome_measure>
      <outcome_measure>Pre, during and post treatment values HCV RNA</outcome_measure>
      <outcome_measure>Pre, during and post treatment values of Thrombocytes</outcome_measure>
      <outcome_measure>Pre, during and post treatment values of leukocytes</outcome_measure>
      <outcome_measure>Pre, during and post treatment values of hemoglobin</outcome_measure>
      <outcome_measure>Treatment duration (in weeks) with peginterferon alfa-2a and ribavirin</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Slovenia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02556307</url>
  </study>
  <study rank="443">
    <nct_id>NCT01987453</nct_id>
    <title>Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Subjects With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-1118</other_id>
      <other_id>2014-001245-24</other_id>
    </other_ids>
    <first_received>November 12, 2013</first_received>
    <start_date>November 2013</start_date>
    <completion_date>November 2015</completion_date>
    <last_updated>December 10, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of adverse events leading to permanent discontinuation of study drug</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV RNA &lt; LLOQ while on treatment</outcome_measure>
      <outcome_measure>Change in HCV RNA from Baseline</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>France</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01987453</url>
  </study>
  <study rank="444">
    <nct_id>NCT02537379</nct_id>
    <title>Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">COPE</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
      <collaborator>Chugai Pharmaceutical</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Ecologic or Community</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-1444 / COPE1501</other_id>
    </other_ids>
    <first_received>August 28, 2015</first_received>
    <start_date>September 2015</start_date>
    <completion_date>May 2018</completion_date>
    <last_updated>December 2, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Incidence of adverse drug reaction (ADR) under real world settings</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) 12 and 24 weeks after discontinuation of therapy (SVR12 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV NS5B resistance associated variants among patients who do not achieve SVR at 12 weeks</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02537379</url>
  </study>
  <study rank="445">
    <nct_id>NCT00274495</nct_id>
    <title>Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
      <condition>Fatty Liver</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rosiglitazone and Pegasys/Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Beth Israel Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>098-04</other_id>
    </other_ids>
    <first_received>January 9, 2006</first_received>
    <start_date>January 2006</start_date>
    <completion_date>October 2007</completion_date>
    <last_updated>October 31, 2007</last_updated>
    <last_verified>January 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>To compare the efficacy of Rosiglitazone in combination with pegylated interferon alfa-2a and ribavirin (weight-based) to that of pegylated interferon alfa-2a and ribavirin alone in terms of sustained viral response.</outcome_measure>
      <outcome_measure>To compare the safety and tolerability of Rosiglitazone in combination with pegylated interferon-2a and ribavirin to that of pegylated interferon alfa-2a and ribavirin alone in terms of adverse events.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00274495</url>
  </study>
  <study rank="446">
    <nct_id>NCT02562742</nct_id>
    <title>Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">REB</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Ecologic or Community</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-1879</other_id>
    </other_ids>
    <first_received>September 28, 2015</first_received>
    <start_date>November 2015</start_date>
    <completion_date>June 2018</completion_date>
    <last_updated>December 3, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Incidence of adverse drug reaction (ADR) under real world settings</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) 12 and 24 weeks after discontinuation of therapy (SVR12 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV NS5B resistance associated variants among patients who do not achieve SVR at 12 weeks</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02562742</url>
  </study>
  <study rank="447">
    <nct_id>NCT01263860</nct_id>
    <title>A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-6 Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Third Affiliated Hospital, Sun Yat-Sen University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>242</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TAH115G6HCV</other_id>
    </other_ids>
    <first_received>December 20, 2010</first_received>
    <start_date>December 2010</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>November 14, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (SVR)</outcome_measure>
      <outcome_measure>Change in health related quality as measured by short from 36 (SF-36) from baseline to 24 weeks after the end of treatment</outcome_measure>
      <outcome_measure>Sick leave in patients treated for 24 or 48 weeks treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01263860</url>
  </study>
  <study rank="448">
    <nct_id>NCT00922779</nct_id>
    <title>A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>7755</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML16709</other_id>
    </other_ids>
    <first_received>June 16, 2009</first_received>
    <start_date>June 2002</start_date>
    <completion_date>June 2012</completion_date>
    <last_updated>September 1, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Adverse events; laboratory parameters</outcome_measure>
      <outcome_measure>Sustained viral response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Russian Federation</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00922779</url>
  </study>
  <study rank="449">
    <nct_id>NCT00211692</nct_id>
    <title>Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">consensus interferon (Interferon Alfacon-1) and ribavirin</intervention>
      <intervention type="Drug">Consensus Interferon alfa (CIFN) and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Minneapolis Veterans Affairs Medical Center</lead_sponsor>
      <collaborator>Minnesota Veterans Research Institute</collaborator>
      <collaborator>InterMune</collaborator>
      <collaborator>Kadmon Pharmaceuticals</collaborator>
      <collaborator>VA Office of Research and Development</collaborator>
      <collaborator>San Diego Veterans Healthcare System</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>64</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>MVRI001</other_id>
    </other_ids>
    <first_received>September 13, 2005</first_received>
    <start_date>July 2005</start_date>
    <completion_date>September 2009</completion_date>
    <last_updated>November 20, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>August 1, 2011</firstreceived_results_date>
    <primary_completion_date>July 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Primary Endpoint Would be the Number Who Achieve a Sustained Virologic Response.</outcome_measure>
      <outcome_measure>Number of Participants Discontinuing Early From Study Treatment</outcome_measure>
      <outcome_measure>Participants Achieving SVR Categorized by Time of Response</outcome_measure>
      <outcome_measure>Overall Number of Serious Adverse Events</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00211692</url>
  </study>
  <study rank="450">
    <nct_id>NCT00990938</nct_id>
    <title>Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Treatment Naïve, Genotype 1 Patients</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">IMO-2125</intervention>
      <intervention type="Drug">Saline</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Idera Pharmaceuticals, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>IMO-2125-201</other_id>
    </other_ids>
    <first_received>October 6, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>January 2011</completion_date>
    <last_updated>May 15, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and tolerability of 3 different dosages of IMO-2125 in combination with standard ribavirin compared to placebo and ribavirin.</outcome_measure>
      <outcome_measure>Assess rapid viral response (RVR) rate, defined as undetectable HCV-RNA at week 4</outcome_measure>
      <outcome_measure>Assess the effects of 3 different dosages of IMO-2125 in combination with standard ribavirin on viral load</outcome_measure>
      <outcome_measure>Characterize the pharmacodynamics in combination with ribavirin in HCV-infected patients</outcome_measure>
      <outcome_measure>Describe the viral kinetics per individual patient</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00990938</url>
  </study>
  <study rank="451">
    <nct_id>NCT02259855</nct_id>
    <title>Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatic Insufficiency</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tipranavir</intervention>
      <intervention type="Drug">Ritonavir</intervention>
      <intervention type="Drug">Pegylated interferon</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1182.59</other_id>
    </other_ids>
    <first_received>September 24, 2014</first_received>
    <start_date>January 2006</start_date>
    <last_updated>October 7, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Area under the concentration-time curve from 0 to 12 hours of ribavirin (RBV), tipranavir (TPV) and ritonavir (RTV) in the plasma (AUC0-12h)</outcome_measure>
      <outcome_measure>Area under the concentration-time curve from 0 to 24 hours of pegylated interferon (Peg IFN) in the plasma (AUC0-24h)</outcome_measure>
      <outcome_measure>Maximum measured concentration of RBV, Peg INF, TPV and RTV in the plasma (Cmax)</outcome_measure>
      <outcome_measure>Measured concentration of RBV, TPV and RTV in the plasma at 12 hours (Cp12h)</outcome_measure>
      <outcome_measure>Measured concentration of Peg INF in the plasma at 24 hours (Cp24h)</outcome_measure>
      <outcome_measure>Area under the concentration-time curve from 0 extrapolated to infinity of TPV and RTV in the plasma (AUC0-∞)</outcome_measure>
      <outcome_measure>Time from dosing to the maximum concentration of the analytes in the plasma (tmax)</outcome_measure>
      <outcome_measure>Terminal half-life of the analytes in the plasma (t1/2)</outcome_measure>
      <outcome_measure>Apparent clearance of the analytes in the plasma after extra vascular administration (CL/F)</outcome_measure>
      <outcome_measure>Apparent volume of distribution of the analytes in the plasma (Vz/F)</outcome_measure>
      <outcome_measure>Number of patients with clinically significant changes in laboratory values</outcome_measure>
      <outcome_measure>Number of patients with adverse events</outcome_measure>
      <outcome_measure>Number of patients with clinically significant changes in vital signs (seated blood pressure, pulse rate)</outcome_measure>
      <outcome_measure>Number of patients with clinically significant changes from baseline in 12-lead ECG</outcome_measure>
      <outcome_measure>Assessment of tolerability by the investigator</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02259855</url>
  </study>
  <study rank="452">
    <nct_id>NCT01573351</nct_id>
    <title>Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Asunaprevir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Peg-interferon Alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>398</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI447-029</other_id>
      <other_id>2011-005422-21</other_id>
    </other_ids>
    <first_received>April 5, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>Hallmark QUAD</acronym>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of genotype 1 subjects with SVR12, defined as HCV RNA &lt; LOQ at post-treatment Week 12, for all subjects infected with HCV genotype 1</outcome_measure>
      <outcome_measure>On-treatment safety, as measured by frequency of Serious Adverse Events (SAEs) and discontinuations due to Adverse Events (AEs) through the end of treatment</outcome_measure>
      <outcome_measure>Proportion of subjects with SVR12 (HCV RNA &lt; LOQ at post-treatment Week 12) by the rs12979860 single nucleotide polymorphisms (SNP) in the IL28 gene</outcome_measure>
      <outcome_measure>Proportion of subjects with HCV RNA undetectable</outcome_measure>
      <outcome_measure>Proportion of subjects with HCV RNA &lt; LOQ</outcome_measure>
      <outcome_measure>Proportion of patients with SVR12 (HCV RNA &lt; LOQ at post-treatment Week 12) for HCV genotype 4 subjects</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Argentina</country>
      <country>Denmark</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Korea, Republic of</country>
      <country>Mexico</country>
      <country>Netherlands</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>Switzerland</country>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01573351</url>
  </study>
  <study rank="453">
    <nct_id>NCT01241760</nct_id>
    <title>VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Genotype 1 Chronic Hepatitis C</condition>
      <condition>Treatment Naive</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Infectious Diseases BVBA</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>744</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR013711</other_id>
      <other_id>OPTIMIZE-HCV</other_id>
      <other_id>VX-950-C211</other_id>
      <other_id>2010-021628-84</other_id>
    </other_ids>
    <first_received>October 28, 2010</first_received>
    <start_date>December 2010</start_date>
    <completion_date>November 2012</completion_date>
    <last_updated>May 14, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>September 23, 2013</firstreceived_results_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After the Last Planned Dose of Study Drugs (SVR12 Planned)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 24 Weeks After the Last Planned Dose of Study Drugs (SVR24 Planned)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 72 Weeks After the Start of Study Medication (SVR72 Planned)</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values of Less Than 25 IU/ml, Target Not Detected, at Different Time Points.</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Virologic Failure Which Required Them to Permanently Discontinue All Study Drugs</outcome_measure>
      <outcome_measure>Percentage of Participants Who Relapsed During Follow-up Period</outcome_measure>
      <outcome_measure>Percentage of Participants of Each IL28B Genotype Achieving Sustained Virologic Response 12 Weeks After the Last Planned Dose of Study Medication (SVR12 Planned)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>France</country>
      <country>Germany</country>
      <country>Ireland</country>
      <country>Mexico</country>
      <country>Poland</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Missouri</state>
      <state>New Hampshire</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>South Carolina</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01241760</url>
  </study>
  <study rank="454">
    <nct_id>NCT01466192</nct_id>
    <title>Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MP-424 (generic name:Telaprevir)</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>108</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>G060-A10</other_id>
    </other_ids>
    <first_received>November 2, 2011</first_received>
    <start_date>May 2012</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>October 29, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>October 29, 2014</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01466192</url>
  </study>
  <study rank="455">
    <nct_id>NCT00656006</nct_id>
    <title>A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Albuferon</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Human Genome Sciences Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>43</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HGS1008-C1052 (ALFR-HC-06)</other_id>
    </other_ids>
    <first_received>December 20, 2005</first_received>
    <start_date>November 2005</start_date>
    <completion_date>April 2007</completion_date>
    <last_updated>August 1, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Primary safety endpoints are the common side effects of IFNa therapy including flu-like symptoms, depression, and hematologic abnormalities.</outcome_measure>
      <outcome_measure>Primary efficacy end point is sustained virologic response (SVR), defined as undetectable HCV RNA at 24 weeks after the end of therapy.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00656006</url>
  </study>
  <study rank="456">
    <nct_id>NCT01441804</nct_id>
    <title>A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for Patients With Genotype 1 Hepatitis C and IL28B CC Polymorphism</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Third Affiliated Hospital, Sun Yat-Sen University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TAHG1IL-28BCC</other_id>
    </other_ids>
    <first_received>September 24, 2011</first_received>
    <start_date>May 2011</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>September 28, 2013</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (SVR)</outcome_measure>
      <outcome_measure>Change in health related quality as measured by short from 36 (SF-36) from baseline to 24 weeks after the end of treatment</outcome_measure>
      <outcome_measure>Sick leave in patients treated for 24 or 48 weeks treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01441804</url>
  </study>
  <study rank="457">
    <nct_id>NCT01429792</nct_id>
    <title>A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 &amp; 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>940</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML21779</other_id>
    </other_ids>
    <first_received>September 5, 2011</first_received>
    <start_date>September 2008</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Rate of genotype 1 patients with partial early viral response (pEVR, a 2-log decrement but with detectable HCV RNA at Week 12 of standard treatment)</outcome_measure>
      <outcome_measure>Rate of genotype 1 patients with complete early viral response (cEVR, undetectable HCV RNA at Week 12 of standard treatment)</outcome_measure>
      <outcome_measure>Rate of genotype 1 patients with pEVR at Week 12 and undetectable HCV RNA at Week 24</outcome_measure>
      <outcome_measure>Rate of genotype 2 &amp; 3 patients not achieving rapid viral response (RVR, defined as undetectable HCV RNA at Week 4 of standard treatment)</outcome_measure>
      <outcome_measure>Rate of genotype 2 &amp; 3 patients achieving virological response at Week 24 (EOT - end of treatment, defined as undetectable HVC RNA)</outcome_measure>
      <outcome_measure>Rate of genotype 4 patients with partial EVR</outcome_measure>
      <outcome_measure>Rate of genotype 4 patients with complete EVR</outcome_measure>
      <outcome_measure>Rate of genotype 4 patients with pEVR at Week 12 and undetectable HCV RNA at Week 24</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Israel</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01429792</url>
  </study>
  <study rank="458">
    <nct_id>NCT00412334</nct_id>
    <title>SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>104</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML20399</other_id>
    </other_ids>
    <first_received>December 15, 2006</first_received>
    <start_date>January 2007</start_date>
    <completion_date>September 2010</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained viral response</outcome_measure>
      <outcome_measure>Percentage of patients with &gt;=2log drop of HCV-RNA</outcome_measure>
      <outcome_measure>Percentage of patients with non-detectable HCV-RNA</outcome_measure>
      <outcome_measure>Relapse rate</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00412334</url>
  </study>
  <study rank="459">
    <nct_id>NCT01468584</nct_id>
    <title>Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MP-424 (generic name:Telaprevir)</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>G060-A11</other_id>
    </other_ids>
    <first_received>November 2, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>October 29, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>October 29, 2014</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01468584</url>
  </study>
  <study rank="460">
    <nct_id>NCT01447420</nct_id>
    <title>A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a</intervention>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>129</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML25592</other_id>
    </other_ids>
    <first_received>October 4, 2011</first_received>
    <start_date>February 2011</start_date>
    <completion_date>November 2012</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Rate of sustained virological response (undetectable HCV RNA 24 weeks after end of treatment) in relation to Interleukin 28B (IL28-b) expression</outcome_measure>
      <outcome_measure>Incidence of anemia</outcome_measure>
      <outcome_measure>Response rate (rapid/early/end of treatment) in relation to IL28-b expression</outcome_measure>
      <outcome_measure>Correlation between sustained virological response and anemia (Hb levels) during the first month of treatment</outcome_measure>
      <outcome_measure>Correlation between sustained virological response and anemia (Hb levels) after the first month of treatment</outcome_measure>
      <outcome_measure>Correlation between viral load (HCV RNA levels) 12 weeks after the end of treatment and sustained virological response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Brazil</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01447420</url>
  </study>
  <study rank="461">
    <nct_id>NCT00001123</nct_id>
    <title>A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hantavirus Pulmonary Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>130</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>95-066</other_id>
    </other_ids>
    <first_received>January 17, 2000</first_received>
    <completion_date>November 2005</completion_date>
    <last_updated>August 26, 2010</last_updated>
    <last_verified>November 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00001123</url>
  </study>
  <study rank="462">
    <nct_id>NCT00780910</nct_id>
    <title>Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MP-424</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon Alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>109</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>G060-A8</other_id>
    </other_ids>
    <first_received>October 24, 2008</first_received>
    <start_date>November 2008</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>April 16, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>June 5, 2012</firstreceived_results_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Subjects Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00780910</url>
  </study>
  <study rank="463">
    <nct_id>NCT00856804</nct_id>
    <title>Thalidomide Plus Peginterferon and Ribavirin in Patients With Interferon Resistance</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">thalidomide</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Valme University Hospital</lead_sponsor>
      <collaborator>University of Seville</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TRITAL</other_id>
    </other_ids>
    <first_received>March 3, 2009</first_received>
    <start_date>March 2009</start_date>
    <completion_date>June 2012</completion_date>
    <last_updated>March 5, 2009</last_updated>
    <last_verified>March 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>TRITAL</acronym>
    <primary_completion_date>June 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Virological response at week 12</outcome_measure>
      <outcome_measure>Sustained virological response 24 weeks after the end of therapy</outcome_measure>
      <outcome_measure>Safety of using thalidomide together with SOC.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00856804</url>
  </study>
  <study rank="464">
    <nct_id>NCT00336518</nct_id>
    <title>Continuing Treatment With Pegasys and Copegus</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Májbetegekért Alapítvány</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>MBA 1/2005</other_id>
      <other_id>ML 20142</other_id>
      <other_id>EuDract: 2005-004531-22</other_id>
    </other_ids>
    <first_received>June 12, 2006</first_received>
    <start_date>June 2006</start_date>
    <completion_date>July 2009</completion_date>
    <last_updated>June 12, 2006</last_updated>
    <last_verified>August 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Sustained viral response given to continuation or prolongation of combined Pegasys&amp;Copegus treatment</outcome_measure>
      <outcome_measure>Histological response given to continuation or prolongation of combined Pegasys&amp;Copegus treatment measured by non-invasive methods</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Hungary</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00336518</url>
  </study>
  <study rank="465">
    <nct_id>NCT01033448</nct_id>
    <title>A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">COPEGUS</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>59</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML21778</other_id>
    </other_ids>
    <first_received>December 15, 2009</first_received>
    <start_date>December 2009</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy: end of treatment response rate (virological), sustained viral response</outcome_measure>
      <outcome_measure>Safety and Tolerability: AEs, laboratory parameters</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Israel</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01033448</url>
  </study>
  <study rank="466">
    <nct_id>NCT00475072</nct_id>
    <title>A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>14</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML16814</other_id>
    </other_ids>
    <first_received>May 16, 2007</first_received>
    <start_date>June 2003</start_date>
    <completion_date>July 2006</completion_date>
    <last_updated>November 2, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR</outcome_measure>
      <outcome_measure>AEs, laboratory parameters.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Mexico</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00475072</url>
  </study>
  <study rank="467">
    <nct_id>NCT01598090</nct_id>
    <title>Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon Lambda-1a</intervention>
      <intervention type="Biological">Peginterferon Alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>636</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI452-020</other_id>
      <other_id>2011-004695-11</other_id>
    </other_ids>
    <first_received>May 9, 2012</first_received>
    <start_date>June 2012</start_date>
    <completion_date>January 2016</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PEDESTAL</acronym>
    <primary_completion_date>February 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Part A: Proportion of subjects achieving efficacy as measured by Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>Part A: Safety as measured by the frequency of deaths, Serious Adverse Events (SAEs), drug related Adverse Events (AEs), dose reductions and discontinuations due to AEs</outcome_measure>
      <outcome_measure>Part B: Proportion of subjects achieving efficacy as measured by Sustained Virologic Response at post-treatment Week12 (SVR 12) defined as HCV RNA &lt; 25 IU/ml</outcome_measure>
      <outcome_measure>Part A: Proportion of subjects who achieve efficacy as measured by SVR12, defined as HCV RNA &lt; 25 IU/ml</outcome_measure>
      <outcome_measure>Part A: Proportion of subjects who achieve efficacy as measured by SVR24, defined as HCV RNA &lt; 25 IU/ml</outcome_measure>
      <outcome_measure>Part B: Proportion of subjects who achieve efficacy as measured by SVR12, defined as hepatitis C virus (HCV) RNA &lt; 25 IU/ml in treatment-naive subjects</outcome_measure>
      <outcome_measure>Part B: Proportion of subjects who achieve efficacy as measured by eRVR, defined as HCV RNA undetectable</outcome_measure>
      <outcome_measure>Part B: Proportion of subjects who achieve efficacy as measured by SVR 24, defined as HCV RNA &lt; 25 IU/ml</outcome_measure>
      <outcome_measure>Part B: Number of incidence for Cytopenic abnormalities (anemia is defined by Hb &lt; 10 g/dL, neutropenia as defined by ANC &lt; 750 mm3, thrombocytopenia as defined by platelets &lt; 50,000 mm3)</outcome_measure>
      <outcome_measure>Part B: Number of incidence for Flu-like symptoms (as defined by pyrexia or chills or pain)</outcome_measure>
      <outcome_measure>Part B: Number of incidence for Musculoskeletal symptoms (as defined by arthralgia or myalgia or back pain)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>Czech Republic</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Poland</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Switzerland</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>Missouri</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01598090</url>
  </study>
  <study rank="468">
    <nct_id>NCT02032875</nct_id>
    <title>Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>116</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-215</other_id>
    </other_ids>
    <first_received>January 9, 2014</first_received>
    <start_date>March 2014</start_date>
    <completion_date>January 2016</completion_date>
    <last_updated>October 20, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>August 18, 2015</firstreceived_results_date>
    <acronym>ALLY 1</acronym>
    <primary_completion_date>November 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Genotype-1 Infected Cirrhotic Participants With Sustained Virologic Response at Post-treatment Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Genotype-1 Infected Post-liver Transplanted Participants With Sustained Virologic Response at Post-treatment Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieved Sustained Virologic Response at Post-treatment Week 12 (SVR12) for All Genotypes and Genotypes 2, 3, 4, 6</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieve Hepatitis C Virus RNA Levels to be &lt; Lower Limit of Quantitation Target Detected or Target Not Detected at Each of the Following Weeks: 1, 2, 4, 6, 8, 12, End of Treatment; Follow Up Weeks 4, 8 and 12</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieve Hepatitis C Virus RNA Levels to be &lt; Lower Limit of Quantitation Target Not Detected at Each of the Following Weeks: 1, 2, 4, 6, 8, 12, End of Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With CC or Non-CC Genotype Who Achieved Sustained Virologic Response at 12 Weeks After the Last Dose of Study Drug (SVR12)</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), AEs Leading to Interruption, Treatment-related AEs/SAEs, Grade 3 to 4 AEs/SAEs, and Who Died During Treatment Period</outcome_measure>
      <outcome_measure>Number of Participants With Treatment Emergent Grade 3-4 Laboratory Abnormalities</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Florida</state>
      <state>Michigan</state>
      <state>Texas</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02032875</url>
  </study>
  <study rank="469">
    <nct_id>NCT01011166</nct_id>
    <title>Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">IDX184</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Biological">Peginterferon alfa-2a (Peg-IFN)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>81</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>2355-004</other_id>
      <other_id>IDX-08C-004</other_id>
    </other_ids>
    <first_received>October 2, 2009</first_received>
    <start_date>November 2009</start_date>
    <completion_date>July 2010</completion_date>
    <last_updated>April 22, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in HCV ribonucleic acid (RNA) level from Baseline to Day 15</outcome_measure>
      <outcome_measure>Percentage of participants experiencing adverse events (AEs)</outcome_measure>
      <outcome_measure>Percentage of participants experiencing serious adverse events (SAEs)</outcome_measure>
      <outcome_measure>Percentage of participants experiencing dose-limiting toxicities (DLTs)</outcome_measure>
      <outcome_measure>Percentage of participants experiencing Grade 1-4 laboratory abnormalities</outcome_measure>
      <outcome_measure>Change in HCV RNA level from Baseline to Day 28</outcome_measure>
      <outcome_measure>Percentage of participants with undetectable HCV RNA at Day 15</outcome_measure>
      <outcome_measure>Percentage of participants with undetectable HCV RNA at Day 28</outcome_measure>
      <outcome_measure>Percentage of participants experiencing virologic breakthrough while on study therapy</outcome_measure>
      <outcome_measure>Change in alanine aminotransferase (ALT) level from Baseline to Day 15</outcome_measure>
      <outcome_measure>Change in ALT level from Baseline to Day 28</outcome_measure>
      <outcome_measure>Maximum concentration (Cmax)</outcome_measure>
      <outcome_measure>Time to maximum concentration (Tmax)</outcome_measure>
      <outcome_measure>Area under the drug concentration-time curve (AUC) from time 0 to last measurable concentration (AUC0-t)</outcome_measure>
      <outcome_measure>AUC from time zero to infinity (AUC0-~)</outcome_measure>
      <outcome_measure>Trough concentration (Ctrough)</outcome_measure>
      <outcome_measure>Observed terminal half-life (Thalf)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01011166</url>
  </study>
  <study rank="470">
    <nct_id>NCT02105454</nct_id>
    <title>Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Grazoprevir</intervention>
      <intervention type="Drug">Elbasvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>79</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>5172-048</other_id>
      <other_id>2013-004213-41</other_id>
    </other_ids>
    <first_received>April 2, 2014</first_received>
    <start_date>May 2014</start_date>
    <completion_date>May 2015</completion_date>
    <last_updated>June 3, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants achieving SVR at 12 weeks after the end of all study therapy (SVR12)</outcome_measure>
      <outcome_measure>Number of participants experiencing adverse events</outcome_measure>
      <outcome_measure>Number of participants discontinuing study drug due to adverse events</outcome_measure>
      <outcome_measure>Percentage of participants achieving SVR12 by prior DAA therapy</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02105454</url>
  </study>
  <study rank="471">
    <nct_id>NCT02207088</nct_id>
    <title>Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Hepatitis C Virus</condition>
      <condition>Compensated Cirrhosis</condition>
      <condition>Severe Renal Impairment</condition>
      <condition>End-stage Renal Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ombitasvir/paritaprevir/ritonavir</intervention>
      <intervention type="Drug">dasabuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M14-226</other_id>
      <other_id>2014-001527-77</other_id>
    </other_ids>
    <first_received>July 31, 2014</first_received>
    <start_date>September 2014</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>October 16, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of subjects with Sustained Virologic Response 12 weeks post-treatment</outcome_measure>
      <outcome_measure>Percentage of subjects with on-treatment virologic failure</outcome_measure>
      <outcome_measure>Percentage of subjects with post-treatment relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02207088</url>
  </study>
  <study rank="472">
    <nct_id>NCT02098616</nct_id>
    <title>Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DCV/ASV/BMS-791325</intervention>
      <intervention type="Drug">DCV/ASV/BMS-791325 + RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Timothy Morgan, MD</lead_sponsor>
      <collaborator>VA Long Beach Healthcare System</collaborator>
      <collaborator>National Cancer Institute (NCI)</collaborator>
      <collaborator>Bristol-Myers Squibb</collaborator>
      <collaborator>Southern California Institute for Research and Education</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>U.S. Fed</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB #1285</other_id>
      <other_id>AI443-128</other_id>
    </other_ids>
    <first_received>March 25, 2014</first_received>
    <start_date>July 2014</start_date>
    <last_updated>July 10, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>RHACE 1</acronym>
    <primary_completion_date>April 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response</outcome_measure>
      <outcome_measure>Safety</outcome_measure>
      <outcome_measure>Sustained virologic response</outcome_measure>
      <outcome_measure>Post treatment virologic response</outcome_measure>
      <outcome_measure>On treatment virologic response</outcome_measure>
      <outcome_measure>Virologic failure</outcome_measure>
      <outcome_measure>Day 2 positive predictive value</outcome_measure>
      <outcome_measure>Interferon lambda genotype and virologic response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02098616</url>
  </study>
  <study rank="473">
    <nct_id>NCT00087594</nct_id>
    <title>A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML17251</other_id>
    </other_ids>
    <first_received>July 12, 2004</first_received>
    <start_date>November 2003</start_date>
    <completion_date>October 2006</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Treatment completion rate\n</outcome_measure>
      <outcome_measure>AEs, laboratory parameters.</outcome_measure>
      <outcome_measure>Beck Depression Inventory, HQLQ, SVR, biochemical response.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Connecticut</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>New York</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00087594</url>
  </study>
  <study rank="474">
    <nct_id>NCT00727077</nct_id>
    <title>Post-marketing Surveillance of Children With Chronic Hepatitis C Treated With Intron A (Vial or Pen) and Rebetol (Study P04397)(TERMINATED)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">IntronA (interferon alfa-2b; SCH 30500)</intervention>
      <intervention type="Drug">Rebetol (ribavirin; SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases/>
    <enrollment>3</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04397</other_id>
    </other_ids>
    <first_received>July 30, 2008</first_received>
    <start_date>June 2006</start_date>
    <completion_date>June 2007</completion_date>
    <last_updated>April 7, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Incidence of serious adverse events</outcome_measure>
      <outcome_measure>Sustained virologic response (defined as undetectable viral load at 24 weeks post-treatment)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00727077</url>
  </study>
  <study rank="475">
    <nct_id>NCT01909401</nct_id>
    <title>Pilot Study With Peginterferon, Ribavirin, and Boceprevir Prior to Transplantation to Clear Virus in Hepatitis C Genotype 1 Infected Individuals Undergoing Orthotopic Liver Transplantation</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Liver Transplantation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Indiana University</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>1</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1301010500</other_id>
    </other_ids>
    <first_received>June 13, 2013</first_received>
    <start_date>June 2013</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>July 23, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of individuals who can remain HCV RNA undetected 6 months post orthotopic liver transplant after receiving peginterferon, ribavirin, and boceprevir.</outcome_measure>
      <outcome_measure>Safety and efficacy of peginterferon, ribavirin, and boceprevir in patients with genotype I undergoing orthotopic liver transplant for cirrhosis and/or hepatocellular carcinoma.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Indiana</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01909401</url>
  </study>
  <study rank="476">
    <nct_id>NCT01482767</nct_id>
    <title>Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated-Interferon Alfa 2b (PEG-IFN)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">Boceprevir (BOC)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>262</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>A5294 (BIRTH)</other_id>
      <other_id>11774</other_id>
      <other_id>ACTG 5294</other_id>
      <other_id>BIRTH</other_id>
    </other_ids>
    <first_received>November 28, 2011</first_received>
    <start_date>April 2012</start_date>
    <completion_date>April 2015</completion_date>
    <last_updated>December 2, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virological Response (SVR) defined as undetectable HCV RNA</outcome_measure>
      <outcome_measure>Grade 3 or higher signs and symptoms and laboratory abnormalities and other serious adverse events (AEs) during the study</outcome_measure>
      <outcome_measure>Undetectable HCV RNA discontinuation (SVR12)</outcome_measure>
      <outcome_measure>Baseline HIV-1 viral load and changes from baseline at each post-entry visit</outcome_measure>
      <outcome_measure>Baseline CD4+ T-cell count and changes from baseline at each post-entry visit</outcome_measure>
      <outcome_measure>Baseline fibrosis stage, race, gender, insulin sensitivity, and HCV viral load level</outcome_measure>
      <outcome_measure>Undetectable HCV RNA</outcome_measure>
      <outcome_measure>Grade 2 or higher signs and symptoms and laboratory abnormalities and other serious AEs</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01482767</url>
  </study>
  <study rank="477">
    <nct_id>NCT02446717</nct_id>
    <title>A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With Genotype 1 HCV Who Failed a Prior DAA Containing Therapy</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Hepatitis C Virus</condition>
      <condition>HCV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-493</intervention>
      <intervention type="Drug">ABT-530</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M15-410</other_id>
      <other_id>2015-002350-13</other_id>
    </other_ids>
    <first_received>May 14, 2015</first_received>
    <start_date>April 2015</start_date>
    <completion_date>June 2016</completion_date>
    <last_updated>November 13, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants with sustained virologic response (SVR) 12</outcome_measure>
      <outcome_measure>Percentage of participants with sustained virologic response (SVR) 4</outcome_measure>
      <outcome_measure>Percentage of participants with virologic failure during treatment</outcome_measure>
      <outcome_measure>Percentage of participants with Post-Treatment relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02446717</url>
  </study>
  <study rank="478">
    <nct_id>NCT01458535</nct_id>
    <title>A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-267 and With and Without Ribavirin (RBV) in Treatment-Naïve Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450/r</intervention>
      <intervention type="Drug">ABT-267</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie (prior sponsor, Abbott)</lead_sponsor>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>61</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M12-998</other_id>
    </other_ids>
    <first_received>September 23, 2011</first_received>
    <start_date>October 2011</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>May 30, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>Navigator</acronym>
    <primary_completion_date>May 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Assess the safety and antiviral activity (proportion of subjects with hepatitis C ribonucleic acid (HCV RNA) &lt; lower limit of quantitation (LLOQ)</outcome_measure>
      <outcome_measure>Assess the percentage of subjects with SVR12 (HCV RNA &lt; LLOQ 12 Weeks post-treatment)</outcome_measure>
      <outcome_measure>Assess the percentage of subjects with SVR24 (HCV RNA &lt; LLOQ 24 Weeks post-treatment)</outcome_measure>
      <outcome_measure>Assess the percentage of subjects with HCV RNA &lt; 1000 IU/mL</outcome_measure>
      <outcome_measure>Assess the percentage of subjects with HCV RNA &lt; LLOQ</outcome_measure>
      <outcome_measure>Assess the time to failure to suppress, rebound or relapse (confirmed increase of at least 1 log10 IU/mL above nadir or confirmed HCV RNA &gt; LLOQ for subjects who previously achieved HCV RNA &lt; LLOQ)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Louisiana</state>
      <state>Missouri</state>
      <state>Ohio</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01458535</url>
  </study>
  <study rank="479">
    <nct_id>NCT02097966</nct_id>
    <title>EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C</title>
    <recruitment open="Y">Available</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Expanded Access</study_types>
    <study_designs/>
    <other_ids>
      <other_id>AI444-237</other_id>
    </other_ids>
    <first_received>March 25, 2014</first_received>
    <last_updated>November 19, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>Austria</country>
      <country>Germany</country>
      <country>Netherlands</country>
      <country>Sweden</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02097966</url>
  </study>
  <study rank="480">
    <nct_id>NCT02150291</nct_id>
    <title>A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin.</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Folic acid</intervention>
      <intervention type="Drug">Neurobion</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>British University In Egypt</lead_sponsor>
      <collaborator>Ain Shams University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
      <study_design>Masking: Single Blind (Subject)</study_design>
    </study_designs>
    <other_ids>
      <other_id>2107</other_id>
    </other_ids>
    <first_received>May 27, 2014</first_received>
    <start_date>May 2014</start_date>
    <completion_date>November 2015</completion_date>
    <last_updated>May 27, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Effect of folic acid and/or Vitamin B complex to prevent adverse effect of pegylated interferon and ribavirin</outcome_measure>
      <outcome_measure>Effect of folic acid and/or Vitamin B complex on the efficacy of pegylated interferon and ribavirin.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02150291</url>
  </study>
  <study rank="481">
    <nct_id>NCT00383864</nct_id>
    <title>Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hospital Clinic of Barcelona</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>55</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>PEG/RBV POST-TOH</other_id>
    </other_ids>
    <first_received>October 2, 2006</first_received>
    <start_date>July 2001</start_date>
    <completion_date>March 2006</completion_date>
    <last_updated>October 5, 2006</last_updated>
    <last_verified>October 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Histological improvement (decrease in at least one fibrosis stage in follow-up liver biop</outcome_measure>
      <outcome_measure>Sustained virological response (persistent HCV-RNA negativation)</outcome_measure>
      <outcome_measure>Safety of antiviral therapy</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00383864</url>
  </study>
  <study rank="482">
    <nct_id>NCT00709059</nct_id>
    <title>Efficacy of PegIntron and Rebetol in Previously Untreated Patients With Chronic Hepatitis C Infected With HCV Genotype 1/4/5/6 (Study P04243)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b; SCH 54031)</intervention>
      <intervention type="Drug">Rebetol (ribavirin; SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>538</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04243</other_id>
    </other_ids>
    <first_received>June 23, 2008</first_received>
    <start_date>December 2004</start_date>
    <completion_date>December 2009</completion_date>
    <last_updated>November 3, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>December 22, 2010</firstreceived_results_date>
    <acronym>PRACTICE</acronym>
    <primary_completion_date>December 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Study Participants Who Had a Virological Response (VR) at Week-72</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00709059</url>
  </study>
  <study rank="483">
    <nct_id>NCT02399345</nct_id>
    <title>Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus (HCV Infection Genotype 1)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ombitasvir/paritaprevir/ritonavir</intervention>
      <intervention type="Drug">dasabuvir</intervention>
      <intervention type="Drug">sofosbuvir (SOF)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M15-310</other_id>
      <other_id>2014-005280-32</other_id>
    </other_ids>
    <first_received>March 23, 2015</first_received>
    <start_date>March 2015</start_date>
    <completion_date>November 2015</completion_date>
    <last_updated>November 18, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of subjects achieving a 12-week sustained virologic response</outcome_measure>
      <outcome_measure>Percentage of subjects with on-treatment virologic failure</outcome_measure>
      <outcome_measure>Percentage of subjects with post-treatment relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
      <country>Australia</country>
      <country>New Zealand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02399345</url>
  </study>
  <study rank="484">
    <nct_id>NCT00077649</nct_id>
    <title>A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>188</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV17318</other_id>
    </other_ids>
    <first_received>February 10, 2004</first_received>
    <start_date>January 2004</start_date>
    <completion_date>April 2006</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Viral response compared to baseline\n</outcome_measure>
      <outcome_measure>SVR and end of treatment virological response\n\n</outcome_measure>
      <outcome_measure>Virological response</outcome_measure>
      <outcome_measure>AEs, laboratory parameters, vital signs, Beck Depression Inventory</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Iowa</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00077649</url>
  </study>
  <study rank="485">
    <nct_id>NCT02358044</nct_id>
    <title>Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Biological">PegIntron</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Grazoprevir/Elbasvir (100 mg/50 mg) FDC</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>257</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>5172-077</other_id>
      <other_id>2014-003836-38</other_id>
    </other_ids>
    <first_received>February 3, 2015</first_received>
    <start_date>February 2015</start_date>
    <completion_date>March 2016</completion_date>
    <last_updated>December 10, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants achieving SVR12</outcome_measure>
      <outcome_measure>Number of participants experiencing at least 1 adverse event (AE) on study</outcome_measure>
      <outcome_measure>Number of participants discontinuing study therapy due to an AE</outcome_measure>
      <outcome_measure>Percentage of participants achieving sustained virologic response 24 weeks after ending study treatment (SVR24)</outcome_measure>
      <outcome_measure>Percentage of participants achieving sustained virologic response 4 weeks after ending study treatment (SVR4)</outcome_measure>
      <outcome_measure>Percentage of participants experiencing a Tier 1 safety event (parameter/AE of special interest identified a priori in protocol subject to inferential testing for statistical significance)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02358044</url>
  </study>
  <study rank="486">
    <nct_id>NCT00077636</nct_id>
    <title>ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>1469</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV17317</other_id>
    </other_ids>
    <first_received>February 10, 2004</first_received>
    <start_date>December 2003</start_date>
    <completion_date>March 2006</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR</outcome_measure>
      <outcome_measure>Virological response</outcome_measure>
      <outcome_measure>AEs, laboratory parameters, vital signs.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Alaska</state>
      <state>Arizona</state>
      <state>Arkansas</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Idaho</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Iowa</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Vermont</state>
      <state>Virginia</state>
      <state>Washington</state>
      <state>Wisconsin</state>
      <state>Wyoming</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00077636</url>
  </study>
  <study rank="487">
    <nct_id>NCT00001729</nct_id>
    <title>Combination Drug Therapy for Patients With Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Fibrosis</condition>
      <condition>Hemolytic Anemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>980003</other_id>
      <other_id>98-DK-0003</other_id>
    </other_ids>
    <first_received>November 3, 1999</first_received>
    <start_date>October 1997</start_date>
    <completion_date>September 2002</completion_date>
    <last_updated>March 3, 2008</last_updated>
    <last_verified>September 2002</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00001729</url>
  </study>
  <study rank="488">
    <nct_id>NCT01821963</nct_id>
    <title>Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon Alfa 2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>M.D. Anderson Cancer Center</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2012-0977</other_id>
    </other_ids>
    <first_received>March 27, 2013</first_received>
    <start_date>April 2013</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>February 23, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>February 23, 2015</firstreceived_results_date>
    <primary_completion_date>February 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Undetectable Viral Load 12 Weeks Post-transplant</outcome_measure>
      <outcome_measure>Sustained Virological Response (SVR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01821963</url>
  </study>
  <study rank="489">
    <nct_id>NCT02105701</nct_id>
    <title>Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Grazoprevir + Elbasvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>420</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>5172-068</other_id>
      <other_id>2014-000824-12</other_id>
    </other_ids>
    <first_received>April 2, 2014</first_received>
    <start_date>June 2014</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>June 29, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants achieving SVR12</outcome_measure>
      <outcome_measure>Number of participants experiencing adverse events</outcome_measure>
      <outcome_measure>Number of participants discontinuing study treatment due to adverse events</outcome_measure>
      <outcome_measure>Percentage of participants achieving SVR 24 weeks after the end of all treatment (SVR24)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02105701</url>
  </study>
  <study rank="490">
    <nct_id>NCT00277758</nct_id>
    <title>Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Interleukin 2</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Biological">Pegylated Interferon Alpha</intervention>
      <intervention type="Biological">Inteleukin-2</intervention>
      <intervention type="Drug">Ribavirin + Pegylated interferon-alpha</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Weill Medical College of Cornell University</lead_sponsor>
      <collaborator>National Institute of Allergy and Infectious Diseases (NIAID)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>00-092</other_id>
      <other_id>UO1 AI48224</other_id>
    </other_ids>
    <first_received>January 12, 2006</first_received>
    <start_date>March 2004</start_date>
    <completion_date>August 2006</completion_date>
    <last_updated>March 6, 2008</last_updated>
    <last_verified>March 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Determination of the safety and tolerability of 12 weeks IL2 monotherapy followed by 48 weeks of IL2 combined with PEG-IFN/RBV</outcome_measure>
      <outcome_measure>Determination of specific immunologic responses to HCV. Immunologic assessment will be performed as the sme time intervals as the assays for plasma virus.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00277758</url>
  </study>
  <study rank="491">
    <nct_id>NCT01830127</nct_id>
    <title>BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">BI 207127 high dose</intervention>
      <intervention type="Drug">Faldaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">BI 207127 low dose</intervention>
      <intervention type="Drug">Faldaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>35</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1241.30</other_id>
      <other_id>2012-003534-17</other_id>
    </other_ids>
    <first_received>March 22, 2013</first_received>
    <start_date>April 2013</start_date>
    <completion_date>October 2014</completion_date>
    <last_updated>October 20, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>October 20, 2015</firstreceived_results_date>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR12: Plasma HCV RNA Level Less Than 25 IU/mL at 12 Weeks After End of Treatment (EOT)</outcome_measure>
      <outcome_measure>SVR4: Plasma HCV RNA Level Less Than 25 IU/mL at 4 Weeks After End of Treatment (EOT)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Germany</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01830127</url>
  </study>
  <study rank="492">
    <nct_id>NCT00262379</nct_id>
    <title>Use or Non-use of Epoetin Beta in Patients Infected by Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">epoetin beta (NeoRecormon®)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Angers</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>229</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CP 2005-01</other_id>
    </other_ids>
    <first_received>December 5, 2005</first_received>
    <start_date>December 2005</start_date>
    <completion_date>June 2009</completion_date>
    <last_updated>December 11, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Viral Response (Week 72)</outcome_measure>
      <outcome_measure>• Viral Response at the End of Treatment (Week 48)</outcome_measure>
      <outcome_measure>• Quality of life</outcome_measure>
      <outcome_measure>• Cumulative dose of ribavirin from D0-W24 and from W24-W48 periods</outcome_measure>
      <outcome_measure>• Clinical and biological tolerance</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00262379</url>
  </study>
  <study rank="493">
    <nct_id>NCT02476617</nct_id>
    <title>Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Hepatitis C (HCV)</condition>
      <condition>Hepatitis C Genotype 1a</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ombitasvir/ABT-450/ritonavir</intervention>
      <intervention type="Drug">dasabuvir</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M14-243</other_id>
    </other_ids>
    <first_received>June 17, 2015</first_received>
    <start_date>June 2015</start_date>
    <completion_date>November 2016</completion_date>
    <last_updated>October 16, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in interferon-stimulated gene (ISG) expression in peripheral blood mononucleated cells (PBMCs)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Massachusetts</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02476617</url>
  </study>
  <study rank="494">
    <nct_id>NCT00423670</nct_id>
    <title>Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">boceprevir (SCH 503034)</intervention>
      <intervention type="Drug">peginterferon-alfa 2b (PegIntron)</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">ribavirin (low-dose)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>765</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P03523</other_id>
      <other_id>EudraCT No. 2006-002543-92</other_id>
    </other_ids>
    <first_received>January 17, 2007</first_received>
    <start_date>January 2007</start_date>
    <completion_date>November 2008</completion_date>
    <last_updated>February 16, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>May 13, 2011</firstreceived_results_date>
    <primary_completion_date>August 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Number of Participants With SVR Based on a 4-week lead-in Treatment With PegIntron and Ribavirin</outcome_measure>
      <outcome_measure>Number of Participants With SVR Based on Duration of Boceprevir Treatment</outcome_measure>
      <outcome_measure>Number of Participants Negative for HCV-RNA at FW 12</outcome_measure>
      <outcome_measure>Number of Participants Negative for HCV-RNA at 72 Weeks Post Randomization</outcome_measure>
      <outcome_measure>Number of Participants With an Early Virologic Response (EVR) That Achieved SVR</outcome_measure>
      <outcome_measure>Number of Participants With a Virologic Response at Follow-up Week 12 That Achieved SVR</outcome_measure>
      <outcome_measure>Number of Participants With a Virologic Response at 72 Weeks Post Randomization That Achieved SVR</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00423670</url>
  </study>
  <study rank="495">
    <nct_id>NCT00008463</nct_id>
    <title>A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Interferon alfa-2a</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>132</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>A5071</other_id>
      <other_id>10675</other_id>
      <other_id>Substudy AACTG A5091s</other_id>
      <other_id>ACTG A5071</other_id>
      <other_id>AACTG A5071</other_id>
    </other_ids>
    <first_received>January 9, 2001</first_received>
    <start_date>November 2000</start_date>
    <completion_date>August 2006</completion_date>
    <last_updated>June 7, 2013</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Indiana</state>
      <state>Iowa</state>
      <state>Massachusetts</state>
      <state>Minnesota</state>
      <state>New York</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00008463</url>
  </study>
  <study rank="496">
    <nct_id>NCT01055821</nct_id>
    <title>Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon and ribavirin</intervention>
      <intervention type="Biological">TG4040 + SOC</intervention>
      <intervention type="Biological">TG4040 + SOC</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Transgene</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>140</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TG4040.02</other_id>
    </other_ids>
    <first_received>January 21, 2010</first_received>
    <start_date>May 2010</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>August 9, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HCVac</acronym>
    <primary_completion_date>October 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>complete early virologic response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01055821</url>
  </study>
  <study rank="497">
    <nct_id>NCT00578825</nct_id>
    <title>A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Severe Acute Respiratory Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lopinavir / Ritonavir plus Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hospital Authority, Hong Kong</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>340</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>KW/FR/04-009</other_id>
      <other_id>HARECCTR0500028</other_id>
      <other_id>NTWC/CREC/349/05</other_id>
    </other_ids>
    <first_received>December 20, 2007</first_received>
    <last_updated>August 21, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Development of severe SARS</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>SARS-CoV Viral load</outcome_measure>
      <outcome_measure>Immunological profile</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00578825</url>
  </study>
  <study rank="498">
    <nct_id>NCT01358864</nct_id>
    <title>Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BI 201335</intervention>
      <intervention type="Drug">Pegylated Interferon-alpha (IFN)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>678</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>1220.7</other_id>
      <other_id>2010-021715-17</other_id>
    </other_ids>
    <first_received>May 23, 2011</first_received>
    <start_date>June 2011</start_date>
    <completion_date>May 2014</completion_date>
    <last_updated>September 22, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>July 3, 2015</firstreceived_results_date>
    <primary_completion_date>February 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virological Response 12 Weeks Post Treatment (SVR12)</outcome_measure>
      <outcome_measure>Virological Response After 24 Weeks of Treatment Discontinuation (SVR24)</outcome_measure>
      <outcome_measure>Early Treatment Success (ETS)</outcome_measure>
      <outcome_measure>ALT Normalisation: ALT in Normal Range at End of Treatment, When SVR12=NO</outcome_measure>
      <outcome_measure>ALT Normalisation: ALT in Normal Range at End of Treatment, When SVR12=YES</outcome_measure>
      <outcome_measure>AST Normalisation: AST in Normal Range at End of Treatment, When SVR12=NO</outcome_measure>
      <outcome_measure>AST Normalisation: AST in Normal Range at End of Treatment, When SVR12=YES</outcome_measure>
      <outcome_measure>ALT Normalisation: ALT in Normal Range 12 Weeks Post Treatment, When SVR12=NO</outcome_measure>
      <outcome_measure>ALT Normalisation: ALT in Normal Range 12 Weeks Post Treatment, SVR12=YES</outcome_measure>
      <outcome_measure>AST Normalisation: AST in Normal Range 12 Weeks Post Treatment, When SVR12=NO</outcome_measure>
      <outcome_measure>AST Normalisation: AST in Normal Range 12 Weeks Post Treatment, SVR12=YES</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Japan</country>
      <country>Portugal</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>Switzerland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arkansas</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Massachusetts</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oregon</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01358864</url>
  </study>
  <study rank="499">
    <nct_id>NCT00230854</nct_id>
    <title>Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Hepatitis, Viral, Human</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">EMZ702</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Transition Therapeutics</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>28</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>IET-202</other_id>
    </other_ids>
    <first_received>September 29, 2005</first_received>
    <start_date>August 2005</start_date>
    <completion_date>July 2007</completion_date>
    <last_updated>June 4, 2013</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>To evaluate the safety and tolerability of repeated intravenous infusions of EMZ702 in combination with pegylated interferon and ribavirin in patients with chronic hepatitis C genotype 1</outcome_measure>
      <outcome_measure>To evaluate the viral response and pharmacokinetic profile of repeated intravenous infusions of EMZ702 in combination with pegylated interferon and ribavirin in patients with chronic hepatitis C genotype 1</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00230854</url>
  </study>
  <study rank="500">
    <nct_id>NCT00143000</nct_id>
    <title>Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a 40KD and Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>NORDynamIC Study Group</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>392</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Swedish MPA nr. 151:2004/3458</other_id>
      <other_id>Ethical Committee nr. Ö 763/03</other_id>
    </other_ids>
    <first_received>September 1, 2005</first_received>
    <start_date>April 2004</start_date>
    <completion_date>October 2006</completion_date>
    <last_updated>April 4, 2008</last_updated>
    <last_verified>April 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Sustained Viral Response (SVR) rate defined as percentage of patients with non-detectable HCV-RNA as measured by COBAS TaqMan 48™ (&lt;50 IU/mL) at 24 weeks post completion of the 12 or 24 week treatment period.</outcome_measure>
      <outcome_measure>ALT measurements at 24 weeks post completion of the 12 or 24 week treatment period.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Sweden</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00143000</url>
  </study>
  <study rank="501">
    <nct_id>NCT01743521</nct_id>
    <title>DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Early Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TPV/PEG-IFN/RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kirby Institute</lead_sponsor>
      <collaborator>Janssen-Cilag Ltd.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VHCRP1102</other_id>
      <other_id>VX-950HCP4010</other_id>
    </other_ids>
    <first_received>November 28, 2012</first_received>
    <start_date>January 2013</start_date>
    <completion_date>February 2016</completion_date>
    <last_updated>August 31, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>DARE-C</acronym>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR12</outcome_measure>
      <outcome_measure>SVR24</outcome_measure>
      <outcome_measure>Undetectable HCV RNA (ETR)</outcome_measure>
      <outcome_measure>Undetectable HCV RNA (weeks 1,2,3,4,5,6,8)</outcome_measure>
      <outcome_measure>gene IL28B polymorphism</outcome_measure>
      <outcome_measure>Baseline resistance-associated variants</outcome_measure>
      <outcome_measure>Resistance-associated variants</outcome_measure>
      <outcome_measure>Indicators of toxicity (ALT, HB, Neutrophils, Platelets)</outcome_measure>
      <outcome_measure>Plasma ribavirin levels and haemoglobin</outcome_measure>
      <outcome_measure>CD4 and HIV RNA</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01743521</url>
  </study>
  <study rank="502">
    <nct_id>NCT00909129</nct_id>
    <title>Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Human Immunodeficiency Virus</condition>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon-alpha (Pegasys)</intervention>
      <intervention type="Drug">ribavirin (COPEGUS)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Karolinska Institutet</lead_sponsor>
      <collaborator>The Swedish Research Council</collaborator>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>03-541</other_id>
    </other_ids>
    <first_received>May 15, 2009</first_received>
    <last_updated>May 26, 2009</last_updated>
    <last_verified>May 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>DICO</acronym>
    <outcome_measures>
      <outcome_measure>Sustained virological response</outcome_measure>
      <outcome_measure>T-cell mediated immune responses</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Sweden</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00909129</url>
  </study>
  <study rank="503">
    <nct_id>NCT00021632</nct_id>
    <title>Effects of Ribavirin on Zidovudine or Stavudine</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs/>
    <other_ids>
      <other_id>ACTG A5092s</other_id>
      <other_id>AACTG A5092s</other_id>
      <other_id>10919</other_id>
    </other_ids>
    <first_received>July 26, 2001</first_received>
    <last_updated>May 15, 2015</last_updated>
    <last_verified>July 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Maryland</state>
      <state>Ohio</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00021632</url>
  </study>
  <study rank="504">
    <nct_id>NCT00332176</nct_id>
    <title>A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Celgosivir</intervention>
      <intervention type="Drug">Celgosivir</intervention>
      <intervention type="Drug">Peginterferon alfa 2b + ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>BioWest Therapeutics Inc</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HCV-06-001</other_id>
    </other_ids>
    <first_received>May 30, 2006</first_received>
    <start_date>June 2006</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>April 3, 2008</last_updated>
    <last_verified>April 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety analysis</outcome_measure>
      <outcome_measure>HCV viral load</outcome_measure>
      <outcome_measure>Pharmacokinetics of celgosivir/castanospermine</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00332176</url>
  </study>
  <study rank="505">
    <nct_id>NCT02328651</nct_id>
    <title>Effect of Xiaoer Jiebiao Oral Liquid on Hand-foot-mouth Disease</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Handfoot-mouth Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin plus Xiao'er jiebiao oral liquid</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Children's Hospital of Fudan University</lead_sponsor>
      <collaborator>Weihai Rensheng Pharmacy</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>398</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Single Blind (Subject)</study_design>
    </study_designs>
    <other_ids>
      <other_id>XEJB_Ver1.0</other_id>
    </other_ids>
    <first_received>December 18, 2014</first_received>
    <start_date>October 2014</start_date>
    <last_updated>December 29, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Time (hours) taken from treatment start till body temperature dropping to normal</outcome_measure>
      <outcome_measure>Time (hours) taken from disease onset till body temperature dropping to normal</outcome_measure>
      <outcome_measure>Top body temperature at the 24th hour, 48th hour and the 72th hour from treatment starting.</outcome_measure>
      <outcome_measure>adverse digestive tract symptoms</outcome_measure>
      <outcome_measure>abnormal blood routine</outcome_measure>
      <outcome_measure>abnormal Urine routine</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02328651</url>
  </study>
  <study rank="506">
    <nct_id>NCT00724854</nct_id>
    <title>Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b; SCH 54031)</intervention>
      <intervention type="Drug">Rebetol (ribavirin; SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1146</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05427</other_id>
      <other_id>001/05</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>August 2006</start_date>
    <completion_date>September 2009</completion_date>
    <last_updated>February 6, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>December 23, 2010</firstreceived_results_date>
    <acronym>APEGIN</acronym>
    <primary_completion_date>September 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Rapid Virologic Response After 4 Weeks of Treatment</outcome_measure>
      <outcome_measure>Number of Participants Who Achieved Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Number of Participants With RVR Who Also Achieved SVR</outcome_measure>
      <outcome_measure>Assessment of Response at Treatment Week 48 for Genotypes 2 and 3, and Treatment Week 72 for Genotypes 1, 4, and 5, in Participants With RVR</outcome_measure>
      <outcome_measure>Assessment of Baseline Characteristics in Participants With SVR</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00724854</url>
  </study>
  <study rank="507">
    <nct_id>NCT01728324</nct_id>
    <title>Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BI 207127-placebo: 8-week treatment</intervention>
      <intervention type="Drug">Ribavirin: 24-week treatment</intervention>
      <intervention type="Drug">BI 207127: 24-week treatment</intervention>
      <intervention type="Drug">Faldaprevir: 24-week treatment</intervention>
      <intervention type="Drug">Faldaprevir: 24-week treatment</intervention>
      <intervention type="Drug">Ribavirin-placebo: 8-week treatment</intervention>
      <intervention type="Drug">BI 207127: 24-week treatment</intervention>
      <intervention type="Drug">Faldaprevir-placebo: 8-week treatment</intervention>
      <intervention type="Drug">Faldaprevir: 16-week treatment</intervention>
      <intervention type="Drug">Ribavirin: 16-week treatment</intervention>
      <intervention type="Drug">RBV: 24-week treatment</intervention>
      <intervention type="Drug">BI 207127: 16-week treatment</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>496</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>1241.36</other_id>
      <other_id>2012-003535-27</other_id>
    </other_ids>
    <first_received>November 2, 2012</first_received>
    <start_date>November 2012</start_date>
    <completion_date>January 2015</completion_date>
    <last_updated>February 4, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR) at Week 12 post-treatment (SVR12)</outcome_measure>
      <outcome_measure>SVR4</outcome_measure>
      <outcome_measure>SVR24</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>Italy</country>
      <country>New Zealand</country>
      <country>Portugal</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arkansas</state>
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01728324</url>
  </study>
  <study rank="508">
    <nct_id>NCT01732796</nct_id>
    <title>IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">BI 201335 (Faldaprevir)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">BI 207127</intervention>
      <intervention type="Drug">BI 201335 (Faldaprevir)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">BI 207127</intervention>
      <intervention type="Drug">Faldaprevir (BI 201335)</intervention>
      <intervention type="Drug">BI 207127</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>470</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>1241.20</other_id>
      <other_id>2012-003533-41</other_id>
    </other_ids>
    <first_received>November 6, 2012</first_received>
    <start_date>December 2012</start_date>
    <completion_date>January 2015</completion_date>
    <last_updated>February 4, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response at Week 12 after end of active treatment (SVR 12)</outcome_measure>
      <outcome_measure>Sustained Virologic Response at Week 4 after end of active treatment (SVR4)</outcome_measure>
      <outcome_measure>Sustained Virologic Response at Week 24 after end of active treatment (SVR24)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Austria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Hungary</country>
      <country>Ireland</country>
      <country>Italy</country>
      <country>Netherlands</country>
      <country>Portugal</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Nevada</state>
      <state>New York</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01732796</url>
  </study>
  <study rank="509">
    <nct_id>NCT00051077</nct_id>
    <title>Treatment of Hepatitis in Patients Who Are Triple-Infected With HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV)</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis B</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Adefovir dipivoxil</intervention>
      <intervention type="Drug">Peginterferon-alfa-2A</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Procedure">Liver Biopsy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>A5149</other_id>
      <other_id>10953</other_id>
      <other_id>ACTG A5149</other_id>
    </other_ids>
    <first_received>January 3, 2003</first_received>
    <last_updated>May 16, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00051077</url>
  </study>
  <study rank="510">
    <nct_id>NCT02582658</nct_id>
    <title>Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>170</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P15-695</other_id>
    </other_ids>
    <first_received>October 20, 2015</first_received>
    <start_date>October 2015</start_date>
    <completion_date>July 2017</completion_date>
    <last_updated>October 20, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>REAL</acronym>
    <primary_completion_date>July 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants achieving sustained virological response 12 Weeks Post-treatment (SVR12)</outcome_measure>
      <outcome_measure>Usage pattern of treatment regimen in Austria</outcome_measure>
      <outcome_measure>Percentage of the direct-acting antiviral (DAA) dose taken in relation to the target dose of DAA</outcome_measure>
      <outcome_measure>Percentage of the Ribavirin (RBV) dose taken in relation to the target dose of RBV</outcome_measure>
      <outcome_measure>Percentage of missed Ribavirin (RBV) treatment days in relation to the target number of RBV treatment days</outcome_measure>
      <outcome_measure>Number of participants with concomitant medications</outcome_measure>
      <outcome_measure>Number of participants with co-morbidities</outcome_measure>
      <outcome_measure>Change in participants workability measured with the Work Productivity and Activity Impairment (WPAI):Hepatitis C questionnaire</outcome_measure>
      <outcome_measure>Change in participants quality of life measured with the EuroQol 5 dimension 5 level (EQ-5D-5L) questionnaire</outcome_measure>
      <outcome_measure>Change of participant activation with the Patient activation Measure (PAM-13) questionnaire.</outcome_measure>
      <outcome_measure>Patient support program (PSP) utilization and satisfaction assessment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02582658</url>
  </study>
  <study rank="511">
    <nct_id>NCT00530972</nct_id>
    <title>Pilot Study of Patients Chronic Hepatitis C in Co-infected HIV Patients Relapsers After Previous Therapies</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a plus ribavirin adjusted to body weight</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hospital Carlos III, Madrid</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2005-001192-34</other_id>
    </other_ids>
    <first_received>September 17, 2007</first_received>
    <start_date>March 2006</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>September 4, 2009</last_updated>
    <last_verified>September 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PILOT-NR</acronym>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>% of patients with RNA-HCV undetectable</outcome_measure>
      <outcome_measure>% of patients with RNA-HCV undetectable at different moments of the treatment according genotype, viremia, liver fibrosis, number of CD4 cells and previous therapy</outcome_measure>
      <outcome_measure>Ribavirin levels</outcome_measure>
      <outcome_measure>Impact of dose reduction peg-interferon and/or ribavirin</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00530972</url>
  </study>
  <study rank="512">
    <nct_id>NCT00901524</nct_id>
    <title>ANRS HC20 Effectiveness of an Optimized Anti HCV PegIFN-alpha2a + Ribavirin on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIV</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-interféron alpha 2a + ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
      <collaborator>Roche Pharma AG</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>58</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2008-000859-10</other_id>
      <other_id>ANRS HC 20</other_id>
    </other_ids>
    <first_received>April 28, 2009</first_received>
    <start_date>June 2009</start_date>
    <completion_date>June 2012</completion_date>
    <last_updated>March 28, 2013</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ETOC</acronym>
    <primary_completion_date>June 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Study the proportion of patients co-infected HIV-HCV, non-responders to treatment for HCV (genotype 1 and 4), with a sustained virological response (6 months after stopping treatment (W72 or W96)) at a re-optimized treatment of hepatitis C.</outcome_measure>
      <outcome_measure>Analyze rapid virological response (W4) and early (W12).</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00901524</url>
  </study>
  <study rank="513">
    <nct_id>NCT00684268</nct_id>
    <title>Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Silibinin</intervention>
      <intervention type="Drug">Silibinin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Medical University of Vienna</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NRSili</other_id>
    </other_ids>
    <first_received>May 19, 2008</first_received>
    <start_date>October 2007</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>October 24, 2012</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>NRSily</acronym>
    <primary_completion_date>February 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>viral response at week 24</outcome_measure>
      <outcome_measure>sustained virologic response</outcome_measure>
      <outcome_measure>Safety</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00684268</url>
  </study>
  <study rank="514">
    <nct_id>NCT00705432</nct_id>
    <title>Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b (PEG)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1472</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05216</other_id>
      <other_id>EUDRACT # 2007-005508-42</other_id>
    </other_ids>
    <first_received>June 24, 2008</first_received>
    <start_date>August 2008</start_date>
    <completion_date>May 2010</completion_date>
    <last_updated>October 16, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>May 13, 2011</firstreceived_results_date>
    <acronym>SPRINT-2</acronym>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR) Rate</outcome_measure>
      <outcome_measure>Sustained Virologic Response (SVR) Rate in Participants Treated With Study Drug (Boceprevir or Placebo)</outcome_measure>
      <outcome_measure>Number of Participants With Undetectable HCV-RNA at Follow-up Week 12 and at 72 Weeks After Randomization.</outcome_measure>
      <outcome_measure>Number of Participants With Early Virologic Response (Undetectable HCV-RNA at Treatment Week 2, 4, 8, 12, 16, or 20)</outcome_measure>
      <outcome_measure>Number of Participants With Early Virologic Response (Undetectable HCV-RNA at Treatment Week 4, 8, 12, 16, or 20) Who Achieved SVR</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00705432</url>
  </study>
  <study rank="515">
    <nct_id>NCT00957866</nct_id>
    <title>Prospective Anti-Hepatitis C Virus (Anti-HCV) Trial of Peg-Interferon and Ribavirin in Subjects of First Nations, Metis and Caucasian Ethnicity</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferons (Peg-IFN) and Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Manitoba</lead_sponsor>
      <collaborator>Roche Pharma AG</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>160</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>B2008:164</other_id>
    </other_ids>
    <first_received>August 12, 2009</first_received>
    <start_date>May 2009</start_date>
    <completion_date>November 2012</completion_date>
    <last_updated>May 15, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>Praire</acronym>
    <primary_completion_date>October 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR is the primary outcome for this study. SVR is defined as a negative serum HCV-RNA by a qualitative test sensitive to &lt;50 IU/ml six months after the completion of therapy14, performed by a Health Canada approved laboratory.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00957866</url>
  </study>
  <study rank="516">
    <nct_id>NCT01674725</nct_id>
    <title>A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450/r/ABT-267, ABT-333</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie (prior sponsor, Abbott)</lead_sponsor>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>187</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M13-389</other_id>
      <other_id>2011-005740-95</other_id>
    </other_ids>
    <first_received>July 27, 2012</first_received>
    <start_date>August 2012</start_date>
    <completion_date>October 2014</completion_date>
    <last_updated>October 13, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>December 23, 2014</firstreceived_results_date>
    <acronym>PEARL-II</acronym>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Primary Analyses</outcome_measure>
      <outcome_measure>Percentage of Participants With Hemoglobin Decrease to Below the Lower Limit of Normal (LLN) At End of Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Secondary Analyses</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Failure During Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Relapse After Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01674725</url>
  </study>
  <study rank="517">
    <nct_id>NCT01726517</nct_id>
    <title>Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-0118</other_id>
    </other_ids>
    <first_received>November 10, 2012</first_received>
    <start_date>October 2012</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>November 7, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>November 7, 2014</firstreceived_results_date>
    <primary_completion_date>July 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)</outcome_measure>
      <outcome_measure>Percentage of Participants With SVR at 2, 4, 8, and 24 Weeks After Discontinuation of Therapy (SVR2, SVR4, SVR8, and SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Viral Breakthrough or Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01726517</url>
  </study>
  <study rank="518">
    <nct_id>NCT01323244</nct_id>
    <title>A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>142</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017983</other_id>
      <other_id>TMC435-TiDP16-C213</other_id>
    </other_ids>
    <first_received>March 24, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>March 2015</completion_date>
    <last_updated>April 7, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The proportion of participants with sustained viral response</outcome_measure>
      <outcome_measure>Number of participants with HCV RNA level &gt;1000 IU/mL</outcome_measure>
      <outcome_measure>Number of participants with viral breakthrough</outcome_measure>
      <outcome_measure>Number of participants with viral relapse</outcome_measure>
      <outcome_measure>Number of participants with normalized alanine aminotransferase levels</outcome_measure>
      <outcome_measure>Number of participants with on-treatment failure</outcome_measure>
      <outcome_measure>Number of participants affected by an adverse event</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>Bulgaria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Mexico</country>
      <country>Netherlands</country>
      <country>New Zealand</country>
      <country>Poland</country>
      <country>Portugal</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Ukraine</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Louisiana</state>
      <state>Mississippi</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01323244</url>
  </study>
  <study rank="519">
    <nct_id>NCT01973049</nct_id>
    <title>UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Asunaprevir</intervention>
      <intervention type="Drug">BMS-791325</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Placebo matching Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>202</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI443-113</other_id>
      <other_id>2013-002458-66</other_id>
    </other_ids>
    <first_received>October 25, 2013</first_received>
    <start_date>December 2013</start_date>
    <completion_date>November 2014</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of treated subjects in each of the naive arms with sustained virologic response (SVR12)</outcome_measure>
      <outcome_measure>Proportion of treated subjects in each of the experienced arms with SVR12</outcome_measure>
      <outcome_measure>Proportion of subjects in each arm who achieve HCV RNA &lt; LOQ TD/TND</outcome_measure>
      <outcome_measure>Proportion of subjects in each arm who achieve HCV RNA &lt; LOQ TND</outcome_measure>
      <outcome_measure>Safety as measured by frequency of Serious Adverse Events(SAEs)and discontinuations due to Adverse Events(AEs)</outcome_measure>
      <outcome_measure>Proportion of subjects with anemia defined as Hg &lt; 10 g/dL on-treatment and Hg ≥ 10 g/dL at baseline in each arm within each cohort</outcome_measure>
      <outcome_measure>Differences in rates of selected Grade 3 - 4 laboratory test result abnormalities</outcome_measure>
      <outcome_measure>Proportion of subjects achieving SVR12 associated with HCV geno subtype 1a vs 1b</outcome_measure>
      <outcome_measure>Proportion of subjects in each arm achieving SVR12 associated with IL28B rs12979860 single nucleotide polymorphism(SNP) status (CC genotype or non-CC genotype)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01973049</url>
  </study>
  <study rank="520">
    <nct_id>NCT01909557</nct_id>
    <title>Acetyl-L-Carnitine Supplementation During HCV Therapy With Peg IFN-α2b Plus Ribavirin: Effect on Work Performance.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Quality of Life</condition>
      <condition>Daily Activity</condition>
      <condition>Fatigue</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Acetyl-L-carnitine</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Catania</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>62</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>Unict10/1997</other_id>
    </other_ids>
    <first_received>July 24, 2013</first_received>
    <start_date>January 2010</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>July 25, 2013</last_updated>
    <last_verified>July 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Work performances</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01909557</url>
  </study>
  <study rank="521">
    <nct_id>NCT01467492</nct_id>
    <title>Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Biological">Pegylated Interferon Alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>121</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX11-950-116</other_id>
    </other_ids>
    <first_received>November 3, 2011</first_received>
    <start_date>January 2012</start_date>
    <completion_date>May 2014</completion_date>
    <last_updated>July 13, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>June 1, 2015</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Viral Response 12 Weeks After Last Actual Dose of Study Drug (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Viral Response 24 Weeks After Last Actual Dose of Study Drug (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With Extended Rapid Viral Response (eRVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Relapse</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With On Treatment Virologic Failure</outcome_measure>
      <outcome_measure>Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
      <outcome_measure>Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01467492</url>
  </study>
  <study rank="522">
    <nct_id>NCT02487030</nct_id>
    <title>Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>280</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-1643</other_id>
    </other_ids>
    <first_received>June 27, 2015</first_received>
    <start_date>September 2015</start_date>
    <completion_date>October 2016</completion_date>
    <last_updated>December 9, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of any adverse event leading to permanent discontinuation of study drug</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02487030</url>
  </study>
  <study rank="523">
    <nct_id>NCT01625338</nct_id>
    <title>Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">Peg-IFN</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>534</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0109</other_id>
      <other_id>2012-000571-16</other_id>
    </other_ids>
    <first_received>June 7, 2012</first_received>
    <start_date>June 2012</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>October 9, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>October 9, 2015</firstreceived_results_date>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event</outcome_measure>
      <outcome_measure>Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Virologic Failure</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>Czech Republic</country>
      <country>Estonia</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Netherlands</country>
      <country>New Zealand</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01625338</url>
  </study>
  <study rank="524">
    <nct_id>NCT01890200</nct_id>
    <title>The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III)</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">TCM-700C</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>TCM Biotech International Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>598</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>TCM-700-02-01</other_id>
    </other_ids>
    <first_received>June 26, 2013</first_received>
    <start_date>June 2015</start_date>
    <completion_date>June 2018</completion_date>
    <last_updated>December 14, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>sustained virologic response (SVR) rate</outcome_measure>
      <outcome_measure>Virologic response (VR)</outcome_measure>
      <outcome_measure>relapse rate</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01890200</url>
  </study>
  <study rank="525">
    <nct_id>NCT01701401</nct_id>
    <title>Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>870</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-0102</other_id>
      <other_id>2012-003387-43</other_id>
    </other_ids>
    <first_received>October 2, 2012</first_received>
    <start_date>September 2012</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>March 17, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>March 17, 2015</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Study Drug (SVR12)</outcome_measure>
      <outcome_measure>Incidence of Adverse Events Leading to Permanent Discontinuation From Any Study Drug</outcome_measure>
      <outcome_measure>Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Study Drug</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 2</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 8</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 2</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 4</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 8</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01701401</url>
  </study>
  <study rank="526">
    <nct_id>NCT00502788</nct_id>
    <title>Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Thalassemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon Alfa-2a and Ribavirin</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>New England Research Institutes</lead_sponsor>
      <collaborator>National Heart, Lung, and Blood Institute (NHLBI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>503</other_id>
      <other_id>U01HL065238</other_id>
      <other_id>U01HL065238-07</other_id>
    </other_ids>
    <first_received>July 16, 2007</first_received>
    <start_date>May 2003</start_date>
    <completion_date>August 2006</completion_date>
    <last_updated>March 3, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HepC</acronym>
    <primary_completion_date>June 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety of peginterferon alfa-2a and ribavirin in individuals with thalassemia (measured by changes in liver iron stores and development of iron overload-related complications)</outcome_measure>
      <outcome_measure>Mean change in hepatic iron concentration from baseline biopsy to follow-up biopsy; relationship of change to baseline level</outcome_measure>
      <outcome_measure>Transfusion frequency and volume required to maintain trough Hb 9.0-10.5 g/dL during treatment, as compared to that required in the 6 months prior to hepatitis C treatment</outcome_measure>
      <outcome_measure>Cumulate change in deferoxamine dose; evidence for deferoxamine toxicity during hepatitis C treatment</outcome_measure>
      <outcome_measure>Response rate (undetectable hepatitis C virus RNA)</outcome_measure>
      <outcome_measure>Sustained virologic response rate (undetectable hepatitis C virus RNA 24 weeks after the end of treatment) and its association with baseline hepatic iron concentration</outcome_measure>
      <outcome_measure>Rate of viral clearance from serum in the first 4 weeks of treatment, rate of early virologic response at week 12, and each rate's association with sustained virologic response</outcome_measure>
      <outcome_measure>Change in liver inflammation and fibrosis scores from baseline to 48 weeks</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>Cardiac adverse events, defined as either symptomatic left ventricular dysfunction requiring medication or pathologic arrhythmia requiring medication</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>New York</state>
      <state>Pennsylvania</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00502788</url>
  </study>
  <study rank="527">
    <nct_id>NCT01183169</nct_id>
    <title>Efficacy and Safety of DEB025 Combined With Peg-IFN Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Relapsers and Non-responders</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DEB025 600 mg QD + PegIFN + RBV</intervention>
      <intervention type="Drug">DEB025 800 mg QD + PegIFN + RBV</intervention>
      <intervention type="Drug">placebo + PegIFN + RBV</intervention>
      <intervention type="Drug">placebo + PegIFN + RBV</intervention>
      <intervention type="Drug">DEB025 400 mg BID + PegIFN + RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>459</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CDEB025A2210</other_id>
      <other_id>2010-020033-14</other_id>
    </other_ids>
    <first_received>August 16, 2010</first_received>
    <start_date>August 2010</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>March 19, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>cEVR (complete early virologic response) i.e. HCV RNA &lt; 25 IU/mL (by Limit of Quantitation, LOQ) ; the primary efficacy comparison is between DEB025 active plus peg-IFNα2a once weekly + RBV BID and DEB025 placebo plus peg-IFNα2a once weekly + RBV BID</outcome_measure>
      <outcome_measure>SVR12: sustained virologic response 12 weeks following cessation of therapy, defined as HCV RNA negative (by LOQ)</outcome_measure>
      <outcome_measure>cEVR after 12 week triple therapy with 600 mg DEB025 daily plus peg-IFNα2a once weekly + RBV BID versus 800 mg daily plus peg-IFNα2a once weekly + RBV BID versus 400 mg BID plus peg-IFNα2a once weekly + RBV BID.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Hungary</country>
      <country>Italy</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
      <country>Spain</country>
      <country>Taiwan</country>
      <country>Turkey</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Kansas</state>
      <state>Massachusetts</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01183169</url>
  </study>
  <study rank="528">
    <nct_id>NCT01716585</nct_id>
    <title>A Study to Evaluate Chronic Hepatitis C Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450/r/ABT-267, ABT-333</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Placebo for ABT-450/r/ABT-267</intervention>
      <intervention type="Drug">Placebo for ABT-333</intervention>
      <intervention type="Drug">Placebo for ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie (prior sponsor, Abbott)</lead_sponsor>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>636</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>M11-646</other_id>
      <other_id>2012-002019-25</other_id>
    </other_ids>
    <first_received>October 18, 2012</first_received>
    <start_date>November 2012</start_date>
    <completion_date>October 2014</completion_date>
    <last_updated>October 9, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>December 23, 2014</firstreceived_results_date>
    <primary_completion_date>October 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Normalization of Alanine Aminotransferase (ALT) at Final Treatment Visit During the Double-Blind Treatment Period</outcome_measure>
      <outcome_measure>Percentage of HCV Genotype 1a-infected Participants With Sustained Virologic Response 12 Weeks After Treatment</outcome_measure>
      <outcome_measure>Percentage of HCV Genotype 1b-infected Participants With Sustained Virologic Response 12 Weeks After Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Virologic Failure During the Double-blind Treatment Period: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Relapse After Treatment: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01716585</url>
  </study>
  <study rank="529">
    <nct_id>NCT02600351</nct_id>
    <title>Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-1746</other_id>
    </other_ids>
    <first_received>November 5, 2015</first_received>
    <start_date>November 2015</start_date>
    <completion_date>April 2017</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) 12 weeks after cessation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Proportion of participants who discontinued from study treatment for an adverse event</outcome_measure>
      <outcome_measure>Proportion of participants with HCV RNA &lt; the lower limit of quantitation (LLOQ) at 4 and 24 weeks posttreatment</outcome_measure>
      <outcome_measure>Proportion of participants with viral breakthrough</outcome_measure>
      <outcome_measure>Proportion of participants with viral relapse</outcome_measure>
      <outcome_measure>Proportion of participants with emerging resistance</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New Jersey</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02600351</url>
  </study>
  <study rank="530">
    <nct_id>NCT01215643</nct_id>
    <title>Efficacy and Safety of DEB025 Alone or Combined With Either Ribavirin or Peg-IFN α2a in Chronic Hepatitis C Genotype 2 and 3 naïve Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Chronic Pain</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DEB025 1000 mg QD</intervention>
      <intervention type="Drug">DEB025 600 mg QD + RBV 400 mg BID</intervention>
      <intervention type="Drug">DEB025 800 mg QD + RBV 400 mg BID</intervention>
      <intervention type="Drug">DEB025 600 mg QD + peg-IFNα2a once weekly</intervention>
      <intervention type="Drug">SOC (peg-IFNα2a once weekly + RBV 400 mg BID)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>340</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CDEB025A2211</other_id>
      <other_id>2010-020034-26</other_id>
    </other_ids>
    <first_received>October 5, 2010</first_received>
    <start_date>October 2010</start_date>
    <last_updated>June 5, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Measure: RVR : Rapid Viral Response : defined as serum HCV RNA undetectable (by LOQ) after 4 weeks of treatment.</outcome_measure>
      <outcome_measure>Measure: SVR24 : Sustained Viral Response Week 24 : defined as serum HCV RNA undetectable (by LOD) after 24 weeks of treatment.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>India</country>
      <country>Italy</country>
      <country>Korea, Republic of</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Taiwan</country>
      <country>Thailand</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Hawaii</state>
      <state>Kansas</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New Hampshire</state>
      <state>New York</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01215643</url>
  </study>
  <study rank="531">
    <nct_id>NCT02243280</nct_id>
    <title>A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Hepatitis C Virus</condition>
      <condition>HCV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-493</intervention>
      <intervention type="Drug">ABT-530</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>170</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M14-867</other_id>
      <other_id>2014-002925-36</other_id>
    </other_ids>
    <first_received>September 4, 2014</first_received>
    <start_date>August 2014</start_date>
    <completion_date>March 2016</completion_date>
    <last_updated>October 10, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of subjects with sustained virologic response (SVR) 12</outcome_measure>
      <outcome_measure>Percentage of subjects with sustained virologic response (SVR) 4</outcome_measure>
      <outcome_measure>Percentage of subjects with virologic failure during treatment</outcome_measure>
      <outcome_measure>Percentage of subjects with Post-Treatment relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02243280</url>
  </study>
  <study rank="532">
    <nct_id>NCT00502099</nct_id>
    <title>Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alpha 2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated interferon alpha 2 b plus ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Amr Hafez</lead_sponsor>
      <collaborator>Ain Shams University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>217</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>LG161190-06</other_id>
    </other_ids>
    <first_received>July 15, 2007</first_received>
    <start_date>January 2006</start_date>
    <completion_date>May 2009</completion_date>
    <last_updated>October 21, 2012</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR, defined as undetectable serum HCV RNA</outcome_measure>
      <outcome_measure>histological response</outcome_measure>
      <outcome_measure>biochemical response</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00502099</url>
  </study>
  <study rank="533">
    <nct_id>NCT00863109</nct_id>
    <title>Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Genotype 1</condition>
      <condition>HCV-1</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b (PEG)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>133</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05278</other_id>
      <other_id>MK-4031-336</other_id>
    </other_ids>
    <first_received>March 12, 2009</first_received>
    <start_date>April 2009</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>April 15, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>May 14, 2014</firstreceived_results_date>
    <acronym>VIDA</acronym>
    <primary_completion_date>May 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline (BL) to Week 72 (WK72) in 36-Item Short-Form Health Survey (SF-36) Scores</outcome_measure>
      <outcome_measure>Change From Baseline (BL) to Week 72 (WK72) in Chronic Liver Disease Questionnaire-Hepatitis C Virus (CLDQ-HCV)</outcome_measure>
      <outcome_measure>Change From Baseline to Week 72 (WK72) in SF-36 Scores Among Participants Who Completed Treatment and Participants Who Had Early End of Treatment (Subset Analysis)</outcome_measure>
      <outcome_measure>Change From Baseline to Week 72 (WK72) in CLDQ-HCV Scores Among Participants Who Completed Treatment and Participants Who Had Early End of Treatment (Subset Analysis)</outcome_measure>
      <outcome_measure>Minimal Clinically Important Difference (MCID) in SF-36 Scores</outcome_measure>
      <outcome_measure>MCID in CLDQ-HCV Scores</outcome_measure>
      <outcome_measure>Percentage of Participants Who Were Compliant With Treatment According To Medication Count (Subset Analysis)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00863109</url>
  </study>
  <study rank="534">
    <nct_id>NCT00700401</nct_id>
    <title>POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>266</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML21543</other_id>
    </other_ids>
    <first_received>June 17, 2008</first_received>
    <start_date>November 2008</start_date>
    <completion_date>November 2010</completion_date>
    <last_updated>January 12, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response</outcome_measure>
      <outcome_measure>Sustained virological response 24 weeks after treatment completion</outcome_measure>
      <outcome_measure>Virological response at end of treatment</outcome_measure>
      <outcome_measure>Virological relapse</outcome_measure>
      <outcome_measure>AEs, laboratory parameters.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Brazil</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00700401</url>
  </study>
  <study rank="535">
    <nct_id>NCT00758043</nct_id>
    <title>A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">telaprevir</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Biological">peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
      <collaborator>Tibotec Pharmaceutical Limited</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>540</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX08-950-111</other_id>
      <other_id>EudraCT 2008-003836-39</other_id>
    </other_ids>
    <first_received>September 19, 2008</first_received>
    <start_date>October 2008</start_date>
    <completion_date>July 2010</completion_date>
    <last_updated>September 30, 2013</last_updated>
    <last_verified>June 2011</last_verified>
    <firstreceived_results_date>June 22, 2011</firstreceived_results_date>
    <primary_completion_date>June 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of Randomized Subjects Achieving Sustained Viral Response (SVR), Demonstrated by Achieving Undetectable HCV RNA 24 Weeks After Last Dose of Study Treatment (SVR24)</outcome_measure>
      <outcome_measure>Proportion of Subjects Who Have Undetectable HCV RNA at Week 72</outcome_measure>
      <outcome_measure>Proportion of Subjects Achieving eRVR (Extended RVR), Demonstrated by Achieving Undetectable HCV RNA at Week 4 and at Week 12</outcome_measure>
      <outcome_measure>Proportion of Randomized Subjects Who Have Undetectable HCV RNA 12 Weeks After Last Dose of Study Treatment</outcome_measure>
      <outcome_measure>Proportion of Randomized Subjects Who Relapse, Defined as Those Who Complete Treatment, Have Undetectable HCV RNA at End of Treatment (EOT; Week 24 or Week 48 Respectively), and Become HCV RNA Detectable During Antiviral Follow-up</outcome_measure>
      <outcome_measure>Proportion of Enrolled Subjects Who Relapse, Defined as Those Who Have Undetectable HCV RNA at the EOT, and Become HCV RNA Detectable During Antiviral Follow-up</outcome_measure>
      <outcome_measure>Proportion of Subjects Who Have Undetectable HCV RNA at the EOT (Week 24 or Week 48 Respectively).</outcome_measure>
      <outcome_measure>Adverse Events, Physical Examination Findings, and Clinical Laboratory, Vital Sign, and Electrocardiogram (ECG) Assessments</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Belgium</country>
      <country>Netherlands</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Hampshire</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00758043</url>
  </study>
  <study rank="536">
    <nct_id>NCT01080222</nct_id>
    <title>A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">telaprevir</intervention>
      <intervention type="Drug">VX-222</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Biological">peginterferon-alfa-2a</intervention>
      <intervention type="Drug">VX-222</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>152</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX09-222-103</other_id>
    </other_ids>
    <first_received>March 1, 2010</first_received>
    <start_date>August 2010</start_date>
    <completion_date>November 2013</completion_date>
    <last_updated>February 28, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and Tolerability</outcome_measure>
      <outcome_measure>Proportion of Subjects Who Achieve a Sustained Viral Response</outcome_measure>
      <outcome_measure>Undetectable HCV RNA Measurements</outcome_measure>
      <outcome_measure>Proportion of Subjects Who Have a Viral Breakthrough or Relapse</outcome_measure>
      <outcome_measure>Plasma Exposures of VX-222 and Telaprevir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>New Zealand</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01080222</url>
  </study>
  <study rank="537">
    <nct_id>NCT00502970</nct_id>
    <title>Short Course of Interferon Treatment in Patients With HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Chronic Disease</condition>
      <condition>Treatment</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">16 weeks Interferon Tiw with Ribavirin</intervention>
      <intervention type="Drug">24 weeks Interferon</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Aga Khan University</lead_sponsor>
      <collaborator>Getz Pharma</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>302-Med/ERC-04</other_id>
    </other_ids>
    <first_received>July 16, 2007</first_received>
    <start_date>May 2004</start_date>
    <completion_date>November 2007</completion_date>
    <last_updated>January 9, 2008</last_updated>
    <last_verified>January 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>STAR</acronym>
    <primary_completion_date>November 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virological response</outcome_measure>
      <outcome_measure>Safety of short course of Interferon &amp; Ribavirin</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Pakistan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00502970</url>
  </study>
  <study rank="538">
    <nct_id>NCT01390844</nct_id>
    <title>Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir (BOC)</intervention>
      <intervention type="Drug">Placebo to boceprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2b (PEG)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">Cross-Over Boceprevir Treatment</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>282</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P07063</other_id>
      <other_id>2007-005151-42</other_id>
      <other_id>3034-033</other_id>
      <other_id>CTRI/2012/04/002540</other_id>
    </other_ids>
    <first_received>July 7, 2011</first_received>
    <start_date>October 2011</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>July 9, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response, defined as undetectable plasma hepatitis C virus ribonucleic acid (HCV-RNA) at Follow-up Week 24 in participants who received at least one dose of any trial medication (i.e. PEG, RBV, BOC, or placebo)</outcome_measure>
      <outcome_measure>Sustained virologic response, defined as undetectable plasma HCV-RNA at Follow-up Week 24 in participants who received at least one dose of experimental trial medication (i.e. placebo or BOC)</outcome_measure>
      <outcome_measure>Number of participants achieving early virologic response (undetectable HCV-RNA at Treatment Week 8)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01390844</url>
  </study>
  <study rank="539">
    <nct_id>NCT00869661</nct_id>
    <title>A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">RO5024048</intervention>
      <intervention type="Drug">RO5024048</intervention>
      <intervention type="Drug">RO5024048</intervention>
      <intervention type="Drug">RO5024048</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>413</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV20536</other_id>
      <other_id>2008-008258-21</other_id>
    </other_ids>
    <first_received>March 25, 2009</first_received>
    <start_date>February 2001</start_date>
    <completion_date>February 2012</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response: Percentage of patients with undetectable Hepatitis C RNA level</outcome_measure>
      <outcome_measure>Virologic response: Percentage of patients with undetectable Hepatitis C RNA level</outcome_measure>
      <outcome_measure>Relapse rate: Percentage of patients who achieved a virologic response at the end of treatment but had detectable Hepatitis C RNA level at the last assessment post treatment</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00869661</url>
  </study>
  <study rank="540">
    <nct_id>NCT00087607</nct_id>
    <title>PEAK Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">PEG-Intron</intervention>
      <intervention type="Drug">Rebetol</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>385</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacodynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML17756</other_id>
    </other_ids>
    <first_received>July 12, 2004</first_received>
    <start_date>December 2003</start_date>
    <completion_date>May 2006</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Viral load reduction from baseline.</outcome_measure>
      <outcome_measure>Viral load reduction</outcome_measure>
      <outcome_measure>Viral AUC and AAUCMB.</outcome_measure>
      <outcome_measure>AEs, laboratory parameters.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arkansas</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Kansas</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>Nebraska</state>
      <state>Nevada</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00087607</url>
  </study>
  <study rank="541">
    <nct_id>NCT00493805</nct_id>
    <title>Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Insulin Resistance</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Combination of pegylated interferon alfa-2b and ribavirin</intervention>
      <intervention type="Drug">Combination of pegylated interferon alfa-2b and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>59</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04823</other_id>
      <other_id>EudraCT number:2006-000757-21</other_id>
    </other_ids>
    <first_received>June 25, 2007</first_received>
    <start_date>April 2007</start_date>
    <completion_date>October 2009</completion_date>
    <last_updated>November 2, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>October 27, 2010</firstreceived_results_date>
    <primary_completion_date>October 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Early Virological Response in Participants With and Without Insulin Resistance</outcome_measure>
      <outcome_measure>Sustained Virological Response (PCR 24 Weeks After End of Treatment)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00493805</url>
  </study>
  <study rank="542">
    <nct_id>NCT00266318</nct_id>
    <title>Study of High Dosage CIFN Plus RBV for HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Interferon Alfacon-1 and Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Beth Israel Medical Center</lead_sponsor>
      <collaborator>InterMune</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>164-04</other_id>
    </other_ids>
    <first_received>December 14, 2005</first_received>
    <start_date>December 2005</start_date>
    <completion_date>May 2007</completion_date>
    <last_updated>April 16, 2008</last_updated>
    <last_verified>April 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>*Assessment of safety and tolerability of high dosage Infergen plus ribavirin including adverse events;study medication dose reduction, interruptions, and discontinuations; and BDI-II scores</outcome_measure>
      <outcome_measure>*Sustained viral response defined as the absence of detectable HCV RNA at week 72</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00266318</url>
  </study>
  <study rank="543">
    <nct_id>NCT01581203</nct_id>
    <title>Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Asunaprevir (ASV)</intervention>
      <intervention type="Drug">Daclatasvir (DCV)</intervention>
      <intervention type="Drug">Pegylated-interferon alfa 2a (PegIFN)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>748</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI447-028</other_id>
      <other_id>2011-005446-35</other_id>
    </other_ids>
    <first_received>April 18, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>Hallmark DUAL</acronym>
    <primary_completion_date>October 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of treated subjects with SVR12, defined as HCV RNA &lt; LOQ at post treatment Week 12, for subjects who are prior null or partial responders to P/R or are treatment-naive</outcome_measure>
      <outcome_measure>Proportion of treated subjects with SVR12, defined as HCV RNA &lt; LOQ at post-treatment Week 12, for subjects who are intolerant or ineligible to P/R</outcome_measure>
      <outcome_measure>On treatment safety, as measured by frequency of Serious Adverse Events (SAEs) and discontinuations due to Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Differences in rates of selected grade 3-4 laboratory abnormalities during the first 12 weeks between treatments (ASV + DCV vs PBO) for naive subjects</outcome_measure>
      <outcome_measure>Proportion of genotype 1b subjects with SVR12 (HCV RNA &lt; LOQ at post treatment Week 12) by the rs12979860 single nucleotide polymorphisms (SNP) in the IL28B gene for each cohort</outcome_measure>
      <outcome_measure>Proportion of genotype 1b subjects with HCV RNA undetectable</outcome_measure>
      <outcome_measure>Proportion of genotypes 1b subjects with HCV RNA &lt; LOQ</outcome_measure>
      <outcome_measure>Proportion of subjects with anemia</outcome_measure>
      <outcome_measure>Proportion of subjects with rash</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Ireland</country>
      <country>Israel</country>
      <country>Italy</country>
      <country>Korea, Republic of</country>
      <country>Netherlands</country>
      <country>New Zealand</country>
      <country>Poland</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Taiwan</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01581203</url>
  </study>
  <study rank="544">
    <nct_id>NCT01260350</nct_id>
    <title>Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">PEG</intervention>
      <intervention type="Drug">LDV</intervention>
      <intervention type="Drug">GS-9669</intervention>
      <intervention type="Drug">LDV/SOF</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>292</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P7977-0523</other_id>
      <other_id>Medsafe</other_id>
    </other_ids>
    <first_received>December 13, 2010</first_received>
    <start_date>December 2010</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>November 7, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>November 7, 2014</firstreceived_results_date>
    <primary_completion_date>October 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Who Experienced Adverse Events</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks Following Completion of Treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LOD at Week 6</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LOD at Week 8</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LOD at Week 12</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 6</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 8</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>New Zealand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01260350</url>
  </study>
  <study rank="545">
    <nct_id>NCT00315432</nct_id>
    <title>NATURAL HISTORY-Hepatitis C Virus/ Human Immunodeficiency Virus Coinfection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV</condition>
      <condition>Anemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon and Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ortho Biotech Products, L.P.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>91</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR005134</other_id>
    </other_ids>
    <first_received>April 14, 2006</first_received>
    <start_date>September 2000</start_date>
    <completion_date>November 2003</completion_date>
    <last_updated>May 17, 2011</last_updated>
    <last_verified>April 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Primary endpoints were change in hemoglobin and serum erythropoietin from baseline to week 8 (or early withdrawal)</outcome_measure>
      <outcome_measure>Other endpoints measured were changes in reticulocytes, platelets, total bilirubin, and RBV dose from baseline to week 8.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00315432</url>
  </study>
  <study rank="546">
    <nct_id>NCT01700179</nct_id>
    <title>Evaluation of Safety Tolerability and Antiviral Activity of ACH-0143102 Plus RBV Treatment Naive HCV GT1b Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ACH-0143102</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Achillion Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>8</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ACH102-005</other_id>
    </other_ids>
    <first_received>October 2, 2012</first_received>
    <start_date>September 2012</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>October 2, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>September 30, 2014</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR12</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Georgia</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01700179</url>
  </study>
  <study rank="547">
    <nct_id>NCT02099604</nct_id>
    <title>Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
      <collaborator>Institut Pasteur</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRS 12226 ViZIR</other_id>
    </other_ids>
    <first_received>March 24, 2014</first_received>
    <start_date>April 2014</start_date>
    <last_updated>July 22, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ViZIR</acronym>
    <primary_completion_date>March 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients with Sustained Virological Response (SVR).</outcome_measure>
      <outcome_measure>Rapid Virological Response (RVR)</outcome_measure>
      <outcome_measure>Early Virological Response (EVR)</outcome_measure>
      <outcome_measure>End of Treatment Response (ETR)</outcome_measure>
      <outcome_measure>Normalization of ALT during treatment and 12 weeks after the end of treatment</outcome_measure>
      <outcome_measure>Incidence of serious adverse events (SAE) grade 3 and 4 (ANRS scale)</outcome_measure>
      <outcome_measure>Evolution of FibroScan values between pre-inclusion and week 60</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02099604</url>
  </study>
  <study rank="548">
    <nct_id>NCT00560274</nct_id>
    <title>A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Anemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">epoetin beta [NeoRecormon]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>190</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML21362</other_id>
    </other_ids>
    <first_received>November 16, 2007</first_received>
    <start_date>March 2008</start_date>
    <completion_date>November 2011</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Blood pressure, pulse rate.</outcome_measure>
      <outcome_measure>AEs, and laboratory parameters.</outcome_measure>
      <outcome_measure>Percentage of patients achieving correction of anemia</outcome_measure>
      <outcome_measure>Percentage of patients not requiring blood transfusion</outcome_measure>
      <outcome_measure>Course of Hb concentration</outcome_measure>
      <outcome_measure>Percentage of patients maintaining initial ribavirin dose</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00560274</url>
  </study>
  <study rank="549">
    <nct_id>NCT01327729</nct_id>
    <title>Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Self Efficacy</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>BioGeneric Pharma</lead_sponsor>
      <collaborator>Xiamen Amoytop Biotech Co., Ltd.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CHT00234</other_id>
    </other_ids>
    <first_received>March 31, 2011</first_received>
    <start_date>November 2010</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>April 1, 2011</last_updated>
    <last_verified>March 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>viral clearance at 72 weeks</outcome_measure>
      <outcome_measure>interferon level</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01327729</url>
  </study>
  <study rank="550">
    <nct_id>NCT00142103</nct_id>
    <title>CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Relapsed Hepatitis C Virus (HCV) Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis, Chronic Active</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CPG10101</intervention>
      <intervention type="Drug">CPG10101</intervention>
      <intervention type="Drug">CPG10101</intervention>
      <intervention type="Drug">CPG10101</intervention>
      <intervention type="Drug">Control</intervention>
      <intervention type="Drug">CPG10101</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>91</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>B1211001</other_id>
      <other_id>CPG10101-003</other_id>
    </other_ids>
    <first_received>August 31, 2005</first_received>
    <start_date>September 2005</start_date>
    <completion_date>February 2007</completion_date>
    <last_updated>May 13, 2011</last_updated>
    <last_verified>May 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Adverse events, vital signs, clinical and laboratory parameters, physical exam, ECG</outcome_measure>
      <outcome_measure>Serum HCV RNA concentrations: Serum HCV concentrations over time to baseline</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Florida</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00142103</url>
  </study>
  <study rank="551">
    <nct_id>NCT00705107</nct_id>
    <title>Adherence to Treatment With PegIntron Pen Plus Rebetol in Treatment-naïve Adult Patients With Hepatitis C in Romania (Study P04247)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron pen (peginterferon alfa-2b; SCH 54031)</intervention>
      <intervention type="Drug">Rebetol (ribavirin; SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>267</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04247</other_id>
    </other_ids>
    <first_received>June 23, 2008</first_received>
    <start_date>November 2004</start_date>
    <completion_date>November 2007</completion_date>
    <last_updated>June 3, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>February 11, 2009</firstreceived_results_date>
    <primary_completion_date>November 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Subjects Who Completed Treatment.</outcome_measure>
      <outcome_measure>Average Length of Treatment.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00705107</url>
  </study>
  <study rank="552">
    <nct_id>NCT00310336</nct_id>
    <title>Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">S-adenosyl-L-methionine</intervention>
      <intervention type="Drug">betaine</intervention>
      <intervention type="Drug">pegylated interferon alpha2b</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Basel, Switzerland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>EKBB 37/06</other_id>
    </other_ids>
    <first_received>March 31, 2006</first_received>
    <start_date>August 2006</start_date>
    <completion_date>September 2009</completion_date>
    <last_updated>October 27, 2010</last_updated>
    <last_verified>October 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained response rate</outcome_measure>
      <outcome_measure>Early virologic response after 12 weeks of therapy with PegIntron, Rebetol, AdoMet and betaine.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Switzerland</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00310336</url>
  </study>
  <study rank="553">
    <nct_id>NCT01132313</nct_id>
    <title>Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BI 207127</intervention>
      <intervention type="Drug">BI 201335</intervention>
      <intervention type="Drug">BI 207127</intervention>
      <intervention type="Drug">BI 201335</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">BI 207127</intervention>
      <intervention type="Drug">BI 207127</intervention>
      <intervention type="Drug">BI 207127</intervention>
      <intervention type="Drug">BI 201335</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">BI 207127</intervention>
      <intervention type="Drug">BI 207127</intervention>
      <intervention type="Drug">BI 201335</intervention>
      <intervention type="Drug">BI 201335</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">BI 201335</intervention>
      <intervention type="Drug">BI 201335</intervention>
      <intervention type="Drug">BI 207127</intervention>
      <intervention type="Drug">BI 201335</intervention>
      <intervention type="Drug">BI 201335</intervention>
      <intervention type="Drug">BI 207127</intervention>
      <intervention type="Drug">BI 201335</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">BI 207217</intervention>
      <intervention type="Drug">BI 201335</intervention>
      <intervention type="Drug">BI 207127</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">BI 207127</intervention>
      <intervention type="Drug">BI 201335</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>489</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1241.21</other_id>
      <other_id>2009-018197-66</other_id>
    </other_ids>
    <first_received>May 3, 2010</first_received>
    <start_date>May 2010</start_date>
    <completion_date>October 2014</completion_date>
    <last_updated>November 5, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Part 1 of the trial: Rapid virological response (RVR), defined as HCV RNA &lt;25IU/mL at Week 4 of treatment</outcome_measure>
      <outcome_measure>Part 2 of the trial: Sustained virological response (SVR), defined as HCV RNA &lt;25 IU/mL and undetectable at 12 weeks after end of treatment</outcome_measure>
      <outcome_measure>Part 3 and 4: Sustained virological response (SVR) defined as HCV RNA &lt;25IU/mL and undetectable at 12 weeks after end of treatment</outcome_measure>
      <outcome_measure>Part 1 and 2: Time to virological response, defined as the timepoint of the first measurement of plasma HCV RNA level &lt;25 IU/mL</outcome_measure>
      <outcome_measure>Part 1 and2: Plasma HCV RNA level not detectable at Week 4</outcome_measure>
      <outcome_measure>Part 2: Sustained virological response at 24 weeks after end of treatment</outcome_measure>
      <outcome_measure>Part 3 and 4: Plasma HCV RNA level &lt;25 IU/mL at week 4 and 12 of treatment</outcome_measure>
      <outcome_measure>Part 3 and 4: Sustained virological response (SVR) at 4 weeks after end of treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>France</country>
      <country>Germany</country>
      <country>New Zealand</country>
      <country>Portugal</country>
      <country>Romania</country>
      <country>Spain</country>
      <country>Switzerland</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Indiana</state>
      <state>Massachusetts</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01132313</url>
  </study>
  <study rank="554">
    <nct_id>NCT01095445</nct_id>
    <title>EXtended Therapy in Hepatitis C Genotype 3 Infected Patients</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2b (Pegetron) plus ribavirin (Rebetol)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Health Network, Toronto</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>2</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>EXACT-R(3)</other_id>
    </other_ids>
    <first_received>March 26, 2010</first_received>
    <start_date>February 2010</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>September 27, 2011</last_updated>
    <last_verified>March 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>EXACT-R(3)</acronym>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>End of treatment response</outcome_measure>
      <outcome_measure>Relapse rate</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01095445</url>
  </study>
  <study rank="555">
    <nct_id>NCT02120274</nct_id>
    <title>Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>RNA Virus Infections</condition>
      <condition>Flaviviridae Infections</condition>
      <condition>Hepatitis C</condition>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Vitamin D</intervention>
      <intervention type="Drug">Vitamin B 12</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Federal University of São Paulo</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>85</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>DB12SHCV</other_id>
      <other_id>U1111-1155-6986</other_id>
    </other_ids>
    <first_received>April 18, 2014</first_received>
    <start_date>March 2014</start_date>
    <completion_date>January 2016</completion_date>
    <last_updated>August 11, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR12</outcome_measure>
      <outcome_measure>RVR, EVR, EOT</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Brazil</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02120274</url>
  </study>
  <study rank="556">
    <nct_id>NCT00866021</nct_id>
    <title>Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV/HCV Co-infection</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lopinavir/ritonavir</intervention>
      <intervention type="Drug">Lopinavir/ritonavir with two nucleoside analogs</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Fundacion SEIMC-GESIDA</lead_sponsor>
      <collaborator>Abbott</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>68</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GESIDA-5506</other_id>
      <other_id>2007-003544-30</other_id>
    </other_ids>
    <first_received>March 18, 2009</first_received>
    <start_date>February 2008</start_date>
    <completion_date>October 2012</completion_date>
    <last_updated>March 21, 2013</last_updated>
    <last_verified>March 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PEKARI</acronym>
    <primary_completion_date>June 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Assess efficacy of concomitant treatment with lopinavir/r monotherapy and PEG-INF plus RBV for the control of both HIV and HCV infection respectively after 12 months of active treatment for HCV</outcome_measure>
      <outcome_measure>Tolerability and safety of concomitant treatment with LPV/r, PEG-INF and RBV</outcome_measure>
      <outcome_measure>CD4</outcome_measure>
      <outcome_measure>Efficacy</outcome_measure>
      <outcome_measure>Adherence</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00866021</url>
  </study>
  <study rank="557">
    <nct_id>NCT00814606</nct_id>
    <title>A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Fluvastatin</intervention>
      <intervention type="Drug">Peginterferon alfa2a</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>16336A</other_id>
    </other_ids>
    <first_received>December 23, 2008</first_received>
    <start_date>February 2010</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>June 28, 2013</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy of adding fluvastatin to pegylated interferon alfa-2a and ribavirin in patients infected with genotype 1 HCV who are previous partial responders to standard treatment.</outcome_measure>
      <outcome_measure>Safety of adding fluvastatin to pegylated interferon alfa-2a and ribavirin in patients infected with genotype 1 HCV who are previous partial responders to standard treatment.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00814606</url>
  </study>
  <study rank="558">
    <nct_id>NCT01838772</nct_id>
    <title>HCV Treatment in HIV Co-Infected Patients in Asia</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated-Interferon and Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>amfAR, The Foundation for AIDS Research</lead_sponsor>
      <collaborator>Kirby Institute</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>188</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TA010</other_id>
    </other_ids>
    <first_received>April 5, 2013</first_received>
    <start_date>December 2013</start_date>
    <completion_date>June 2016</completion_date>
    <last_updated>March 3, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The proportion of patients with sustained virological response (SVR), defined as an undetectable HCV RNA, 24 weeks after completion of therapy</outcome_measure>
      <outcome_measure>Proportion of patients with Rapid Virological Response (RVR)</outcome_measure>
      <outcome_measure>Proportion of patients with Early Virological Response (EVR)</outcome_measure>
      <outcome_measure>Proportion of patients with End of Treatment Response (ETR)</outcome_measure>
      <outcome_measure>Proportions of patients who discontinue treatment prematurely</outcome_measure>
      <outcome_measure>Clinical and laboratory safety parameters</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Indonesia</country>
      <country>Malaysia</country>
      <country>Thailand</country>
      <country>Vietnam</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01838772</url>
  </study>
  <study rank="559">
    <nct_id>NCT02074514</nct_id>
    <title>Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>117</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0116</other_id>
    </other_ids>
    <first_received>February 26, 2014</first_received>
    <start_date>March 2014</start_date>
    <completion_date>November 2015</completion_date>
    <last_updated>December 7, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of adverse events leading to permanent discontinuation of study drug</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure and viral relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>India</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02074514</url>
  </study>
  <study rank="560">
    <nct_id>NCT01054729</nct_id>
    <title>Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">PEG</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>64</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P7977-0221</other_id>
    </other_ids>
    <first_received>January 21, 2010</first_received>
    <start_date>January 2010</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>March 31, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>January 6, 2014</firstreceived_results_date>
    <primary_completion_date>April 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Who Experienced Adverse Events During the Sofosbuvir Treatment Period</outcome_measure>
      <outcome_measure>Change in Circulating HCV RNA at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Virologic Response at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) at 12 and 24 Weeks After Last Dose of PEG+RBV Following Completion of 48 Weeks of Treatment</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of Sofosbuvir: Cmax at Day 0</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of Sofosbuvir: Cmax at Day 27</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of Sofosbuvir: AUCinf at Day 0</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of Sofosbuvir: AUCtau at Day 27</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007: Cmax at Day 0</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007: Cmax at Day 27</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007: AUCinf at Day 0</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007: AUCtau at Day 27</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-566500: Cmax at Day 0</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-566500: Cmax at Day 27</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-566500: AUCinf at Day 0</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-566500: AUCtau at Day 27</outcome_measure>
      <outcome_measure>Percentage of Participants Who Developed Resistance to Sofosbuvir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01054729</url>
  </study>
  <study rank="561">
    <nct_id>NCT00514111</nct_id>
    <title>Factors Associated to Success of Hepatitis C Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated-interferon, conventional-interferon, ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UPECLIN HC FM Botucatu Unesp</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>upeclin/HC/FMB-Unesp-16</other_id>
    </other_ids>
    <first_received>August 8, 2007</first_received>
    <start_date>August 2007</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>March 19, 2009</last_updated>
    <last_verified>March 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2008</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>Brazil</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00514111</url>
  </study>
  <study rank="562">
    <nct_id>NCT00114361</nct_id>
    <title>48 Weeks Combination Therapy for Patients With HBeAg-negative Chronic Hepatitis B Virus (HBV) Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alpha 2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Foundation for Liver Research</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>138</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>HBV05-01</other_id>
      <other_id>EudraCT: 2004-004736-30</other_id>
    </other_ids>
    <first_received>June 14, 2005</first_received>
    <start_date>March 2005</start_date>
    <completion_date>April 2010</completion_date>
    <last_updated>June 18, 2010</last_updated>
    <last_verified>June 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The combined presence of HBV DNA level &lt; 10E4 copies/ml and ALT normalization at the end of follow-up</outcome_measure>
      <outcome_measure>ALT normalization</outcome_measure>
      <outcome_measure>HBV DNA negativity(undetectable by Taqman PCR)</outcome_measure>
      <outcome_measure>HBsAg loss from serum</outcome_measure>
      <outcome_measure>Improvement liver histology</outcome_measure>
      <outcome_measure>Combined virological, biochemical and histological response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00114361</url>
  </study>
  <study rank="563">
    <nct_id>NCT01340573</nct_id>
    <title>Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PegIntron Pen</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>3</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04896</other_id>
    </other_ids>
    <first_received>November 18, 2010</first_received>
    <start_date>March 2007</start_date>
    <completion_date>October 2007</completion_date>
    <last_updated>January 20, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>October 4, 2011</firstreceived_results_date>
    <primary_completion_date>October 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Genotype-1 Participants Who Experienced Serious Adverse Events (SAE) at Week-48 of Study Treatment</outcome_measure>
      <outcome_measure>Number of Genotype-1 Participants Who Experienced Serious Adverse Events (SAE) at Week-24 Follow-up</outcome_measure>
      <outcome_measure>Number of Non-genotype-1 Participants Who Experienced Serious Adverse Events (SAE) at Week-24 of Study Treatment</outcome_measure>
      <outcome_measure>Number of Non-genotype 1 Participants Who Experienced Serious Adverse Events (SAE) on Week-24 Follow-up</outcome_measure>
      <outcome_measure>Number of Non-genotype-1 Participants Who Have Achieved Sustained Virologic Response (SVR) at Week-24 of Study Treatment</outcome_measure>
      <outcome_measure>Number of Non-genotype-1 Participants Who Have Achieved Sustained Virologic Response (SVR) at Week-24 Follow-up</outcome_measure>
      <outcome_measure>Number of Genotype-1 Participants Who Have Achieved Sustained Virologic Response (SVR) at Week-48 of Study Treatment</outcome_measure>
      <outcome_measure>Number of Genotype-1 Participants Who Have Achieved Sustained Virologic Response (SVR) at Week-24 Follow-up</outcome_measure>
      <outcome_measure>Participants' Overall Rating of Satisfaction and the Use of Training Materials for the Pegintron Pen, as Provided in a Study Questionnaire</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01340573</url>
  </study>
  <study rank="564">
    <nct_id>NCT02247401</nct_id>
    <title>Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV</condition>
      <condition>Hepatitis C Infection</condition>
      <condition>Genotype 4</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">2 DAA</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>160</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M14-250</other_id>
    </other_ids>
    <first_received>September 19, 2014</first_received>
    <start_date>November 2014</start_date>
    <completion_date>August 2016</completion_date>
    <last_updated>October 16, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of subjects with sustained virologic response 12 weeks post-treatment (SVR12) in each arm</outcome_measure>
      <outcome_measure>Incidence of Adverse Events</outcome_measure>
      <outcome_measure>Percentage of subjects with on-treatment virologic failure in each treatment arm</outcome_measure>
      <outcome_measure>Percentage of subjects with post-treatment relapse within 12 weeks following end of treatment in each arm</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02247401</url>
  </study>
  <study rank="565">
    <nct_id>NCT00724230</nct_id>
    <title>Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PegIntron (peginterferon alfa-2b; SCH 54031)</intervention>
      <intervention type="Drug">Rebetol (ribavirin; SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>505</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04841</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>February 2006</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>February 2, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Overall incidence of adverse events and adverse drug reactions.</outcome_measure>
      <outcome_measure>Assessment of trends of adverse drug reactions by patient factors and concomitant medications; Incidence, severity, and outcome of adverse events (AEs) between the elderly vs younger patients</outcome_measure>
      <outcome_measure>Sustained virologic response rate by HCV genotype, baseline viral load, and patient demographic characteristics</outcome_measure>
      <outcome_measure>Rate of ALT normalization at end of treatment period and at 24 weeks post completing therapy.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00724230</url>
  </study>
  <study rank="566">
    <nct_id>NCT01439776</nct_id>
    <title>Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Vit D</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hanyang University</lead_sponsor>
      <collaborator>Roche Pharma AG</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>222</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML25569</other_id>
    </other_ids>
    <first_received>September 16, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>September 22, 2011</last_updated>
    <last_verified>September 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>Addwin</acronym>
    <primary_completion_date>February 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants with Sustained virologic response (SVR)</outcome_measure>
      <outcome_measure>Number of participants with End of treatment response (ETR)</outcome_measure>
      <outcome_measure>Number of participants with Rapid virological response (RVR)</outcome_measure>
      <outcome_measure>Number of participants with Early virological response (EVR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Korea, Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01439776</url>
  </study>
  <study rank="567">
    <nct_id>NCT00611819</nct_id>
    <title>Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Co-Infection HIV-HCV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg interferon + Ribavirin</intervention>
      <intervention type="Drug">Peg interferon + Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Valencia</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>59</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KHRONOS</other_id>
      <other_id>2005-000203-34</other_id>
    </other_ids>
    <first_received>January 25, 2008</first_received>
    <start_date>November 2005</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>January 25, 2008</last_updated>
    <last_verified>January 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>% of patients with RNA-HCV undetectable 24 weeks</outcome_measure>
      <outcome_measure>% of patients at the end of treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00611819</url>
  </study>
  <study rank="568">
    <nct_id>NCT01482390</nct_id>
    <title>A Study of Mericitabine in Combination With Telaprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">mericitabine</intervention>
      <intervention type="Drug">mericitabine</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV27779</other_id>
      <other_id>2011-002715-28</other_id>
    </other_ids>
    <first_received>November 28, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>March 9, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response 12 weeks after treatment (SVR-12)</outcome_measure>
      <outcome_measure>Sustained virological response 4 weeks after treatment (SVR-4)</outcome_measure>
      <outcome_measure>Virologic response over time</outcome_measure>
      <outcome_measure>Proportion of patients who develop treatment resistance</outcome_measure>
      <outcome_measure>Safety (incidence of adverse events)</outcome_measure>
      <outcome_measure>Pharmacokinetics: trough concentration of RO4995855</outcome_measure>
      <outcome_measure>Pharmacokinetics: trough concentration of RO5012433</outcome_measure>
      <outcome_measure>Pharmacokinetics: trough concentration of telaprevir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01482390</url>
  </study>
  <study rank="569">
    <nct_id>NCT01482403</nct_id>
    <title>A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">boceprevir</intervention>
      <intervention type="Drug">boceprevir</intervention>
      <intervention type="Drug">mericitabine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>58</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV27780</other_id>
      <other_id>2011-002714-37</other_id>
    </other_ids>
    <first_received>November 28, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response 12 weeks after treatment (SVR-12)</outcome_measure>
      <outcome_measure>Sustained virological response 4 weeks after treatment</outcome_measure>
      <outcome_measure>Virologic response over time</outcome_measure>
      <outcome_measure>Proportion of patients who develop treatment resistance</outcome_measure>
      <outcome_measure>Safety (incidence of adverse events)</outcome_measure>
      <outcome_measure>Pharmacokinetics: trough concentration of RO4995855</outcome_measure>
      <outcome_measure>Pharmacokinetics: trough concentration of RO5012433</outcome_measure>
      <outcome_measure>Pharmacokinetics: trough concentration of boceprevir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Colorado</state>
      <state>Illinois</state>
      <state>Louisiana</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01482403</url>
  </study>
  <study rank="570">
    <nct_id>NCT01682720</nct_id>
    <title>Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">Placebo to match SOF</intervention>
      <intervention type="Drug">Placebo to match RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>421</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0133</other_id>
      <other_id>2012-001942-16</other_id>
    </other_ids>
    <first_received>September 5, 2012</first_received>
    <start_date>September 2012</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>October 8, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>October 2, 2014</firstreceived_results_date>
    <primary_completion_date>October 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Adverse Events Leading to Permanent Discontinuation of Study Drug(s)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Viral Breakthrough or Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
      <country>Estonia</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Netherlands</country>
      <country>Poland</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01682720</url>
  </study>
  <study rank="571">
    <nct_id>NCT01435226</nct_id>
    <title>GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GS-5885</intervention>
      <intervention type="Drug">GS-9451</intervention>
      <intervention type="Drug">tegobuvir</intervention>
      <intervention type="Drug">placebo to match tegobuvir</intervention>
      <intervention type="Drug">placebo to match RBV</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>170</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-248-0131</other_id>
    </other_ids>
    <first_received>September 13, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>July 2013</completion_date>
    <last_updated>November 22, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and Tolerability</outcome_measure>
      <outcome_measure>Antiviral Activity</outcome_measure>
      <outcome_measure>Viral Dynamics</outcome_measure>
      <outcome_measure>Composite (or Profile) of Pharmacokinetics Composite (or Profile) of Pharmacokinetics</outcome_measure>
      <outcome_measure>Antiviral Efficacy</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Kansas</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01435226</url>
  </study>
  <study rank="572">
    <nct_id>NCT01425203</nct_id>
    <title>The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Genotype 1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Biological">peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>238</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P08160</other_id>
      <other_id>MK-3034-046</other_id>
    </other_ids>
    <first_received>August 26, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>October 2013</completion_date>
    <last_updated>July 6, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>July 29, 2014</firstreceived_results_date>
    <primary_completion_date>October 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response At Follow-up Week 24 (SVR24) Among Participants Who Received At Least One Dose of Any Trial Medication (Full Analysis Set Population)</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR24 Among Participants Who Received At Least One Dose of Experimental Trial Drug (Modified Intent-To-Treat [mITT] Population)</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Early Virologic Response (EVR) At Treatment Week (TW) 8</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01425203</url>
  </study>
  <study rank="573">
    <nct_id>NCT01012895</nct_id>
    <title>Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-790052</intervention>
      <intervention type="Drug">BMS-650032</intervention>
      <intervention type="Drug">BMS-650032</intervention>
      <intervention type="Drug">BMS-650032</intervention>
      <intervention type="Drug">Pegylated-interferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>215</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI447-011</other_id>
      <other_id>2010-024637-23</other_id>
    </other_ids>
    <first_received>November 12, 2009</first_received>
    <start_date>December 2009</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Hepatitis C virus (HCV) ribonucleic acid (RNA) levels in subjects' blood before, during and after treatment</outcome_measure>
      <outcome_measure>Safety assessments will be based on medical review of the frequency of SAEs and AEs, discontinuations due to AEs, and abnormalities observed from vital sign and ECG measurements, physical examinations and clinical laboratory results</outcome_measure>
      <outcome_measure>Pharmacokinetic parameter maximum observed concentration [Cmax] will be derived from plasma concentration versus time. Trough concentration (Ctrough) and sparse Pharmacokinetics (PK) samples will also be collected.</outcome_measure>
      <outcome_measure>Pharmacokinetic parameter trough observed concentration [Cmin] will be derived from plasma concentration versus time. Trough concentration (Ctrough) and sparse Pharmacokinetics (PK) samples will also be collected.</outcome_measure>
      <outcome_measure>Pharmacokinetic parameter time of maximum observed concentration [Tmax] will be derived from plasma concentration versus time. Trough concentration (Ctrough) and sparse Pharmacokinetics (PK) samples will also be collected.</outcome_measure>
      <outcome_measure>Pharmacokinetic parameter area under the concentration-time curve in one dosing interval [AUC(TAU)] will be derived from plasma concentration versus time. Trough concentration (Ctrough) and sparse Pharmacokinetics (PK) samples will also be collected.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>France</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01012895</url>
  </study>
  <study rank="574">
    <nct_id>NCT01866930</nct_id>
    <title>Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated Interferon Lambda-1a</intervention>
      <intervention type="Drug">Daclatasvir (DCV)</intervention>
      <intervention type="Drug">Ribasphere (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI452-032</other_id>
      <other_id>2012-003280-22</other_id>
    </other_ids>
    <first_received>May 29, 2013</first_received>
    <start_date>July 2013</start_date>
    <completion_date>August 2015</completion_date>
    <last_updated>September 10, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>DIMENSION</acronym>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Antiviral activity, as determined by the proportion of subjects with SVR12, defined as HCV RNA &lt;LLOQ (25 IU/mL), target detected or target not detected, for each treatment arm</outcome_measure>
      <outcome_measure>Proportion of subjects with Rapid virologic response (RVR) and Extended Rapid Virologic Response (eRVR), where RVR is defined as &lt;LLOQ target not detected at week 4 and eRVR defined as &lt;LLOQ target not detected at Weeks 4 and 12</outcome_measure>
      <outcome_measure>Proportion of subjects in each group/duration who achieve HCV RNA &lt;LLOQ target detected or not detected, at end of therapy (SVR24)</outcome_measure>
      <outcome_measure>Proportion of subjects with treatment emergent cytopenic abnormalities (anemia as defined by Hb &lt;10 g/dL, and/or neutropenia as defined by ANC &lt;750 mm3 and/or thrombocytopenia as defined by platelets &lt;50,000 mm3) during the treatment period</outcome_measure>
      <outcome_measure>Proportion of subjects with the following on treatment IFN-associated symptoms: flu-like symptoms (as defined by pyrexia or chills or pain) and musculoskeletal symptoms (as defined by arthralgia or myalgia or back pain)</outcome_measure>
      <outcome_measure>Frequency of deaths, serious adverse events (SAEs), discontinuations due to Adverse Events (AEs), dose reductions, and severity Grade 3/4 laboratory abnormalities</outcome_measure>
      <outcome_measure>Absolute and percent change from baseline in the CD4 cell count, lymphocyte cell count, and platelet count</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Argentina</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Mexico</country>
      <country>Poland</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01866930</url>
  </study>
  <study rank="575">
    <nct_id>NCT01498068</nct_id>
    <title>Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Genotype 1 Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Pegylated-interferon-alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen-Cilag International NV</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100676</other_id>
      <other_id>VX-950HPC3007</other_id>
    </other_ids>
    <first_received>December 6, 2011</first_received>
    <start_date>January 2012</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>January 29, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>September 11, 2013</firstreceived_results_date>
    <primary_completion_date>April 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>Median Change in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>Number of Participants With Rapid Virologic Response (RVR) at Week 4</outcome_measure>
      <outcome_measure>Number of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Less Than 25 IU/mL, (Target Not Detected) at Weeks 8, 12, 24, 32, 40 and 48</outcome_measure>
      <outcome_measure>Number of Participants With Virologic Failure</outcome_measure>
      <outcome_measure>Number of Participants in Each Specific Category of Treatment Outcome</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Russian Federation</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01498068</url>
  </study>
  <study rank="576">
    <nct_id>NCT01364090</nct_id>
    <title>A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa 2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kirby Institute</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VHCRP1007</other_id>
    </other_ids>
    <first_received>May 31, 2011</first_received>
    <start_date>June 2012</start_date>
    <completion_date>September 2015</completion_date>
    <last_updated>August 31, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ACTIVATE</acronym>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Treatment Efficacy</outcome_measure>
      <outcome_measure>Safety and Tolerability</outcome_measure>
      <outcome_measure>Treatment Adherence</outcome_measure>
      <outcome_measure>Treatment response (ETR &amp; SVR24)</outcome_measure>
      <outcome_measure>Behavioral and Quality of Life</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
      <country>Australia</country>
      <country>Belgium</country>
      <country>Germany</country>
      <country>Norway</country>
      <country>Switzerland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01364090</url>
  </study>
  <study rank="577">
    <nct_id>NCT01713283</nct_id>
    <title>Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0114</other_id>
    </other_ids>
    <first_received>October 17, 2012</first_received>
    <start_date>October 2012</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>November 18, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>November 18, 2014</firstreceived_results_date>
    <primary_completion_date>November 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing On-treatment Virologic Failure</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01713283</url>
  </study>
  <study rank="578">
    <nct_id>NCT00687999</nct_id>
    <title>NIDDM and IR in Combination Therapy for CHC</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Insulin Resistance</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon alpha and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kaohsiung Medical University Chung-Ho Memorial Hospital</lead_sponsor>
      <collaborator>National Science Council, Taiwan</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KMUH-IRB-940055</other_id>
    </other_ids>
    <first_received>May 28, 2008</first_received>
    <start_date>December 2005</start_date>
    <completion_date>June 2008</completion_date>
    <last_updated>August 3, 2009</last_updated>
    <last_verified>May 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (SVR) rate, HCV RNA seronegative by PCR throughout 24-week off-treatment period; biochemical, virological and histological characteristics of CHC patients; HOMA-IR change after combination therapy</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00687999</url>
  </study>
  <study rank="579">
    <nct_id>NCT01517308</nct_id>
    <title>24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon alpha 2a + ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Federico II University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>C.E. Federico II 47/11</other_id>
    </other_ids>
    <first_received>January 17, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>November 2015</completion_date>
    <last_updated>March 16, 2012</last_updated>
    <last_verified>March 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (SVR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01517308</url>
  </study>
  <study rank="580">
    <nct_id>NCT01497366</nct_id>
    <title>Phase 3 Study of Sofosbuvir and Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">PEG</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>527</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P7977-1231</other_id>
    </other_ids>
    <first_received>December 19, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>April 2013</completion_date>
    <last_updated>March 4, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>January 15, 2014</firstreceived_results_date>
    <acronym>FISSION</acronym>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After Stopping All Study Drugs (SVR12)</outcome_measure>
      <outcome_measure>Number of Participants Who Experienced Adverse Events (AEs) and Graded Laboratory Abnormalities</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 24 Weeks After Stopping All Study Drugs (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ on Treatment</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Failure During Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse Following Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Italy</country>
      <country>Netherlands</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
      <country>Sweden</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Mississippi</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01497366</url>
  </study>
  <study rank="581">
    <nct_id>NCT01054573</nct_id>
    <title>VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">pegylated interferon (Peg-IFN) alfa-2a</intervention>
      <intervention type="Drug">ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Infectious Diseases BVBA</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR016678</other_id>
      <other_id>VX-TiDP24-C219</other_id>
      <other_id>2009-012613-21</other_id>
    </other_ids>
    <first_received>January 21, 2010</first_received>
    <start_date>April 2010</start_date>
    <completion_date>May 2012</completion_date>
    <last_updated>May 6, 2013</last_updated>
    <last_verified>May 2013</last_verified>
    <firstreceived_results_date>March 8, 2013</firstreceived_results_date>
    <primary_completion_date>March 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response (SVR) 24 Weeks After the Last Dose of Study Drug (SVR24 Actual)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values of Less Than 25 IU/ml, Target Not Detected at Different Time Points</outcome_measure>
      <outcome_measure>Percentage of Participants Who Met a Virologic Stopping Rule That Required Them to Permanently Discontinue Telaprevir and Continue Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) at Week 4 or Week 8</outcome_measure>
      <outcome_measure>Percentage of Participants Who Met a Virologic Stopping Rule That Required Them to Permanently Discontinue All Study Drugs at Week 12, 24, or 36</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants Who Relapsed During Follow-Up</outcome_measure>
      <outcome_measure>Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values Over Time</outcome_measure>
      <outcome_measure>Change From Baseline in Log 10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Level</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>France</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Netherlands</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>Switzerland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01054573</url>
  </study>
  <study rank="582">
    <nct_id>NCT00207311</nct_id>
    <title>Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Fatty Liver</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Xenical, Pegasys, Copegus</intervention>
      <intervention type="Behavioral">Xenicare Program</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Brooke Army Medical Center</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
      <collaborator>The Geneva Foundation</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>C.2004.140</other_id>
    </other_ids>
    <first_received>September 13, 2005</first_received>
    <start_date>August 2005</start_date>
    <completion_date>May 2009</completion_date>
    <last_updated>February 13, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HCVNASH</acronym>
    <primary_completion_date>May 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (SVR) defined as the percentage of participants with undetectable HCV-RNA as measured by the Roche AMPLICORTM HCV Test, v 2.0 (detection limit 50 IU/mL) at 24 weeks post completion of the treatment period</outcome_measure>
      <outcome_measure>Hepatic steatosis, necroinflammatory activity and fibrosis improvement at week 36 as determined by Dr. Elizabeth Brunt at Saint Louis University</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00207311</url>
  </study>
  <study rank="583">
    <nct_id>NCT00624325</nct_id>
    <title>Subcutaneous Continuous Infusion of Interferon Alfa-2b and Ribavirin in Hepatitis C Genotype 1 Nonresponders</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">interferon alfa-2b</intervention>
      <intervention type="Drug">interferon alfa-2b</intervention>
      <intervention type="Drug">interferon alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Foundation for Liver Research</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HCV 06-01</other_id>
      <other_id>eudract 2006-000592-15</other_id>
    </other_ids>
    <first_received>January 7, 2008</first_received>
    <start_date>July 2007</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>March 10, 2011</last_updated>
    <last_verified>March 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>SCIN-C</acronym>
    <primary_completion_date>June 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and tolerability of high-dose continuous subcutaneous infused IFN-a2b (serious adverse events, grade 4 NCI toxicity, percentage of patients completing treatment or reasons for dose adjustments).</outcome_measure>
      <outcome_measure>HCV RNA negativity at week 48 and 24 weeks after end of treatment</outcome_measure>
      <outcome_measure>Biological activity of IFN-a2b</outcome_measure>
      <outcome_measure>Pharmacokinetics by IFN-a2b levels</outcome_measure>
      <outcome_measure>HCV-specific immune responses</outcome_measure>
      <outcome_measure>Quality of life assessment using SF-36 and SCL-90 questionnaires</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00624325</url>
  </study>
  <study rank="584">
    <nct_id>NCT00275548</nct_id>
    <title>Safety and Effectiveness Using Pegasys and Copegus in Recipients of Liver Transplantation With Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Liver Transplant</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">Copegus</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
      <collaborator>Roche Pharma AG</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1404-04</other_id>
    </other_ids>
    <first_received>January 10, 2006</first_received>
    <start_date>July 2004</start_date>
    <completion_date>April 2009</completion_date>
    <last_updated>November 9, 2011</last_updated>
    <last_verified>November 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The proportion of patients in each group who experienced histologically confirmed recurrence of HCV at 120 weeks post randomization.</outcome_measure>
      <outcome_measure>The proportion of patients who have non-detectable serum HCV-RNA measured by Quanta Sure plus HCV test and HCV RNA negative by quantitative PCR at week 12, 24, and 48 following initiation of treatment or on observation.</outcome_measure>
      <outcome_measure>Virological response rate to antiviral therapy at week 12, week 24, and week 48 of therapy among patients who received antiviral therapy in either study arm.</outcome_measure>
      <outcome_measure>Sustained virological response rate: the virological response at the conclusion of the 24 weeks treatment free follow-up period or 72 weeks on observation (for patients who received no treatment).</outcome_measure>
      <outcome_measure>The virological response at the conclusion of the 24 weeks treatment-free follow-up period among patients who received antiviral therapy in either arm of the study.</outcome_measure>
      <outcome_measure>Patient death or graft failure (as indicated by retransplantation).</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Minnesota</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00275548</url>
  </study>
  <study rank="585">
    <nct_id>NCT01896193</nct_id>
    <title>Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>127</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0119</other_id>
    </other_ids>
    <first_received>July 2, 2013</first_received>
    <start_date>June 2013</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>May 7, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>April 7, 2015</firstreceived_results_date>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing On-treatment Virologic Failure</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Virologic Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Russian Federation</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01896193</url>
  </study>
  <study rank="586">
    <nct_id>NCT02128542</nct_id>
    <title>Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>66</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-1379</other_id>
    </other_ids>
    <first_received>April 29, 2014</first_received>
    <start_date>June 2014</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>July 1, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>VALOR-HCV</acronym>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) at 4 weeks after discontinuation of therapy (SVR4)</outcome_measure>
      <outcome_measure>Proportion of participants experiencing viral breakthrough</outcome_measure>
      <outcome_measure>Proportion of participants experiencing viral relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>Missouri</state>
      <state>North Carolina</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02128542</url>
  </study>
  <study rank="587">
    <nct_id>NCT00097435</nct_id>
    <title>A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Albuferon</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Human Genome Sciences Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>115</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Clinical Protocol ALFR-HC-05</other_id>
    </other_ids>
    <first_received>November 23, 2004</first_received>
    <start_date>October 2004</start_date>
    <completion_date>August 2007</completion_date>
    <last_updated>August 1, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The major safety endpoints are the common side effects of IFNa therapy including flu-like symptoms, depression, and hematologic abnormalities.</outcome_measure>
      <outcome_measure>Sustained virologic response (SVR), defined as undetectable virus at 24 weeks after the end of therapy. The primary efficacy assessment is HCV RNA level.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>Minnesota</state>
      <state>North Carolina</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00097435</url>
  </study>
  <study rank="588">
    <nct_id>NCT01336010</nct_id>
    <title>Treatment of Recently Acquired Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kirby Institute</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>82</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>5R01DA015999-07</other_id>
    </other_ids>
    <first_received>April 13, 2011</first_received>
    <start_date>August 2011</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>August 31, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ATAHC-II</acronym>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evaluate the safety and efficacy of response-guided pegylated interferon and ribavirin for the treatment of recent HCV infection. Response-guided means the duration of treatment will be determined by the subject's early response to treatment.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01336010</url>
  </study>
  <study rank="589">
    <nct_id>NCT00781274</nct_id>
    <title>Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MP-424</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon Alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>G060-A9</other_id>
    </other_ids>
    <first_received>October 24, 2008</first_received>
    <start_date>December 2008</start_date>
    <completion_date>July 2010</completion_date>
    <last_updated>April 16, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>June 5, 2012</firstreceived_results_date>
    <primary_completion_date>July 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Subjects Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00781274</url>
  </study>
  <study rank="590">
    <nct_id>NCT01667731</nct_id>
    <title>Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Human Immunodeficiency Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>224</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0123</other_id>
    </other_ids>
    <first_received>August 9, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>November 14, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>November 14, 2014</firstreceived_results_date>
    <primary_completion_date>November 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 1</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 2</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 4</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 6</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 8</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing On-treatment Virologic Failure</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Texas</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01667731</url>
  </study>
  <study rank="591">
    <nct_id>NCT02442271</nct_id>
    <title>A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ombitasvir/Paritaprevir/Ritonavir</intervention>
      <intervention type="Drug">Dasabuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>220</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M14-225</other_id>
    </other_ids>
    <first_received>May 11, 2015</first_received>
    <start_date>April 2015</start_date>
    <completion_date>October 2016</completion_date>
    <last_updated>December 10, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants achieving sustained virologic response SVR12</outcome_measure>
      <outcome_measure>Percentage of participants achieving SVR12</outcome_measure>
      <outcome_measure>Change in general health-related quality of life using the HCV-Patient Related Outcome (HCV PRO) scores</outcome_measure>
      <outcome_measure>Change in general health-related quality of life using the SF36V2 Physical Component Summary (PCS) scores</outcome_measure>
      <outcome_measure>Change in general health-related quality of life using the SF36V2 Mental Component Summary (MCS) scores</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Brazil</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02442271</url>
  </study>
  <study rank="592">
    <nct_id>NCT00895882</nct_id>
    <title>Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN)</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Genotype 1 Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">vaniprevir (MK7009)</intervention>
      <intervention type="Drug">Comparator: vaniprevir (MK7009)</intervention>
      <intervention type="Drug">Comparator: Pegylated Interferon (peg-IFN) alfa-2a</intervention>
      <intervention type="Drug">Comparator: Ribavirin</intervention>
      <intervention type="Drug">Comparator: Placebo to vaniprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>7009-019</other_id>
      <other_id>2009_586</other_id>
    </other_ids>
    <first_received>May 6, 2009</first_received>
    <start_date>November 2010</start_date>
    <completion_date>January 2013</completion_date>
    <last_updated>October 21, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients achieving SVR24 in Treatment Regimens 1 to 4</outcome_measure>
      <outcome_measure>Evaluate the safety and tolerability of the MK7009 treatment regiments as assessed by review of the accumulated safety data</outcome_measure>
      <outcome_measure>1) Proportion of patients achieving SVR24 in Treatment Regimen 5</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00895882</url>
  </study>
  <study rank="593">
    <nct_id>NCT02226549</nct_id>
    <title>Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">VDV</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>47</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-1512</other_id>
    </other_ids>
    <first_received>August 25, 2014</first_received>
    <start_date>July 2014</start_date>
    <completion_date>February 2015</completion_date>
    <last_updated>February 19, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of any adverse event leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response 4 weeks after discontinuation of therapy (SVR4)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02226549</url>
  </study>
  <study rank="594">
    <nct_id>NCT00277238</nct_id>
    <title>CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis, Chronic Active</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CPG10101</intervention>
      <intervention type="Drug">CPG10101</intervention>
      <intervention type="Drug">Control</intervention>
      <intervention type="Drug">CPG10101</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>113</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>B1211002</other_id>
      <other_id>CPG 10101-004</other_id>
    </other_ids>
    <first_received>January 13, 2006</first_received>
    <start_date>February 2006</start_date>
    <completion_date>July 2007</completion_date>
    <last_updated>April 21, 2011</last_updated>
    <last_verified>April 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Serum HCV RNA concentrations, over 12wks, relative to baseline, early virologic response (EVR)</outcome_measure>
      <outcome_measure>Serum HCV RNA concentrations, 6months after treatment completed, relative to baseline, sustained virologic response (SVR)</outcome_measure>
      <outcome_measure>Safety and Tolerability: adverse events, vital signs, clinical and laboratory parameters, depression score, physical exam, electrocardiogram (ECG), ophthalmologic exam (if required)</outcome_measure>
      <outcome_measure>Dose exposure</outcome_measure>
      <outcome_measure>Child-Pugh score</outcome_measure>
      <outcome_measure>Serum Biomarkers: cytokines and chemokines, over time, relative to baseline</outcome_measure>
      <outcome_measure>Immunophenotyping profile, over time, relative to baseline, HCV specific immune response, over time, relative to baseline, level of innate immune activation at baseline</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00277238</url>
  </study>
  <study rank="595">
    <nct_id>NCT02300103</nct_id>
    <title>Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF/VEL</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-342-1553</other_id>
    </other_ids>
    <first_received>November 20, 2014</first_received>
    <start_date>December 2014</start_date>
    <completion_date>September 2016</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV RNA &lt; LLOQ on-treatment</outcome_measure>
      <outcome_measure>HCV RNA change from baseline</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02300103</url>
  </study>
  <study rank="596">
    <nct_id>NCT02515279</nct_id>
    <title>An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>463</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML22273</other_id>
    </other_ids>
    <first_received>July 29, 2015</first_received>
    <start_date>November 2008</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>July 31, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Incidence of adverse events</outcome_measure>
      <outcome_measure>Sustained virologic response (SVR) rate</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02515279</url>
  </study>
  <study rank="597">
    <nct_id>NCT01045278</nct_id>
    <title>Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon-alfa-2b and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Region Skane</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>277</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>EU-nr 2007-001130-13</other_id>
    </other_ids>
    <first_received>September 11, 2009</first_received>
    <start_date>April 2008</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>October 1, 2013</last_updated>
    <last_verified>October 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To determine the completion rates of HCV treatment with pegylated interferon-alfa-2b and ribavirin in patients who are under opiate maintenance treatment and eligible for HCV therapy.</outcome_measure>
      <outcome_measure>Prevalence of chronic HCV infection in the patient population eligible for part I in the study.</outcome_measure>
      <outcome_measure>Clinical and histological characteristics of chronic hepatitis C.</outcome_measure>
      <outcome_measure>Prevalence of hepatic decompensation and cirrhosis/advanced liver disease.</outcome_measure>
      <outcome_measure>Risk factors for advanced liver disease.</outcome_measure>
      <outcome_measure>Proportion of sustained virological responders, defined as a plasma HVC RNA level below Lower Level of Quantification at 24 week post-treatment.</outcome_measure>
      <outcome_measure>Rates of relapse in opiate drug abuse.</outcome_measure>
      <outcome_measure>Prevalence of depressive symptoms and assessment of quality of life before, under and after HCV treatment.</outcome_measure>
      <outcome_measure>Potential pharmacokinetic interactions between ribavirin and methadone or buprenorphine.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Sweden</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01045278</url>
  </study>
  <study rank="598">
    <nct_id>NCT00867139</nct_id>
    <title>TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Influenza</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TCAD</intervention>
      <intervention type="Drug">Zanamivir or Oseltamivir</intervention>
      <intervention type="Other">Open label treatment with TCAD</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Fred Hutchinson Cancer Research Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>7</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2323.00</other_id>
      <other_id>6895</other_id>
    </other_ids>
    <first_received>March 20, 2009</first_received>
    <start_date>March 2009</start_date>
    <completion_date>January 2010</completion_date>
    <last_updated>August 8, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>December 21, 2012</firstreceived_results_date>
    <primary_completion_date>August 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Adverse Events (AEs), Drug Specific AEs or AEs Resulting in Treatment Interruption</outcome_measure>
      <outcome_measure>Number of Participants With Viral Load Decrease as a Function of Time</outcome_measure>
      <outcome_measure>Number of Patients Not Shedding Virus at Day 5 +/-1 and Day 10 +/- 1</outcome_measure>
      <outcome_measure>Number of Participants With Viral Resistance as a Function of Drug Exposure</outcome_measure>
      <outcome_measure>Duration of Symptoms</outcome_measure>
      <outcome_measure>Frequency of Confirmed Pneumonia</outcome_measure>
      <outcome_measure>Duration of Hospitalization</outcome_measure>
      <outcome_measure>Days on Supplemental Oxygen</outcome_measure>
      <outcome_measure>Number of Participants With ICU Admissions</outcome_measure>
      <outcome_measure>Number of Participants With Intubations</outcome_measure>
      <outcome_measure>Number of Deaths</outcome_measure>
      <outcome_measure>Pharmacokinetics (AUC0-last) of TCAD</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00867139</url>
  </study>
  <study rank="599">
    <nct_id>NCT02120300</nct_id>
    <title>Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>122</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-1274</other_id>
    </other_ids>
    <first_received>April 18, 2014</first_received>
    <start_date>April 2014</start_date>
    <completion_date>August 2015</completion_date>
    <last_updated>August 25, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) at 4 weeks after discontinuation of therapy (SVR4)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV RNA &lt; LLOQ on treatment</outcome_measure>
      <outcome_measure>HCV RNA change from baseline</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
      <outcome_measure>For HIV-1/HCV co-infected participants, the proportion of participants that maintain HIV-1 RNA &lt; 50 copies/mL while on HCV treatment</outcome_measure>
      <outcome_measure>For HIV-1/HCV co-infected participants, change from baseline of serum creatinine at the end of treatment</outcome_measure>
      <outcome_measure>For HIV-1/HCV co-infected participants, change from baseline of serum creatinine at posttreatment Week 12</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>District of Columbia</state>
      <state>Georgia</state>
      <state>Massachusetts</state>
      <state>Minnesota</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02120300</url>
  </study>
  <study rank="600">
    <nct_id>NCT00892697</nct_id>
    <title>Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Weill Medical College of Cornell University</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>0810010040</other_id>
    </other_ids>
    <first_received>April 30, 2009</first_received>
    <start_date>May 2009</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>March 9, 2015</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>December 18, 2014</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Intrahepatic and Plasma HCV Viral Kinetics</outcome_measure>
      <outcome_measure>Intrahepatic and Peripheral Pharmacokinetic Assessment of Telaprevir</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00892697</url>
  </study>
  <study rank="601">
    <nct_id>NCT02536313</nct_id>
    <title>Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF/VEL/GS-9857</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>49</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-367-1871</other_id>
    </other_ids>
    <first_received>August 27, 2015</first_received>
    <start_date>July 2015</start_date>
    <completion_date>June 2016</completion_date>
    <last_updated>November 6, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) 12 weeks after cessation of treatment (SVR12)</outcome_measure>
      <outcome_measure>Incidence of any adverse event (AE) leading to permanent discontinuation of study drug(s).</outcome_measure>
      <outcome_measure>Proportion of participants with SVR at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>The proportion of participants with HCV RNA &lt; LLOQ on treatment</outcome_measure>
      <outcome_measure>HCV RNA change from Baseline/Day 1</outcome_measure>
      <outcome_measure>The proportion of participants with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02536313</url>
  </study>
  <study rank="602">
    <nct_id>NCT00709228</nct_id>
    <title>Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PegIntron</intervention>
      <intervention type="Drug">Rebetol</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>496</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04793</other_id>
    </other_ids>
    <first_received>June 23, 2008</first_received>
    <start_date>May 2006</start_date>
    <completion_date>November 2008</completion_date>
    <last_updated>January 14, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>November 9, 2009</firstreceived_results_date>
    <primary_completion_date>November 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of HCV LVL G1 Participants Who Relapsed</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00709228</url>
  </study>
  <study rank="603">
    <nct_id>NCT00107653</nct_id>
    <title>Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>569</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML18179</other_id>
    </other_ids>
    <first_received>April 6, 2005</first_received>
    <start_date>August 2004</start_date>
    <completion_date>February 2008</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of patients with sustained virologic response</outcome_measure>
      <outcome_measure>Percentage of patients with early virologic response</outcome_measure>
      <outcome_measure>Percentage of patients with virologic response</outcome_measure>
      <outcome_measure>AEs, laboratory parameters, premature withdrawals</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00107653</url>
  </study>
  <study rank="604">
    <nct_id>NCT01858961</nct_id>
    <title>Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BI 201335</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">BI 207127</intervention>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">Pegylated Interferon</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1241.37</other_id>
      <other_id>2012-004544-30</other_id>
    </other_ids>
    <first_received>May 17, 2013</first_received>
    <start_date>May 2013</start_date>
    <completion_date>July 2016</completion_date>
    <last_updated>January 22, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response at Week 12 after end of treatment (SVR12)</outcome_measure>
      <outcome_measure>SVR4: Plasma HCV RNA level &lt;25 IU/mL1 at 4 weeks after end of treatment</outcome_measure>
      <outcome_measure>SVR24: Plasma HCV RNA level &lt;25 IU/mL1 at 24 weeks after end of treatment</outcome_measure>
      <outcome_measure>Virological Response at Week 4 -Plasma HCV RNA level undetectable at Week 4 -Plasma HCV RNA level &lt;25 IU/mL at Week 4</outcome_measure>
      <outcome_measure>Plasma HCV level undetectable at Week 12</outcome_measure>
      <outcome_measure>Time to achieving HCV RNA undetectable</outcome_measure>
      <outcome_measure>Virological breakthrough</outcome_measure>
      <outcome_measure>ETR: Plasma HCV RNA level undetected at the end of treatment</outcome_measure>
      <outcome_measure>Lack of on-treatment viral response</outcome_measure>
      <outcome_measure>Relapse</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>Adverse events leading to discontinuation</outcome_measure>
      <outcome_measure>Serious Adverse Events</outcome_measure>
      <outcome_measure>Laboratory test abnormalities by DAIDS grades</outcome_measure>
      <outcome_measure>Rate of red blood cell transfusion</outcome_measure>
      <outcome_measure>Time to discontinuation of trial medication</outcome_measure>
      <outcome_measure>Liver disease progression, fibroscan and FibroSURE</outcome_measure>
      <outcome_measure>Rate of ESA use</outcome_measure>
      <outcome_measure>Change in laboratory test values over time</outcome_measure>
      <outcome_measure>Patients requiring hospitalisation due to AEs related to study drugs</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
      <country>Spain</country>
      <country>Sweden</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01858961</url>
  </study>
  <study rank="605">
    <nct_id>NCT01528735</nct_id>
    <title>This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BI 207127 NA</intervention>
      <intervention type="Drug">peginterferon</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">BI 207127 NA</intervention>
      <intervention type="Drug">BI 201335 NA</intervention>
      <intervention type="Drug">BI 201335 NA</intervention>
      <intervention type="Drug">peginterferon</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1241.25</other_id>
    </other_ids>
    <first_received>February 6, 2012</first_received>
    <start_date>February 2012</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>April 30, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Virological response at Week 4</outcome_measure>
      <outcome_measure>Virological response at Week 8</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01528735</url>
  </study>
  <study rank="606">
    <nct_id>NCT01392742</nct_id>
    <title>An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>443</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML25670</other_id>
    </other_ids>
    <first_received>July 11, 2011</first_received>
    <start_date>May 2011</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>November 9, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>November 9, 2015</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virological Response (SVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Relapse</outcome_measure>
      <outcome_measure>Percentage of Participants Who Were Non-Responders</outcome_measure>
      <outcome_measure>Percentage of Participants With Positive Predictive Value on SVR at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Positive Predictive Value on SVR at Week 12</outcome_measure>
      <outcome_measure>Correlation of SVR With Rapid Virological Response (RVR)</outcome_measure>
      <outcome_measure>Correlation of SVR With Early Virological Response (EVR)</outcome_measure>
      <outcome_measure>Predictive Power Values of Host-, Virus- and Treatment-related Factors and Virological Response</outcome_measure>
      <outcome_measure>Duration of Treatment in Participants With SVR by HCV Genotype</outcome_measure>
      <outcome_measure>Cumulative PEG-IFN Alfa-2a Dose in Participants With SVR by HCV Genotype</outcome_measure>
      <outcome_measure>Cumulative Ribavirin Dose in Participants With SVR by HCV Genotype</outcome_measure>
      <outcome_measure>Percentage of Participants With Virological Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Bulgaria</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01392742</url>
  </study>
  <study rank="607">
    <nct_id>NCT00556504</nct_id>
    <title>The Effects of Adding TCM-700C on the Standard Combination Treatment for Patients With Genotype 1 Hepatitis C Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TCM-700C</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>TCM Biotech International Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>84</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>TCM-700-01-04</other_id>
    </other_ids>
    <first_received>November 8, 2007</first_received>
    <start_date>July 2007</start_date>
    <completion_date>May 2011</completion_date>
    <last_updated>August 4, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>June 5, 2013</firstreceived_results_date>
    <acronym>TCM-700C</acronym>
    <primary_completion_date>January 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Virologic Response</outcome_measure>
      <outcome_measure>ALT Response</outcome_measure>
      <outcome_measure>Sustained ALT Response</outcome_measure>
      <outcome_measure>Combined ALT and Virologic Response</outcome_measure>
      <outcome_measure>Immune Cell Normalization</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00556504</url>
  </study>
  <study rank="608">
    <nct_id>NCT00527540</nct_id>
    <title>Effectiveness and Side Effects of Pegylated Interferon Alpha-2a (Pegaferon®) Plus Ribavirin in the Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon alpha 2a + Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tehran Hepatitis Center</lead_sponsor>
      <collaborator>Kermanshah University of Medical Sciences</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>THC-10</other_id>
    </other_ids>
    <first_received>September 8, 2007</first_received>
    <start_date>February 2007</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>January 18, 2009</last_updated>
    <last_verified>January 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>End of treatment response rate (HCV RNA:Neg)</outcome_measure>
      <outcome_measure>Sustain response rate (HCV RNA:Neg) 6 month after end of treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Iran, Islamic Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00527540</url>
  </study>
  <study rank="609">
    <nct_id>NCT01434212</nct_id>
    <title>Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Interferon Alfa-2b, Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>First Hospital of Jilin University</lead_sponsor>
      <collaborator>Chinese Academy of Sciences</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>2008ZX10004-002-jida01</other_id>
      <other_id>2008ZX10002-014-jida01</other_id>
      <other_id>2009ZX10004-105-jida01</other_id>
    </other_ids>
    <first_received>September 8, 2011</first_received>
    <start_date>May 2010</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>October 27, 2011</last_updated>
    <last_verified>October 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>sIFN-pred1</acronym>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Blood HCV RNA Copies</outcome_measure>
      <outcome_measure>IL-28B polymorphism</outcome_measure>
      <outcome_measure>Microarray Analysis of PBMC Gene Expression</outcome_measure>
      <outcome_measure>HCV genotype</outcome_measure>
      <outcome_measure>Blood Anti-HCV,HBV Antibody</outcome_measure>
      <outcome_measure>HCV genome sequencing</outcome_measure>
      <outcome_measure>Alanine Aminotransferase (ALT) and Aspartate transaminase (AST)</outcome_measure>
      <outcome_measure>Fibrosis stage</outcome_measure>
      <outcome_measure>Regular blood test</outcome_measure>
      <outcome_measure>Electrocardiography</outcome_measure>
      <outcome_measure>Alcohol ,smoking condition</outcome_measure>
      <outcome_measure>Drug abuse history</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01434212</url>
  </study>
  <study rank="610">
    <nct_id>NCT00487318</nct_id>
    <title>Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">standard of care</intervention>
      <intervention type="Drug">fluvastatin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bader, Ted, M.D.</lead_sponsor>
      <collaborator>VA Office of Research and Development</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>13358</other_id>
    </other_ids>
    <first_received>June 15, 2007</first_received>
    <start_date>June 2007</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>August 20, 2012</last_updated>
    <last_verified>August 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Viral response</outcome_measure>
      <outcome_measure>Viral load at 4, 12 and 24 weeks</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Oklahoma</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00487318</url>
  </study>
  <study rank="611">
    <nct_id>NCT01975675</nct_id>
    <title>Efficacy and Safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>341</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-0113</other_id>
    </other_ids>
    <first_received>October 29, 2013</first_received>
    <start_date>October 2013</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>June 4, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>June 4, 2015</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12), Treatment-naive, Noncirrhotic Participants</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Virologic Failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01975675</url>
  </study>
  <study rank="612">
    <nct_id>NCT01344889</nct_id>
    <title>An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>4459</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>MV22255</other_id>
    </other_ids>
    <first_received>April 27, 2011</first_received>
    <start_date>October 2009</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Correlation between baseline patient characteristics and safety related dose reductions/treatment discontinuations of the long-acting interferon or ribavirin</outcome_measure>
      <outcome_measure>Correlation between safety related dose reductions/treatment discontinuations and sustained virological response (SVR: defined as HCV RNA &lt;50 IU/mL at 24 weeks after completion of treatment)</outcome_measure>
      <outcome_measure>Correlation of on-treatment factors and dose reduction/treatment discontinuation</outcome_measure>
      <outcome_measure>Correlation between degree of dose reductions/treatment interruptions (percentage of actual exposure/treatment administrations in relation to target exposure) and SVR</outcome_measure>
      <outcome_measure>Comparison of on-treatment virological response (rapid virological response, early virological response) in treatment-naïve and treatment experienced patients</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Albania</country>
      <country>Algeria</country>
      <country>Bahrain</country>
      <country>Belgium</country>
      <country>Bosnia and Herzegovina</country>
      <country>Brazil</country>
      <country>Egypt</country>
      <country>Greece</country>
      <country>Hungary</country>
      <country>India</country>
      <country>Iran, Islamic Republic of</country>
      <country>Italy</country>
      <country>Korea, Republic of</country>
      <country>Kuwait</country>
      <country>Lebanon</country>
      <country>Macedonia, The Former Yugoslav Republic of</country>
      <country>Morocco</country>
      <country>Pakistan</country>
      <country>Poland</country>
      <country>Portugal</country>
      <country>Qatar</country>
      <country>Romania</country>
      <country>Serbia</country>
      <country>Slovakia</country>
      <country>United Arab Emirates</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01344889</url>
  </study>
  <study rank="613">
    <nct_id>NCT01547312</nct_id>
    <title>Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022)</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-Interferon</intervention>
      <intervention type="Procedure">Liver Samples from FNA</intervention>
      <intervention type="Procedure">Liver Samples from CNB</intervention>
      <intervention type="Procedure">Blood Samples</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">800 mg Grazoprevir</intervention>
      <intervention type="Drug">100 mg Grazoprevir</intervention>
      <intervention type="Procedure">Liver samples from CNB and FNA</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>5172-022</other_id>
      <other_id>2011-004978-29</other_id>
    </other_ids>
    <first_received>February 2, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>November 2012</completion_date>
    <last_updated>October 13, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants from whom detectable concentrations of hepatic Grazoprevir are obtained by FNA.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01547312</url>
  </study>
  <study rank="614">
    <nct_id>NCT01649245</nct_id>
    <title>Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Reiferon retard</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>MinaPharm Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>5000</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HAPIC Trial</other_id>
    </other_ids>
    <first_received>July 20, 2012</first_received>
    <start_date>August 2012</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>January 12, 2013</last_updated>
    <last_verified>January 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HAPIC</acronym>
    <primary_completion_date>August 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>End of Treatment Response (ETR)</outcome_measure>
      <outcome_measure>Safety</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01649245</url>
  </study>
  <study rank="615">
    <nct_id>NCT02175758</nct_id>
    <title>Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF (oral tablets)</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">SOF (oral granules)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-1112</other_id>
      <other_id>2014-002283-32</other_id>
    </other_ids>
    <first_received>June 24, 2014</first_received>
    <start_date>July 2014</start_date>
    <completion_date>April 2018</completion_date>
    <last_updated>November 10, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>PK Lead-in Phase: PK parameters of GS-331007 as measured by AUCtau for determining the appropriate SOF dose</outcome_measure>
      <outcome_measure>Treatment Phase: proportion of participants achieving SVR12</outcome_measure>
      <outcome_measure>Treatment Phase: incidence of any adverse event leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>PK Lead-in Phase: change from baseline in HCV RNA</outcome_measure>
      <outcome_measure>PK Lead-in Phase: incidence of adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Treatment Phase: proportion of participants achieving SVR4</outcome_measure>
      <outcome_measure>Treatment Phase: proportion of participants achieving SVR24</outcome_measure>
      <outcome_measure>Treatment Phase: proportion of participants with virologic breakthrough</outcome_measure>
      <outcome_measure>Treatment Phase: proportion of participants with virologic relapse</outcome_measure>
      <outcome_measure>Palatability of SOF oral granules</outcome_measure>
      <outcome_measure>Treatment Phase: growth and development measurements as assessed by height</outcome_measure>
      <outcome_measure>Treatment Phase: growth and development measurements as assessed by weight</outcome_measure>
      <outcome_measure>Treatment Phase: growth and development measurements as assessed by Tanner Stage Assessment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>Belgium</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>New Zealand</country>
      <country>Russian Federation</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Washington</state>
      <state>West Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02175758</url>
  </study>
  <study rank="616">
    <nct_id>NCT00422838</nct_id>
    <title>Study Investigating Immunological Effects of Treatment for Chronic Hepatitis C Patients.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Liver</condition>
      <condition>Immunology</condition>
      <condition>Regulation</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">fine-needle aspiration biopsy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Foundation for Liver Research</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>27</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>CIRES</other_id>
    </other_ids>
    <first_received>January 15, 2007</first_received>
    <start_date>January 2007</start_date>
    <completion_date>November 2010</completion_date>
    <last_updated>September 6, 2011</last_updated>
    <last_verified>September 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>CIRES</acronym>
    <primary_completion_date>June 2010</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00422838</url>
  </study>
  <study rank="617">
    <nct_id>NCT01609049</nct_id>
    <title>An Observational Study of Pegasys (Peginterferon Alfa-2a) in Combination With Ribavirin in Patients With Chronic Hepatitis C and Compensated Liver Cirrhosis (STANDART)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1496</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML27851</other_id>
    </other_ids>
    <first_received>May 29, 2012</first_received>
    <start_date>December 2011</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (SVR) rate: Percentage of patients with undetectable HCV RNA 24 weeks after therapy completion</outcome_measure>
      <outcome_measure>Virologic response rate: Percentage of patients with SVR and negative HCV RNA at Week 4 and 12 (naïve patients)</outcome_measure>
      <outcome_measure>Virologic response rate: Percentage of patients with SVR and negative HCV RNA at Week 12 (previously treated patients)</outcome_measure>
      <outcome_measure>Virologic response rate: Percentage of patients with SVR and decrease in HCV RNA by &gt;/= log 10 from baseline (previously treated and naïve patients)</outcome_measure>
      <outcome_measure>Virologic response rate: Percentage of patients with SVR who had dose reduction of any drug (ribavirin or Pegasys) due to adverse events</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Korea, Republic of</country>
      <country>Russian Federation</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01609049</url>
  </study>
  <study rank="618">
    <nct_id>NCT00979251</nct_id>
    <title>Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Influenza</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Oseltamivir Phosphate</intervention>
      <intervention type="Drug">ADS-8902</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Adamas Pharmaceuticals, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>2</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ADS-TCAD-PO206</other_id>
    </other_ids>
    <first_received>September 16, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>March 17, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PO206</acronym>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Time to clearing of viral shedding</outcome_measure>
      <outcome_measure>Time to alleviation of influenza clinical symptoms</outcome_measure>
      <outcome_measure>Proportion of subjects who enter the study with mild to moderate influenza and progress to severe influenza</outcome_measure>
      <outcome_measure>Proportion of subjects with a treatment-sensitive influenza A strain at baseline who develop a resistant strain during treatment</outcome_measure>
      <outcome_measure>Safety and tolerability (adverse events (AEs), AEs resulting in treatment discontinuation, and Serious AEs)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Netherlands</country>
      <country>Singapore</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Hawaii</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Nevada</state>
      <state>New York</state>
      <state>South Dakota</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00979251</url>
  </study>
  <study rank="619">
    <nct_id>NCT00736242</nct_id>
    <title>Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Hepatitis C</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PEG-IFN alfa-2b</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>232</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04584</other_id>
    </other_ids>
    <first_received>July 30, 2008</first_received>
    <start_date>December 2005</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>February 2, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>December 21, 2012</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Number of Participants With Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Number of Participants With Early Virologic Response (EVR)</outcome_measure>
      <outcome_measure>Participant Study Status at End of Follow-up (EOF)</outcome_measure>
      <outcome_measure>Number of Participants With Hepatitis C Virus (HCV)-RNA Negativity During PEG-IFN Alfa-2b/RBV Treatment</outcome_measure>
      <outcome_measure>Number of Participants With Human Immunodeficiency Virus (HIV)-RNA Negativity During PEG-IFN Alfa-2b/RBV Treatment</outcome_measure>
      <outcome_measure>Median Cluster of Differentiation 4 (CD4) Cell Count During PEG-IFN Alfa-2b/RBV Treatment</outcome_measure>
      <outcome_measure>Number of Participants With A Serious Adverse Event (SAE) During PEG-IFN Alfa-2b/RBV Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00736242</url>
  </study>
  <study rank="620">
    <nct_id>NCT01841775</nct_id>
    <title>Interferon α 2b Pharmacovigilance Study</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">interferon α 2b + ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)</lead_sponsor>
      <collaborator>Hospital Federal de Bonsucesso (Bonsucesso Federal Hospital)</collaborator>
      <collaborator>Hospital Universitário Clementino Fraga Filho (Clementino Fraga Filho University Hospital)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>85</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VIGAT-RJ IFNα2b</other_id>
    </other_ids>
    <first_received>April 19, 2013</first_received>
    <start_date>May 2009</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>April 24, 2013</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>Sustained virological response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Brazil</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01841775</url>
  </study>
  <study rank="621">
    <nct_id>NCT00466219</nct_id>
    <title>Ribavirin/Pegasys Treatment of Recurrent Hepatitis C After Liver Transplant</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated interferon alpha2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Geneva</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>SASL17</other_id>
    </other_ids>
    <first_received>April 25, 2007</first_received>
    <start_date>May 2002</start_date>
    <completion_date>December 2006</completion_date>
    <last_updated>April 25, 2007</last_updated>
    <last_verified>April 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Biochemical (normalization of serum transaminases levels),</outcome_measure>
      <outcome_measure>virological (disappearance of HCV RNA from serum)</outcome_measure>
      <outcome_measure>and histological (amelioration of the histological signs of hepatitis) response.</outcome_measure>
      <outcome_measure>Correlation of the above outcome measures with early on-treatment HCV RNA dynamics (if applicable).</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00466219</url>
  </study>
  <study rank="622">
    <nct_id>NCT01758939</nct_id>
    <title>Predictors of Response to Combined Pegylated Interferon and Ribavirin in Chronic Hepatitis C Infected Egyptian Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Cairo University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
    </study_designs>
    <other_ids>
      <other_id>2</other_id>
      <other_id>NZEKRI2</other_id>
    </other_ids>
    <first_received>December 25, 2012</first_received>
    <start_date>January 2011</start_date>
    <completion_date>January 2017</completion_date>
    <last_updated>April 15, 2013</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Assess the response to the Interferon therapy.</outcome_measure>
      <outcome_measure>Predictors of response to therapy</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01758939</url>
  </study>
  <study rank="623">
    <nct_id>NCT01962441</nct_id>
    <title>Sofosbuvir+RBV for 16 or 24 Weeks and Sofosbuvir+PEG+RBV for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">PEG</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>601</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0153</other_id>
    </other_ids>
    <first_received>October 10, 2013</first_received>
    <start_date>September 2013</start_date>
    <completion_date>June 2016</completion_date>
    <last_updated>October 27, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants achieving sustained viral response 12 weeks after discontinuation of treatment (SVR12)</outcome_measure>
      <outcome_measure>Adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV RNA &lt; LLOQ during treatment</outcome_measure>
      <outcome_measure>Change from baseline in HCV RNA (log10 IU/mL)</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants experiencing viral breakthrough</outcome_measure>
      <outcome_measure>Proportion of participants experiencing viral relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>New Zealand</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Louisiana</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01962441</url>
  </study>
  <study rank="624">
    <nct_id>NCT01442311</nct_id>
    <title>Directly Observed Hepatitis C Treatment in Methadone Clinics</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Medication Adherence</condition>
    </conditions>
    <interventions>
      <intervention type="Other">enhanced DOT (both pegylated interferon alfa-2a and ribavirin)</intervention>
      <intervention type="Other">standard DOT (PEG-DOT control arm)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Albert Einstein College of Medicine of Yeshiva University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2006-224</other_id>
      <other_id>K23DA022454-01A1</other_id>
    </other_ids>
    <first_received>September 27, 2011</first_received>
    <start_date>October 2007</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>June 25, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Adherence</outcome_measure>
      <outcome_measure>sustained viral response (SVR)</outcome_measure>
      <outcome_measure>end of treatment response (ETR)</outcome_measure>
      <outcome_measure>treatment completion</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01442311</url>
  </study>
  <study rank="625">
    <nct_id>NCT00087633</nct_id>
    <title>PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">Copegus</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>115</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML18124</other_id>
    </other_ids>
    <first_received>July 12, 2004</first_received>
    <start_date>October 2004</start_date>
    <completion_date>October 2008</completion_date>
    <last_updated>December 22, 2010</last_updated>
    <last_verified>December 2010</last_verified>
    <firstreceived_results_date>October 14, 2009</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Percentage of Patients With Histologically-confirmed Recurrence of Hepatitis C Virus (HCV)</outcome_measure>
      <outcome_measure>Summary of Virologic Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>Nebraska</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Washington</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00087633</url>
  </study>
  <study rank="626">
    <nct_id>NCT00704756</nct_id>
    <title>An Observational Study of Patients With Chronic Hepatitis C Undergoing Treatment With PegIntron and Rebetol in Clinical Practice in Belgium (Study P05494)(WITHDRAWN)</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b; SCH 54031)</intervention>
      <intervention type="Drug">Rebetol (ribavirin; SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05494</other_id>
    </other_ids>
    <first_received>June 23, 2008</first_received>
    <start_date>January 2009</start_date>
    <completion_date>March 2010</completion_date>
    <last_updated>August 8, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PEGIMPACT</acronym>
    <primary_completion_date>March 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety parameters: common adverse events [AEs], drug-to-drug interaction AEs, and dose modifications</outcome_measure>
      <outcome_measure>Relapse rates and Sustained Virologic Response (SVR) rates and their association with demographic, virologic, histological, and safety parameters</outcome_measure>
      <outcome_measure>Predictors of response at End-of-Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00704756</url>
  </study>
  <study rank="627">
    <nct_id>NCT01770223</nct_id>
    <title>A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">boceprevir</intervention>
      <intervention type="Biological">PegIFN-2b</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>3034-113</other_id>
      <other_id>2012-002771-33</other_id>
    </other_ids>
    <first_received>January 15, 2013</first_received>
    <start_date>January 2014</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>October 29, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants with sustained virologic response (SVR) at 24 weeks after the end of 48 weeks of study treatment</outcome_measure>
      <outcome_measure>Change from baseline in Homeostasis Model of Assessment - Insulin Resistance (HOMA-IR)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01770223</url>
  </study>
  <study rank="628">
    <nct_id>NCT01740089</nct_id>
    <title>Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Algeron</intervention>
      <intervention type="Drug">PegIntron</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Biocad</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>PEG-IFNа-2</other_id>
    </other_ids>
    <first_received>November 30, 2012</first_received>
    <start_date>November 2011</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>July 22, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>March 1, 2015</firstreceived_results_date>
    <primary_completion_date>July 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Randomized Patients Achieving Early Virologic Response (EVR) - Negative PCR Result for HCV RNA (&lt; 15 IU/ml) or ≥ 2log10 Decrease of Viral Load After 12 Weeks of Study Treatment.</outcome_measure>
      <outcome_measure>Number of Randomized Patients Achieving Rapid Virologic Response (RVR) - Negative PCR Result for HCV RNA (&lt; 15 IU/ml) After 4 Weeks of Treatment.</outcome_measure>
      <outcome_measure>Number of Randomized Patients Achieving Sustained Virologic Response (SVR) - Negative PCR Result for HCV RNA (&lt; 15 IU/ml) 24 Weeks After Last Dose of Study Treatment.</outcome_measure>
      <outcome_measure>Number of Patients Who Have Undetectable HCV RNA (&lt; 15 IU/ml) at the End of Treatment.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Russian Federation</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01740089</url>
  </study>
  <study rank="629">
    <nct_id>NCT01685203</nct_id>
    <title>A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450/r</intervention>
      <intervention type="Drug">ABT-267</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie (prior sponsor, Abbott)</lead_sponsor>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>316</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M13-393</other_id>
      <other_id>2011-005762-38</other_id>
    </other_ids>
    <first_received>September 12, 2012</first_received>
    <start_date>August 2012</start_date>
    <completion_date>February 2015</completion_date>
    <last_updated>August 3, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>June 9, 2015</firstreceived_results_date>
    <acronym>PEARL-I</acronym>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants in Each Treatment Group With Sustained Virologic Response 12 Weeks Post-treatment</outcome_measure>
      <outcome_measure>Percentage of Participants in Each Treatment Group With Sustained Virologic Response 24 Weeks Post-treatment</outcome_measure>
      <outcome_measure>Percentage of Participants in Each Treatment Group With On-treatment Virologic Failure.</outcome_measure>
      <outcome_measure>Percentage of Participants in Each Treatment Group With Post-treatment Virologic Relapse.</outcome_measure>
      <outcome_measure>Percentage of Participants in Each Treatment Group With Treatment-emergent Adverse Events</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01685203</url>
  </study>
  <study rank="630">
    <nct_id>NCT00724893</nct_id>
    <title>Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIFN-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>2430</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04423</other_id>
      <other_id>MK-4031-267</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>August 2005</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>July 20, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>July 29, 2013</firstreceived_results_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Achieving Viral Response at Any Evaluation Point (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving Viral Response at 12 Weeks After EOT (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving Sustained Viral Response (SVR) (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Discontinued From Study Treatment Due to Adverse Events (Stage 1 and Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving Viral Response at Any Evaluation Point, Excluding Participants Who Discontinued Treatment Prior to Early Virologic Response (EVR) Evaluation (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving Viral Response at 12 Weeks After EOT, Excluding Participants Who Discontinued Prior to EVR Evaluation (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR, Excluding Participants Who Discontinued Prior to EVR Evaluation (Stage 1)</outcome_measure>
      <outcome_measure>The Number of Participants Achieving Viral Response at 12 Weeks After EOT, Excluding Participants Who Discontinued Prior to EVR Evaluation and Participants With Missing Data (Stage 1)</outcome_measure>
      <outcome_measure>The Number of Participants Achieving SVR Excluding Participants Who Discontinued Prior to EVR Evaluation and Participants With Missing Data (Stage 1)</outcome_measure>
      <outcome_measure>The Number of Participants Achieving Viral Response at 12 Weeks After EOT by Chronic HCV Genotype (Stage 1)</outcome_measure>
      <outcome_measure>The Number of Participants Achieving Viral Response at 12 Weeks After EOT by Liver Fibrosis Stage (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Liver Fibrosis Stage (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Chronic HCV Genotype (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Viral Load (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Weight (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Chronic HCV Genotype + Liver Fibrosis Stage (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Chronic HCV Genotype + Viral Load (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Weight + Chronic HCV Genotype (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving EVR (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by EVR Type (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Gender (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Race (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Human Immunodeficiency Virus (HIV) Status (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants With End of Treatment (EOT) Response (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants With EOT Response by Chronic HCV Genotype (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants With EVR by Selected Chronic HCV Genotypes (Stage 1)</outcome_measure>
      <outcome_measure>Relapse Rate by HCV Genotype (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Discontinued From Study Drug Due to Adverse Events by Chronic HCV Genotype (Stage 1)</outcome_measure>
      <outcome_measure>Number of Participants Achieving Rapid Virologic Response (RVR) (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving EVR (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving RVR by Race (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving EVR by Race (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Race (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving RVR Who Achieved SVR (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving EVR Who Achieved SVR (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving RVR by Liver Fibrosis Stage (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving EVR by Liver Fibrosis Stage (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Liver Fibrosis Score (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving RVR by Weight (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving EVR by Weight (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Weight (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving RVR by Chronic HCV Genotype 1 Subtype (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving EVR by Chronic HCV Genotype 1 Subtype (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Chronic HCV Genotype 1 Subtype (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving RVR by Gender (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving EVR by Gender (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by Gender (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving RVR by HIV Status (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving EVR by HIV Status (Stage 2)</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR by HIV Status (Stage 2)</outcome_measure>
      <outcome_measure>Percentage of Compliance for Participants Achieving SVR Based on Medication Adherence Questionnaire (MAQ) (Stage 2)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00724893</url>
  </study>
  <study rank="631">
    <nct_id>NCT01567540</nct_id>
    <title>A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sitagliptin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institut National de la Santé Et de la Recherche Médicale, France</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>3</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>C10-54</other_id>
      <other_id>2011-000823-34</other_id>
    </other_ids>
    <first_received>March 2, 2012</first_received>
    <start_date>March 2013</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>January 17, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety (Number of adverse events, Toxicity grade &gt; 3)</outcome_measure>
      <outcome_measure>Change in Viral Load as compared to baseline</outcome_measure>
      <outcome_measure>Metabolic studies: Oral glucose tolerance will be assessed</outcome_measure>
      <outcome_measure>Immunologic study</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01567540</url>
  </study>
  <study rank="632">
    <nct_id>NCT00055341</nct_id>
    <title>Treatment of Hepatitis C in Hemophilic Patients With HIV</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C</condition>
      <condition>Hemophilia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>22</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1R01AI049508-01</other_id>
      <other_id>5R01AI049508-02</other_id>
    </other_ids>
    <first_received>February 25, 2003</first_received>
    <start_date>March 2002</start_date>
    <completion_date>June 2005</completion_date>
    <last_updated>July 29, 2008</last_updated>
    <last_verified>December 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Ohio</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00055341</url>
  </study>
  <study rank="633">
    <nct_id>NCT01276756</nct_id>
    <title>Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis c</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa-2a</intervention>
      <intervention type="Drug">Nitazoxanide</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Cairo University</lead_sponsor>
      <collaborator>Egyptian Railway Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>RAIL001</other_id>
    </other_ids>
    <first_received>January 12, 2011</first_received>
    <start_date>December 2010</start_date>
    <completion_date>November 2012</completion_date>
    <last_updated>March 19, 2013</last_updated>
    <last_verified>March 2013</last_verified>
    <firstreceived_results_date>January 30, 2013</firstreceived_results_date>
    <primary_completion_date>November 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response</outcome_measure>
      <outcome_measure>Rapid Virological Response</outcome_measure>
      <outcome_measure>Early Virological Response</outcome_measure>
      <outcome_measure>End-of-treatment Response</outcome_measure>
      <outcome_measure>Safety of Nitazoxanide (Number of Participants Experiencing Adverse Events)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01276756</url>
  </study>
  <study rank="634">
    <nct_id>NCT00136318</nct_id>
    <title>Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Depression</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Escitalopram</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Charite University, Berlin, Germany</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>208</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
      <study_design>Masking: Double Blind (Subject, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML18075</other_id>
    </other_ids>
    <first_received>August 26, 2005</first_received>
    <start_date>January 2004</start_date>
    <completion_date>September 2008</completion_date>
    <last_updated>March 20, 2013</last_updated>
    <last_verified>March 2013</last_verified>
    <firstreceived_results_date>October 25, 2012</firstreceived_results_date>
    <acronym>CIPPAD</acronym>
    <primary_completion_date>September 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Montgomery Asberg Depression Scale (MADRS) With a Score of 13 or Higher</outcome_measure>
      <outcome_measure>Proportion of Patients Without Depression (Defined as a MADRS Score of 13 or Higher)</outcome_measure>
      <outcome_measure>Incidence of Major Depression Defined by Diagnostic and Statistical Manual IV (DSM-IV) Criteria</outcome_measure>
      <outcome_measure>Severe Depression Defined as a MADRS Score of 25 or Higher</outcome_measure>
      <outcome_measure>Health Related Quality of Life (HRQOL) Measured by the Short Form 36 (SF-36)</outcome_measure>
      <outcome_measure>Sustained Virologic Response</outcome_measure>
      <outcome_measure>Tolerability</outcome_measure>
      <outcome_measure>Safety</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00136318</url>
  </study>
  <study rank="635">
    <nct_id>NCT01178749</nct_id>
    <title>Exploration of Chronic Hepatitis C Infection Receiving 24-week Interferon-α With Ribavirin Treatments</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>National Science Council, Taiwan</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>390</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>200708003R</other_id>
    </other_ids>
    <first_received>April 11, 2010</first_received>
    <start_date>September 2007</start_date>
    <completion_date>July 2011</completion_date>
    <last_updated>August 9, 2010</last_updated>
    <last_verified>August 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>symptom distress Scale</outcome_measure>
      <outcome_measure>Fatigue symptom inventory</outcome_measure>
      <outcome_measure>The SF-12 health survey</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01178749</url>
  </study>
  <study rank="636">
    <nct_id>NCT01443923</nct_id>
    <title>Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis</condition>
      <condition>HIV/AIDS</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Peg-Interferon-alfa 2B</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>4</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>110253</other_id>
      <other_id>11-I-0253</other_id>
    </other_ids>
    <first_received>September 29, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>July 9, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>February 25, 2015</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy, Defined as Sustained Viral Response (SVR) Six Months After the End of Specified Treatment.</outcome_measure>
      <outcome_measure>Change in Early HCV Viral Load Kinetics Between Mono and Co-infected Subjects</outcome_measure>
      <outcome_measure>Safety and Treatment Outcome Measures Stratified by ESA Use</outcome_measure>
      <outcome_measure>Proportion of Subjects Who Are Receiving HAART Who Remain With an HIV RNA &amp; lt; 400 Copies/mL and Those With HIV RNA &amp; gt; 400 Copies/mL at End of Treatment</outcome_measure>
      <outcome_measure>Efficacy (SVR) Rates as Predicted by Viral Response at the End of the 4-week lead-in Therapy With PEG/RBV and Comparison Between HCV Monoinfected and HIV/HCV Coinfected Subjects</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>District of Columbia</state>
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01443923</url>
  </study>
  <study rank="637">
    <nct_id>NCT00377182</nct_id>
    <title>A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">PEGASYS</intervention>
      <intervention type="Drug">RO5024048</intervention>
      <intervention type="Drug">RO5024048</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>107</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>PV18369</other_id>
    </other_ids>
    <first_received>September 15, 2006</first_received>
    <start_date>September 2006</start_date>
    <completion_date>August 2008</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>AEs and laboratory parameters.</outcome_measure>
      <outcome_measure>Plasma concentration of HCV polymerase inhibitor</outcome_measure>
      <outcome_measure>Antiviral activity</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00377182</url>
  </study>
  <study rank="638">
    <nct_id>NCT00689390</nct_id>
    <title>Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepacivirus</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Boceprevir</intervention>
      <intervention type="Biological">Narlaprevir</intervention>
      <intervention type="Biological">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Other">Blood/Plasma Collection</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1954</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05063</other_id>
      <other_id>2006-006529-25</other_id>
    </other_ids>
    <first_received>May 27, 2008</first_received>
    <start_date>February 2007</start_date>
    <completion_date>October 2014</completion_date>
    <last_updated>September 1, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>September 1, 2015</firstreceived_results_date>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Relapse During the LTFU Among Sustained Responders From Previous Treatment Studies With Boceprevir or Narlaprevir (Durability of Virologic Response)</outcome_measure>
      <outcome_measure>Kaplan-Meier Exposure-adjusted Relapse Rate</outcome_measure>
      <outcome_measure>Number of Participants With HCV Treatment-Emergent Resistance Associated Variants (TE-RAVs) of NS3/4A Protease Loci</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs) Reported During the LTFU</outcome_measure>
      <outcome_measure>Number of Participants That Discontinued the LTFU Due to SAEs</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00689390</url>
  </study>
  <study rank="639">
    <nct_id>NCT02613403</nct_id>
    <title>Efficacy and Safety of MK-3682B (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis</condition>
      <condition>Hepatitis C</condition>
      <condition>Digestive System Diseases</condition>
      <condition>Flaviviridae Infections</condition>
      <condition>Hepatitis, Viral, Human</condition>
      <condition>Liver Diseases</condition>
      <condition>RNA Virus Infections</condition>
      <condition>Virus Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MK- 3682B</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>3682-021</other_id>
      <other_id>2015-001483-19</other_id>
    </other_ids>
    <first_received>November 20, 2015</first_received>
    <start_date>December 2015</start_date>
    <completion_date>January 2017</completion_date>
    <last_updated>November 20, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After The End of Study Therapy (SVR12)</outcome_measure>
      <outcome_measure>Number of participants who experienced at least one adverse event</outcome_measure>
      <outcome_measure>Number of participants who discontinued study drug due to an adverse event</outcome_measure>
      <outcome_measure>Number of participants who experienced at least one serious adverse event</outcome_measure>
      <outcome_measure>Number of participants who experienced at least one drug-related adverse event</outcome_measure>
      <outcome_measure>Number of participants who experienced at least one serious and drug-related adverse event</outcome_measure>
      <outcome_measure>Number of participants who experienced at least one laboratory adverse event of interest</outcome_measure>
      <outcome_measure>Number of participants who experienced AST/ALT &gt;5 x upper limit normal at Week 4 or later</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02613403</url>
  </study>
  <study rank="640">
    <nct_id>NCT02469012</nct_id>
    <title>Neurocognitive Performance and Emotional State in HCV Patients With IFN-free Antiviral Therapy</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Combination #1</intervention>
      <intervention type="Drug">Combination #2</intervention>
      <intervention type="Drug">Combination #3</intervention>
      <intervention type="Drug">Combination #4</intervention>
      <intervention type="Drug">Combination #5</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Wuerzburg</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Screening</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>228/14</other_id>
    </other_ids>
    <first_received>May 5, 2015</first_received>
    <start_date>October 2014</start_date>
    <completion_date>April 2017</completion_date>
    <last_updated>June 8, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>IFNfreeCOG</acronym>
    <primary_completion_date>October 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Neurocognitive Performance (computerized TAP - Test Battery for Attentional Performance)</outcome_measure>
      <outcome_measure>Change in Fatigue (Fatigue Impact Scale - FIS-D, questionnaire)</outcome_measure>
      <outcome_measure>Change in Health-Related Quality of Life (SF-36, questionnaire)</outcome_measure>
      <outcome_measure>Change in Emotional State (Hospital Anxiety and Depression Scale HADS, questionnaire)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02469012</url>
  </study>
  <study rank="641">
    <nct_id>NCT00088504</nct_id>
    <title>Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Hepatitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Merimepodib</intervention>
      <intervention type="Drug">PEG-Interferon-alpha 2a (Pegasys®)</intervention>
      <intervention type="Drug">Ribavirin (Copegus®)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>315</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX03-497-205</other_id>
    </other_ids>
    <first_received>July 27, 2004</first_received>
    <start_date>July 2004</start_date>
    <completion_date>October 2006</completion_date>
    <last_updated>December 17, 2007</last_updated>
    <last_verified>December 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Idaho</state>
      <state>Illinois</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00088504</url>
  </study>
  <study rank="642">
    <nct_id>NCT02605304</nct_id>
    <title>12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV-1 Infection</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ledipasvir/sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AIDS Clinical Trials Group</lead_sponsor>
      <collaborator>National Institute of Allergy and Infectious Diseases (NIAID)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ACTG A5348</other_id>
      <other_id>UM1AI068636</other_id>
    </other_ids>
    <first_received>November 12, 2015</first_received>
    <start_date>November 2015</start_date>
    <completion_date>May 2017</completion_date>
    <last_updated>November 12, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response 12 weeks after HCV antiviral therapy (SVR12)</outcome_measure>
      <outcome_measure>Occurrence of Grade 3 or higher AE, serious AE (SAE), or AE reported as the reason for permanent discontinuation of study treatment</outcome_measure>
      <outcome_measure>Renal toxicity</outcome_measure>
      <outcome_measure>Sustained Virologic Response at 4 weeks after treatment discontinuation (SVR4)</outcome_measure>
      <outcome_measure>Sustained Virologic Response at 24 weeks after treatment discontinuation (SVR24)</outcome_measure>
      <outcome_measure>HCV RNA &lt;LLOQ (lower limit of quantification)</outcome_measure>
      <outcome_measure>HIV-1 RNA &gt; 50 copies/mL</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02605304</url>
  </study>
  <study rank="643">
    <nct_id>NCT01970904</nct_id>
    <title>Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Liver Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DEB025 200mg</intervention>
      <intervention type="Drug">DEB025 300mg</intervention>
      <intervention type="Drug">DEB025 400mg</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>146</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CDEB025A2222</other_id>
      <other_id>2012-004185-17</other_id>
    </other_ids>
    <first_received>September 30, 2013</first_received>
    <start_date>October 2013</start_date>
    <completion_date>March 2015</completion_date>
    <last_updated>March 19, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Pharmacodynamics (PD)</outcome_measure>
      <outcome_measure>Safety</outcome_measure>
      <outcome_measure>SVR12</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
      <country>Poland</country>
      <country>Sweden</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01970904</url>
  </study>
  <study rank="644">
    <nct_id>NCT01716403</nct_id>
    <title>Telaprevir Exposure and Severe Anemia in HCV Infected Patients Treated by Tri-therapy</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>C Hepatitis, Tri Therapy</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Diagnostic: protocol designed to evaluate one or more interventions aimed at identifying a disease or health condition</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Grenoble</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>1211</other_id>
    </other_ids>
    <first_received>October 25, 2012</first_received>
    <start_date>October 2012</start_date>
    <last_updated>January 25, 2013</last_updated>
    <last_verified>January 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>Ribatela</acronym>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>telaprevir concentration and area under the curve</outcome_measure>
      <outcome_measure>ribavirin concentration and area under the curve</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01716403</url>
  </study>
  <study rank="645">
    <nct_id>NCT00475176</nct_id>
    <title>S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">S-adenosyl methionine for Chronic Liver Disease</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Pharmacodynamics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>070143</other_id>
      <other_id>07-DK-0143</other_id>
    </other_ids>
    <first_received>May 17, 2007</first_received>
    <start_date>May 2007</start_date>
    <completion_date>May 2011</completion_date>
    <last_updated>May 31, 2013</last_updated>
    <last_verified>May 2013</last_verified>
    <firstreceived_results_date>May 1, 2012</firstreceived_results_date>
    <primary_completion_date>May 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Improvement in Viral Kinetics During the First 2 Weeks of Therapy</outcome_measure>
      <outcome_measure>2-log Decline in HCV RNA by Week 12 (Early Virological Response) and Sustained Eradication of HCV RNA (Sustained Virological Response).</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00475176</url>
  </study>
  <study rank="646">
    <nct_id>NCT01074008</nct_id>
    <title>A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HCV</condition>
      <condition>Chronic Hepatitis C Infection</condition>
      <condition>Hepatitis C Genotype 1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450</intervention>
      <intervention type="Drug">ABT-072</intervention>
      <intervention type="Drug">ABT-333</intervention>
      <intervention type="Drug">Ritonavir</intervention>
      <intervention type="Drug">Peginterferon alpha-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie (prior sponsor, Abbott)</lead_sponsor>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>74</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>M11-602</other_id>
    </other_ids>
    <first_received>February 22, 2010</first_received>
    <start_date>March 2010</start_date>
    <completion_date>January 2012</completion_date>
    <last_updated>December 29, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>December 29, 2014</firstreceived_results_date>
    <acronym>Champion2</acronym>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Maximal Change From Baseline in Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels During ABT-450/r, ABT-333, or ABT-072 Monotherapy Treatment</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of ABT-450</outcome_measure>
      <outcome_measure>Time to Maximum Plasma Concentration (Tmax) of ABT-450</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of ABT-450</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of Ritonavir</outcome_measure>
      <outcome_measure>Time to Maximum Plasma Concentration (Tmax) of Ritonavir</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of Ritonavir</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of ABT-072</outcome_measure>
      <outcome_measure>Time to Maximum Plasma Concentration (Tmax) of ABT-072</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of ABT-072</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of ABT-333</outcome_measure>
      <outcome_measure>Time to Maximum Plasma Concentration (Tmax) of ABT-333</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From 0 to 12 Hours (AUC12) Post-dose of ABT-333</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Virologic Response (RVR) at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Partial Early Virologic Response (EVR) at Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With Complete Early Virologic Response (cEVR) at Week 12</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Washington</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01074008</url>
  </study>
  <study rank="647">
    <nct_id>NCT01405027</nct_id>
    <title>Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Genotype 1</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Educational Intervention</intervention>
      <intervention type="Other">Patient education and management skills training</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Chronic Liver Disease Foundation</lead_sponsor>
      <collaborator>SCRI Development Innovations, LLC</collaborator>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>197</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CLDF-MER-001-00</other_id>
      <other_id>20111013</other_id>
    </other_ids>
    <first_received>July 25, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>December 22, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>November 17, 2014</firstreceived_results_date>
    <acronym>OPTIMAL</acronym>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Treatment Duration Compliance Rate</outcome_measure>
      <outcome_measure>Drug Exposure</outcome_measure>
      <outcome_measure>Determination of the Rate of Sustained Viral Response (SVR) for HCV Patients Treated With Boceprevir, Peginterferon and Ribavirin at Community Sites and at HCEEs.</outcome_measure>
      <outcome_measure>Short Form Health Survey Measuring Quality of Life Reported at Baseline, End of Treatment, and Follow-up Week 24 (36 Multiple Choice Questions)</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Iowa</state>
      <state>Louisiana</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01405027</url>
  </study>
  <study rank="648">
    <nct_id>NCT00963885</nct_id>
    <title>A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">danoprevir</intervention>
      <intervention type="Drug">danoprevir</intervention>
      <intervention type="Drug">danoprevir</intervention>
      <intervention type="Drug">danoprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>229</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV21075</other_id>
      <other_id>2009-009608-38</other_id>
    </other_ids>
    <first_received>August 18, 2009</first_received>
    <start_date>August 2009</start_date>
    <completion_date>January 2012</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response</outcome_measure>
      <outcome_measure>Virological response over time</outcome_measure>
      <outcome_measure>Adverse events; laboratory parameters</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Louisiana</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Washington</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00963885</url>
  </study>
  <study rank="649">
    <nct_id>NCT00911963</nct_id>
    <title>Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">VCH-222 or matching placebo</intervention>
      <intervention type="Drug">VCH-222 or matching placebo</intervention>
      <intervention type="Biological">peginterferon alfa-2a</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
      <collaborator>ViroChem Pharma</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>49</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>VCH-222-102</other_id>
    </other_ids>
    <first_received>May 29, 2009</first_received>
    <start_date>April 2009</start_date>
    <completion_date>September 2012</completion_date>
    <last_updated>February 6, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To assess the antiviral activity of VCH-222, in subjects with genotype 1 hepatitis C virus (HCV) infection after once (QD) or twice (b.i.d.) daily dosing for 3 days (Part A)</outcome_measure>
      <outcome_measure>To assess the antiviral activity of VCH-222, in subjects with genotype 1 HCV infection after b.i.d. daily dosing for 12 weeks in combination with Peg-interferon-alfa-2a and ribavirin (Part B)</outcome_measure>
      <outcome_measure>Assess the safety and tolerability of VCH-222 when administered in combination with Peg-IFN-alfa-2a/RBV for 12 weeks (Part B)</outcome_measure>
      <outcome_measure>To assess the safety and tolerability of VCH-222 when administered for 3 days in monotherapy (Part A)</outcome_measure>
      <outcome_measure>To evaluate the pharmacokinetic (PK) profile of VCH-222 in HCV infected subjects (Part B)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Argentina</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Georgia</state>
      <state>Michigan</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00911963</url>
  </study>
  <study rank="650">
    <nct_id>NCT00216775</nct_id>
    <title>Comparative Trial of Standard Versus Low-dose Peg-Interferon Plus Ribavirin in the Treatment of Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">interferon-alfa-2b and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kyoto University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>H16-697</other_id>
    </other_ids>
    <first_received>September 10, 2005</first_received>
    <start_date>December 2004</start_date>
    <completion_date>May 2008</completion_date>
    <last_updated>September 1, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>rate of sustained viral response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00216775</url>
  </study>
  <study rank="651">
    <nct_id>NCT00122616</nct_id>
    <title>Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alpha-2a (Pegasys®)</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">HIV antiretroviral therapy</intervention>
      <intervention type="Drug">HIV antiretroviral therapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Agency for Research on AIDS and Viral Hepatitis</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>52</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRSHC12 FIBROSTOP</other_id>
    </other_ids>
    <first_received>July 19, 2005</first_received>
    <start_date>November 2003</start_date>
    <completion_date>March 2009</completion_date>
    <last_updated>February 21, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of patients who experienced one point decreases of their fibrosis histological score (Metavir).</outcome_measure>
      <outcome_measure>Distribution of the change of fibrosis Metavir score in each group</outcome_measure>
      <outcome_measure>Distribution of fibrosis score from Chevallier classification</outcome_measure>
      <outcome_measure>Plasmatic fibrosis markers dosages</outcome_measure>
      <outcome_measure>Viral load quantification for HIV and HCV</outcome_measure>
      <outcome_measure>Number and percentage of CD4/CD8 cell count throughout the study</outcome_measure>
      <outcome_measure>Number and percentage of patient had more thand 200 copies/ml throughout the study</outcome_measure>
      <outcome_measure>Occurrence of hepatic complication related to HCV</outcome_measure>
      <outcome_measure>Survival throughout the study</outcome_measure>
      <outcome_measure>Quality of life questionnaire</outcome_measure>
      <outcome_measure>Fibrotest (plasmatic fibrosis marker)</outcome_measure>
      <outcome_measure>Histological improvement according to the total interferon dose received</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00122616</url>
  </study>
  <study rank="652">
    <nct_id>NCT00517439</nct_id>
    <title>A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">RO4588161</intervention>
      <intervention type="Drug">RO4588161</intervention>
      <intervention type="Drug">RO4588161</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>516</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV19865</other_id>
    </other_ids>
    <first_received>August 16, 2007</first_received>
    <start_date>December 2007</start_date>
    <completion_date>January 2010</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (SVR)</outcome_measure>
      <outcome_measure>Virological response over time</outcome_measure>
      <outcome_measure>SVR</outcome_measure>
      <outcome_measure>Relapse rate</outcome_measure>
      <outcome_measure>AEs, laboratory parameters.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Minnesota</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00517439</url>
  </study>
  <study rank="653">
    <nct_id>NCT00496912</nct_id>
    <title>Management of Hepatitis C in HIV-Infected and Uninfected IDUs</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon/Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>410</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>RO1 DA016065-01</other_id>
    </other_ids>
    <first_received>July 5, 2007</first_received>
    <start_date>January 2004</start_date>
    <completion_date>June 2008</completion_date>
    <last_updated>April 17, 2009</last_updated>
    <last_verified>April 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>1. The proportion of IDUs who have clear medical contraindications to HCV treatment. 2. The prevalence of significant hepatic fibrosis among treatment eligible IDUs. 3. The proportion of treatment-eligible IDUs who initiate PEG/RBV therapy.</outcome_measure>
      <outcome_measure>The proportion of IDUs without clear contraindications who might be excluded by each of the 7 controversial contraindications.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00496912</url>
  </study>
  <study rank="654">
    <nct_id>NCT02160080</nct_id>
    <title>Boceprevir Treatment in Liver Pre-transplant HCV Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Late Complication From Liver Transplant</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hu Tsung-Hui</lead_sponsor>
      <collaborator>Chang Gung Memorial Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB:102-4331A</other_id>
    </other_ids>
    <first_received>April 11, 2014</first_received>
    <start_date>January 2014</start_date>
    <completion_date>February 2017</completion_date>
    <last_updated>June 10, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants with Adverse Events</outcome_measure>
      <outcome_measure>HCV-RNA (Hepatitis C virus RNA) level</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02160080</url>
  </study>
  <study rank="655">
    <nct_id>NCT00100581</nct_id>
    <title>Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Efavirenz</intervention>
      <intervention type="Drug">Lamivudine</intervention>
      <intervention type="Drug">Lopinavir/ritonavir</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Tenofovir disoproxil fumarate</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>2</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>A5184</other_id>
      <other_id>10133</other_id>
      <other_id>ACTG A5184</other_id>
    </other_ids>
    <first_received>January 3, 2005</first_received>
    <completion_date>January 2007</completion_date>
    <last_updated>May 17, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>HCV viral load at least 2 log10 less than baseline or below the limit of detection by quantitative assay at 12 weeks after the start of HCV treatment (early virologic response)</outcome_measure>
      <outcome_measure>HIV and/or HCV treatment-limiting or Grade 4 or higher signs and symptoms and laboratory values</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New York</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00100581</url>
  </study>
  <study rank="656">
    <nct_id>NCT00612755</nct_id>
    <title>Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a + ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hospital Clinico Universitario San Cecilio</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>43</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Extrados</other_id>
      <other_id>2004-004948-45</other_id>
    </other_ids>
    <first_received>January 29, 2008</first_received>
    <start_date>October 2005</start_date>
    <completion_date>January 2008</completion_date>
    <last_updated>January 29, 2008</last_updated>
    <last_verified>January 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>% of patients with RNA-HCV undetectable</outcome_measure>
      <outcome_measure>% of percentage of patients with RNA-HCV undetectable</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00612755</url>
  </study>
  <study rank="657">
    <nct_id>NCT02103439</nct_id>
    <title>An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis</condition>
      <condition>Hepatitis C</condition>
      <condition>Hepatitis C/ Human Immunodeficiency Virus Coinfection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Algeron</intervention>
      <intervention type="Drug">PegIntron</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Biocad</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>140</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>BCD-016-4</other_id>
    </other_ids>
    <first_received>April 1, 2014</first_received>
    <start_date>September 2013</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>July 22, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>May 21, 2015</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Early Virological Response</outcome_measure>
      <outcome_measure>Early Virological Response in Patients With Different Hepatitis C Virus Genotypes</outcome_measure>
      <outcome_measure>Rapid Virological Response</outcome_measure>
      <outcome_measure>Rapid Virological Response in Patients With Different Hepatitis C Virus Genotypes</outcome_measure>
      <outcome_measure>Viral Breakthrough</outcome_measure>
      <outcome_measure>Biochemical Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Russian Federation</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02103439</url>
  </study>
  <study rank="658">
    <nct_id>NCT01525628</nct_id>
    <title>Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">midazolam</intervention>
      <intervention type="Drug">BI 201335</intervention>
      <intervention type="Drug">tenofovir</intervention>
      <intervention type="Drug">caffeine</intervention>
      <intervention type="Drug">tolbutamide</intervention>
      <intervention type="Drug">tolbutamide</intervention>
      <intervention type="Drug">midazolam</intervention>
      <intervention type="Drug">caffeine</intervention>
      <intervention type="Drug">pegylated interferon</intervention>
      <intervention type="Drug">BI 201335</intervention>
      <intervention type="Drug">BI 201335</intervention>
      <intervention type="Drug">BI 207127</intervention>
      <intervention type="Drug">BI 207127</intervention>
      <intervention type="Drug">BI 201335</intervention>
      <intervention type="Drug">BI 207127</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">pegylated interferon</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">caffeine</intervention>
      <intervention type="Drug">tolbutamide</intervention>
      <intervention type="Drug">BI 207127</intervention>
      <intervention type="Drug">midazolam</intervention>
      <intervention type="Drug">BI 201335</intervention>
      <intervention type="Drug">BI 207127</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>72</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1241.27</other_id>
      <other_id>2012-004102-10</other_id>
    </other_ids>
    <first_received>February 1, 2012</first_received>
    <start_date>April 2012</start_date>
    <completion_date>October 2014</completion_date>
    <last_updated>February 4, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Cmax BI 201335</outcome_measure>
      <outcome_measure>C24hr BI 201335</outcome_measure>
      <outcome_measure>AUC 0-24hr BI 201335</outcome_measure>
      <outcome_measure>AUC 0-24h BI 201335</outcome_measure>
      <outcome_measure>Cmax BI 207127</outcome_measure>
      <outcome_measure>C6h BI 207127</outcome_measure>
      <outcome_measure>AUC0-6h BI 207127</outcome_measure>
      <outcome_measure>Cmax Midazolam</outcome_measure>
      <outcome_measure>AUC 0-24h Midazolam</outcome_measure>
      <outcome_measure>Cmax Caffeine</outcome_measure>
      <outcome_measure>AUC 0-24h Caffeine</outcome_measure>
      <outcome_measure>Cmax Tenofovir</outcome_measure>
      <outcome_measure>C24h Tenofovir</outcome_measure>
      <outcome_measure>AUC 0-24hr Tenofovir</outcome_measure>
      <outcome_measure>Cmax Raltegravir</outcome_measure>
      <outcome_measure>C12h Raltegravir</outcome_measure>
      <outcome_measure>AUC 0-12h Raltegravir</outcome_measure>
      <outcome_measure>C12 hr BI 207127</outcome_measure>
      <outcome_measure>AUC 0-12 hr BI 207127</outcome_measure>
      <outcome_measure>Cmax Tolbutamide</outcome_measure>
      <outcome_measure>AUC 0-24 hr Tolbutamide</outcome_measure>
      <outcome_measure>Sustained Virological Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Maryland</state>
      <state>New Jersey</state>
      <state>Pennsylvania</state>
      <state>Utah</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01525628</url>
  </study>
  <study rank="659">
    <nct_id>NCT02486406</nct_id>
    <title>A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ombitasvir</intervention>
      <intervention type="Drug">paritaprevir</intervention>
      <intervention type="Drug">ritonavir</intervention>
      <intervention type="Drug">dasabuvir</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>186</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M14-748</other_id>
      <other_id>2015-000111-41</other_id>
    </other_ids>
    <first_received>June 17, 2015</first_received>
    <start_date>October 2015</start_date>
    <completion_date>January 2023</completion_date>
    <last_updated>October 16, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ZIRCON</acronym>
    <primary_completion_date>September 2019</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Part1: Maximum plasma concentration (Cmax) of OBV</outcome_measure>
      <outcome_measure>Part 1: Maximum plasma concentration (Cmax) of PTV</outcome_measure>
      <outcome_measure>Part 1: Maximum plasma concentration (Cmax) of DSV</outcome_measure>
      <outcome_measure>Part 1: Maximum plasma concentration (Cmax) of RTV</outcome_measure>
      <outcome_measure>Part 1: concentration of drug in blood plasma against time [Area under the curve (AUC)] of OBV</outcome_measure>
      <outcome_measure>Part 1: concentration of drug in blood plasma against time [Area under the curve (AUC)] of PTV</outcome_measure>
      <outcome_measure>Part 1: concentration of drug in blood plasma against time [Area under the curve (AUC)] of DSV</outcome_measure>
      <outcome_measure>Part 1: concentration of drug in blood plasma against time [Area under the curve (AUC)] of RTV</outcome_measure>
      <outcome_measure>Part 1: Lowest plasma concentration (Ctrough) of OBV</outcome_measure>
      <outcome_measure>Part 1: Lowest plasma concentration (Ctrough) of PTV</outcome_measure>
      <outcome_measure>Part 1: Lowest plasma concentration (Ctrough) of DSV</outcome_measure>
      <outcome_measure>Part 1: Lowest plasma concentration (Ctrough) of RTV</outcome_measure>
      <outcome_measure>Part 2: Percentage of treatment-naïve participants with sustained virologic response 24 weeks after the last actual dose of study drug (SVR24)</outcome_measure>
      <outcome_measure>Part 3: Percentage of participants who relapse out of participants who achieved sustained virologic response (SVR) in Part 1 or Part 2 of the study.</outcome_measure>
      <outcome_measure>Part 3: Percentage of participants who have new HCV infection</outcome_measure>
      <outcome_measure>Part 1: Percentage of participants achieving sustained virologic response 12 weeks after the last actual dose of study drug (SVR12)</outcome_measure>
      <outcome_measure>Part 1: Percentage of participants achieving SVR24</outcome_measure>
      <outcome_measure>Part 2: Percentage of treatment-naive participants achieving SVR12</outcome_measure>
      <outcome_measure>Part 2: Percentage of participants with Alanine aminotransferase (ALT) normalization during treatment</outcome_measure>
      <outcome_measure>Part 3: Assess the impact of OBV, PTV, RTV with or without DSV and with or without RBV on height</outcome_measure>
      <outcome_measure>Part 3: Assess the impact of OBV, PTV, RTV with or without DSV and with or without RBV on waist circumference</outcome_measure>
      <outcome_measure>Part 3: Assess the impact of OBV, PTV, RTV with or without DSV and with or without RBV on tanner staging</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Massachusetts</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02486406</url>
  </study>
  <study rank="660">
    <nct_id>NCT00062816</nct_id>
    <title>Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ISIS 14803, peginterferon alfa, ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Isis Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>22</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>ISIS 14803-CS3</other_id>
    </other_ids>
    <first_received>June 16, 2003</first_received>
    <start_date>May 2004</start_date>
    <last_updated>October 15, 2007</last_updated>
    <last_verified>October 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Idaho</state>
      <state>Louisiana</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00062816</url>
  </study>
  <study rank="661">
    <nct_id>NCT01741545</nct_id>
    <title>Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated-Interferon-lambda</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>51</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI452-030</other_id>
      <other_id>2012-003463-22</other_id>
    </other_ids>
    <first_received>December 3, 2012</first_received>
    <start_date>March 2013</start_date>
    <completion_date>January 2015</completion_date>
    <last_updated>March 16, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>MAGNITUDE</acronym>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects who achieve SVR12 (HCV RNA &lt; LLOQ target not detected)</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve Rapid virologic response (RVR) [HCV RNA &lt; LLOQ target not detected at Week 4]</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve Complete early virologic response (cEVR) [HCV RNA &lt; LLOQ target not detected at Week 12]</outcome_measure>
      <outcome_measure>Proportion of subjects who have HCV RNA &lt; LLOQ target not detected at Week 24</outcome_measure>
      <outcome_measure>Proportion of subjects with treatment emergent cytopenic abnormalities through end of treatment (Week 12 for Genotype-2, -3 and Week 24 for Genotype-1b, -4)</outcome_measure>
      <outcome_measure>Proportion of subjects who experience on-treatment Interferon (IFN)-associated symptoms such as flu-like systems or musculoskeletal symptoms</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve SVR24 by treatment group</outcome_measure>
      <outcome_measure>Proportion of subjects with serious adverse events (SAEs), discontinuation due to adverse events (AEs) and dose reductions through end of follow-up (maximum of 60 weeks for Genotype-2, -3 and 72 weeks for Genotype-1b, -4)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>France</country>
      <country>Italy</country>
      <country>Netherlands</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Illinois</state>
      <state>Pennsylvania</state>
      <state>Utah</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01741545</url>
  </study>
  <study rank="662">
    <nct_id>NCT01463592</nct_id>
    <title>To Study the Efficacy and Safety of Renessans in Chronic HCV Patients</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">RENESSANS , INTERFERON ALPHA 2b, Ribavirin</intervention>
      <intervention type="Drug">Interferon Alfa-2b AND RIBAVIRIN</intervention>
      <intervention type="Biological">RENESSANS</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>MTI Medical Private Limited, Pakistan</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>REN1</other_id>
    </other_ids>
    <first_received>August 30, 2011</first_received>
    <start_date>June 2010</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>November 21, 2011</last_updated>
    <last_verified>October 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy of Renessans based triple therapy versus dual therapy</outcome_measure>
      <outcome_measure>Assess the safety and tolerability of Renessans in patients with chronic HCV patients</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Pakistan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01463592</url>
  </study>
  <study rank="663">
    <nct_id>NCT00167557</nct_id>
    <title>Orthotopic Liver Transplant (OLT) Recipients With Hepatitis C Virus (HCV) Under Preemptive Treatment</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Procedure">Liver Biopsy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>The University of Texas Health Science Center, Houston</lead_sponsor>
      <collaborator>Astellas Pharma US, Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HSC-MS-04-0346</other_id>
      <other_id>Astellas Pharma</other_id>
      <other_id>FHIprojectno.JK-04-002</other_id>
    </other_ids>
    <first_received>September 9, 2005</first_received>
    <start_date>January 2005</start_date>
    <completion_date>March 2008</completion_date>
    <last_updated>November 18, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Viral clearance after liver transplantation</outcome_measure>
      <outcome_measure>histological progression of fibrosis and inflammation</outcome_measure>
      <outcome_measure>rate of rejection on HCV treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00167557</url>
  </study>
  <study rank="664">
    <nct_id>NCT00919633</nct_id>
    <title>Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">interferon alfa-2b</intervention>
      <intervention type="Drug">peginterferon alfa-2b</intervention>
      <intervention type="Drug">ribavirin, USP</intervention>
      <intervention type="Device">external drug infusion pump</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Medtronic Corporate Technologies and New Ventures</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>116</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Single Blind (Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>4316001</other_id>
    </other_ids>
    <first_received>June 10, 2009</first_received>
    <start_date>June 2009</start_date>
    <completion_date>July 2012</completion_date>
    <last_updated>March 28, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>March 28, 2014</firstreceived_results_date>
    <acronym>COPE-HCV</acronym>
    <primary_completion_date>July 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Viral Load: Incidence of Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Safety/Tolerability</outcome_measure>
      <outcome_measure>Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Early Virologic Response (EVR)</outcome_measure>
      <outcome_measure>End-of-treatment Response (EOT)</outcome_measure>
      <outcome_measure>Pharmacokinetics</outcome_measure>
      <outcome_measure>Pharmacodynamics</outcome_measure>
      <outcome_measure>Functional Health, Depression Score, and Fatigue Level</outcome_measure>
      <outcome_measure>Viral Decay</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>North Carolina</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00919633</url>
  </study>
  <study rank="665">
    <nct_id>NCT01137383</nct_id>
    <title>Pegaferon and Ribavirin for Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegaferon (pegylated interferon alpha 2a) + ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tehran University of Medical Sciences</lead_sponsor>
      <collaborator>Pars No Tarkib Co</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>108</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>DDRC.86.90</other_id>
    </other_ids>
    <first_received>June 3, 2010</first_received>
    <start_date>December 2007</start_date>
    <completion_date>February 2010</completion_date>
    <last_updated>June 28, 2010</last_updated>
    <last_verified>June 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained viral response</outcome_measure>
      <outcome_measure>Adverse drug events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Iran, Islamic Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01137383</url>
  </study>
  <study rank="666">
    <nct_id>NCT01226446</nct_id>
    <title>Efficacy of Vitamin D on Top of Pegylated Interferon and Ribavirin in Patients With Chronic Viral Hepatitis C Null-Responders</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">vitamin D</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Agency for Research on AIDS and Viral Hepatitis</lead_sponsor>
      <collaborator>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2010-021967-34</other_id>
    </other_ids>
    <first_received>October 20, 2010</first_received>
    <start_date>November 2010</start_date>
    <completion_date>January 2013</completion_date>
    <last_updated>August 8, 2014</last_updated>
    <last_verified>June 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ANRS VITAVIC</acronym>
    <primary_completion_date>February 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Negativity of HCV RNA below 12UI/mL after 12 weeks of antiviral combination therapy</outcome_measure>
      <outcome_measure>Changes in HCV viral load after correction of vitamin D deficiency (delta log)</outcome_measure>
      <outcome_measure>Changes in HCV viral load (delta log)</outcome_measure>
      <outcome_measure>Negativity of HCV RNA below 12 UI/ml</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01226446</url>
  </study>
  <study rank="667">
    <nct_id>NCT02332707</nct_id>
    <title>Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Genotype (GT) 1 and GT2 Infection (MK-3682-011)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Grazoprevir</intervention>
      <intervention type="Drug">MK-3682</intervention>
      <intervention type="Drug">Elbasvir</intervention>
      <intervention type="Drug">MK-8408</intervention>
      <intervention type="Drug">MK-3682B</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>465</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>3682-011</other_id>
      <other_id>2014-003304-73</other_id>
    </other_ids>
    <first_received>January 6, 2015</first_received>
    <start_date>January 2015</start_date>
    <completion_date>November 2016</completion_date>
    <last_updated>November 11, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants achieving sustained virologic response 12 weeks after completing treatment (SVR12)</outcome_measure>
      <outcome_measure>Number of participants experiencing an adverse event (AE)</outcome_measure>
      <outcome_measure>Number of participants who had study drug discontinued due to an AE</outcome_measure>
      <outcome_measure>Percentage of participants achieving Sustained Virologic Response 24 weeks after ending study treatment (SVR24)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Poland</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>New Jersey</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02332707</url>
  </study>
  <study rank="668">
    <nct_id>NCT00351871</nct_id>
    <title>Influence of Marker of Insulin Resistance Upon Hepatitis C Virus (HCV) Treatment Responses to PEG Intron and Rebetol Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG-Intron Plus REBETOL</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Louisiana State University Health Sciences Center in New Orleans</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P03851</other_id>
    </other_ids>
    <first_received>July 12, 2006</first_received>
    <start_date>April 2002</start_date>
    <completion_date>November 2007</completion_date>
    <last_updated>February 3, 2009</last_updated>
    <last_verified>February 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Difference in treatment response rates between those with insulin resistance those without.</outcome_measure>
      <outcome_measure>Which marker of Insulin Resistance (i.e. the HOMA score, Waste Circumference or BMI) is the best measure for risk of hypo responsiveness.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00351871</url>
  </study>
  <study rank="669">
    <nct_id>NCT00823862</nct_id>
    <title>Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SD-101</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Dynavax Technologies Corporation</lead_sponsor>
      <collaborator>Synteract, Inc.</collaborator>
      <collaborator>PPD</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>34</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Single Blind (Subject)</study_design>
    </study_designs>
    <other_ids>
      <other_id>DV3-HCV-01</other_id>
      <other_id>2008-001708-22</other_id>
    </other_ids>
    <first_received>January 14, 2009</first_received>
    <start_date>October 2008</start_date>
    <completion_date>February 2010</completion_date>
    <last_updated>August 19, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Adverse event timing, duration, and severity.</outcome_measure>
      <outcome_measure>Biomarker analysis of blood sample</outcome_measure>
      <outcome_measure>Viral load in blood sample</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Poland</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00823862</url>
  </study>
  <study rank="670">
    <nct_id>NCT00301509</nct_id>
    <title>Antiviral Therapy in Decompensated Hepatitis C Virus (HCV) Cirrhosis</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Liver Cirrhosis, Experimental</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Casa Sollievo della Sofferenza IRCCS</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>630/DS</other_id>
    </other_ids>
    <first_received>March 10, 2006</first_received>
    <start_date>January 2002</start_date>
    <completion_date>December 2005</completion_date>
    <last_updated>March 10, 2006</last_updated>
    <last_verified>December 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00301509</url>
  </study>
  <study rank="671">
    <nct_id>NCT01858766</nct_id>
    <title>Safety and Efficacy of Sofosbuvir Plus GS-5816 With or Without Ribavirin in Treatment-naive Subjects With Chronic HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">GS-5816</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>378</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-342-0102</other_id>
    </other_ids>
    <first_received>May 10, 2013</first_received>
    <start_date>April 2013</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>February 25, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of adverse events leading to permanent discontinuation of study drug</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01858766</url>
  </study>
  <study rank="672">
    <nct_id>NCT00367887</nct_id>
    <title>A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-Intron</intervention>
      <intervention type="Drug">REBETOL</intervention>
      <intervention type="Drug">HCV 796</intervention>
      <intervention type="Drug">Peg-Intron</intervention>
      <intervention type="Drug">REBETOL</intervention>
      <intervention type="Drug">HCV 796</intervention>
      <intervention type="Drug">Peg-Intron</intervention>
      <intervention type="Drug">REBETOL</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Wyeth is now a wholly owned subsidiary of Pfizer</lead_sponsor>
      <collaborator>ViroPharma</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>246</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>3173A1-200</other_id>
      <other_id>B3381001</other_id>
    </other_ids>
    <first_received>August 21, 2006</first_received>
    <start_date>October 2006</start_date>
    <completion_date>July 2008</completion_date>
    <last_updated>February 7, 2013</last_updated>
    <last_verified>February 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Hepatitis C Virus (HCV) RNA concentrations in the blood.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Kentucky</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00367887</url>
  </study>
  <study rank="673">
    <nct_id>NCT01909804</nct_id>
    <title>Safety and Efficacy of Sofosbuvir Plus GS-5816 With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">GS-5816</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>323</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-342-0109</other_id>
    </other_ids>
    <first_received>July 17, 2013</first_received>
    <start_date>June 2013</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>February 25, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of adverse events leading to permanent discontinuation of study drug</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01909804</url>
  </study>
  <study rank="674">
    <nct_id>NCT00038974</nct_id>
    <title>Hepatitis C Antiviral Resistance in African-Americans</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Virahep-C (completed)</other_id>
      <other_id>U01DK060329</other_id>
    </other_ids>
    <first_received>June 5, 2002</first_received>
    <start_date>August 2002</start_date>
    <last_updated>March 15, 2011</last_updated>
    <last_verified>March 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>North Carolina</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00038974</url>
  </study>
  <study rank="675">
    <nct_id>NCT00006164</nct_id>
    <title>Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Cirrhosis, Liver</condition>
      <condition>Fibrosis, Liver</condition>
      <condition>Hepatic Cirrhosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a + Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>National Institute of Allergy and Infectious Diseases (NIAID)</collaborator>
      <collaborator>National Institute on Minority Health and Health Disparities (NIMHD)</collaborator>
      <collaborator>National Cancer Institute (NCI)</collaborator>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1050</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HALT C</other_id>
      <other_id>N01-DK-9-2328</other_id>
      <other_id>N01-DK-9-2323</other_id>
      <other_id>N01-DK-9-2324</other_id>
      <other_id>N01-DK-9-2325</other_id>
      <other_id>N01-DK-9-2326</other_id>
      <other_id>N01-DK-9-2321</other_id>
      <other_id>N01-DK-9-2327</other_id>
      <other_id>N01-DK-9-2319</other_id>
      <other_id>N01-DK-9-2318</other_id>
      <other_id>N01-DK-9-2320</other_id>
      <other_id>N01-DK-9-2322</other_id>
    </other_ids>
    <first_received>August 8, 2000</first_received>
    <start_date>June 2000</start_date>
    <completion_date>October 2009</completion_date>
    <last_updated>January 12, 2010</last_updated>
    <last_verified>January 2010</last_verified>
    <firstreceived_results_date>June 9, 2009</firstreceived_results_date>
    <acronym>HALT-C</acronym>
    <primary_completion_date>April 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Progression of Liver Disease as Indicated by Death, Hepatic Decompensation, Hepatocellular Carcinoma, or for Patients With Noncirrhotic Fibrosis at Baseline, an Increase in the Ishak Hepatic Fibrosis Score of 2 or More Points</outcome_measure>
      <outcome_measure>Increase in Ishak Fibrosis Score by 2 Points or More at 2 or 4 Year Biopsies</outcome_measure>
      <outcome_measure>Death From Any Cause</outcome_measure>
      <outcome_measure>Development of Hepatocellular Carcinoma (HCC)</outcome_measure>
      <outcome_measure>Child-Turcotte-Pugh (CTP) Score of 7 or Higher at Two Consecutive Study Visits</outcome_measure>
      <outcome_measure>Variceal Hemorrhage</outcome_measure>
      <outcome_measure>Ascites</outcome_measure>
      <outcome_measure>Spontaneous Bacterial Peritonitis</outcome_measure>
      <outcome_measure>Hepatic Encephalopathy</outcome_measure>
      <outcome_measure>Serious Adverse Events</outcome_measure>
      <outcome_measure>Events Requiring Dose Reductions (in Both Treatment Groups).</outcome_measure>
      <outcome_measure>Changes in Fibrosis From Baseline at Year 2 or Year 4 Biopsy.</outcome_measure>
      <outcome_measure>Presumed Hepatocellular Carcinoma (HCC)</outcome_measure>
      <outcome_measure>Quality of Life</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00006164</url>
  </study>
  <study rank="676">
    <nct_id>NCT01678131</nct_id>
    <title>Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Vaniprevir 600 mg</intervention>
      <intervention type="Biological">Peg-IFN alfa-2b</intervention>
      <intervention type="Biological">Ribavirin</intervention>
      <intervention type="Procedure">Liver samples from FNA</intervention>
      <intervention type="Drug">Vaniprevir 300 mg</intervention>
      <intervention type="Procedure">Liver samples from CNB</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>31</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>7009-048</other_id>
      <other_id>2012-003284-21</other_id>
    </other_ids>
    <first_received>August 30, 2012</first_received>
    <start_date>October 2012</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>September 1, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>September 26, 2014</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants From Whom Detectable Concentrations of Hepatic Vaniprevir Are Obtained by FNA</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01678131</url>
  </study>
  <study rank="677">
    <nct_id>NCT02214420</nct_id>
    <title>SMV + SOF With/Without RBV for IFN-II Patients With CHC</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>SC Liver Research Consortium, LLC</lead_sponsor>
      <collaborator>Janssen, LP</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>PJPIIS-01-14</other_id>
    </other_ids>
    <first_received>August 8, 2014</first_received>
    <start_date>October 2014</start_date>
    <completion_date>February 2017</completion_date>
    <last_updated>November 27, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Viral Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>New York</state>
      <state>Utah</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02214420</url>
  </study>
  <study rank="678">
    <nct_id>NCT00845676</nct_id>
    <title>Treatment of Acute Hepatitis C Virus in HIV Co-Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Human Immunodeficiency Virus</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa-2a + Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of California, San Francisco</lead_sponsor>
      <collaborator>California HIV/AIDS Research Program</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CHRP ID06-SF-218</other_id>
    </other_ids>
    <first_received>February 17, 2009</first_received>
    <start_date>March 2008</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>April 10, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>August 13, 2013</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Safety and Tolerability of Treatment</outcome_measure>
      <outcome_measure>Association of SVR With Entry HCV RNA, Entry ALT, Entry CD4, and IL28B Genotype</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00845676</url>
  </study>
  <study rank="679">
    <nct_id>NCT02461745</nct_id>
    <title>Real World Study: Genotype 1 Chronic HCV Treatment and Evaluation of Real World SVR and PROs</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ombitasvir, paritaprevir/r, dasabuvir + ribavirin</intervention>
      <intervention type="Drug">ombitasvir, paritaprevir/r, dasabuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kaiser Permanente</lead_sponsor>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KPSC IRB 10568</other_id>
    </other_ids>
    <first_received>May 31, 2015</first_received>
    <start_date>June 2015</start_date>
    <completion_date>June 2016</completion_date>
    <last_updated>May 31, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of subjects achieving sustained virological response (SVR) at Week 12</outcome_measure>
      <outcome_measure>Percentage of subjects achieving sustained virological response (SVR) at Week 4</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02461745</url>
  </study>
  <study rank="680">
    <nct_id>NCT01455090</nct_id>
    <title>Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-650032</intervention>
      <intervention type="Drug">BMS-790052</intervention>
      <intervention type="Drug">BMS-791325</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>320</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI443-014</other_id>
      <other_id>2011-002788-11</other_id>
    </other_ids>
    <first_received>October 18, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>July 2015</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (SVR) at 12 weeks post-treatment (SVR12)</outcome_measure>
      <outcome_measure>Proportion of subjects with HCV ribonucleic acid (RNA) &lt; limit of quantification (LOQ) (detectable and undetectable)</outcome_measure>
      <outcome_measure>Proportion of subjects with HCV ribonucleic acid (RNA) undetectable</outcome_measure>
      <outcome_measure>Proportion of subjects who experience viral breakthrough</outcome_measure>
      <outcome_measure>Proportion of subjects who experience viral relapse defined as confirmed quantifiable HCV RNA ≥ 25 IU/mL (&gt;LOQ) in a subject with HCV RNA &lt; LOQ or undetectable at End of treatment (EOT)</outcome_measure>
      <outcome_measure>Maximum observed plasma concentration (Cmax) of BMS-650032, BMS-790052, BMS 791325, and BMS-794712</outcome_measure>
      <outcome_measure>Observed plasma concentration at 12 hours (C12) of BMS-650032, BMS-790052, BMS 791325, and BMS-794712</outcome_measure>
      <outcome_measure>Observed plasma concentration at 24 hours (C24) of BMS-650032, BMS-790052, BMS 791325, and BMS-794712</outcome_measure>
      <outcome_measure>Trough observed plasma concentration (Ctrough) of BMS-650032, BMS-790052, BMS 791325, and BMS-794712</outcome_measure>
      <outcome_measure>Time of maximum observed plasma concentration (Tmax) of BMS-650032, BMS-790052, BMS 791325, and BMS-794712</outcome_measure>
      <outcome_measure>Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-650032, BMS-790052, BMS 791325, and BMS-794712</outcome_measure>
      <outcome_measure>HCV genomic substitutions associated with exposure of BMS-650032, BMS-790052, and BMS-791325</outcome_measure>
      <outcome_measure>Frequency of deaths, serious adverse events (SAEs), discontinuations due to adverse events (AEs), severity Grade 3/4 AEs, and severity Grade 3/4 laboratory abnormalities</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>France</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>Oklahoma</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01455090</url>
  </study>
  <study rank="681">
    <nct_id>NCT00147784</nct_id>
    <title>HEPMET-1: Evaluate the Feasibility, Mental Sideeffects and the Efficacy of Hepatitis C Treatment in a MMT Group.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opiate Dependence</condition>
      <condition>Hepatitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated Interferon</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Sorlandet Hospital HF</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>SSHF-70332</other_id>
      <other_id>Protocol no 9772387</other_id>
      <other_id>EudraCT no 2005-002869-37</other_id>
    </other_ids>
    <first_received>September 6, 2005</first_received>
    <start_date>March 2006</start_date>
    <completion_date>January 2008</completion_date>
    <last_updated>March 26, 2008</last_updated>
    <last_verified>March 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>- Percent of patients with sustained virological response, defined as undetectable HCV RNA 24 weeks after end of treatment</outcome_measure>
      <outcome_measure>Retention in treatment, compliance, psychological distress, measures of quality of life, perceived drug use control and urine toxicology</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Norway</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00147784</url>
  </study>
  <study rank="682">
    <nct_id>NCT01783678</nct_id>
    <title>A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Human Immunodeficiency Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>275</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0124</other_id>
    </other_ids>
    <first_received>January 31, 2013</first_received>
    <start_date>January 2013</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>April 15, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>April 15, 2015</firstreceived_results_date>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>HCV RNA Change From Baseline at Week 1</outcome_measure>
      <outcome_measure>HCV RNA Change From Baseline at Week 2</outcome_measure>
      <outcome_measure>HCV RNA Change From Baseline at Week 4</outcome_measure>
      <outcome_measure>HCV RNA Change From Baseline at Week 6</outcome_measure>
      <outcome_measure>HCV RNA Change From Baseline at Week 8</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Virologic Failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01783678</url>
  </study>
  <study rank="683">
    <nct_id>NCT02356562</nct_id>
    <title>A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Ombitasvir/ABT-450/Ritonavir and Dasabuvir With Sofosbuvir in DAA Treatment-experienced Adults With Chronic Hepatitis C Virus Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ombitasvir/ABT-450/r</intervention>
      <intervention type="Drug">Dasabuvir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M14-224</other_id>
    </other_ids>
    <first_received>February 2, 2015</first_received>
    <start_date>February 2015</start_date>
    <completion_date>August 2016</completion_date>
    <last_updated>October 10, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of subjects with sustained virologic response 12 weeks post-treatment</outcome_measure>
      <outcome_measure>Percentage of subjects with virologic failure during treatment</outcome_measure>
      <outcome_measure>Percentage of subjects with virologic relapse after treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>North Carolina</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02356562</url>
  </study>
  <study rank="684">
    <nct_id>NCT02581189</nct_id>
    <title>Effectiveness of Paritaprevir/r - Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada</title>
    <recruitment open="N">Enrolling by invitation</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
      <collaborator>Cato Research</collaborator>
      <collaborator>IST GmbH, Germany</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P15-651</other_id>
    </other_ids>
    <first_received>October 19, 2015</first_received>
    <start_date>October 2015</start_date>
    <completion_date>March 2018</completion_date>
    <last_updated>October 27, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>AMBER</acronym>
    <primary_completion_date>March 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants achieving sustained virological response at week 12 (SVR12)</outcome_measure>
      <outcome_measure>Percentage of the direct-acting antiviral (DAA) dose taken in relation to the target dose of DAA</outcome_measure>
      <outcome_measure>Percentage of the ribavirin (RBV) dose taken in relation to the target dose of RBV</outcome_measure>
      <outcome_measure>Percentage of missed ribavirin (RBV) treatment days in relation to the target number of RBV treatment days</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02581189</url>
  </study>
  <study rank="685">
    <nct_id>NCT00535847</nct_id>
    <title>A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated interferon alfa 2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
      <collaborator>Tibotec, Inc</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>117</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX06-950-107</other_id>
    </other_ids>
    <first_received>September 25, 2007</first_received>
    <start_date>October 2007</start_date>
    <completion_date>February 2010</completion_date>
    <last_updated>July 9, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>June 22, 2011</firstreceived_results_date>
    <primary_completion_date>February 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Treatment</outcome_measure>
      <outcome_measure>Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
      <outcome_measure>Percentage of Prior Relapsers With Undetectable HCV RNA</outcome_measure>
      <outcome_measure>Percentage of Subjects With End of Treatment Response</outcome_measure>
      <outcome_measure>Percentage of Subjects With Undetectable HCV RNA at Week 48 After Completion of Treatment Among Subjects Who Completed Assigned Treatment</outcome_measure>
      <outcome_measure>Cross Tabulation of Extended Rapid Viral Response (eRVR) and Sustained Viral Response (SVR) in With Prior Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Austria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Netherlands</country>
      <country>Puerto Rico</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maine</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>Nebraska</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00535847</url>
  </study>
  <study rank="686">
    <nct_id>NCT00375895</nct_id>
    <title>Switch From Tacrolimus to Cyclosporin in the Treatment of Recurrent Hepatitis C After Liver Transplantation</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Evidence of Liver Transplantation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ciclosporin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Rennes University Hospital</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>EudraCT 2006-002714-35</other_id>
      <other_id>LOC/06-05</other_id>
      <other_id>CIC0203/058</other_id>
    </other_ids>
    <first_received>September 12, 2006</first_received>
    <start_date>June 2006</start_date>
    <completion_date>December 2009</completion_date>
    <last_updated>March 1, 2012</last_updated>
    <last_verified>March 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Prolonged virological response</outcome_measure>
      <outcome_measure>Virological response 4, 7 and 13 months after the initiation of cyclosporin treatment</outcome_measure>
      <outcome_measure>Histological response: METAVIR score at 19 months</outcome_measure>
      <outcome_measure>Biological response: liver function at 4, 7, 13 and 19 months</outcome_measure>
      <outcome_measure>Incidence of acute or chronic graft rejection at 19 months</outcome_measure>
      <outcome_measure>Incidence of death, graft loss and retransplantation at 13 and 19 months</outcome_measure>
      <outcome_measure>Renal function at 4, 7, 13 and 19 months</outcome_measure>
      <outcome_measure>Incidence of treatment discontinuation at 4, 7, 13 and 19 months</outcome_measure>
      <outcome_measure>Incidence of adverse events (cancers in particular).</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00375895</url>
  </study>
  <study rank="687">
    <nct_id>NCT02113631</nct_id>
    <title>Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C,</condition>
      <condition>Cirrhosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Peg-IFN</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Louis Stokes VA Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB #: 11064-H40</other_id>
    </other_ids>
    <first_received>March 30, 2014</first_received>
    <start_date>September 2011</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>April 10, 2014</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety/Adverse Event Outcome Measure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Ohio</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02113631</url>
  </study>
  <study rank="688">
    <nct_id>NCT01121705</nct_id>
    <title>Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Patients Infected With Genotype 3 (HCV-3)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg Interferon alpha2b + Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Casa Sollievo della Sofferenza IRCCS</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>360</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Single Blind (Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>2007-00437470</other_id>
    </other_ids>
    <first_received>May 4, 2010</first_received>
    <start_date>January 2007</start_date>
    <completion_date>June 2009</completion_date>
    <last_updated>August 9, 2011</last_updated>
    <last_verified>June 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>genotype-3</acronym>
    <primary_completion_date>June 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (SVR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01121705</url>
  </study>
  <study rank="689">
    <nct_id>NCT00144469</nct_id>
    <title>A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a</intervention>
      <intervention type="Drug">rivavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Chugai Pharmaceutical</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>JV15725</other_id>
    </other_ids>
    <first_received>September 2, 2005</first_received>
    <start_date>May 2002</start_date>
    <completion_date>March 2005</completion_date>
    <last_updated>January 29, 2009</last_updated>
    <last_verified>January 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response, defined as undetectable HCV-RNA (&lt;50IU per milliliter) after 24 weeks of untreated follow-up (week 72).</outcome_measure>
      <outcome_measure>Biochemical response (normalization of serum alanine aminotransferase activity),</outcome_measure>
      <outcome_measure>Virological response (HCV-RNA &lt;50IU per milliliter) at the end of therapy.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00144469</url>
  </study>
  <study rank="690">
    <nct_id>NCT00279565</nct_id>
    <title>Buprenorphine Versus Methadone Maintenance in Hepatitis C Patients Receiving Peg-Intron and Rebetol (Study P04279)(TERMINATED)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">buprenorphine</intervention>
      <intervention type="Drug">methadone</intervention>
      <intervention type="Drug">pegylated interferon alfa-2b plus ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Reckitt Benckiser Pharmaceuticals Inc.</lead_sponsor>
      <collaborator>AESCA Pharma GmbH</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>128</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P04279</other_id>
    </other_ids>
    <first_received>January 17, 2006</first_received>
    <start_date>August 2005</start_date>
    <completion_date>February 2007</completion_date>
    <last_updated>November 21, 2012</last_updated>
    <last_verified>February 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2007</primary_completion_date>
    <outcome_measures/>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00279565</url>
  </study>
  <study rank="691">
    <nct_id>NCT02628717</nct_id>
    <title>Interferon/Ribavirin-Free Sofosbuvir Based Treatment (AURIC)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Cirrhosis</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Medical University of Vienna</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>450</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>I3MHCV</other_id>
    </other_ids>
    <first_received>December 3, 2015</first_received>
    <start_date>July 2013</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>December 10, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>AURIC</acronym>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of patients with sustained virologic response (SVR)</outcome_measure>
      <outcome_measure>On treatment predictability of SVR</outcome_measure>
      <outcome_measure>Number of patients with liver events (Mortality, Hepatic decompensation, Variceal Bleeding,Hepatocellular Carcinoma, Need for Liver Transplantation) on longterm clinical outcome</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02628717</url>
  </study>
  <study rank="692">
    <nct_id>NCT00031343</nct_id>
    <title>The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">highly active antiretroviral therapy (HAART)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>128</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>020139</other_id>
      <other_id>02-I-0139</other_id>
    </other_ids>
    <first_received>March 2, 2002</first_received>
    <start_date>February 2002</start_date>
    <completion_date>April 2004</completion_date>
    <last_updated>March 3, 2008</last_updated>
    <last_verified>April 2004</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00031343</url>
  </study>
  <study rank="693">
    <nct_id>NCT01220947</nct_id>
    <title>A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">daneprovir</intervention>
      <intervention type="Drug">danoprevir</intervention>
      <intervention type="Drug">danoprevir</intervention>
      <intervention type="Drug">danoprevir</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ritonavir</intervention>
      <intervention type="Drug">ritonavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>421</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV22776</other_id>
      <other_id>2010-019584-10</other_id>
    </other_ids>
    <first_received>October 7, 2010</first_received>
    <start_date>November 2010</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (HCV RNA measured by Roche COBAS TaqMan HCV test)</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
      <outcome_measure>Evaluation of relapse rate</outcome_measure>
      <outcome_measure>Characterization of resistance profile (HCV RNA sequencing and/or phenotypic analyses)</outcome_measure>
      <outcome_measure>Virological response at scheduled visits over time (HCV RNA measured by Roche COBAS TaqMan HCV test)</outcome_measure>
      <outcome_measure>Evaluation of virological breakthrough (viral load rebound) rate</outcome_measure>
      <outcome_measure>Evaluation of pharmacokinetics (serum concentrations assessed by validated methods)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Austria</country>
      <country>Brazil</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Mexico</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oregon</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01220947</url>
  </study>
  <study rank="694">
    <nct_id>NCT01760148</nct_id>
    <title>Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy (sIFN-pred2)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Liver Diseases</condition>
      <condition>Interferon Deficiency</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">interferon alpha 2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Junqi Niu</lead_sponsor>
      <collaborator>Chinese Academy of Sciences</collaborator>
      <collaborator>First Hospital of Jilin University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>2012ZX10002007</other_id>
      <other_id>2009ZX10004-105-jida02</other_id>
      <other_id>2008ZX10002-014-jida02</other_id>
    </other_ids>
    <first_received>September 8, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>January 1, 2013</last_updated>
    <last_verified>January 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>sIFN-pred2</acronym>
    <primary_completion_date>February 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Absolute Blood HCV RNA Copies at designed time points</outcome_measure>
      <outcome_measure>IL-28B polymorphism</outcome_measure>
      <outcome_measure>HCV genotype</outcome_measure>
      <outcome_measure>Alanine Aminotransferase (ALT) and Aspartate transaminase (AST)</outcome_measure>
      <outcome_measure>Fibrosis stage</outcome_measure>
      <outcome_measure>Regular blood test</outcome_measure>
      <outcome_measure>Electrocardiography</outcome_measure>
      <outcome_measure>Alcohol ,smoking condition</outcome_measure>
      <outcome_measure>Drug abuse history</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01760148</url>
  </study>
  <study rank="695">
    <nct_id>NCT00516321</nct_id>
    <title>Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">eltrombopag</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>687</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>TPL103922</other_id>
    </other_ids>
    <first_received>August 13, 2007</first_received>
    <start_date>October 2007</start_date>
    <completion_date>May 2011</completion_date>
    <last_updated>October 10, 2013</last_updated>
    <last_verified>August 2012</last_verified>
    <firstreceived_results_date>March 22, 2012</firstreceived_results_date>
    <primary_completion_date>April 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase</outcome_measure>
      <outcome_measure>Number of Participants Whose Platelet Count Increased From a Baseline Count of &lt;75 Gi/L to a Count Greater Than or Equal to (&gt;=) 90 Giga (10^9) Cells Per Liter (Gi/L) During the Open-label (OL) Pre-Antiviral Treatment Phase</outcome_measure>
      <outcome_measure>Number of Participants Receiving the Indicated Doses of Eltrombopag in the OL Phase Who Initiated Antiviral Therapy (Peginterferon Alfa-2a and Ribavirin) in the DB Phase</outcome_measure>
      <outcome_measure>Median Platelet Count at the Indicated Time Points During the OL Phase</outcome_measure>
      <outcome_measure>Median Platelet Count at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants in the Indicated Categories for Minimum Platelet Count With Antiviral Therapy During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants With Rapid Virological Response (RVR) and Extended RVR (eRVR) During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants With Early Virological Response (EVR) and Complete EVR (cEVR) During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants With End of Treatment Response (ETR) and Sustained Virological Response at Week 12 of Follow-up (SVR12) During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants in the Indicated Categories for Antiviral Therapy Dose Reductions in the DB Phase</outcome_measure>
      <outcome_measure>Time to First Dose Reduction of Peginterferon Alfa-2a and Ribavirin Therapy in the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Levels of Peginterferon Dose Reductions in the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants Who Prematurely Discontinued Antiviral Therapy in the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants (Par.) Categorized as Responders (R) and Non-responders (NR) for SVR and RVR to Antiviral Therapy in the Indicated Variants of Interleukin 28B (IL28B) (or Interferon, Lambda 3) During the DB Phase</outcome_measure>
      <outcome_measure>Number of Par. With the Indicated Shift From Baseline (BL) in Severity Grades for Clinical Chemistry Parameters (Calcium, Glucose [Glu.], Potassium [Pot.], and Sodium [Sod.]), Per Division of Acquired Immunodeficiency Syndrome (DAIDS) During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters (Hemoglobin, Lymphocytes [Lym.], Total Neutrophils [Tot Neu.], and White Blood Cells [WBC]), Per DAIDS During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants in the Indicated Categories for Cataract Event During the DB Phase, Per Clinical Events Committee (CEC) Adjudication During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants Assessed as Normal and Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants With CS and NCS Change From Baseline for 12-lead ECG at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Heart Rate at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Weight at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Body Mass Index (BMI) at the Indicated Time Points During the DB Phase</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>Czech Republic</country>
      <country>France</country>
      <country>Germany</country>
      <country>Hong Kong</country>
      <country>India</country>
      <country>Israel</country>
      <country>Italy</country>
      <country>Korea, Republic of</country>
      <country>Netherlands</country>
      <country>Pakistan</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Slovakia</country>
      <country>Spain</country>
      <country>Taiwan</country>
      <country>Thailand</country>
      <country>Ukraine</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>Arkansas</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Kentucky</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00516321</url>
  </study>
  <study rank="696">
    <nct_id>NCT00529568</nct_id>
    <title>Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">eltrombopag</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>759</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>TPL108390</other_id>
    </other_ids>
    <first_received>September 12, 2007</first_received>
    <start_date>October 2007</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>October 10, 2013</last_updated>
    <last_verified>March 2013</last_verified>
    <firstreceived_results_date>April 19, 2012</firstreceived_results_date>
    <primary_completion_date>August 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase</outcome_measure>
      <outcome_measure>Number of Participants Whose Platelet Count Increased From a Baseline Count of &lt;75 Gi/L to a Count Greater Than or Equal to (&gt;=) 100 Giga (10^9) Cells Per Liter (Gi/L) During the Open-label (OL) Pre-Antiviral Treatment Phase</outcome_measure>
      <outcome_measure>Number of Participants Receiving the Indicated Doses of Eltrombopag in the OL Phase Who Initiated Antiviral Therapy (Peginterferon Alfa-2a and Ribavirin) in the DB Phase</outcome_measure>
      <outcome_measure>Median Platelet Count at the Indicated Time Points During the OL Phase</outcome_measure>
      <outcome_measure>Median Platelet Count at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants in the Indicated Categories for Minimum Platelet Count With Antiviral Therapy</outcome_measure>
      <outcome_measure>Number of Participants With Rapid Virological Response (RVR) and Extended RVR (eRVR) During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants With Early Virological Response (EVR) and Complete EVR (cEVR) During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants With End of Treatment Response (ETR) and Sustained Virological Response at Week 12 of Follow-up (SVR12) During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants in the Indicated Categories for Antiviral Therapy Dose Reductions in the DB Phase</outcome_measure>
      <outcome_measure>Time to First Dose Reduction of Peginterferon Alfa-2a and Ribavirin Therapy in the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Levels of Peginterferon Dose Reductions in the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants Who Prematurely Discontinued Antiviral Therapy in the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants Categorized as Responders (R) and Non-responders (NR) for SVR and RVR to Antiviral Therapy in the Indicated Variants of Interleukin 28B (IL28B) (or Interferon, Lambda 3)</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Shift From Baseline (BL) in Severity Grades for Clinical Chemistry Parameters (Calcium, Glucose [Glu.], Potassium [Pot.], and Sodium [Sod.]), Per Division of Acquired Immunodeficiency Syndrome (DAIDS)</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters (Hemoglobin, Lymphocytes [Lym.], Total Neutrophils [Tot Neu.], and White Blood Cells [WBC]), Per DAIDS</outcome_measure>
      <outcome_measure>Number of Participants in the Indicated Categories for Cataract Event During the DB Phase, Per Clinical Events Committee (CEC) Adjudication</outcome_measure>
      <outcome_measure>Number of Participants Assessed as Normal and Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants With CS and NCS Change From Baseline for 12-lead ECG at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Heart Rate at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Weight at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Body Mass Index (BMI) at the Indicated Time Points During the DB Phase</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>Czech Republic</country>
      <country>Egypt</country>
      <country>France</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>India</country>
      <country>Israel</country>
      <country>Italy</country>
      <country>Korea, Republic of</country>
      <country>Pakistan</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Slovakia</country>
      <country>Spain</country>
      <country>Taiwan</country>
      <country>Ukraine</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New Hampshire</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00529568</url>
  </study>
  <study rank="697">
    <nct_id>NCT00164073</nct_id>
    <title>Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Liver biopsy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bayside Health</lead_sponsor>
      <collaborator>University of Adelaide</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Defined Population</study_design>
      <study_design>Observational Model: Natural History</study_design>
      <study_design>Time Perspective: Longitudinal</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>122/03</other_id>
    </other_ids>
    <first_received>September 13, 2005</first_received>
    <start_date>February 2004</start_date>
    <completion_date>February 2007</completion_date>
    <last_updated>July 31, 2007</last_updated>
    <last_verified>September 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>Australia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00164073</url>
  </study>
  <study rank="698">
    <nct_id>NCT00630058</nct_id>
    <title>A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MP-424(H), PEG-IFN-a-2b, RBV</intervention>
      <intervention type="Drug">MP-424 (L), PEG-IFN-a-2b, RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>G060-A5</other_id>
    </other_ids>
    <first_received>February 24, 2008</first_received>
    <start_date>April 2008</start_date>
    <completion_date>March 2009</completion_date>
    <last_updated>April 16, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>December 12, 2012</firstreceived_results_date>
    <primary_completion_date>March 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Cmax (Maximum Observed Concentration in Plasma) of MP-424</outcome_measure>
      <outcome_measure>Tmax (Time of Maximum Concentration in Plasma) of MP-424</outcome_measure>
      <outcome_measure>AUC 0-8h (Area Under the Concentration-time Curve From Time Zero to 8 Hours) of MP-424</outcome_measure>
      <outcome_measure>Ctrough (Minimum Observed Concentration in Plasma) of MP-424</outcome_measure>
      <outcome_measure>T1/2(Time of Half-Life) of MP-424</outcome_measure>
      <outcome_measure>Antiviral Effects of TVR on HCV Were Assessed by Measuring Plasma HCV RNA Levels</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00630058</url>
  </study>
  <study rank="699">
    <nct_id>NCT01565889</nct_id>
    <title>Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">EFV/FTC/TDF</intervention>
      <intervention type="Drug">EFV</intervention>
      <intervention type="Drug">ZDV/3TC</intervention>
      <intervention type="Drug">ATV</intervention>
      <intervention type="Drug">Ritonavir</intervention>
      <intervention type="Drug">FTC/TDF</intervention>
      <intervention type="Drug">DRV</intervention>
      <intervention type="Drug">RAL</intervention>
      <intervention type="Drug">PEG</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>52</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P7977-1910</other_id>
    </other_ids>
    <first_received>March 27, 2012</first_received>
    <start_date>March 2012</start_date>
    <completion_date>November 2013</completion_date>
    <last_updated>September 25, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>August 28, 2014</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Part A: Plasma Pharmacokinetics of SOF, EFV, Tenofovir (TFV), and FTC: AUCtau at Day 7</outcome_measure>
      <outcome_measure>Part A: Plasma Pharmacokinetics of SOF, EFV, TFV, and FTC: Cmax at Day 7</outcome_measure>
      <outcome_measure>Part B: Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)</outcome_measure>
      <outcome_measure>Part B: Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Part B: Percentage of Participants Experiencing Viral Breakthrough or Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01565889</url>
  </study>
  <study rank="700">
    <nct_id>NCT01704521</nct_id>
    <title>Viral Kinetics in HCV Clearance in Subjects With Hemophilia</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Hemophilia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PegInterferon</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kenneth Sherman</lead_sponsor>
      <collaborator>National Heart, Lung, and Blood Institute (NHLBI)</collaborator>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
      <collaborator>Genentech, Inc.</collaborator>
      <collaborator>University of Cincinnati</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>5</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>12053004</other_id>
      <other_id>R34HL109334</other_id>
    </other_ids>
    <first_received>October 5, 2012</first_received>
    <start_date>December 2012</start_date>
    <completion_date>October 2014</completion_date>
    <last_updated>March 26, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>February 3, 2015</firstreceived_results_date>
    <acronym>HCV/Hemophil</acronym>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Sustained Virological Response at Week 12 (SVR12)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Ohio</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01704521</url>
  </study>
  <study rank="701">
    <nct_id>NCT02618928</nct_id>
    <title>The Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in France</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>700</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P15-405</other_id>
    </other_ids>
    <first_received>November 24, 2015</first_received>
    <start_date>November 2015</start_date>
    <completion_date>October 2018</completion_date>
    <last_updated>November 30, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>OPALE</acronym>
    <primary_completion_date>April 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants achieving sustained virologic response 12 Weeks Post-treatment (SVR12)</outcome_measure>
      <outcome_measure>Evaluate the Usage Pattern of the Treatment Regimen</outcome_measure>
      <outcome_measure>Number of participants who experience adverse events</outcome_measure>
      <outcome_measure>Change in EuroQol 5 dimension 5 level (EQ-5D-5L) total score</outcome_measure>
      <outcome_measure>Change in Healthcare Resource Utilization</outcome_measure>
      <outcome_measure>Change in Work Productivity and Activity Impairment (WPAI) total score</outcome_measure>
      <outcome_measure>Change in Fatigue Total Score</outcome_measure>
      <outcome_measure>Change in Participant Satisfaction regarding the Patient Support Program</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02618928</url>
  </study>
  <study rank="702">
    <nct_id>NCT02243293</nct_id>
    <title>A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 or Genotype 3 Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-493</intervention>
      <intervention type="Drug">ABT-530</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>350</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M14-868</other_id>
      <other_id>2014-002927-90</other_id>
    </other_ids>
    <first_received>September 4, 2014</first_received>
    <start_date>September 2014</start_date>
    <completion_date>January 2017</completion_date>
    <last_updated>November 3, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of subjects who achieve 12-week sustained virologic response (SVR12) in each treatment arm</outcome_measure>
      <outcome_measure>Percentage of subjects who achieve 4-week sustained virologic response (SVR4) in each treatment arm</outcome_measure>
      <outcome_measure>Percentage of subjects with virologic failure during treatment</outcome_measure>
      <outcome_measure>Percentage of subjects with Post-Treatment relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>France</country>
      <country>Italy</country>
      <country>Korea, Republic of</country>
      <country>New Zealand</country>
      <country>Taiwan</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Hampshire</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02243293</url>
  </study>
  <study rank="703">
    <nct_id>NCT01416610</nct_id>
    <title>An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>88</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML25159</other_id>
    </other_ids>
    <first_received>August 12, 2011</first_received>
    <start_date>April 2010</start_date>
    <completion_date>October 2014</completion_date>
    <last_updated>November 4, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>November 4, 2015</firstreceived_results_date>
    <acronym>PEGHOPE</acronym>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virological Response 24 Weeks After Completing Treatment (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With SVR 12</outcome_measure>
      <outcome_measure>Percentage of Participants With End of Treatment Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Virological Relapse</outcome_measure>
      <outcome_measure>Short Form Health Survey (SF-36) Scores by Visit</outcome_measure>
      <outcome_measure>Fatigue Severity Scale (FSS) Score by Visit</outcome_measure>
      <outcome_measure>Beschwerdeliste (BL) Score by Visit</outcome_measure>
      <outcome_measure>Beck Depression Inventory (BDI) Score by Visit</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01416610</url>
  </study>
  <study rank="704">
    <nct_id>NCT00560690</nct_id>
    <title>The Effect of Adding Metformin to the Treatment of Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Metformin</intervention>
      <intervention type="Drug">pegylated interferon</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tehran University of Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>140</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>83/53</other_id>
    </other_ids>
    <first_received>November 19, 2007</first_received>
    <start_date>December 2007</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>April 2, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained viral response, defined as undetectable virus RNA 6 months after end of treatment</outcome_measure>
      <outcome_measure>adverse effects leading to discontinuation of treatment</outcome_measure>
      <outcome_measure>Rapid viral response, defined as undetectable viral RNA one month after start of treatment</outcome_measure>
      <outcome_measure>Early viral response, defined as undetectable viral RNA or 2 log drop in viral count three month after start of treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Iran, Islamic Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00560690</url>
  </study>
  <study rank="705">
    <nct_id>NCT00395421</nct_id>
    <title>Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">NM283 plus Peg-IFNα-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
      <collaborator>Novartis Pharmaceuticals</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>114</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Single Blind (Subject)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV-08A-008</other_id>
    </other_ids>
    <first_received>November 1, 2006</first_received>
    <start_date>October 2006</start_date>
    <completion_date>August 2008</completion_date>
    <last_updated>June 9, 2010</last_updated>
    <last_verified>June 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Georgia</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00395421</url>
  </study>
  <study rank="706">
    <nct_id>NCT00905632</nct_id>
    <title>4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BI 207127 middle dose +SOC</intervention>
      <intervention type="Drug">BI 207127 high dose+SOC</intervention>
      <intervention type="Drug">Placebo + SOC</intervention>
      <intervention type="Drug">BI 207127 low dose + SOC</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>1241.7</other_id>
      <other_id>2008-008292-34</other_id>
    </other_ids>
    <first_received>May 19, 2009</first_received>
    <start_date>May 2009</start_date>
    <last_updated>November 21, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary efficacy endpoint is virologic response defined as &gt;= 3 log drop in viral load from baseline at day 28 with no evidence of virologic rebound during these 28 days. Virologic rebound is defined as &gt;= 1 log increase in viral load from nadir.</outcome_measure>
      <outcome_measure>early virological response</outcome_measure>
      <outcome_measure>end of treatment response</outcome_measure>
      <outcome_measure>sustained virological response</outcome_measure>
      <outcome_measure>Plasma concentration time profiles of BI 207127 and CD 6168</outcome_measure>
      <outcome_measure>rapid virological response</outcome_measure>
      <outcome_measure>Safety (vital signs, adverse events, safety laboratory tests, ECG)</outcome_measure>
      <outcome_measure>Viral load (Log10) at each visit up to day 28, both actual and change from baseline</outcome_measure>
      <outcome_measure>Virologic response at day 28, defined as achieving viral load below the limit of quantification (BLQ) at day 28</outcome_measure>
      <outcome_measure>Cmax of first day of BI 207127 and CD 6168</outcome_measure>
      <outcome_measure>Tmax of first day of BI 207127 and CD 6168</outcome_measure>
      <outcome_measure>AUC0-6 of first day of BI 207127 and CD 6168</outcome_measure>
      <outcome_measure>Cpre,1 of first day of BI 207127 and CD 6168</outcome_measure>
      <outcome_measure>Cpre,2 of first day of BI 207127 and CD 6168</outcome_measure>
      <outcome_measure>Cpre Pharmacokinetic parameter of BI 207127 and CD 6168</outcome_measure>
      <outcome_measure>Cmax,ss Pharmacokinetic parameters of BI 207127 and CD 6168 at steady state after the last dose</outcome_measure>
      <outcome_measure>Tmax,ss Pharmacokinetic parameters of BI 207127 and CD 6168 at steady state after the last dose</outcome_measure>
      <outcome_measure>C6,ss Pharmacokinetic parameters of BI 207127 and CD 6168 at steady state after the last dose</outcome_measure>
      <outcome_measure>AUC0-6,ss Pharmacokinetic parameters of BI 207127 and CD 6168 at steady state after the last dose</outcome_measure>
      <outcome_measure>AUC0-infinity,ss Pharmacokinetic parameters of BI 207127 and CD 6168 at steady state after the last dose</outcome_measure>
      <outcome_measure>λz Pharmacokinetic parameters of BI 207127 and CD 6168 at steady state after the last dose</outcome_measure>
      <outcome_measure>t1/2,ss Pharmacokinetic parameters of BI 207127 and CD 6168 at steady state after the last dose</outcome_measure>
      <outcome_measure>MRTpo,ss Pharmacokinetic parameters of BI 207127 and CD 6168 at steady state after the last dose</outcome_measure>
      <outcome_measure>RA,Cmax Pharmacokinetic parameters of BI 207127 and CD 6168 at steady state after the last dose</outcome_measure>
      <outcome_measure>Number of patients with changes in Vital signs (pulse rate, systolic and diastolic blood pressure)</outcome_measure>
      <outcome_measure>Number of patients with changes in body temperature</outcome_measure>
      <outcome_measure>Number of patients with changes in electrocardiogram (ECG)</outcome_measure>
      <outcome_measure>Number of patients with changes in safety laboratory test</outcome_measure>
      <outcome_measure>Incidence and Intensity of Adverse events</outcome_measure>
      <outcome_measure>Number of patients with Discontinuations due to AEs</outcome_measure>
      <outcome_measure>Number of patients with changes in Physical examination</outcome_measure>
      <outcome_measure>Global Assessment of tolerability</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
      <country>Germany</country>
      <country>Switzerland</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00905632</url>
  </study>
  <study rank="707">
    <nct_id>NCT00512278</nct_id>
    <title>Infliximab Treatment Along With Pegylated Interferon and Ribavirin in the Treatment of Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Infliximab</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Nizar Zein</lead_sponsor>
      <collaborator>Centocor, Inc.</collaborator>
      <collaborator>The Cleveland Clinic</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>149</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>PARTNER</other_id>
    </other_ids>
    <first_received>August 3, 2007</first_received>
    <start_date>July 2007</start_date>
    <completion_date>May 2012</completion_date>
    <last_updated>November 14, 2012</last_updated>
    <last_verified>November 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PARTNER</acronym>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Compare proportion of chronic hepatitis C subjects (treatment naive,Genotype 1) who achieve SVR at week 72, after 48 weeks of treatment.</outcome_measure>
      <outcome_measure>Compare proportion with non-detectable HCV-RNA after 24 and 48 wks of therapy. Compare the proportion with normal ALT after 12 , 24, 48 wks and after 24 wks of tx-free FU after 48 wks of tx.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Kentucky</state>
      <state>Ohio</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00512278</url>
  </study>
  <study rank="708">
    <nct_id>NCT00194857</nct_id>
    <title>Treatment of Anemia and Neutropenia in HIV/HCV Coinfected Patients Treated With Pegylated Interferon and Ribavirin</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Anemia</condition>
      <condition>Neutropenia</condition>
      <condition>Hepatitis C Virus</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">erythropoietin, GCSF</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Weill Medical College of Cornell University</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P03850-001</other_id>
      <other_id>0801-858</other_id>
    </other_ids>
    <first_received>September 12, 2005</first_received>
    <start_date>February 2002</start_date>
    <completion_date>December 2005</completion_date>
    <last_updated>December 14, 2012</last_updated>
    <last_verified>December 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2005</primary_completion_date>
    <outcome_measures>
      <outcome_measure>change in hemoglobin</outcome_measure>
      <outcome_measure>change in absolute neutrophil count</outcome_measure>
      <outcome_measure>HCV RNA</outcome_measure>
      <outcome_measure>depression</outcome_measure>
      <outcome_measure>fatigue</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00194857</url>
  </study>
  <study rank="709">
    <nct_id>NCT01634919</nct_id>
    <title>Histologic Changes and Noninvasive Assessment in Hepatitis C Patients Treated With Peginterferon Alpha-2a and Ribavirin</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Device">chronic hepatitis C</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Seoul National University Boramae Hospital</lead_sponsor>
      <collaborator>Roche Pharma AG</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>55</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>06-2012-74</other_id>
    </other_ids>
    <first_received>July 3, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Anti-fibrotic response</outcome_measure>
      <outcome_measure>Histologic and noninvasive fibrosis assessments</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Korea, Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01634919</url>
  </study>
  <study rank="710">
    <nct_id>NCT00150904</nct_id>
    <title>Peginterferon and Ribavirin on Virologic and Immunologic Parameters in Hepatitis C Mono- and Coinfected Patient (PRIVICOP)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">venous blood puncture</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UMC Utrecht</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>28</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>04-247E</other_id>
    </other_ids>
    <first_received>September 6, 2005</first_received>
    <start_date>August 2005</start_date>
    <completion_date>January 2009</completion_date>
    <last_updated>February 13, 2009</last_updated>
    <last_verified>February 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2008</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00150904</url>
  </study>
  <study rank="711">
    <nct_id>NCT01798576</nct_id>
    <title>An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>282</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML28498</other_id>
    </other_ids>
    <first_received>February 22, 2013</first_received>
    <start_date>November 2012</start_date>
    <completion_date>July 2016</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (SVR) rate, defined as percentage of patients with HCV RNA &lt;50 IU/mL at 24 weeks post completion of treatment (overall and stratified by prior treatment outcome: non-response and relapse)</outcome_measure>
      <outcome_measure>Percentage of patients with rapid virological response (RVR), defined as HCV RNA &lt;50 IU/mL at Week 4 (overall and stratified by prior treatment outcome: non-response and relapse)</outcome_measure>
      <outcome_measure>Percentage of patients with early virological response (EVR), defined as HCV RNA &lt;50 IU/mL or an at least 2-log drop from baseline in HCV RNA at Week 12, but with no RVR (overall and stratified by prior treatment outcome: non-response and relapse)</outcome_measure>
      <outcome_measure>Percentage of patients with non-response/relapse/virological breakthrough/virological rebound</outcome_measure>
      <outcome_measure>Duration of treatment</outcome_measure>
      <outcome_measure>Time to safety-related dose reduction/treatment discontinuation of any of the treatment compounds</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Romania</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01798576</url>
  </study>
  <study rank="712">
    <nct_id>NCT01949168</nct_id>
    <title>A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets)</intervention>
      <intervention type="Drug">Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection</intervention>
      <intervention type="Drug">Rebetol® (ribavirin), 1000/1200mg by mouth daily</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>St Vincent's Hospital Melbourne</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme (Australia) Pty Ltd</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HCV-6 study</other_id>
    </other_ids>
    <first_received>September 4, 2013</first_received>
    <start_date>September 2013</start_date>
    <last_updated>September 19, 2013</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HCV-6</acronym>
    <primary_completion_date>September 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Early viral kinetics</outcome_measure>
      <outcome_measure>Rates of virological response</outcome_measure>
      <outcome_measure>Number of patients eligible for Response Guided Therapy</outcome_measure>
      <outcome_measure>Rates of virological breakthrough</outcome_measure>
      <outcome_measure>Rates of SVR12 and relapse</outcome_measure>
      <outcome_measure>Rates of anaemia on treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01949168</url>
  </study>
  <study rank="713">
    <nct_id>NCT02220998</nct_id>
    <title>Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF/VEL</intervention>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>269</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-342-1139</other_id>
    </other_ids>
    <first_received>August 18, 2014</first_received>
    <start_date>September 2014</start_date>
    <completion_date>September 2015</completion_date>
    <last_updated>September 16, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ASTRAL-2</acronym>
    <primary_completion_date>July 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV RNA &lt; LLOQ on treatment</outcome_measure>
      <outcome_measure>HCV RNA change from baseline</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02220998</url>
  </study>
  <study rank="714">
    <nct_id>NCT02201953</nct_id>
    <title>Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF/VEL</intervention>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>558</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-342-1140</other_id>
      <other_id>2014-001682-27</other_id>
    </other_ids>
    <first_received>July 24, 2014</first_received>
    <start_date>July 2014</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ASTRAL-3</acronym>
    <primary_completion_date>September 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV RNA &lt; LLOQ on treatment</outcome_measure>
      <outcome_measure>HCV RNA change from baseline</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02201953</url>
  </study>
  <study rank="715">
    <nct_id>NCT02508090</nct_id>
    <title>Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC) Who Have Not Responded to Pegylated-Interferon Alpha Plus Ribavirin</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
      <collaborator>Santaris Pharma A/S</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>NP29711</other_id>
    </other_ids>
    <first_received>July 23, 2015</first_received>
    <start_date>August 2013</start_date>
    <completion_date>November 2016</completion_date>
    <last_updated>September 1, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Incidence of adverse events</outcome_measure>
      <outcome_measure>Incidence of sustained virologic response (SVR)</outcome_measure>
      <outcome_measure>Change from Baseline in HCV ribonucleic acid (RNA) level</outcome_measure>
      <outcome_measure>Incidence of HCV resistance</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02508090</url>
  </study>
  <study rank="716">
    <nct_id>NCT00135798</nct_id>
    <title>Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LADR Treatment</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
      <collaborator>Ortho Biotech Clinical Affairs, L.L.C.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>79</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>A2ALL LADR Protocol 62498(IND)</other_id>
      <other_id>U01DK062498</other_id>
      <other_id>U01DK062536</other_id>
      <other_id>U01DK062444</other_id>
      <other_id>U01DK062467</other_id>
      <other_id>U01DK062483</other_id>
      <other_id>U01DK062484</other_id>
      <other_id>U01DK062494</other_id>
      <other_id>U01DK062496</other_id>
      <other_id>U01DK062505</other_id>
      <other_id>U01DK062531</other_id>
      <other_id>CRADA through NIH-NIDDK</other_id>
      <other_id>CTA through NIH-NIDDK</other_id>
      <other_id>HRSA</other_id>
      <other_id>ASTS</other_id>
    </other_ids>
    <first_received>August 24, 2005</first_received>
    <start_date>September 2005</start_date>
    <completion_date>December 2009</completion_date>
    <last_updated>April 11, 2013</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>June 13, 2012</firstreceived_results_date>
    <acronym>LADR</acronym>
    <primary_completion_date>December 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Patients Who Are Negative for Hepatitis C Virus (HCV) RNA at 3 Months Post-transplant: Intent-to-Treat Analysis (ITT)</outcome_measure>
      <outcome_measure>Patients Who Are Negative for HCV RNA at 3 Months Post-transplant: Per-Protocol Analysis (PP)</outcome_measure>
      <outcome_measure>Patients With Combined Virologic Response (CVR): Intent-to-Treat Analyses (ITT)</outcome_measure>
      <outcome_measure>Patients With Combined Virologic Response (CVR): Per-Protocol Analysis (PP)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Illinois</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00135798</url>
  </study>
  <study rank="717">
    <nct_id>NCT02581163</nct_id>
    <title>Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, +/- Dasabuvir, +/- Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C, Genotype 1 or 4</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>440</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P15-650</other_id>
    </other_ids>
    <first_received>October 19, 2015</first_received>
    <start_date>October 2015</start_date>
    <completion_date>September 2018</completion_date>
    <last_updated>October 19, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants achieving sustained virological response at week 12 (SVR12)</outcome_measure>
      <outcome_measure>Percentage of participants with virological response.</outcome_measure>
      <outcome_measure>Percentage of participants who relapse</outcome_measure>
      <outcome_measure>Percentage of participants who achieved breakthrough</outcome_measure>
      <outcome_measure>Percentage of patients meeting On-treatment virologic failure</outcome_measure>
      <outcome_measure>Percentage of patients meeting relapse</outcome_measure>
      <outcome_measure>Percentage of patients meeting Premature study drug discontinuation with no on-treatment virologic failure</outcome_measure>
      <outcome_measure>Percentage of patients missing SVR12 data and/or none of the above criteria</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02581163</url>
  </study>
  <study rank="718">
    <nct_id>NCT01330316</nct_id>
    <title>A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BI 201335</intervention>
      <intervention type="Drug">PegIFN/RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>119</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1220.48</other_id>
      <other_id>2011-000141-20</other_id>
    </other_ids>
    <first_received>April 5, 2011</first_received>
    <start_date>July 2011</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>July 3, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>July 3, 2015</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virological Response (SVR): Plasma HCV RNA Level &lt; 25 IU/mL</outcome_measure>
      <outcome_measure>Sustained Virological Response After 24 Weeks of Treatment Discontinuation (SVR24)</outcome_measure>
      <outcome_measure>Early Treatment Success (ETS)</outcome_measure>
      <outcome_measure>Alanine Aminotransferase (ALT) Normalisation: ALT in Normal Range at End of Treatment (EoT)</outcome_measure>
      <outcome_measure>Alanine Aminotransferase (ALT) Normalisation: ALT in Normal Range at 12 Weeks Post-treatment.</outcome_measure>
      <outcome_measure>Aspartate Aminotransferase (AST) Normalisation: AST in Normal Range at End of Treatment (EoT)</outcome_measure>
      <outcome_measure>Aspartate Aminotransferase (AST) Normalisation: AST in Normal Range at 12 Weeks Post-treatment.</outcome_measure>
      <outcome_measure>Occurrence of Adverse Events (Overall and by DAIDS Grade)</outcome_measure>
      <outcome_measure>Occurrence of Adverse Events Leading to Treatment Discontinuation</outcome_measure>
      <outcome_measure>Occurrence of Serious Adverse Events (SAEs)</outcome_measure>
      <outcome_measure>Occurrence of Drug-related AEs as Assessed by the Investigator</outcome_measure>
      <outcome_measure>Laboratory Test Abnormalities by DAIDS Grades</outcome_measure>
      <outcome_measure>Changes From Baseline in Laboratory Test Values Over Time [Haemoglobin]</outcome_measure>
      <outcome_measure>Changes From Baseline in Laboratory Test Values Over Time [ALT]</outcome_measure>
      <outcome_measure>Changes From Baseline in Laboratory Test Values Over Time [AST]</outcome_measure>
      <outcome_measure>Changes From Baseline in Laboratory Test Values Over Time [Bilirubin Total]</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Japan</country>
      <country>Korea, Republic of</country>
      <country>Portugal</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Switzerland</country>
      <country>Taiwan</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arkansas</state>
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Louisiana</state>
      <state>Massachusetts</state>
      <state>Mississippi</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>Oregon</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01330316</url>
  </study>
  <study rank="719">
    <nct_id>NCT00217139</nct_id>
    <title>A Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Celgosivir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>BioWest Therapeutics Inc</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HCV-05-002</other_id>
    </other_ids>
    <first_received>September 13, 2005</first_received>
    <start_date>September 2005</start_date>
    <completion_date>September 2006</completion_date>
    <last_updated>September 27, 2006</last_updated>
    <last_verified>September 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Safety analysis</outcome_measure>
      <outcome_measure>HCV viral load</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00217139</url>
  </study>
  <study rank="720">
    <nct_id>NCT00292084</nct_id>
    <title>An Extension Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Celgosivir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>BioWest Therapeutics Inc</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HCV-05-004</other_id>
    </other_ids>
    <first_received>February 13, 2006</first_received>
    <start_date>February 2006</start_date>
    <completion_date>October 2007</completion_date>
    <last_updated>January 17, 2008</last_updated>
    <last_verified>January 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Safety analysis</outcome_measure>
      <outcome_measure>HCV viral load reduction from baseline</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00292084</url>
  </study>
  <study rank="721">
    <nct_id>NCT02452814</nct_id>
    <title>Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>8</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>NP29710</other_id>
    </other_ids>
    <first_received>May 11, 2015</first_received>
    <start_date>May 2014</start_date>
    <completion_date>May 2017</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants with adverse changes in liver ultrasound results</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02452814</url>
  </study>
  <study rank="722">
    <nct_id>NCT01441180</nct_id>
    <title>GS-7977 With Ribavirin for Hepatitis C (SPARE)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GS7977</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>110258</other_id>
      <other_id>11-I-0258</other_id>
    </other_ids>
    <first_received>September 24, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>September 25, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>April 23, 2014</firstreceived_results_date>
    <primary_completion_date>March 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Participants With Adverse Events</outcome_measure>
      <outcome_measure>Sustained Virologic Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01441180</url>
  </study>
  <study rank="723">
    <nct_id>NCT01938430</nct_id>
    <title>Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>339</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-0123</other_id>
    </other_ids>
    <first_received>September 5, 2013</first_received>
    <start_date>September 2013</start_date>
    <completion_date>March 2015</completion_date>
    <last_updated>November 4, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR12), defined as HCV RNA &lt; lower limit of quantitation (LLOQ) 12 weeks after last dose of study drug</outcome_measure>
      <outcome_measure>Proportion of participants who discontinue study drug due to an adverse event</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) at 2, 4, 8 and 24 weeks after discontinuation of therapy (SVR2, SVR4, SVR8 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants who have HCV RNA &lt; LLOQ by visit while on treatment</outcome_measure>
      <outcome_measure>HCV RNA levels and change from Day 1 through Week 8</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
      <outcome_measure>Change in model for end-stage liver disease (MELD) and Child-Pugh-Turcotte (CPT) scores</outcome_measure>
      <outcome_measure>Proportion of participants with post-transplant virologic response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Kansas</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01938430</url>
  </study>
  <study rank="724">
    <nct_id>NCT02010255</nct_id>
    <title>Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>334</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-0124</other_id>
      <other_id>2013-002802-30</other_id>
    </other_ids>
    <first_received>December 9, 2013</first_received>
    <start_date>January 2014</start_date>
    <completion_date>August 2015</completion_date>
    <last_updated>September 9, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after last dose of study drug (SVR12)</outcome_measure>
      <outcome_measure>Proportion of participants who discontinue study drug due to an adverse event</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) 2, 4, 8, and 24 weeks after last dose of study drug (SVR2, SVR4, SVR8 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants who have HCV RNA &lt; LLOQ by visit while on treatment</outcome_measure>
      <outcome_measure>HCV RNA levels and change from Day 1 through Week 8</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
      <outcome_measure>Change in model for end-stage liver disease (MELD) and Child-Pugh-Turcotte (CPT) scores</outcome_measure>
      <outcome_measure>Proportion of participants with post-transplant virologic response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Netherlands</country>
      <country>New Zealand</country>
      <country>Spain</country>
      <country>Switzerland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02010255</url>
  </study>
  <study rank="725">
    <nct_id>NCT00196664</nct_id>
    <title>Efficacy of Paroxetine in the Prevention of Depressive Syndrome in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alfa Plus Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Paroxetine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Agency for Research on AIDS and Viral Hepatitis</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>144</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>2004-004102-24</other_id>
      <other_id>ANRS HC18 PAROPEG</other_id>
    </other_ids>
    <first_received>September 13, 2005</first_received>
    <start_date>October 2005</start_date>
    <completion_date>February 2009</completion_date>
    <last_updated>May 12, 2009</last_updated>
    <last_verified>May 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Incidence of depression based on MINI International Neuropsychiatric Interview (MINI, DSM IV)from D0 to W74</outcome_measure>
      <outcome_measure>Evolution of depression score (MADRS and BDI scales) to W74,Quality of life (HQL questionnaire), Fatigue, Compliance to PEG-interferon and ribavirin, Virological response at W74 ,Safety</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00196664</url>
  </study>
  <study rank="726">
    <nct_id>NCT02309450</nct_id>
    <title>Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Genotype 4 Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">.Asunaprevir, Daclatasvir and BMS - 791325</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
      <collaborator>Bristol-Myers Squibb</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRSHC33QUATTROTURBO</other_id>
      <other_id>2014-002724-27</other_id>
    </other_ids>
    <first_received>October 31, 2014</first_received>
    <start_date>December 2014</start_date>
    <completion_date>August 2016</completion_date>
    <last_updated>December 3, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>QUATTROTURBO</acronym>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HCV sustained virological response rate</outcome_measure>
      <outcome_measure>Number of patients with adverse events</outcome_measure>
      <outcome_measure>Treatment interruptions</outcome_measure>
      <outcome_measure>Causes of treatment discontinuation</outcome_measure>
      <outcome_measure>Self-reported symptoms</outcome_measure>
      <outcome_measure>Patients adherence rate</outcome_measure>
      <outcome_measure>HCV viral load</outcome_measure>
      <outcome_measure>Evaluation of the relationship between HCV subtypic distribution at baseline (by sequencing of the HCV NS5B domain) and the virological kinetics and response</outcome_measure>
      <outcome_measure>Proportion of patients with resistance mutations to Asunaprevir and/or Daclatasvir and/or BMS in case of virological failure</outcome_measure>
      <outcome_measure>Child-Pugh score (composite measure)</outcome_measure>
      <outcome_measure>Insulin resistance measured using the HOMA-IR score</outcome_measure>
      <outcome_measure>Parameters that define metabolic syndrome</outcome_measure>
      <outcome_measure>Evolution of liver fibrosis</outcome_measure>
      <outcome_measure>MELD score (composite measure)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02309450</url>
  </study>
  <study rank="727">
    <nct_id>NCT01957319</nct_id>
    <title>Silybin Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin Reduces Depression and Increases Work Ability</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Work Ability</condition>
      <condition>Depression</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg</intervention>
      <intervention type="Drug">sugar pill</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Catania</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>72</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>12/1997</other_id>
    </other_ids>
    <first_received>September 25, 2013</first_received>
    <start_date>February 2010</start_date>
    <completion_date>July 2013</completion_date>
    <last_updated>September 30, 2013</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Work ability index</outcome_measure>
      <outcome_measure>depression</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01957319</url>
  </study>
  <study rank="728">
    <nct_id>NCT01567735</nct_id>
    <title>A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>107</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100695</other_id>
      <other_id>TMC435HPC3011</other_id>
      <other_id>2011-004097-29</other_id>
    </other_ids>
    <first_received>January 24, 2012</first_received>
    <start_date>March 2012</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>April 13, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>RESTORE</acronym>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants achieving sustained virologic response 12 weeks after planned end of treatment (SVR12)</outcome_measure>
      <outcome_measure>Efficacy of TMC435 with respect to proportion of participants achieving sustained virologic response 24 weeks after planned end of treatment (SVR24)</outcome_measure>
      <outcome_measure>On-treatment virologic response</outcome_measure>
      <outcome_measure>On-treatment virologic failure</outcome_measure>
      <outcome_measure>Evaluation of the viral breakthrough rate</outcome_measure>
      <outcome_measure>Evaluation of viral relapse rate</outcome_measure>
      <outcome_measure>Evaluation the safety and tolerability</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01567735</url>
  </study>
  <study rank="729">
    <nct_id>NCT01194037</nct_id>
    <title>A Phase 1b/2a, Open-label,Randomized, Safety, Tolerability, Dose Finding, PK/PD, and Preliminary Efficacy Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
      <condition>Genotype 1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">recombinant variant of interferon-alpha 2b</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>HanAll BioPharma Co., Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HL-143IFN-SC-US-001</other_id>
    </other_ids>
    <first_received>September 1, 2010</first_received>
    <start_date>June 2011</start_date>
    <completion_date>June 2012</completion_date>
    <last_updated>February 24, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HCV RNA level</outcome_measure>
      <outcome_measure>Proportion of patients who reach RVR</outcome_measure>
      <outcome_measure>PK &amp; PD</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01194037</url>
  </study>
  <study rank="730">
    <nct_id>NCT02063607</nct_id>
    <title>The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon lambda</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Nanogen Pharmaceutical Biotechnology Co., Ltd</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NNG01</other_id>
    </other_ids>
    <first_received>February 11, 2014</first_received>
    <start_date>December 2013</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>February 13, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Area Under the Concentration-Time Curve (AUC 0-336)</outcome_measure>
      <outcome_measure>Percentage of Patients achieving Rapid Virological Response (RVR)</outcome_measure>
      <outcome_measure>Number of subjects with incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Vietnam</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02063607</url>
  </study>
  <study rank="731">
    <nct_id>NCT01750216</nct_id>
    <title>An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>196</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML28344</other_id>
    </other_ids>
    <first_received>December 12, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>January 2015</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (SVR) rate, in relation to rapid virological response (RVR) in different stages of liver fibrosis in treatment-naïve patients with chronic hepatitis C genotype 1</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
      <outcome_measure>Sustained virological response (SVR) rate, in relation to early virological response (EVR) in different stages of liver fibrosis in treatment naïve patients with chronic hepatitis C genotype 1</outcome_measure>
      <outcome_measure>Response rates (RVR, EVR, SVR) according to host/virus/treatment-related factors in different stages of liver fibrosis (F&gt;/=3 and &lt;/=3)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Poland</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01750216</url>
  </study>
  <study rank="732">
    <nct_id>NCT01965535</nct_id>
    <title>Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">Placebo to match LDV/SOF</intervention>
      <intervention type="Drug">Placebo to match RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>155</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-0121</other_id>
      <other_id>2013-002296-17</other_id>
    </other_ids>
    <first_received>October 16, 2013</first_received>
    <start_date>October 2013</start_date>
    <completion_date>November 2014</completion_date>
    <last_updated>August 27, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>August 27, 2015</firstreceived_results_date>
    <primary_completion_date>August 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ (ie, &lt; 25 IU/mL) at Weeks 1, 2, 4, 8, 12, and 24</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Weeks 1, 2, 4, 8, and 12</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01965535</url>
  </study>
  <study rank="733">
    <nct_id>NCT01337375</nct_id>
    <title>A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa 2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>31</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML22936</other_id>
    </other_ids>
    <first_received>March 29, 2011</first_received>
    <start_date>March 2011</start_date>
    <completion_date>April 2012</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HCV RNA levels (IU/ml, COBAS TaqMan HCV Test) in correlation with area under the plasma concentration-time curve (AUC) after sc and iv administration</outcome_measure>
      <outcome_measure>Evaluation of predictors of response to i.v. treatment</outcome_measure>
      <outcome_measure>Effect of waist to hip ratio on pharmacokinetics</outcome_measure>
      <outcome_measure>Effect of waist to hip ratio on viral response</outcome_measure>
      <outcome_measure>Incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01337375</url>
  </study>
  <study rank="734">
    <nct_id>NCT01903278</nct_id>
    <title>Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis c</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG-IFN-SA /RBV</intervention>
      <intervention type="Drug">Pegasys /RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Beijing Kawin Technology Share-Holding Co., Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>719</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KAWIN-002-2</other_id>
    </other_ids>
    <first_received>July 17, 2013</first_received>
    <start_date>June 2013</start_date>
    <completion_date>August 2015</completion_date>
    <last_updated>September 24, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR (sustained virologic response)</outcome_measure>
      <outcome_measure>RVR(rapid virologic response)</outcome_measure>
      <outcome_measure>cEVR (complete early virologic response)</outcome_measure>
      <outcome_measure>ETVR( end of treatment virologic response)</outcome_measure>
      <outcome_measure>eRVR ( extended rapid virologic response)</outcome_measure>
      <outcome_measure>No-responses</outcome_measure>
      <outcome_measure>Breakthrough</outcome_measure>
      <outcome_measure>Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01903278</url>
  </study>
  <study rank="735">
    <nct_id>NCT01964742</nct_id>
    <title>Analysis of Host Genetic Factors in the Occurrence of Anemia and on the Virological Response to a Peg-interferon/Ribavirin Therapy in HIV-HCV Co-infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV-HCV Co-infected Patients</condition>
    </conditions>
    <interventions>
      <intervention type="Genetic">blood samples</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Assistance Publique Hopitaux De Marseille</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>68</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2013-A00505-40</other_id>
      <other_id>2013-12</other_id>
    </other_ids>
    <first_received>October 15, 2013</first_received>
    <start_date>October 2013</start_date>
    <completion_date>August 2015</completion_date>
    <last_updated>August 6, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>blood samples</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01964742</url>
  </study>
  <study rank="736">
    <nct_id>NCT00361179</nct_id>
    <title>Long Term Effects of Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/B Co-Infection and Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coinfection With Hepatitis B Virus and Hepatitis C Virus</condition>
      <condition>Monoinfection With Hepatitis C Virus</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>320</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Defined Population</study_design>
      <study_design>Observational Model: Natural History</study_design>
      <study_design>Time Perspective: Longitudinal</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>9561706020</other_id>
    </other_ids>
    <first_received>August 4, 2006</first_received>
    <start_date>May 2006</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>August 4, 2006</last_updated>
    <last_verified>August 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00361179</url>
  </study>
  <study rank="737">
    <nct_id>NCT01908335</nct_id>
    <title>A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG-IFN-SA /RBV low dose</intervention>
      <intervention type="Drug">PEG-IFN-SA /RBV middle dose</intervention>
      <intervention type="Drug">PEG-IFN-SA /RBV high dose</intervention>
      <intervention type="Drug">Pegasys /RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Beijing Kawin Technology Share-Holding Co., Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>212</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KAWIN-002-1</other_id>
    </other_ids>
    <first_received>July 23, 2013</first_received>
    <start_date>October 2012</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>October 16, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>cEVR (complete early virologic response)</outcome_measure>
      <outcome_measure>Proportion of patients who had undetectable plasma HCV RNA</outcome_measure>
      <outcome_measure>HCV RNA load reduction</outcome_measure>
      <outcome_measure>eRVR ( extended rapid virologic response)</outcome_measure>
      <outcome_measure>Breakthrough</outcome_measure>
      <outcome_measure>Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01908335</url>
  </study>
  <study rank="738">
    <nct_id>NCT01718145</nct_id>
    <title>A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Asunaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Biological">pegIFNα-2b</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>258</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI447-031</other_id>
    </other_ids>
    <first_received>October 29, 2012</first_received>
    <start_date>November 2012</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects with SVR12, defined as HCV RNA target detected or target not detected below LLOQ in the naive cohort</outcome_measure>
      <outcome_measure>Proportion of subjects with hemoglobin &lt; 10g/dL</outcome_measure>
      <outcome_measure>Proportion of subjects with rash-related dermatologic events</outcome_measure>
      <outcome_measure>Proportion of subjects with HCV RNA target detected or target not detected below LLOQ in the naive cohort</outcome_measure>
      <outcome_measure>Proportion of subjects with HCV RNA target not detected in the naive cohort</outcome_measure>
      <outcome_measure>Proportion of subjects with SVR12, defined as HCV RNA target detected or target not detected below LLOQ in the relapser cohort</outcome_measure>
      <outcome_measure>Proportion of subjects with HCV RNA target detected or target not detected below LLOQ in the relapser cohort</outcome_measure>
      <outcome_measure>Proportion of subjects with HCV RNA target not detected in the relapser cohort</outcome_measure>
      <outcome_measure>On treatment safety, as measured by the frequency of Severe adverse events (SAEs), discontinuation and dose modification/interruption due to Adverse events (AEs), Grade 3-4 abnormalities observed from clinical laboratory tests for each treatment group</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01718145</url>
  </study>
  <study rank="739">
    <nct_id>NCT02109744</nct_id>
    <title>Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Myelogenous Leukemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Decitabine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Rochester</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>48721</other_id>
      <other_id>ULEU13049</other_id>
    </other_ids>
    <first_received>October 14, 2013</first_received>
    <start_date>February 2014</start_date>
    <completion_date>December 2020</completion_date>
    <last_updated>April 6, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>AML</acronym>
    <primary_completion_date>December 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>change in blast percentage in the bone marrow</outcome_measure>
      <outcome_measure>change in blast percentage in peripheral blood</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02109744</url>
  </study>
  <study rank="740">
    <nct_id>NCT01579019</nct_id>
    <title>A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">RO5024048</intervention>
      <intervention type="Drug">RO5024048</intervention>
      <intervention type="Drug">danoprevir</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
      <intervention type="Drug">ritonavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV22877</other_id>
      <other_id>2010-022659-41</other_id>
    </other_ids>
    <first_received>April 16, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (defined as unquantifiable serum HCV RNA) 12 weeks after treatment (SVR-12)</outcome_measure>
      <outcome_measure>Sustained virologic response 4 weeks after treatment (SVR-4)</outcome_measure>
      <outcome_measure>Sustained virologic response 24 weeks after treatment (SVR-24)</outcome_measure>
      <outcome_measure>Change in serum HCV RNA levels</outcome_measure>
      <outcome_measure>Virologic response over time</outcome_measure>
      <outcome_measure>Correlation between trough concentrations of RO4995855 and virologic response</outcome_measure>
      <outcome_measure>Incidence of direct-acting antiviral (DAA) resistance, including re-emergence of protease inhibitor resistant virus</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01579019</url>
  </study>
  <study rank="741">
    <nct_id>NCT01025297</nct_id>
    <title>Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy Alone</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Interleukin-7</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Cytheris SA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CLI-107-07</other_id>
    </other_ids>
    <first_received>December 2, 2009</first_received>
    <start_date>July 2008</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>October 17, 2012</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>Eclipse 2</acronym>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate at W 12 the safety of biologically active doses of CYT107 added to a combination therapy by pegylated interferon-alpha and ribavirin</outcome_measure>
      <outcome_measure>To characterize pharmacokinetics and pharmacodynamics of CYT107</outcome_measure>
      <outcome_measure>To evaluate in the context of a dose escalation strategy the potential anti-viral effect of CYT107</outcome_measure>
      <outcome_measure>To evaluate the immune specific response to HCV</outcome_measure>
      <outcome_measure>To document the long-term safety and viral load variations</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
      <country>Italy</country>
      <country>Switzerland</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01025297</url>
  </study>
  <study rank="742">
    <nct_id>NCT01024894</nct_id>
    <title>Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in Asiatic HCV Patients Resistant to Bitherapy</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Interleukin-7</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Cytheris SA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CLI-107-09</other_id>
    </other_ids>
    <first_received>December 2, 2009</first_received>
    <start_date>January 2009</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>October 17, 2012</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ECLIPSE 3</acronym>
    <primary_completion_date>November 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>safety of biologically active doses of CYT107 added to a combination therapy by pegylated interferon-alpha and ribavirin in Asian patients with a chronic infection by a genotype 1 HCV not responding to this combination therapy</outcome_measure>
      <outcome_measure>Pharmacokinetics and pharmacodynamics of CYT107 in this patients population.</outcome_measure>
      <outcome_measure>potential anti-viral effect of CYT107</outcome_measure>
      <outcome_measure>long-term safety and viral load variations</outcome_measure>
      <outcome_measure>immune specific response to HCV</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01024894</url>
  </study>
  <study rank="743">
    <nct_id>NCT00774397</nct_id>
    <title>Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&amp;2)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BI 201335 NA 240 mg QD / LI</intervention>
      <intervention type="Drug">PegIFN/RBV</intervention>
      <intervention type="Drug">BI 201335 NA 120mg QD / LI</intervention>
      <intervention type="Drug">PegIFN/RBV</intervention>
      <intervention type="Drug">BI 201335 NA 240 mg QD</intervention>
      <intervention type="Drug">PegIFN/RBV</intervention>
      <intervention type="Drug">BI 201335 NA 240 mg QD</intervention>
      <intervention type="Drug">PegIFN/RBV</intervention>
      <intervention type="Drug">BI 201335 NA 240 mg BID</intervention>
      <intervention type="Drug">PegIFN/RBV</intervention>
      <intervention type="Drug">PegIFN/RBV</intervention>
      <intervention type="Drug">BI 201335 NA 240 mg QD</intervention>
      <intervention type="Drug">PegIFN/RBV</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>719</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>1220.5</other_id>
      <other_id>2008-003538-11</other_id>
    </other_ids>
    <first_received>October 16, 2008</first_received>
    <start_date>October 2008</start_date>
    <last_updated>October 14, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>July 3, 2015</firstreceived_results_date>
    <primary_completion_date>November 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Virological Response 4 Weeks After the End of Treatment With BI 201335 or Placebo</outcome_measure>
      <outcome_measure>Sustained Virological Response 24 Weeks (SVR24) After Completion of All Therapy</outcome_measure>
      <outcome_measure>Virological Response at Week 2</outcome_measure>
      <outcome_measure>Virological Response at Week 4</outcome_measure>
      <outcome_measure>Early Virological Response (EVR)</outcome_measure>
      <outcome_measure>Extended Rapid Virological Response (eRVR)</outcome_measure>
      <outcome_measure>Complete Early Virological Response (cEVR)</outcome_measure>
      <outcome_measure>End of Treatment Response at Week 24</outcome_measure>
      <outcome_measure>End of Treatment Response at End of All Therapy</outcome_measure>
      <outcome_measure>Sustained Virological Response 12 Weeks (SVR12) After Completion of All Therapy</outcome_measure>
      <outcome_measure>Time to Reach a Plasma HCV RNA Level Below the Lower Limit of Detection</outcome_measure>
      <outcome_measure>Time to Loss of Virological Response</outcome_measure>
      <outcome_measure>Virological Rebound</outcome_measure>
      <outcome_measure>Breakthrough on BI 201335/Placebo (Rebound While All 3 Treatments Were Still Ongoing)</outcome_measure>
      <outcome_measure>Breakthrough on PegIFN/RBV (Rebound While Only PegIFN/RBV Treatment Alone Was Still Ongoing)</outcome_measure>
      <outcome_measure>Relapse</outcome_measure>
      <outcome_measure>Change From Baseline to Week 24 in Diastolic Blood Pressure and Systolic Blood Pressure</outcome_measure>
      <outcome_measure>Change From Baseline to Week 24 in Pulse Rate</outcome_measure>
      <outcome_measure>Change From Baseline to Week 24 in Weight of the Patients</outcome_measure>
      <outcome_measure>Global Assessment of Tolerability</outcome_measure>
      <outcome_measure>Change From Baseline to Week 24 in Haemoglobin of the Patients</outcome_measure>
      <outcome_measure>Number of Patients [N(%)] With Transitions Relative to Reference Range for Laboratory Parameter Haemoglobin</outcome_measure>
      <outcome_measure>Change From Baseline to Week 24 in Absolute Neutrophils of the Patients</outcome_measure>
      <outcome_measure>Number of Patients [N(%)] With Transitions Relative to Reference Range for Laboratory Parameter Absolute Neutrophils</outcome_measure>
      <outcome_measure>Change From Baseline to Week 24 in ALT/GPT,SGPT of the Patients</outcome_measure>
      <outcome_measure>Number of Patients [N(%)] With Transitions Relative to Reference Range for Laboratory Parameter ALT/GPT,SGPT</outcome_measure>
      <outcome_measure>Change From Baseline to Week 24 in Total Bilirubin of the Patients</outcome_measure>
      <outcome_measure>Number of Patients [N(%)] With Transitions Relative to Reference Range for Laboratory Parameter Total Bilirubin</outcome_measure>
      <outcome_measure>Trough Concentration (Cpre,ss) of Faldaprevir at Steady State</outcome_measure>
      <outcome_measure>Trough Concentration (Cpre,ss) of Ribavirin at Steady State (Receiving 1000 mg/Day RBV)</outcome_measure>
      <outcome_measure>Trough Concentration (Cpre,ss) of Ribavirin at Steady State (Receiving 1200 mg/Day RBV)</outcome_measure>
      <outcome_measure>Trough Concentration (Cpre,ss) of PegIFN at Steady State</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>Czech Republic</country>
      <country>France</country>
      <country>Germany</country>
      <country>Korea, Republic of</country>
      <country>Netherlands</country>
      <country>Portugal</country>
      <country>Romania</country>
      <country>Spain</country>
      <country>Switzerland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00774397</url>
  </study>
  <study rank="744">
    <nct_id>NCT01925183</nct_id>
    <title>Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>HIV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alpha-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Markus Peck-Radosavljevic</lead_sponsor>
      <collaborator>Medical University of Vienna</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HIVCOBOC-RGT</other_id>
      <other_id>2012-005591-33</other_id>
    </other_ids>
    <first_received>August 15, 2013</first_received>
    <start_date>August 2013</start_date>
    <last_updated>August 16, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HIVCOBOC-RGT</acronym>
    <primary_completion_date>May 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (SVR12)</outcome_measure>
      <outcome_measure>Adverse events (AEs) and severe adverse events (SAEs)</outcome_measure>
      <outcome_measure>Sustained virologic response (SVR24)</outcome_measure>
      <outcome_measure>Anemia</outcome_measure>
      <outcome_measure>Thrombocytopenia</outcome_measure>
      <outcome_measure>Neutropenia</outcome_measure>
      <outcome_measure>Erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) analogues use</outcome_measure>
      <outcome_measure>Treatment discontinuation due to AEs</outcome_measure>
      <outcome_measure>Drop-outs</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01925183</url>
  </study>
  <study rank="745">
    <nct_id>NCT02064049</nct_id>
    <title>Surveillance and Treatment of Prisoners With Hepatitis C</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kirby Institute</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>650</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VHCRP1302</other_id>
    </other_ids>
    <first_received>February 12, 2014</first_received>
    <start_date>October 2014</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>August 31, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>SToP-C</acronym>
    <primary_completion_date>December 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Hepatitis C virus (HCV) incidence</outcome_measure>
      <outcome_measure>Hepatitis C virus prevalence</outcome_measure>
      <outcome_measure>SVR12</outcome_measure>
      <outcome_measure>ETR</outcome_measure>
      <outcome_measure>Rapid Virological Response (RVR)</outcome_measure>
      <outcome_measure>Very rapid virological response (vRVR)</outcome_measure>
      <outcome_measure>Treatment adherence</outcome_measure>
      <outcome_measure>Number of patients with adverse events</outcome_measure>
      <outcome_measure>Treatment uptake</outcome_measure>
      <outcome_measure>On-treatment change in illicit drug use</outcome_measure>
      <outcome_measure>HCV reinfection rate</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02064049</url>
  </study>
  <study rank="746">
    <nct_id>NCT01581398</nct_id>
    <title>Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ypeginterferon alfa-2b</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">Ypeginterferon alfa-2b</intervention>
      <intervention type="Drug">Pegasys</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Xiamen Amoytop Biotech Co., Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>770</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TB1203IFN</other_id>
    </other_ids>
    <first_received>February 16, 2012</first_received>
    <start_date>April 2012</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>October 6, 2014</last_updated>
    <last_verified>April 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients with sustained virologic response (defined as HCV RNA&lt;15IU/ml at 24 weeks after the end of therapy)</outcome_measure>
      <outcome_measure>Proportion of patients with HCV RNA undetectable (defined as HCV RNA &lt;15IU/ml)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01581398</url>
  </study>
  <study rank="747">
    <nct_id>NCT00519792</nct_id>
    <title>Phase 1b Study of Omega DUROS® in Patients With Chronic Hepatitis C Who Relapsed After Prior Treatment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Omega DUROS device</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Intarcia Therapeutics</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ITCA 638-CLP-08</other_id>
    </other_ids>
    <first_received>August 21, 2007</first_received>
    <start_date>August 2007</start_date>
    <completion_date>March 2010</completion_date>
    <last_updated>June 6, 2011</last_updated>
    <last_verified>June 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00519792</url>
  </study>
  <study rank="748">
    <nct_id>NCT01854697</nct_id>
    <title>A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450/r/ABT-267</intervention>
      <intervention type="Drug">ABT-333</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Pegylated Interferon alpha 2-alpha (PegIFN)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>311</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M13-774</other_id>
      <other_id>2012-003754-84</other_id>
    </other_ids>
    <first_received>April 8, 2013</first_received>
    <start_date>March 2013</start_date>
    <completion_date>July 2015</completion_date>
    <last_updated>July 20, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>MALACHITE 1</acronym>
    <primary_completion_date>November 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The percentage of all dosed subjects with sustained virologic response following the last actual dose of study drug.</outcome_measure>
      <outcome_measure>Change in general health-related quality of life using the Short-Form 36 Version 2 health status survey (SF-36V2) Mental Component Summary (MCS)</outcome_measure>
      <outcome_measure>Change in general health-related quality of life using the SF-36V2 Physical Component Summary (PCS) scores</outcome_measure>
      <outcome_measure>Percentage of subjects with sustained virologic response 12 weeks post-treatment</outcome_measure>
      <outcome_measure>Percentage of subjects with virologic failures during treatment</outcome_measure>
      <outcome_measure>Percentage of subjects with post-treatment relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Chile</country>
      <country>Finland</country>
      <country>Hungary</country>
      <country>Norway</country>
      <country>Poland</country>
      <country>Romania</country>
      <country>Slovakia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01854697</url>
  </study>
  <study rank="749">
    <nct_id>NCT02216422</nct_id>
    <title>A Study to Evaluate Chronic Hepatitis C Infection in Cirrhotic Adults With Genotype 1b Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450/r/ABT-267</intervention>
      <intervention type="Drug">ABT-333</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M14-252</other_id>
    </other_ids>
    <first_received>August 12, 2014</first_received>
    <start_date>September 2014</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>October 3, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>Turquoise-IV</acronym>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of subjects with sustained virologic response 12 weeks post-treatment</outcome_measure>
      <outcome_measure>Percentage of subjects with virologic failure during treatment</outcome_measure>
      <outcome_measure>Percentage of subjects with virologic relapse after treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belarus</country>
      <country>Russian Federation</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02216422</url>
  </study>
  <study rank="750">
    <nct_id>NCT00192569</nct_id>
    <title>Australian Trial in Acute Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon alfa 2a</intervention>
      <intervention type="Drug">Ribavirin (HIV conifected patients only)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kirby Institute</lead_sponsor>
      <collaborator>The University of New South Wales</collaborator>
      <collaborator>National Institutes of Health (NIH)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>167</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1R01DA015999-01</other_id>
      <other_id>ATAHC</other_id>
    </other_ids>
    <first_received>September 11, 2005</first_received>
    <start_date>July 2004</start_date>
    <completion_date>June 2010</completion_date>
    <last_updated>April 13, 2011</last_updated>
    <last_verified>October 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy of peg-interferon alpha 2a (and ribavirin for HIV/HCV coifection)</outcome_measure>
      <outcome_measure>Natural history of acute hepatitis C</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00192569</url>
  </study>
  <study rank="751">
    <nct_id>NCT00938860</nct_id>
    <title>Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Liver Transplantation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">cyclosporin (Neoral)</intervention>
      <intervention type="Drug">tacrolimus (Prograf)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>92</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>COLO400A2430</other_id>
      <other_id>2009-010806-12</other_id>
    </other_ids>
    <first_received>July 13, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>May 5, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>April 25, 2014</firstreceived_results_date>
    <acronym>SUSTAIN</acronym>
    <primary_completion_date>May 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Sustained Virological Response (SVR) Following Treatment of Hepatitis C Virus (HCV) Infection With Peg-IFN and Ribavirin in Liver Transplanted Recipients on Maintenance Therapy With Neoral or Tacrolimus</outcome_measure>
      <outcome_measure>Number of Events of the Composite Endpoint of Biopsy Proven Acute Rejections (BPAR), Death or Graft Loss and of the Individual Components</outcome_measure>
      <outcome_measure>Number of Participants With Fibrosis Progression (Increase in Ishak-Knodell (IK) Score by at Least One Point From the Baseline)</outcome_measure>
      <outcome_measure>Number of Participants of Rapid Viral Response (RVR)</outcome_measure>
      <outcome_measure>Number of Participants of Early Viral Response (EVR)</outcome_measure>
      <outcome_measure>Number of Participants for the End of Treatment Response (ETR)</outcome_measure>
      <outcome_measure>Number of Participants of True Non-responder Rate</outcome_measure>
      <outcome_measure>Number of Participants for Relapse Rate</outcome_measure>
      <outcome_measure>Number of Participants With Dose Reduction or Discontinuation of Antiviral (AV) Therapy Due to Poor Tolerability at Any Time During the Study for Any Reason</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>Colombia</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Korea, Republic of</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Switzerland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Florida</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Texas</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00938860</url>
  </study>
  <study rank="752">
    <nct_id>NCT01973855</nct_id>
    <title>Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Viral Haemorrhagic Fever</condition>
      <condition>Dengue Fever</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Western Medicine</intervention>
      <intervention type="Drug">TCM and Western Medicine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Guangzhou 8th People's Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Bio-availability Study</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2012ZX10004301-003</other_id>
    </other_ids>
    <first_received>October 24, 2013</first_received>
    <start_date>January 2012</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>October 31, 2013</last_updated>
    <last_verified>October 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Safety outcome</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01973855</url>
  </study>
  <study rank="753">
    <nct_id>NCT01884402</nct_id>
    <title>Observational,Prospective Study to Develop and Validate a Prognostic Tool to Optimize Therapy in Patients With HCV G1/4</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>770</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>FPS-PEG-2010-01</other_id>
    </other_ids>
    <first_received>June 18, 2013</first_received>
    <start_date>October 2010</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>September 3, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>OPTIM</acronym>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Viral Response (RVS)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01884402</url>
  </study>
  <study rank="754">
    <nct_id>NCT01900886</nct_id>
    <title>Epidemiological Study to Evaluate Personality Disorders in Prison Populations in Treatment for Hepatitis C</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Personality Disorders in Prison</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Grupo de Enfermedades Infecciosas de la Sociedad Española de Sanidad Penitenciaria</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>263</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>GEI-HCC-2010-01</other_id>
    </other_ids>
    <first_received>July 8, 2013</first_received>
    <start_date>December 2010</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>July 12, 2013</last_updated>
    <last_verified>December 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>Perseo</acronym>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Viral Response (SVR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01900886</url>
  </study>
  <study rank="755">
    <nct_id>NCT00317746</nct_id>
    <title>Trial of Citalopram for the Prevention of Depression</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Depression</condition>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Citalopram</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Marina Klein</lead_sponsor>
      <collaborator>Ontario HIV Treatment Network</collaborator>
      <collaborator>Schering-Plough</collaborator>
      <collaborator>CIHR Canadian HIV Trials Network</collaborator>
      <collaborator>McGill University Health Center</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>76</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CTN194</other_id>
      <other_id>Schering #2229</other_id>
    </other_ids>
    <first_received>April 21, 2006</first_received>
    <start_date>November 2006</start_date>
    <completion_date>March 2012</completion_date>
    <last_updated>April 4, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PICCO</acronym>
    <primary_completion_date>March 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary outcome is the average proportion of PEG-IFN and ribavirin doses received in participants receiving citalopram compared with placebo</outcome_measure>
      <outcome_measure>A second major objective is to compare arms with respect to the rate of moderate-to-severe depressive symptoms during the first 24 weeks of therapy.</outcome_measure>
      <outcome_measure>Secondary measures will assess impact of citalopram versus placebo on anxiety, neurocognitive function, quality of life and adherence to therapy. HCV and HIV control will also be examined.</outcome_measure>
      <outcome_measure>Substudies aimed at understanding the pathogenesis of neuropsychiatric side effects and neurocognitive function in this population will be performed.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00317746</url>
  </study>
  <study rank="756">
    <nct_id>NCT00720434</nct_id>
    <title>A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PF-00868554</intervention>
      <intervention type="Drug">PF-00868554</intervention>
      <intervention type="Drug">PF-00868554</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>35</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>A8121007</other_id>
    </other_ids>
    <first_received>July 18, 2008</first_received>
    <start_date>August 2008</start_date>
    <completion_date>March 2010</completion_date>
    <last_updated>June 18, 2013</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>June 18, 2013</firstreceived_results_date>
    <primary_completion_date>March 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in Plasma Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 4 - Full Analysis Set</outcome_measure>
      <outcome_measure>Change From Baseline in Plasma Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 4 - Modified Analysis Set</outcome_measure>
      <outcome_measure>Proportion of Participants Achieving Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>Alanine Aminotransferase (ALT) Levels</outcome_measure>
      <outcome_measure>Population Pharmacokinetics (PK) of PF-00868554</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Massachusetts</state>
      <state>New York</state>
      <state>Oklahoma</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00720434</url>
  </study>
  <study rank="757">
    <nct_id>NCT00996216</nct_id>
    <title>Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Eltrombopag</intervention>
      <intervention type="Drug">Antiviral therapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>27</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>108392</other_id>
    </other_ids>
    <first_received>October 1, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>February 2013</completion_date>
    <last_updated>October 10, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>October 10, 2013</firstreceived_results_date>
    <acronym>ENABLE-ALL</acronym>
    <primary_completion_date>February 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) in Part 1</outcome_measure>
      <outcome_measure>Number of Participants With Any AE and Any SAE in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Worst-case Division of Acquired Immune Deficiency Syndrome (DAIDS) Grade Increases From Screening for the Indicated Clinical Chemistry Parameters During Part 1</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Worst-case DAIDS Grade Increases From the Antiviral Baseline Visit for the Indicated Clinical Chemistry Parameter During Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Worst-case DAIDS Grade Increases From Screening for the Indicated Hematology Parameters During Part 1</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Worst-case DAIDS Grade Increases From the Antiviral Baseline Visit for the Indicated Hematology Parameters During Part 2</outcome_measure>
      <outcome_measure>Number of Participants With a Decrease in Visual Acuity During Parts 1 and 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Change in logMAR Scale Values During Parts 1 and 2</outcome_measure>
      <outcome_measure>Number of Participants With a logMAR Change &gt;=0.15 During Parts 1 and 2</outcome_measure>
      <outcome_measure>Platelet Counts at the Indicated Time Points</outcome_measure>
      <outcome_measure>Number of Particpants Who Initiated Antiviral Therapy</outcome_measure>
      <outcome_measure>Number of Participants Achieving Antiviral Treatment Milestones of Sustained Virological Response (SVR), Rapid Virological Response (RVR), Early Virological Response (EVR), and End of Treatment Response (ETR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>France</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>Italy</country>
      <country>Pakistan</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Connecticut</state>
      <state>Hawaii</state>
      <state>New York</state>
      <state>Tennessee</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00996216</url>
  </study>
  <study rank="758">
    <nct_id>NCT00987337</nct_id>
    <title>Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Filibuvir</intervention>
      <intervention type="Drug">Filibuvir</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>288</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>A8121014</other_id>
    </other_ids>
    <first_received>September 29, 2009</first_received>
    <start_date>November 2009</start_date>
    <completion_date>January 2012</completion_date>
    <last_updated>December 10, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>December 10, 2013</firstreceived_results_date>
    <acronym>FITNESS</acronym>
    <primary_completion_date>January 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Viral Response (SVR) at Week 72</outcome_measure>
      <outcome_measure>Percentage of Participants With Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 4, 12, 24 and 48</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Viral Response at 12 Weeks Following Completion of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Viral Response at 24 Weeks Following Completion of Therapy (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With Breakthrough Viremia</outcome_measure>
      <outcome_measure>Percentage of Participants With Relapsed Response</outcome_measure>
      <outcome_measure>Change From Baseline in Plasma Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 4, 12 and 24</outcome_measure>
      <outcome_measure>Number of Adverse Events (AEs) by Severity (All Causality)</outcome_measure>
      <outcome_measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Relationship to Study Drug (Any Therapy)</outcome_measure>
      <outcome_measure>Number of Participants Who Discontinued Study Due to Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Number of Participants With Dose Reduction or Temporary Discontinuation Due to Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Number of Participants With Laboratory Test Abnormalities by Severity</outcome_measure>
      <outcome_measure>Plasma Concentration of Filibuvir, Pegylated Interferon and Ribavirin</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Hungary</country>
      <country>Korea, Republic of</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Massachusetts</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00987337</url>
  </study>
  <study rank="759">
    <nct_id>NCT00959699</nct_id>
    <title>A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C</condition>
      <condition>HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PegIFN-2b</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">Placebo to Boceprevir</intervention>
      <intervention type="Drug">Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>99</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05411</other_id>
      <other_id>MK-3034-025</other_id>
    </other_ids>
    <first_received>July 29, 2009</first_received>
    <start_date>November 2009</start_date>
    <completion_date>October 2012</completion_date>
    <last_updated>September 4, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>May 8, 2013</firstreceived_results_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Viral Response (SVR) at Follow-up Week 24 (FW24) Among Randomized Participants Who Received At Least One Dose of Trial Medication</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR24 Among Randomized Participants Who Received At Least One Dose of Boceprevir (Experimental) or Placebo (Control)</outcome_measure>
      <outcome_measure>Percentage of Participants With Early Virologic Response (EVR) Who Achieved SVR24</outcome_measure>
      <outcome_measure>Percentage of Participants With Undetectable HCV-RNA at Follow-up Week 12 (FW12)</outcome_measure>
      <outcome_measure>Change From Baseline in log10 HCV-RNA at Treatment Week 4 (TW4)</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV Virologic Breakthrough or Incomplete Virologic Response/Rebound</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00959699</url>
  </study>
  <study rank="760">
    <nct_id>NCT02023112</nct_id>
    <title>Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450/r/ABT-267 plus Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>171</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M14-153</other_id>
    </other_ids>
    <first_received>December 23, 2013</first_received>
    <start_date>January 2014</start_date>
    <completion_date>September 2015</completion_date>
    <last_updated>October 10, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>GIFT II</acronym>
    <primary_completion_date>April 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of non-cirrhotic, treatment-naive subjects in each treatment group with a sustained virologic response 12 weeks post-treatment</outcome_measure>
      <outcome_measure>The percentage of subjects in each treatment arm with on-treatment virologic failure during the treatment period</outcome_measure>
      <outcome_measure>The percentage of subjects in each arm with post-treatment relapse</outcome_measure>
      <outcome_measure>The percentage of subjects with sustained virologic response 12 weeks post-treatment for each treatment arm within different subpopulations</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02023112</url>
  </study>
  <study rank="761">
    <nct_id>NCT01587586</nct_id>
    <title>Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With HCV Genotype 1 Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegasys</intervention>
      <intervention type="Biological">P1101, 48 doses</intervention>
      <intervention type="Biological">P1101, 24 doses</intervention>
      <intervention type="Biological">P1101, 12 doses</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>PharmaEssentia</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>208</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>A11-201</other_id>
    </other_ids>
    <first_received>April 26, 2012</first_received>
    <start_date>October 2011</start_date>
    <last_updated>April 27, 2012</last_updated>
    <last_verified>April 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01587586</url>
  </study>
  <study rank="762">
    <nct_id>NCT01250366</nct_id>
    <title>Study of the Safety &amp; PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV (Genotype 1)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">INX-08189</intervention>
      <intervention type="Drug">INX-08189</intervention>
      <intervention type="Drug">INX-08189</intervention>
      <intervention type="Drug">INX-08189</intervention>
      <intervention type="Drug">INX-08189</intervention>
      <intervention type="Drug">INX-08189</intervention>
      <intervention type="Drug">INX-08189</intervention>
      <intervention type="Drug">Placebo matching with INX-08189</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI472-002</other_id>
      <other_id>INH-189-002</other_id>
    </other_ids>
    <first_received>November 22, 2010</first_received>
    <start_date>October 2010</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>July 11, 2012</last_updated>
    <last_verified>July 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety will be evaluated in an integrated way on the basis of the Adverse Event profiles, changes in laboratory values (serum chemistry, hematology and urinalysis), ECG data, and vital signs, viral resistance testing and results of Physical Exams.</outcome_measure>
      <outcome_measure>PK parameters following administration of INX-08189 will be determined using concentration data obtained via the assay of INX-08189 and INX-08032 in plasma, and the analysis of INX-08032 in urine</outcome_measure>
      <outcome_measure>The primary efficacy outcome is the maximum change from baseline in HCV RNA following 7 days of dosing.</outcome_measure>
      <outcome_measure>Secondary efficacy outcome measures include the change in HCV RNA over time during the seven days of dosing and during the follow-up period thereafter. Additionally, viral load changes will be compared across the two genotypes 1a and 1b.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Minnesota</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01250366</url>
  </study>
  <study rank="763">
    <nct_id>NCT01485991</nct_id>
    <title>TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">TVR</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>771</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100677</other_id>
      <other_id>TMC435HPC3001</other_id>
    </other_ids>
    <first_received>November 25, 2011</first_received>
    <start_date>February 2012</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>April 9, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>March 27, 2015</firstreceived_results_date>
    <acronym>ATTAIN</acronym>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>Bulgaria</country>
      <country>Czech Republic</country>
      <country>Denmark</country>
      <country>France</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>Hungary</country>
      <country>Israel</country>
      <country>Norway</country>
      <country>Poland</country>
      <country>Portugal</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>Switzerland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>Montana</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01485991</url>
  </study>
  <study rank="764">
    <nct_id>NCT01958281</nct_id>
    <title>Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF 100 mg</intervention>
      <intervention type="Drug">SOF 400 mg</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">LDV/SOF</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>35</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0154</other_id>
      <other_id>2013-002897-30</other_id>
    </other_ids>
    <first_received>October 6, 2013</first_received>
    <start_date>October 2013</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>November 12, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of treatment (SVR12)</outcome_measure>
      <outcome_measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</outcome_measure>
      <outcome_measure>Plasma pharmacokinetics (PK) of sofosbuvir and its metabolites, and RBV, including AUCtau, Cmax, and Ctau</outcome_measure>
      <outcome_measure>Plasma pharmacokinetics (PK) of sofosbuvir and its metabolites, and RBV, including AUClast, Clast, Tmax, Tlast, λz, and t1/2</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response 4 and 24 weeks after discontinuation of treatment (SVR4 and SVR 24)</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>Germany</country>
      <country>Netherlands</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>Texas</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01958281</url>
  </study>
  <study rank="765">
    <nct_id>NCT00078403</nct_id>
    <title>Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C</condition>
      <condition>Liver Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>338</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>A5178</other_id>
      <other_id>10008</other_id>
    </other_ids>
    <first_received>February 24, 2004</first_received>
    <start_date>July 2004</start_date>
    <completion_date>February 2009</completion_date>
    <last_updated>August 13, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>November 5, 2010</firstreceived_results_date>
    <primary_completion_date>May 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Time-scaled Change in Metavir Liver Fibrosis Score (SCMFS)</outcome_measure>
      <outcome_measure>Number of Participants With Detectable HCV RNA Viral Load (&gt;= 60 IU/mL)</outcome_measure>
      <outcome_measure>Time-scaled Change in Ishak Liver Inflammation Score (SCIIS)</outcome_measure>
      <outcome_measure>Number of Participants With Anemia</outcome_measure>
      <outcome_measure>Number of Participants With Neutropenia</outcome_measure>
      <outcome_measure>Number of Participants With Thrombocytopenia</outcome_measure>
      <outcome_measure>Number of Participants With Depression and/or Other Psychological Events</outcome_measure>
      <outcome_measure>Other High-grade Signs and Symptoms and Laboratory Values</outcome_measure>
      <outcome_measure>Number of Participants With Dose Modifications, Temporary Stops, and Premature Treatment Discontinuations</outcome_measure>
      <outcome_measure>Symptom Distress</outcome_measure>
      <outcome_measure>Quality of Life</outcome_measure>
      <outcome_measure>Number of Participants Adherent to Study Medications</outcome_measure>
      <outcome_measure>HCV Polymorphisms</outcome_measure>
      <outcome_measure>HCV-specific Immune Response in Intrahepatic Lymphocytes</outcome_measure>
      <outcome_measure>Noninvasive Measures of Liver Fibrosis, Including Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Bilirubin, Albumin, and Protein Measurements</outcome_measure>
      <outcome_measure>Number of Participants With Undetectable HIV Viral Load (&lt;50 Copies/mL)</outcome_measure>
      <outcome_measure>Metabolic Parameters Including Insulin Resistance, Defined as Fasting Glucose, and Weight.</outcome_measure>
      <outcome_measure>Sustained Virologic Response</outcome_measure>
      <outcome_measure>Use of Antianorexia Agents, Such as Megestrol and Dronabinol</outcome_measure>
      <outcome_measure>Prescription as Needed of Erythropoietin (EPO), Granulocyte Colony-stimulating Factor (GCSF), and Granulocyte-monocyte Colony-stimulating Factor (GM-CSF)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>Nebraska</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00078403</url>
  </study>
  <study rank="766">
    <nct_id>NCT00561015</nct_id>
    <title>A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Peg-IFN-alfa-2a + Ribavirin (Standard Treatment)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec BVBA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>52</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR013513</other_id>
      <other_id>VX-950-TiDP24-C209</other_id>
    </other_ids>
    <first_received>November 19, 2007</first_received>
    <start_date>December 2007</start_date>
    <completion_date>May 2009</completion_date>
    <last_updated>June 7, 2013</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>March 8, 2013</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in Log 10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Level at Day 15</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) for Telaprevir on Day 1</outcome_measure>
      <outcome_measure>Time to Reach Maximum Plasma Concentration (Tmax) for Telaprevir on Day 1</outcome_measure>
      <outcome_measure>Area Under Plasma Concentration-Time Curve Over Dosing Interval (AUCtau) for Telaprevir on Day 1</outcome_measure>
      <outcome_measure>Area Under Plasma Concentration-Time Curve Over Dosing Interval (AUCtau) for Telaprevir on Day 15</outcome_measure>
      <outcome_measure>Change From Baseline in Log 10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Level at Week 24 and Week 26</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) for Telaprevir on Day 15</outcome_measure>
      <outcome_measure>Minimum Plasma Concentration (Cmin) for Telaprevir on Day 15</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Virological Response (HCV RNA Level &lt; 10 IU/ml)</outcome_measure>
      <outcome_measure>Median Time to Virological Response (HCV RNA Level &lt; 10 IU/ml)</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants Who Demonstrated Virological Relapse</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieved Sustained Virological Response (SVR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
      <country>Sweden</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00561015</url>
  </study>
  <study rank="767">
    <nct_id>NCT01850745</nct_id>
    <title>Multidisciplinary Support Program in Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Multidisciplinary support program</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Parc de Salut Mar</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>447</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
    </study_designs>
    <other_ids>
      <other_id>HMAR-MSP-CHC</other_id>
    </other_ids>
    <first_received>May 7, 2013</first_received>
    <start_date>January 2003</start_date>
    <completion_date>January 2010</completion_date>
    <last_updated>May 7, 2013</last_updated>
    <last_verified>May 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Adherence to treatment</outcome_measure>
      <outcome_measure>Efficacy of treatment measured by sustained virological response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01850745</url>
  </study>
  <study rank="768">
    <nct_id>NCT02060058</nct_id>
    <title>Boceprevir-based Therapy to Rescue HCV Genotype 1/HBV Infected Patients Refractory to Combination Therapy</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Stop trial intervention for boceprevir, PEG-IFN and RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kaohsiung Medical University Chung-Ho Memorial Hospital</lead_sponsor>
      <collaborator>National Taiwan University Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KMUHIRB-2013-10-03 (I)</other_id>
    </other_ids>
    <first_received>January 27, 2014</first_received>
    <start_date>November 2013</start_date>
    <completion_date>April 2016</completion_date>
    <last_updated>February 9, 2014</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>BOLERO-CB</acronym>
    <primary_completion_date>April 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Primary endpoint of this clinical trial-SVR and FAS for HCV RNA</outcome_measure>
      <outcome_measure>Key secondary endpoint of this clinical trial-SVR in mITT and HBV DNA surge</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02060058</url>
  </study>
  <study rank="769">
    <nct_id>NCT01995071</nct_id>
    <title>A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Hepatitis C Virus</condition>
      <condition>Compensated Cirrhosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-493</intervention>
      <intervention type="Drug">ABT-530</intervention>
      <intervention type="Drug">ABT-450/r/ABT-267</intervention>
      <intervention type="Drug">ABT-333</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>89</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M13-595</other_id>
    </other_ids>
    <first_received>November 21, 2013</first_received>
    <start_date>November 2013</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>June 25, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Maximal decrease in log10 hepatitis C virus ribonucleic acid levels from baseline</outcome_measure>
      <outcome_measure>The percentage of subjects with sustained virologic response 12 weeks post-treatment</outcome_measure>
      <outcome_measure>The percentage of subjects with on-treatment virologic failure during the treatment period</outcome_measure>
      <outcome_measure>The percentage of subjects with post-treatment relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01995071</url>
  </study>
  <study rank="770">
    <nct_id>NCT01200225</nct_id>
    <title>An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1155</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML22790</other_id>
    </other_ids>
    <first_received>September 10, 2010</first_received>
    <start_date>February 2010</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Effect of insulin resistance, defined as HOMA index &gt; 2, on sustained virological response (HCV RNA assessed by Polymerase Chain Reaction assay)</outcome_measure>
      <outcome_measure>Host-, virus- and treatment-related factors influencing virological response and sustained virological response</outcome_measure>
      <outcome_measure>Parameters of metabolic syndrome</outcome_measure>
      <outcome_measure>Management of insulin resistance</outcome_measure>
      <outcome_measure>Quality of life: Hepatitis Quality of Life Questionnaire (HQLQ)</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
      <outcome_measure>Patient characteristics</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01200225</url>
  </study>
  <study rank="771">
    <nct_id>NCT00897312</nct_id>
    <title>Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Melanoma</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">infliximab</intervention>
      <intervention type="Biological">pegylated interferon alfa</intervention>
      <intervention type="Biological">ticilimumab</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Other">high performance liquid chromatography</intervention>
      <intervention type="Other">laboratory biomarker analysis</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vanderbilt-Ingram Cancer Center</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>7</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>VICC MEL0651</other_id>
      <other_id>VU-VICC-MEL-0651</other_id>
      <other_id>VU-VICC-060614</other_id>
    </other_ids>
    <first_received>May 9, 2009</first_received>
    <start_date>August 2006</start_date>
    <completion_date>August 2008</completion_date>
    <last_updated>April 6, 2011</last_updated>
    <last_verified>April 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Systemic indoleamine 2, 3 dioxygenase levels in tissue at baseline and 3 to 4 weeks after treatment is initiated (timepoints for cancer and hepatitis patients)</outcome_measure>
      <outcome_measure>Serum TRP levels at baseline and at 3 to 4 weeks after treatment is initiated (timepoints for cancer and hepatitis patients)</outcome_measure>
      <outcome_measure>Serum KYN levels at baseline and at 3 to 4 weeks after treatment is initiated (timepoints for cancer and hepatitis patients)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00897312</url>
  </study>
  <study rank="772">
    <nct_id>NCT01641094</nct_id>
    <title>Effect of Teleprevir in Triple Therapy on Intrahepatic Immunological Mechanisms</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Foundation for Liver Research</lead_sponsor>
      <collaborator>Janssen-Cilag B.V.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ETIM</other_id>
    </other_ids>
    <first_received>July 12, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>March 10, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ETIM</acronym>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Determine functionality of immune cells in the liver and blood in chronic HCV patients before, during and after treatment with telaprevir, pegylated-IFN-a and ribavirin</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01641094</url>
  </study>
  <study rank="773">
    <nct_id>NCT00980161</nct_id>
    <title>Micro RNA-122 and the Clinical Course of Patients With Chronic Hepatitis C</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>National Science Council, Taiwan</collaborator>
      <collaborator>Department of Health, Executive Yuan, R.O.C. (Taiwan)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>200908039R</other_id>
    </other_ids>
    <first_received>September 16, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>March 25, 2010</last_updated>
    <last_verified>March 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Serum micro RNA-122 and sustained virologic response (SVR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00980161</url>
  </study>
  <study rank="774">
    <nct_id>NCT00249860</nct_id>
    <title>A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Interferon-beta-1a</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Ribavirin plus Interferon-beta-1a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>EMD Serono</lead_sponsor>
      <collaborator>Merck Pte. Ltd., Singapore</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>257</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>23744</other_id>
    </other_ids>
    <first_received>November 4, 2005</first_received>
    <start_date>September 2002</start_date>
    <completion_date>August 2005</completion_date>
    <last_updated>August 4, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2005</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of subjects achieving sustained viral response (SVR) at Week 24</outcome_measure>
      <outcome_measure>Percentage of subjects achieving sustained viral response (SVR) at Week 48</outcome_measure>
      <outcome_measure>Change from baseline in viral load (Hepatitis C virus ribonucleic acid [HCV RNA]) at Week 12, 24, and 48</outcome_measure>
      <outcome_measure>Percentage of subjects with Alanine transaminase (ALT) normalization</outcome_measure>
      <outcome_measure>Percentage of subjects with viral clearance</outcome_measure>
      <outcome_measure>Percentage of subjects with both SVR and sustained ALT normalization</outcome_measure>
      <outcome_measure>Number of subjects with improvement in the liver necroinflammation score by at least two points</outcome_measure>
      <outcome_measure>Number of subjects with improvement in architectural staging (liver fibrosis) by at least one point</outcome_measure>
      <outcome_measure>Number of subjects with adverse events and serious adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00249860</url>
  </study>
  <study rank="775">
    <nct_id>NCT00842205</nct_id>
    <title>Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic HCV Infection</condition>
      <condition>Nonalcoholic Steatohepatitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon</intervention>
      <intervention type="Drug">Ribavarin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Charles University, Czech Republic</lead_sponsor>
      <collaborator>IGA MZ, Czech Republic</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>IGA MZ CR NR9412-3</other_id>
    </other_ids>
    <first_received>February 11, 2009</first_received>
    <start_date>January 2007</start_date>
    <completion_date>December 2009</completion_date>
    <last_updated>February 11, 2009</last_updated>
    <last_verified>February 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>1. the relation between HO activity and basic virologic and histologic parameters in chronic HCV patients. 2. changes of HO activity within antiviral treatment 3. relation of HO gene polymorphisms to the course of disease</outcome_measure>
      <outcome_measure>Relation of HO gene polymorphisms and UGT1A1*28 polymorphism.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Czech Republic</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00842205</url>
  </study>
  <study rank="776">
    <nct_id>NCT00146016</nct_id>
    <title>Study on Chronic Hepatitis C Treatment With Interferon Alpha, Ribavirin and Amantadine in Naive Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Amantadine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UMC Utrecht</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>390</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>CIRA-study</other_id>
    </other_ids>
    <first_received>September 1, 2005</first_received>
    <start_date>February 2000</start_date>
    <completion_date>January 2007</completion_date>
    <last_updated>September 1, 2005</last_updated>
    <last_verified>September 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Response rate at end of treatment and end of follow-up (sustained response rate)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00146016</url>
  </study>
  <study rank="777">
    <nct_id>NCT01782495</nct_id>
    <title>A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450/r/ABT-267</intervention>
      <intervention type="Drug">ABT-333</intervention>
      <intervention type="Drug">ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>195</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M12-999</other_id>
      <other_id>2012-004792-39</other_id>
    </other_ids>
    <first_received>January 22, 2013</first_received>
    <start_date>February 2013</start_date>
    <completion_date>July 2017</completion_date>
    <last_updated>October 16, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>CORAL-I</acronym>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of subjects with sustained virologic response 12 weeks post-treatment</outcome_measure>
      <outcome_measure>Percentage of subjects with sustained virologic response 24 weeks post treatment</outcome_measure>
      <outcome_measure>Percentage of subjects with virologic failure during treatment</outcome_measure>
      <outcome_measure>Percentage of subjects with post-treatment relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>France</country>
      <country>Germany</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01782495</url>
  </study>
  <study rank="778">
    <nct_id>NCT00071916</nct_id>
    <title>Racial Difference in HCV/Host Interactions</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>260</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>00-091</other_id>
    </other_ids>
    <first_received>November 4, 2003</first_received>
    <start_date>March 2001</start_date>
    <completion_date>June 2010</completion_date>
    <last_updated>October 28, 2010</last_updated>
    <last_verified>March 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Determine if there is a difference in interferon-induced signaling between patients that respond to therapy and those that do not.</outcome_measure>
      <outcome_measure>Measure and compare the sustained virologic response to standard treatment for hepatitis C between African American (AA) and non AA patients.</outcome_measure>
      <outcome_measure>Determine how human leukocyte antigen (HLA) class II-dependent immune regulation and T cell specificities affect differences in immune responses to hepatitis C (HCV) and response to therapy in African American (AA) patients compared to non AA patients.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arkansas</state>
      <state>Tennessee</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00071916</url>
  </study>
  <study rank="779">
    <nct_id>NCT00370617</nct_id>
    <title>Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Insulin Resistance</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">metformin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Turin, Italy</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>METVIRAL</other_id>
    </other_ids>
    <first_received>August 30, 2006</first_received>
    <start_date>September 2006</start_date>
    <completion_date>January 2009</completion_date>
    <last_updated>November 13, 2006</last_updated>
    <last_verified>November 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Combined end-point of non-detectable serum HCV-RNA (&lt;100 copies/mL) and</outcome_measure>
      <outcome_measure>normal serum ALT activity at the end of the 24 week treatment-free follow up period</outcome_measure>
      <outcome_measure>End-of-treatment virological and biochemical response</outcome_measure>
      <outcome_measure>Sustained virological and biochemical response</outcome_measure>
      <outcome_measure>End-of-treatment improvement of insulin resistance</outcome_measure>
      <outcome_measure>End-of-treatment improvement of liver histology</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00370617</url>
  </study>
  <study rank="780">
    <nct_id>NCT01727934</nct_id>
    <title>Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Miravirsen sodium</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Santaris Pharma A/S</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>SPC3649-207</other_id>
    </other_ids>
    <first_received>November 12, 2012</first_received>
    <start_date>November 2012</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>January 3, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The proportion of subjects with sustained virological response 24 weeks after the end of therapy.</outcome_measure>
      <outcome_measure>The proportion of subjects with a sustained virological response 12 and 48 weeks after the end of therapy.</outcome_measure>
      <outcome_measure>The proportion of subjects with undetectable HCV RNA levels at the end of treatment.</outcome_measure>
      <outcome_measure>Change in HCV RNA levels from baseline throughout the study.</outcome_measure>
      <outcome_measure>The proportion of subjects who experience virological failure throughout the study.</outcome_measure>
      <outcome_measure>Safety will be assessed by evaluation of adverse events, physical examinations, vital signs, 12-lead ECGs, and laboratory assessments (clinical chemistry, hematology, urinalysis).</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01727934</url>
  </study>
  <study rank="781">
    <nct_id>NCT01585584</nct_id>
    <title>Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed Treatment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Calgary</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>MISP #39897</other_id>
      <other_id>24411</other_id>
    </other_ids>
    <first_received>April 18, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>July 2015</completion_date>
    <last_updated>August 22, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>August 22, 2015</firstreceived_results_date>
    <acronym>LeeG3</acronym>
    <primary_completion_date>December 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR) at 24 Weeks Post Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01585584</url>
  </study>
  <study rank="782">
    <nct_id>NCT02175966</nct_id>
    <title>Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DCV/ASV/BMS-791325</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Peginterferon α-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI443-131</other_id>
    </other_ids>
    <first_received>June 25, 2014</first_received>
    <start_date>July 2014</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>FOURward</acronym>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of treated subjects with SVR12, defined as HCV RNA &lt; LLOQ target detected or target not detected (LLOQ TD/TND) for each treatment arm</outcome_measure>
      <outcome_measure>On-treatment safety, as measured by frequency of deaths, SAEs, discontinuations due to AEs, and Grade 3/4 laboratory abnormalities (hematologic and liver function, based on DAIDs criteria) by each arm and overall</outcome_measure>
      <outcome_measure>Proportion of subjects in each arm who achieve HCV RNA &lt;LLOQ TD/TND</outcome_measure>
      <outcome_measure>Proportion of subjects in each arm who achieve HCV RNA &lt;LLOQ TND</outcome_measure>
      <outcome_measure>Proportion of subjects in each arm achieving SVR12 associated with HCV geno subtype 1a vs 1b</outcome_measure>
      <outcome_measure>Proportion of subjects in each arm achieving SVR12 associated with interleukin-28B (IL28B) rs12979860 SNP status (CC genotype or non-CC genotype)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02175966</url>
  </study>
  <study rank="783">
    <nct_id>NCT02582671</nct_id>
    <title>The Effectiveness of ABT-450/r - Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P15-702</other_id>
    </other_ids>
    <first_received>October 20, 2015</first_received>
    <start_date>November 2015</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>November 13, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>REACH</acronym>
    <primary_completion_date>December 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants achieving 12 Week sustained virologic response (SVR12)</outcome_measure>
      <outcome_measure>Percentage of patients with virological response at end of treatment (EOT)</outcome_measure>
      <outcome_measure>Percentage of participants with relapse at end of treatment (EoT)</outcome_measure>
      <outcome_measure>Percentage of participants who experienced breakthrough.</outcome_measure>
      <outcome_measure>Percentage of patients meeting any of the non-response categories of 12 Week sustained virologic response (SVR12)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Ireland</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02582671</url>
  </study>
  <study rank="784">
    <nct_id>NCT01980290</nct_id>
    <title>Telaprevir With Peginterferon Alfa &amp; Ribavirin in Ex-People Who INject Drugs Infected by Genotype 1 Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Janssen Pharmaceutica N.V., Belgium</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100966</other_id>
      <other_id>VX-950HPC4017</other_id>
    </other_ids>
    <first_received>November 4, 2013</first_received>
    <start_date>May 2013</start_date>
    <completion_date>February 2015</completion_date>
    <last_updated>March 6, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>INTEGRATE</acronym>
    <primary_completion_date>February 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response at 12 weeks (SVR12)</outcome_measure>
      <outcome_measure>adherence to telaprevir until Week 12</outcome_measure>
      <outcome_measure>adherence to PegIFN alfa and RBV</outcome_measure>
      <outcome_measure>on-treatment virologic response undetectable</outcome_measure>
      <outcome_measure>on treatment virologic response</outcome_measure>
      <outcome_measure>health-related quality of life based on EQ-5D</outcome_measure>
      <outcome_measure>Hospital Anxiety and Depression Scale (HADS)</outcome_measure>
      <outcome_measure>alcohol use disorders identification test (AUDIT)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Netherlands</country>
      <country>Switzerland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01980290</url>
  </study>
  <study rank="785">
    <nct_id>NCT00927290</nct_id>
    <title>Pioglitazone vs. Placebo in Association With Pegylated Interferon and Ribavirin in HCV Patients With Insulin Resistance</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Insulin Resistance</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pioglitazone</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Agency for Research on AIDS and Viral Hepatitis</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>2008-006225-14</other_id>
    </other_ids>
    <first_received>June 22, 2009</first_received>
    <start_date>December 2009</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>February 20, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PEGLIST C</acronym>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Decrease in the HOMA score below 2 after 4 months of treatment with pioglitazone or placebo(at W16). The efficiency is defined as a higher proportion of subjects with HOMA &lt;2 in the pioglitazone group than in the group treated with placebo pioglitazone.</outcome_measure>
      <outcome_measure>Kinetics of decrease in viral response to pegylated interferon. Early virological response rates. Rates of sustained virological response. Effect on steatosis</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00927290</url>
  </study>
  <study rank="786">
    <nct_id>NCT01579474</nct_id>
    <title>Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BI 201335 high dose</intervention>
      <intervention type="Drug">BI 201335 low dose</intervention>
      <intervention type="Drug">BI 201335 high dose</intervention>
      <intervention type="Drug">BI 201335 high dose</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>131</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>1220.54</other_id>
    </other_ids>
    <first_received>April 12, 2012</first_received>
    <start_date>April 2012</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>July 3, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>July 3, 2015</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Patients With Investigator Defined Drug-related Adverse Events</outcome_measure>
      <outcome_measure>Sustained Virological Response (SVR12), Defined as Plasma HCV RNA Undetectable at 12 Weeks After End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Sustained Virological Response (SVR24), Defined as Plasma HCV RNA Undetectable at 24 Weeks After End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Early Treatment Success (ETS), Defined as Plasma HCV RNA &lt;25 IU/mL at Week 4 and HCV RNA Undetectable at Week 8</outcome_measure>
      <outcome_measure>Alanine Aminotransferase (ALT) Normalisation: ALT in Normal Range at End of Treatment (EOT) When SVR12=YES</outcome_measure>
      <outcome_measure>Alanine Aminotransferase (ALT) Normalisation: ALT in Normal Range at End of Treatment (EOT) When SVR12= NO</outcome_measure>
      <outcome_measure>Alanine Aminotransferase (ALT) Normalisation: ALT in Normal Range at Sustained Virological Response 12 Weeks Post-treatment (SVR12) Visit, When SVR12=YES</outcome_measure>
      <outcome_measure>Alanine Aminotransferase (ALT) Normalisation: ALT in Normal Range at Sustained Virological Response 12 Weeks Post-treatment (SVR12) Visit, When SVR12=NO</outcome_measure>
      <outcome_measure>Aspartate Aminotransferase (AST) Normalisation: AST in Normal Range at End of Treatment (EOT) When SVR12=YES</outcome_measure>
      <outcome_measure>Aspartate Aminotransferase (AST) Normalisation: AST in Normal Range at End of Treatment (EOT) When SVR12=NO</outcome_measure>
      <outcome_measure>Aspartate Aminotransferase (AST) Normalisation: AST in Normal Range at Sustained Virological Response 12 Weeks Post-treatment (SVR12) Visit, When SVR12=YES</outcome_measure>
      <outcome_measure>Aspartate Aminotransferase (AST) Normalisation: AST in Normal Range at Sustained Virological Response 12 Weeks Post-treatment (SVR12) Visit, When SVR12=NO</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01579474</url>
  </study>
  <study rank="787">
    <nct_id>NCT02031133</nct_id>
    <title>Long-term Extension to Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Miravirsen</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Santaris Pharma A/S</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>SPC3649-207E</other_id>
    </other_ids>
    <first_received>January 7, 2014</first_received>
    <start_date>January 2014</start_date>
    <completion_date>January 2017</completion_date>
    <last_updated>November 17, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and tolerability will be assessed by evaluation of liver ultrasound, physical examinations, vital signs, and routine laboratory assessments (serum chemistry, hematology, coagulation, and urinalysis).</outcome_measure>
      <outcome_measure>Change in HCV RNA level from baseline through end of study.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02031133</url>
  </study>
  <study rank="788">
    <nct_id>NCT00723242</nct_id>
    <title>The Role of Dendritic Cells in Hepatitis C Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Viraferon-peg and Rebetol</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University College, London</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>unknown</other_id>
    </other_ids>
    <first_received>July 24, 2008</first_received>
    <start_date>April 2002</start_date>
    <completion_date>December 2004</completion_date>
    <last_updated>July 24, 2008</last_updated>
    <last_verified>July 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2004</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Basic science research (immunology of hepatitis C)in hepatitis c patients receiving established, standard antiviral treatment (pegylated Interferon+Ribavirin)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00723242</url>
  </study>
  <study rank="789">
    <nct_id>NCT01889433</nct_id>
    <title>An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Algeron</intervention>
      <intervention type="Drug">Pegasys</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Biocad</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>BCD-016-3</other_id>
    </other_ids>
    <first_received>June 26, 2013</first_received>
    <start_date>November 2013</start_date>
    <completion_date>November 2016</completion_date>
    <last_updated>November 12, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>EVR</outcome_measure>
      <outcome_measure>RVR</outcome_measure>
      <outcome_measure>SVR (24)</outcome_measure>
      <outcome_measure>EOT</outcome_measure>
      <outcome_measure>Biochemical Response</outcome_measure>
      <outcome_measure>Histological Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belarus</country>
      <country>India</country>
      <country>Russian Federation</country>
      <country>Thailand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01889433</url>
  </study>
  <study rank="790">
    <nct_id>NCT00148031</nct_id>
    <title>Improving Hepatitis C Treatment in Injection Drug Users</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Liver Diseases</condition>
      <condition>Drug Abuse</condition>
      <condition>Alcoholism</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon and Ribavirin</intervention>
      <intervention type="Behavioral">Psychosocial</intervention>
      <intervention type="Behavioral">On-site (MMT Clinic) HCV evaluation and treatment</intervention>
      <intervention type="Behavioral">Off-site HCV evaluation and treatment</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>State University of New York - Upstate Medical University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>111</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>SUNY UMU IRB # 4929</other_id>
      <other_id>R01DA016764</other_id>
    </other_ids>
    <first_received>September 2, 2005</first_received>
    <start_date>September 2003</start_date>
    <completion_date>March 2007</completion_date>
    <last_updated>April 23, 2013</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy of On-site versus Off-site delivery of HCV medical care for methadone maintenance treatment (MMT) patients, as evaluated by the proportion of patients achieving sustained virological response (SVR).</outcome_measure>
      <outcome_measure>psychiatric diagnoses and symptom severity</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00148031</url>
  </study>
  <study rank="791">
    <nct_id>NCT02339337</nct_id>
    <title>A Pilot Study To Evaluate the Efficacy of Response Guided Therapy of Peginterferon Alfa Plus Ribavirin in the Treatment of Patients With HCV/HBV Co-Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HBV/HCV Co-infection</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Abbreviation of treatment duration</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kaohsiung Medical University Chung-Ho Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>203</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KMUH-IRB-980019</other_id>
    </other_ids>
    <first_received>January 12, 2015</first_received>
    <start_date>June 2010</start_date>
    <last_updated>January 12, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Rate of HCV sustained virological response</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02339337</url>
  </study>
  <study rank="792">
    <nct_id>NCT01297270</nct_id>
    <title>Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BI201335</intervention>
      <intervention type="Drug">PegIFN/RBV</intervention>
      <intervention type="Drug">BI201335</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>658</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>1220.47</other_id>
      <other_id>2010-021716-42</other_id>
    </other_ids>
    <first_received>February 15, 2011</first_received>
    <start_date>April 2011</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>August 18, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>July 3, 2015</firstreceived_results_date>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response 12 Weeks Post Treatment (SVR12)</outcome_measure>
      <outcome_measure>Sustained Virologic Response 24 Weeks Post-treatment (SVR24)</outcome_measure>
      <outcome_measure>Early Treatment Success (ETS)</outcome_measure>
      <outcome_measure>ALT Normalisation: ALT in Normal Range at End of Treatment (EOT) When SVR12=YES</outcome_measure>
      <outcome_measure>ALT Normalisation: ALT in Normal Range at End of Treatment (EOT) When SVR12= NO</outcome_measure>
      <outcome_measure>ALT Normalisation: ALT in Normal Range 12 Weeks Post-treatment, When SVR12=YES</outcome_measure>
      <outcome_measure>ALT Normalisation: ALT in Normal Range 12 Weeks Post-treatment, When SVR12=NO</outcome_measure>
      <outcome_measure>AST Normalisation: AST in Normal Range at End of Treatment (EOT) When SVR12=YES</outcome_measure>
      <outcome_measure>AST Normalisation: AST in Normal Range at End of Treatment (EOT) When SVR12=NO</outcome_measure>
      <outcome_measure>AST Normalisation: AST in Normal Range 12 Weeks Post-treatment, When SVR12=YES</outcome_measure>
      <outcome_measure>AST Normalisation: AST in Normal Range 12 Weeks Post-treatment, When SVR12=NO</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Korea, Republic of</country>
      <country>Puerto Rico</country>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>Arkansas</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Mississippi</state>
      <state>Nevada</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Vermont</state>
      <state>Virginia</state>
      <state>Washington</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01297270</url>
  </study>
  <study rank="793">
    <nct_id>NCT02106156</nct_id>
    <title>Observational Study Evaluating the Quality of Pegasys and Copegus Treatment for Chronic Hepatitis C in Cooperation With the BNG (Association of German Resident Gastroenterologists)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>9729</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML21645</other_id>
    </other_ids>
    <first_received>April 3, 2014</first_received>
    <start_date>January 2008</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Rapid virologic response (RVR)</outcome_measure>
      <outcome_measure>Early virologic response (EVR)</outcome_measure>
      <outcome_measure>End of treatment response (EOT)</outcome_measure>
      <outcome_measure>Sustained virologic response (SVR)</outcome_measure>
      <outcome_measure>Incidence of severe adverse events</outcome_measure>
      <outcome_measure>Patient demographics</outcome_measure>
      <outcome_measure>Hepatitis C medical history</outcome_measure>
      <outcome_measure>Treatment/dosage data</outcome_measure>
      <outcome_measure>Viral genotype</outcome_measure>
      <outcome_measure>Viral load</outcome_measure>
      <outcome_measure>Concomitant treatment information (medication type, dosage)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02106156</url>
  </study>
  <study rank="794">
    <nct_id>NCT01343888</nct_id>
    <title>Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PegIFN/RBV</intervention>
      <intervention type="Drug">BI 201335</intervention>
      <intervention type="Drug">BI 201335</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>656</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>1220.30</other_id>
      <other_id>2010-021716-42</other_id>
    </other_ids>
    <first_received>April 20, 2011</first_received>
    <start_date>April 2011</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>August 18, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>July 3, 2015</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virological Response 12 Weeks Post-treatment (SVR12)</outcome_measure>
      <outcome_measure>Sustained Virological Response 24 Weeks Post-treatment (SVR24)</outcome_measure>
      <outcome_measure>Early Treatment Success (ETS)</outcome_measure>
      <outcome_measure>Alanine Aminotransferase (ALT) Normalisation: ALT in Normal Range at End of Treatment (EoT) When SVR12=YES</outcome_measure>
      <outcome_measure>Alanine Aminotransferase (ALT) Normalisation: ALT in Normal Range at End of Treatment (EoT) When SVR12= NO</outcome_measure>
      <outcome_measure>Alanine Aminotransferase (ALT) Normalisation: ALT in Normal Range at Sustained Virological Response 12 Weeks Post-treatment (SVR12) Visit, When SVR12=YES</outcome_measure>
      <outcome_measure>Alanine Aminotransferase (ALT) Normalisation: ALT in Normal Range at Sustained Virological Response 12 Weeks Post-treatment (SVR12) Visit, When SVR12=NO</outcome_measure>
      <outcome_measure>Aspartate Aminotransferase (AST) Normalisation: AST in Normal Range at End of Treatment (EoT) When SVR12=YES</outcome_measure>
      <outcome_measure>Aspartate Aminotransferase (AST) Normalisation: AST in Normal Range at End of Treatment (EoT) When SVR12=NO</outcome_measure>
      <outcome_measure>Aspartate Aminotransferase (AST) Normalisation: AST in Normal Range at Sustained Virological Response 12 Weeks Post-treatment (SVR12) Visit, When SVR12=YES</outcome_measure>
      <outcome_measure>Aspartate Aminotransferase (AST) Normalisation: AST in Normal Range at Sustained Virological Response 12 Weeks Post-treatment (SVR12) Visit, When SVR12=NO</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Japan</country>
      <country>Portugal</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Switzerland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01343888</url>
  </study>
  <study rank="795">
    <nct_id>NCT01464008</nct_id>
    <title>The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa-2a and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Beijing Ditan Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>297</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>DTH-XY001</other_id>
    </other_ids>
    <first_received>October 28, 2011</first_received>
    <start_date>January 2004</start_date>
    <completion_date>September 2011</completion_date>
    <last_updated>November 1, 2011</last_updated>
    <last_verified>October 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virus response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01464008</url>
  </study>
  <study rank="796">
    <nct_id>NCT01514890</nct_id>
    <title>French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>675</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRS CO20</other_id>
      <other_id>2010-A01273-36</other_id>
    </other_ids>
    <first_received>January 18, 2012</first_received>
    <start_date>February 2011</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>December 26, 2012</last_updated>
    <last_verified>December 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>CUPIC</acronym>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Rate of sustained virological response (SVR) defined by an undetectable RNA by real-time PCR.</outcome_measure>
      <outcome_measure>Virological response during and after the treatment with determination of HCV RNA levels as prevised by the French Early Access Program for the use of protease inhibitors and after the approval.</outcome_measure>
      <outcome_measure>early viral kinetic</outcome_measure>
      <outcome_measure>Rate of premature discontinuation of protease inhibitor, RBV and/or PEG-IFN</outcome_measure>
      <outcome_measure>occurrence of resistant mutants in partial responders (detectable RNA) or after the occurrence of virological breakthrough and long term evolution of these mutations (on serum bank)</outcome_measure>
      <outcome_measure>Evolution of quality of life scores</outcome_measure>
      <outcome_measure>Evaluation of therapeutic observance with auto-questionnaires</outcome_measure>
      <outcome_measure>Rate of adaptation of dosage of protease inhibitors, RBV and/or PEG-IFN</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01514890</url>
  </study>
  <study rank="797">
    <nct_id>NCT02472886</nct_id>
    <title>Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection.</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>153</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-1463</other_id>
      <other_id>2015-000690-13</other_id>
    </other_ids>
    <first_received>June 12, 2015</first_received>
    <start_date>June 2015</start_date>
    <completion_date>July 2016</completion_date>
    <last_updated>November 6, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of any adverse events leading to permanent discontinuation of study drug</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV RNA &lt; LLOQ on treatment</outcome_measure>
      <outcome_measure>HCV RNA change from Day 1</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
      <outcome_measure>Proportion of HIV/HCV coinfected participants that maintain HIV-1 RNA &lt; 50 copies/mL while on HCV treatment and at Posttreatment Week 4</outcome_measure>
      <outcome_measure>For HIV/HCV coinfected participants, change from baseline in CD4 T-cell count at the end of treatment and Posttreatment Week 4</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Estonia</country>
      <country>Russian Federation</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02472886</url>
  </study>
  <study rank="798">
    <nct_id>NCT00811967</nct_id>
    <title>Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Liver Cirrhosis</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b; SCH 54031)</intervention>
      <intervention type="Drug">Rebetol (ribavirin; SCH 18908)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P03811</other_id>
      <other_id>JPC-02-320-34</other_id>
    </other_ids>
    <first_received>December 18, 2008</first_received>
    <start_date>February 2003</start_date>
    <completion_date>May 2006</completion_date>
    <last_updated>April 9, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response rate, defined as the proportion of subjects with undetectable HCV-RNA at 24-week post-treatment follow-up</outcome_measure>
      <outcome_measure>Rate of subject with undetectable HCV-RNA at the end of treatment (or at discontinuation of treatment)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00811967</url>
  </study>
  <study rank="799">
    <nct_id>NCT02094443</nct_id>
    <title>Pharmacokinetics, Pharmacodynamics and Safety of DEB025/Alisporivir in Combination With Ribavirin Therapy in Chronic Hepatitis C Genotype 2 and 3 Patients Who Have Previously Failed Interferon Therapy or Are Intolerant or Unable to Take Interferon</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Liver Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DEB025 and RBV</intervention>
      <intervention type="Drug">DEB025 and RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>52</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CDEB025A2233</other_id>
      <other_id>2013-003751-38</other_id>
    </other_ids>
    <first_received>March 18, 2014</first_received>
    <start_date>March 2014</start_date>
    <completion_date>April 2015</completion_date>
    <last_updated>April 22, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ALtitude II</acronym>
    <primary_completion_date>April 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Difference in the level of Heptatis C virus decrease</outcome_measure>
      <outcome_measure>Difference in number of subjects with adverse events or with abnormal lab values</outcome_measure>
      <outcome_measure>Pharmacokinetic</outcome_measure>
      <outcome_measure>Sustained Virologic Response (SVR) 12</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Missouri</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02094443</url>
  </study>
  <study rank="800">
    <nct_id>NCT00655226</nct_id>
    <title>Prevention of Depression in HIV/HCV Co-infected Substance Abuse Patients</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Depressive Disorder, Major</condition>
      <condition>Depressive Disorder</condition>
      <condition>Depression</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Hepatitis C educational support groups</intervention>
      <intervention type="Behavioral">Cognitive Behavioral Therapy skills based group sessions</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Icahn School of Medicine at Mount Sinai</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>26</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GCO# 05-0961</other_id>
      <other_id>R21DA021531</other_id>
    </other_ids>
    <first_received>April 3, 2008</first_received>
    <start_date>March 2008</start_date>
    <completion_date>May 2010</completion_date>
    <last_updated>August 5, 2011</last_updated>
    <last_verified>August 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Depression measured by PHQ-9</outcome_measure>
      <outcome_measure>Depressive symptoms (measured by Beck Depression Inventory-II)</outcome_measure>
      <outcome_measure>medication adherence</outcome_measure>
      <outcome_measure>hepatitis C treatment completion</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00655226</url>
  </study>
  <study rank="801">
    <nct_id>NCT01756079</nct_id>
    <title>A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">boceprevir</intervention>
      <intervention type="Biological">PegIFN-2b</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>58</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>3034-105</other_id>
      <other_id>2012-002772-13</other_id>
    </other_ids>
    <first_received>December 19, 2012</first_received>
    <start_date>February 2013</start_date>
    <completion_date>November 2015</completion_date>
    <last_updated>November 29, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants who achieve sustained viral response (SVR) at 24 weeks after the end of all study treatment</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01756079</url>
  </study>
  <study rank="802">
    <nct_id>NCT01197157</nct_id>
    <title>Study of the Impact of Nitazoxanide on Chronic Hepatitis Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Nitazoxanide</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Liver Institute, Egypt</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEAR trial</other_id>
    </other_ids>
    <first_received>August 9, 2010</first_received>
    <start_date>September 2010</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>September 27, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Assessment of efficacy of Nitazoxanide as an add-on therapy in terms of achieving a sustained virologic response</outcome_measure>
      <outcome_measure>assessment of rapid virologic response</outcome_measure>
      <outcome_measure>Assessment of early virologic response</outcome_measure>
      <outcome_measure>Assessment of end-of-treatment response</outcome_measure>
      <outcome_measure>Safety of Nitazoxanide</outcome_measure>
      <outcome_measure>Assessment of the efficacy of Nitazoxanide monotherapy following the lead-in phase</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01197157</url>
  </study>
  <study rank="803">
    <nct_id>NCT00001547</nct_id>
    <title>Neuropsychiatric Effects of Interferon-Alpha and Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Mental Disorder</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>National Institute of Mental Health (NIMH)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs/>
    <other_ids>
      <other_id>960103</other_id>
      <other_id>96-M-0103</other_id>
    </other_ids>
    <first_received>November 3, 1999</first_received>
    <start_date>June 1996</start_date>
    <completion_date>June 2002</completion_date>
    <last_updated>March 3, 2008</last_updated>
    <last_verified>June 2002</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00001547</url>
  </study>
  <study rank="804">
    <nct_id>NCT01465516</nct_id>
    <title>Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Arrowhead Regional Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>105</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>38950</other_id>
    </other_ids>
    <first_received>November 2, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>June 27, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR based on intention to treat analysis</outcome_measure>
      <outcome_measure>Tolerance</outcome_measure>
      <outcome_measure>BDI II score 31 or above</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01465516</url>
  </study>
  <study rank="805">
    <nct_id>NCT01500616</nct_id>
    <title>Telaprevir Open-Label Study in Co-Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen-Cilag International NV</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>122</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR018787</other_id>
      <other_id>VX-950HPC3005</other_id>
      <other_id>2011-003593-85</other_id>
    </other_ids>
    <first_received>December 22, 2011</first_received>
    <start_date>June 2012</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>August 21, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Treatment-emergent Adverse Events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Germany</country>
      <country>Hungary</country>
      <country>Ireland</country>
      <country>Luxembourg</country>
      <country>Portugal</country>
      <country>Russian Federation</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01500616</url>
  </study>
  <study rank="806">
    <nct_id>NCT00216268</nct_id>
    <title>Treatment of Japanese Encephalitis</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Japanese Encephalitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Indian Council of Medical Research</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>5/8/7/1/13/2001-ECD1</other_id>
    </other_ids>
    <first_received>September 20, 2005</first_received>
    <start_date>July 2005</start_date>
    <completion_date>May 2008</completion_date>
    <last_updated>February 8, 2006</last_updated>
    <last_verified>September 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Mortality during hospital stay</outcome_measure>
      <outcome_measure>Sequelae at 3 months</outcome_measure>
      <outcome_measure>Duration of hospital stay</outcome_measure>
      <outcome_measure>Days to return to oral feeds</outcome_measure>
      <outcome_measure>Days to become convulsion free</outcome_measure>
      <outcome_measure>Days to become afebrile</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>India</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00216268</url>
  </study>
  <study rank="807">
    <nct_id>NCT01483742</nct_id>
    <title>A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">RO5024048</intervention>
      <intervention type="Drug">danoprevir</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">ritonavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>43</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NP27946</other_id>
      <other_id>2011-004129-28</other_id>
    </other_ids>
    <first_received>November 30, 2011</first_received>
    <start_date>April 2012</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>September 1, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
      <outcome_measure>Pharmacokinetics: Area under the concentration-time curve (AUC)</outcome_measure>
      <outcome_measure>Antiviral activity: HCV RNA levels assessed by Roche COBAS Taqman HCV Test</outcome_measure>
      <outcome_measure>Emergence of viral resistance: HCV RNA gene sequence variations</outcome_measure>
      <outcome_measure>Virologic response: HCV RNA levels</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>France</country>
      <country>New Zealand</country>
      <country>Poland</country>
      <country>Slovakia</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Louisiana</state>
      <state>Michigan</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01483742</url>
  </study>
  <study rank="808">
    <nct_id>NCT00593151</nct_id>
    <title>Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Locteron (controlled-release interferon alpha 2b)</intervention>
      <intervention type="Biological">pegylated IFNa2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Biolex Therapeutics, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>S07-200-02-003</other_id>
    </other_ids>
    <first_received>January 2, 2008</first_received>
    <start_date>January 2008</start_date>
    <completion_date>March 2009</completion_date>
    <last_updated>February 1, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PLUS</acronym>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To assess in subjects with chronic hepatitis C the safety and tolerability of Locteron in comparison with PEG-Intron.</outcome_measure>
      <outcome_measure>To assess in subjects with chronic hepatitis C receiving a weight-based oral daily dose of ribavirin: • The PK profile of Locteron (IFNa2b) • The preliminary efficacy of Locteron assessed by serial quantitation of HCV RNA levels</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Michigan</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00593151</url>
  </study>
  <study rank="809">
    <nct_id>NCT00211848</nct_id>
    <title>Antiviral &amp; Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Polyenylphosphatidylcholine (PPC)</intervention>
      <intervention type="Drug">Pegylated Interferon</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Icahn School of Medicine at Mount Sinai</lead_sponsor>
      <collaborator>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</collaborator>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>207</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>AA12867</other_id>
      <other_id>99-1097</other_id>
    </other_ids>
    <first_received>September 13, 2005</first_received>
    <start_date>June 2000</start_date>
    <completion_date>December 2005</completion_date>
    <last_updated>April 27, 2007</last_updated>
    <last_verified>April 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>To evaluate the effect of a combined antiviral, antifibrotic and antioxidant treatment on the progression of liver disease in patients with hepatitis C who abstain from alcohol or consume it.</outcome_measure>
      <outcome_measure>To validate the reliability of various circulating markers as substitute for liver biopsies to indicate the stage of liver pathology and its propensity for progression.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00211848</url>
  </study>
  <study rank="810">
    <nct_id>NCT00209898</nct_id>
    <title>Hepatitis C Treatment of Inmates</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Fast initiation procedure</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Haukeland University Hospital</lead_sponsor>
      <collaborator>Bergen Prison, Norwegian correctional service</collaborator>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>42</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>12952</other_id>
    </other_ids>
    <first_received>September 13, 2005</first_received>
    <start_date>August 2003</start_date>
    <completion_date>January 2009</completion_date>
    <last_updated>March 19, 2015</last_updated>
    <last_verified>June 2003</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PEGPRI</acronym>
    <primary_completion_date>January 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>- adherence</outcome_measure>
      <outcome_measure>- Sustained virologic response rates defined as percentage of patients with non-detectable HCV-RNA as measured by Roche AMPLICOR HCV Test, v2.0 (&gt;50 IU/mL).</outcome_measure>
      <outcome_measure>Percentage of patients with non-detectable HCV-RNA at study week 12, 24 and 48 as measured by Roche AMPLICOR HCV Test v2.0 (&lt;50 IU/mL).</outcome_measure>
      <outcome_measure>- adverse event rate and profile</outcome_measure>
      <outcome_measure>- Hemoglobin</outcome_measure>
      <outcome_measure>- Other laboratory tests</outcome_measure>
      <outcome_measure>- Medical Outcomes Study 36 Item Short Form health Survey (SF-36)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Norway</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00209898</url>
  </study>
  <study rank="811">
    <nct_id>NCT01058512</nct_id>
    <title>A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">NOV-205</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Cellectar Biosciences, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NOV205-C201</other_id>
    </other_ids>
    <first_received>January 26, 2010</first_received>
    <start_date>March 2010</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>July 9, 2013</last_updated>
    <last_verified>January 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>NOV-205</acronym>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate changes in viral load</outcome_measure>
      <outcome_measure>To evaluate changes in serum ALT and AST levels</outcome_measure>
      <outcome_measure>To evaluate the durability of any changes in viral load and serum ALT and AST</outcome_measure>
      <outcome_measure>To establish the safety profile of NOV-205</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Florida</state>
      <state>Massachusetts</state>
      <state>North Carolina</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01058512</url>
  </study>
  <study rank="812">
    <nct_id>NCT00363259</nct_id>
    <title>Pegintron Induction Therapy in HCV Non-Responders</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Foundation for Liver Research</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>110</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HCV01-01</other_id>
    </other_ids>
    <first_received>August 10, 2006</first_received>
    <start_date>July 2002</start_date>
    <completion_date>November 2005</completion_date>
    <last_updated>August 10, 2006</last_updated>
    <last_verified>August 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>sustained virological response (HCV-RNA negative 24 weeks after end of treatment)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00363259</url>
  </study>
  <study rank="813">
    <nct_id>NCT01563536</nct_id>
    <title>Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-267</intervention>
      <intervention type="Drug">ABT-450</intervention>
      <intervention type="Drug">ABT-333</intervention>
      <intervention type="Drug">Ritonavir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie (prior sponsor, Abbott)</lead_sponsor>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M13-386</other_id>
    </other_ids>
    <first_received>January 27, 2012</first_received>
    <start_date>February 2012</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>December 29, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>December 29, 2014</firstreceived_results_date>
    <primary_completion_date>April 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of ABT-267 Following Monotherapy on Day 1</outcome_measure>
      <outcome_measure>Time of Maximum Plasma Concentration (Tmax) of ABT-267 Following Monotherapy on Day 1</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC[24]) of ABT-267 Following Monotherapy on Day 1</outcome_measure>
      <outcome_measure>Plasma Concentration of ABT-267 Pre-dose (Ctrough) on Day 2 and Day 3</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Mean Maximal Decrease From Baseline in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During ABT-267 Monotherapy</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks and 24 Weeks After Combination Therapy</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Virologic Response</outcome_measure>
      <outcome_measure>Percentage of Participants With End-of-Treatment Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Extended Rapid Virologic Response</outcome_measure>
      <outcome_measure>Mean Change in Viral Load From Baseline to Pre-dose on Day 2 and Day 3 of ABT-267 Monotherapy</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01563536</url>
  </study>
  <study rank="814">
    <nct_id>NCT01025596</nct_id>
    <title>Dose Escalation Study of IL-7 and Bi-therapy in HCV Patients Resistant After 12 Weeks of Bi-therapy (ECLIPSE 1)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Interleukin-7</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Cytheris SA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CLI-107-05</other_id>
      <other_id>EudraCT number 2006-006024-20</other_id>
    </other_ids>
    <first_received>December 1, 2009</first_received>
    <start_date>May 2007</start_date>
    <completion_date>March 2012</completion_date>
    <last_updated>October 17, 2012</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ECLIPSE 1</acronym>
    <primary_completion_date>February 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety of biologically active doses of CYT107 added to a standard bi-therapy in patients with a chronic infection by a genotype 1 Hepatitis C Virus (HCV) not responding to this combination therapy 12 weeks after its initiation.</outcome_measure>
      <outcome_measure>Pharmacokinetics and pharmacodynamics of CYT107 in this patients population.</outcome_measure>
      <outcome_measure>potential anti-viral effect of CYT107</outcome_measure>
      <outcome_measure>immune specific response to HCV</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
      <country>Italy</country>
      <country>Switzerland</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01025596</url>
  </study>
  <study rank="815">
    <nct_id>NCT00728936</nct_id>
    <title>Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 in Hepatitis C-infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">IMO-2125</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Idera Pharmaceuticals, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>IMO-2125-001</other_id>
    </other_ids>
    <first_received>August 1, 2008</first_received>
    <start_date>September 2007</start_date>
    <completion_date>May 2010</completion_date>
    <last_updated>May 15, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evaluation of safety.</outcome_measure>
      <outcome_measure>Includes evaluation of Pharmacodynamic and Pharmacokinetics</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Colorado</state>
      <state>Georgia</state>
      <state>Michigan</state>
      <state>North Carolina</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00728936</url>
  </study>
  <study rank="816">
    <nct_id>NCT01913964</nct_id>
    <title>Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Work Productivity and Activity Impairment in Workers With Chronic C Hepatitis</condition>
      <condition>Fatigue in Workers With Chronic C Hepatitis</condition>
      <condition>Fatigue</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Acetylcarnitine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Catania</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>10/1997</other_id>
    </other_ids>
    <first_received>July 26, 2013</first_received>
    <start_date>October 1997</start_date>
    <completion_date>October 1997</completion_date>
    <last_updated>July 31, 2013</last_updated>
    <last_verified>July 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 1997</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Work Productivity and Activity Impairment in workers with chronic hepatitis C</outcome_measure>
      <outcome_measure>Fatigue in workers with chronic hepatitis C</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01913964</url>
  </study>
  <study rank="817">
    <nct_id>NCT00372983</nct_id>
    <title>Safety and PK Study of NOV-205 to Treat Chronic HCV Who Fail Standard Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">NOV-205</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Cellectar Biosciences, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>NOV205-C101</other_id>
    </other_ids>
    <first_received>September 5, 2006</first_received>
    <start_date>August 2006</start_date>
    <completion_date>December 2007</completion_date>
    <last_updated>December 17, 2007</last_updated>
    <last_verified>December 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>To evaluate the pharmacokinetic profile of different dosing regimens of NOV-205.</outcome_measure>
      <outcome_measure>To establish the safety profile of NOV-205 in comparison to that of placebo.</outcome_measure>
      <outcome_measure>To compare changes in viral load after treatment with NOV-205 or placebo (as evidenced by a quantitative reduction of &gt;0.5 log10 in serum HCV RNA levels by quantitative analysis as compared to the average of the screening and baseline values).</outcome_measure>
      <outcome_measure>To evaluate the impact of NOV-205 on serum ALT and AST levels in comparison to that of placebo.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00372983</url>
  </study>
  <study rank="818">
    <nct_id>NCT00120861</nct_id>
    <title>Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">valopicitabine</intervention>
      <intervention type="Drug">pegylated interferon</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV-08A-004</other_id>
    </other_ids>
    <first_received>July 11, 2005</first_received>
    <start_date>January 2005</start_date>
    <last_updated>June 9, 2010</last_updated>
    <last_verified>June 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00120861</url>
  </study>
  <study rank="819">
    <nct_id>NCT00239252</nct_id>
    <title>Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Interferon alfacon-1</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Astellas Pharma Inc</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>B6431/HCT1</other_id>
    </other_ids>
    <first_received>September 13, 2005</first_received>
    <last_updated>August 25, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00239252</url>
  </study>
  <study rank="820">
    <nct_id>NCT01997203</nct_id>
    <title>Long Term Vitamin D Therapy in HCV Treated Patients</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Vitamin D</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Dr. Nadia AbdelAaty AbdelKader</lead_sponsor>
      <collaborator>Ain Shams University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HCV-VD2013</other_id>
    </other_ids>
    <first_received>November 19, 2013</first_received>
    <start_date>April 2012</start_date>
    <completion_date>April 2013</completion_date>
    <last_updated>November 27, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>VD-HCV</acronym>
    <primary_completion_date>April 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>composite measures of Vitamin D, IL-6, Visfatin and Hyaluronic acid in Hepatitis C Virus Patients under antiviral therapy</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01997203</url>
  </study>
  <study rank="821">
    <nct_id>NCT00152581</nct_id>
    <title>Analysis of the Duration of Combination Therapy That is Necessary for HCV Genotype 1 Eradication</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C, HCV Genotype 1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon-alfa2a (Pegasys); ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University College London Hospitals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>01/0277</other_id>
    </other_ids>
    <first_received>September 7, 2005</first_received>
    <start_date>April 2002</start_date>
    <last_updated>November 29, 2005</last_updated>
    <last_verified>September 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (HCV RNA negative) 6 months post-treatment cessation</outcome_measure>
      <outcome_measure>Hepatic and serum HCV RNA levels as a predictor for treatment duration</outcome_measure>
      <outcome_measure>HCV-specific T-cell reactivity as a predictor for treatment duration</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00152581</url>
  </study>
  <study rank="822">
    <nct_id>NCT02008214</nct_id>
    <title>Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepacivirus</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pentoxifylline</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Centro Universitario de Ciencias de la Salud, Mexico</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>PTX-HCV/HIV</other_id>
    </other_ids>
    <first_received>December 3, 2013</first_received>
    <start_date>December 2013</start_date>
    <completion_date>March 2016</completion_date>
    <last_updated>December 6, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>sustained virologic rate 24 weeks post treatment with IFNalpha 2a/RBV/PTX with genotype 1 chronic HCV infection + HIV infection</outcome_measure>
      <outcome_measure>grade of hepatic fibrosis</outcome_measure>
      <outcome_measure>rapid virologic response (RVR) and extended rapid virologic response (eRVR) rates</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Mexico</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02008214</url>
  </study>
  <study rank="823">
    <nct_id>NCT01912495</nct_id>
    <title>Dutch Acute HCV in HIV Study (DAHHS)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Human Immunodeficiency Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Erasmus Medical Center</lead_sponsor>
      <collaborator>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</collaborator>
      <collaborator>Onze Lieve Vrouwe Gasthuis</collaborator>
      <collaborator>UMC Utrecht</collaborator>
      <collaborator>University Medical Center Groningen</collaborator>
      <collaborator>Maastricht University Medical Center</collaborator>
      <collaborator>Rijnstate Hospital</collaborator>
      <collaborator>Slotervaart Hospital</collaborator>
      <collaborator>Radboud University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NL44825.078.13</other_id>
    </other_ids>
    <first_received>July 29, 2013</first_received>
    <start_date>August 2013</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>February 2, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>DAHHS</acronym>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Viral Responds(SVR) 12 weeks of follow up after the end of all therapy for the Rapid Viral Response at week 4(RVR4) population.</outcome_measure>
      <outcome_measure>SVR 12 weeks after the end of all therapy in the entire study population (with or without RVR4).</outcome_measure>
      <outcome_measure>SVR 12 weeks after end of therapy in patients with already a RVR at week 1.</outcome_measure>
      <outcome_measure>SVR 12 weeks after end of therapy in patients that started therapy ≤12weeks after the presumed HCV infection date versus those after 12 weeks.</outcome_measure>
      <outcome_measure>Alterations of biomarkers by therapy induced viral eradication: Viral sequencing, mutation analysis, gene expression analysis, and RNA analysis.</outcome_measure>
      <outcome_measure>Safety: Treatment related (serious) adverse events ((S)AE) and treatment discontinuation for (S)AE.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01912495</url>
  </study>
  <study rank="824">
    <nct_id>NCT00133276</nct_id>
    <title>Prophylaxis of Psychiatric Symptoms During Anti-HCV Treatment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Escitalopram</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Foundation for Liver Research</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>HCV05-01</other_id>
    </other_ids>
    <first_received>August 22, 2005</first_received>
    <start_date>August 2005</start_date>
    <completion_date>December 2009</completion_date>
    <last_updated>February 18, 2010</last_updated>
    <last_verified>February 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Occurrence of peginterferon-induced psychiatric disturbance</outcome_measure>
      <outcome_measure>Occurrence of major depression</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00133276</url>
  </study>
  <study rank="825">
    <nct_id>NCT01888900</nct_id>
    <title>New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cirrhosis</condition>
      <condition>Chronic Hepatitis C</condition>
      <condition>Hepatitis C</condition>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Asunaprevir and Daclatsvir</intervention>
      <intervention type="Drug">Asunaprevir, daclatsvir, peginterferon, ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>Bristol-Myers Squibb</collaborator>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>37</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>130150</other_id>
      <other_id>13-DK-0150</other_id>
    </other_ids>
    <first_received>June 26, 2013</first_received>
    <start_date>May 2013</start_date>
    <completion_date>November 2015</completion_date>
    <last_updated>November 6, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Changes in interferon stimulated genes during therapy with asunaprevir and dacalatsvir</outcome_measure>
      <outcome_measure>Safety and efficacy of asunaprevir and dacalatsvir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01888900</url>
  </study>
  <study rank="826">
    <nct_id>NCT02460133</nct_id>
    <title>Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Paritaprevir</intervention>
      <intervention type="Drug">Ritonavir</intervention>
      <intervention type="Drug">Dasabuvir</intervention>
      <intervention type="Drug">Ombitasvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Nova Scotia Health Authority</lead_sponsor>
      <collaborator>PEI Provincial Correction Centre</collaborator>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>SAIL-001</other_id>
    </other_ids>
    <first_received>May 22, 2015</first_received>
    <start_date>July 2015</start_date>
    <completion_date>January 2018</completion_date>
    <last_updated>May 29, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Re-infection rate in individuals treated with DAA therapy</outcome_measure>
      <outcome_measure>Percentage of subjects with sustained virologic response at 12 weeks post treatment</outcome_measure>
      <outcome_measure>Change in fibrosis measured by transient elastography</outcome_measure>
      <outcome_measure>Global and HCV-specific T cell function before and after treatment with DAA therapy.</outcome_measure>
      <outcome_measure>Global and HCV-specific B cell function before and after treatment with DAA therapy.</outcome_measure>
      <outcome_measure>Global and HCV-specific NK cell function before and after treatment with DAA therapy.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02460133</url>
  </study>
  <study rank="827">
    <nct_id>NCT00040027</nct_id>
    <title>Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a</intervention>
      <intervention type="Drug">placebo + PEGinterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>SciClone Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>Ta1-CHC-2K0803a</other_id>
    </other_ids>
    <first_received>June 18, 2002</first_received>
    <start_date>April 2002</start_date>
    <last_updated>January 8, 2008</last_updated>
    <last_verified>January 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Idaho</state>
      <state>Illinois</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00040027</url>
  </study>
  <study rank="828">
    <nct_id>NCT00039962</nct_id>
    <title>Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">thymalfasin (thymosin alpha 1)</intervention>
      <intervention type="Drug">PEGinterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>SciClone Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>Ta1-CHC-2K0804</other_id>
    </other_ids>
    <first_received>June 17, 2002</first_received>
    <start_date>May 2002</start_date>
    <last_updated>January 8, 2008</last_updated>
    <last_verified>January 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Idaho</state>
      <state>Illinois</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00039962</url>
  </study>
  <study rank="829">
    <nct_id>NCT00108563</nct_id>
    <title>VISN 20: Prophylactic Treatment of Interferon-Induced Depression in Hepatitis C Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Depression</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Citalopram or Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>VA Office of Research and Development</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>CLIN-012-02S</other_id>
    </other_ids>
    <first_received>April 15, 2005</first_received>
    <start_date>October 2003</start_date>
    <completion_date>September 2006</completion_date>
    <last_updated>January 20, 2009</last_updated>
    <last_verified>May 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Oregon</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00108563</url>
  </study>
  <study rank="830">
    <nct_id>NCT00166296</nct_id>
    <title>Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Major Depressive Disorder.</condition>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Escitalopram</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Germans Trias i Pujol Hospital</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
      <collaborator>H. Lundbeck A/S</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>133</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>PSQHEPGTP1</other_id>
      <other_id>EudraCT number: 2004-002982-19</other_id>
    </other_ids>
    <first_received>September 9, 2005</first_received>
    <start_date>March 2005</start_date>
    <completion_date>October 2007</completion_date>
    <last_updated>March 4, 2011</last_updated>
    <last_verified>March 2011</last_verified>
    <firstreceived_results_date>February 8, 2011</firstreceived_results_date>
    <primary_completion_date>October 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Who Developed a Major Depressive Episode According to Diagnostic &amp; Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) Criteria During the First 12 Weeks of Antiviral Treatment.</outcome_measure>
      <outcome_measure>Number of Participants With Sustained Hepatitis C Viral Response (Negativization of Serum Hepatitis C Virus Ribonucleic Acid).</outcome_measure>
      <outcome_measure>Total Score in the Montgomery-Asberg Depression Rating Scale</outcome_measure>
      <outcome_measure>Total Score in the Depression Subscale of the Hospital Anxiety and Depression Scale.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00166296</url>
  </study>
  <study rank="831">
    <nct_id>NCT00272389</nct_id>
    <title>Prediction of Response to Treatment of Patients With Chronic HCV Infection by Genetic Profile</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Chronic Infection</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hadassah Medical Organization</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Defined Population</study_design>
      <study_design>Observational Model: Natural History</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>tBEB1t-HMO-CTIL</other_id>
    </other_ids>
    <first_received>January 4, 2006</first_received>
    <start_date>March 2006</start_date>
    <completion_date>May 2006</completion_date>
    <last_updated>January 4, 2006</last_updated>
    <last_verified>January 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>Israel</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00272389</url>
  </study>
  <study rank="832">
    <nct_id>NCT00048724</nct_id>
    <title>Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Cirrhosis</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">peginterferon alfa-2b (SCH 54031)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>631</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P02569</other_id>
    </other_ids>
    <first_received>November 6, 2002</first_received>
    <start_date>June 2002</start_date>
    <completion_date>April 2008</completion_date>
    <last_updated>March 26, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>April 23, 2009</firstreceived_results_date>
    <primary_completion_date>April 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Time to Observation of the First Clinical Event Experienced by a Subject</outcome_measure>
      <outcome_measure>Time to Observation of the Disease Progression Experienced by a Subject</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00048724</url>
  </study>
  <study rank="833">
    <nct_id>NCT01701336</nct_id>
    <title>Study of a Novel Therapeutic Vaccine Against Hepatitis C Using Ad6NSmut and MVA-NSmut in Chronically Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Ad6NSmut, MVA-NSmut</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>ReiThera Srl</lead_sponsor>
      <collaborator>European Commission</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>9</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HCV004</other_id>
      <other_id>2010-022700-49</other_id>
    </other_ids>
    <first_received>August 28, 2012</first_received>
    <start_date>March 2012</start_date>
    <completion_date>February 2013</completion_date>
    <last_updated>August 28, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HCV004</acronym>
    <primary_completion_date>October 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number and severity of adverse events</outcome_measure>
      <outcome_measure>IFNγ ELISpot. Unit: IFNγ spot forming cells (SFC)/ million splenocytes</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01701336</url>
  </study>
  <study rank="834">
    <nct_id>NCT01995266</nct_id>
    <title>Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Asunaprevir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>159</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI447-036</other_id>
    </other_ids>
    <first_received>November 21, 2013</first_received>
    <start_date>February 2014</start_date>
    <completion_date>July 2015</completion_date>
    <last_updated>July 21, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of treated subjects who achieve Sustained Virologic Response (SVR) 24</outcome_measure>
      <outcome_measure>Proportion of treated subjects who achieve SVR12</outcome_measure>
      <outcome_measure>Safety, as measured by the frequency of Serious Adverse Events (SAEs) and discontinuations due to Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve SVR24 by the rs12979860 single nucleotide polymorphism (SNP) in the Interferon lambda 3 (IL28B) gene</outcome_measure>
      <outcome_measure>Proportion of subjects with HCV RNA target not detected</outcome_measure>
      <outcome_measure>Proportion of subjects with HCV RNA &lt; LLOQ target detected or not detected</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
      <country>Korea, Republic of</country>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01995266</url>
  </study>
  <study rank="835">
    <nct_id>NCT02069665</nct_id>
    <title>Effectiveness Study of Integrative Treatment for Pediatric Pneumonia</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Fuxiong San</intervention>
      <intervention type="Drug">Xiyanping injection</intervention>
      <intervention type="Drug">Ribavirin Injection</intervention>
      <intervention type="Drug">Xiaoer Qingfei Heji (mixture)</intervention>
      <intervention type="Drug">Zhi Ke San</intervention>
      <intervention type="Drug">Hua Tan San</intervention>
      <intervention type="Drug">Guaifenesin Syrup</intervention>
      <intervention type="Drug">Ibuprofen Suspension</intervention>
      <intervention type="Drug">salbutamol</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Liaoning University of Traditional Chinese Medicine</lead_sponsor>
      <collaborator>Beijing University of Chinese Medicine</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases/>
    <enrollment>451</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AHLN-TCM-01</other_id>
    </other_ids>
    <first_received>December 26, 2013</first_received>
    <start_date>December 2011</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>February 20, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Cured rate</outcome_measure>
      <outcome_measure>Effectiveness time window</outcome_measure>
      <outcome_measure>TCM syndrome scores and effective rate</outcome_measure>
      <outcome_measure>Effect in fever, cough, phlegm and gasp</outcome_measure>
      <outcome_measure>Time of lung rales disappear completely</outcome_measure>
      <outcome_measure>Check-out time</outcome_measure>
      <outcome_measure>Pulmonary disease incidence</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02069665</url>
  </study>
  <study rank="836">
    <nct_id>NCT00751426</nct_id>
    <title>Treatment of Hepatitis C in Psychiatric Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Mental Disorders</condition>
      <condition>Drug Addiction</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Charite University, Berlin, Germany</lead_sponsor>
      <collaborator>Ludwig-Maximilians - University of Munich</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>81</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs/>
    <other_ids>
      <other_id>Psy 225/98</other_id>
    </other_ids>
    <first_received>September 11, 2008</first_received>
    <start_date>August 1999</start_date>
    <completion_date>May 2002</completion_date>
    <last_updated>September 11, 2008</last_updated>
    <last_verified>August 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2002</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Response</outcome_measure>
      <outcome_measure>Sustained Virological Response</outcome_measure>
      <outcome_measure>Adherence</outcome_measure>
      <outcome_measure>Occurrence of depression</outcome_measure>
      <outcome_measure>Occurrence of other psychiatric side effects</outcome_measure>
      <outcome_measure>Long term outcome</outcome_measure>
      <outcome_measure>Psychiatric side effects (group comparison)</outcome_measure>
      <outcome_measure>Long term outcome after treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00751426</url>
  </study>
  <study rank="837">
    <nct_id>NCT02293941</nct_id>
    <title>Liver Test Study of Using JKB-122 in HCV-Positive Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">JKB-122</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>TaiwanJ Pharmaceuticals Co., Ltd</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>148</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>JKB122</other_id>
    </other_ids>
    <first_received>November 13, 2014</first_received>
    <start_date>May 2014</start_date>
    <completion_date>April 2018</completion_date>
    <last_updated>September 21, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>JKB122</acronym>
    <primary_completion_date>August 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>ALT</outcome_measure>
      <outcome_measure>Pharmacokinetic analysis (plasma concentration of JKB-122)</outcome_measure>
      <outcome_measure>Clinical laboratory tests (Includes hematology, coagulation, and serum chemistry.)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02293941</url>
  </study>
  <study rank="838">
    <nct_id>NCT01854528</nct_id>
    <title>A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450/r/ABT-267</intervention>
      <intervention type="Drug">ABT-333</intervention>
      <intervention type="Drug">Ribavrin</intervention>
      <intervention type="Drug">Pegylated Interferon alpha 2-alpha (PegINF)</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>154</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M13-862</other_id>
      <other_id>2012-003738-18</other_id>
    </other_ids>
    <first_received>May 13, 2013</first_received>
    <start_date>June 2013</start_date>
    <completion_date>July 2015</completion_date>
    <last_updated>July 29, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of subjects with sustained virologic response 12 weeks post-treatment</outcome_measure>
      <outcome_measure>Change in Mental Component Summary (MCS) of the SF-36 v.2</outcome_measure>
      <outcome_measure>Change in Physical Component Summary (PCS) of the SF-36 v.2</outcome_measure>
      <outcome_measure>Percentage of subjects with virologic failure during treatment</outcome_measure>
      <outcome_measure>Percentage of subjects with post-treatment relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Chile</country>
      <country>Finland</country>
      <country>Hungary</country>
      <country>Poland</country>
      <country>Romania</country>
      <country>Slovakia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01854528</url>
  </study>
  <study rank="839">
    <nct_id>NCT02204475</nct_id>
    <title>Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Grazoprevir/Elbasvir</intervention>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">PegIntron</intervention>
      <intervention type="Drug">Ribavarin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>5172-066</other_id>
      <other_id>2014-001841-25</other_id>
    </other_ids>
    <first_received>July 28, 2014</first_received>
    <start_date>November 2014</start_date>
    <completion_date>September 2016</completion_date>
    <last_updated>October 13, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants achieving SVR12</outcome_measure>
      <outcome_measure>Proportion of TN participants achieving SVR12</outcome_measure>
      <outcome_measure>Number of participants experiencing an adverse event (AE)</outcome_measure>
      <outcome_measure>Number of participants withdrawing from study treatment due to AEs</outcome_measure>
      <outcome_measure>Proportion of PTF participants achieving SVR12</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02204475</url>
  </study>
  <study rank="840">
    <nct_id>NCT00759109</nct_id>
    <title>Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Carcinoma, Hepatocellular</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b</intervention>
      <intervention type="Other">Observation (no treatment)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P02733</other_id>
    </other_ids>
    <first_received>August 26, 2008</first_received>
    <start_date>March 2002</start_date>
    <completion_date>November 2009</completion_date>
    <last_updated>June 8, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>March 24, 2011</firstreceived_results_date>
    <primary_completion_date>November 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With the Development of Hepatocellular Carcinoma (HCC)</outcome_measure>
      <outcome_measure>Number of Participants With Development of Hepatic Decompensation</outcome_measure>
      <outcome_measure>Survival Time of Participants</outcome_measure>
      <outcome_measure>Number of Patients With a Virological Response Rate</outcome_measure>
      <outcome_measure>Change in the Proliferating Cell Nuclear Antigen Labeling Index (PCNA-LI)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00759109</url>
  </study>
  <study rank="841">
    <nct_id>NCT00565539</nct_id>
    <title>Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEGylated recombinant interleukin 29 (PEG-rIL-29)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>ZymoGenetics</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>56</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>526F06</other_id>
    </other_ids>
    <first_received>November 29, 2007</first_received>
    <start_date>December 2007</start_date>
    <completion_date>October 2009</completion_date>
    <last_updated>October 6, 2009</last_updated>
    <last_verified>October 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Adverse events and standard clinical laboratory abnormalities</outcome_measure>
      <outcome_measure>HCV RNA levels, serum concentrations of PEG-rIL-29, serum beta2-microglobulin (B2M) levels, serum 2'5' oligoadenylate synthetase (OAS) levels, the presence of anti-PEG-rIL-29 antibodies</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Illinois</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>New Jersey</state>
      <state>North Carolina</state>
      <state>Oregon</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00565539</url>
  </study>
  <study rank="842">
    <nct_id>NCT00132210</nct_id>
    <title>Pegylated Interferon Therapy for Acute Hepatitis C Infection in HIV-infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Bonn</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>BN-102/02</other_id>
    </other_ids>
    <first_received>August 17, 2005</first_received>
    <start_date>September 2002</start_date>
    <completion_date>June 2010</completion_date>
    <last_updated>October 20, 2010</last_updated>
    <last_verified>November 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Negative hepatitis C ribonucleic acid (HCV-RNA) in peripheral serum</outcome_measure>
      <outcome_measure>Normal liver enzymes</outcome_measure>
      <outcome_measure>Negative HCV-RNA</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00132210</url>
  </study>
  <study rank="843">
    <nct_id>NCT01608737</nct_id>
    <title>A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infection</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PegIFN/RBV</intervention>
      <intervention type="Drug">BI 201335</intervention>
      <intervention type="Drug">BI 201335</intervention>
      <intervention type="Drug">PegIFN/RBV</intervention>
      <intervention type="Drug">BI 201335</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>1220.8</other_id>
      <other_id>2012-001242-18</other_id>
    </other_ids>
    <first_received>May 29, 2012</first_received>
    <start_date>September 2012</start_date>
    <last_updated>February 23, 2013</last_updated>
    <last_verified>February 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virological Response 12 weeks post-treatment (SVR12): Plasma Hepatitis C Virus (HCV) Ribonucleic Acid ( RNA) &lt;25 IU/mL undetected at 12 weeks after the originally planned treatment duration.</outcome_measure>
      <outcome_measure>Virological response after 24 weeks of treatment discontinuation (SVR24): Plasma HCV RNA level &lt;25 IU/mL, undetected; 24 weeks after the originally planned treatment duration</outcome_measure>
      <outcome_measure>Early Treatment Success (ETS): Plasma HCV RNA level &lt;25 IU/mL (detected or undetected) at Week 4 and HCV RNA &lt;25 IU/mL, undetected at Week 8</outcome_measure>
      <outcome_measure>Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) normalisation. ALT and AST normal at end of treatment and post treatment.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01608737</url>
  </study>
  <study rank="844">
    <nct_id>NCT00239733</nct_id>
    <title>Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Thrombocytopenia</condition>
      <condition>Hepatitis C</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Anti-D</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>K23AI065319-01</other_id>
    </other_ids>
    <first_received>October 13, 2005</first_received>
    <start_date>March 2005</start_date>
    <completion_date>March 2010</completion_date>
    <last_updated>September 25, 2008</last_updated>
    <last_verified>September 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Frequency and severity of adverse events</outcome_measure>
      <outcome_measure>Absolute change in platelet count from baseline</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00239733</url>
  </study>
  <study rank="845">
    <nct_id>NCT00747539</nct_id>
    <title>Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV</condition>
      <condition>Hepatitis C</condition>
      <condition>Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa and ribavirin (PEG-IFN/RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
      <collaborator>National Institute of Mental Health (NIMH)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>330</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>R01MH083553</other_id>
      <other_id>DAHBR 9A-ASNM</other_id>
    </other_ids>
    <first_received>September 4, 2008</first_received>
    <start_date>September 2008</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>December 10, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Neurobehavioral deficits as observed on neuropsychological testing in HIV/HCV-coinfected individuals before and after receiving anti-HCV treatment.</outcome_measure>
      <outcome_measure>Psychiatric symptoms</outcome_measure>
      <outcome_measure>Neuroimaging data (from a nested cohort of participants)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00747539</url>
  </study>
  <study rank="846">
    <nct_id>NCT00188240</nct_id>
    <title>Insulin Resistance Associated With Chronic Hepatitis C (CHC) and the Effect of Antiviral Therapy</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegasys; Copegus.</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Health Network, Toronto</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>03-0510-AE 04-0292-A</other_id>
    </other_ids>
    <first_received>September 9, 2005</first_received>
    <start_date>August 2003</start_date>
    <last_updated>November 28, 2005</last_updated>
    <last_verified>September 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Phase I - To evaluate the prevalence of insulin resistance in patients with hepatitis C without cirrhosis and compare it to that observed in patients with hepatitis B also without cirrhosis.</outcome_measure>
      <outcome_measure>Phase II - Interventional phase - To evaluate the effect of anti-viral therapy on insulin resistance, determined by the OGTT method, in patients with hepatitis C found to have insulin resistance pre-treatment.</outcome_measure>
      <outcome_measure>- To evaluate the safety, efficacy and tolerability of Pegasys (peginterferon alfa-2a) given in combination with Copegus (ribavirin) given for 24 weeks or 48 weeks in treatment naïve patients with chronic hepatitis C (CHC).</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00188240</url>
  </study>
  <study rank="847">
    <nct_id>NCT00495768</nct_id>
    <title>Reducing Depressive Symptoms During HCV Therapy: A Randomized Study</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Depression</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Group Training</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>South Texas Veterans Health Care System</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>034-0013-391</other_id>
    </other_ids>
    <first_received>July 2, 2007</first_received>
    <start_date>July 2004</start_date>
    <completion_date>December 2007</completion_date>
    <last_updated>December 13, 2007</last_updated>
    <last_verified>December 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Patients in the experimental group will have less of an increase in their HAM-D score over the first 6 months of treatment; score on a depression rating scale at study visits 1-5.</outcome_measure>
      <outcome_measure>Patients in the experimental group will have less of an increase in their PHQ-9 score over the first 6 months of treatment; score on a rating scale at study visits 1-5.</outcome_measure>
      <outcome_measure>Patients in the experimental group will have less of an increase in their BDI score over the first 6 months of treatment; score on a rating scale at study visits 1-5.</outcome_measure>
      <outcome_measure>Fewer patients in the experimental group will have developed a major depressive episode over the first 6 months of treatment; score on MDD module (MINI)at study visits 1-5.</outcome_measure>
      <outcome_measure>Patients in the experimental group will have less of a decline in their self-rated general health (item #1 of the SF-36) over the first 6 months of treatment.</outcome_measure>
      <outcome_measure>Patients in the experimental group will have less of an increase in self-rated irritability (item #6 of the BSI ) over the first 6 months of treatment.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00495768</url>
  </study>
  <study rank="848">
    <nct_id>NCT01413490</nct_id>
    <title>Hepatitis C Rimantadine and Antiviral Combination Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">rimantadine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>The Leeds Teaching Hospitals NHS Trust</lead_sponsor>
      <collaborator>Cancer Research UK</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>2011-002781-21</other_id>
    </other_ids>
    <first_received>August 9, 2011</first_received>
    <start_date>May 2012</start_date>
    <completion_date>March 2015</completion_date>
    <last_updated>March 30, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HepRiACT</acronym>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01413490</url>
  </study>
  <study rank="849">
    <nct_id>NCT01296451</nct_id>
    <title>Study of a New MVA Vaccine for Hepatitis C Virus</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">MVA-NSmut</intervention>
      <intervention type="Biological">AdCh3NSmut</intervention>
      <intervention type="Biological">AdCh3NSmut1</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>ReiThera Srl</lead_sponsor>
      <collaborator>University of Oxford</collaborator>
      <collaborator>Oxford University Hospitals NHS Trust</collaborator>
      <collaborator>University Hospital Birmingham</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HCV003</other_id>
      <other_id>2009-018260-10</other_id>
    </other_ids>
    <first_received>February 9, 2011</first_received>
    <start_date>December 2010</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>July 10, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participant with adverse events, type and severity of adverse events</outcome_measure>
      <outcome_measure>Immunogenicity</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01296451</url>
  </study>
  <study rank="850">
    <nct_id>NCT01403181</nct_id>
    <title>Effect of Boceprevir on HCV-specific T Cell Responses</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Azienda Ospedaliero-Universitaria di Parma</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>AZOSPA</other_id>
    </other_ids>
    <first_received>July 26, 2011</first_received>
    <start_date>April 2012</start_date>
    <last_updated>November 5, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>Boce-Par</acronym>
    <primary_completion_date>October 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Levels of HCV-specific T cell functions before, during and after therapy to measure functional restoration induced by therapy</outcome_measure>
      <outcome_measure>Correlation of quality and intensity of pre-treatment HCV-specific T cell responses with outcome of therapy</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01403181</url>
  </study>
  <study rank="851">
    <nct_id>NCT01062659</nct_id>
    <title>Cellular Immune Responses in the Liver in Chronic Hepatitis C (CHC) Patients</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Liver Diseases</condition>
      <condition>Virus Diseases</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>University of Ulm</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>TCell</other_id>
    </other_ids>
    <first_received>February 3, 2010</first_received>
    <start_date>February 2010</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>March 31, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01062659</url>
  </study>
  <study rank="852">
    <nct_id>NCT01500772</nct_id>
    <title>Alisporivir With pegIFN/RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Alisporivir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>6</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CDEB025A2306</other_id>
      <other_id>2011-004653-31</other_id>
    </other_ids>
    <first_received>December 23, 2011</first_received>
    <start_date>February 2012</start_date>
    <last_updated>May 4, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR12</outcome_measure>
      <outcome_measure>SVR24</outcome_measure>
      <outcome_measure>SVR12LOD</outcome_measure>
      <outcome_measure>Overall safety profile</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>Ohio</state>
      <state>Rhode Island</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01500772</url>
  </study>
  <study rank="853">
    <nct_id>NCT00633230</nct_id>
    <title>Effects of Sho-saiko-to, a Herbal Formula, in Reducing Viral Load in Hepatitis C</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">standardized herbal formula, Sho-saiko-to (SST)</intervention>
      <intervention type="Other">placebo capsule identical to the active herbal formula</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Virginia</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AGT006</other_id>
      <other_id>IRB-HSR #12957</other_id>
    </other_ids>
    <first_received>March 3, 2008</first_received>
    <last_updated>June 24, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Reduction in HCV viral load, improvement in liver enzymes (ALT and AST), improvement in CD4+ and CD8+ T-cell counts.</outcome_measure>
      <outcome_measure>Improvement in symptoms of depression/sadness, fear related to HCV disease progression, uncertainty, and hopelessness over time</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00633230</url>
  </study>
  <study rank="854">
    <nct_id>NCT01826981</nct_id>
    <title>Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Subjects With Chronic Genotype 1, 2, 3, or 6 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF FDC</intervention>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">PEG</intervention>
      <intervention type="Drug">GS-9669</intervention>
      <intervention type="Drug">GS-5816</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>362</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-0122</other_id>
    </other_ids>
    <first_received>April 1, 2013</first_received>
    <start_date>April 2013</start_date>
    <completion_date>May 2015</completion_date>
    <last_updated>June 3, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Proportion of participants with adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with SVR through posttreatment Week 24</outcome_measure>
      <outcome_measure>Proportion of participants with on-treatment virologic failure and relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>New Zealand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01826981</url>
  </study>
  <study rank="855">
    <nct_id>NCT01659567</nct_id>
    <title>An Observational Study of Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>530</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML25544</other_id>
    </other_ids>
    <first_received>July 27, 2012</first_received>
    <start_date>April 2011</start_date>
    <completion_date>October 2015</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Predictive values of sustained virological response</outcome_measure>
      <outcome_measure>Correlation of patient characteristics and sustained virological response</outcome_measure>
      <outcome_measure>Overall treatment duration</outcome_measure>
      <outcome_measure>Treatment duration after sustained virological response</outcome_measure>
      <outcome_measure>Correlation of treatment dose and sustained virological response</outcome_measure>
      <outcome_measure>Sustained virological response</outcome_measure>
      <outcome_measure>Safety: incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Georgia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01659567</url>
  </study>
  <study rank="856">
    <nct_id>NCT01470651</nct_id>
    <title>Armodafinil for Patients Starting Hepatitis C Virus Treatment</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Armodafinil</intervention>
      <intervention type="Drug">Placebo Comparator</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Research Foundation for Mental Hygiene, Inc.</lead_sponsor>
      <collaborator>Icahn School of Medicine at Mount Sinai</collaborator>
      <collaborator>Weill Medical College of Cornell University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>26</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>C10953/6285</other_id>
    </other_ids>
    <first_received>October 13, 2011</first_received>
    <start_date>October 2011</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>May 4, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Adherence to Medications Form</outcome_measure>
      <outcome_measure>Fatigue Severity Scale (FSS)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01470651</url>
  </study>
  <study rank="857">
    <nct_id>NCT02332720</nct_id>
    <title>Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3 Infection (MK-3682-012)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Grazoprevir</intervention>
      <intervention type="Drug">MK-3682</intervention>
      <intervention type="Drug">Elbasvir</intervention>
      <intervention type="Drug">MK-8408</intervention>
      <intervention type="Drug">MK-3682B</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>460</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>3682-012</other_id>
      <other_id>2014-003347-35</other_id>
    </other_ids>
    <first_received>January 6, 2015</first_received>
    <start_date>January 2015</start_date>
    <completion_date>October 2016</completion_date>
    <last_updated>November 11, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants achieving SVR12</outcome_measure>
      <outcome_measure>Number of participants experiencing an adverse event (AE)</outcome_measure>
      <outcome_measure>Number of participants who had study drug discontinued due to an AE</outcome_measure>
      <outcome_measure>Percentage of participants achieving SVR24</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Denmark</country>
      <country>France</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>New Zealand</country>
      <country>Switzerland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Michigan</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02332720</url>
  </study>
  <study rank="858">
    <nct_id>NCT02555475</nct_id>
    <title>The Prime Study - Comparing Hepatitis C Care and Treatment in a Primary Health Care Service With a Tertiary Hospital</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Other">community based hepatitis C care and treatment</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Macfarlane Burnet Institute for Medical Research and Public Health Ltd</lead_sponsor>
      <collaborator>St Vincent's Hospital Melbourne</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>380</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HREC/15/SVHM/41</other_id>
    </other_ids>
    <first_received>September 17, 2015</first_received>
    <start_date>October 2015</start_date>
    <completion_date>October 2017</completion_date>
    <last_updated>September 18, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To measure the proportion of people attending at a Primary Health Care Service for their genotype 1 HCV infection who commence antiviral treatment (Viekira Pak and ribavirin) and have a SVR 12.</outcome_measure>
      <outcome_measure>To measure the proportion of people attending a PHCS with G1 HCV infection who commence antiviral treatment (Viekira Pak and ribavirin) if they are managed at a PHCS compared to those who are referred to and managed at a tertiary hospital.</outcome_measure>
      <outcome_measure>To measure the proportion of people with G1 HCV who have an SVR12 at a PHCS compared a tertiary hospital.</outcome_measure>
      <outcome_measure>To measure the reduction in HCV viraemia (community viral load) among participants considering retention through the cascade of care and SVR12.</outcome_measure>
      <outcome_measure>To measure the cost effectiveness of managing and treating people in a primary health service compared to a tertiary hospital.</outcome_measure>
      <outcome_measure>To define the cascade of care for patients referred to a community hepatitis nurse for assessment of HCV.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02555475</url>
  </study>
  <study rank="859">
    <nct_id>NCT01140997</nct_id>
    <title>Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ypeginterferon alfa-2b</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Xiamen Amoytop Biotech Co., Ltd.</lead_sponsor>
      <collaborator>Peking University People's Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>211</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TB1006IFN</other_id>
    </other_ids>
    <first_received>June 8, 2010</first_received>
    <start_date>July 2010</start_date>
    <completion_date>March 2012</completion_date>
    <last_updated>January 31, 2013</last_updated>
    <last_verified>June 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PEGIFN</acronym>
    <primary_completion_date>January 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01140997</url>
  </study>
  <study rank="860">
    <nct_id>NCT01070550</nct_id>
    <title>PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>4598</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>MV21012</other_id>
    </other_ids>
    <first_received>February 9, 2010</first_received>
    <start_date>June 2007</start_date>
    <completion_date>July 2011</completion_date>
    <last_updated>November 2, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Predictive values of virological response 4 and 12 weeks after treatment initiation on sustained virological response (SVR) by HCV genotype</outcome_measure>
      <outcome_measure>Identification and confirmation of host-, virus- and treatment-related factors influencing viral response, SVR and relapse</outcome_measure>
      <outcome_measure>Correlation between overall treatment duration/treatment duration after HCV RNA becomes negative and SVR by genotype</outcome_measure>
      <outcome_measure>Correlation of cumulative ribavirin and peginterferon dose with SVR by genotype</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
      <country>Austria</country>
      <country>Brazil</country>
      <country>Croatia</country>
      <country>France</country>
      <country>Hungary</country>
      <country>Macedonia, The Former Yugoslav Republic of</country>
      <country>Mexico</country>
      <country>Morocco</country>
      <country>Poland</country>
      <country>Romania</country>
      <country>Serbia</country>
      <country>Slovenia</country>
      <country>Sweden</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01070550</url>
  </study>
  <study rank="861">
    <nct_id>NCT01066819</nct_id>
    <title>PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1611</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>MV21542</other_id>
    </other_ids>
    <first_received>February 9, 2010</first_received>
    <start_date>January 2008</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>November 2, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Predictive values of virological response 4 and 12 weeks after treatment initiation on sustained virological response (SVR) by HCV genotype</outcome_measure>
      <outcome_measure>Identification and confirmation of host-, virus- and treatment-related factors influencing viral response, SVR and relapse</outcome_measure>
      <outcome_measure>Correlation between overall treatment duration/treatment duration after HCV RNA becomes negative and SVR by genotype</outcome_measure>
      <outcome_measure>Correlation of cumulative ribavirin and peginterferon dose with SVR by genotype</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Iowa</state>
      <state>Kansas</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New Hampshire</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
      <state>West Virginia</state>
      <state>Wyoming</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01066819</url>
  </study>
  <study rank="862">
    <nct_id>NCT01066793</nct_id>
    <title>PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>2272</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>MV21020</other_id>
    </other_ids>
    <first_received>February 9, 2010</first_received>
    <start_date>October 2007</start_date>
    <completion_date>May 2011</completion_date>
    <last_updated>November 2, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Predictive values of virological response 4 and 12 weeks after treatment initiation on sustained virological response (SVR) by HCV genotype</outcome_measure>
      <outcome_measure>Identification and confirmation of host-, virus- and treatment-related factors influencing viral response, SVR and relapse</outcome_measure>
      <outcome_measure>Correlation between overall treatment duration/treatment duration after HCV RNA becomes negative and SVR by genotype</outcome_measure>
      <outcome_measure>Correlation of cumulative ribavirin and peginterferon dose with SVR by genotype</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
      <country>Ireland</country>
      <country>Italy</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01066793</url>
  </study>
  <study rank="863">
    <nct_id>NCT01094873</nct_id>
    <title>Study of a Novel Therapeutic Vaccine for Hepatitis C Virus</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">AdCh3NSmut</intervention>
      <intervention type="Biological">Ad6NSmut</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>ReiThera Srl</lead_sponsor>
      <collaborator>University of Oxford</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>35</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HCV002TV</other_id>
      <other_id>2008-006127-32</other_id>
      <other_id>GTAC162</other_id>
    </other_ids>
    <first_received>March 25, 2010</first_received>
    <start_date>November 2009</start_date>
    <completion_date>April 2013</completion_date>
    <last_updated>April 22, 2015</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and immunogenicity</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01094873</url>
  </study>
  <study rank="864">
    <nct_id>NCT02480686</nct_id>
    <title>Neutrino Regimen for Treatment-experienced HCV GT1 Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF+PEG+RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Humanity &amp; Healthy GI and Liver Centre</lead_sponsor>
      <collaborator>Beijing 302 Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>H&amp;H_Neutrino Therapy</other_id>
    </other_ids>
    <first_received>June 21, 2015</first_received>
    <start_date>January 2015</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>June 22, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Proportion of participants with adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Change in HCV RNA From Baseline to Week 12</outcome_measure>
      <outcome_measure>Proportion of participants with on-treatment virologic breakthrough and relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02480686</url>
  </study>
  <study rank="865">
    <nct_id>NCT02482077</nct_id>
    <title>Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF+RBV</intervention>
      <intervention type="Drug">SOF+DCV</intervention>
      <intervention type="Drug">LDV/SOF</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Humanity &amp; Healthy GI and Liver Centre</lead_sponsor>
      <collaborator>Beijing 302 Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>H&amp;H_HCV G2 Study</other_id>
    </other_ids>
    <first_received>June 23, 2015</first_received>
    <start_date>January 2015</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>June 23, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy</outcome_measure>
      <outcome_measure>Proportion of participants with adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with unquantifiable HCV viral load at specified time points during and after treatment</outcome_measure>
      <outcome_measure>HCV RNA levels and change during and after treatment.</outcome_measure>
      <outcome_measure>Proportion of participants with on-treatment virologic breakthrough and relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02482077</url>
  </study>
  <study rank="866">
    <nct_id>NCT01342003</nct_id>
    <title>HCV Genotype 1a Shows a Better Virological Response to Antiviral Therapy Than HCV Genotype 1b</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Azienda Ospedaliera San Camillo Forlanini</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>388</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>01</other_id>
    </other_ids>
    <first_received>April 25, 2011</first_received>
    <start_date>February 2007</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>April 25, 2011</last_updated>
    <last_verified>October 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>genotype</acronym>
    <primary_completion_date>July 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary end point was sustained undetectable serum HCVRNA 24 weeks after treatment cessation (SVR).</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01342003</url>
  </study>
  <study rank="867">
    <nct_id>NCT01691235</nct_id>
    <title>SIMpill Medication Dispensing Device in the Treatment of HCV</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Device">SIMpill device</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>12-1293</other_id>
    </other_ids>
    <first_received>September 17, 2012</first_received>
    <start_date>September 2012</start_date>
    <completion_date>January 2013</completion_date>
    <last_updated>October 6, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>SIMpill HCV</acronym>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Improved SVR Rates</outcome_measure>
      <outcome_measure>Improved Patient Adherence Rates</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Illinois</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01691235</url>
  </study>
  <study rank="868">
    <nct_id>NCT02194998</nct_id>
    <title>Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450/r/ABT-267</intervention>
      <intervention type="Drug">ABT-333</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>A5329</other_id>
      <other_id>11935</other_id>
    </other_ids>
    <first_received>July 17, 2014</first_received>
    <start_date>August 2015</start_date>
    <last_updated>November 27, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evaluation of sustained virologic response (SVR)12</outcome_measure>
      <outcome_measure>Evaluation of serious adverse events (SAEs) as defined by International Conference on Harmonisation (ICH) criteria</outcome_measure>
      <outcome_measure>Number of premature HCV study treatment discontinuations due to any reason other than HCV VF</outcome_measure>
      <outcome_measure>Presence of signs/symptoms Grade 3 or higher during HCV study treatment and up to 30 days following HCV study treatment discontinuation</outcome_measure>
      <outcome_measure>Number of diagnoses leading to HCV study treatment or HIV-1 antiretroviral (ARV) discontinuation</outcome_measure>
      <outcome_measure>Presence of laboratory abnormalities Grade 3 or higher during HCV study treatment and up to 30 days following HCV study treatment discontinuation</outcome_measure>
      <outcome_measure>Measurement of HIV-1 VF as defined in the protocol</outcome_measure>
      <outcome_measure>Presence of genotypic mutations conferring major resistance to any HIV-1 protease inhibitor (PI) at time of HIV-1 RNA VF (or confirmation of HIV-1 RNA VF)</outcome_measure>
      <outcome_measure>Measurement of soluble CD14 (sCD14) levels</outcome_measure>
      <outcome_measure>Measurement of interferon gamma-induced protein 10 (IP10) levels as biomarkers of immune activation</outcome_measure>
      <outcome_measure>Frequency of HCV mutations conferring resistance to any component of the HCV treatment regimen in the first sample with a HCV viral load (VL) greater than 1000 IU/mL among the subset of participants who are non-responders for SVR12</outcome_measure>
      <outcome_measure>Measurement of SVR24 in 12- and 24-week cohorts</outcome_measure>
      <outcome_measure>Participant-specific estimates of ARV pharmacokinetic (PK) parameter area under the curve (AUC), estimated from nonlinear mixed-effect population PK models</outcome_measure>
      <outcome_measure>Participant-specific estimates of ARV PK parameter clearance, estimated from nonlinear mixed-effect population PK models</outcome_measure>
      <outcome_measure>Participant-specific estimates of ARV PK parameter Cmax, estimated from nonlinear mixed-effect population PK models</outcome_measure>
      <outcome_measure>Participant-specific estimates of ARV PK parameter Cmin, estimated from nonlinear mixed-effect population PK models</outcome_measure>
      <outcome_measure>Participant-specific estimates of direct acting antivirals (DAA) PK parameter AUC, estimated from nonlinear mixed-effect population PK models</outcome_measure>
      <outcome_measure>Participant-specific estimates of DAA PK parameter clearance, estimated from nonlinear mixed-effect population PK models</outcome_measure>
      <outcome_measure>Participant-specific estimates of DAA PK parameter Cmax, estimated from nonlinear mixed-effect population PK models</outcome_measure>
      <outcome_measure>Participant-specific estimates of DAA PK parameter Cmin, estimated from nonlinear mixed-effect population PK models</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02194998</url>
  </study>
  <study rank="869">
    <nct_id>NCT02128217</nct_id>
    <title>Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV-1 Infection</condition>
      <condition>Hepatitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ledipasvir/Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AIDS Clinical Trials Group</lead_sponsor>
      <collaborator>National Institute of Allergy and Infectious Diseases (NIAID)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ACTG A5327</other_id>
      <other_id>UM1AI068636</other_id>
    </other_ids>
    <first_received>April 29, 2014</first_received>
    <start_date>April 2014</start_date>
    <completion_date>November 2016</completion_date>
    <last_updated>October 5, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>SWIFT-C</acronym>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR12 defined as HCV RNA undetectable (&lt;LLOQ TND) of the assay at 12 weeks after date of last dose of study treatment.</outcome_measure>
      <outcome_measure>Occurrence of a Grade ≥ 2 adverse event (AE: diagnosis, sign, symptom or laboratory abnormality), Serious AE according to ICH criteria, or treatment-limiting AE (ie, an AE reported as the reason for permanent discontinuation of study treatment)</outcome_measure>
      <outcome_measure>HCV RNA undetectable during study treatment</outcome_measure>
      <outcome_measure>HCV RNA undetectable after end of study treatment</outcome_measure>
      <outcome_measure>HCV virologic relapse</outcome_measure>
      <outcome_measure>Development of SOF or LDV-associated resistance mutations</outcome_measure>
      <outcome_measure>Occurrence of each type of adverse event</outcome_measure>
      <outcome_measure>Change in HIV-1 RNA from last measurement prior to start of study treatment</outcome_measure>
      <outcome_measure>Change in CD4+ cell count from last measurement prior to start of study treatment.</outcome_measure>
      <outcome_measure>Self-reported adherence to SOF</outcome_measure>
      <outcome_measure>Self-reported adherence to RBV</outcome_measure>
      <outcome_measure>Adherence as measured by SOF pill count</outcome_measure>
      <outcome_measure>Adherence as measured by RBV pill count</outcome_measure>
      <outcome_measure>Self-reported adherence to LDV/SOF</outcome_measure>
      <outcome_measure>Adherence as measured by LDV/SOF pill count</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02128217</url>
  </study>
  <study rank="870">
    <nct_id>NCT00381953</nct_id>
    <title>High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Interferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Foundation for Liver Research</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>33</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HCV02-01</other_id>
    </other_ids>
    <first_received>September 27, 2006</first_received>
    <start_date>February 2003</start_date>
    <completion_date>July 2006</completion_date>
    <last_updated>March 12, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To compare pharmacokinetics by IFN assays and pharmacodynamics by patient's HCV RNA suppression of 360 mug peginterferon alfa-2a QW, 9 MU interferon alfa-2a daily or 4,5 interferon alfa-2a daily in combination with 180 mug peginterferon alfa-2a QW</outcome_measure>
      <outcome_measure>To compare the virological breakthrough/relapse rate after dose adjustments (at 4,24,72) weeks.</outcome_measure>
      <outcome_measure>To compare the sustained virological response rate at 24 weeks after end of treatment.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00381953</url>
  </study>
  <study rank="871">
    <nct_id>NCT00241618</nct_id>
    <title>Timing and Duration of Acute Hepatitis C Treatment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alpha 2</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ain Shams University</lead_sponsor>
      <collaborator>University Hospital Freiburg</collaborator>
      <collaborator>Beth Israel Deaconess Medical Center</collaborator>
      <collaborator>Alexander von Humboldt Association</collaborator>
      <collaborator>Fulbright</collaborator>
      <collaborator>National Institute of Allergy and Infectious Diseases (NIAID)</collaborator>
      <collaborator>TEMPUS</collaborator>
      <collaborator>International Society for Infectious Diseases</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>180</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>994058402</other_id>
      <other_id>AI054887</other_id>
      <other_id>AI41563</other_id>
      <other_id>Fulbright</other_id>
      <other_id>TEMPUS</other_id>
      <other_id>ISID</other_id>
    </other_ids>
    <first_received>October 18, 2005</first_received>
    <start_date>January 2002</start_date>
    <completion_date>January 2006</completion_date>
    <last_updated>September 7, 2006</last_updated>
    <last_verified>September 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Sustained viral response rate in treatment group versus control</outcome_measure>
      <outcome_measure>End of treatment virologic response</outcome_measure>
      <outcome_measure>Early virologic response at week 4</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00241618</url>
  </study>
  <study rank="872">
    <nct_id>NCT00049842</nct_id>
    <title>Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Liver Fibrosis</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">peginterferon alfa-2b (SCH 54031)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>540</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P02570</other_id>
    </other_ids>
    <first_received>November 14, 2002</first_received>
    <start_date>October 2002</start_date>
    <completion_date>October 2009</completion_date>
    <last_updated>September 24, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>October 7, 2010</firstreceived_results_date>
    <primary_completion_date>October 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Fibrosis Response Status (ie, Improvement, no Change, or the Worsening of the Fibrosis Score in Participants With Baseline METAVIR Fibrosis Score of F2 or F3).</outcome_measure>
      <outcome_measure>Inflammation Response Status (ie, Improvement, no Change, or the Worsening of the METAVIR Activity Score as Compared to Baseline)</outcome_measure>
      <outcome_measure>Mean Change From Baseline to up to Month-36 in the METAVIR Fibrosis Score (Using a Continuous Scale)</outcome_measure>
      <outcome_measure>The Number of Participants Whose METAVIR Fibrosis Score Did Not Worsen (ie, the Response Status of Improved/no Change) During Treatment Compared to Baseline</outcome_measure>
      <outcome_measure>Mean Change in the METAVIR Activity Score (Using a Continuous Scale)</outcome_measure>
      <outcome_measure>Number of Participants With no Worsening (ie, the Response Status of Improved/ no Change) in the METAVIR Activity Score During the Treatment.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00049842</url>
  </study>
  <study rank="873">
    <nct_id>NCT00382798</nct_id>
    <title>Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy Volunteers</condition>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">RO5024048</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pharmasset</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P7081-5101</other_id>
    </other_ids>
    <first_received>September 28, 2006</first_received>
    <start_date>October 2006</start_date>
    <completion_date>September 2008</completion_date>
    <last_updated>April 23, 2009</last_updated>
    <last_verified>April 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>R7128</acronym>
    <primary_completion_date>September 2008</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Iowa</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00382798</url>
  </study>
  <study rank="874">
    <nct_id>NCT01192698</nct_id>
    <title>Intravenous Interferon During the Anhepatic Phase of Liver Transplantation and Prevention of Recurrence of Hepatitis C Virus</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Liver Transplant</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">IV interferon</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Carolinas Healthcare System</lead_sponsor>
      <collaborator>American College of Gastroenterology</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>04-05-09A</other_id>
    </other_ids>
    <first_received>August 30, 2010</first_received>
    <start_date>October 2009</start_date>
    <completion_date>February 2013</completion_date>
    <last_updated>March 31, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HCV RNA result</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01192698</url>
  </study>
  <study rank="875">
    <nct_id>NCT01753557</nct_id>
    <title>Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C (CHC)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MP-424</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">PEG-IFN alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>54</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>G060-A12</other_id>
    </other_ids>
    <first_received>December 13, 2012</first_received>
    <start_date>December 2012</start_date>
    <completion_date>November 2014</completion_date>
    <last_updated>August 17, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Undetectable HCV (Hepatitis C Virus) RNA (Ribonucleic Acid) at 24 weeks after completion of drug administration (SVR, sustained viral response)</outcome_measure>
      <outcome_measure>Undetectable HCV RNA at 4 weeks after beginning of drug administration (RVR, rapid viral response)</outcome_measure>
      <outcome_measure>Undetectable HCV RNA at completion of drug administration (ETR, end-of-treatment response)</outcome_measure>
      <outcome_measure>Undetectable HCV RNA at 12 weeks after completion of drug administration</outcome_measure>
      <outcome_measure>Transition of serum HCV RNA levels</outcome_measure>
      <outcome_measure>Viral sequencing at the NS3 protease region of HCV virus</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01753557</url>
  </study>
  <study rank="876">
    <nct_id>NCT00983164</nct_id>
    <title>Blood Antioxidant Status in Chronic Hepatitis C Patients Before and After Antioxidant Supplementation: a Randomized Clinical Trial</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Oxidative Stress</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Antioxidant Supplementation</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Universidade do Sul de Santa Catarina</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>120/07 CEP</other_id>
    </other_ids>
    <first_received>September 22, 2009</first_received>
    <start_date>January 2007</start_date>
    <completion_date>April 2009</completion_date>
    <last_updated>September 22, 2009</last_updated>
    <last_verified>September 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HepCAntSup</acronym>
    <primary_completion_date>December 2007</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>Brazil</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00983164</url>
  </study>
  <study rank="877">
    <nct_id>NCT01623336</nct_id>
    <title>BIP48 (Peginterferon Alfa 2b 48kDa) Compared With Pegasys® (Peginterferon 2a 40kDa) for Treatment of Chronic Hepatitis C</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BIP 48 (Peginterferon alfa 2b 48kDA)</intervention>
      <intervention type="Drug">Peginterferon alfa 2a 40kDA</intervention>
      <intervention type="Drug">BIP 48 (Peginterferon alfa 2b 48kDA)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)</lead_sponsor>
      <collaborator>Hospital de Clinicas de Porto Alegre</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>740</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Bio-equivalence Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>11/0468</other_id>
    </other_ids>
    <first_received>June 13, 2012</first_received>
    <start_date>January 2012</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>June 15, 2012</last_updated>
    <last_verified>November 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>BIP48II/III</acronym>
    <primary_completion_date>August 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The rate of sustained virologic response - SVR - measured by PCR at 24 weeks after treatment.</outcome_measure>
      <outcome_measure>Frequency of adverse events</outcome_measure>
      <outcome_measure>Virologic response at the end of treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Brazil</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01623336</url>
  </study>
  <study rank="878">
    <nct_id>NCT01753570</nct_id>
    <title>Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C(CHC)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MP-424</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">IFN beta</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
      <collaborator>Toray Industries, Inc</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>74</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>G060-F1</other_id>
    </other_ids>
    <first_received>December 13, 2012</first_received>
    <start_date>December 2012</start_date>
    <completion_date>October 2015</completion_date>
    <last_updated>October 23, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Undetectable HCV (Hepatitis C Virus) RNA (Ribonucleic Acid) at 24 weeks after completion of drug administration (SVR, sustained viral response)</outcome_measure>
      <outcome_measure>Undetectable HCV RNA at 4 weeks after beginning of drug administration (RVR, rapid viral response)</outcome_measure>
      <outcome_measure>Undetectable HCV RNA at completion of drug administration (ETR, end-of-treatment response)</outcome_measure>
      <outcome_measure>Undetectable HCV RNA at 12 weeks after completion of drug administration</outcome_measure>
      <outcome_measure>Transition of serum HCV RNA levels</outcome_measure>
      <outcome_measure>Viral sequencing at the NS-3 protease region of HCV virus</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01753570</url>
  </study>
  <study rank="879">
    <nct_id>NCT02102451</nct_id>
    <title>Control and Elimination Within Australia of Hepatitis C From People Living With HIV</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV</condition>
      <condition>HIV-HCV Coinfection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kirby Institute</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VHCRP1208</other_id>
    </other_ids>
    <first_received>March 20, 2014</first_received>
    <start_date>July 2014</start_date>
    <completion_date>December 2018</completion_date>
    <last_updated>April 28, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>CEASE</acronym>
    <primary_completion_date>December 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HCV viraemia</outcome_measure>
      <outcome_measure>Needs, behaviour and attitudes towards HCV treatment</outcome_measure>
      <outcome_measure>HCV treatment uptake</outcome_measure>
      <outcome_measure>Factors associated with HCV treatment and retreatment</outcome_measure>
      <outcome_measure>HCV treatment response rates</outcome_measure>
      <outcome_measure>Rates of HCV retreatment</outcome_measure>
      <outcome_measure>HCV transmission history</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02102451</url>
  </study>
  <study rank="880">
    <nct_id>NCT02597270</nct_id>
    <title>An Observational/Non-interventional, Study of NS3/4a Protease and NS5A Protein of Hepatitis C Virus in Brazilian Participants With Chronic HCV Infection</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Janssen-Cilag Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR107065</other_id>
      <other_id>TMC435HPC4012</other_id>
    </other_ids>
    <first_received>November 3, 2015</first_received>
    <start_date>January 2016</start_date>
    <completion_date>August 2016</completion_date>
    <last_updated>November 27, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>MAPPING</acronym>
    <primary_completion_date>May 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With HCV NS3/4a Protease and NS5A Protein</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Brazil</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02597270</url>
  </study>
  <study rank="881">
    <nct_id>NCT00723645</nct_id>
    <title>Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>279</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05181</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>April 2008</start_date>
    <completion_date>February 2011</completion_date>
    <last_updated>November 26, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>March 23, 2012</firstreceived_results_date>
    <acronym>FAST-4</acronym>
    <primary_completion_date>April 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Relapse At 24 Weeks After the End Of Treatment (EOT)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Relapsed After EOT at Week 72 (Late Relapser)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00723645</url>
  </study>
  <study rank="882">
    <nct_id>NCT02468648</nct_id>
    <title>Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">GS-5816</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>140</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>150143</other_id>
      <other_id>15-DK-0143</other_id>
    </other_ids>
    <first_received>June 9, 2015</first_received>
    <start_date>June 2015</start_date>
    <completion_date>July 2017</completion_date>
    <last_updated>September 12, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary endpoints will be changes in interferon stimulated gene and protein expression in the liver and changes in HCV RNA levels in liver and serum between baseline and 4 weeks.</outcome_measure>
      <outcome_measure>Proportion who achieve SVR12 stratified by viral genotype</outcome_measure>
      <outcome_measure>Secondary endpoints will be safety and rates of sustained virologic response 24 weeks off therapy</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02468648</url>
  </study>
  <study rank="883">
    <nct_id>NCT01821625</nct_id>
    <title>Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Thrombocytopenia</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Eltrombopag</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Texas Southwestern Medical Center</lead_sponsor>
      <collaborator>GlaxoSmithKline</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>STU 032013-020</other_id>
    </other_ids>
    <first_received>March 23, 2013</first_received>
    <start_date>April 2013</start_date>
    <last_updated>August 15, 2013</last_updated>
    <last_verified>March 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>SQUELCH-C</acronym>
    <primary_completion_date>April 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of study patients completing antiviral therapy, as per boceprevir prescribing guidelines.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01821625</url>
  </study>
  <study rank="884">
    <nct_id>NCT00308048</nct_id>
    <title>14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon alfa 2b and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ullevaal University Hospital</lead_sponsor>
      <collaborator>Schering-Plough</collaborator>
      <collaborator>Oslo University Hospital</collaborator>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>435</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P03720</other_id>
    </other_ids>
    <first_received>March 27, 2006</first_received>
    <start_date>March 2004</start_date>
    <completion_date>September 2006</completion_date>
    <last_updated>July 3, 2011</last_updated>
    <last_verified>March 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (SVR) =HCV RNA negativity (&lt;20 IU/ml) six months after end of treatment.</outcome_measure>
      <outcome_measure>Change in health related quality as measured by short from 36 (SF-36) from baseline to 6 months after end of treatment.</outcome_measure>
      <outcome_measure>Sick leave in patients treated for 14 or 24 weeks treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Norway</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00308048</url>
  </study>
  <study rank="885">
    <nct_id>NCT01577069</nct_id>
    <title>Predictive Factors of the Treatment Failure in Hepatitis C Virus (HCV) Infected Patients Treated With Telaprevir</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Association HGE CHU Bordeaux Sud</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>73</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>UDPS-100211</other_id>
    </other_ids>
    <first_received>April 12, 2012</first_received>
    <start_date>February 2011</start_date>
    <completion_date>January 2013</completion_date>
    <last_updated>July 29, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>GENUPI</acronym>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>virological resitance</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01577069</url>
  </study>
  <study rank="886">
    <nct_id>NCT01146626</nct_id>
    <title>Does Vitamin D Improves Sustained Virologic Response (SVR) in Genotype 2,3 Chronic Hepatitis C Patients?</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg+ Vitamin D+ Ribavirine</intervention>
      <intervention type="Drug">Peg+ Ribavirine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ziv Hospital</lead_sponsor>
      <collaborator>Hillel Yaffe Medical Center</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HCV +Vitamin D</other_id>
    </other_ids>
    <first_received>June 16, 2010</first_received>
    <start_date>August 2011</start_date>
    <completion_date>May 2012</completion_date>
    <last_updated>April 27, 2011</last_updated>
    <last_verified>June 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR rate</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Israel</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01146626</url>
  </study>
  <study rank="887">
    <nct_id>NCT01377909</nct_id>
    <title>HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">statin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bader, Ted, M.D.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Bader 15859</other_id>
    </other_ids>
    <first_received>June 20, 2011</first_received>
    <start_date>March 2012</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>August 21, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Improvement in peginterferon response as measured by change in HCV RNA levels</outcome_measure>
      <outcome_measure>The response of interferon stimulated genes</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Oklahoma</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01377909</url>
  </study>
  <study rank="888">
    <nct_id>NCT02118597</nct_id>
    <title>An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Pegasys and Ribivarin in the Re-Treatment of Chronic Hepatitis C Patients</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML29278</other_id>
    </other_ids>
    <first_received>April 16, 2014</first_received>
    <start_date>May 2014</start_date>
    <completion_date>April 2017</completion_date>
    <last_updated>April 16, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response 24 (SVR24), defined as percentage of patients with HCV RNA &lt; 15 IU/mL after the 24-week follow-up</outcome_measure>
      <outcome_measure>Virological response (HCV RNA &lt; 15 IU/mL)</outcome_measure>
      <outcome_measure>Virological breakthrough, defined as either HCV RNA &gt;/= 15 IU/mL in patients with prior virological response or as an increase in RCV RNA &gt;/= 1 log10 above nadir</outcome_measure>
      <outcome_measure>Virological relapse defined as HCV RNA &gt;/= 15 IU/mL during the treatment free follow-up period in patients with virological response at the end of treatment</outcome_measure>
      <outcome_measure>Incidence of treatment discontinuation due to futility, defined as: HCV RNA drop &lt; 3 log10 at Week 8, HCV RNA &gt;/= 100 IU/mL at Week 12, or HCV RNA &gt;/= 15 IU/mL at Week 24</outcome_measure>
      <outcome_measure>Incidence of treatment discontinuation</outcome_measure>
      <outcome_measure>Incidence of adverse events</outcome_measure>
      <outcome_measure>Predictive value of patient demographics</outcome_measure>
      <outcome_measure>Predictive value of liver fibrosis</outcome_measure>
      <outcome_measure>Predictive value of HCV disease characteristics</outcome_measure>
      <outcome_measure>Predictive value of previous virological response (null-response, partial response, or relapse)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02118597</url>
  </study>
  <study rank="889">
    <nct_id>NCT00546442</nct_id>
    <title>Treatment Insulin Resistence in HCV G-1 Patient</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Metformine</intervention>
      <intervention type="Other">Placebo of metformine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Valme University Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>126</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Single Blind (Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>2005-02446-19</other_id>
    </other_ids>
    <first_received>October 17, 2007</first_received>
    <start_date>May 2006</start_date>
    <completion_date>January 2007</completion_date>
    <last_updated>October 17, 2007</last_updated>
    <last_verified>October 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>TRIC-1</acronym>
    <outcome_measures>
      <outcome_measure>Percentage of patients with HCV-RNA</outcome_measure>
      <outcome_measure>Percentage of patients who has erradicated the insulin resistance</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00546442</url>
  </study>
  <study rank="890">
    <nct_id>NCT01625793</nct_id>
    <title>Inflammation, Stress &amp; Social Behavior: Using Ecological Assessments &amp; Model Systems to Enhance Relevance to Health Outcomes</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Interferon-alpha</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Arizona</lead_sponsor>
      <collaborator>Emory University</collaborator>
      <collaborator>National Center for Complementary and Integrative Health (NCCIH)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
      <study_design>Masking: Single Blind (Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>12-0166-02</other_id>
      <other_id>5R01AT007297-03</other_id>
    </other_ids>
    <first_received>June 11, 2012</first_received>
    <start_date>June 2012</start_date>
    <completion_date>July 2013</completion_date>
    <last_updated>July 18, 2013</last_updated>
    <last_verified>July 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percent time laughing</outcome_measure>
      <outcome_measure>Percent time expressing empathy for others</outcome_measure>
      <outcome_measure>Percent of time spent in substantive conversations</outcome_measure>
      <outcome_measure>Percent of time spent alone</outcome_measure>
      <outcome_measure>Cortisol concentrations in blood in response to stress test</outcome_measure>
      <outcome_measure>Interleukin (IL)-6 concentrations in the blood in response to stress test</outcome_measure>
      <outcome_measure>Diurnal plasma concentrations of interleukin-6 and tumor necrosis factor-alpha type II receptors in response to a stress test</outcome_measure>
      <outcome_measure>Diurnal plasma concentrations of inflamcortisol in response to a stress test</outcome_measure>
      <outcome_measure>Wake time after sleep onset measured by actigraphy</outcome_measure>
      <outcome_measure>Sleep latency by measured by actigraphy</outcome_measure>
      <outcome_measure>Total sleep time by actigraphy</outcome_measure>
      <outcome_measure>Sleep efficiency by actigraphy</outcome_measure>
      <outcome_measure>Structured Interview Guide for the Hamilton Depression Scale and Inventory of Depressive Symptomatology (SIGH-IDS)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>Georgia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01625793</url>
  </study>
  <study rank="891">
    <nct_id>NCT02202980</nct_id>
    <title>Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">GS-9857</intervention>
      <intervention type="Drug">SOF/GS-5816</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>273</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-1468</other_id>
    </other_ids>
    <first_received>July 25, 2014</first_received>
    <start_date>August 2014</start_date>
    <completion_date>July 2016</completion_date>
    <last_updated>November 17, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of any adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with on treatment virologic failure and relapse</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response (ie, HCV RNA &lt; LLOQ) while on treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>New Zealand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02202980</url>
  </study>
  <study rank="892">
    <nct_id>NCT00682591</nct_id>
    <title>Evaluation of Neurocognitive Performance in Drug Substituted Patients Under Hepatitis C Therapy</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>University of Wuerzburg</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>190</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05595</other_id>
    </other_ids>
    <first_received>May 20, 2008</first_received>
    <start_date>July 2008</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>February 3, 2009</last_updated>
    <last_verified>February 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Time course of neurocognitive performance (as assessed by the TAP - Test Battery for Attentional Performance)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00682591</url>
  </study>
  <study rank="893">
    <nct_id>NCT01497834</nct_id>
    <title>A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-790052 (Daclatasvir)</intervention>
      <intervention type="Drug">BMS-650032 (Asunaprevir)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>224</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI447-026</other_id>
    </other_ids>
    <first_received>December 2, 2011</first_received>
    <start_date>January 2012</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Antiviral activity, as determined by the proportion of subjects with SVR24</outcome_measure>
      <outcome_measure>Antiviral activity, as determined by the proportion of subjects who achieve Hepatitis C virus (HCV) ribonucleic acid (RNA) below lower limit of quantitation (LLOQ) target detected or not detected</outcome_measure>
      <outcome_measure>Antiviral activity, as determined by the proportion of subjects who achieve HCV RNA below LLOQ, target not detected</outcome_measure>
      <outcome_measure>Safety, as measured by the frequency of serious adverse events (SAEs), discontinuations due to adverse events (AEs), AEs by intensity and laboratory abnormalities by toxicity grade</outcome_measure>
      <outcome_measure>Proportion of subjects with SVR24 by IL28B status [CC, CT, or TT genotype at the IL28B rs12979860 single nucleotide polymorphisms (SNP)]</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01497834</url>
  </study>
  <study rank="894">
    <nct_id>NCT01310205</nct_id>
    <title>Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SCV-07</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>SciClone Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs/>
    <other_ids>
      <other_id>SCI-SCV-HCV-P2-001-Extension</other_id>
    </other_ids>
    <first_received>March 4, 2011</first_received>
    <start_date>August 2010</start_date>
    <completion_date>March 2012</completion_date>
    <last_updated>March 7, 2012</last_updated>
    <last_verified>March 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2012</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Kentucky</state>
      <state>Ohio</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01310205</url>
  </study>
  <study rank="895">
    <nct_id>NCT00128271</nct_id>
    <title>Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Bavituximab</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Peregrine Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>PPHM 0501</other_id>
    </other_ids>
    <first_received>August 8, 2005</first_received>
    <start_date>August 2005</start_date>
    <last_updated>April 28, 2008</last_updated>
    <last_verified>August 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>adverse events</outcome_measure>
      <outcome_measure>laboratory evaluations</outcome_measure>
      <outcome_measure>human anti-chimeric antibody</outcome_measure>
      <outcome_measure>pharmacokinetic analysis</outcome_measure>
      <outcome_measure>viral kinetic analysis</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Florida</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00128271</url>
  </study>
  <study rank="896">
    <nct_id>NCT01250743</nct_id>
    <title>A Pilot Study of High-Dose, Intravenous Ascorbic Acid (Vitamin C) to Treat Hepatitis C</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">ascorbic acid (vitamin C)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Health Innovations, Frontier Research Institute</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>FRI-101</other_id>
    </other_ids>
    <first_received>November 29, 2010</first_received>
    <start_date>January 2009</start_date>
    <completion_date>June 2012</completion_date>
    <last_updated>February 17, 2011</last_updated>
    <last_verified>November 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>number of participants with adverse events as a measure of safety and tolerability</outcome_measure>
      <outcome_measure>anti-viral efficacy</outcome_measure>
      <outcome_measure>aspartate aminotransferase (AST or SGOT)</outcome_measure>
      <outcome_measure>alanine aminotransferase (ALT or SGPT)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Kansas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01250743</url>
  </study>
  <study rank="897">
    <nct_id>NCT00759200</nct_id>
    <title>Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">alb-interferon alfa 2b</intervention>
      <intervention type="Drug">alb-interferon alfa 2b</intervention>
      <intervention type="Drug">alb-interferon alfa 2b</intervention>
      <intervention type="Drug">alb-interferon alfa 2b</intervention>
      <intervention type="Drug">peg-interferon</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis</lead_sponsor>
      <collaborator>Human Genome Sciences Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>525</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CABF656B2202</other_id>
    </other_ids>
    <first_received>September 23, 2008</first_received>
    <start_date>October 2008</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>April 18, 2011</last_updated>
    <last_verified>April 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>Viral load</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
      <country>Australia</country>
      <country>France</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>India</country>
      <country>Italy</country>
      <country>Poland</country>
      <country>Spain</country>
      <country>Taiwan</country>
      <country>Thailand</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00759200</url>
  </study>
  <study rank="898">
    <nct_id>NCT01433133</nct_id>
    <title>Safety and Biological Activity of InfraDure Biopump Secreting Sustained Interferon in HCV Patients</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">implantation</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Medgenics Medical Israel Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>3</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>MG-002-02</other_id>
    </other_ids>
    <first_received>September 5, 2011</first_received>
    <start_date>October 2012</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>October 20, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Viral Load: incidence of sustained virologic response (SVR)</outcome_measure>
      <outcome_measure>Rapid virologic response (RVR)</outcome_measure>
      <outcome_measure>Early virologic response (EVR)</outcome_measure>
      <outcome_measure>End-of-treatment response (EOT)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01433133</url>
  </study>
  <study rank="899">
    <nct_id>NCT01399619</nct_id>
    <title>Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PegIFN/RBV</intervention>
      <intervention type="Drug">PegIFN/RBV</intervention>
      <intervention type="Drug">BI201335</intervention>
      <intervention type="Drug">BI201335 24W</intervention>
      <intervention type="Drug">PegIFN/RBV</intervention>
      <intervention type="Drug">Bi 201335</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>310</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1220.19</other_id>
      <other_id>2010-021734-59</other_id>
    </other_ids>
    <first_received>July 20, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>August 6, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>July 3, 2015</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virological Response (SVR12)</outcome_measure>
      <outcome_measure>Virological Response 24 Weeks Post Treatment (SVR24)</outcome_measure>
      <outcome_measure>Early Treatment Success (ETS)</outcome_measure>
      <outcome_measure>The Number of Participants With Alanine Aminotransferase (ALT) Normalisation at End of Treatment (EoT) When SVR12=Yes</outcome_measure>
      <outcome_measure>The Number of Participants With Alanine Aminotransferase (ALT) Normalisation at End of Treatment When SVR12=no</outcome_measure>
      <outcome_measure>The Number of Participants With Alanine Aminotransferase (ALT) Normalisation at Post Treatment When SVR12=Yes</outcome_measure>
      <outcome_measure>The Number of Participants With Alanine Aminotransferase (ALT) Normalisation at Post Treatment When SVR12=no</outcome_measure>
      <outcome_measure>The Number of Participants With Aspartate Aminotransferase (AST) Normalisation at End of Treatment When SVR12=Yes</outcome_measure>
      <outcome_measure>The Number of Participants With Aspartate Aminotransferase (AST) Normalisation at End of Treatment When SVR12=no</outcome_measure>
      <outcome_measure>The Number of Participants With Aspartate Aminotransferase (AST) Normalisation at Post Treatment When SVR12=Yes</outcome_measure>
      <outcome_measure>The Number of Participants With Aspartate Aminotransferase (AST) Normalisation at Post Treatment When SVR12=no</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Brazil</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Spain</country>
      <country>Switzerland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01399619</url>
  </study>
  <study rank="900">
    <nct_id>NCT00793793</nct_id>
    <title>Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BI201335</intervention>
      <intervention type="Drug">BI201335</intervention>
      <intervention type="Drug">BI201335</intervention>
      <intervention type="Drug">BI201335</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>96</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>1220.2</other_id>
      <other_id>2007-001158-19</other_id>
    </other_ids>
    <first_received>September 23, 2008</first_received>
    <start_date>September 2007</start_date>
    <last_updated>August 18, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>July 3, 2015</firstreceived_results_date>
    <primary_completion_date>January 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy: VR (Virologic Response) of &gt;=2 log10 Reduction in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) From Baseline at Any Time up to Day 14 (naïve Patients) or Day 28 (Experienced Patients)</outcome_measure>
      <outcome_measure>Occurrence of Adverse Events (AEs) During BI201335 + Washout Period</outcome_measure>
      <outcome_measure>Occurrence of Serious Adverse Events (SAEs) During BI201335 + Washout Period</outcome_measure>
      <outcome_measure>Occurrence of Laboratory Test Abnormalities and With Respect to Division of AIDS (DAIDS) Classification and Laboratory Test Values Change Over Time</outcome_measure>
      <outcome_measure>Maximum Viral Load Reduction From Baseline up to Day 14 for Treatment-naïve Patients and Day 28 Treatment for Treatment-experienced Patients</outcome_measure>
      <outcome_measure>Change From Baseline in Viral Load on Day 14 for Treatment-naïve Patients and on Day 28 Treatment for Treatment-experienced Patients</outcome_measure>
      <outcome_measure>Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Early Virologic Response (EVR)</outcome_measure>
      <outcome_measure>Complete EVR1 (cEVR1)</outcome_measure>
      <outcome_measure>Complete EVR2 (cEVR2)</outcome_measure>
      <outcome_measure>End of Treatment Response (ETR)</outcome_measure>
      <outcome_measure>Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Achievement of an HCV RNA Level Below the Limit of Detection Over Time</outcome_measure>
      <outcome_measure>Achievement of an HCV RNA Level Below the Limit of Quantification Over Time</outcome_measure>
      <outcome_measure>Achievement of a &gt;= 2 log10 Reduction in Plasma HCV RNA Level From Baseline Over Time</outcome_measure>
      <outcome_measure>Occurrence of AEs, by Action Taken With Regard to Study Medication</outcome_measure>
      <outcome_measure>Occurrence of Discontinuations Due to AEs During BI201335 or BI201335+PegIFN/RBV Combination Treatment Period</outcome_measure>
      <outcome_measure>PK (Pharmacokinetic) Parameter After the First Dose: Cmax ( Maximum Measured Concentration of the Analyte in Plasma)</outcome_measure>
      <outcome_measure>PK Parameter After the First Dose: Tmax (Time From (Last) Dosing to the Maximum Measured Concentration of the Analyte in Plasma)</outcome_measure>
      <outcome_measure>PK Parameter After the First Dose: AUCτ,1 (Area Under the Concentration-time Curve of the Analyte in Plasma Over a Uniform Dosing Interval τ on Day 1)</outcome_measure>
      <outcome_measure>PK Parameter at Steady State After the Last Dose: Cmax,ss (Maximum Measured Concentration of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval τ)</outcome_measure>
      <outcome_measure>PK Parameter at Steady State After the Last Dose: Tmax,ss (Time From Last Dosing to the Maximum Measured Concentration of the Analyte in Plasma at Steady State )</outcome_measure>
      <outcome_measure>PK Parameter at Steady State After the Last Dose: Cmin,ss (Minimum Measured Concentration of the Analyte in Plasma)</outcome_measure>
      <outcome_measure>PK Parameter at Steady State After the Last Dose: AUCτ,ss (Area Under the Concentration-time Curve of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval τ)</outcome_measure>
      <outcome_measure>PK Parameter at Steady State After the Last Dose: t1/2,ss (Terminal Half-life of the Analyte in Plasma at Steady State )</outcome_measure>
      <outcome_measure>PK Parameter at Steady State After the Last Dose: MRTpo,ss (Mean Residence Time of the Analyte in the Body at Steady State After Oral Administration)</outcome_measure>
      <outcome_measure>PK Parameter at Steady State After the Last Dose: CL/F,ss (Apparent Clearance of the Analyte in Plasma at Steady State Following Multiple Oral Dose Administration )</outcome_measure>
      <outcome_measure>PK Parameter at Steady State After the Last Dose: Vz/F,ss (Apparent Volume of Distribution During the Terminal Phase z at Steady State Following an Oral Administration )</outcome_measure>
      <outcome_measure>PK Parameter for Drug-drug Interaction (naïve Patients With ≥1 Log Reduction on Day 10): AUCτ,ss (Area Under the Concentration-time Curve of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval τ )</outcome_measure>
      <outcome_measure>PK Parameter for Drug-drug Interaction (naïve Patients With ≥1 Log Reduction on Day 10): Cmax,ss</outcome_measure>
      <outcome_measure>PK Parameter for Drug-drug Interaction (naïve Patients With ≥1 Log Reduction on Day 10): Cmin, ss</outcome_measure>
      <outcome_measure>Accumulation Ratio of the Analyte in Plasma Following Multiple Doses Over a Uniform Dosing Interval: RAcmax</outcome_measure>
      <outcome_measure>Accumulation Ratio of the Analyte in Plasma Following Multiple Doses Over a Uniform Dosing Interval: RAauc</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>France</country>
      <country>Germany</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Maryland</state>
      <state>New York</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00793793</url>
  </study>
  <study rank="901">
    <nct_id>NCT02057003</nct_id>
    <title>Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Human Immunodeficiency Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DAA against HCV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Valme University Hospital</lead_sponsor>
      <collaborator>Hospital Universitario Reina Sofia</collaborator>
      <collaborator>Hospital Universitario Virgen de la Victoria</collaborator>
      <collaborator>Hospital Universitario de la Princesa</collaborator>
      <collaborator>Hospitales Universitarios Virgen del Rocío</collaborator>
      <collaborator>Hospital Universitario Carlos Haya</collaborator>
      <collaborator>Hospital Torrecárdenas</collaborator>
      <collaborator>Complejo Hospitalario Universitario de Huelva</collaborator>
      <collaborator>Hospital Puerta del Mar</collaborator>
      <collaborator>Hospital Universitario Virgen Macarena</collaborator>
      <collaborator>Hospital de La Línea</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>HEPAVIR-DAA</other_id>
    </other_ids>
    <first_received>January 6, 2014</first_received>
    <start_date>January 2012</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>November 10, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of patients who achieve SVR to DAA-based therapy as measure of efficacy</outcome_measure>
      <outcome_measure>Number of patients who develop severe adverse events as measure of safety</outcome_measure>
      <outcome_measure>Number of patients who achieve SVR to a BOC-based regimen as compared to numbers of patients who achieve SVR to a TVR-based regimen.</outcome_measure>
      <outcome_measure>Number of patients who reach undetectable HCV-RNA at week 4 of PI-based therapy as a measure of on-treatment response to therapy.</outcome_measure>
      <outcome_measure>Number of patients who develop adverse events during a BOC-based regimen as compared to numbers of patients who develop adverse events during a TVR-based regimen.</outcome_measure>
      <outcome_measure>Number of patients who achieve SVR to an interferon-free regimen.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02057003</url>
  </study>
  <study rank="902">
    <nct_id>NCT00247884</nct_id>
    <title>Pender Assisted Therapy (PATh) - Prospective Study of the Treatment of HCV</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>University of British Columbia</lead_sponsor>
      <collaborator>Canadian Institutes of Health Research (CIHR)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>C05-0219</other_id>
    </other_ids>
    <first_received>October 31, 2005</first_received>
    <start_date>June 2005</start_date>
    <completion_date>October 2009</completion_date>
    <last_updated>October 9, 2009</last_updated>
    <last_verified>October 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00247884</url>
  </study>
  <study rank="903">
    <nct_id>NCT02604017</nct_id>
    <title>A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Hepatitis C Virus</condition>
      <condition>HCV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-493/ABT-530</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M13-590</other_id>
      <other_id>2015-002087-17</other_id>
    </other_ids>
    <first_received>November 11, 2015</first_received>
    <start_date>October 2015</start_date>
    <completion_date>January 2017</completion_date>
    <last_updated>November 11, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants achieving a 12-week sustained virologic response (SVR12) Post-treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment in the 8-week Arm compared to the 12-week Arm in the per protocol (PP) population.</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment in the 8-week Arm compared to the 12-week Arm in the intent-to-treat (ITT) population.</outcome_measure>
      <outcome_measure>Percentage of participants with on-treatment virologic failure</outcome_measure>
      <outcome_measure>Percentage of participants with Post-Treatment relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Chile</country>
      <country>France</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Italy</country>
      <country>Korea, Republic of</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>New Jersey</state>
      <state>North Carolina</state>
      <state>Tennessee</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02604017</url>
  </study>
  <study rank="904">
    <nct_id>NCT02582632</nct_id>
    <title>A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ombitasvir/Paritaprevir/Ritonavir</intervention>
      <intervention type="Drug">dasabuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>160</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M15-684</other_id>
      <other_id>2015-003370-33</other_id>
    </other_ids>
    <first_received>October 20, 2015</first_received>
    <start_date>November 2015</start_date>
    <completion_date>February 2017</completion_date>
    <last_updated>October 20, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants who achieve sustained virologic response 12 weeks post-treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of participants with virologic failure during treatment</outcome_measure>
      <outcome_measure>Percentage of participants with post-treatment relapse</outcome_measure>
      <outcome_measure>Percentage of female participants who achieve sustained virologic response 12 (SVR12) weeks post-treatment</outcome_measure>
      <outcome_measure>Percentage of participants with low baseline viral load who achieve sustained virologic response 12 (SVR12) weeks post-treatment</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02582632</url>
  </study>
  <study rank="905">
    <nct_id>NCT02219503</nct_id>
    <title>A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
      <condition>Compensated Cirrhosis</condition>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ombitasvir/ABT-450/ritonavir</intervention>
      <intervention type="Drug">dasabuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M14-490</other_id>
      <other_id>2014-001953-18</other_id>
    </other_ids>
    <first_received>August 15, 2014</first_received>
    <start_date>September 2014</start_date>
    <completion_date>September 2015</completion_date>
    <last_updated>October 9, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>TURQUOISE-III</acronym>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants with Sustained Virologic Response 12 weeks post-treatment</outcome_measure>
      <outcome_measure>Percentage of participants with on-treatment virologic failure</outcome_measure>
      <outcome_measure>Percentage of participants with post-treatment relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Belgium</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02219503</url>
  </study>
  <study rank="906">
    <nct_id>NCT00825877</nct_id>
    <title>Long-term Follow-up of HALT-C Sustained Virological Responders</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Hepatocellular Carcinoma</condition>
      <condition>Ascites</condition>
      <condition>Variceal Hemorrhage</condition>
      <condition>Death</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>4</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs/>
    <other_ids>
      <other_id>090067</other_id>
      <other_id>09-DK-0067</other_id>
    </other_ids>
    <first_received>January 17, 2009</first_received>
    <start_date>January 2009</start_date>
    <completion_date>June 2012</completion_date>
    <last_updated>October 9, 2014</last_updated>
    <last_verified>June 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00825877</url>
  </study>
  <study rank="907">
    <nct_id>NCT01182298</nct_id>
    <title>Open Label Study to Evaluate Chronic Hepatitis C Treatment in Latino Subjects With and Without HIV Co-infection</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>Fundación de Investigación de Diego</collaborator>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>100159</other_id>
      <other_id>10-I-0159</other_id>
    </other_ids>
    <first_received>August 13, 2010</first_received>
    <start_date>July 2010</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>September 26, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>April 23, 2014</firstreceived_results_date>
    <acronym>LATHCV</acronym>
    <primary_completion_date>March 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Median Log Change in HCV RNA Levels on Day 7</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01182298</url>
  </study>
  <study rank="908">
    <nct_id>NCT01750515</nct_id>
    <title>Acupuncture as an Adjunctive Treatment for Hepatitis C Patients</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C (HCV)</condition>
      <condition>Acupuncture</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Acupuncture</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Assy Nimer</lead_sponsor>
      <collaborator>Ziv Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs/>
    <other_ids>
      <other_id>0094-12-ZIV</other_id>
    </other_ids>
    <first_received>November 26, 2012</first_received>
    <start_date>January 2013</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>December 12, 2012</last_updated>
    <last_verified>December 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>Israel</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01750515</url>
  </study>
  <study rank="909">
    <nct_id>NCT02485262</nct_id>
    <title>Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir and simeprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Arrowhead Regional Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>340</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>1234</other_id>
      <other_id>14-25</other_id>
    </other_ids>
    <first_received>June 19, 2015</first_received>
    <start_date>November 2013</start_date>
    <completion_date>November 2016</completion_date>
    <last_updated>June 29, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR 12</outcome_measure>
      <outcome_measure>Safety and Tolerability as measured by the number of participants with AEs, Change in baseline laboratory results</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02485262</url>
  </study>
  <study rank="910">
    <nct_id>NCT01492478</nct_id>
    <title>Psychobiological Characterization of Depression in Hepatitis C</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Depression</condition>
      <condition>Hepatitis c</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Centro Hospitalar Lisboa Norte</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>39772</other_id>
    </other_ids>
    <first_received>December 13, 2011</first_received>
    <start_date>January 2012</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>December 14, 2011</last_updated>
    <last_verified>December 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2015</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>Portugal</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01492478</url>
  </study>
  <study rank="911">
    <nct_id>NCT01360268</nct_id>
    <title>The Metabolic Profile and Adipocytokine Alterations of Patients With HCV Infection Before and After HCV Therapy</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Metabolic Syndrome</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Chang Gung Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>Merck (MISP) # 38846</other_id>
    </other_ids>
    <first_received>May 24, 2011</first_received>
    <start_date>January 2011</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>May 24, 2011</last_updated>
    <last_verified>February 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01360268</url>
  </study>
  <study rank="912">
    <nct_id>NCT00029107</nct_id>
    <title>Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Vasculitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rituximab</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>47</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>020096</other_id>
      <other_id>02-I-0096</other_id>
    </other_ids>
    <first_received>January 5, 2002</first_received>
    <start_date>December 2001</start_date>
    <completion_date>May 2011</completion_date>
    <last_updated>April 10, 2012</last_updated>
    <last_verified>April 2012</last_verified>
    <firstreceived_results_date>October 26, 2011</firstreceived_results_date>
    <primary_completion_date>May 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percent of Patients in Remission</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00029107</url>
  </study>
  <study rank="913">
    <nct_id>NCT00807001</nct_id>
    <title>Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C (HCV)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">IDX184</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>41</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>2355-003</other_id>
      <other_id>IDX-08C-003</other_id>
    </other_ids>
    <first_received>December 10, 2008</first_received>
    <start_date>December 2008</start_date>
    <completion_date>July 2009</completion_date>
    <last_updated>April 22, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>October 8, 2010</firstreceived_results_date>
    <primary_completion_date>July 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Subjects With Any Adverse Event (Side Effect) and the Severity of Those Adverse Events</outcome_measure>
      <outcome_measure>Antiviral Activity at Day 4. Change in Plasma HCV RNA (Hepatitis C Virus Ribonucleic Acid)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00807001</url>
  </study>
  <study rank="914">
    <nct_id>NCT00979979</nct_id>
    <title>Clinical Performance of Abbott RealTime Hepatitis C Virus (HCV) Genotype II Test</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>Abbott Diagnostics Division</collaborator>
      <collaborator>National Science Council, Taiwan</collaborator>
      <collaborator>Department of Health, Executive Yuan, R.O.C. (Taiwan)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>255</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>200906047D</other_id>
    </other_ids>
    <first_received>September 16, 2009</first_received>
    <start_date>July 2009</start_date>
    <completion_date>October 2013</completion_date>
    <last_updated>October 19, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Diagnostic accuracy for HCV genotype testing</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00979979</url>
  </study>
  <study rank="915">
    <nct_id>NCT01535092</nct_id>
    <title>Legalon SIL for the Treatment of HCV Recurrence in Liver Transplanted Patients</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV Recurrence After Liver Transplantation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Silibinin</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Rottapharm</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>14</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>LEG-SIL-LTX-03</other_id>
    </other_ids>
    <first_received>February 7, 2012</first_received>
    <start_date>September 2010</start_date>
    <completion_date>November 2011</completion_date>
    <last_updated>February 14, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (SVR), defined as Virological Response (undetectable HCV-RNA) that lasts 6 months after the transplant</outcome_measure>
      <outcome_measure>Virologic response (VR) defined as undetectable HCV RNA</outcome_measure>
      <outcome_measure>Percentage of patients who has a decreased of at least 2 log10 the levels of HCV-RNA</outcome_measure>
      <outcome_measure>Number of patients with AE</outcome_measure>
      <outcome_measure>laboratory parameters</outcome_measure>
      <outcome_measure>blood levels of immunosuppressive drugs</outcome_measure>
      <outcome_measure>Vital signs</outcome_measure>
      <outcome_measure>ECG</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01535092</url>
  </study>
  <study rank="916">
    <nct_id>NCT00028275</nct_id>
    <title>Gamma Interferon Therapy for Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Gamma Interferon 1b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>020072</other_id>
      <other_id>02-DK-0072</other_id>
    </other_ids>
    <first_received>December 18, 2001</first_received>
    <start_date>December 2001</start_date>
    <completion_date>November 2003</completion_date>
    <last_updated>March 3, 2008</last_updated>
    <last_verified>November 2003</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00028275</url>
  </study>
  <study rank="917">
    <nct_id>NCT00749138</nct_id>
    <title>Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">tamoxifen</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bader, Ted, M.D.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>102453081873</other_id>
    </other_ids>
    <first_received>September 4, 2008</first_received>
    <start_date>November 2008</start_date>
    <completion_date>October 2009</completion_date>
    <last_updated>March 7, 2010</last_updated>
    <last_verified>March 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>No significant changes in ALT or total bilirubin</outcome_measure>
      <outcome_measure>HCV RNA reduction</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Oklahoma</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00749138</url>
  </study>
  <study rank="918">
    <nct_id>NCT01465919</nct_id>
    <title>Efficacy Study of Mirtazapine to Treat Interferon-related Depression During Antiviral Therapy for Hepatitis C</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Depression</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Mirtazapine</intervention>
      <intervention type="Other">Supportive psychotherapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Seoul National University Boramae Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>56</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>06-2011-130</other_id>
    </other_ids>
    <first_received>October 31, 2011</first_received>
    <start_date>August 2011</start_date>
    <completion_date>March 2016</completion_date>
    <last_updated>May 18, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from baseline in Hamilton Depression Rating Scale (HAMD)-17 at 8 weeks</outcome_measure>
      <outcome_measure>Change from baseline in quality of life at 8 weeks</outcome_measure>
      <outcome_measure>Genetic polymorphism</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Korea, Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01465919</url>
  </study>
  <study rank="919">
    <nct_id>NCT00821587</nct_id>
    <title>Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cyclosporine</intervention>
      <intervention type="Drug">Tacrolimus</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Florida</lead_sponsor>
      <collaborator>Novartis Pharmaceuticals</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>39</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>20040658</other_id>
    </other_ids>
    <first_received>January 9, 2009</first_received>
    <start_date>June 2004</start_date>
    <completion_date>May 2008</completion_date>
    <last_updated>November 2, 2011</last_updated>
    <last_verified>November 2011</last_verified>
    <firstreceived_results_date>August 4, 2011</firstreceived_results_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Hepatitis C Viral Level</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00821587</url>
  </study>
  <study rank="920">
    <nct_id>NCT00763568</nct_id>
    <title>4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitazoxanide</intervention>
      <intervention type="Biological">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Romark Laboratories L.C.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>RM01-3037</other_id>
    </other_ids>
    <first_received>September 26, 2008</first_received>
    <start_date>August 2006</start_date>
    <completion_date>September 2008</completion_date>
    <last_updated>September 26, 2008</last_updated>
    <last_verified>September 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response</outcome_measure>
      <outcome_measure>End of treatment virologic response</outcome_measure>
      <outcome_measure>Early virologic response</outcome_measure>
      <outcome_measure>Rapid virologic response</outcome_measure>
      <outcome_measure>ALT normalization</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00763568</url>
  </study>
  <study rank="921">
    <nct_id>NCT02378935</nct_id>
    <title>Safety and Efficacy of GS-9857 Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GS-9857</intervention>
      <intervention type="Drug">SOF/VEL</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>205</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-367-1168</other_id>
    </other_ids>
    <first_received>February 27, 2015</first_received>
    <start_date>February 2015</start_date>
    <completion_date>April 2016</completion_date>
    <last_updated>September 22, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of any adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV RNA &lt; LLOQ on treatment</outcome_measure>
      <outcome_measure>HCV RNA change from baseline</outcome_measure>
      <outcome_measure>The proportion of participants with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02378935</url>
  </study>
  <study rank="922">
    <nct_id>NCT00804752</nct_id>
    <title>Vitamin D Treatment in Patients With Chronic Hepatitis C</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Adding vitamin D</intervention>
      <intervention type="Drug">Vitamin D</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hillel Yaffe Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs/>
    <other_ids>
      <other_id>0040-08-HYMC</other_id>
    </other_ids>
    <first_received>December 7, 2008</first_received>
    <last_updated>December 8, 2008</last_updated>
    <last_verified>December 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>To increase the sustained virological response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Israel</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00804752</url>
  </study>
  <study rank="923">
    <nct_id>NCT00466271</nct_id>
    <title>Prediction of Significant Hepatic Fibrosis in HCV Carriers With PNALT by SAPI- A Validation Study</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Hepatic Fibrosis</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>102</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>200611011R</other_id>
    </other_ids>
    <first_received>April 24, 2007</first_received>
    <start_date>April 2007</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>December 21, 2008</last_updated>
    <last_verified>December 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2008</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00466271</url>
  </study>
  <study rank="924">
    <nct_id>NCT00695019</nct_id>
    <title>Interferon-alpha Lozenges for Prevention of Relapse in Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">interferon-alpha lozenges</intervention>
      <intervention type="Drug">placebo lozenges</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Amarillo Biosciences, Inc.</lead_sponsor>
      <collaborator>CytoPharm, Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>169</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>07HWHC09</other_id>
    </other_ids>
    <first_received>June 9, 2008</first_received>
    <start_date>June 2009</start_date>
    <completion_date>February 2012</completion_date>
    <last_updated>August 27, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>February 5, 2013</firstreceived_results_date>
    <primary_completion_date>November 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Relapse Rate</outcome_measure>
      <outcome_measure>Sustained Virologic Response Rate</outcome_measure>
      <outcome_measure>Normalization of ALT</outcome_measure>
      <outcome_measure>Change in Serum HCV RNA Concentration</outcome_measure>
      <outcome_measure>Change in Serum ALT</outcome_measure>
      <outcome_measure>Change in Social Functioning</outcome_measure>
      <outcome_measure>Change in Fibrotest Score</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00695019</url>
  </study>
  <study rank="925">
    <nct_id>NCT02201901</nct_id>
    <title>Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF/VEL</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>268</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-342-1137</other_id>
    </other_ids>
    <first_received>July 24, 2014</first_received>
    <start_date>July 2014</start_date>
    <completion_date>November 2015</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ASTRAL-4</acronym>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV RNA &lt; LLOQ on treatment</outcome_measure>
      <outcome_measure>Model for end-stage liver disease (MELD) and CPT score changes from baseline</outcome_measure>
      <outcome_measure>HCV RNA change from baseline</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Kansas</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02201901</url>
  </study>
  <study rank="926">
    <nct_id>NCT01679834</nct_id>
    <title>An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>7500</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML25724</other_id>
    </other_ids>
    <first_received>September 3, 2012</first_received>
    <start_date>November 2014</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response</outcome_measure>
      <outcome_measure>Rapid virological response</outcome_measure>
      <outcome_measure>Early Virological Response</outcome_measure>
      <outcome_measure>Safety: incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01679834</url>
  </study>
  <study rank="927">
    <nct_id>NCT02545335</nct_id>
    <title>Neutrophil Function During Therapy With Protease Inhibitors in Chronic Hepatitis C</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Medical University of Graz</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>HCV-neutrophil</other_id>
    </other_ids>
    <first_received>July 29, 2015</first_received>
    <start_date>November 2014</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>September 7, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>neutrophil phagocytosis</outcome_measure>
      <outcome_measure>number of infections</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02545335</url>
  </study>
  <study rank="928">
    <nct_id>NCT02125500</nct_id>
    <title>Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Viral Hepatitis C</condition>
      <condition>HIV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir/Ledipasvir fixed dose</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>68</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRS HC31 SOFTRIH</other_id>
    </other_ids>
    <first_received>April 24, 2014</first_received>
    <start_date>September 2014</start_date>
    <completion_date>November 2015</completion_date>
    <last_updated>December 9, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response 12 weeks after discontinuation of therapy (SVR12), i.e. at week 36.</outcome_measure>
      <outcome_measure>Adverse clinical and biological events that occur during the treatment and up to 24 weeks after the end of the treatment</outcome_measure>
      <outcome_measure>Number and causes of poor adherence and treatment interruptions</outcome_measure>
      <outcome_measure>SVR rate 24 weeks (i.e. W48) after the end of treatment and according to the HCV sub-type</outcome_measure>
      <outcome_measure>Number of patients with HCV resistance mutations to Sofosbuvir and/or Ledipasvir</outcome_measure>
      <outcome_measure>HCV viral load</outcome_measure>
      <outcome_measure>Plasma HIV RNA levels</outcome_measure>
      <outcome_measure>Assess drug-drug interactions between HCV et HIV drugs</outcome_measure>
      <outcome_measure>Patient's reported outcomes evaluation</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02125500</url>
  </study>
  <study rank="929">
    <nct_id>NCT01335711</nct_id>
    <title>CHRONVAC-C Study Followed by Standard of Care in Chronic Hepatitis C Virus (HCV) Subjects</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ChronVac-C + SOC</intervention>
      <intervention type="Drug">SOC</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>ChronTech Pharma AB</lead_sponsor>
      <collaborator>Inovio Pharmaceuticals</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CVC-202</other_id>
      <other_id>2010-022960-10</other_id>
    </other_ids>
    <first_received>April 13, 2011</first_received>
    <start_date>April 2011</start_date>
    <completion_date>June 2012</completion_date>
    <last_updated>October 11, 2011</last_updated>
    <last_verified>October 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Early viral kinetics - Second phase slope of viral decline</outcome_measure>
      <outcome_measure>Rapid Viral Response (RVR). Percent subjects reaching non-detectable level of HCV-RNA.</outcome_measure>
      <outcome_measure>Partial Early Viral Response (pEVR). Percent HCV-RNA positive subjects with more than 2 log 10 decline in HCV-RNA.</outcome_measure>
      <outcome_measure>Complete Early Viral Response (cEVR). Percent subjects reaching non-detectable level of HCV-RNA.</outcome_measure>
      <outcome_measure>Local tolerance</outcome_measure>
      <outcome_measure>Change from baseline in vital signs</outcome_measure>
      <outcome_measure>Number of patients with AEs</outcome_measure>
      <outcome_measure>Change of blood status from baseline</outcome_measure>
      <outcome_measure>Exploratory Analysis - Characterization and quantification of the vaccine primed NS3-immune response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Sweden</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01335711</url>
  </study>
  <study rank="930">
    <nct_id>NCT00841243</nct_id>
    <title>Nutritional Support During Antiviral Therapy for Hepatitis C</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Weight Loss</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Nutrison (Nutricia)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UMC Utrecht</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>08-70</other_id>
    </other_ids>
    <first_received>February 10, 2009</first_received>
    <start_date>March 2009</start_date>
    <completion_date>August 2010</completion_date>
    <last_updated>February 10, 2009</last_updated>
    <last_verified>February 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Weight loss</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00841243</url>
  </study>
  <study rank="931">
    <nct_id>NCT01672983</nct_id>
    <title>A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450/ritonavir, ABT-267</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie (prior sponsor, Abbott)</lead_sponsor>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>110</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M12-536</other_id>
    </other_ids>
    <first_received>July 27, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>May 2014</completion_date>
    <last_updated>October 27, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>October 27, 2015</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 24 Weeks After Treatment (SVR24)</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With End of Treatment (EOT) Response</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01672983</url>
  </study>
  <study rank="932">
    <nct_id>NCT01604291</nct_id>
    <title>An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
      <collaborator>Clalit Health Services</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>959</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML28268</other_id>
    </other_ids>
    <first_received>May 21, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virological Response (SVR)-24 rate: Percentage of patients with HCV RNA &lt;50 IU/mL at 24 weeks post completion of treatment</outcome_measure>
      <outcome_measure>Dual versus triple Pegasys-based therapy: SVR-24 rates</outcome_measure>
      <outcome_measure>Correlation between SVR-24 and clinical/demographic baseline values</outcome_measure>
      <outcome_measure>Predictive value of on-treatment factors (RVR, eRVR, EVR, EOT) on virological response (HCV-RNA &lt;50 IU/mL): Percentage of patients with rapid/rapid extended/early/end of treatment response</outcome_measure>
      <outcome_measure>Treatment duration</outcome_measure>
      <outcome_measure>Dose reductions/treatment discontinuations</outcome_measure>
      <outcome_measure>Correlation between dose reductions/treatment interruptions and sustained virological response (SVR)</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events (dual versus triple therapy)</outcome_measure>
      <outcome_measure>Rate of treatment-induced anemia (dual versus triple therapy)</outcome_measure>
      <outcome_measure>Treatment regimens for HCV treatment induced anemia in routine clinical practice</outcome_measure>
      <outcome_measure>Rate of virological relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Israel</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01604291</url>
  </study>
  <study rank="933">
    <nct_id>NCT00703872</nct_id>
    <title>HDV-Interferon in the Treatment of Chronic Hepatitis C Nonresponders and Naive Hepatitis C Patients</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Oral HDV-Interferon + ribavarin</intervention>
      <intervention type="Drug">Injectable HDV-Interferon + ribavarin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hepasome Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HP 01-2006-01</other_id>
    </other_ids>
    <first_received>June 23, 2008</first_received>
    <start_date>May 2008</start_date>
    <completion_date>December 2009</completion_date>
    <last_updated>January 8, 2009</last_updated>
    <last_verified>January 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Rapid Virologic Response</outcome_measure>
      <outcome_measure>Early Virologic Response</outcome_measure>
      <outcome_measure>Sustained Virologic Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>India</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00703872</url>
  </study>
  <study rank="934">
    <nct_id>NCT00703560</nct_id>
    <title>Study of Hepatitis C Virus (HCV) Viral Kinetics in HIV/HCV and HCV Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>University of Texas Southwestern Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>72</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>102005-009</other_id>
      <other_id>K23AI065630</other_id>
    </other_ids>
    <first_received>June 19, 2008</first_received>
    <start_date>September 2005</start_date>
    <completion_date>January 2013</completion_date>
    <last_updated>January 18, 2013</last_updated>
    <last_verified>January 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>VK</acronym>
    <primary_completion_date>September 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Comparison of interferon effectiveness (as measured by epsilon) in HIV/HCV to HCV alone and African American to Caucasians.</outcome_measure>
      <outcome_measure>SVR rate in HIV/HCV vs. HCV and African Americans vs. Caucasians</outcome_measure>
      <outcome_measure>Comparison of HCV quasi-species diversity</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00703560</url>
  </study>
  <study rank="935">
    <nct_id>NCT01447446</nct_id>
    <title>An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>4449</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>MV25599</other_id>
    </other_ids>
    <first_received>October 4, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>September 2015</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response rate, defined as percentage of patients with HCV RNA &lt;50 IU/mL at 24 weeks past completion of treatment</outcome_measure>
      <outcome_measure>Virological response (in correlation with on-treatment factors)</outcome_measure>
      <outcome_measure>Duration of treatment</outcome_measure>
      <outcome_measure>Percentage of patients treated according to label / Summary of Product Characteristics (SPC)</outcome_measure>
      <outcome_measure>Treatment discontinuation (time, reasons)</outcome_measure>
      <outcome_measure>Sustained virological response in correlation with dose reductions/treatment interruptions</outcome_measure>
      <outcome_measure>Treatment (drugs, regimen) in relation to medical history/concomitant medical conditions</outcome_measure>
      <outcome_measure>Incidence of viral rebound on DAA based triple therapy</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
      <country>Egypt</country>
      <country>Estonia</country>
      <country>France</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>Hungary</country>
      <country>Ireland</country>
      <country>Italy</country>
      <country>Kuwait</country>
      <country>Lebanon</country>
      <country>Macedonia, The Former Yugoslav Republic of</country>
      <country>Morocco</country>
      <country>Oman</country>
      <country>Pakistan</country>
      <country>Portugal</country>
      <country>Qatar</country>
      <country>Romania</country>
      <country>Saudi Arabia</country>
      <country>Serbia</country>
      <country>Sweden</country>
      <country>Switzerland</country>
      <country>Syrian Arab Republic</country>
      <country>Taiwan</country>
      <country>Turkey</country>
      <country>United Arab Emirates</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01447446</url>
  </study>
  <study rank="936">
    <nct_id>NCT02531269</nct_id>
    <title>Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
      <collaborator>Basel Institute of Clinical Epidemiology (BICE)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-319</other_id>
    </other_ids>
    <first_received>August 11, 2015</first_received>
    <start_date>March 2015</start_date>
    <completion_date>January 2016</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR12</outcome_measure>
      <outcome_measure>SVR4</outcome_measure>
      <outcome_measure>SVR24</outcome_measure>
      <outcome_measure>On-treatment Virological response at week 4 assessed by measuring viral load</outcome_measure>
      <outcome_measure>Virological response at the end of treatment (EOT) assessed by measuring viral load</outcome_measure>
      <outcome_measure>The occurrence of virological failure (on-treatment and relapse) assessed by measuring viral load</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Switzerland</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02531269</url>
  </study>
  <study rank="937">
    <nct_id>NCT01636778</nct_id>
    <title>Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SB-497115-GR</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>116101</other_id>
    </other_ids>
    <first_received>July 5, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>November 2014</completion_date>
    <last_updated>September 10, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>January 22, 2015</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Whose Platelet Count Increased From a Baseline Count of &lt; 80 Gi/L to a Count &gt;=100 Gi/L During Part 1</outcome_measure>
      <outcome_measure>Number of Participants Whose Platelet Counts Maintained at &gt;=50 Gi/L During Part 2</outcome_measure>
      <outcome_measure>Median Platelet Count at the Indicated Time Points in Part 1</outcome_measure>
      <outcome_measure>Time in Weeks to Achieve Platelet Count &gt;= 100 Gi/L</outcome_measure>
      <outcome_measure>Median Platelet Count at the Indicated Time Points in Part 2</outcome_measure>
      <outcome_measure>Median Platelet Count at the Indicated Time Points During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Minimum Platelet Count on Antiviral Therapy</outcome_measure>
      <outcome_measure>Dose of Eltrombopag That Enabled Initiation of Antiviral Therapy</outcome_measure>
      <outcome_measure>Number of Antiviral Therapy Dose Reductions in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Levels of Peg-IFN Alpha-2a Therapy Dose Reductions in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Levels of Peg-IFN Alpha-2b Therapy Dose Reductions in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Levels of RBV Therapy Dose Reductions in Part 2</outcome_measure>
      <outcome_measure>Time to First Dose Reduction of Antiviral Therapy in Part 2</outcome_measure>
      <outcome_measure>Number of Participants Who Discontinued Antiviral Therapy in Part 2</outcome_measure>
      <outcome_measure>Number of Participants Who Discontinued Peg-IFN Alpha-2a Therapy in Part 2</outcome_measure>
      <outcome_measure>Number of Participants Who Discontinued Peg-IFN Alpha-2b Therapy in Part 2</outcome_measure>
      <outcome_measure>Number of Participants Achieving Adherence to Antiviral Therapy in Part 2</outcome_measure>
      <outcome_measure>Number of Participants Achieving Adherence to Peg-IFN Alpha 2a Antiviral Therapy in Part 2</outcome_measure>
      <outcome_measure>Number of Participants Achieving Adherence to Peg-IFN Alpha-2b Antiviral Therapy in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With Sustained Virologic Response (SVR) in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With Rapid Virological Response (RVR) and Extended RVR (eRVR) in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With Early Virological Response (EVR) and Complete EVR (cEVR) in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With End of Treatment Response (ETR) for Undetectable HCV RNA at the End of Peg-IFN/RBV Treatment in Part 2</outcome_measure>
      <outcome_measure>Mean Serum HCV RNA at the Indicated Time Points In Part 2</outcome_measure>
      <outcome_measure>Mean Serum HCV RNA at the Indicated Time Points During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) in Part1</outcome_measure>
      <outcome_measure>Number of Participants With Any AE and Any SAE in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With Any AE and Any SAE During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points in Part 1 With Follow-up Period</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points in Part 2</outcome_measure>
      <outcome_measure>Mean Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Heart Rate at the Indicated Time Points in Part 1 With Follow-up Period</outcome_measure>
      <outcome_measure>Mean Change From Antiviral Baseline in Heart Rate at the Indicated Time Points in Part 2</outcome_measure>
      <outcome_measure>Mean Heart Rate at the Indicated Time Points During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Weight at the Indicated Time Points in Part 1 With Follow-up Period</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Weight at the Indicated Time Points in Part 2</outcome_measure>
      <outcome_measure>Mean Weight at the Indicated Time Points During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Body Temperature at the Indicated Time Points in Part 1 With Follow-up Period</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Body Temperature at the Indicated Time Points in Part 2</outcome_measure>
      <outcome_measure>Mean Body Temperature at the Indicated Time Points During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Body Mass Index (BMI) at the Indicated Time Points in Part 1 With Follow-up Periodc</outcome_measure>
      <outcome_measure>Mean Change From Baseline in BMI at the Indicated Time Points in Part 2</outcome_measure>
      <outcome_measure>Mean BMI at the Indicated Time Points During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Shift From Baseline in Severity Grades for Clinical Chemistry Parameters Per Division of Acquired Immunodeficiency Syndrome (DAIDS) in Part 1</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Shift From Baseline in Severity Grades for Clinical Chemistry Parameters Per DAIDS in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Shift From Baseline in Severity Grades for Clinical Chemistry Parameters Per DAIDS During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters Per DAIDS in Part 1</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters Per DAIDS in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Shifts From BL in Severity Grades for Hematology Parameters Per DAIDS During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Urinalysis Parameters Tested by Dipstick at the Indicated Time Points in Part1 With Follow Up Period</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Urinalysis Parameters Tested by Dipstick at the Indicated Time Points in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Urinalysis Parameters Tested by Dipstick at the Indicated Time Points During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Number of Participants Assessed as Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) at the Indicated Time Points</outcome_measure>
      <outcome_measure>Number of Participants Assessed as Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) During Follow-up After Part 2</outcome_measure>
      <outcome_measure>Number of Participants With Abdominal Ultrasound With Doppler at the Indicated Time Points</outcome_measure>
      <outcome_measure>Number of Participants With Abdominal Ultrasound With Doppler During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Spleen Measurements as Assessed by Abdominal Ultrasound With Doppler in the Study</outcome_measure>
      <outcome_measure>Spleen Measurements as Assessed by Abdominal Ultrasound With Doppler During Follow-up Period After Part 2</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01636778</url>
  </study>
  <study rank="938">
    <nct_id>NCT01935817</nct_id>
    <title>Silybin - Vitamin E- Phospholipids Complex Reduces Liver Fibrosis in Patients With Chronic Hepatitis C Treated With Peg-IFN-a and RBV</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Liver Fibrosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg complex</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Catania</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>64</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>unict11/1997</other_id>
    </other_ids>
    <first_received>September 1, 2013</first_received>
    <start_date>June 2010</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>September 4, 2013</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>transforming growth factor beta</outcome_measure>
      <outcome_measure>hyaluronic acid</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01935817</url>
  </study>
  <study rank="939">
    <nct_id>NCT02176525</nct_id>
    <title>Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BI 207127 NA</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>1241.2</other_id>
    </other_ids>
    <first_received>June 26, 2014</first_received>
    <start_date>December 2007</start_date>
    <last_updated>June 26, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Virologic response (VR)</outcome_measure>
      <outcome_measure>Time-dependent change from baseline in viral load</outcome_measure>
      <outcome_measure>Cmax (maximum measured concentration of the analyte in plasma at different time points)</outcome_measure>
      <outcome_measure>tmax,ss (time from dosing to maximum measured concentration at different time points)</outcome_measure>
      <outcome_measure>Cmin,ss (minimum measured concentration of the analyte in plasma at different time points)</outcome_measure>
      <outcome_measure>AUC (area under the concentration-time curve of the analyte in plasma at different time points)</outcome_measure>
      <outcome_measure>λz,ss (terminal rate constant in plasma, steady state)</outcome_measure>
      <outcome_measure>t1/2,ss (terminal half-life of the analyte in plasma, steady state)</outcome_measure>
      <outcome_measure>CL/F,ss (apparent clearance of the analyte in plasma after oral administration, steady state)</outcome_measure>
      <outcome_measure>Vz/F,ss (apparent volume of distribution during the terminal phase λz following an oral dose, steady state)</outcome_measure>
      <outcome_measure>Plasma concentration time profiles</outcome_measure>
      <outcome_measure>Number of patients with clinically significant changes in vital signs (pulse rate, systolic and diastolic blood pressure)</outcome_measure>
      <outcome_measure>Number of patients with abnormal findings in 12-lead ECG (electrocardiogram)</outcome_measure>
      <outcome_measure>Number of patients with abnormal changes in laboratory tests</outcome_measure>
      <outcome_measure>Number of patients with adverse events</outcome_measure>
      <outcome_measure>Number of patients with abnormal findings in physical examination</outcome_measure>
      <outcome_measure>Assessment of global tolerability on a 4-point scale</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02176525</url>
  </study>
  <study rank="940">
    <nct_id>NCT02555943</nct_id>
    <title>DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
      <condition>HBV Coinfection</condition>
      <condition>Hepatitis B Reactivation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ledipasvir/Sofosbuvir</intervention>
      <intervention type="Drug">Sofosbuvir and Daclatasvir</intervention>
      <intervention type="Drug">Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir</intervention>
      <intervention type="Drug">Entecavir</intervention>
      <intervention type="Drug">Tenofovir disoproxil</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Humanity &amp; Healthy GI and Liver Centre</lead_sponsor>
      <collaborator>Beijing 302 Hospital</collaborator>
      <collaborator>Nanfang Hospital of Southern Medical University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>H&amp;H_DASCO</other_id>
    </other_ids>
    <first_received>September 20, 2015</first_received>
    <start_date>February 2015</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>September 20, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>DASCO</acronym>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants who experience virological breakthrough</outcome_measure>
      <outcome_measure>Proportion of participants who experience virological rebound</outcome_measure>
      <outcome_measure>Proportion of participant who experience biochemical rebound</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02555943</url>
  </study>
  <study rank="941">
    <nct_id>NCT01508130</nct_id>
    <title>An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>672</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML27900</other_id>
    </other_ids>
    <first_received>January 9, 2012</first_received>
    <start_date>January 2012</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>September 1, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety: Time to premature treatment discontinuation due to any reason</outcome_measure>
      <outcome_measure>Efficacy: Sustained virological response rate, defined as percentage of patients with undetectable HCV RNA (HCV RNA &lt;/= 50 IU/mL) at 24 weeks post-completion of treatment</outcome_measure>
      <outcome_measure>Occurrence of premature discontinuation of treatment according to reasons (VR/resistance development/AE/compliance)</outcome_measure>
      <outcome_measure>Association between degree of dose reductions/treatment interruptions and sustained virological response</outcome_measure>
      <outcome_measure>Occurrence of virological rebound</outcome_measure>
      <outcome_measure>Virological response/virological rebound in correlation with hepatitis C virus genotype</outcome_measure>
      <outcome_measure>Virological response in relation to treatment duration after becoming HCV RNA undetectable</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
      <outcome_measure>Work Productivity and Activity Impairment Questionnaire: General Health (WPAI:GH)</outcome_measure>
      <outcome_measure>Virological response in correlation with baseline clinical/demographic patient characteristics</outcome_measure>
      <outcome_measure>Virological response in correlation with treatment (regimen/dosage/compliance/co-medication)</outcome_measure>
      <outcome_measure>Treatment duration according to treatment regimens</outcome_measure>
      <outcome_measure>Percentage of patients treated according to US labeling</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arkansas</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Hampshire</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Vermont</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01508130</url>
  </study>
  <study rank="942">
    <nct_id>NCT00244751</nct_id>
    <title>Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GI262570</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>225</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>FBX104114</other_id>
    </other_ids>
    <first_received>October 25, 2005</first_received>
    <start_date>November 2005</start_date>
    <completion_date>February 2008</completion_date>
    <last_updated>November 5, 2009</last_updated>
    <last_verified>November 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from baseline in liver biopsy immunohistochemical markers. Change from baseline in fibrosis in liver biopsy. Histological assessment of paired biopsies (baseline and Week 52). Safety and tolerability of two doses of GI262570.</outcome_measure>
      <outcome_measure>Proportion of subjects progressing at least 1 point in fibrosis score. Proportion of subjects regressing at least 1 point in fibrosis score. Change from baseline in markers of liver fibrosis.</outcome_measure>
      <outcome_measure>·Proportion of subjects progressing at least 1 point on the Ishak fibrosis score at Week 52 on each arm of the study. Progression is defined as an increase of at least one point in the fibrosis score.</outcome_measure>
      <outcome_measure>·Proportion of subjects regressing at least 1 point on the Ishak fibrosis score at Week 52 on each arm of the study.</outcome_measure>
      <outcome_measure>·Proportion of subjects whose Ishak fibrosis score remains unchanged at Week 52 on each arm of the study.</outcome_measure>
      <outcome_measure>·Change from baseline in total Ishak Score (necroinflammatory score and fibrosis score) at Week 52.</outcome_measure>
      <outcome_measure>·Change from baseline in Metavir scores.</outcome_measure>
      <outcome_measure>·Change from baseline in serum FibroSure (FibroTest/ActiTest) score.</outcome_measure>
      <outcome_measure>·Change from baseline in serum ALT levels.</outcome_measure>
      <outcome_measure>·Change from baseline in measures of insulin resistance.</outcome_measure>
      <outcome_measure>·Median serum ALT over time.</outcome_measure>
      <outcome_measure>·Change from baseline in serum HCV RNA levels.</outcome_measure>
      <outcome_measure>·Median serum HCV RNA levels over time.</outcome_measure>
      <outcome_measure>·Pharmacokinetic measures:</outcome_measure>
      <outcome_measure>·GI262570 serum PK parameters on Week 2 in a subset of subjects.</outcome_measure>
      <outcome_measure>·GI262570 serum concentrations on Week 2, 16, 28, 40, and Week 52.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Czech Republic</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Korea, Republic of</country>
      <country>Malaysia</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Singapore</country>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>Arkansas</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Indiana</state>
      <state>Iowa</state>
      <state>Kentucky</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00244751</url>
  </study>
  <study rank="943">
    <nct_id>NCT02250807</nct_id>
    <title>Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Genotype 4 Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR105429</other_id>
      <other_id>TMC435HPC3021</other_id>
      <other_id>2014-003446-27</other_id>
    </other_ids>
    <first_received>September 24, 2014</first_received>
    <start_date>January 2015</start_date>
    <completion_date>January 2016</completion_date>
    <last_updated>September 25, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Subjects With Sustained Virologic Response (SVR 12) at Week 12 After End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Percentage of Subjects With Sustained Virologic Response at Week 4 (SVR 4) and 24 (SVR 24) After EOT</outcome_measure>
      <outcome_measure>Percentage of Subjects With On-treatment Virologic Response of Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>Percentage of Subjects With on-treatment failure along with Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Subjects With Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02250807</url>
  </study>
  <study rank="944">
    <nct_id>NCT00119119</nct_id>
    <title>Efficacy and Safety of Pentoxyphilline and Tocopherol on the Fibrosis in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Liver Fibrosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pentoxyphilline</intervention>
      <intervention type="Drug">tocopherol</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Agency for Research on AIDS and Viral Hepatitis</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRSHC10 PENTO</other_id>
    </other_ids>
    <first_received>July 4, 2005</first_received>
    <start_date>February 2002</start_date>
    <completion_date>December 2006</completion_date>
    <last_updated>January 11, 2007</last_updated>
    <last_verified>January 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Variation of the percentage of liver fibrosis evaluated with morphometric analysis between the liver biopsies performed at the end and before the trial (defined as significant if over 5 percent).</outcome_measure>
      <outcome_measure>Variation of fibrosis Metavir score between the two biopsies</outcome_measure>
      <outcome_measure>Variation of activity Metavir score between the two biopsies</outcome_measure>
      <outcome_measure>Variation of liver markers of fibrosis : hyaluronate, N-terminal peptide of procollagen III, TNF-alfa and fibrotest</outcome_measure>
      <outcome_measure>Variation of ALT</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00119119</url>
  </study>
  <study rank="945">
    <nct_id>NCT01378104</nct_id>
    <title>100% VS 80% Of Pegasys In Koreans With Chronic Hepatitis C (CHC)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Sustained Virologic Response</condition>
      <condition>IL28B Polymorphism</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa 2a (pegasys)</intervention>
      <intervention type="Drug">peginterferon alfa-2a (pegasys)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>The Catholic University of Korea</lead_sponsor>
      <collaborator>Ulsan University Hospital</collaborator>
      <collaborator>NHIC Ilsan hospital</collaborator>
      <collaborator>Inje University</collaborator>
      <collaborator>Soonchunhyang University Hospital</collaborator>
      <collaborator>Yonsei University</collaborator>
      <collaborator>Chungnam National University</collaborator>
      <collaborator>Keimyung University</collaborator>
      <collaborator>Kyungpook National University</collaborator>
      <collaborator>Konyang University Hospital</collaborator>
      <collaborator>Inha University Hospital</collaborator>
      <collaborator>Hallym University Medical Center</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>178</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>PEGASYS100:80</other_id>
    </other_ids>
    <first_received>June 16, 2011</first_received>
    <start_date>October 2008</start_date>
    <completion_date>September 2012</completion_date>
    <last_updated>February 3, 2013</last_updated>
    <last_verified>February 2013</last_verified>
    <firstreceived_results_date>December 14, 2012</firstreceived_results_date>
    <primary_completion_date>September 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response Depending on the Dosage of Peginterferon Alfa 2a</outcome_measure>
      <outcome_measure>IL28B Polymorphism Effect on SVR</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Korea, Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01378104</url>
  </study>
  <study rank="946">
    <nct_id>NCT00110799</nct_id>
    <title>SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C</condition>
      <condition>Thrombocytopenia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SB497115</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>TPL102357</other_id>
    </other_ids>
    <first_received>May 13, 2005</first_received>
    <start_date>April 2005</start_date>
    <completion_date>November 2006</completion_date>
    <last_updated>May 31, 2012</last_updated>
    <last_verified>March 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Treatment response, assessed by the proportion of subjects with a shift from baseline platelet count (20, 000 to &lt;70,000µL) to =100,000/µL after 4 weeks of study treatment.</outcome_measure>
      <outcome_measure>Mean increase in platelet counts and markers of thrombopoiesis. Safety and tolerability, population PK, pharmacodynamics. Effect of antiviral outcome measures during and after therapy.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>France</country>
      <country>Germany</country>
      <country>Puerto Rico</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Colorado</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00110799</url>
  </study>
  <study rank="947">
    <nct_id>NCT00778843</nct_id>
    <title>Antioxidant and Immunomodulator Properties of Viusid in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Viusid</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Catalysis SL</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>VIU-CHC-08</other_id>
    </other_ids>
    <first_received>October 21, 2008</first_received>
    <start_date>October 2008</start_date>
    <completion_date>May 2009</completion_date>
    <last_updated>May 2, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The improvement of serum parameters related to oxidative stress (SOD, AT, MDA, MDA/HNE, GPx, GR, AOP, MPO, PAOP, GSH) at 24 weeks (end of the treatment).</outcome_measure>
      <outcome_measure>The improvement of serum parameters related to immune response (IFN alpha, IFN gamma, IL-1 alpha, IL-2, IL-6, IL-10, IL-12, TNF alpha, Anti TNF alpha, Cathepsin L) at 24 weeks (end of the treatment).</outcome_measure>
      <outcome_measure>Improvement of aminotransferase levels (ALAT and ASAT) at 24 weeks (end of the treatment).</outcome_measure>
      <outcome_measure>Improvement of clinical symptoms and signs at 24 weeks (end of the treatment).</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Cuba</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00778843</url>
  </study>
  <study rank="948">
    <nct_id>NCT00255177</nct_id>
    <title>Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">VGX-410 (Mifepristone)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>VGX Pharmaceuticals, LLC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>44</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>VT003</other_id>
      <other_id>Viral Genomix, Inc. (VGX)</other_id>
      <other_id>450 Sentry Parkway</other_id>
      <other_id>Blue Bell, PA 19422</other_id>
      <other_id>C. Jo White, M.D.</other_id>
    </other_ids>
    <first_received>November 15, 2005</first_received>
    <start_date>November 2005</start_date>
    <completion_date>January 2008</completion_date>
    <last_updated>October 30, 2009</last_updated>
    <last_verified>October 2009</last_verified>
    <firstreceived_results_date>April 22, 2009</firstreceived_results_date>
    <primary_completion_date>September 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Mean Log Change in Viral Load From Baseline (Day 1) to Day 28</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Missouri</state>
      <state>Pennsylvania</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00255177</url>
  </study>
  <study rank="949">
    <nct_id>NCT00590564</nct_id>
    <title>SHO-SAIKO-TO for Patients With Chronic Hepatitis C: A Phase II Study</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sho-saiko-to</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Memorial Sloan Kettering Cancer Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>41</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>02-073</other_id>
    </other_ids>
    <first_received>December 21, 2007</first_received>
    <start_date>October 2002</start_date>
    <completion_date>February 2011</completion_date>
    <last_updated>April 28, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To determine the effects of Sho-saiko-to on hepatic injury in patients with chronic hepatitis C who are intolerant or have a specific contraindication to interferon-based therapy.</outcome_measure>
      <outcome_measure>To determine the effects of SST therapy on liver function and viral load</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00590564</url>
  </study>
  <study rank="950">
    <nct_id>NCT00473993</nct_id>
    <title>Hepatitis C Among Opioid Addicts in Opioid Maintenance Treatment in Zurich, Switzerland</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Substance Abuse Treatment Centers</condition>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Seidenberg, Arztpraxis A., M.D.</lead_sponsor>
      <collaborator>University of Zurich</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>HepCOP Zurich</other_id>
    </other_ids>
    <first_received>May 15, 2007</first_received>
    <start_date>July 2007</start_date>
    <completion_date>December 2007</completion_date>
    <last_updated>February 13, 2009</last_updated>
    <last_verified>May 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HepCOP</acronym>
    <outcome_measures/>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00473993</url>
  </study>
  <study rank="951">
    <nct_id>NCT00209118</nct_id>
    <title>Paroxetine for the Treatment of Interferon Related Side Effects for Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Depression</condition>
      <condition>Interferon-alpha Associated Side Effects</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">paroxetine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Emory University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>0112-1998</other_id>
    </other_ids>
    <first_received>September 14, 2005</first_received>
    <completion_date>July 2005</completion_date>
    <last_updated>January 27, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Depressive Symptom Scores</outcome_measure>
      <outcome_measure>Development of Major Depression</outcome_measure>
      <outcome_measure>neurotoxicity</outcome_measure>
      <outcome_measure>dosage reduction</outcome_measure>
      <outcome_measure>discontinuation</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00209118</url>
  </study>
  <study rank="952">
    <nct_id>NCT00547716</nct_id>
    <title>Use of Omega-3 Fatty Acids (Fish Oil) in Patients With Chronic Hepatitis C Infection</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Omega-3 Fatty Acids</intervention>
      <intervention type="Drug">Placebo comparator</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Truman Medical Center</lead_sponsor>
      <collaborator>Reliant Pharmaceuticals</collaborator>
      <collaborator>Saint Luke's Health System Foundation</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>07-48</other_id>
    </other_ids>
    <first_received>October 19, 2007</first_received>
    <start_date>June 2009</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>September 13, 2013</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To assess whether omega-3 fatty acids can improve early and sustained viral responses to treatment with interferon in patients with chronic infection.</outcome_measure>
      <outcome_measure>To look at the effect of treatment of Hepatitis C on insulin resistance.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Missouri</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00547716</url>
  </study>
  <study rank="953">
    <nct_id>NCT01572233</nct_id>
    <title>Effects of Activity and Education Program on Patients With Chronic Hepatitis C Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection, Response to Therapy of</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Personalized Physical Activity and Psycho-Education (PPAPE) Program</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>National Health Research Institutes, Taiwan</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>201103086RC</other_id>
    </other_ids>
    <first_received>April 4, 2012</first_received>
    <start_date>December 2011</start_date>
    <completion_date>June 2018</completion_date>
    <last_updated>December 26, 2012</last_updated>
    <last_verified>November 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Effects of Activity and Education Program on Patients with Chronic Hepatitis C Infection</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01572233</url>
  </study>
  <study rank="954">
    <nct_id>NCT01835938</nct_id>
    <title>Clinical Investigation of Erlotinib as an HCV Entry Inhibitor</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
      <condition>HCV Genotype 1b</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">1- Erlotinib</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Strasbourg, France</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>5189</other_id>
    </other_ids>
    <first_received>April 9, 2013</first_received>
    <start_date>May 2013</start_date>
    <completion_date>May 2015</completion_date>
    <last_updated>June 14, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Assessment of virologic response and short-term safety of Erlotinib in patients infected with HCV genotype 1b</outcome_measure>
      <outcome_measure>Assessment of pharmacokinetics of Erlotinib in HCV-infected patients</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01835938</url>
  </study>
  <study rank="955">
    <nct_id>NCT02126137</nct_id>
    <title>Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ezetimibe</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pontificia Universidad Catolica de Chile</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>12-199</other_id>
      <other_id>1130357</other_id>
    </other_ids>
    <first_received>April 27, 2014</first_received>
    <start_date>October 2013</start_date>
    <completion_date>March 2016</completion_date>
    <last_updated>November 3, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>EZE-1</acronym>
    <primary_completion_date>January 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HCV plasma viral load</outcome_measure>
      <outcome_measure>HCV biliary viral load</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Chile</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02126137</url>
  </study>
  <study rank="956">
    <nct_id>NCT01816490</nct_id>
    <title>THISTLE - The HIV-HCV Silibinin Trial</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Intravenous Silibinin (iSIL)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Zurich</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>THISTLE</other_id>
    </other_ids>
    <first_received>March 8, 2013</first_received>
    <start_date>April 2013</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>March 4, 2015</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>THISTLE</acronym>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Frequency of adverse events during iSIL treatment.</outcome_measure>
      <outcome_measure>Kinetics of the decline in HCV-RNA after 2 weeks of iSIL treatment (difference in IU/ml from day 1 to day 15).</outcome_measure>
      <outcome_measure>Drug levels of iSIL and its influence on the drug-level of co-administrated ART.</outcome_measure>
      <outcome_measure>Proportion of patients with HIV virological failure, i.e. confirmed viremia &gt;50cp/ml.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Switzerland</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01816490</url>
  </study>
  <study rank="957">
    <nct_id>NCT02124044</nct_id>
    <title>Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV-HCV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Asunaprevir and Dalatasvir</intervention>
      <intervention type="Drug">Daclatasvir and Asunaprevir, with or without BMS-791325</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institutes of Health Clinical Center (CC)</lead_sponsor>
      <collaborator>National Institute of Allergy and Infectious Diseases (NIAID)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>39</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>140065</other_id>
      <other_id>14-CC-0065</other_id>
    </other_ids>
    <first_received>April 25, 2014</first_received>
    <start_date>February 2014</start_date>
    <completion_date>January 2017</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The incidence of grade 3 and 4 adverse events (AEs) followingtreatment with DCV/ASV or DCV/ASV/BMS-791325 in HIV-HCV coinfected subjects</outcome_measure>
      <outcome_measure>The proportion of subjects who achieve SVR12</outcome_measure>
      <outcome_measure>Log change in HCV response</outcome_measure>
      <outcome_measure>The association between HIV Viral load &amp; lt; 40 copies/mL but detectable vs. undetectable while on therapy and HIV virologic failure or HIV VL blips.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02124044</url>
  </study>
  <study rank="958">
    <nct_id>NCT01945008</nct_id>
    <title>Observational Study in HCV Chronic Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Istituto Superiore di Sanità</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>10000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>PITER 01</other_id>
    </other_ids>
    <first_received>September 13, 2013</first_received>
    <start_date>April 2014</start_date>
    <completion_date>June 2021</completion_date>
    <last_updated>March 24, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Survival</outcome_measure>
      <outcome_measure>Liver disease progression</outcome_measure>
      <outcome_measure>Sustained virological response (SVR) in treated patients</outcome_measure>
      <outcome_measure>Occurrence of severe adverse events and side effects correlated to treatment</outcome_measure>
      <outcome_measure>Quality of life and adherence to treatment</outcome_measure>
      <outcome_measure>Evolution of the possible comorbidities ( HIV and/or HBV coinfections)</outcome_measure>
      <outcome_measure>Occurrence of antiviral resistances</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01945008</url>
  </study>
  <study rank="959">
    <nct_id>NCT01401400</nct_id>
    <title>Genetic Study of Peginterferon Treatment in Hepatitis B Patients: The GIANT-B Study</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Foundation for Liver Research</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1350</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>HBV10-03</other_id>
    </other_ids>
    <first_received>July 22, 2011</first_received>
    <start_date>May 2010</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>August 13, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>GIANT-B</acronym>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Response to (PEG)IFN in relation to single-nucleotide polymorphisms identified by a GWAS</outcome_measure>
      <outcome_measure>Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01401400</url>
  </study>
  <study rank="960">
    <nct_id>NCT01437969</nct_id>
    <title>Pharmacogenomics Study on IL28B Genetic Variants in Italian Patients With HCV Infection naïve to Treatment.</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Liver Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Genetic">genotyping and/or sequencing</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Casa Sollievo della Sofferenza IRCCS</lead_sponsor>
      <collaborator>INMI L Spallanzani IRCCS Roma</collaborator>
      <collaborator>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</collaborator>
      <collaborator>Azienda Ospedaliera San Camillo Forlanini</collaborator>
      <collaborator>IRCCS Policlinico S. Matteo</collaborator>
      <collaborator>Azienda ospedaliera Garibaldi Nesinma Catania</collaborator>
      <collaborator>Azienda Ospedaliero-Universitaria Careggi</collaborator>
      <collaborator>University of Milan</collaborator>
      <collaborator>Catholic University, Italy</collaborator>
      <collaborator>Ospedale Francesco Ferrari</collaborator>
      <collaborator>Ospedale di Canosa di Puglia</collaborator>
      <collaborator>Ospedale di Venosa</collaborator>
      <collaborator>Clinica Santa Rita Bari</collaborator>
      <collaborator>Ospedale SS. Annunziata, Taranto</collaborator>
      <collaborator>Ospedali Riuniti di Foggia</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>EPAT-IL28B</other_id>
    </other_ids>
    <first_received>September 20, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>September 2012</completion_date>
    <last_updated>April 14, 2012</last_updated>
    <last_verified>April 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2012</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01437969</url>
  </study>
  <study rank="961">
    <nct_id>NCT02073656</nct_id>
    <title>Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
      <condition>HIV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>335</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-0115</other_id>
    </other_ids>
    <first_received>February 25, 2014</first_received>
    <start_date>February 2014</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV RNA &lt; LLOQ on treatment</outcome_measure>
      <outcome_measure>For retreatment group only: Proportion of participants with HCV RNA &lt; LLOQ on treatment</outcome_measure>
      <outcome_measure>Change in HCV RNA from baseline</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
      <outcome_measure>For retreatment group only: Proportion of participants with sustained virologic response at 4, 12 and 24 weeks after discontinuation of therapy (SVR4, SVR12, and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants that maintain HIV-1 RNA &lt; 50 copies/mL while on treatment</outcome_measure>
      <outcome_measure>Change from baseline of serum creatinine at end of treatment, posttreatment weeks 12 and 24</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02073656</url>
  </study>
  <study rank="962">
    <nct_id>NCT01813266</nct_id>
    <title>Prospective Cohort Study: To Provide Evidence &amp; Guidance in Hepatitis C Virus Screening, Comparing the New Birth Cohort Recommendations From the CDC, Versus Classical Traditional Strategies With Established Risk Factors</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Intermountain Health Care, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>6000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>hepcvirusscreeningtrial</other_id>
    </other_ids>
    <first_received>March 11, 2013</first_received>
    <start_date>May 2013</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>March 13, 2013</last_updated>
    <last_verified>March 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>TPEGHCVS</acronym>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>superiority of Hepatitis C virus screening between three different strategies as far as identifying those with chronic hepatitis C virus infection.</outcome_measure>
      <outcome_measure>Cost of testing of screening for HCV.</outcome_measure>
      <outcome_measure>Develop a registry of patients with chronic HCV infection to follow through treatment.</outcome_measure>
      <outcome_measure>Identify new risk factors for Chronic Hepatitis C virus infection.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Utah</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01813266</url>
  </study>
  <study rank="963">
    <nct_id>NCT00951223</nct_id>
    <title>Observational Prospective Registry of the Efficacy, Safety, and Adherence to Infergen® in Patients Infected With Hep C</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Infergen® (Interferon alfacon-1)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kadmon Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>CIFN 003</other_id>
    </other_ids>
    <first_received>August 3, 2009</first_received>
    <start_date>August 2009</start_date>
    <completion_date>April 2011</completion_date>
    <last_updated>September 1, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>REACHSVR</acronym>
    <primary_completion_date>November 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Determine the incidence of SVR, defined as undetectable HCV RNA measured 24 weeks after therapy ends, associated with prescribed, patient-administered therapy with Infergen® (Interferon alfacon 1) in patients chronically infected with HCV.</outcome_measure>
      <outcome_measure>Capture of defined adverse events (AEs),dose changes or cessation, and adherence to the prescribed dose of Infergen and other prescribed therapies over the course of treatment</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00951223</url>
  </study>
  <study rank="964">
    <nct_id>NCT01544582</nct_id>
    <title>Drug Utilization of Boceprevir and Clinical Management of Health Outcomes of Interest in Chronic Hepatitis C Participants (P08518)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>719</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P08518</other_id>
      <other_id>EP08043.001</other_id>
      <other_id>SCH 503034 P08518</other_id>
    </other_ids>
    <first_received>February 2, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>June 30, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Boceprevir utilization versus other therapies</outcome_measure>
      <outcome_measure>Clinical management of health outcomes of interest ([HOI], anemia, neutropenia, thrombocytopenia, or serious rash)</outcome_measure>
      <outcome_measure>Incidence of anemia, neutropenia, thrombocytopenia, and serious skin rash</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01544582</url>
  </study>
  <study rank="965">
    <nct_id>NCT01771653</nct_id>
    <title>Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Southern Illinois University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>37</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>KOI-SIUSOM-12-002</other_id>
    </other_ids>
    <first_received>January 16, 2013</first_received>
    <start_date>September 2011</start_date>
    <completion_date>July 2015</completion_date>
    <last_updated>August 5, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Virologic Response</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>Effect of baseline variables on treatment outcome</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Illinois</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01771653</url>
  </study>
  <study rank="966">
    <nct_id>NCT00945880</nct_id>
    <title>Safety and Tolerability Study of Clemizole Hydrochloride to Treat Hepatitis C in Subjects Who Are Treatment-Naive</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">clemizole hydrochloride</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Eiger BioPharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>EIG-101</other_id>
    </other_ids>
    <first_received>July 23, 2009</first_received>
    <start_date>July 2009</start_date>
    <completion_date>August 2010</completion_date>
    <last_updated>February 24, 2011</last_updated>
    <last_verified>February 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>CLEAN-1</acronym>
    <primary_completion_date>August 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evaluate the pharmacodynamic (PD) activity of a 100 mg po BID dose of clemizole hydrochloride on HCV viral load</outcome_measure>
      <outcome_measure>Evaluate the pharmacokinetics (PK) of a 100 mg po BID dose of clemizole hydrochloride in subjects chronically infected with HCV</outcome_measure>
      <outcome_measure>Evaluate the safety and tolerability of four weeks of treatment with a 100 mg po BID dose of clemizole hydrochloride through review of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00945880</url>
  </study>
  <study rank="967">
    <nct_id>NCT01517529</nct_id>
    <title>Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor Mutations</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>University of Cincinnati</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>UC 11101915</other_id>
    </other_ids>
    <first_received>January 20, 2012</first_received>
    <start_date>January 2012</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>October 20, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>August 25, 2015</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Who Completed Standard Treatment</outcome_measure>
      <outcome_measure>Number of Participants Who Cleared the Virus</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Ohio</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01517529</url>
  </study>
  <study rank="968">
    <nct_id>NCT01432080</nct_id>
    <title>Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant</title>
    <recruitment open="N">Suspended</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Respiratory Tract Infections</condition>
      <condition>Bronchiolitis Obliterans</condition>
      <condition>Cryptogenic Organizing Pneumonia</condition>
      <condition>Lung Diseases, Interstitial</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Prednisone</intervention>
      <intervention type="Drug">Azithromycin</intervention>
      <intervention type="Drug">Montelukast</intervention>
      <intervention type="Drug">Symbicort</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Maisonneuve-Rosemont Hospital</lead_sponsor>
      <collaborator>The Canadian Blood and Marrow Transplant Group</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HMR1102</other_id>
    </other_ids>
    <first_received>September 8, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>October 2016</completion_date>
    <last_updated>April 8, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Cumulative incidence of new chronic lung disease</outcome_measure>
      <outcome_measure>Prevalence of non-infectious pulmonary complications</outcome_measure>
      <outcome_measure>Long-term functional impairment as defined by need for supplemental oxygen</outcome_measure>
      <outcome_measure>Patient-perceived long-term functional impairment</outcome_measure>
      <outcome_measure>Time to clearance of viral infection</outcome_measure>
      <outcome_measure>Incidence of progression to respiratory failure</outcome_measure>
      <outcome_measure>Incidence of bacterial or fungal superinfection</outcome_measure>
      <outcome_measure>Incidence of various other infectious complications</outcome_measure>
      <outcome_measure>Overall survival from date of viral respiratory tract infection</outcome_measure>
      <outcome_measure>Overall survival from date of transplant to end of study follow-up</outcome_measure>
      <outcome_measure>Overall survival at 1 year post-transplant</outcome_measure>
      <outcome_measure>Cumulative incidence of death attributable to transplant associated lung disease</outcome_measure>
      <outcome_measure>Cumulative incidence of death from other causes</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01432080</url>
  </study>
  <study rank="969">
    <nct_id>NCT01605513</nct_id>
    <title>Safety Study of Recombinant Interferon Variant(PEG-IFN-SA) to Treat HCV Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">interferon</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>First Hospital of Jilin University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver)</study_design>
    </study_designs>
    <other_ids>
      <other_id>2011L0901</other_id>
    </other_ids>
    <first_received>May 10, 2012</first_received>
    <start_date>June 2011</start_date>
    <completion_date>May 2012</completion_date>
    <last_updated>May 23, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PEG-IFN-SA</acronym>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The proportions of absence of detectable HCV RNA after the 12th treatment</outcome_measure>
      <outcome_measure>The proportions of absence of detectable HCV RNA after the 4th and 8th treatment</outcome_measure>
      <outcome_measure>HCV RNA levels after the 4th, 8th and 12th treatment</outcome_measure>
      <outcome_measure>The test of Liver function</outcome_measure>
      <outcome_measure>The test of Kidney function</outcome_measure>
      <outcome_measure>The test of Peripheral blood</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01605513</url>
  </study>
  <study rank="970">
    <nct_id>NCT01818856</nct_id>
    <title>Pharmacokinetic Interactions Between Telaprevir and Un-boosted Atazanavir</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>HIV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ritonavir withdrawal, atazanavir 200 mg/12h</intervention>
      <intervention type="Drug">Telaprevir interactions</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hospitales Universitarios Virgen del Rocío</lead_sponsor>
      <collaborator>Bristol-Myers Squibb</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>14</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>LLC-TEL-2012-1</other_id>
      <other_id>2012-002515-25</other_id>
    </other_ids>
    <first_received>December 29, 2012</first_received>
    <start_date>December 2012</start_date>
    <completion_date>April 2013</completion_date>
    <last_updated>April 19, 2013</last_updated>
    <last_verified>April 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Changes in pharmacokinetic parameters of TVR</outcome_measure>
      <outcome_measure>Changes in pharmacokinetic parameters of ATV</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01818856</url>
  </study>
</search_results>
